

© NACO, MoHFW, Gol, 2024

All rights reserved

You may copy, redistribute and adapt the publication for non-commercial purposes, provided the publication is appropriately cited. In any use of this publication, there should be no suggestion that NACO endorses any specific organization, products, or services. The use of the NACO logo is not permitted. If you adapt the publication, then you must license your work allowing free copy, redistribute and adapt the work for non-commercial purposes. If you create a translation of this publication, you should add the following disclaimer: "This translation was not created by the NACO. NACO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

General disclaimers

NACO has made every effort to ensure the accuracy of data and verify the information contained in this publication. However, errors and omissions excepted. The publication is being distributed without warranty of any kind, either expressed or implied. Maps (if any), used in this publication, are only to provide visual impressions on the given indicator. These are not for scale and must not be construed or used as a "Legal Description" of any State/UT/district.

Suggested citation

National AIDS Control Organisation (2024). Sankalak: Status of National AIDS & STD Response (Sixth edition, 2024). New Delhi: NACO, Ministry of Health and Family Welfare, Government of India.

For additional information about Sankalak: Status of National AIDS & STD Response (Sixth edition, 2024), please contact

Monitoring & Evaluation - Strategic Information Division National AIDS Control Organisation (NACO) Ministry of Health and Family Welfare, Government of India 6th and 9th Floor Chanderlok Building, 36 Janpath, New Delhi, 110001









Status of National AIDS & STD Response

SIXTH EDITION **2024**



वी. हेकाली झिमोमी, भा.प्र.से. अपर सचिव एवं महानिदेशक V. Hekali Zhimomi, IAS Additional Secretary & Director General









राष्ट्रीय एड्स नियंत्रण संगठन स्वास्थ्य और परिवार कल्याण मंत्रालय भारत सरकार National AIDS Control Organisation Ministry of Health & Family Welfare Government of India

As we step into the fourth year of India's National AIDS and STD Control Programme (Phase-V), we find ourselves at a pivotal juncture, acknowledging significant progress while remaining vigilant against complacency. The national adult HIV prevalence is 0.20%, below the global average of 0.70%. However, Mizoram's prevalence is 2.73% and Nagaland's is 1.37%. Between 2010 and 2023, annual new infections in India decreased by 44%, compared to the global average of 39%. Yet, new infections surged by over 400% in Tripura and Arunachal Pradesh and doubled in Punjab and Meghalaya. While progress is evident, significant challenges remain.

In 2023-24, the third year of NACP-V implementation, we have employed integrated STI, HIV, TB, and Hepatitis campaigns within prison and other closed settings. Additionally, we have launched integrated health campaigns targeting High-Risk Groups (HRGs) and other vulnerable populations in selected states. We witnessed more than 6 crore of HIV testing in 2023-24, highest since inception of programme.

This year, we have introduced Index testing campaign for partners and biological children of individuals living with HIV and intensified our Information, Education and Communication (IEC) efforts. Furthermore, a fast-track city strategy is currently under development. These initiatives aim to enhance the country's progress towards the first 95 target, which stood at approximately 81% as of March 2024. This represents an increase of nearly 4% from March 2023, but it remains around 14% below the target of 95% set for March 2026.

The sixth edition of the NACP flagship publication 'Sankalak' highlights significant achievements and provides valuable insights through meticulous documentation and comprehensive analysis. I am confident that all stakeholders will fully utilize this evidence repository to ensure the continued implementation of location- and population-specific strategies towards ending the AIDS epidemic as a public health threat by 2030

(V. Hekal Zhimomi)

निखिल गजराज, भा.प्र.से. संयुक्त सचिव Nikhil Gajraj, IAS Joint Secretary





भारत सरकार स्वास्थ्य एवं परिवार कल्याण मंत्रालय निर्माण भवन, नई दिल्ली - 110011 Government of India Ministry of Health & Family Welfare Nirman Bhawan, New Delhi - 110011



PREFACE

'Sankalak: Status of the Nationa AIDS and STD Response' is the flagship report of India's National AIDS and STD Control Programme (NACP). As we present the sixth edition of 'Sankalak', we reflect on the progress made, challenges faced, and ongoing efforts in combating these public health issues.

In 2023-24, we conducted the highest number of HIV tests, more than 6 crores, since the inception of the NACP. We introduced new strategies that included integrated health campaigns for high-risk groups and combined STI, HIV, TB, and Hepatitis campaigns within prisons and other closed settings. Consequently, the number of people living with HIV who were aware of their status increased from approximately 77% in March 2023 to around 81% in March 2024. However, this figure remains far away from the target of 95%. This edition aims to provide a comprehensive overview of where we stand today, highlighting successes, identifying gaps, and indicating the path forward.


The 'Sankalak' report maintains separate sections for narratives and factsheets. The narrative section, consisting of 12 chapters, outlines the scale and trends of the epidemic and responses across prevention, detection, and treatment domains for HIV and STIs within the framework of the HIV and AIDS (Prevention & Control) Act, 2017. The factsheet provides data for India and each State/UT, corresponding to the narrative chapters. Where available, the data is disaggregated by gender in accordance with the NACP phase-V principles for a gender-sensitive response.

This report, anchored by M&E team of NACO, is the result of extensive collaboration among all divisions of NACO under the leadership of their respective heads. Their insights, experiences, and expertise have been invaluable in shaping this document, ensuring that it reflects the current reality of the AIDS and STD response.

This report is not just a compilation of data and statistics; it is a testament to the resilience, dedication, and unwavering commitment of countless individuals and organizations working tirelessly to combat HIV/AIDS and STDs in India. I am confident that this report will inspire renewed efforts, foster collaboration, and drive meaningful action towards the country's goal of the attainment of ending of AIDS epidemic as a public health threat by 2030.

Nikhil Gajraj)











Government of India Ministry of Health & Family Welfare National AIDS Control Organisation 6th & 9th Floor, Chandralok Building, 36 Janpath, New Delhi – 110 001 Tel.: 011-43509994

ACKNOWLEDGEMENT

The National AIDS and STD Control Programme (NACP)-Phase V is currently in its fourth year of implementation. Since the commencement of Phase V in 2021-22, the program has maintained its trajectory of success. The present edition of 'Sankalak: Status of National AIDS and STD Response', which is the sixth in the series, provides a comprehensive data-driven report on the advancements achieved under NACP in FY 2023-24. The encouragement, engagement, and participation of all NACO officials have been instrumental in the development and publication of this edition. We extend our sincere gratitude to everyone for their valuable contributions.

The development and publication of 'Sankalak' have been fully institutionalized by NACO under the leadership and guidance of Ms. V. Hekali Zhimomi (Additional Secretary & Director General, NACO) and Mr. Nikhil Gajraj (Joint Secretary, NACO). We sincerely thank the leadership of NACO for their continued mentorship and support in the development of this edition. NACO's leadership support was complemented by guidance from programme division on data and narratives. We thank Dr. Anoop Kumar Puri, Dr. Uday Bhanu Das, and Dr. Shobini Rajan, for their technical stewardship and finalization of the sixth edition. We also acknowledge the contributions of Dr. Bhawna Rao and Dr. Saiprasad P. Bhavsar (Deputy Directors).

The development and publication of 'Sankalak,' from inception to final release, is anchored by the Strategic Information (Monitoring and Evaluation) division of NACP. The process is supported by the IEC division of NACO for designing and printing. We recognize the contributions of Dr. Pradeep Kumar, Dr. P. Sujith, Dr. Sandeep Dhoundiyal, and Ms. Nidhi Rawat for their collaboration and coordination in the timely publication of the sixth edition of 'Sankalak'. We extend our appreciation to all National Consultants, Consultants, Associate Consultants, and Technical Experts of NACO and SI officers of State AIDS Control Societies (SACS) for their contribution in drafting and review of data and narratives for the draft chapters (list of contributors is Annexed).

Finally, we extend our sincere gratitude to all Project Directors of SACS. We acknowledge the valuable contributions of peer educators, outreach workers, counsellors, nurses, laboratory technicians, and medical officers at NACP's facilities for their efforts in generating substantial evidence documented in the sixth edition of SANKALAK.

(Dr Chinmoyee Das)

Contributors

I. National AIDS Control Organization

- 1. Ms. V. Hekali Zhimomi, Additional Secretary & Director General
- 2. Mr. Nikhil Gajraj, Joint Secretary
- 3. Dr. Anoop Kumar Puri, Deputy Director General,
- 4. Dr. Uday Bhanu Das, Senior Chief Medical Officer
- 5. Dr. Shobini Rajan, Chief Medical Officer
- 6. Dr. Bhawna Rao, Deputy Director
- 7. Dr. Saiprasad P. Bhavsar, Deputy Director
- 8. Dr. Pradeep Kumar, National Consultant, Strategic Information (S&E and M&E)
- 9. Ms. Nidhi Rawat, National Consultant, Information, Education and Communication
- 10. Ms. Vinita Verma, National Consultant, Strategic Information (R&E and Data)
- 11. Dr. Shantanu Purohit, National Consultant, Prevention
- 12. Dr. Vibhavari Deshmukh, National Consultant, HIV Counselling and Testing Services
- 13. Dr. Purnima Parmar, Consultant, Care, Support and Treatment Services
- 14. Dr. Arvind Kumar, Consultant, Care, Support and Treatment Services
- 15. Dr. Shivali Kamal, Consultant, Laboratory Services
- 16. Ms. Smita Mishra, Consultant, Laboratory Services
- 17. Mr. Ginlianmung Ngaihte, Consultant, Prevention
- 18. Mr. Benjamin Franklin, Consultant, Information, Education and Communication
- 19. Dr. P Sujith, Consultant, Strategic Information (M&E)
- 20. Dr. Subrata Biswas, Consultant, Strategic Information (S&E)
- 21. Dr. Vishal Yadav, Consultant, STI/RTI Management
- 22. Mr. Mubarak Ali Ansari, Consultant, HIV Counselling and Testing Services
- 23. Mr. Rajiv Tiwari, Consultant, Strategic Information (R&E and Data)
- 24. Mr. Anuj Kumar, Associate Consultant, Information Technology
- 25. Mr. Rahul Ahuja, Associate Consultant, Prevention
- 26. Mr. Arvind Kumar, Associate Consultant, Prevention
- 27. Dr. Hansa Lala, Associate Consultant, STI/RTI Management
- 28. Mr. M. Thirunavukkarasu, Associate Consultant, HIV Counselling and Testing Services
- 29. Ms. Parul, Associate Consultant, Information, Education and Communication
- 30. Ms. Suchi Gautam, Associate Consultant, Information, Education and Communication
- 31. Dr. Vishakha, Associate Consultant, Laboratory Services
- 32. Mr. Sanjay Verma, Associate Consultant, Prevention
- 33. Ms. Rachana Shukla Pandey, Associate Consultant, Prevention
- 34. Dr. Nidhi Priyam, Associate Consultant, Strategic Information (S&E)
- 35. Dr. Sandeep Dhoundiyal, Associate Consultant, Strategic Information (M&E)
- 36. Ms. Soumya Shukla, Associate Consultant, Laboratory Services
- 37. Dr. Samiksha Sharma, Associate Consultant, Prevention
- 38. Mr. Ajin Ayodh, Associate Consultant, HIV Counselling and Testing Services

II. State AIDS Control Societies

- 39. Mr. S. Senthil Nathan, Andaman & Nicobar SACS
- 40. Mr. Ganesh Debnath, Andaman & Nicobar SACS
- 41. Mr Vijay, Andhra Pradesh SACS
- 42. Mr. Balaji, Andhra Pradesh SACS

- 43. Mr. Sukumar, Andhra Pradesh SACS
- 44. Mr. Koj Tara, Arunachal Pradesh SACS
- 45. Ms. Nopnya Kamhua, Arunachal Pradesh SACS
- 46. Mr. Ranjanjyoti Deka, Assam SACS
- 47. Md Yasir Imam, Bihar SACS
- 48. Mr. Prabodh Kumar, Bihar SACS
- 49. Ms. Poonam Bakshi, Chandigarh SACS
- 50. Mr. Md. Hashim Khan, Chhattisgarh SACS
- 51. Mr. Kshitiz Diwan, Chhattisgarh SACS
- 52. Ms. Piyali Dey, Delhi SACS
- 53. Mr. Praveen Kumar, Delhi SACS
- 54. Mr. Sunilkumar Bais, DNH&DD SACS
- 55. Ms. Harshada Valvaikar, Goa SACS
- 56. Ms. Sulaksha Galyekar, Goa SACS
- 57. Mr. Praveen Gupta, Gujarat SACS
- 58. Mr. Janak Agaja, Gujarat SACS
- 59. Ms. Heena Modi, Ahmedabad MACS
- 60. Dr. Navneet Sarwal, Haryana SACS
- 61. Ms. Kavita, Haryana SACS
- 62. Mr. Vinay Agnihotri, Himachal Pradesh SACS
- 63. Dr. Lalit Thakur, Himachal Pradesh SACS
- 64. Mr. Imran Ahmad Rather, J&K SACS
- 65. Mr. Irfan Farooq Bhat, J&K SACS
- 66. Dr. Sami Akhter Shams, Jharkhand SACS
- 67. Dr. Sanjay B. Patil, Karnataka SACS
- 68. Mr. Sadashiv Havanagi, Karnataka SACS
- 69. Mr. Kannan R, Kerala SACS
- 70. Ms. Ragi Ravi, Kerala SACS
- 71. Dr. Adarsh Mahesh Shukla, Madhya Pradesh SACS
- 72. Dr. Shivani Vaidya, Madhya Pradesh SACS
- 73. Dr. Rahul Jadhav, Maharashtra SACS
- 74. Mr. Imran Shaikh, Maharashtra SACS
- 75. Mr. Pradeep Sonavane, Maharashtra SACS
- 76. Dr. H. Teressa, Manipur SACS
- 77. Ms. Paonam Tilotama Devi, Manipur SACS
- 78. Ms. L. Radhabino Devi, Manipur SACS
- 79. Ms. Safeeda G Warjri, Meghalaya SACS
- 80. Mr. Herman Nadon, Meghalaya SACS
- 81. Mr. J. Vanlalhruaia, Mizoram SACS
- 82. Mr. Thurochami, Mizoram SACS
- 83. Dr. Richard CLR Hluna, Mizoram SACS
- 84. Mr. Anil Shinde, Mumbai DACS
- 85. Mr. Amit Afre, Mumbai DACS
- 86. Mr. Shashi Patil, Mumbai DACS
- 87. Mr. Medovilhou Kire, Nagaland SACS
- 88. Mr. Avilie Sekhose, Nagaland SACS
- 89. Mr. Prabodh Kumar Siya, Odisha SACS
- 90. Mr. Santanu Prusty, Odisha SACS
- 91. Mr. T. Balamurugan, Puducherry SACS

- 92. Mr. R. Abinesh, Puducherry SACS
- 93. Dr. Amrinderpaul Singh, Punjab SACS
- 94. Ms. Dolly Khurana, Punjab SACS
- 95. Mr. Prakash Narwani, Rajasthan SACS
- 96. Mr. Dheeraj Sharma, Rajasthan SACS
- 97. Mr. Gyan Tamang, Sikkim SACS
- 98. Mr. Balaram Thapa, Sikkim SACS
- 99. Dr. K. Vaishnavi, Tamil Nadu SACS
- 100. Ms. M. Parkavi, Tamil Nadu SACS
- 101. Mr. Karthikeyan, Tamil Nadu SACS
- 102. Mr. T. Durga Srinivas, Telangana SACS
- 103. Mr. A Bheemewar Reddy, Telangana SACS
- 104. Ms. Srabani Datta, Tripura SACS
- 105. Mr. Tamal Deb, Tripura SACS
- 106. Mr. Arindam Kumar Singh, Uttar Pradesh SACS
- 107. Mr. Awnish Kispotta, Uttar Pradesh SACS
- 108. Mr. Gagandeep Luthra, Uttarakhand SACS
- 109. Mr. Vinod Kumar, Uttarakhand SACS
- 110. Dr. Rahul Biswas, West Bengal SACS
- 111. Dr. Debjani Guchhait, West Bengal SACS
- 112. Mr. Rupam Mishra, West Bengal SACS
- 113. Mr. Dhurubotara Naskar, West Bengal SACS

III. SOCH Project team

- 114. Mr. Neeraj Singh Mehta, SOCH Project
- 115. Mr. Varinder Singh, SOCH Project
- 116. Mr. Gourav Pundir, SOCH Project
- 117. Mr. Vivek Singh Mahar, SOCH Project

IV. Technical Support

- 118. Mr. Lalit S. Kharayat
- 119. Dr. Mahesh Mhetre
- 120. Mr. Samresh Kumar
- 121. Ms. Gunjan Pandey
- 122. Mr. Dew Stanley
- 123. Mr. Prashant Patra
- 124. Mr. Abraham Lincoln
- 125. Dr. Upma Sharma
- 126. Mr. Haresh Patel
- 127. Mr. Abin Khungur Ganlary
- 128. Mr. Amol Palkar
- 129. Mr. Utpal Das
- 130. Ms. Ira Madan
- 131. Dr. Nikhil Patil
- 132. Mr. Ganesh Kumar

CONTENT



ARRI	REVIATIONS	/
EXE	CUTIVE SUMMARY2	! 0
1.	INTRODUCTION	<u>26</u>
	1.1. Background2	27
	1.2. Organisation of the Report2	27
2.	STATUS OF THE EPIDEMIC	10
	2.1. Background3	1
	2.2. Overview3	31
	2.3. State/UT-wise levels and trends4	2
	2.4. Vertical HIV transmission5	6
3.	PROGRESS ON 95-95-955	8
	3.1. Background5	9
	3.2. Method5	9
	3.3. National Progress6	0
	3.4. State/UT-wise progress6	0
4.	IEC, YOUTH & MAINSTREAMING6	4
	4.1. IEC6	5
	4.2. Social Media6	5
	4.3. National Toll-Free AIDS Helpline 10976	6
	4.4. Operational Highlights for 2023-246	6
	4.5. Emerging Trends and Observations6	7
	4.6. Strategic Outlook for the Future6	7
	4.7. Youth Intervention6	8
	4.8. Adolescence Education Programme (AEP)6	9
	4.9. Status of implementation of the HIV and AIDS (Prevention & Control) Act 20177	'0
5.	PREVENTION OF NEW HIV AND STI INFECTIONS AMONG HIGH-RISK GROUPS AND BRIDGE POPULATION	′2

	5.1. Background	73
	5.2. Coverage of HRG and bridge population through TI projects: An overview	75
	5.3. FSW coverage through TI projects	76
	5.4. MSM coverage through TI projects	79
	5.5. H/TG persons coverage through TI projects	81
	5.6. PWID coverage through TI projects	83
	5.7. Opioid Substitution Therapy (OST) for PWID	84
	5.8. Migrants coverage through TI projects	87
	5.9. Truckers coverage through TI projects	87
	5.10. Prison Intervention	90
	5.11. Link Workers Scheme (LWS	91
6.	MANAGEMENT OF SEXUALLY TRANSMITTED INFECTIONS / REPRODUCTIVE TRACT INFECTIONS	95
	6.1. Background	95
	6.2. STI/RTI Service Delivery Model under NACP	96
	6.3. Clinic visit for STI/RTI services	97
	6.4. Average number of clients visit per day per DSRC	97
	6.5. Syndromic Case Management	98
	6.6. Laboratory Diagnosis at DSRC	100
7.	HIV COUNSELING AND TESTING SERVICES	102
	7.1. Background	103
	7.2. HIV Counselling and Testing Service (HCTS) Facilities	103
	7.3. HCTS Uptake	104
	7.4. Risk assessment	107
	7.5. HIV Sero-positives and Yield trends	107
	7.6. Gender difference in HIV testing	108
	7.7. Spouse/Partner testing among HIV positive detected	109
	7.8. Sampoorna Suraksha Kendra	110
8.	INITIATION AND RETENTION ON ART	112
	8.1. Background	113
	8.2. Facilities	113
	8.3. On-ART PLHIV	114
	8.4. ART initiation and retention	116
	8.5. Differentiated Care Mode	119

9.	HIV-TB CO-INFECTION MANAGEMENT	122
	9.1. Background	123
	9.2. TB Screening and Referral	123
	9.3. Pulmonary and Extra Pulmonary TB cases	124
	9.4. HIV-TB Co-infection management	125
	9.5. TB preventive Therapy among PLHIV	127
10.	LABORATORY SERVICES	130
	10.1. Background	131
	10.2. Viral load testing	131
	10.3. CD4 testing	132
	10.4. Quality Management under NACP	134
	10.5. Accreditation	137
	10.6. Certificate of Excellence to ICTCs	138
	10.7. Early Infant Diagnosis (EID)	139
	10.8. Sexually Transmitted Infection (STI)	139
11.	ELIMINATION OF VERTICAL TRANSMISSION OF HIV AND SYPHILIS (EV	/THS)142
	11.1. Background	143
	11.2. ANC registration, HIV and Syphilis Testing	143
	11.3. Treatment Coverage among infected pregnant women	146
	11.4. Management of Babies exposed to HIV and/ or Syphilis infection	140
12.	SCORECARD	156
	12.1 Background	157
	12.2 Methodology	157
	12.3 Performance of SACS in Programme Implementation	161
13.	FACTSHEETS	164

ABBREVIATIONS

1HP	Daily isoniazid and Rifapentine for one month
45	
	4 Symptoms TB screening
AAP	Annual Action Plan
AEP	Adolescence Education Programme
AIDS	Acquired Immunodeficiency Syndrome
AIIMS	All India Institutes of Medical Science
AIR	All India Radio
ANC	Antenatal Care
ANI	Andaman and Nicobar Islands
ANM	Auxiliary Nurse and Midwife
ARD	Anorectal discharge
ARTC	Antiretroviral Therapy Centers
ART	Antiretroviral Therapy
ARV	Antiretroviral Drugs
ATT	Anti-TB treatment
BPG	Benzathine Penicillin G
CARG	Community ART Refill Groups
СВО	Community-Based Organizations
CD4	Cluster of differentiation 4
CHC	Community Health Centers
CHLIV	Children living with HIV
CoE	Centres of Excellence
CPT	Cotrimoxazole preventive therapy
CQI	Continuous Quality Improvement
CSC	Care Support Centers
CST	Care Support and Treatment
СТС	Counselling and Testing center
DACS	District AIDS Control Society
DIC	Drop-In Center
DNHⅅ	Dadra Nager Haveli and Daman Diu
DSRC	Designated STI&RTI Clinics
EID	Early Infant Diagnosis
EQA	External Quality Assessment
EVTHS	Elimination of Vertical Transmission of HIV and Syphilis
FM	Frequency Modulation
FSW	Female Sex Workers
GUD-H	
	Genital ulcer disease – herpetic
GUD-NH	Genital ulcer disease – non herpetic
H/TG	Hijra /Transgender
HBV	Hepatitis B virus

HCV	Hepatitis C virus
HCTS	HIV Counselling and Testing Service
HIV	Human Immunodeficiency Virus
HMIS	Health Management Information System
HRG	High-Risk Groups
HSS	HIV Sentinel Surveillance
IB	Inguinal bubo
ICF	Intensified Case findings
ICMR	Indian Council for Medical Research
ICTC	Integrated Counselling and Testing Center
IDU	Injected Drug users
IHC	Integrated Health Campaign
IMR	Incidence Mortality Ratio
IPC	Interpersonal Communication
IPR	Incidence prevalence ratio
IPT	Isoniazid Preventive Therapy
ISHTH	Integrated STI, HIV, Tuberculosis and Hepatitis
JWG	Joint Working Group
KK	Kshamta Kendras
LAC	Link Antiretroviral Therapy Centers
LAP	Lower abdominal pain
LFU	Lost to Follow-up
LTBI	Latent TB infection
LWS	Link Worker Scheme
M&E	Monitoring and Evaluation
MMD	Multi-month dispensing
MO	Medical Officers
MSM	Men who have Sex with Men
MTB	Mycobacterium Tuberculosis
MTCT	Mother to Child transmission of HIV and Syphilis
NACO	National AIDS Control Organisation
NACP	National AIDS and STD Control Programme
NARI	National AIDS Research Institute
NCD	Non-communicable diseases
NCERT	National Council of Educational Research and Training
NGO	Non-Governmental Organizations
NHM	National Health Mission
NICED	National Institute of Cholera and Enteric Diseases
NIMHANS	National Institute of Mental Health & Neuro Science
NIRT	National Institute for Research in Tuberculosis
NITVAR	National Institute of Translational Virology and AIDS Research
NMC	National Medical Commission
NRL	National Research Laboratories
NTEP	National Tuberculosis Elimination Programme
NPSVH	National Programme for Surveillance of Viral Hepatitis
OI	Opportunistic Infection
ORW	Outreach Workers
OSC	One Stop Center
OST	Opioid Substitution Therapy
001	Spisia substitution merupy

P&OCS	Prison and Other closed Settings
PHC	Primary Health Centre
PIP	Project Implementation Plan
PLHIV	People Living with HIV
PMPSE	Programmatic Mapping and Population Size Estimation
PMTCT	Prevention of Mother to Child transmission of HIV
PMSMA	Pradhan Mantri Surakshit Matritva Abhiyan
PPP	Public private partnership
PPTCT	Prevention of Parent-to-Child Transmission
PPW	Positive Pregnant women
PSS	Painful scrotal swelling
PWID	People who Inject Drugs
QMS	Quality Management System
RCH	Reproductive and Child Health
RDT	Rapid Diagnostic Test
RPR	Rapid Plasma Reagin
RRC	Red Ribbon Club
RSTRRL	Regional STI Training, Research & Reference Laboratories
RTI	Reproductive Tract Infection
SACS	State AIDS Control Societies
SC	Sub-centres
SA-ICTC	Stand Alone Integrated Counseling and Testing Center
SBCC	Social and Behaviour Change Communication
SDG	Sustainable Development Goal
SDNS	Secondary distribution of Needle and Syringes
SMM	Single Male Migrant
SNCU	Special Newborn Care Unit
SOCH	Strengthening Overall care for HIV beneficiaries
SPD	State Prison Department
SRC	State STI training and Reference Laboratory
SRL	State Research Laboratories
SSK	Sampoorna Sureksha Kendra
SSS	Sampoorna Suraksha Strategy
STD	Sexually Transmitted Diseases
STI	Sexually Transmitted Infection
TAT	Turn Around Time
ТВ	Tuberculosis
TI	Targeted Intervention
TNA-PCR	Total Nucleic Acid-Polymerase Chain Reaction
TPT	TB preventive treatment
UNAIDS	Joint United Nations Programme on HIV/AIDS
UD	Urethral discharge
UT	Union Territories
VCD	Vagino cervical discharge
VDRL	Venereal Disease Research Laboratory
VHSND	Village Health Sanitation and Nutrition Days
VL	Viral Load
WCD	Women and Child Development
WLHIV	Women Living with HIV



EXECUTIVE SUMMARY

- 1. India's efforts to combat HIV/AIDS have been characterized by years of government commitment, concerted initiatives, strategic and steadfast resilience. interventions. "Sankalak: Status of National AIDS and STD Response" is the flagship annual publication that highlights the achievements under the National AIDS and STD Control Program. Its main goal is to present a clear, data-driven overview of India's current progress in HIV/AIDS and STDs response, thereby providing evidence to inform future strategies. The latest edition, the sixth in the series, reflects progress up to 2023-24.
- 2. HIV epidemic continues to maintain a low level nationally with an estimated adult HIV prevalence of 0.20% (0.17-0.25) and around 25.44 lakh (21.68-30.38) people living with HIV (PLHIV) in 2023. Globally, adult HIV prevalence is higher at 0.70% with approximately 3.99 crore PLHIV. The continued low prevalence nationally is outcome of years of sustained and comprehensive evidence-driven response. New infections in 2023 are estimated at almost 44% lower than in 2010, while AIDS-related deaths declined by 79%. Globally, new infections fell by 39% and AIDS-related deaths by 51% between 2010 and 2023.
- 3. It is important to remain vigilant, sustaining and expanding evidence-driven high-impact interventions. Despite a lower national prevalence, HIV rates in Mizoram (2.73%), Nagaland (1.37%), and Manipur (0.87%) significantly exceed the national average. New infections are rising in Tripura, Arunachal Pradesh, Meghalaya, Assam, and Punjab. Notably, from 2010 to 2023, new infections in Tripura and Arunachal Pradesh surged by over 400%, and doubled in Punjab and Meghalaya. Injecting drug use is the main transmission route in these states, accounting for 61-77% of newly detected cases in Assam, Arunachal Pradesh, Punjab, and Tripura in 2023-24.
- 4. HIV prevalence remains very high among key populations such as migrants, truckers, female sex workers (FSW), prison inmates, men who

- have sex with men (MSM), hijra/transgender (H/TG) person and, people who inject drugs (PWID). These groups experience HIV rates 9-43 times higher than the general adult population. According to a 2021 report by the National Centre for Disease Control (Directorate General of Health Services) based on HIV sentinel surveillance under NACP, HBV seroprevalence ranges from 0.95% in FSW to 3.09% in PWID, whereas HCV seroprevalence varies from 0.67% in migrants to 33.41% in PWID.
- 5. The Government, along with various stakeholders, responded with a series of initiatives in 2023-24 aimed at addressing the epidemic's multifaceted nature. Specifically, local intelligence-based integrated health campaigns (IHC) for 'at-risk' population and integrated STI, HIV, TB and Hepatitis (ISHTH) campaign for prisoners and inmates in closed settings reflected strong and tailored encompassing prevention, response, treatment, care, and support.
- 6. The number of PLHIV who are diagnosed, on treatment, and virally suppressed continues to rise. By March 2024, those aware of their status increased by 21%, from 17 lakh in March 2019 to 20.49 lakh. The number on ART grew by 28%, from 13.98 lakh to 17.95 lakh. An estimated 17.49 lakh PLHIV had suppressed viral loads as of March 2024.
- 7. As on March 2024, approximately 81% of PLHIV were aware of their status, 88% of whom were receiving ART, and 97% of those on ART achieved viral suppression. Globally, 86% knew their status, 89% were on ART, and 93% of those on ART were virally suppressed. Nationally, 71% of all PLHIV were on ART, and 69% achieved viral suppression. In Andaman & Nicobar Islands, Arunachal Pradesh, Assam, Bihar, Chhattisgarh, Haryana, Jammu & Kashmir and Ladakh, Manipur, Odisha, Puducherry, Sikkim, Tripura, Uttar Pradesh, and Uttarakhand, less than 70% of PLHIV were aware of their HIV status. In four States (Delhi, Arunachal Pradesh, Assam, and Chhattisgarh),

- less than 80% of PLHIV who know their HIV status were on-ART.
- 8. In 2023-24, the NACP provided coverage to approximately 1.44 crore individuals from key populations (including prison inmates, FSW, MSM, H/TG person, and PWID), bridge populations (such as migrants and truckers), and other vulnerable groups through various intervention strategies including peer-led targeted interventions (TI) and link worker scheme (LWS). This achievement marks the highest coverage of key and bridge population through TI in the history of NACP, reaching over 95% of the estimated population size for FSW, MSM, and migrants. Coverage for PWID and H/TG person stands at 90% and 91%, respectively, against their estimated sizes, compared to previous coverages of 72% and 68%. Number of PWID on opioid substitution therapy (OST) increased from 44.60 thousand on March 2023 to 54.20 thousand on March 2024. Overall, around 19% of estimated PWID were on OST as on March 2024. In 2023-24, approximately 13.72 lakh prison inmates were tested for HIV with overall HIV seropositivity rate of 0.48%, including those tested under the ISHTH campaign. This progress is almost twice of the testing done in 2021-22.
- 9. While the overall coverage of key and bridge populations through TI is increasing nationally, there remains potential for improvement. In Assam, FSW coverage was 39%, while MSM coverage was 36%. In Haryana, PWID coverage against size estimates was 51%, whereas the coverage of H/TG person in Himachal Pradesh was 20%.
- 10. During the year 2023-24, a total of 104.8 lakh STI/RTI clients were managed under the NACP, encompassing those treated at designated STI/RTI centres (DSRC), targeted intervention sites, as well as in prisons and other closed settings. Approximately 41.5 lakh samples underwent syphilis testing at DSRC, with an overall positivity rate of approximately 0.90%. The syphilis positivity rates at DSRC were reported to be 0.60% and 0.70% for the years 2021-22 and 2022-23, respectively.
- 11. Approximately 6.49 crore HIV tests were conducted in 2023-24, including 2.64 crore tests for pregnant women and around 3.85 crore tests among other clients.


- This represents the highest number of tests under the NACP since its inception. A total of 1,77,887 HIV-positive individuals were identified as a result of this testing. The HIV sero-positivity rate among pregnant women was highest in Nagaland (0.73%), followed by Mizoram (0.58%) and Meghalaya (0.25%). Among clients other than pregnant women, sero-positivity was highest in Mizoram (2.52%), followed by Assam (2.15%), Arunachal Pradesh (1.55%), Meghalaya (1.54%), Punjab (1.31%), Tripura (1.30%), and Nagaland (1.23%).
- 12. Spouse or partner testing is a strategy aimed at reducing the transmission of HIV infection. This approach involves testing all sexual or injection-sharing partners and biological children of individuals diagnosed with HIV (index cases) and linking HIV-positive individuals to treatment and care services. During 2023-24, spouse or partner testing coverage was at 36% with a seropositivity rate among partners at 43%. Andhra Pradesh (78%), Manipur (52%), Goa (51%), West Bengal (47%), DD (44%), Delhi (41%), Telangana (40%), DNH (39%), Jharkhand (39%), Uttar Pradesh and J&K (37%) reported higher coverage than the national average.
- 13. Many individuals at risk of HIV and STI may not see themselves as part of key populations. To reach these persons, NACO introduced the Sampoorna Suraksha Kendra (SSK) at 150 selected facilities in 150 districts across 20 States. By integrating STI services into the ICTC framework, a comprehensive approach provides sexual health and preventive services. This strategy has enrolled about 1.05 lakh at-risk negative clients for comprehensive prevention packages.
- 14. Around 93% of newly diagnosed HIV-positive persons were initiated on ART. However, in States/UT of Assam, Chandigarh, Delhi, Himachal Pradesh, Puducherry, and Sikkim, ART initiation ranged between around 47% in Puducherry and 76% in Assam. Overall, around 17.95 lakh PLHIV were on-ART as on March 2024 including around 1.06 lakh in private sector. Twelve months retention rate was as high as 93% in 2023-24. A total of around 1.69 lakh PLHIV were lost-to-follow up as on March 2024 vis-à-vis 1.80 lakh noted in March 2023.

- 15. Co-infections management is a critical need to reduce morbidities and mortalities among PLHIV. The population is aging with around 37% of total PLHIV estimated to be aged 50 years. The program focuses on HIV-TB co-infection management, with about 4% of PLHIV showing presumptive TB and 4-6% having TB among those tested. Over 99% of PLHIV with TB started anti-tuberculosis treatment. Additionally, higher seroprevalence rates of syphilis, HBV, and HCV are key concerns under NACP, with HCV prevalence among HIV-positive individuals ranging from 1.28% in pregnant women to 82.23% among PWID in 2021.
- 16. India has made significant progress in eliminating vertical transmission of HIV and syphilis under NACP-V goal 3. In 2023-24, about 19,100 HIV-positive pregnant women were identified, a 63% increase from 2020-21 and 38% from 2021-22. The resultant increase in treatment coverage reduced the vertical transmission rate from over 25% in 2020 to around 11.75% in 2023. Additionally, treatment coverage for syphilis-infected pregnant women increased from 78% in 2021-22 to around 90% in 2023-24.
- 17. Expanding the utilization of laboratory services while continuously maintaining and enhancing the quality of testing remains central to NACP-V's committed goal of reducing new HIV infections, AIDS-related mortalities, eliminating vertical transmission. promoting STI/RTI management. The viral load laboratory network has been expanded by incorporating 12 high-throughput viral load machines installed by Indian Council for Medical Research (ICMR) and collaborating with State governments to install viral load machines on a reagent rental basis, as seen in Mizoram and Nagaland. Approximately 54.4 lakh viral load tests were conducted cumulatively between 2018-19 and 2023-24 under NACP. Annual viral load tests have been

- increasing: 2.4 lakh in 2018-19, 10.3 lakh in 2021-22, 12.3 lakh in 2022-23 (including public-private partnerships), and 13.78 lakh in 2023-24 through both programmatic and non-programmatic labs.
- 18. To maintain reliable medical lab testing, NACP employs a robust external quality assessment (EQA) system and accreditation process using a four-tier structure. This involves strategies such as panel testing and re-testing/reverse testing. For HIV serology, the panel testing showed a concordance result of 99.6%, with discordance at around 0.03% in retesting. In 2023 and 2024, 64 out of 66 viral load laboratories achieved satisfactory results on EQA.
- 19. Setting clear targets and tracking their achievement are essential for an effective national public health response. Targets provide a framework for action and require regular monitoring to track progress, identify gaps, and make data-driven decisions. NACP-V has specific annual outputs and outcome targets that promote accountability and reinforce commitment, supporting efforts to address the AIDS epidemic. The table below summarizes the progress made against the committed targets in the first three years of NACP-V.

S	S Indicator		021-22	2	.022-23	2	023-24
No		Target	Achievement	Target	Achievement	Target	Achievement
Phy	sical and output targets						
1	No. of calls received at AIDS	5.3	4.88	6.1	4.77	6.7	4.77
	Helpline (1097) (In lakh)	5.5	4.00	0.1	4.77	6.7	4.77
2	No. of Targeted Interventions	1,663	1,512	1,735	1,543	1,808	1,577
	(TI)	1,005	1,512	1,733	1,040	1,000	1,577
3	No. of districts with the Link	165	146	175	168	185	191
	Worker Scheme (LWS)	100	110	170	100	100	101
4	No. of HRG, bridge and the vulnerable population						
	covered through TI/LWS (In	102.4	109.86	105.92	123.68	109.12	132.39
	lakh)						
5	No. of OST Centres						
	(excluding Satellite-OST	400	238	450	246	500	263
	centres)						
6	No. of IDU on OST (In lakh)	0.38	0.42	0.42	0.44	0.48	0.54
7	No. of 'Sampoorna Suraksha'	25	0	75	75	150	150
	Centres						
8	No. of contacts with 'at-risk'						
	population through	0.22	-	0.65	0.10	1.31	1.05
	'Sampoorna Suraksha' Centres (In lakh)						
9	No. of STI/RTI patients						
9	managed (In lakh)	100.16	50	106.7	99.27	112.1	104.88
10	No. of 'at-risk' population						
	(excluding pregnant women)	252	235	265	339.79	278	385.05
	tested for HIV (In lakh)						
11	No. of pregnant women	252	249	265	220 07**	270	262 70**
	tested for HIV (In lakh)	252	248	265	238.07**	278	263.70**
12	No. of pregnant women	176.4	169.4	190.8	208.65	205.72	256.03
	tested for Syphilis (In lakh)						
13	No. of ART Centres	597	664	627	712	657	775
14	No. of Link ART Centres	1294	1261	1324	1261	1354	1,307
15	No. of Care Support Centres	100	319	200	319	300	320
16	No. of PLHIV on ART	45.00	45.50	40.77	40.00	40.05	47.05
	(Cumulative)*	15.30	15.56	16.77	16.80	18.25	17.95
17	(In lakh) No. of viral load tests						
17	conducted among PLHIV on	11.0	10.32	13.50	12.30	16.0	13.78
	ART (In lakh)	11.0	10.52	13.30	12.50	10.0	13.70
Out	Outcome targets						
1	Estimated PLHIV who know			0.5			00 -
	their HIV status (%)	79	73.1	82	76.7	86	80.5
2	PLHIV who know their HIV	0.4	02.0	07	96.0	00	07.0
	status and are on ART (%)	84	83.8	87	86.2	90	87.6
3	PLHIV who are on ART and	84	84.8	87	93.1	90	>=95
	are virally suppressed (%)	04	04.0	07	90.1	90	/-90
4	Estimated pregnant women	84	84	88	81	93	87.3
	tested for HIV (%)	0 1	0 1		0 1		00

^{*}Including Private sectors; **Excluding repeat testing



INTRODUCTION



1.1. Background

In the endeavours to attain ending of AIDS epidemic as a public health threat by 2030, the utilization of data-driven reports has become an indispensable tool for monitoring and enhancing the effectiveness of the response. These reports serve as the backbone for evidence-based decision-making, allowing healthcare providers, policymakers, and stakeholders to gain accurate insights into the prevalence, trends, and impacts of the disease and the responses thereof. By integrating robust data collection and analysis, a data-driven approach ensures that resources are allocated efficiently, interventions are tailored to specific populations, and progress is meticulously tracked. The dynamic nature of AIDS and it's multifaceted challenges demand a responsive and informed strategy, where data serves as the compass guiding efforts towards eradication and improved quality of life for those affected.

India's response to the HIV/AIDS epidemic has been characterized by decades of dedicated efforts, strategic interventions, and unwavering resilience. "Sankalak: Status of National AIDS and STD Response" is a comprehensive document to provide a clear, data-driven overview of India's current position in combating HIV/AIDS and guide future strategies. The first edition was published in December 2017. Since then, five editions have been released as annual flagship publications of the National AIDS and STD Control Programme (NACP), coinciding with World AIDS Day. These publications serve as crucial evidence tools as well as aide-memoire for policymakers, program managers, healthcare providers, and other stakeholders, offering detailed analyses of the current status of the HIV/AIDS response. The current edition, the sixth in the series, aims to update progress through the year 2023-24.

1.2. Organization of the report

This report, as in previous rounds, is structured to guide the reader through a clear and logical progression of the epidemic's history, its present context, and the multifaceted responses it has elicited.

Chapter two provides an overview of the HIV/AIDS epidemic at national, State, and district levels, covering past trends and future projections. For the first time, it includes data on co-infections among key populations and PLHIV, based on NACP data and the 2021 report on Hepatitis B and C seroprevalence by the National Centre for Disease Control. It also updates progress toward eliminating vertical transmission of HIV.

Chapter 3 delves into national and States/UTs -level progress on the 95-95-95 indicators. It also details national treatment cascade progress using PLHIV size estimates as the denominator for all indicators and includes global progress for reference.

Chapter 4 details the progress in the Information, Education, and Communication (IEC) component, including the operation of the 1097 national helpline and the implementation of the HIV and AIDS (Prevention and Control) Act of 2017. Chapter 5 concentrates on the preventative measures taken to reduce new infections among high-risk groups and bridge populations through targeted intervention (TI) projects, link worker schemes (LWS), and initiatives within the prison system.

While Chapter 6 summarises, the progress made in the management of sexually transmitted


infections (STIs)/Reproductive Tract Infections (RTIs), Chapter 7 details the progress made under HIV counselling and testing services for 'at-risk' clients. The care, support and treatment services are covered in Chapter 8, whereas the management of HIV-TB co-morbidities is summarized in Chapter 9. This chapter builds upon the detailed data on HIV-TB co-infections documented under NACP and offers insights into the prevention, early detection, and subsequent treatment of TB/HIV, as well as the management of special cases involving TB/HIV.


Chapter 10 offers a comprehensive overview of the laboratory services, including viral load testing and external quality assessment. Chapter 11 details the progress achieved in eliminating vertical transmission of HIV and Syphilis. Chapter 12 provides the score sheet for each State/UT, evaluating their performance in the implementation of NACP across all components.

Subsequently, data on HIV epidemic level and response in 2023-24 is presented for India and by States/UTs. The importance of this factsheet as a ready reckoner cannot be overstated.

"Sankalak: Status of National AIDS and STD Response" is not merely a report; it is a testament to India's unwavering commitment to achieving the 2030 SDG goal of ending the HIV/AIDS epidemic as a public health threat, thereby ensuring a healthier future for all.

Figure 1.1. Chapters in the sixth edition of 'Sankalak'





STATUS OF THE EPIDEMIC



2.1. Background

The implementation of NACP Phase-V is at a critical juncture. The year 2023-24 marked the third year of the NACP Phase-V. Funded as a Central Sector Scheme until March 2026 with Rs 15,471.94 crore, NACP Phase-V aims to reduce new HIV infections and AIDS-related deaths by 80% from 2010 levels by 2025-26. Comprehensive strategic information, gathered through an integrated system of programme monitoring, surveillance and epidemiology, as well as research and evaluation, indicates that the country has continued to make progress in preventing new infections and AIDS-related deaths through an integrated approach to the prevention, detection, and treatment of HIV, STIs, and related co-infections during 2023-24. the year Nevertheless, challenges persist.

2.2. Overview

2.2.1. Global and national scenario

The HIV/AIDS epidemic in India is now in its fourth decade since the discovery of the first case in 1986. As the surveillance sites expanded, it soon became clear that the virus has spread to all States/UTs infecting various population groups.

To combat this growing epidemic, the NACP was launched in 1991. Currently, Phase-V is being implemented to guide the national response until 2025-26.

As a result of the sustained and comprehensive evidence-driven response, HIV epidemic continues to maintain a low level nationally with an estimated adult HIV prevalence of 0.20% (0.17-0.25) and around 25.44 lakh (21.68-30.38) people living with HIV (PLHIV) in 2023. Globally, adult HIV prevalence is higher at 0.70% with approximately 3.99 crore PLHIV (Table 2.1]ⁱ.

India's national HIV prevalence is comparable to that of the Asia and Pacific region but is lower than the prevalence rates in Thailand (1.10%), Papua New Guinea (1%), Myanmar (0.90%), Cambodia (0.50%), Fiji, Indonesia, Lao People's Democratic Republic (0.40% each), Malaysia, Philippines, and Vietnam (0.30% each). Despite the low prevalence, India's PLHIV size is second only to South Africa (around 77 lakh) on account of its population size. India has the highest PLHIV size in the Asia and Pacific region, contributing nearly 34% of the total PLHIV in the region.

Table 2.1. Overview of HIV epidemic: Global, Asia and the Pacific and India, 2023

Indicator	Global	Asia and the Pacific	India
Adult (15-49) prevalence	0.70% (0.60-0.80)	0.20% (0.20-0.20)	0.20% (0.17-0.25)
People living with HIV	3.99 crore (3.61-4.46)	67 lakh (61-75)	25.44 lakh (21.68-30.38)
HIV incidence	0.17 (0.13-0.21)	0.07 (0.06-0.08)	0.05 (0.03-0.08)
Annual new infections ⁱⁱ	13 lakh (10-17)	3 lakh (2.70-3.70)	0.68 lakh (0.46-1.07)
Change in annual new infections since 2010	-39.00%	-13.00%	-44.23%
Annual AIDS-related deaths	6.30 lakh (5-8.20)	1.50 lakh (1.10-2.00)	35.89 thousand (24.32-54.41)
AIDS mortality per 1000 population	0.08 (0.06-0.10)	0.03 (0.03-0.05)	0.026 (0.017-0.04)
Change in annual AIDS-related deaths Since 2010	-51.00%	-51.00%	-79.26%

i UNAIDS HIV Estimates 2024

ii HIV incidence as new infections per 1000 uninfected population


2.2.2. National-level trend

HIV/AIDS epidemic in India peaked during 1997-1998 at around 0.59%-0.60% and then started to decline (Figure 2.1). The adult prevalence declined to around 0.44% in 2005,


0.32% in 2010, 0.27% in 2015 and 0.22% in 2020. The PLHIV size hovered around 37 lakh at peak of the epidemic and then declined to around 32 lakh in 2005 and to around 27 lakh in 2010. Since 2013, the epidemic size is almost stable in the range between 25 lakh and 26 lakh.

Figure 2.1. Level and trend of adult HIV prevalence (in %) and PLHIV size (1990-2023)

A. Adult HIV Prevalence (1990-2023)




B. PLHIV Size Estimates



The epidemic trajectory aligns with new AIDS response measures implemented since 2014, such as test and treat and universal viral load testing, supported by the HIV and AIDS (Prevention and Control) Act, 2017. This era is notably backed by the Government of India, with the NACP Phase-V budget nearly 12 times that of FY 2014-15 and 1.63 times that of NACP Phase-IV Extension. About 93% of this budget comes from domestic

funds, emphasizing AIDS response as a public health priority aimed at keeping over 99.70% of the adult population HIV-free and improving the quality of life for those affected. In 2023, integrated health campaigns for HIV, syphilis, hepatitis B, and hepatitis C in targeted locations facilitated the detection of previously undiagnosed cases (Figure 2.2).

Figure 2.2. Ten years of game changers (2014-2023)



The increase in treatment services resulted into prevention of new HIV infections and reductions of AIDS-related deaths among PLHIV (Figure 2.3). According to India's 2023 HIV estimates, around 68.50 thousand people were newly infected with HIV, and 35.90 thousand died from AIDS-related death that year. This equates to approximately

188 new infections and 98 deaths daily. New infections in 2023 are almost 44% lower than in 2010, while AIDS-related deaths declined by 79%. Globally, new infections fell by 39% and AIDS-related deaths by 51% between 2010 and 2023 (UNAIDS 2024 Estimates).




Figure 2.3. New HIV infections, deaths and PLHIV size, 1981-2023


Consolidating prevention and scaling up treatment services has resulted in nearly equal number of new HIV infections and deaths among PLHIV. The incidence mortality ratio (IMR), the ratio of new HIV infections to the number of people living with HIV who die per year, has been hovering around 1.15 since 2019. Incidence prevalence ratio (IPR), the ratio of new HIV infections to the number of PLHIV, has been declining in the country and stands at 2.69 in 2023.


IPR and IMR are essential metrics for monitoring the HIV epidemicⁱⁱⁱ. An IPR below 3 indicates a

declining epidemic, while maintaining this threshold will lead to elimination. An IMR above 1 means the population of PLHIV is growing; below 1, it shrinks. Nationally, India's IPR is under 3, but its IMR is slightly above 1 and with an upward trajectory in recent past indicating decline in annual new infections is slower than that of mortalities among PLHIV (Figure 2.4). Accelerating prevention efforts is crucial to reducing IMR below 1, signalling positive epidemic trends towards attainment of 2030 end goal.

iii Ghys PD, Williams BG, Over M, Hallett TB, Godfrey-Faussett P. Epidemiological metrics and benchmarks for a transition in the HIV epidemic. PLoS medicine. 2018 Oct 25;15(10):e1002678.

Figure 2.4. HIV epidemic transition in India, 2000-2023





2.2.3. Aging HIV epidemic

With the significant decline in AIDS-related mortality due to the widespread availability and rapid increase in uptake of antiretroviral treatment (ART), HIV has transitioned into a manageable chronic condition, enabling individuals with HIV to live long and healthy lives—a phenomenon often referred to as the greying of the epidemiciv. However, this success introduces new challenges, particularly concerning comorbid conditions and the risks associated with polypharmacy.


The HIV/AIDS epidemic in India follows global trends (Figure 2.5). The demographics of the HIV epidemic have evolved since the introduction of the ART program under NACP. The number of people living with HIV (PLHIV) aged 50 and above

has shown a steady increase since 2010. In 2000 and 2005, approximately 17% of the total estimated PLHIV were within the age group of 50 and above. By 2010, this proportion had risen to about 19.5% (approximately 5,26,000 PLHIV). Comparatively, in 2023, around 37% (9,44,000 PLHIV) of the total estimated PLHIV were aged 50 years or older.

HIV infection is linked to chronic comorbidities such as cardiovascular disease, osteoporosis, chronic renal diseases, and geriatric syndromes. These challenges are exacerbated as individuals with HIV age. The NACP is addressing these comorbidities by strengthening linkages and referrals with other national programmes to enhance the quality of care and reduce morbidity and mortality among PLHIV.

iV Weinstein ER, Lee JS, Mendez NA, Harkness A, Safren SA, El-Sadr W. HIV/AIDS and aging: The new frontier for HIV/AIDS research and care. AIDS. 2021 Oct 1;35(12):2043-5.

Figure 2.5. Age-sex-wise percent distribution of HIV-infected persons, 1990-2023




2.2.4. Routes of transmission

Understanding the probable routes of transmission is not only critical to characterise the HIV/AIDS epidemic and understand the change in transmission dynamics, if any, but also to tailor the responses. The self-reported route of transmission by newly diagnosed PLHIV is key data source to provide the information on transmission dynamics under NACP.

In 2023-24, a total of 1,64,807 newly diagnosed HIV positive cases were reported in IT-enabled routine programme monitoring information management system (SOCH). In around 5% of the cases (8,482), route of transmission was not reported.

Out of total 1.56.325 cases for which route of transmission was mentioned, around three-fourth (75%) of the cases were through heterosexual route: 15% through commercial partner, 32% through non-commercial/non-regular casual partner and 27% through regular partner. Around 12% (19,490) infections were reported to be acquired though infected needles/syringes. Around 5% (7,302) were through homosexual / bisexual route followed by 3% as vertical transmission and 1% through blood and blood products. In around 4% cases, route of transmission was reported 'not specified/unknown'.

Figure 2.6. Proportional distribution of newly detected HIV positive cases by route of transmission (self-reported), 2023-24



The HIV transmission pattern is evolving as share of transmission through infected needles/syringes increases in total transmission. In 2017-18. Less than 3% of total new detections (1,80,900) were reported to happened through infected needles/syringes which increased to around 5.6% in 2019-20 (1,67,967) and stands at 12% in 2023-24°. HIV transmission probability through

needle-sharing injection drug use is much higher than that of heterosexual route^{vi}. The rising proportion and cases of HIV transmission through infected needles/syringes underlines need to scale-up and maintain high-intensity coverage among people who inject drugs (PWID) and their injecting/sexual partners.


2.2.5. HIV Epidemic Among Key Population

HIV epidemic in India continues to be concentrated in nature with much higher prevalence and incidence reported among key population than the rest. As per HIV sentinel surveillance (HSS) 2021 and 2023, HIV prevalence among migrants, truckers, female sex worker

(FSW), prison inmates, men who have sex with men (MSM), hijra/transgender (H/TG) person and PWID is 9-43 times of the overall adults (15-49) prevalence (Figure 2.7).


Figure 2.7. HIV prevalence (%) and incidence (per 1000 uninfected population) in different population groups, 2021 and 2023

A. HIV prevalence (%), 2021 and 2023



As evident, PWID continues to have most elevated risk of HIV infection. While lower HIV prevalence have been noted among FSW and MSM in recent HSS rounds vis-à-vis levels seen in 2007/2009, HIV prevalence continues to be recorded at a much higher levels. In-fact, the data indicates that prevalence among PWID has appeared between 2017 and 2021. This data is consistent with rising cases being reported through infected needles/syringes as explained in previous section.

B. Estimated HIV incidence, 2023



Higher HIV sero-positivity among PWID is also reflected among the testing data from targeted intervention (TI) projects. While sero-positivity among FSW is hovering around 0.10%, among MSM around 0.30% and among H/TG people around 0.40%, the seropositivity among PWID has been around 1% during April'17 to March'22 and has increased to 2% during the period of April-September 2023. Some of the recent rise seen among the PWID may also be attributed to tailored programmatic strategies like expansion of TI projects' coverage among PWID and integrated health campaigns. Still, much higher risk of HIV among PWID remains a cause of concern.

V. National AIDS Control Organization (2020). Sankalak: Status of National AIDS Response (Second edition, 2020). New Delhi: NACO, Ministry of Health and Family Welfare, Government of India.

Vi. Patel P, Borkowf CB, Brooks JT, Lasry A, Lansky A, Mermin J. Estimating per-act HIV transmission risk: a systematic review. Aids. 2014 Jun 19;28(10):1509-19.






Figure 2.8. HIV prevalence among key population, 2007,2009, 2011, 2017 and 2021





2.2.6. Related infections


Infections such as tuberculosis (TB), hepatitis B (HBV), hepatitis C (HCV), and syphilis are relevant to the AIDS response due to their occurrence among key populations and co-infections among people living with HIV (PLHIV). TB is a major cause of illness and death among PLHIV. Both HBV and HCV share transmission routes with HIV and have a higher impact on key populations compared to other groups. Additionally, there is a documented higher prevalence of syphilis among key populations and PLHIV^{vii}.

Eligible PLHIV are screened for TB through 4-S in each of the visit to the anti-retroviral treatment (ART) centre as a part of routine service delivery activity under NACP. In 2023-24, on an average, around 10.83 lakh PLHIV were monthly screened

(97% of total monthly visits by PLHIV) for TB in 2023-24 vis-à-vis around 8.95 lakh average monthly screening in 2022-23 and 8.35 lakh monthly screening in 2021-22. Among screened PLHIV, % PLHIV with presumptive TB hovered around 4% monthly in 2023-24. During the period of April'21 to March'24, this had been in range of 4% to 6% (Figure 2.10).

PLHIV with presumptive TB are then tested for TB. In 2023-24, out of total of 5,20,717 PLHIV identified with presumptive TB, around 88% were tested for TB. In 2021-22 and 2022-23, around 80% and 85% of PLHIV with presumptive TB were tested for TB. Out of those tested for TB, overall, around 5.79% of the PLHIV (26,557) were found to have TB in 2023-24 vis-à-vis around 7.20% and 7.00% noted in 2021-22 and 2022-23 respectively.






Vii. Consolidated guidelines on HIV, viral hepatitis and STI prevention, diagnosis, treatment and care for key populations. Geneva: World Health Organization; 2022. Licence: CC BY-NC-SA 3.0 IGO.

4-S screening, testing and treatment at TI projects is core to the national framework for joint HIV/TB collaboration framework between NACP and National Tuberculosis Elimination Programme (NTEP). Percent of diagnosed TB cases among key and bridge population tested for TB in 2023-24 ranged from 0.88% among FSW to 2.55% among migrants. Overall, a declining trend has been

noted in % diagnosed TB among those tested since 2021-22 (Figure 2.11). However, relatively higher % diagnosed cases among PWID and migrants remains a cause of concern and calls for further augmentation of intensified case findings among these population group.

Figure 2.11. Key and bridge population diagnosed with TB (In %), 2021-22 to 2023-24 $\,$



In the 2021 round of HSS, samples were tested for hepatitis B and hepatitis C across all eight population groups in collaboration with the National Programme for Surveillance of Viral Hepatitis (NPSVH). As in previous HSS rounds, tests for syphilis were conducted among samples collected from pregnant women and the prison population.

HIV-infected individuals across all surveillance population groups in India exhibited higher prevalence rates for syphilis, HBV, and HCV. While the seropositivity among total pregnant women and prisoners recruited in HSS 2021 was 0.10%

and 0.34% respectively, the seropositivity rate for syphilis among HIV-positive pregnant women and prisoners was 1.84% and 1.00% respectively. Similarly, the seroprevalence of HBV among HIV-positive pregnant women and prisoners was noted at 1.06% and 7.75% respectively. The seroprevalence for HCV among HIV-positive respondents in the 2021 round ranged from 1.28% in pregnant women to 82.23% among PWID. According to the report published by NPSVH, the seroprevalence for HBV ranged from 0.85% in pregnant women to 3.09% in PWID, while that for HCV ranged from 0.29% in pregnant women to 33.41% in PWID (Table 2.2).

National Program for Surveillance of Viral Hepatitis. Seroprevalence of Hepatitis B and Hepatitis C (HIV Sentinel Surveillance Plus 2021, round 17): Report. National Centre for Disease Control. Directorate General of Health Services. Ministry of Health and Family Welfare; 2023.

Table 2.2 Prevalence/Sero-positivity of HIV and related infections among various population groups, HSS 2021

							0	- -	•		 			
	≥H		Syphilis		Hep B		Hep C		HIV-Syphilis	ilis	-∕IIH	HIV-Hep B	Ī	HIV-Hep C
Population Groups	z	%	z	%	z	%	z	%	Z	%	Z	%	z	%
All Respondents														
Pregnant Women	3,38,890	0.22	3,09,467	0.10	3,38,633	0.85	3,38,883	0.29	3,09,467	0.004	889'88'8	0.002	3,38,883	0.003
Migrants	8,276	0.89	1	1	8,268	2.02	8,268	0.67			8,268	0.05	8,268	0.05
Truckers	8,428	-	,	ı	8,420	1.44	8,420	1.26		ı	8,420	0.05	8,420	0.1
FSW	60,131	1.85	1	ı	29,686	0.95	29,686	0.93		ı	29,686	0.04	29,686	0.17
Prisoners	20,695	1.93	19,895	0.34	20,696	1.89	20,696	4.75	19,895	0.019	20,695	0.15	20,695	1.07
MSM	24,393	3.26	,	1	24,338	1.36	24,338	1.03		ı	24,338	0.16	24,338	0.19
H/TG people	4,679	3.78	ı		4,647	0.97	4,647	0.41		1	4,647	0.09	4,647	0.06
PWID	26,755	9.03	1		26,639	3.09	26,638	33.41		1	26,639	0.62	26,638	7.45
HIV-positive respondents	lents													
Pregnant Women		ı	681	1.84	746	1.06	746	1.28		1	1	1		ı
Migrants		1	1	1	74	5.41	74	5.41		ı	1	1		
Truckers	,	1	1	1	84	4.76	84	9.52				1		,
FSW		1	1	1	1,112	2.17	1,112	90.6	ı	1	ı			,
Prisoners	,	1	384	1.00	399	7.75	399	55.25	1	1	ı	1		
MSM	,	ı	,	ı	786	4.79	786	5.80	ı	ı	1	1		
H/TG people		Î		ı	177	2.30	177	1.72		ı		1		ı
PWID	-	-		-	2,416	6.84	2,416	82.23		-	-	1		-


2.3. State/UT-wise epidemic levels and trends


2.3.1. Epidemic levels

India's overall HIV/AIDS prevalence is low, but it varies significantly by States/UTs in terms of magnitude and direction (Table 2.3). Mizoram has the highest estimated adult HIV prevalence at 2.73%, followed by Nagaland at 1.37% and Manipur at 0.87% (Figure 2.12). Andhra Pradesh (0.62%), Telangana (0.44%), Meghalaya (0.43%), Karnataka (0.42%), and Punjab (0.42%) also have higher rates. Other States/UTs with prevalence above the national average of 0.20% include Tripura, Delhi, Goa, Maharashtra, Chandigarh,

Figure 2.12. Adult HIV prevalence (%), 2023

Arunachal Pradesh, Haryana, and Tamil Nadu. Overall, six States in the northeastern India has adult HIV prevalence higher than the national average including three with the highest prevalence. The States/UTs of Gujarat, Puducherry, Dadra & Nagar Haveli & Daman & Diu (DNH&DD), Chhattisgarh, Andaman and Nicobar Islands, Bihar, Assam, Uttarakhand, Rajasthan, Odisha, Himachal Pradesh, Sikkim, Uttar Pradesh, and Madhya Pradesh had an estimated adult prevalence within the range of 0.10% to 0.20%. West Bengal, Jharkhand, Jammu and Kashmir, and Kerala had adult HIV prevalence of less than 0.10%.







Maharashtra has the highest number of PLHIV in India, with 3.90 lakh cases, followed by Andhra Pradesh (3.20 lakh) and Karnataka (2.80 lakh). Uttar Pradesh, Tamil Nadu, Telangana, Bihar, Gujarat, and Punjab each have over 1 lakh PLHIV cases, together accounting for 74% of India's total. Five of these States are from erstwhile high prevalence States in southern and western India

but also includes States in northern (Punjab), central (Uttar Pradesh) and eastern (Bihar) India. Rajasthan, West Bengal, Madhya Pradesh, Delhi, and Haryana have between 0.50 lakh and 1 lakh cases, making up 14%. The remaining 20 States/UTs have less than 0.50 lakh PLHIV each, collectively representing 12% of the total burden (Figure 2.13).

Figure 2.13. PLHIV size (In lakh), 2023






Mizoram had the highest estimated HIV incidence per 1,000 uninfected population at 1.02, followed by Nagaland (0.46), Tripura (0.32), Meghalaya (0.28), Arunachal Pradesh (0.23), Manipur (0.22), and Punjab (0.30). Delhi, Haryana, Telangana,

DNH&DD, Chandigarh, Andhra Pradesh, Bihar, Goa, Assam, and Puducherry also had rates above the national average of 0.05. Seventeen other States/UTs had an incidence rate below 0.05 (Figure 2.14).

Figure 2.14. States/UTs-wise HIV incidence per 1,000 uninfected population, 2023



Status of the Epidemic

In 2023, seven states had over 3000 new HIV infections: Punjab (9.10 thousand), Bihar (8.27 thousand), Uttar Pradesh (7.84 thousand), Maharashtra (4.44 thousand), Andhra Pradesh (3.51 thousand), Rajasthan (3.36 thousand), and Karnataka (3.18 thousand), accounting for 58% of the total estimated annual new infections (ANI) in

India (Figure 2.15). States with 1000 to 3000 estimated ANI included Telangana, Haryana, Delhi, Gujarat, Assam, West Bengal, Tamil Nadu, Madhya Pradesh, Tripura, Chhattisgarh, Mizoram, Odisha, and Nagaland, representing 36% of new infections. The remaining 14 States/UTs made up the final 6%.




Figure 2.15. States/UTs-wise new HIV infections (In 1,000), 2023

2.3.1.1. District-wise HIV Prevalence (%), PLHIV Size, Annual New Infection and Incidence (Per 1000 uninfected population)


District-level HIV estimates (2023) have highlighted the significant diversity of the HIV epidemic in India. The findings reveals that 29 districts had adult HIV prevalence of 1% or higher with nearly all of these located in the northeastern states, except for one district in Karnataka. Additionally, there were 146 districts with an estimated 5,000 or more people living with HIV, with only one of these districts situated in the northeastern States.

The PLHIV number in the districts ranged between <100 and 54,000. One hundred and sixty-five districts (22% of total districts) in 18 States of the country had estimated PLHIV of 5,000 or more, comprising 64% of the total epidemic burden. Among the districts with 5,000 or more PLHIV, 24 districts were estimated to have PLHIV size of 15,000 or more (21% of total PLHIV). Almost two thirds (452) of the total districts in the country were estimated to have less than 2,500 PLHIV.

The annual new HIV infections in the districts ranged between <50 and 1,500, with around 90% of new infections in 340 districts. Ninety-five districts had 200 or more new HIV infections in 2023, comprising more than half (54%) of the new infections in the country. Another 104 districts had

new HIV infections in the range of \geq 100 to <200, comprising 21% of the total epidemic. Each of the rest of 563 districts had less than 100 new infections in 2023, comprising around 25% of total new infections.


Figure 2.16. District wise Prevalence (%), PLHIV Size, Annual New Infection and Incidence, 2023



2.3.1.2 District Prioritisation:

District prioritization 2023 showed a significant shift in the distribution of the epidemic across India. There were 192 high-priority districts in

Figure 2.17. District Prioritisation, 2023



2023, followed by 161 moderate priority, 183 low priority and 226 very low priority districts.

Districts Prioritization Category	Description	District (N=762)
High	Adult prevalence of ≥1% or PLHIV size of ≥5,000	192
Moderate	Adult prevalence of 0.4% - <1% or PLHIV size of 2,500 - <5,000	161
Low	Adult prevalence of 0.20% - <0.40% or PLHIV size of 1,000 - <2,500	183
Very Low	Adult prevalence of <0.20% or PLHIV size of <1.000	226

Table. 2.3. States/UTs wise HIV prevalence, incidence, mortality, PLHIV size, IPR and IMR, 2023

0.15 (0.08-0.33) 5.13 (266-1031) 0.05 (0.02-0.22) 0.02 (0.23-0.74) 320222 (282756-368070) 0.07 (0.04-0.11) 0.25 (0.21-0.32) 2465 (2073-3101) 0.23 (0.18-0.33) 0.16 (0.14-0.20) 1.55646 (132714-196039) 0.07 (0.05 (0.04-0.09) 0.16 (0.14-0.20) 1.55646 (132714-196039) 0.07 (0.05 (0.04-0.09) 0.16 (0.14-0.20) 1.55646 (132714-196039) 0.07 (0.05 (0.04-0.09) 0.16 (0.14-0.20) 1.55646 (132714-196039) 0.07 (0.05 (0.04-0.13) 0.16 (0.14-0.23) 1.752 (1351-2426) 0.07 (0.03-0.05) 0.13 (0.04-0.13) 0.13 (0.25-0.38) 5.8869 (17456-71876) 0.13 (0.09-0.13) 0.13 (0.09-0.13) 0.13 (0.12-0.23) 0.13 (0.12-0.23) 0.13 (0.12-0.23) 0.13 (0.09-0.13) 0.13 (0.09-0	20 (8-87) 3509 (2219-5753) 359 (278-502) 2021 (1260-3277) 8271 (6096-12456) 81 (40-278) 1252 (862-1583) 89 (51-154) 2710 (1811-3991) 96 (67-175) 2671 (1796-4490) 209 (144-292) 2898 (1995-3875) 744 (510-1145) 175 (90-340) 3175 (2104-4026)	53.49 3.90 76.08 1.10 -469.84 14.5 6.22.11 6.31 9.50 5.31 53.18 3.12 60.81 3.12 -67.92 5.08 21.83 4.60 4.95 2.15 56.86 2.22 61.01 2.65 61.01 2.65 77.94 3.13 77.11 2.62 77.13 2.62 77.14 2.62 77.11 2.62 77.11 2.62 77.13 2.62 77.14 2.62	2.46 (0.75-7.00) 1.004 (7.15-14.89) 1.40 (1.10-1.87) 1.41 (1.14-1.90) 1.42 (0.69-1.45) 1.43 (0.78-3.04) 2.2 3.29 (2.53-4.45) 2.3 3.29 (2.53-4.45) 2.4 3.29 (2.53-4.45) 2.5 3.29 (2.53-4.5) 2.6 0.97 (0.66-1.76) 2.7 1.13 (0.77-1.68) 2.8 0.87 (0.62-1.21) 2.9 0.80 (0.69-1.44) 2.9 0.80 (0.30-0.79) 2.1 (1.02 (0.69-1.44) 2.1 (1.02 (0.69-1.44) 2.2 (1.01 (0.48-1.96) 2.3 (2.81 (0.53-1.39)	10 (3-28) 5311 (3783-7876) 22 (17-29) 337 (243-513) 1838 (1435-2386) 17 (9-37) 984 (756-1332) 1026 (449-1929) 33 (24-57) 800 (547-1194) 64 (46-90) 305 (208-431) 194 (115-309) 137 (64-264)	86.26 86.26 -214.29 34.94 37.50 50.00 50.00 65.12 79.31 1.3.37 93.24 66.44 66.44 66.44 66.44 66.49 64.58	1.67 0.41 12.8 2 3.95 2.71 2.45 0.93 4.94 4.94 2.01 1.60 1.49 3.74 1.37 1.37 0.96
	3509 (2219-5753) 359 (278-502) 2021 (1260-3277) 8271 (6096-12456) 81 (40-278) 1252 (862-1583) 89 (51-154) 2710 (1811-3991) 96 (67-175) 2671 (1796-4490) 209 (144-292) 2898 (1995-3875) 744 (510-1145) 175 (90-340) 3175 (2104-4026) 325 (211-775)		10	5311 (3783-7876) 22 (17-29) 337 (243-513) 1838 (1435-2386) 17 (9-37) 984 (756-1332) 12 (8-21) 1026 (449-1929) 33 (24-57) 800 (547-1194) 64 (46-90) 305 (208-431) 194 (115-309) 137 (64-264) 5599 (3842-7865)	86.26 -214.29 34.94 57.50 50.00 65.12 79.31 -13.37 93.24 66.44 66.44 66.44 66.44 66.49 84.58 79.36	0.41 12.8 2 3.95 2.71 2.45 0.93 4.94 2.01 1.60 1.49 3.74 1.49 0.96
	359 (278-502) 2021 (1260-3277) 8271 (6096-12456) 81 (40-278) 1252 (862-1583) 89 (51-154) 2710 (1811-3991) 96 (67-175) 2671 (1796-4490) 209 (144-292) 2898 (1995-3875) 744 (510-1145) 175 (90-340) 3325 (211-775)		0	22 (17-29) 337 (243-513) 1838 (1435-2386) 17 (9-37) 984 (756-1332) 12 (8-21) 1026 (449-1929) 33 (24-57) 800 (547-1194) 64 (46-90) 305 (208-431) 194 (115-309) 137 (64-264) 5599 (3842-7865)	-214.29 34.94 57.50 50.00 65.12 79.31 -13.37 93.24 66.44 66.44 66.44 66.44 66.44 66.44 66.44 66.49 79.36 64.79	2.8 3.95 2.71 2.45 0.93 4.94 4.94 2.01 1.60 1.37 1.37 1.49 0.96
32031 (27018-39735) 155646 (132714-196039) 2596 (1744-3831) 40169 (3763-44526) 1752 (1351-2426) 58869 (4745-571876) 4474 (3862-5864) 120312 (110101-138915) 7883 (662-9024) 56578 (46186-67190) 23794 (18731-28455) 6689 (4846-9128) 6689 (4846-9128) 389629 (341587-450958) 24472 (20994-30911) 9501 (7992-12088) 389629 (341587-450958) 24472 (20978-28363) 70170 (52556-101535) 25294 (2041-31097) 23086 (21764-25191) 47508 (42917-53422) 27793 (1640-4803) 105791 (98034-119596) 82454 (63709-107966) 605 (330-984) 168893 (14338-200222)	2021 (1260-3277) 8271 (6096-12456) 81 (40-278) 1252 (862-1583) 89 (51-154) 2710 (1811-3991) 96 (67-175) 2671 (1796-4490) 209 (144-292) 2898 (1995-3875) 744 (510-1145) 175 (90-340) 3175 (2104-4026) 325 (211-775)			337 (243-513) 1838 (1435-2386) 17 (9-37) 984 (756-1332) 1026 (449-1929) 33 (24-57) 800 (547-1194) 64 (46-90) 305 (208-431) 194 (115-309) 137 (64-264) 5599 (3842-7865)	34.94 57.50 50.00 65.12 79.31 -13.37 93.24 66.44 66.44 66.44 66.44 66.44 66.49 79.36 64.79	3.95 2.71 2.45 0.93 4.94 2.01 1.60 1.49 3.74 1.85 0.96
155646 (132714-196039) 2596 (1744-3831) 40169 (37653-44526) 1752 (1351-2426) 58869 (4745-71876) 4474 (3862-5864) 120312 (110101-138915) 7888 (6626-9024) 56578 (46186-67190) 23794 (18731-28455) 6689 (4846-9128) 6689 (4846-9128) 389629 (341587-450958) 24472 (20994-30911) 9501 (7992-12088) 389629 (341587-450958) 2472 (20978-28363) 70170 (52556-101535) 25294 (2041-31097) 25294 (2041-31097) 25294 (2041-31097) 2793 (1640-4803) 105791 (98034-119596) 82454 (63709-107966) 605 (330-984) 168893 (143378-200222)	8271 (6096-12456) 81 (40-278) 1252 (862-1583) 89 (51-154) 2710 (1811-3991) 96 (67-175) 2671 (1796-4490) 209 (144-292) 2898 (1995-3875) 744 (510-1145) 175 (90-340) 3175 (2104-4026) 325 (211-775)			1838 (1435-2386) 17 (9-37) 984 (756-1332) 12 (8-21) 1026 (449-1929) 33 (24-57) 800 (547-1194) 64 (46-90) 305 (208-431) 194 (115-309) 137 (64-264) 5599 (3842-7865)	57.50 50.00 65.12 79.31 -13.37 93.24 66.44 66.44 84.58 79.36 64.79 64.79	2.71 2.45 0.93 4.94 2.01 1.60 1.49 3.74 1.85 0.96
2596 (1744-3831) 40169 (37653-44526) 1752 (1351-2426) 58869 (4745-71876) 4474 (3362-5864) 120312 (11010-1.38915) 7888 (6626-9024) 56578 (46186-67190) 23794 (18731-28455) 6689 (4846-9128) 6689 (4846-9128) 9501 (7992-12088) 389629 (341587-450958) 24472 (20994-30911) 9501 (77992-12088) 389629 (341587-450958) 2472 (20924-3191) 70170 (52556-101535) 25294 (20441-31097) 7208 (421764-28191) 47508 (421764-28191) 47508 (421764-28191) 605 (330-984) 605 (330-984) 168893 (143378-200222)	81 (40-278) 1252 (862-1583) 89 (51-154) 2710 (1811-3991) 96 (67-175) 2671 (1796-4490) 209 (144-292) 2898 (1995-3875) 744 (510-1145) 175 (90-340) 3175 (2104-4026) 325 (211-775)			17 (9-37) 984 (756-1332) 12 (8-21) 1026 (449-1929) 33 (24-57) 800 (547-1194) 64 (46-90) 305 (208-431) 194 (115-309) 137 (64-264) 5599 (3842-7865)	50.00 65.12 79.31 -13.37 93.24 66.44 66.44 84.58 79.36 64.79	2.45 0.03 4.94 2.01 1.60 1.37 1.49 3.74 1.85 0.96
40169 (37653-44526) 1752 (1351-2426) 58869 (47456-71876) 4474 (3962-5864) 120312 (110101-138915) 7888 (6626-9024) 56578 (46186-67190) 23794 (18731-28455) 6689 (4846-9128) 6689 (4846-9128) 280497 (246258-314661) 24416 (20994-30911) 9501 (7992-12088) 389629 (341587-450958) 24472 (20978-28363) 70170 (5255-101535) 25294 (20413-31097) 25294 (20413-31097) 123086 (21764-25191) 47508 (42917-53422) 7793 (1640-4803) 105791 (98034-119596) 82454 (63709-107966) 605 (330-984) 168893 (143378-200222)	1252 (862-1583) 89 (51-154) 2710 (1811-3991) 96 (67-175) 2671 (1796-4490) 209 (144-292) 2898 (1995-3875) 744 (510-1145) 175 (90-340) 3175 (2104-4026) 325 (211-775)			984 (756-1332) 12 (8-21) 1026 (449-1929) 33 (24-57) 800 (547-1194) 64 (46-90) 305 (208-431) 194 (115-309) 137 (64-264) 5599 (3842-7865)	65.12 79.31 -13.37 93.24 66.44 84.58 79.36 64.79 52.92	0.93 4.94 2.01 1.60 1.37 3.74 1.85 0.96
1752 (1351-2426) 58869 (47456-71876) 4474 (3962-5864) 120312 (110101-138915) 7883 (6626-9024) 56578 (46186-67190) 23794 (18731-28455) 6689 (4846-9128) 6689 (4846-9128) 280497 (246258-314661) 24416 (20994-30911) 9501 (7992-12088) 389629 (341587-450958) 24472 (20978-28363) 70170 (5256-101535) 25294 (2041-31097) 23086 (21764-25191) 47508 (42917-53422) 2793 (1640-4803) 105791 (98034-119596) 82454 (63709-107966) 605 (330-984) 168893 (143378-200222)	89 (51-154) 2710 (1811-3991) 96 (67-175) 2671 (1796-4490) 209 (144-292) 2898 (1995-3875) 744 (510-1145) 175 (90-340) 3175 (2104-4026) 325 (211-775)			12 (8-21) 1026 (449-1929) 33 (24-57) 800 (547-1194) 64 (46-90) 305 (208-431) 194 (115-309) 137 (64-264) 5599 (3842-7865)	19.31 -13.37 93.24 66.44 84.58 79.36 64.79 52.92	2.01 1.60 1.37 1.49 3.74 1.85 0.96 0.37
58869 (47456-71876) 4474 (3962-5864) 120312 (110101-138915) 7883 (6626-9024) 56578 (46186-67190) 23794 (18731-28455) 6689 (4846-9128) 6689 (4846-9128) 280497 (246258-314661) 24416 (20994-30911) 9501 (7992-12088) 24472 (2095-8333) 70170 (5256-101535) 25294 (20441-31097) 25294 (20441-31097) 25294 (20441-31097) 2793 (1640-4803) 105791 (98034-119596) 82454 (63709-107966) 605 (330-984) 168893 (143378-200222)	2710 (1811-3991) 96 (67-175) 2671 (1796-4490) 209 (144-292) 2898 (1995-3875) 744 (510-1145) 175 (90-340) 3175 (2104-4026) 325 (211-775)			1026 (449-1929) 33 (24-57) 800 (547-1194) 64 (46-90) 305 (208-431) 194 (115-309) 137 (64-264) 5599 (3842-7865)	-13.37 93.24 66.44 84.58 79.36 64.79 52.92	2.01 1.60 1.37 1.49 3.74 1.85 0.96
4474 (3962-5864) 120312 (110101-138915) 7883 (6626-9024) 56578 (46186-67190) 23794 (18731-28455) 6689 (4846-9128) 6689 (4846-9128) 280497 (246258-314661) 24416 (20994-30911) 9501 (7992-12088) 24472 (20978-28363) 70170 (5256-101535) 25294 (20441-31097) 25294 (20441-31097) 25294 (20441-31097) 2793 (1640-4803) 105791 (98034-119596) 82454 (63709-107966) 605 (330-984) 168893 (143378-200222)	96 (67-175) 2671 (1796-4490) 209 (144-292) 2898 (1995-3875) 744 (510-1145) 175 (90-340) 3175 (2104-4026) 325 (211-775)			33 (24-57) 800 (547-1194) 64 (46-90) 305 (208-431) 194 (115-309) 137 (64-264) 5599 (3842-7865)	93.24 66.44 84.58 79.36 64.79 52.92	1.60 1.37 1.49 3.74 1.85 0.96 0.37
120312 (110101-138915) 7883 (6626-9024) 56578 (46186-67190) 23794 (18731-28455) 6689 (4846-9128) 280497 (246258-314661) 24416 (20994-30911) 9501 (7992-12088) 24472 (20978-28363) 70170 (5256-101535) 25294 (20441-31097) 25294 (20441-31097) 25294 (20441-31097) 2793 (1640-4803) 105791 (98034-119596) 82454 (63709-107966) 605 (330-984) 168893 (143378-200222)	2671 (1796-4490) 209 (144-292) 2898 (1995-3875) 744 (510-1145) 175 (90-340) 3175 (2104-4026) 325 (211-775)		8	800 (547-1194) 64 (46-90) 305 (208-43.1) 134 (115-309) 137 (64-264) 5599 (3842-7865)	66.44 84.58 79.36 64.79 52.92	1.37 1.49 3.74 1.85 0.96 0.37
7883 (6626-9024) 56578 (46186-67190) 23794 (18731-28455) 6689 (4846-9128) 280497 (246258-314661) 24416 (20994-30911) 9501 (7992-12088) 389629 (341587-450958) 24472 (20978-28363) 70170 (5256-101535) 25294 (20441-31097) 25294 (20441-31097) 2793 (1640-4803) 105791 (98034-119596) 82454 (63709-107966) 605 (330-984) 168893 (143378-200222)	209 (144-292) 2898 (1995-3875) 744 (510-1145) 175 (90-340) 3175 (2104-4026) 325 (211-775)		8	64 (46-90) 305 (208-431) 194 (115-309) 137 (64-264) 5599 (3842-7865)	84.58 79.36 64.79 52.92	1.49 3.74 1.85 0.96 0.37 0.63
56578 (46186-67190) 23794 (18731-28455) 6689 (4846-9128) 280497 (246258-314661) 24416 (20994-30911) 9501 (7992-12088) 389629 (341587-450958) 24472 (20978-28363) 70170 (5256-101535) 25294 (20441-31097) 25294 (20441-31097) 25294 (20441-31097) 2798 (42917-53422) 2793 (1640-4803) 105791 (98034-119596) 82454 (63709-107966) 605 (330-984) 168893 (143378-200222)	2898 (1995-3875) 744 (510-1145) 175 (90-340) 3175 (2104-4026) 325 (211-775)		8	305 (208-431) 194 (115-309) 137 (64-264) 5599 (3842-7865)	52.92	3.74 1.85 0.96 0.37 0.63
23794 (18731-28455) 6689 (4846-9128) 6689 (4846-9128) 24416 (20994-30911) 9501 (7992-12088) 389629 (341587-450958) 24472 (20978-28363) 70170 (5256-101535) 25294 (20441-31097) 23086 (21764-25191) 47508 (42917-5422) 105791 (98034-119596) 82454 (63709-107966) 605 (330-984) 168893 (143378-200222)	744 (510-1145) 175 (90-340) 3175 (2104-4026) 325 (211-775)		8	194 (115-309) 137 (64-264) 5599 (3842-7865)	52.92	1.85 0.96 0.37 0.63
6689 (4846-9128) 280497 (246258-314661) 24416 (20994-30911) 9501 (7992-12088) 389629 (341587-450958) 24472 (20978-28363) 70170 (5256-101535) 25294 (2044-31097) 23086 (21764-25191) 47508 (42917-53422) 2793 (1640-4803) 105791 (98034-119596) 82454 (63709-107966) 605 (330-984) 168893 (143378-200222)	175 (90-340) 3175 (2104-4026) 325 (211-775)		8	137 (64-264)	52.92	0.96
280497 (246258-314661) 24416 (20994-30911) 9501 (7992-12088) 389629 (341587-450958) 24472 (20978-28363) 70170 (52556-101535) 25294 (20441-31097) 23086 (21764-25191) 47508 (42917-53422) 2793 (1640-4803) 105791 (98034-119596) 82454 (63709-107966) 605 (330-984) 168893 (143378-200222)	3175 (2104-4026) 325 (211-775)	+		5599 (3842-7865)	20	0.37
20416 (2094-30911) 24016 (20994-30911) 9501 (7992-12088) 389629 (341587-450958) 24472 (20978-28363) 70170 (52556-101535) 25294 (20441-31097) 23086 (21764-25191) 47508 (42917-53422) 2793 (1640-4803) 105791 (98034-119596) 82454 (63709-107966) 605 (330-984) 168893 (143378-200222)	325 (211-775)		9	(2007-2406)		0.63
9501 (7992-12088) 389629 (341587-450958) 24472 (20978-28363) 70170 (52556-101535) 25294 (2044-31097) 23086 (21764-25191) 47508 (42917-53422) 2793 (1640-4803) 105791 (98034-119596) 82454 (63709-107966) 605 (330-984) 168893 (143378-200222)		+		288 (190-495)	71.54	
389629 (341587-450958) 24472 (20978-28363) 70170 (5256-101535) 25294 (20441-31097) 23086 (21764-25191) 47508 (42917-53422) 2793 (160-4803) (105791 (98034-119596) 82454 (63709-107966) 605 (330-984) 168893 (143378-200222)	928 (646-1470)	+		52 (38-78)	29.73	10.3
389629 (341587-450958) 24472 (20978-28363) 70170 (52556-101535) 25294 (20441-31097) 23086 (21764-25191) 47508 (42917-53422) 2793 (1640-4803) (105791 (98034-119596) 82454 (63709-107966) 605 (330-984) 168893 (143378-200222)	,	72.6		()		1
24472 (20978-28363) 70170 (52556-101535) 25294 (20441-31097) 23086 (21764-25191) 47508 (42917-53422) 2793 (1640-4803) 105791 (98034-119596) 82454 (63709-107966) 605 (330-984) 168893 (143378-200222)	4443 (2786-7233)	66.69 1.14	.4 5.94 (3.93-9.39)	7462 (4939-11783)	78.59	0.40
70170 (52556-101535) 25294 (20441-31097) 23086 (21764-25191) 47508 (42917-53422) 2793 (1640-4803) 105791 (98034-119596) 82454 (63709-107966) 605 (330-984) 16893 (143378-200222)	686 (356-1030)	43.91 2.80	15.3	490 (342-681)	68.63	1.08
25294 (20441-31097) 23086 (21764-25191) 47508 (42917-53422) 2793 (1640-4803) (105791 (98034-119596) 82454 (63709-107966) 605 (330-984) 168893 (143378-200222)	1515 (883-2678)	68.46 2.16	.6 (0.88-1.82)	1082 (751-1562)	79.63	0.87
23086 (21764-25191) 47508 (42917-53422) 2793 (1640-4803) 105791 (98034-119596) 82454 (63709-107966) 605 (330-984) 168893 (143378-200222)	1226 (840-1727)	17.33 4.85	10.81 (6.88-16.20)	133 (84-199)	77.72	4.13
47508 (42917-53422) 2793 (1640-4803) 105791 (98034-119596) 82454 (63709-107966) 605 (330-984) 168893 (143378-200222)	1008 (857-1231)	37.08 4.37	9.68 (7.58-12.98)	214 (167-287)	76.22	2.86
2793 (1640-4803) 105791 (98034-119596) 82454 (63709-107966) 605 (330-984) 168893 (143378-200222)	1135 (874-1509)	70.17 2.39		955 (748-1299)	64.79	0.79
105791 (98034-119596) 82454 (63709-107966) 605 (330-984) 168893 (143378-200222)	89 (8-311)	12.75 3.19	3.19 (1.26-8.46)	52 (21-137)	73.87	1.19
82454 (63709-107966) 605 (330-984) 168893 (143378-200222)	9103 (8050-10944)	-116.69 8.60	30 1.85 (1.30-2.81)	298-857)	-41.50	6.54
605 (330-984) 168893 (143378-200222)	3355 (1512-5929)	23.07 4.07	0.55 (0.36-0.91)	442 (291-731)	75.15	2.80
168893 (143378-200222)	28 (10-77)	22.22 4.63	33 0.76 (0.30-1.65)	5 (2-11)	-25.00	3.11
	1762 (1007-3768)	69.01 1.04	2.44 (1.66-3.69)	1867 (1267-2827)	84.70	0.48
0.44 (0.35-0.57) 158164 (133921-193201) 0.08 (0.04-0.15)	2962 (1548-5673)	57.98 1.87	7.44 (4.11-13.13)	2816 (1557-4971)	81.69	89.0
0.37 (0.33-0.44) 10126 (8766-12112) 0.32 (0.27-0.42)	1330 (1093-1722)	-524.41 13.1 3	.1 1.08 (0.80-1.48) 3	44 (33-61)	-300.00	17.5
0.13 (0.09-0.17) 12301 (9308-15872) 0.04 (0.03-0.06)	479 (327-734)	55.36 3.89	1.60 (0.86-2.91)	184 (99-335)	39.07	1.68
0.10 (0.07-0.14) 197451 (137546-258777) 0.03 (0.02-0.06)	7841 (4124-14955)	31.94 3.97	0.78 (0.40-1.50)	1816 (939-3508)	75.14	2.06
0.08 (0.08-0.10) 77220 (70552-88518) 0.02 (0.02-0.03)	1956 (1509-2766)	54.73 2.53	0.72 (0.53-1.03)	709 (524-1015)	85.28	1.44
0.20 (0.17-0.25) 2544364 (2167577- 0.05 (0.03-0.08) 3038032)	68451 (45853- 107075)	44.23	2.61 (1.77-3.95)	35866 (24322-54404)	79.26	1.15

2.3.2. Epidemic trends


India exhibits diverse HIV prevalence trends across its States and UT (Figure 2.18). There is an overall declining trend observed in Andhra Pradesh, Chhattisgarh, Goa, Himachal Pradesh, Karnataka, Kerala, Maharashtra, Manipur, Madhya Pradesh, Odisha, Tamil Nadu, West Bengal, Puducherry, and Telangana. A broadly stable trend is noted in Gujarat, Nagaland, Rajasthan, and Uttar Pradesh. Meanwhile, Jammu & Kashmir and Ladakh, and DNH&DD show a declining trend after reaching their peak around 2011-12 and 2000-02, respectively.

An increasing trend is evident in Arunachal Pradesh, Assam, Meghalaya, Mizoram, Punjab,


Sikkim, Tripura, Uttarakhand, Andaman & Nicobar Islands, and Chandigarh. In contrast, Bihar, Delhi, Haryana, and Jharkhand display a long-term rising trend which has stabilized since 2010.

In terms of PLHIV size, the long-term decline is estimated only in States/UTs of Andhra Pradesh, Karnataka, Maharashtra, Manipur, Tamil Nadu, Telangana, and Puducherry. In Jammu & Kashmir and Ladakh and Odisha, the decline has been estimated in recent past. Stable size of PLHIV is estimated in States/UTs of Chhattisgarh, Goa, Himachal Pradesh, Kerala, Madhya Pradesh, and West Bengal. In all other States/UTs, the PLHIV size is estimated to be increasing.

Figure 2.18. States/UTs-wise adult HIV prevalence (%) and PLHIV size (In 1000), 1990-2023



Note: Adult HIV prevalence (in %) in orange line primary 'Y' axis, PLHIV size (in 1000) in brown line on secondary 'Y' axis




The overall epidemic trend is being determined by different incidence and mortality trends in different States/UTs (Figure 2.19). In Andhra Pradesh, Karnataka, Maharashtra, Tamil Nadu, and Telangana, the decline is driven by substantial decline in both of new infections and AIDS-related mortalities. In all of these States, the value of IPR and IMR are well below the recommended threshold level with ART coverage of at-least 70%

indicating a successful AIDS response with declining epidemic size.

The declining trend being seen in Manipur need to be seen in challenging programmatic context. Estimated deaths among PLHIV has been relatively higher in State on account of ART coverage. Accordingly, epidemic size is declining in the State as estimated deaths are higher than the estimated new infections.

Figure 2.19. New infections, PLHIV size and deaths among PLHIV, 1990-2023



Note: PLHIV size (in blue line) on primary 'Y' axis; new infections (in red line) and deaths among PLHIV (in green line) on secondary 'Y' axis: year on 'X' axis

A noticeable increasing trend in the prevalence of new infections has been observed in the northeastern states of Tripura, Arunachal Pradesh, Meghalaya, and Assam, as well as in the northern state of Punjab, primarily driven by the rise in new infections (Figure 2.20). In Tripura and Arunachal Pradesh, the number of new infections in 2023 has increased by over 400% compared to the 2010. Similarly, in Punjab and Meghalaya, the annual

new infections estimated for 2023 have nearly doubled compared to the 2010.

In Mizoram, annual new infections reached its peak in 2017/2018 and then started to show decline. However, as new infections is still higher than the deaths (IMR >4 in 2023), the epidemic is continuing to expand in the State that reflects into rising prevalence.




Figure 2.20. States/UT-wise change (%) in annual new HIV infections during 2010 and 2023

2.3.3. Routes of transmission (Self-reported)

The patterns of HIV transmission vary by route across different States and Union Territories (Table 2.4 and Figure 2.21). In Assam, Arunachal Pradesh, Punjab, and Tripura, the primary mode of transmission is injecting drug use, accounting for 61-77% of newly detected HIV-positive cases in 2023-24. This is attributed to the use of infected syringes or needles. In Delhi, Haryana, Mizoram, and Uttarakhand, approximately 21% of cases reported acquiring the infection through infected needles or syringes, while in Chandigarh, Himachal Pradesh, and Manipur, the proportion was between 14-17%. An increasing adult HIV prevalence has been observed in many of these States. The epidemic trajectory in Arunachal Pradesh, Assam, and Tripura has significantly shifted in recent years, with a notable rise in HIV cases among (PWID). There are

indications that injecting drug behavior is increasingly contributing to the HIV epidemic in several northeastern States. For instance, in Assam, the percentage of HIV cases reporting injecting drug use as a transmission route rose from 2.10% in 2017-18 to 7.40% in 2019-20; similarly, in Tripura, it increased from around 18% in 2017-18 to approximately 39% in 2019-20.

In other States, heterosexual transmission remains the predominant route. In Meghalaya and Chandigarh, 52-57% of cases reported HIV transmission through heterosexual casual partners, whereas in Andhra Pradesh, Andaman, Chhattisgarh, DNHDD, Jammu and Kashmir, Nagaland, Tamil Nadu, and Telangana, 40-50% of respondents indicated this mode of transmission. In Mizoram and Puducherry, around 40% reported

transmission through heterosexual regular partners, followed by 30%-36% in Andhra Pradesh, Bihar, Goa, Karnataka, Madhya Pradesh, Maharashtra, Manipur, Nagaland, Rajasthan, and Telangana. Moreover, in Bihar, Jharkhand, Maharashtra, Odisha, and West Bengal, 21%-29% of newly detected cases indicated acquiring HIV

infection through heterosexual commercial partners. In Kerala and Sikkim, 24%-28% of cases reported HIV transmission through homosexual routes, followed by approximately 10%-18% in the Andaman and Nicobar Islands, Goa, Odisha, and West Bengal.

Figure 2.21. States/UTs-wise proportional distribution of route of transmission (self-reported) in newly diagnosed cases, 2023-24




Table: 2.4. States/UTs-wise proportional distribution of route of transmission (self- reported) in newly diagnosed cases, 2023-24

			Prop	ortional dis	tribution (In %	6)			-
States/UTs	Heterose xual: Commerc ial partner	Heterosexu al: Casual/non- commercial, non- regular partner	Heterosex ual (Regular partner / spouse)	Homos exual/ Bi- sexual	Through Blood and Blood products	Through infected Syringe and Needles	Parent to Child	Not specified/ Unknown	Total newly diagnos ed HIV- positive cases
ANI	2	49	17	12	2	2	0	15	41
Andhra Pradesh	16	42	36	2	0	0	2	2	13513
Arunachal Pradesh	1	7	6	4	1	77	0	3	489
Assam	7	9	9	7	1	64	1	2	6472
Bihar	29	27	30	4	0	1	4	4	7287
Chandigarh	8	57	11	7	1	14	2	1	673
Chhattisgarh	16	41	28	3	1	3	4	4	1900
Delhi	9	35	19	6	3	24	1	3	2509
DNHⅅ	9	44	28	6	0	0	6	8	89
Goa	11	39	31	13	0	1	2	2	260
Gujarat	18	40	27	5	1	0	3	5	7702
Haryana	10	29	20	3	2	21	2	13	6033
Himachal Pradesh	16	38	16	5	1	17	1	5	564
J&K and Ladakh	5	49	16	6	4	8	4	9	278
Jharkhand	25	27	28	7	2	0	4	6	1625
Karnataka	17	38	35	3	1	1	3	3	13387
Kerala	17	28	16	24	0	7	1	6	1235
Madhya Pradesh	16	35	32	3	1	5	4	5	6220
Maharashtra	21	33	31	5	1	0	4	4	17017
Manipur	11	28	32	5	0	17	5	2	709
Meghalaya	3	52	28	3	0	8	3	3	1347
Mizoram	2	24	40	3	0	27	2	1	2109
Nagaland	1	49	35	1	0	8	3	4	1581
Odisha	23	36	20	10	2	1	4	3	3245
Puducherry	13	27	39	9	0	1	1	11	159
Punjab	5	16	13	1	0	61	1	3	12308
Rajasthan	12	32	30	2	1	6	5	12	7048
Sikkim	24	17	19	28	0	0	0	12	58
Tamil Nadu	11	47	27	9	0	0	2	3	7016
Telangana	13	44	33	4	1	0	3	2	8985
Tripura	6	6	8	3	1	76	1	0	1569
Uttar Pradesh	17	29	27	3	3	9	4	8	14851
Uttarakhand	13	28	21	3	1	27	3	2	1439
West Bengal	23	27	20	18	2	3	2	4	6607
India	15	32	27	5	1	12	3	5	156325

2.3.4. HIV and related co-infections among different population groups


Similar to adult HIV prevalence, significantly higher rates are observed among various key populations in the northeastern states compared to national averages, as indicated in the 2021 rounds of surveillance (Table 2.5). Notably, among PWID, the seroprevalence levels of HIV and related infections are particularly concerning. The elevated epidemic levels in the northeastern states are also evident from the positivity rates recorded during routine testing.


Figure 2.22. outlines the annual seropositivity observed in various key population groups during 2023-24 in India, with a specific focus on selected northeastern States. Among 'at-risk' clients, the national seropositivity was recorded at 0.44%, compared to 2.52% in Mizoram, 2.15% in Assam, 1.55% in Arunachal Pradesh, 1.54% in Meghalaya, 1.30% in Tripura, 1.23% in Nagaland, and 0.68% in Manipur. Similarly, six States/UTs where HIV seropositivity among positivity was more than 0.10%; four are in the northeastern region: Nagaland (0.73%), Mizoram (0.58%), Meghalaya (0.25%), and Manipur (0.11%). A similar pattern was also reported among key and bridge population groups.


However, relatively higher annual seropositivity in routine program testing has also been noted in other States/UTs. Punjab had a seropositivity of more than 1% among 'at-risk' clients, while in Delhi, Telangana, and Andhra Pradesh, it ranged between 0.78% and 0.96%. Punjab and Chandigarh are two States/UT from northern India with seropositivity of more than 0.10% among pregnant women. Haryana has a seropositivity of around 0.34%, and Telangana has seropositivity of 0.31% among FSW, with Punjab at 0.26%. Among MSM, Harvana recorded a seropositivity of 1.14%, West Bengal 1.07%, Punjab 0.84%, Chhattisgarh 0.83%, and Uttar Pradesh 0.71%. Haryana recorded a seropositivity of around 3.54% among PWID and Punjab 1.70%. The highest HIV positivity among truckers was noted in Harvana (0.72%) and Bihar (0.60%).


The varying seropositivity levels reported in the program may result from differences in coverage and testing practices across States/UTs. These figures offer important context for understanding the epidemiological scenarios within each State or region.


Figure 2.22. Annual HIV sero-positivity (in %) noted in routine testing, 2023-24




















Status of the Epidemic

 ${\it Table.\ 2.5.\ States/UTs\ wise\ distribution\ of\ prevalence\ of\ HIV\ related\ co-infection\ among\ different\ population\ group}$

		1A	NC			Priso	ners	
States/UTs	HIV	Syphilis	Hep B*	Hep C*	HIV	Syphilis	Нер В*	Hep C*
A&N Islands	0.13	0	0.94	0	-	-	-	1
Andhra Pradesh	0.3	0.05	0.58	0.03	2.58	0.67	2.75	0.5
Arunachal Pradesh	0.1	0.52	0.75	0.04	-	-	1	1
Assam	0.24	0.04	0.21	0.02	4.17	0.42	0.88	5.51
Bihar	0.16	-	1.46	0.1	0.17	-	2.93	0
Chandigarh	0	0	0.36	0.29	3.25	0.25	1.98	12.62
Chhattisgarh	0.29	0.08	0.35	0.1	1.07	0.57	1.26	0.98
DD & DNH	0.17	0	0.08	0	-	-	1	ı
Delhi	0.25	0.03	1.36	0.51	2.63	0.5	2.45	8.84
Goa	0.08	0.17	0.76	0.28	-	-	-	-
Gujarat	0.26	-	0.92	0.11	0.5	-	1.75	0.75
Haryana	0.12	0.29	0.81	0.86	2.75	0.37	1.75	8.63
Himachal Pradesh	0.08	0	0.11	0.09	0	0	1	2.25
J&K and Ladakh	0.02	0.05	0.62	0.11	-	-	-	-
Jharkhand	0.18	0.01	0.42	0.08	0.38	0.13	1.17	0.15
Karnataka	0.57	0.1	0.63	0.63	1.03	0	0.92	0.5
Kerala	0.11	0.05	0.15	0.02	0.25	0.38	1.75	2.5
Madhya Pradesh	0.12	0.31	1.28	0.11	1.42	1.58	3.17	2.33
Maharashtra	0.36	0.04	0.67	0.04	1.13	1.01	2.25	0.88
Manipur	0.32	2.68	0.84	0.19	2.99	1.49	2.01	16.83
Meghalaya	0.58	2.01	1.19	0.08	5.5	4.5	-	-
Mizoram	0.63	0.29	1.38	1.7	21.5	1.25	4.25	47.75
Nagaland	0.51	0.24	0.37	0.06	6.64	0.41	0	1.02
Odisha	0.33	0.3	0.77	0.05	0.25	0.88	0	0
Puducherry	0	0	0.35	0	-	-	-	-
Punjab	0.23	0.1	0.59	1.01	9.25	0.42	2.25	27.95
Rajasthan	0.21	0.15	0.76	0.03	1.58	0.57	2.08	1.58
Sikkim	0.16	0.33	0.27	0.08	-	-	-	-
Tamil Nadu	0.16	0.09	0.58	0.16	0.81	0.13	1.08	0.58
Telangana	0.32	0.17	0.31	0.07	2.75	1	1.5	0
Tripura	0.43	0.07	0.46	0	6	0.5	1.5	4.75
Uttar Pradesh	0.12	0.15	1.04	0.81	2.5	0.67	3	1.38
Uttarakhand	0.06	0.33	0.88	0.84	1.38	5.88	0.5	0.75
West Bengal	0.11	0.08	0.47	0.02	0.42	0.58	1.51	0.67
India	0.23	0.11	0.85	0.29	1.99	0.71	1.89	4.75

Table. 2.6. States/UTs wise distribution of prevalence of HIV related co-infection among different population group

		FSW			MSM			IDN			HTG			Truckers			Migrant	
		Hep	Hep		Hep	Hep		Hep	Hep		Hep	Hep		Hep	Hep		Hep	Hep
State/UT	≥ H	· *	· *	≥H	· *	*	≧	· *	· *	≥	· *	*	≥H	*a	*	ΑI	· *	*
A&N Islands																		
Andhra Pradesh	1.78	1.15	0.12	2.06	1.81	0.49	1.32	99.0	20.96	4.61	0.46	0	9.0	2.2	1.8	0.93	1.47	0.53
Arunachal Pradesh	0.27	1.6	4				1.6	0.8	72.8									
Assam	1.65	0.34	1.38	3.61	0.54	0	11.24	3.75	47.53				2.12	1.06	1.48	3.21	1.61	2.01
Bihar	0.62	1.64	0.23	0.41	9.76	0.41	2.86	1.23	8.4									
Chandigarh	8.0	0.27	0.4	1.61	0.4	2.41	2.8	1.6	57.2							0.4	1.4	2
Chhattisgarh	1.92	0.49	0	4.01	0	0	7.2	4.67	54.21	9	0.4	0	2	0.2	1	1.2	0.4	0
DD & DNH																		
Delhi	0.81	0.4	0.3	2.59	0	0	15.87	2.93	32.18	3.6	0.4	0.4	8.0	3.2	3.2	0.75	0	0
Goa	9.0	0.2	0	2.4	1.4	0	0	8.0	0									
Gujarat	1.34	0.67	0.63	4.61	99.0	0.51	2	2.8	9.5	3.6	0.4	0	0.3	8.0	0.5	0.13	1.07	0.2
Haryana	1.33	0.31	0.63	68.9	1.1	4.5	9.24	3.48	34.46									
Himachal Pradesh	0.55	0.55	0.95	1.56	0.78	1.17	4.4	2	28							0	2	2.8
J&K and Ladakh	0.4	0	0				0.5	2.58	34.89									
Jharkhand	0.55	0.55	90.0	89.9	0.48	1.43							0	0	0			
Karnataka	3.01	1.15	0.27	2.81	2.86	0.61	0	0	0	3.2	1.6	0.4	1.2	1.2	2.4	0.2	8.6	0
Kerala	0.44	0.36	0	0.35	6.0	9.0	0.4	0.67	33.6	0.56	1.82	0	1.2	2.4	0	0	1	0.2
Madhya Pradesh	0.75	0.98	0.09	1.84	1.92	0.8	2.96	2.9	13.8				0	3.2	0	0.78	0.8	0
Maharashtra	2.54	1.08	0.24	4.18	0.59	0.08	18.41	4.98	32.34	9	0.4	0.4	0.4	8.0	8.0	0.13	1.87	0.8
Manipur	1.13	0.93	2.4	9.43	2.07	6.9	8.84	3.6	36.57									
Meghalaya	10.92	1.99	0.57	60.6	2.27	6.82	11.48	7.42	77.51									
Mizoram	56.15	4.62	50.77	12.8	0	4.8	32.08	6.3	81.68							4.8	1.2	0.8
Nagaland	2	8.0	1.2	3.06	0.41	0.41	2.53	1.04	5.31				1.2	0.8	1.2			
Odisha	0.65	0.18	0.25	1.2	0	0.4	1.9	0.8	2.7	1.49	0.17	0.33	2	0.8	0.4	1.6	2	0
Puducherry	0.5	6.9	0	0	0.67	0.27										0	1.6	0
Punjab	3.38	0.52	7.36	11.62	3.47	7.61	19.57	3.81	62.41				2.33	1.56	8.17	3.01	1.8	9.0
Rajasthan	2.75	8.0	0.45	6.4	0	1.6				3.6	0	0.4	0	0.8	0	0.39	2.75	0
Sikkim	0	0	0				0.2	0	2.44									
Tamil Nadu	1.52	0.82	0.42	2.07	1.38	0.09				4.8	3.6	0.8	9.0	9.0	0.2	0	1.2	0
Telangana	1.81	1.52	0.27	2.67	0.21	0	0.4	2.8	0	4	0	0	0.8	0.2	0.2	0.8	0.4	1
Tripura	2.9	1.2	0.2				18	7.6	62									
Uttar Pradesh	1.04	98.0	1.31	1.1	2.68	0.83	5.45	3.44	14.24	3.6	0.8	2.8	0.7	2.8	1.6	0.67	2.13	0
Uttarakhand	0.42	0.55	2.63	2.68	0.89	0	9.77	3.61	26.33				2.1	1.26	0			
West Bengal	1.27	6.0	0.83	4.36	0.54	1.07	7.4	3.61	37.88	9.15	1.3	0.43	2.01	2.95	2.54	3.2	4	1
India	1.85	0.95	0.93	3.26	1.36	1.03	9.03	3.09	33.41	3.78	0.97	0.41	7	1.44	1.26	0.89	2.02	0.67

Note: (i) HIV prevalence and seropositivity for ANC and Prisoners refer to the 2023. HIV prevalence for key and bridge population refers to the 2021. (ii) HBV and HCV seropositivity for all groups refer to the year 2021 and is based on the report titled 'Seroprevalence of Hepatitis B and Hepatitis C (HIV Sentinel Surveillance Plus 2021, round 17). Report of National Centre for Disease Control. Directorate General of Health Services. Ministry of Health and Family Welfare.

2.4 Vertical HIV transmission

Eliminating vertical HIV transmission is key to NACO's goal of ending the HIV/AIDS epidemic as a public health threat in India. This involves reducing the paediatric HIV incidence to fewer than 50 per 100,000 live births and keeping vertical transmission rates below 5% in breastfeeding populations (or less than 2% in non-breastfeeding populations). Annual estimations under NACP provide data on these indicators.

The final MTCT rate is estimated based on transmission probabilities across different prophylaxis/treatment groups during perinatal or breastfeeding periods. Under the UNAIDS-recommended Spectrum model, the highest risk occurs when HIV infections in women develop during pregnancy or breastfeeding. Women on antiretroviral therapy prior to pregnancy have the lowest transmission risks.

In 2023, an estimated 19,962 (16,403-24,737)

HIV-positive mothers needed ART to prevent vertical transmission, with a coverage rate of 90.09% (Figure 2.23). The overall final transmission rate was 11.75% (7.93-17.66), down from more than 25% in 2020 underlining significant gains being made under NACP-V.

There were an estimated 2339 (1372-4344) new vertical HIV infections among children, with 44% from incident infections in women during pregnancy or breastfeeding, and 22% from women not receiving ARVs during pregnancy. Additionally, 12% were due to HIV-positive mothers not receiving ARVs during breastfeeding, 8% from discontinuing ARV treatment during pregnancy, and 5% from discontinuing during breastfeeding. This highlights the importance of primary prevention, identifying incident infections during pregnancy and breastfeeding, and ensuring ART initiation and retention to meet vertical transmission goals.

Figure 2.23. Vertical transmission rate for HIV, key statistics, 2023

19.96 Thousand

Estimated number of HIV-positive women to give birth (PMTCT need)

17.98 Thousand

Number of HIV positive PW on-ART, either newly initiated or already on-ART

2.34 thousand

Number of Children estimated to acquire HIV transmission through vertical transmission

90.09%


Percentage of HIV PW on-ART against the estimated need

5%

Vertical transmission rate at 6 weeks

11.75%

Final transmission rate including perinatal transmission and up to 36 months of breastfeeding





PROGRESS ON 95-95-95



3.1. Background

The UNAIDS 95-95-95 targets aim for a significant impact on the HIV epidemic by 2025: 95% of PLHIV should be aware of their status, 95% of those aware of their status should be receiving treatment, and 95% of those on treatment should have achieved viral suppression. Achieving these coverage milestones is essential for reducing new HIV infections and AIDS-related mortality by 90% by 2030, which is a vital step towards the global goal of ending AIDS as a public health threat by 2030.

In alignment with global targets, NACP Phase-V has prioritized the attainment of the 95-95-95 goals by 2025 as a key outcome indicator. Achieving the full 95-95-95 targets would mean that 86% of all PLHIV have achieved viral suppression—a critical benchmark in the testing and treatment cascade. This is essential to meeting the three of program's primary

objectives: (1) reducing new HIV infections by 80%, (2) reducing AIDS-related mortality by 80%, and (3) eliminating vertical transmission of HIV. This chapter outlines the progress of each State and Union Territory in advancing toward the 95-95-95 targets.

3.2. Method

The method for calculating the progress on 95-95-95 has been detailed in previous editions of 'Sankalak'. Table 3.1. below summarises the numerator and denominator for calculation of 95-95-95.

The HIV testing and treatment cascade, also known as the HIV care continuum, is another related framework used to describe the progress on sequential steps and key stages involved in the diagnosis, treatment, and management of HIV. Here the denominator at each step remains the same i.e., estimated PLHIV.

Table 3.1. Method of calculating progress on 95-95-95


Indicator	Description	Calculation	details
		Numerator	Denominator
First 95	Percent of all PLHIV who know their HIV status	Number of PLHIV who know their HIV status	Estimated number of PLHIV
Second 95	Percent of PLHIV who are on ART among those who know their HIV status	Number of PLHIV who are on ART	Number of PLHIV who know their HIV status
Third 95	Percent of PLHIV on ART who are virally suppressed	Number of PLHIV on ART who are virally suppressed	Number of PLHIV on ART who are tested for viral load


3.3. National Progress

As of March 2024, approximately 81% (about 20.49 lakh) of PLHIV in India were aware of their HIV status. Of those aware, 88% were receiving ART, and >=95 of those on ART achieved viral suppression (Figure 3.1). Overall, this means 71% of total PLHIV were on ART, and 69% achieved viral suppression. Progress in these indicators was

slightly higher among women living with HIV compared to men. Globally, 86% of PLHIV knew their HIV status. Among them, 89% were on ART, and 93% of those on ART were virally suppressed indicating that 77% of the global PLHIV size were on ART while 72% were virally suppressed. The target is to have 86% of all PLHIV achieve viral suppression.

Figure 3.1. Gender-wise progress on 95-95-95 and treatment cascade (in %), 2023-24





The number of PLHIV diagnosed, placed on treatment, and virally suppressed is increasing. Number of PLHIV who knew their HIV status, increased from around 17 lakh in March 2019 to 20.49 lakh in March 2024 (around 21% increase). In the same reference period, number of PLHIV on-ART increased from around 13.98 lakh to 17.95 lakh (around 28% increase). As on March 2024, based on the extrapolation of the viral load suppressions rate among on-ART PLHIV tested for viral load to the total on-ART PLHIV, around 17.49 lakh PLHIV were estimated to have suppressed viral load (Figure 3.2).

Overall, proportion of total PLHIV who knew their HIV status increased from around 68% in March 2019 to 81% in March 2024. Similarly, proportion of total PLHIV on-ART who knew their HIV status increased from 56% to 71% and proportion of total PLHIV who were virally suppressed increased from 40% to 69% in the same reference period.

In 2023-24, the majority of States/UT made notable progress towards the first 95 target, with many reaching or exceeding 80% of PLHIV aware of their HIV status. Union Territories such as Chandigarh, DNH&DD, and Delhi reached 95% or higher, while other States like Andhra Pradesh, Goa, Gujarat, Karnataka, Maharashtra, Rajasthan, Tamil Nadu, and West Bengal also progressed above 80%. However, data for UT shall be interpreted with caution in view of the hub-spoke effect as the PLHIV from neighbouring States also avail services from these UT. Data from DNH&DD is under reconciliation in collaboration with Gujarat SACS.

Several States/UTs including Andaman & Nicobar Islands, Arunachal Pradesh, Assam, Bihar, Chhattisgarh, Haryana, J&K and Ladakh, Manipur, Odisha, Puducherry, Sikkim, Tripura, Uttar Pradesh, and Uttarakhand reported progress on first 95 below 70%, indicating areas for further improvement. For progress on second 95 target,


^{3.4.} State/UT-wise progress

i. UNAIDS Estimates 2024

which measures ART coverage among those aware of their status, two States/UT achieved or exceeded 95%, including Kerala and Telangana. Six States/UT (Arunachal Pradesh, Assam, Chhattisgarh, Delhi, Nagaland, and Uttarakhand) recorded second 95 at less than 80% in 2023-24 indicating challenges with retention in treatment. Most other States/UT achieved ART coverage

rates between 80-94%. In all States/UT where 80% or more of PLHIV were aware of their status, over 80% of those aware were also on ART, except for Delhi. Progress of less than 95% on second 95 is indicative of significant lost-to-follow up (LFU) issue and requires urgent attention.

Figure 3.2. Trend in progress on 95-95-95 and treatment cascade (in %), 2018-19 to 2021-22




In terms of viral suppression among those on ART, all except four States/UT showed strong outcomes, with most achieving 95% or greater viral suppression. Four States with viral load suppression of less than 95% but more than 90% included Chhattisgarh, Haryana, Jammu & Kashmir and Ladakh, and Odisha.

There was slight variation in the 95-95-95 progress trends by States/UT. The first 95 has seen a rising trend across all States/UT in the last three years.

However, for the second 95, some States/UT have shown a decline. Assam's progress on the second 95 decreased from 77% in 2018-19 to around 73% in 2023-24. Delhi saw a decline from over 75% in 2018-19 to around 73% in 2023-24. Similar stable-to-declining trends were noted in Goa, Manipur, Nagaland, and Odisha. This may be due to slower detection and retention of PLHIV compared to epidemic expansion, or higher deaths among PLHIV than new detections in a given year.

2023-24 >=95 >=95 >=95 94.2 >=95 >=95 >=95 >=95 >=95 >=95 >=95 >=95 >=95 >=95 >=95 >=95 92.2 >=95 >=95 >=95 >=95 >=95 >=95 >=95 >=95 >=95 >=95 >=95 >=95 >=95 88 >=95 23 83 85 89 89 89 >=95 93 =95 >=95 90 90 93 98 94 93 87 93 93 81 82 2021-98 89 9/ 88 89 84 73 81 88 88 85 83 29 85 86 77 78 85 86 86 87 83 12 9 2020-21 74 88 85 93 86 93 90 87 81 8 83 84 84 87 2019 82 80 73 87 8 6 87 98 88 81 8 83 73 98 73 9/ 99 2 29 98 74 99 78 62 80 72 60 58 9 2 22 6/ 72 51 26 2 1 29 91.5 88.6 83.6 91.0 87.8 84.6 72.6 78.7 87.0 92.3 83.7 90.4 79.8 85.6 86.8 >=95 83.9 73.3 73.2 89.8 86.2 87.3 81.1 83.4 8.98 87.7 90.1 83.7 85 =95 ×=95 90 86 77 86 86.2 83 76 88 88 29 74 98 88 88 86 92 81 88 78 84 86 86 86 86 86 2 83 2021 ×=95 90 74 85 76 848 78 67 72 85 85 73 8 2 78 84 83 86 87 88 88 12 87 98 86 84 67 2020-21 87 84 85 85 85 83 >=95 75 69 72 84 88 74 82 92 92 73 85 78 78 78 9/ 73 84 73 98 11 89 84 71 85 83 -95 63 83 12 85 86 89 7 85 22 83 92 83 85 8 98 87 98 89 84 87 84 12 83 89 69 77 77 81 9/ 22 87 27 87 2.92 60.7 >=95 67.9 >=95 >=95 72.0 93.0 72.5 65.8 76.4 63.6 91.1 83.7 75.9 76.3 76.3 68.5 67.4 63.3 2.7 67.7 62.4 82.9 65.1 84.7 65.2 79.7 91.7 36 52 58 =95 195 35 33 ္မ 82 63 22 87 45 22 54 88 68 68 68 61 77 77 77 73.1 31 9 28 92 84 79 71 75 61 86 63 64 66 66 67 29 11 54 >=95 9/ 42 78 23 17 23 8 89 72 66 58 87 6 54 >=95 28 75 20 42 93 79 78 9 70 55 55 56 60 60 60 75 82 68 37 71 71 5 55 47 >=95 19 33 74 34 68 64 81 55 53 63 63 63 63 4 73 35 55 65 65 68 71 46 62 62 7 81 87 22 Arunachal Pradesh Himachal Pradesh India/State/UT Madhya Pradesh Andhra Pradesh Uttar Pradesh Chhattisgarh Maharashtra Uttarakhand West Bengal Chandigarh Puducherry amil Nadu Jharkhand Meghalaya elangana -Karnataka DNH&DD Haryana Mizoram Tripura Manipur -adakh Delhi Goa

Note: (i) Denominator for first 95 is based on the HIV Estimates 2023, (ii) Progress on third 95 is interim as data for Viral Load tests is being updated in SOCH. (iii) Progress on third 95 for Chhattisgarh have not been provided in view of very less data reporting in SOCH. (iv) Progress for Gujarat and DNH&DD is interim as data is being reconciled.



IEC, YOUTH & MAINSTREAMING

4.1. IEC

IEC is the key to generate awareness on prevention as well as motivation to access testing, treatment, care and support. Activities under IEC have made significant progress in promoting behaviour change, to encourage and sustain positive healthy behaviours among individuals and communities. These activities are being implemented using multi-media approach such as mass-media, mid-media and social media both at the National and State level in close coordination with other programme divisions. The thematic campaigns are identified based on the programme needs and targets under NACP. Accordingly, the budgeting, mediums, channels and durations are being worked out. In the last three years, NACO has conducted campaigns on Youth & HIV and promotion of HIV counselling and testing through different media channels such as Doordarshan, Cable and Satellite channels, All India Radio (AIR), FM Radio, different outdoor mediums, Internet, etc. Innovative technologies like dissemination of advertisements through cinema, theatres and the internet have also been utilized to amplify the reach of mass media campaigns. NACP has extensively used the folk media as an innovative tool for developing an effective communication package to reach the unreached in the remote and media dark areas. In order to ensure effective and efficient utilization of folk media to disseminate HIV/AIDS messages, standardized scripts are developed by State AIDS Control Societies (SACS) in regional languages. Folk troupes are selected and trained on SACS/NACO vetted scripts by SACS. The National Toll-Free AIDS Helpline - 1097 is also widely publicized for information dissemination and actively linking the target population for access to services.

4.2. Social Media

In a world where information travels at the speed of a tweet and a single hashtag can spark a global National **AIDS** Control movement. the Organisation (NACO) has harnessed the power of social media to revolutionize the fight against HIV/AIDS in India. By leveraging platforms such as Facebook, X, Instagram and YouTube, NACO has effectively disseminated vital information regarding prevention methods, treatment options and the importance of regular testing. In addition to raising awareness, social media has been instrumental in reducing the stigma surrounding HIV/AIDS. NACO's campaigns utilize engaging content that challenges misconceptions and promotes empathy, while assimilating to the latest trends.

With creative campaigns that resonate with diverse audiences, the digital media platforms have emerged as a powerful ally in spreading awareness, combating stigma and fostering community support. Apart from this, high-energy events like the Red Run, World AIDS Day 2023, Red Fest (Northeast Multimedia Campaign) acted as game-changers by creating a digital ripple effect which amplified their impact far beyond the day of the event. Overall, the promotion of these events serves as a catalyst for broadening NACO's digital footprint and enhancing the impact of its initiatives. Also, such eye-catching visuals, engaging videos, and compelling graphics led to a higher engagement rate across various digital platforms of NACO which gave a boost of 9.5 Million reach on Facebook, 6.4 Million on Instagram and an average 160 impressions per post' on X.

Notably, the sway of such digital interventions in the NACP-V has been profound, not only in enhancing awareness and education across diverse populations but also in significantly expanding the program's reach and engagement. By combining innovative digital strategies with grassroots efforts, NACO has transformed the wav India approaches HIV/AIDS—moving from a space of silence and stigma to one of open dialogue, understanding, and action. The ripple effects of this digital revolution are clear: more people are informed, empowered, encouraged to take control of their health, ultimately paving the way for a future where HIV/AIDS is no longer seen as an insurmountable challenge, but as a manageable condition within the collective effort to end the epidemic. With these continued efforts, NACO is not just changing the narrative on HIV/AIDS in India but is also setting a global benchmark for public health campaigns in the digital age.







4.3. National Toll-Free AIDS Helpline 1097

The National Toll-Free AIDS Helpline- 1097 continues to serve as a critical and indispensable lifeline for individuals seeking confidential information, counselling, and support related to HIV/AIDS. Throughout the 2023-24 period, the helpline recorded more than 4 lakhs calls, providing round-the-clock assistance in 16 languages, ensuring accessibility across the entire country. This platform remains crucial in offering anonymous, stigma-free support to both the general public and high-risk populations.



4.4. Operational Highlights for 2023-24:

- Call Volume Trends: The helpline maintained a consistent call volume throughout the year. Notably, there was a 48% increase in call traffic between October and December, primarily driven by targeted outreach efforts and SMS-based promotional campaigns. However, there was a 51% decline in calls in January 2024, following the seasonal peak, reflecting a temporary dip in public engagement.
- Language and Geographic Trends: The majority of calls were serviced in Hindi, followed by Bengali and Telugu, reflecting the linguistic diversity of callers. Significant call volumes were recorded from telecom circles covering Madhya Pradesh (MP) & Chhattisgarh, Andhra Pradesh & Telangana (AP&TS), and West Bengal. In contrast, regions like Jammu & Kashmir and parts of

- the North East showed lower levels of engagement, highlighting areas where further outreach may be necessary.
- Peak Hours: The helpline consistently experienced the highest call volumes between 12:00 noon and 01:00 P.M., across all months. Conversely, there was very low engagement during the early morning hours, particularly between 03:00 A.M. and 04:00 A.M., which is consistent with expected user behaviour patterns.
- Purpose of Calls: A consistent 99% of serviced calls were related to information dissemination and counselling, underscoring the helpline's primary role as both an educational and emotional support resource. These services were especially valuable in helping individuals cope with anxiety and uncertainty, particularly for those seeking confirmation of HIV test results and requiring counselling related to their status.
- Abandoned Calls: The helpline made significant strides in reducing the rate of abandoned calls, from 14% in April 2023 to just 8% by March 2024, demonstrating improvements in call management and service delivery over the year.

4.5. Emerging Trends and Observations:

- Gender and Age Dynamics: While men continued to form the majority of callers, representing 92% of total calls, there was a noticeable increase in calls from women this year, reflecting the helpline's expanding reach across gender lines. The largest demographic of callers remained those in the 25 to 35-year age group, aligning with global trends indicating a heightened need for HIV awareness and testing among younger populations.
- Counselling and Mental Health Support: The helpline has proven to be an essential resource for addressing not only HIV-related queries but also mental health concerns.

- Many callers sought support for anxiety, depression and the social stigma associated with HIV. The impact of compassionate counselling has been transformative, as evidenced by numerous success stories where individuals reported feeling reassured and more confident in managing their health and well-being following counselling sessions.
- The helpline features a dedicated Online Grievance Redressal Management Portal. During the 2023-24 period, 1,145 grievances were registered and more than 80% of the grievances were successfully redressed within the stipulated timelines. These grievances predominantly relate to anonymity concerns, discriminatory attitudes towards PLHIV and challenges related to migration. The efficiency of the grievance redressal system reflects the helpline's commitment to addressing the systemic and social challenges faced by PLHIV, thereby improving access to care and support.

4.6. Strategic Outlook for the Future:

The data from 2023-24 reaffirms the helpline's role as a trusted and critical resource for HIV-related information, support and care, both for the general public and PLHIV. As the call volumes are expected to increase with continued promotional efforts, the helpline will focus on expanding its reach, especially in underrepresented regions and further reducing call abandonment rates. These efforts will ensure that seamless access to vital HIV information, testing support and care continues to be available to all who need it, further strengthening the national response to HIV/AIDS.

4.7. Youth Intervention

4.7.1 Red Ribbon Club (RRC)

 The Red Ribbon Club (RRC) initiative targets the youth aged 15-29 years, encouraging them to adopt a safe and healthy lifestyle. The • RRCs aim to raise awareness about HIV/AIDS and related issues, empowering youth to act as change agents for the HIV/AIDS programme as well as the community in which they live. The objective of the RRC is to educate the youth with accurate and comprehensive information, increasing their awareness of HIV/AIDS, Sexually Transmitted Infections and related issues. These clubs provide access to information on HIV/AIDS, voluntary blood donation, and safe sexual practices. Currently, there are over 14,000 functional RRCs in colleges across the country.

Activities undertaken by RRC members include:

- Observing important days and events (e.g., International Youth Day, World AIDS Day, college fests etc.)
- To prepare the youth as peer educators and agents of change by developing their skills on leadership and team building.
- Constituting Joint Working Group (JWG) for youth at the State level for smooth functioning of the program.

Table 4.1. States/UTs wise functional RRCs in colleges.

		operational Red Ribbon
		Club as on 31st
		March 2024
1	Andaman & Nicobar Islands	14
2	Andhra Pradesh	207
3	Arunachal Pradesh	57
4	Assam	300
5	Bihar	456
6	Chandigarh	25
7	Chhattisgarh	225
8	DNH & DD	24
9	Delhi	85
10	Goa	170
11	Gujarat	451
12	Haryana	429
13	Himachal Pradesh	309
14	J&K	332
15	Jharkhand	321
16	Karnataka	1736
17	Kerala	293
19	Madhya Pradesh	700
20	Maharashtra	882
21	Manipur	61
22	Meghalaya	83
23	Mizoram	45
24	Mumbai	140
25	Nagaland	106
26	Odisha	640
27	Puducherry	80
28	Punjab	700
29	Rajasthan	755
30	Sikkim	125
31	Tamil Nadu	2329
32	Telangana	770
33	Tripura	31
34	Uttar Pradesh	373
35	Uttarakhand	100
36	West Bengal	666
	Total	14,270

4.8. Adolescence Education Programme (AEP)

The Adolescence Education Programme (AEP) is a key intervention under NACP aimed at building 'life skill developments' among adolescents. The AEP helps them cope with negative peer pressure, develop positive behaviours, improve sexual health and prevent HIV infections. The objective of AEP is to reinforce positive behaviours and strengthen life skills, enabling young people to protect themselves from risky situations.

AEP is being implemented in Government schools in collaboration with NCERT. A 16-hour curriculum is delivered to adolescent students in classes IX and XI, covering more than 68,000 schools nationwide. The current status of the AEP's implementation is as follows:

Table 4.2. Status of AEP implementation in States/UT

Functional	Andaman & Nicobar Islands, Andhra Pradesh, Arunachal Pradesh, Assam, Bihar, Chandigarh, Chhattisgarh, Dadra & Nagar Haveli, Daman & Diu, Delhi, Goa, Gujarat, Haryana, Himachal Pradesh, J&K, Jharkhand, Karnataka, Kerala, Mizoram, Manipur, Meghalaya, Maharashtra, Nagaland, Odisha, Puducherry, Punjab, Rajasthan, Sikkim, Tamil Nadu, Telangana, Tripura, Uttarakhand, West Bengal
Non -	Uttar Pradesh
Functional	
Suspended	Madhya Pradesh

4.9. Status of implementation of the HIV and AIDS (Prevention & Control) Act 2017.

The Government of India enacted the HIV and AIDS (Prevention & Control) Act, 2017 that aims at preventing the spread of HIV and AIDS and to protect the rights of people affected by the virus. The Act prohibits stigma and discrimination against people living with HIV/AIDS, seeks to create an environment that is enabling for people living with HIV/AIDS and enhancing access to services. It also protects the rights of healthcare providers.


Under Section 12 of the Act, the HIV and AIDS Policy for Establishments was notified in 2022 by the Central Government. The policy mandates the establishments to generate awareness on HIV and AIDS, prevent transmission of HIV infection

amongst workers, protect rights of those infected with and affected by HIV/AIDS, ensure safe non-stigmatised and non-discriminatory working environment and maintaining the confidentiality of HIV-related data for protected persons.

The Act also provides for a empower for a robust grievance redressal mechanism in the form of an Ombudsman at the State level and a Complaints Officer at the establishment level aiming to provide speedy redressal. The State/UT-wise status of Rules notification, placement of Ombudsman & Complaints Officer and development of Web-sites, wherein the Ombudsman may receive complaints through electronic form, is as below:

Table 4.3. Status of Implementation of the HIV & AIDS (Prevention & Control) Act 2017 in States/UT

Status	States/UTs
States/UTs where Rules have been notified	Andaman & Nicobar Islands, Andhra Pradesh, Arunachal Pradesh, Assam, Bihar, Chandigarh, Chhattisgarh, Delhi, Goa, Gujarat, Himachal Pradesh, Jammu & Kashmir, Karnataka, Jharkhand, Kerala, Madhya Pradesh, Maharashtra, Manipur, Meghalaya, Mizoram, Nagaland, Puducherry, Punjab, Rajasthan, Sikkim, Tamil Nadu, Tripura, Uttar Pradesh, West Bengal
Ombudsman	Andaman & Nicobar Islands, Andhra Pradesh, Arunachal Pradesh, Assam, Bihar, Chandigarh, Chhattisgarh, DNHⅅ, Delhi, Goa, Gujarat, Haryana, Himachal Pradesh, Jammu & Kashmir, Karnataka, Jharkhand, Kerala, Madhya Pradesh, Maharashtra, Manipur, Meghalaya, Mizoram, Nagaland, Odisha, Puducherry, Punjab, Rajasthan, Sikkim, Tamil Nadu, Tripura, Uttar Pradesh, West Bengal
States/UTs where Complaints Officer have been deputed/ designated	Andaman & Nicobar Islands, Andhra Pradesh, Arunachal Pradesh, Assam, Bihar, Chandigarh, Chhattisgarh, DD & DNH, Delhi, Goa, Gujarat, Haryana, Himachal Pradesh, Karnataka, Jharkhand, Kerala, Madhya Pradesh, Maharashtra, Manipur, Meghalaya, Mizoram, Nagaland, Odisha, Puducherry, Punjab, Rajasthan, Sikkim, Tamil Nadu, Tripura, Uttar Pradesh, West Bengal
Website developed for Ombudsman	Andaman & Nicobar Islands, Arunachal Pradesh, Assam, Bihar, Chandigarh, Chhattisgarh, Delhi, Gujarat, Himachal Pradesh, Jammu & Kashmir, Karnataka, Jharkhand, Kerala, Madhya Pradesh, Maharashtra, Manipur, Meghalaya, Mizoram, Nagaland, Odisha, Puducherry, Punjab, Rajasthan, Sikkim, Tamil, Nadu, Tripura, Uttar Pradesh, West Bengal



PREVENTION OF NEW HIV AND STI INFECTIONS AMONG HIGH-RISK GROUPS AND BRIDGE POPULATION

5.1. Background

Prevention of HIV and STI infections among High-Risk Groups (HRGs) and Bridge Population, is one of the core strategies of the NACP since its inception. HRGs include Female Sex Workers (FSW), Men who have Sex with Men (MSM), People who Inject Drugs (PWID), Hijra/Transgender persons (H/TG), as well as population incarcerated in prisons, while Migrants and Transport workers are categorized as Bridge Population. Prevention services for these groups are delivered through various projects, such as Targeted Interventions (TI), Link Worker Schemes (LWS), Opioid Substitution Therapy (OST) centers, and interventions in Prisons and Other Closed Settings (P&OCS).

The TI and LWS projects are executed through Non-Governmental Organizations (NGOs) and Community-Based Organizations (CBOs). engaged by State AIDS Control Societies (SACS) through the Social Contracting Mechanism under the NACP. These prevention initiatives are strategically located in urban and rural settings to target specific groups, based on scientific evidence derived from programmatic mapping and population size estimations (PMPSE) as well as field intelligence. Furthermore, interventions for inmates within P&OCS are implemented in collaboration with the State Prison Department, Department of Women and Development, and other relevant State-level Government departments. In addition to regular interventions for inmates in prisons and other closed settings, a national "Integrated STI, HIV, Tuberculosis, and Hepatitis (ISHTH)" campaign was implemented in 2023-24 with the objective to enhance the provision of testing and treatment services for individuals residing in these environments.

OST plays a pivotal role in mitigating the risks of HIV and related infection like Hepatitis C among PWIDs. As a fundamental harm reduction strategy within the NACP, OST addresses opioid dependence by administering long-acting opioid agonist medication sublingually. This approach minimizes cravings and withdrawal symptoms, thus aiding in the cessation of drug injection. The therapy is primarily provided as "Directly Observed Treatment" at clinic-based OST Centres under the supervision of a Medical Officer, with take-home doses available for stable clients. OST is delivered through three models: the Collaborative Model at public health facilities, the NGO-Based Model at targeted intervention NGOs, and the Satellite Model, which includes provision of OST in prisons and other closed settings.

NACP offer comprehensive package of HIV and STI services to HRGs and bridge population through a peer-led outreach model. Efforts focus on identifying new HRGs, exploring their networks, reaching beyond traditional areas, targeting emerging hotspots, conducting index testing, and ensuring linkages to ART centers through peer navigation. Focus is also given on secondary needle and syringe distribution (SDNS) and establishing satellite OST centers to bring services closer to the community. The impact of the prevention program is demonstrated by its effectiveness in reaching HRG and bridge populations and delivering a comprehensive range of health and related services. This has been achieved through extensive community outreach, a person-based approach, and the establishment of linkages and referrals. Third parties conducts external evaluations of the NGOs/CBOs implementing TI & LWS projects. Currently, these evaluations are supported by the Global Fund (GF) grant. The key components and service delivery framework of TI projects are outlined in the table 5.1.

Table 5.1. Key components and service delivery framework of Targeted Intervention Projects

Components	Activities for Service Delivery*	Strategic Places /locations of Service Delivery
Behavior Change	Interpersonal Communication (IPC), Counselling, One-to-One, One-to-	Drop-In Centre (DIC)
Communication	Group Sessions, Use of SBCC Materials, NACO Help Line	Static Clinic
	Syndromic Case Management, Syphilis Screening (Biannual) and treatment,	Preferred Public Providers (PPP)
Clinical Services	Regular Medical Check-ups, Counselling and Follow-up visits, Partner	Health Camps
Cillical Services	management, Opioid Substitution Therapy (OST) for PWID, Abscess	Hotspots
	Management in the Static clinic set up in TI /Through referral or health camps	Congregation Sites / Halt Points
Commodity Provision	Condoms, Lubes, Clean Needle/Syringes etc. are distributed through	OST Centers (Public Health
	Peers, Outreach team, secondary distribution centres	Facility/ NGO run OST center)
Referral and Linkages	Referral to ICTC, ART, DSRC, Preferred Providers, TB, Other referred Centres as per the demand of the Community	Satellite OST Centers
Facility of Facility and the	Advocacy, Liaison with Key Stakeholders such as Community Gate Keepers	Secondary Distribution of
Enabling Environment	like Dera Heads, Police, Lawyers etc. Networking	Needle/Syringe Sites
Community Mobilization	Mobilization of Community Groups, Strengthening of CBOs and Community Systems	Referred Centers

^{*}Service delivery activities and locations/places of service delivery varies based on the types of subgroups of population covered under TI

To build the capacities of TIs/LWS staff, NACO, with the support of the GF grant, established Kshamta Kendras (KKs). These centers are designed to enhance the capacity and skills of project staff working with TI and LWS, as well as the implementing NGOs/CBOs under NACP. The KKs provide comprehensive training aimed at

improving service delivery and enhancing the efficiency of NGO/CBO staff by increasing their programmatic, technical, and managerial capacities. As of March 2024, a total of 19 Kshamta Kendras had been established serving all SACS/DACS (Table 5.2).

Table 5.2. States/UTs-wise distribution of Kshamta Kendra, March 2024

SACS/DACS	Location of Kshamta Kendra	Language Competency
Andhra Pradesh	Vijayawada	Telugu
Assam, Meghalaya, Arunachal Pradesh, Sikkim, Mizoram	Guwahati	Assamese, Hindi, English
Bihar, Chhattisgarh, Jharkhand	Patna	Hindi
Chandigarh, Himachal Pradesh, Jammu & Kashmir, Ladakh, Punjab	Mohali	Hindi, Punjabi
Delhi, Haryana, Uttarakhand	Delhi	Hindi
Gujarat, Dadra and Nagar Haveli and Daman & Diu	Kutch	Gujarati
Karnataka	Mysore	Kannada
Kerala, Lakshadweep	Thiruvananthapuram	Malayalam
Madhya Pradesh	Bhopal	Hindi
Maharashtra	Nagpur	Marathi
Manipur	Imphal	English
Mumbai, Goa	Mumbai	Hindi
Nagaland	Kohima	English
Odisha	Sundargarh	Odia
Rajasthan	Jaipur	Hindi
Tamil Nadu, Puducherry	Dindigul	Tamil
Telangana	Warangal	Telugu
Uttar Pradesh	Prayagraj	Hindi
West Bengal, Tripura	Kolkata	Bengali

One Stop Centres (OSCs) have been established with the GF grant support to enhance prevention efforts under NACP for HRG and bridge population. These centres provide comprehensive services to key groups like PWID, H/TG persons, and their partners through a person-centric approach in community settings. As on March

2024, there were 74 OSCs in 64 districts across 25 States. Around 60,000 bridge population members, 6,000 PWID, and 5,000 H/TG persons received services at these centres during 2023-24. State and typology-wise distribution is detailed in Table 5.3.

Table 5.3. States/UT-wise distribution of One Stop Centres, March 2024

S.No	States/UT	Bridge population	Hijra/ Transgender people	People who inject drugs	Total
1	Arunachal Pradesh	-	-	2	2
2	Assam	2	2	2	6
3	Bihar	-	1	1	2
4	Chhattisgarh	-	1	1	2
5	Delhi	2	2	2	6
6	Gujarat	3	-	-	3
7	Haryana	2	-	2	4
8	Himachal Pradesh	2	-	1	3
9	J&K and Ladakh	1	-	1	2
10	Jharkhand	3	1	-	4
11	Karnataka	1	2	-	3
12	Kerala	-	1	-	1
13	Maharashtra	4	2	-	6
14	Madhya Pradesh	-	2	-	2
15	Manipur	1	-	-	1
16	Mizoram	-	-	1	1
17	Meghalaya	1	-		1
18	Nagaland	-	-	1	1
19	Odisha	3	-	-	3
20	Punjab	-	1	-	1
21	Tamil Nadu	3	1	-	4
22	Telangana	1	-	-	1
23	Tripura	-	-	4	4
24	Uttar Pradesh	4	2	1	7
25	West Bengal	1	2	1	4
	India	34	20	20	74

5.2. Coverage of HRG and bridge population through TI projects: An overview

In the financial year 2023-24, a total of 1,577 TI projects out of sanctioned 1,633 were onboarded with coverage of 90% or more, except for truckers where coverage was at 56% (Table 5.4). HRG

coverage improved in 2023-24, with PWID up by 18% and H/TG persons up by 23% from 2022-23. Coverage was maintained over 95% for FSW and MSM. Among the bridge population, coverage of migrants was over 95%, while coverage among truckers witnessed a 3% rise from the previous year. Overall national coverage of HRG reached ≥ 95%.


Table 5.4. Typology wise number of TIs and population coverage, 2023-24

S.No	Typology	Size Estimate (in Lakh)	Exclusive TI	Composite TI	TI projects (Exclusive + Composite) by typology	Coverage (in Lakh)	Coverage (In %)
1	FSW	9.95	292	612	904	10.75	≥95
2	MSM	3.51	75	548	623	3.91	≥95
3	PWID	2.89	197	297	494	2.60	90
4	H/TG people	0.96	41	379	420	0.87	91
5	Migrants	72	203	262	465	77.75	≥95
6	Truckers	20	77	127	204	11.21	56
7	Total	109.31		1,5	77	107.09	≥95

Number of TI projects and coverage of HRGs and bridge population has increased over the last seven years (Figure 5.1). Although coverage dropped in 2020-21 due to COVID-19, it increased afterwards. In 2023-24, coverage

increased by about 6% compared to the previous year. Efforts to reach unreached populations and new registrations within and beyond catchment areas contributed to this increase.

Figure 5.1. Number of TI projects and population coverage, 2017-18 to 2023-24



5.3. FSW coverage through TI projects

Overall, around 10.75 lakh FSW were covered in 2023-24, representing an increase of approximately 1 lakh FSW compared to the previous year, 2022-23 (Figure 5.2). The TI projects focused on reaching previously unreached individuals, new registrations of sex workers, enhancing outreach activities, and expanding access to social and sexual networks. This approach resulted in an increase in the coverage of overall population with services.

The total clinic visits by FSW saw a significant rise, reaching approximately around 31 lakh in 2023-24, up from around 25.9 lakh in 2022-23 (Table 5.5). Additionally, the average number of clinic visits per FSW increased from 2.7 visits in 2022-23 to 2.9 visits in 2023-24. Of the total clinic visits, around 1.5% were for the treatment of sexually transmitted infections (STI). There were 14.85 lakh syphilis screening tests, detecting 1,072 positive cases at a 0.07% positivity rate. Free condom distribution decreased to around 14.49 crores in 2023-24.



Figure 5.2. Key prevention services provided to FSW, 2017-18 to 2023-24

HIV screenings among FSW increased from 13.54 lakh in 2022-23 to 15.36 lakh in 2023-24, with 2,053 tested positive. The sero-positivity rate for HIV among tests conducted increased from 0.11% to 0.13%, yet remains below 0.2%. ART linkage for HIV-positive FSW improved from 85% to 89%.

Twenty States/UTs reported over 95% coverage against the estimated FSW size, with Assam at the lowest (around 39%). Eleven States/UTs achieved

ART linkage of 95% or more for HIV-positive FSW (Table 5.5). Efforts continue to link all identified HIV-positive FSWs to ART centres through peer navigation. The State/UT-wise distribution of FSW coverage in key service parameters for 2023-24 is shown in table 5.5. Overall, 2023-24 data shows progress in coverage, clinic visits, HIV screening, STI screening and treatment, and ART linkage.

Table 5.5. States/UTs-wise coverage of FSW on key service parameters, 2023-24

States /UTs	Total coverage	Covera ge (%)	Clinic visit (Lakh)	STI treated	Syphilis screening (lakh)	Syphilis- positive detected	Condom distributi on (Lakh)	HIV screenin g (Lakh)	HIV- positive detecte d	Linked to ART	ART linkage (%)
ANI	28	-	-	-	0	0	0.01	0.02	0	0	-
Andhra Pradesh	1,57,169	≥95	4.89	2,043	2.32	6	245.72	2.47	75	55	73
Arunachal Pradesh	6,157	88.71	0.15	154	0.09	107	6.23	0.09	9	6	67
Assam	15,466	38.94	0.47	688	0.21	94	20.61	0.21	50	45	90
Bihar	6,539	55.98	0.19	174	0.09	24	11.84	0.1	18	18	≥95
Chandig arh	4,863	<u>≥</u> 95	0.12	147	0.06	0	11.77	0.06	10	10	<u>≥</u> 95
Chhattis garh	23,911	<u>≥</u> 95	0.73	2,649	0.35	60	52.6	0.38	87	72	83
Delhi	69,039	78.1	2.14	3,521	0.93	16	31.31	0.9	103	87	84
Goa	6,832	≥95	0.23	246	0.11	0	19.85	0.12	2	0	0
Gujarat	33,690	90.76	1.2	1,885	0.59	49	123.21	0.58	29	29	≥95
Haryana	16,426	92.97	0.42	1,024	0.18	26	22.03	0.2	68	44	65
Himachal Pradesh	7,799	59.04	0.24	921	0.13	5	10.63	0.13	6	6	≥95
Jammu and Kashmir Ladakh	2,903	62.65	0.09	926	0.01	0	0.45	0.04	0	0	-
Jharkhand	18,588	≥95	0.61	700	0.28	1	27.06	0.29	15	14	93
Karnataka	1,47,020	≥95	4.43	4,173	2.11	73	73.6	2.07	200	190	≥95
Kerala	29,379	≥95	0.59	573	0.22	19	20.88	0.32	3	3	≥95
Madhya Pradesh	50,875	≥95	1.58	3,575	0.8	79	46.99	0.82	72	64	89
Maharas htra	1,00,599	≥95	3.3	7,485	1.68	149	196.8	1.55	185	146	79
Manipur	6,639	<u>≥</u> 95	0.17	119	0.08	1	11.87	0.06	8	8	≥95
Meghalaya	2,297	69.68	0.08	304	0.04	44	3.68	0.03	19	14	74
Mizoram	1,167	81.41	0.04	84	0.02	11	1.76	0.01	21	21	<u>≥</u> 95
Nagaland	4,040	≥95	0.14	70	0.06	0	7.26	0.07	19	14	74
Odisha	17,916	72.77	0.56	2,269	0.29	39	19.57	0.28	38	35	92
Puduche rry	3,196	≥95	0.1	82	0.05	5	6.05	0.05	2	2	≥95
Punjab	27,583	<u>></u> 95	0.6	894	0.27	24	18.12	0.31	81	65	80
Rajasthan	23,682	<u>≥</u> 95	0.64	1,545	0.17	18	28.62	0.3	19	17	89
Sikkim	1,109	≥95	0.03	81	0.02	4	2.83	0.02	0	0	-
Tamil Nadu	61,349	<u>≥</u> 95	1.1	1,282	0.73	84	60.8	0.72	64	57	89
Telanga na	1,60,718	<u>≥</u> 95	4.08	3,358	1.98	49	223.07	2.16	673	650	<u>≥</u> 95
Tripura	6,079	≥95	0.14	231	0.07	1	4.83	0.07	14	12	86
Uttar Pradesh	32,368	79.96	0.9	3,068	0.47	28	61.59	0.48	105	88	84
Uttarakh and	7,368	≥95	0.23	1,098	0.11	7	10.74	0.11	18	18	≥95
West Bengal	22,282	<u>≥</u> 95	0.62	672	0.33	49	67.04	0.34	40	36	90
India	10,75,076	<u>≥</u> 95	30.81	46,041	14.85	1,072	1,449.42	15.36	2,053	1,826	89

5.4. MSM coverage through TI projects

In 2023-24, 3.91 lakh MSM were covered, an increase of over 0.56 lakh from the previous year's coverage (Figure 5.3). This increase resulted from TI Projects' efforts to reach new MSM populations, improve outreach, and enhance social and sexual networks. Clinic visits by MSM increased significantly to 10.61 lakh in 2023-24 from 9.05 lakh in 2022-23, with each MSM visiting thrice on an average for STI-related services. Of these visits, around 9,412 were for treatment of STI episodes. Around 5.12 lakh MSM were screened for syphilis, with 1,679 testing positive, resulting in a seropositivity rate of 0.33% nationally. With the increase in coverage, HIV screening among MSM also increased from 4.83 lakh in 2022-23 to 5.25

lakh in 2023-24, wherein a total of 2,014 MSM were diagnosed HIV positive. The percentage of HIV- positive MSM linked to ART increased from 92% to 93%. The provision of free condom distribution decreased in 2023-24 to around 4.71 crore, compared to 6.43 crore in 2022-23. Twenty-one States/UTs reported 95% or higher coverage of the estimated MSM population, with Assam at the lowest coverage of 36%. Nineteen States/UTs achieved 100% ART linkage. Efforts are underway to link all identified HIV-positive MSMs to ART centres through the peer navigation approach. The States/UT- wise distribution of MSM coverage in key service parameters for 2023-24 is shown in table 5.6. Overall, 2023-24 data shows progress in coverage, clinic visits, HIV screening, STI screening and treatment, and ART linkage.

Figure 5.3. Key prevention services provided to MSM, 2017-2018 to 2023-2024




Table 5.6. States/UT-wise coverage of MSM on key service parameters, 2023-24

States	Total	Coverag	Clinic	STI	Syphilis	Syphilis-	Condom	HIV	HIV-	Linked	ART
/UT	Coverag e	e (%)	Visit (Lakh)		Screening (lakh)	positive detected	Distributi on (Lakh)	Testing (Lakh)	positive detected	to ART	Linkage (%)
ANI	26	-	0	3	0	3	0	0.02	1	1	≥95
Andhra Pradesh	32,931	≥95	0.99	174	0.48	18	52.98	0.51	50	33	84
Arunachal Pradesh	942	<u>></u> 95	0.02	24	0.01	42	0.7	0.01	21	21	<u>></u> 95
Assam	6,082	36	0.19	160	0.09	61	6.34	0.09	99	83	94
Bihar	1,427	60	0.04	18	0.02	8	1.91	0.02	9	8	≥95
Chandig arh	3,438	≥95	0.1	60	0.05	9	7.17	0.05	22	20	≥95
Chhattis garh	4,539	<u>≥</u> 95	0.14	420	0.07	39	11.22	0.07	60	57	≥95
Delhi	29,355	<u>≥</u> 95	0.81	286	0.34	46	16.84	0.27	104	94	<u>≥</u> 95
Goa	4,841	<u>≥</u> 95	0.15	160	0.07	1	9.32	0.08	14	10	≥95
Gujarat	31,891	93	1.14	1,173	0.55	183	81.73	0.53	100	90	93
Haryana	6,068	76	0.19	273	0.08	40	7.48	0.09	100	73	84
Himachal Pradesh	1,463	≥95	0.04	154	0.02	10	1.83	0.02	14	13	≥95
Jammu and Kashmir	716	≥95	0.03	86	0.01	-	0.17	0.01	-	0	-
Ladakh											
Jharkhand	2,562	≥95	0.09	60	0.05	-	3.56	0.05	16	16	≥95
Karnataka	49,093	≥95	1.42	623	0.71	101	35.35	0.7	210	206	≥95
Kerala	22,786	≥95	0.44	365	0.15	76	13.23	0.22	33	27	94
Madhya Pradesh	18,641	≥95	0.6	752	0.3	96	12.43	0.31	112	96	87
Maharas htra	32,658	81	1.14	2,028	0.57	120	49.39	0.49	134	110	93
Manipur	2,054	≥95	0.04	4	0.02	4	2.12	0.02	5	5	≥95
Meghala ya	259	75	0.01	-	0	1	0.33	0	1	1	≥95
Mizoram	1,032	<u>≥</u> 95	0.03	2	0.02	10	0.84	0.02	10	10	90
Nagaland	2,920	≥95	0.08	19	0.04	4	5.38	0.04	15	15	≥95
Odisha	4,420	74	0.13	380	0.06	25	4.37	0.07	33	31	≥95
Puduche rry	3,097	≥95	0.1	31	0.05	30	6.7	0.05	7	7	≥95
Punjab	6,269	78	0.19	209	0.08	50	5.01	0.1	80	71	90
Rajasthan	8,259	≥95	0.24	309	0.06	29	8.18	0.11	63	49	76
Sikkim	-	0	-	-	-	-	-	-	-	0	-
Tamil Nadu	42,885	<u>≥</u> 95	0.8	380	0.52	526	43.3	0.5	163	158	≥95
Telangana	47,577	<u>≥</u> 95	0.81	213	0.36	40	49.11	0.48	301	260	90
Tripura	896	<u>≥</u> 95	0.02	20	0.01	7	0.57	0.01	18	18	≥95
Uttar Pradesh	16,180	82	0.47	682	0.23	59	26.88	0.24	168	146	≥95
Uttarakh and	3,191	≥95	0.1	309	0.05	16	4.32	0.05	18	17	94
West Bengal	2,966	84	0.06	35	0.03	25	2.02	0.03	33	31	≥95
India	3,91,464	<u>></u> 95	10.61	9,412	5.10	1,679	470.78	5.26	2,014	1,777	93

5.5. H/TG persons coverage through TI projects

In 2023-24, around 0.87 lakh H/TG persons were covered, an increase of 0.21 lakh from 2022-23 (Figure 5.4). The increase in service coverage resulted from efforts to reach the unreached and new registrations through improved outreach activities. Clinic visits by H/TG persons increased significantly from 1.85 lakh in 2022-23 to 2.55 lakh in 2023-24. Average clinic visits per H/TG person increased from 2.84 in 2022-23 to 2.95 in 2023-24. Additionally, 3 thousand H/TG persons received STI treatment in 2023-24. Around 1.23 lakh syphilis screenings were conducted among H/TG population, with 536 cases testing positive (0.43%). HIV screening increased from 99,000 in 2022-23 to 126,000 in 2023-24, wherein a total of 516 H/TG persons tested positive for HIV. The

percentage of HIV-positive H/TG persons linked to ART dropped from 91% to 87%. Free condom distribution decreased from 1.80 crore to 1.34 crore. Fifteen States/UTs reported coverage of 95% or more H/TG people against size estimates, with Himachal pradesh at the lowest with 20%. Eight States/UTs achieved 95% or more ART linkage. Efforts are ongoing to link all identified HIV positive HRGs to ART centres through peer navigation. The State/UTs-wise distribution of H/TG coverage in key service parameters for 2023-24 is shown in table 5.7. Overall, 2023-24 data shows progress in coverage, clinic visits, HIV screening, STI screening and treatment, and ART linkage.

Figure 5.4. Key prevention services provided to H/TG persons, 2017-2018 to 2023-2024




Table 5.7. States/UT-wise coverage of H/TG people on key service parameters, 2023-24

States /UTs	Total Coverag e	Coverag e (%)	Clinic Visit (Lakh)	STI Treated	Syphilis Screenin g (lakh)	Syphilis- positive detected	Condom Distributi on (Lakh)	HIV Testing (Lakh)	HIV- positive detected	Linked to ART	ART Linkage (%)
ANI	4	-	0	1	0	1	0	0.02	-	-	-
Andhra Pradesh	5,172	>95	0.17	38	0.08	3	10.21	0.08	29	16	55
Arunach al Pradesh	155	>95	0	4	0	4	0.13	0	4	4	<u>></u> 95
Assam	929	37	0.03	39	0.01	12	1.1	0.01	-	4	80
Bihar	-	0	-	-	-	-	-	-	-	-	-
Chandig arh	236	>95	0.01	2	0	1	0.56	0	-	-	-
Chhattis garh	1,385	>95	0.04	169	0.02	13	4.01	0.02	-	7	58
Delhi	15,562	87	0.49	285	0.22	29	13.62	0.2	88	44	94
Goa	214	>95	0.01	18	0	-	0.34	0.00	1	1	50
Gujarat	1,932	74	0.07	17	0.03	2	3.88	0.03	14	3	50
Haryana	506	35	0.01	13	0.01	-	0.39	0.01	2	4	80
Himacha I Pradesh	51	20	0	-	0	-	0.05	0	-	-	-
J&K and Ladakh	=	0	-	-	-	-	-	-	-	-	-
Jharkhan d	721	>95	0.02	4	0.01	-	0.82	0.01	2	1	<u>≥</u> 95
Karnatak a	11,342	>95	0.34	221	0.15	31	10.05	0.15	38	53	≥95
Kerala	4,351	>95	0.09	65	0.05	19	3.49	0.05	3	6	86
Madhya Pradesh	1,059	66	0.03	23	0.02	5	0.61	0.02	5	6	86
Maharashtra	10,690	>95	0.36	23	0.19	105	31.26	0.17	56	76	86
Manipur	792	>95	0.02	3	0.01	2	0.76	0.01	2	1	50
Meghala ya	38	35	0	-	0	-	0.07	0	-	-	-
Mizoram	-	0	-	-	-	-	-	-	-	-	-
Nagalan d	151	>95	0.01	1	0	-	0.32	0	1	1	≥95
Odisha	4,844	67	0.15	523	0.07	109	6.73	0.07	54	53	90
Puduche rry	257	>95	0.01	1	0	4	0.71	0	1	1	≥95
Punjab	1,345	>95	0.05	17	0.02	7	1.24	0.02	5	7	88
Rajastha n	1,893	89	0.06	59	0.02	4	1.68	0.03	0	8	89
Sikkim	-	0	-	-	-	-	-	-	-	-	-
Tamil Nadu	9,481	>95	0.17	58	0.11	143	12.16	0.11	22	39	≥95
Telanga na	3,853	>95	0.12	18	0.06	3	15.91	0.07	0	41	79
Tripura	141	89	0	-	0	-	0.05	0	-	-	-
Uttar Pradesh	6,444	65	0.19	244	0.1	23	10.96	0.1	46	49	<u>≥</u> 95
Uttarakh and	280	87	0.01	53	0.01	-	0.42	0	2	2	≥95
West Bengal	2,712	53	0.08	78	0.04	16	2.53	0.04	25	22	88
India	86,540	90	2.54	1,977	1.23	536	134.06	1.23	401	449	87

5.6. PWID coverage through TI projects

In 2023-24, around 2.60 lakh PWID were covered, an increase of 0.52 lakh from the previous year, reaching to around 90% of the estimated population (Figure 5.5 and Table 5.8). Seventeen States/UTs reported at least 95% coverage, with Haryana at the lowest with 51%. Efforts to reach new PWID and enhance outreach led to increased coverage. Provision of free needles/syringes increased from 4.16 crore to 5.46 crore over the same period. Clinic visits increased to 7.14 lakh in 2023-24 from 5.81 lakh in 2022-23, though average clinic visits per PWID slightly decreased from 2.81 to 2.75. A total of 2,165 PWID were treated for STI in 2023-24. Around 3.36 lakh

syphilis tests were conducted, detecting 350 positive cases with a national sero-positivity of 0.10%. HIV screening among PWID increased from 2.78 lakh in 2022-23 to 3.39 lakh in 2023-24 with detection of 5,516 HIV-positive PWID. The percentage of HIV-positive PWID linked to ART improved from 76% to 79%, wherein nine States/UTs achieved ART linkage of 95% or more. Efforts are being made via peer navigator approach to link all identified HIV-positive PWIDs to ART centres. The States/UTs-wise distribution of PWID coverage in key service parameters for 2023-24 is shown in table 5.8. Overall, 2023-24 data shows progress in coverage, clinic visits, HIV screening, STI screening and treatment, and ART linkage.

Figure 5.5. Key prevention services provided to PWID, 2017-2018 to 2023-2024




Table 5.8. States/UT-wise coverage of PWID on key service Parameters , 2023-24

States /UT	Tota l coverag e	Cov erag e (%)	Clinic visit (lakh)	STI treated	Syphilis screeni ng (lakh)	Syphilis - positive	Condo m distribut ion (lakh)	N/S distribut ion (lakh)	HIV testing (akh)	HIV- positive	Linked to ART	ART Iinkage (%)
ANI	-	-	-	-	-	-	-	0.00	0.02	-	-	
Andhra Pradesh	2,415	≥95	0.08	28	0.04	-	2.46	7.88	0.04	3	3	≥95
Arunachal Pradesh	7,800	≥95	0.12	56	0.09	39	1.01	9.74	0.09	307	267	87
Assam	17,128	65	0.42	93	0.2	47	3.46	67.24	0.2	1,999	1,572	79
Bihar	3,020	66	0.11	66	0.05	-	0.8	21.50	0.06	20	20	<u>≥</u> 95
Chandigarh	2,624	≥95	0.08	4	0.04	-	1.06	11.05	0.04	4	3	75
Chhattisgarh	4,391	≥95	0.15	214	0.07	2	1.33	13.27	0.07	15	6	40
De l hi	18,566	57	0.59	97	0.28	5	0.6	125.43	0.24	262	189	72
Goa	769	≥95	0.02	33	0.01	-	0.42	1.91	0.02	-	-	-
Gujarat	1,053	≥95	0.04	1	0.02	-	0.15	2.89	0.02	1	1	≥95
Haryana	9,709	51	0.2	59	0.1	111	1.62	30.46	0.11	389	262	67
Himachal Pradesh	3,163	86	0.08	7	0.05	1	0.7	9.26	0.05	35	28	80
Jammu and Kashmir Ladakh	5,886	58	0.17	548	0.05	1	0.6	21.97	0.09	10	10	≥95
Jharkhand	1,429	≥95	0.05	9	0.02	-	0.61	7.79	0.02	4	3	75
Karnataka	2,641	61	0.07	5	0.04	-	0.4	9.23	0.04	4	4	≥95
Kerala	3,927	≥95	0.1	1	0.05	2	0.35	8.73	0.05	-	-	-
Madhya Pradesh	13,492	<u>≥</u> 95	0.36	55	0.18	11	2.76	29.40	0.18	101	77	76
Maharashtra	810	74	0.03	21	0.01	3	0.14	0.81	0.01	7	7	≥95
Manipur	29,126	<u>></u> 95	0.73	72	0.35	8	19.45	118.76	0.36	75	56	75
Meghalaya	2,746	86	0.08	13	0.04	12	0.6	6.34	0.04	52	34	65
Mizoram	14,923	≥95	0.47	37	0.19	16	5.94	50.88	0.15	206	183	89
Nagaland	31,652	≥95	0.81	48	0.38	29	14.51	39.76	0.4	193	150	78
Odisha	3,611	80	0.12	110	0.06	2	0.8	10.65	0.06	15	13	87
Puducherry	-	0	-	-	-	-	-	-	-	-	-	-
Punjab	31,555	70	0.91	108	0.38	33	4.55	71.55	0.4	686	553	81
Rajasthan	2,479	82	0.07	8	0.03	-	0.41	13.42	0.03	26	23	88
Sikkim	1,690	<u>≥</u> 95	0.04	3	0.02	1	0.96	8.18	0.02	1	1	<u>≥</u> 95
Tamil Nadu	557	≥95	0.02	2	0.01	3	0.08	0.79	0.01	3	3	<u>≥</u> 95
Telangana	1,437	≥95	0.04	11	0.02	-	0.95	8.55	0.02	2	2	≥95
Tripura	7,648	<u>></u> 95	0.25	1	0.11	-	1.13	30.45	0.09	640	503	79
Uttar Pradesh	26,923	76	0.78	237	0.38	21	7	170.82	0.39	356	301	85
Uttarakhand	3,509	91	0.1	217	0.05	1	0.96	24.12	0.05	75	68	91
West Bengal	2,914	≥95	0.06	1	0.03	2	0.2	16.03	0.03	25	20	80
India	2,59,593	90	7.15	2,165	3.35	350	76.01	948.89	3.39	5,516	4,362	79

5.7. Opioid Substitution Therapy (OST) for PWID

Since 2007, NACP has used Opioid Substitution Therapy (OST) to reduce HIV and other infections among PWIDs. OST involves treating patients with long-acting opioid agonists to minimize craving and withdrawals, allowing them to stop injecting drugs. Combined with psycho-social support, the program has effectively reduced drug-related harms, including HIV/HCV transmission and overdose.

OST is mainly provided as "Directly Observed Treatment" at clinic-based OST centres supervised by a Medical Officer. Take-home doses are available for stable clients at the discretion of the medical officer. The program operates through three models: Public health facilities-based collaborative model, NGO-based Targeted Intervention NGOs, and Satellite Models in prisons and closed settings.

Collaborative Model: This model places the OST center in a Government healthcare facility (e.g., medical college hospital, district hospital). It operates as a standalone center with a Nodal

Officer, Medical Doctor, Nurse, Counsellor, and Data Manager. The staff handle clinical assessments, diagnose opioid dependence, prescribe treatments, dispense medications daily, provide psychosocial counselling, and manage follow-ups and referrals. The center collaborates with nearby PWID TI project/s to boost service uptake through demand generation activities and client referrals.

NGO Model: This model places the OST centre within an existing PWID TI project that offers HIV prevention services like needle syringe exchange programs. Existing staff such as Medical Doctors, Nurses, Counsellors, Data Managers, and outreach workers are trained for OST service delivery. The NGO OST centre operates as a Standalone facility, responsible for clinical assessment, diagnosis, treatment prescription, medication dispensing, counseling, follow-up, referrals, and linkages. Additional Auxiliary Nurse Midwifery (ANM) and outreach workers support the team.

Satellite OST Model: A Satellite OST center is a sub-center of a full-fledged OST center, typically located far from the main center to serve clients in remote areas (more than 15-20 km away) or to reduce congestion at high daily client load centers. It provides accessible OST services for those with long travel times and helps ensure quality service delivery. These centers are linked to a parent/main center from either of the two models above.

The number of OST clients increased from 29.1 thousand in 2018-19 to 54.2 thousand in 2023-24 (Figure 5.6). This increase is due to the expansion of OST centers from 215 to 263 facilities over six years. The proportion of PWIDs on OST treatment also increased from 19% to 22% during this period (Figure 5.7).




Figure 5.6. OST centers and client coverage, 2018-19 to 2023-24

The OST program under NACP Phase V primarily implements a public health model, with 214 centers in public health settings and 49 in TI NGO settings as of 2023-24 (Table 5.9). Additionally,

there are 164 satellite OST centers linked to the main OST centres, significantly enhancing accessibility, coverage and service uptake among the PWID population.




Figure 5.7. Proportion of PWID on OST, 2018-19 to 2023-24

Table 5.9. States/UT-wise OST facilities and active population on OST (2023-24)

States/UT	OSTC in Public Health	OSTC in NGO Settings	PWID on OST
	Settings		
ANI	0	0	-
Andhra Pradesh	2	0	453
Arunachal Pradesh	4	0	775
Assam	6	0	3,329
Bihar	2	0	227
Chandigarh	0	4	909
Chhattisgarh	6	0	1,218
Delhi	8	4	2,793
DNHⅅ	0	0	-
Goa	0	1	126
Gujarat	2	0	88
Haryana	13	0	2,094
Himachal Pradesh	1	0	214
Jammu & Kashmir	,	_	2.11
Ladakh	6	0	841
Lakshadweep	0	0	-
Jharkhand	3	0	124
Karnataka	2	0	141
Kerala	7	3	549
Madhya Pradesh	13	4	1,854
Maharashtra	1	2	199
Manipur	19	7	5,033
Meghalaya	3	3	1,117
Mizoram	13	4	3,348
Nagaland	26	5	8,826
Odisha	4	1	484
Puducherry	0	0	0
Punjab	26	9	10,305
Rajasthan	3	0	342
Sikkim	4	0	2095
Tamil Nadu	1	0	75
Telangana	1	0	26
Tripura	6	0	2,640
Uttarakhand	7	1	657
Uttar Pradesh	18	0	2,380
West Bengal	7	1	948
India	214	49	54,210


 $[\]star\star$ In addition to the above-mentioned OST Centre, there are 164 Satellite OST centers.

5.8. Migrants coverage through TI projects

In 2023-24, around 77.8 lakh migrants were covered, an increase of 3.3 lakh from 2022-23 (Figure 5.8). Coverage declined in 2020-21 due to COVID-19 but improved in later years. About 9.13

lakh migrants were tested for HIV in 2023-24, with a sero-positivity of 0.15%. This is a decrease from 9.53 lakh tested in 2022-23, though sero-positivity increased from 0.12% to 0.15%. The overall sero-positivity remains below 0.2%, with 86% of HIV-positive migrants linked to ART.

Figure 5.8. Key prevention services provided to migrants, 2017-2018 to 2023-2024



Nineteen States/UTs reported coverage of 95% or more of the estimated migrants population. Meghalaya reported the lowest coverage at 1.94%. Eleven States/UTs achieved ART linkage of 95% or more. The States/UTs-wise distribution of coverage of migrants in key service parameters during 2023-24 is provided in table 5.10.

5.9. Truckers coverage through TI projects

In 2023-24, 11.2 lakh truckers were covered, an increase of around 0.6 lakh from 2022-23 (Figure 5.9). About 3.11 lakh truckers were screened for HIV, with a sero-positivity rate of 0.14%, an increase from 0.12% in 2022-23. Around 73% of HIV-positive truckers were linked to ART.

Fourteen States/UTs reported at least 95% coverage of truckers, with Goa being the lowest at 43% (Table 5.11). Five States/UTs achieved ART linkage of 95% or more. Efforts continue to link all identified HIV-positive Truckers to ART centers by strengthening outreach.

Figure 5.9. Key prevention services provided to truckers, 2017-2018 to 2023-2024




Table 5.10. States/UT-wise coverage of migrants on key service parameters, 2023-24

Charac/UT	Tatal account	Coverage	HIV testing	HIV-	Linked to	ART linkage
States/UT	Total coverage	(%)	(lakh)	positive	ART	(%)
ANI	288	-	0.00	22	20	91
Andhra Pradesh	92,485	46	0.34	22	14	64
Arunachal Pradesh	83,298	<u>≥</u> 95	0.15	21	17	81
Assam	17,515	88	0.05	46	29	63
Bihar	0	-	-	-	-	-
Chandigarh	64,093	<u>≥</u> 95	0.09	5	5	≥95
Chhattisgarh	2,64,060	<u>≥</u> 95	0.44	32	24	75
DNHⅅ	0	-	-	-	-	-
Delhi	7,33,483	≥95	0.37	110	87	79
Goa	98,015	<u>≥</u> 95	0.12	9	7	78
Gujarat	8,68,629	66	0.56	48	46	<u>≥</u> 95
Haryana	2,29,943	<u>></u> 95	0.15	31	30	≥95
Himachal Pradesh	97,344	67	0.1	11	10	91
J&K and Ladakh	55,664	<u>≥</u> 95	0.05	3	3	<u>≥</u> 95
Lakshadweep	0	=	-	-	-	=
Jharkhand	80,058	>95	0.08	4	4	>95
Karnataka	4,58,807	<u>≥</u> 95	0.64	69	66	≥95
Kerala	1,22,875	82	0.44	81	62	77
Madhya Pradesh	3,05,663	≥95	0.34	48	41	85
Maharashtra	27,94,269	<u>></u> 95	3.07	398	347	87
Manipur	4,729	30	0.01	2	2	≥95
Meghalaya	978	2	0.01	1	-	0
Mizoram	66,521	<u>></u> 95	0.11	86	72	84
Nagaland	27,199	<u>></u> 95	0.04	6	6	<u>></u> 95
Odisha	2,77,200	<u>≥</u> 95	0.43	56	52	93
Puducherry	17,818	<u>></u> 95	0.08	5	5	<u>></u> 95
Punjab	93,148	71	0.09	9	6	67
Rajasthan	2,11,587	<u>></u> 95	0.2	28	24	86
Sikkim	-		-	-	-	-
Tamil Nadu	66,237	34	0.21	28	24	86
Telangana	91,253	<u>></u> 95	0.37	54	51	94
Tripura	20,709	58	0.05	5	5	<u>≥</u> 95
Uttarakhand	1,24,475	38	0.18	47	43	91
Uttar Pradesh	3,48,300	<u>></u> 95	0.22	22	22	<u>≥</u> 95
West Bengal	58,574	<u>></u> 95	0.12	7	6	86
India	7,775,217	<u>></u> 95	9.13	1,316	1,130	86

Table 5.11. States/UT-wise coverage of truckers on key service parameters, 2023-24

State/UT	Total coverage	Coverage (%)	HIV testing (Lakh)	HIV-positive	Linked to ART	ART linkage (%)
ANI	5,000	-	0.00	1	1	<u>≥</u> 95
Andhra Pradesh	30,500	58	0.16	10	6	60
Arunachal Pradesh	-	-	-	-	-	-
Assam	27,500	<u>≥</u> 95	0.05	19	11	58
Bihar	10,000	67	0.02	13	13	<u>></u> 95
Chandigarh	10,000	65	0.03	3	2	67
Chhattisgarh	65,000	<u>></u> 95	0.35	31	20	65
Delhi	40,000	67	0.06	15	10	67
Goa	10,000	43	0.03	2	2	<u>≥</u> 95
Gujarat	55,000	46	0.09	12	9	75
Haryana	45,000	<u>></u> 95	0.07	49	45	92
Himachal Pradesh	10,000	71	0.03	2	0	0
J&K and Ladakh	35,000	<u>≥</u> 95	0.04	4	0	0
Jharkhand	32,500	93	0.06	5	4	80
Karnataka	87,500	<u>≥</u> 95	0.16	24	18	75
Kerala	30,000	<u>≥</u> 95	0.10	18	4	22
Madhya Pradesh	74,500	88	0.43	36	31	86
Maharashtra	205,000	<u>≥</u> 95	0.58	75	49	65
Manipur	-	-	-	-	-	-
Meghalaya	-	-	-	-	-	-
Mizoram	-	-	-	-	-	-
Nagaland	10,000	<u>≥</u> 95	0.03	1	0	0
Odisha	20,000	<u>≥</u> 95	0.08	18	17	94
Puducherry	-	-	-	-	-	-
Punjab	25,000	-	0.04	6	5	83
Rajasthan	20,000	52	0.03	2	2	<u>≥</u> 95
Sikkim	-	-	-	-	-	-
Tamil Nadu	59,000	<u>≥</u> 95	0.13	22	16	73
Telangana	49,000	<u>></u> 95	0.17	10	10	<u>≥</u> 95
Tripura	5,000	<u>></u> 95	0.02	10	8	80
Uttar Pradesh	55,000	76	0.14	28	24	86
Uttarakhand	45,000	<u>></u> 95	0.06	7	5	71
West Bengal	60,000	<u>></u> 95	0.15	22	15	68
India	11,20,500	56	3.11	445	327	73

5.10. Prison Intervention

NACO in collaboration with respective SACS, the State Prison Department (SPD), and the Depart ment of Women and Child Development (WCD), has been implementing HIV and TB interventions for inmates in prison and other closed settings across all States. The number of prisons covered under the program increased from 805 in 2018-19 to 1,262 in 2023-24 (Figure 5.10). As service uptake by inmates was promoted, coverage increased from 4.12 lakh in 2017-18 to around

13.72 lakh in 2023-24, indicating an increase of more than three times. This increase in coverage is also reflected in the uptake of HIV screening services, which increased from around 2.79 lakh in 2018-19 to around 13.72 lakh in 2023-24. Approximately 6,600 HIV-positive inmates were identified, with an overall seropositivity rate of around 0.48%. Around 89% of HIV-positive inmates identified in 2023-24 were linked to ART centres (Table 5.12).

Figure 5.10. Number of prisons covered under NACP, 2018-19 to 2023-24




Table 5.12 Prison inmates tested for HIV, diagnosed HIV positive and linked to ART, 2018-19 to 2023-24

Indicators	2018-19	2019-20	2020-21	2021-22	2022-23	2023-24
Inmates covered	4,12,500	4,13,572	9,06,806	7,08,544	14,24,763	13,72,205
Screened/tested for HIV	2,78,705	2,77,015	4,79,880	6,56,749	12,45,209	13,72,205
HIV positives inmates	1,330	1,728	2,122	2,886	5,894	6,607
Linked to ART centre	1,050	1,259	1,814	2,362	5,001	5,912

To ensure that inmates are informed of their HIV status and related co-infections, a national Integrated STI, HIV, TB, and Hepatitis (ISHTH) campaign was implemented across all prisons and other closed settings. Approximately 13.72 lakh inmates were tested for HIV, including those tested under the ISHTH campaign. The overall HIV sero-positivity rate was 0.48%. Since 2018

-19, the HIV sero-positivity rate has ranged from 0.43% to 0.63%. In the year 2023-24, a total of 6,607 HIV-positive inmates were identified, with 89% of them being linked to ART centers (Table 5.12). The State/UT-wise distribution of coverage of Prison inmates in key service parameters for 2023-24 is shown in table 5.13.

Table 5.13. States/UT-wise coverage of prison inmates on key service parameters, 2023-24

States/UTs	Total coverage	Coverage (%)	STI treated	Syphilis screening	HIV screening	HIV positive	Linked to ART	% linked to ARTC	TB screened	Hep C screened
ANI	712	79	20	580	712	1	1	100	850	580
Andhra Pradesh	44,432	49	-	34,380	44,432	75	69	92	44,000	30,109
Arunachal Pradesh	600	63	-	599	600	25	4	16	595	560
Assam	26,282	55	110	12,186	26,282	753	598	79	23,536	3,893
Bihar	1,57,697	47	1,780	59,689	1,57,697	667	399	60	89,587	52,337
Chandigarh	2,073	64	1	974	2,073	10	5	50	2,073	1,667
Chhattisgarh	32,305	45	152	9,569	32,305	40	36	90	32,697	8,981
DNHⅅ	505	88	-	505	505	1	1	100	505	505
Delhi	11,077	17	1,744	371	11,077	174	167	96	16,102	6,463
Goa	651	35	6	377	651	3	3	100	601	377
Gujarat	26,213	31	88	22,836	26,213	52	44	85	26,153	21,611
Haryana	41,952	46	263	14,319	41,952	474	467	99	43,391	25,588
Himachal Pradesh	6,985	83	7	3,514	6,985	21	20	95	8,296	4,990
Jammu & Kashmir Ladakh	6,895	49	-	5,369	6,895	6	5	83	10,169	5,108
Jharkhand	37,069	59	142	11,084	37,069	22	22	100	37,375	5,528
Karnataka	50,529	70	88	17,838	50,529	98	86	88	50,409	12,190
Kerala	29,505	56	1	4,739	29,505	63	43	68	25,548	11,336
Lakshadweep	-	-	-	-	-	-	-	-	-	-
Madhya Pradesh	1,77,275	<u>≥</u> 95	1639	1,40,170	1,77,275	204	182	89	1,75,157	1,09,295
Maharashtra	77,333	55	446	31,891	77,333	255	235	91	31,047	29,758
Manipur	514	22	-	492	514	2	1	50	737	493
Meghalaya	2,318	92	10	2,249	2,318	10	11	110	2,335	566
Mizoram	3,235	50	83	1,980	3,235	103	67	65	3,341	1,270
Nagaland	1,171	51	1	1,047	1,171	42	44	105	976	962
Odisha	56,825	55	102	33,739	56,825	95	90	95	57,771	21,790
Puducherry	1,263	57	-	1,271	1,263	2	2	100	1,280	886
Punjab	64,324	72	877	52,462	64,324	1,691	1,734	103	73,906	41,726
Rajasthan	1,29,622	91	481	74,179	1,29,622	353	323	92	1,28,573	47,545
Sikkim	602	74	2	508	602	1	1	100	418	418
Tamil Nadu	68,184	55	40	48,428	68,184	102	89	87	70,142	36,462
Telangana	43,960	89	148	7,608	43,960	120	115	96	42,367	6,659
Tripura	3,340	61	22	3,226	3,340	68	50	74	3,320	1,665
Uttar Pradesh	2,11,262	91	7,593	86,712	2,11,262	786	747	95	2,39,800	72,123
Uttarakhand	13,909	57	206	5,037	13,909	210	194	92	14,986	4,865
West Bengal	41,586	27	249	18,618	41,586	78	57	73	37,197	23,934
India	13,72,205	61	16,301	7,20,788	13,72,205	6,607	5912	89	13,03,365	5,97,305

5.11. Link Workers Scheme (LWS)

The LWS scheme is implemented in priority districts, blocks, and villages to target rural HRG and other vulnerable population. In addition to rural HRGs, the scheme addresses vulnerable groups such as antenatal mothers, spouses and partners of HRGs, migrants, truckers, youth, individuals with Tuberculosis (TB), and People Living with HIV (PLHIV). The scheme aims to generate demand for various HIV/AIDS-related services by linking the target population to existing services, creating an enabling and stigma-free environment, and increasing access to information and services through connections with other departments and programs. However, the scheme

itself does not establish any service delivery points within the program villages. LWS schemes are strategically placed in high-risk or vulnerable districts based on factors such as the presence of HRGs, migration patterns and the burden of PLHIV. Each LWS scheme is implemented in one or more districts, covering approximately 60-100 villages.

The year-wise progress of onboarding the number of LWS in states and the population covered under various prevention services is shown in figure 5.11 and table 5.14 below. The figure indicates that the number of LWS has increased over the years. A total of 173 Link Worker Schemes cover 188 districts, reaching approximately 25.3 lakh people during 2023-24.

Figure 5.11. LWS numbers and population covered, 2017-18 to 2023-24





Table 5.14. Year-wise coverage of various population groups through LWS, 2017-18 to 2023-24

Toology	Coverage							Total tested for HIV	or HIV					
ypology.	2017-18	2018-19	2019-20	2020-21	2021-22	2022-23	2023-24	2017-18	2018-19	2019-20	2020-21	2021-22	2022-23	2023-24
FSW	67,470	50,311	669'59	11769	78,528	80,684	74,127	57,454	37,077	51,692	57,292	73929	71463	65398
naı	4,106	4,121	4,564	0229	10,412	15,658	21,118	969'8	3,696	4,234	4,603	7648	6734	11277
MSM	7,247	5,100	7,611	9850	17,438	12,200	13,228	5,672	3,373	5,126	7,298	8835	9017	5101
H/TG	297	226	471	642	1,047	1,021	1,412	122	139	313	435	634	747	468
Migrant	410,007	501,979	477,812	520985	594,729	698,015	867,333	310,956	278,341	287,763	276,957	342237	418020	363123
Trucker	98,547	78,772	97,539	105600	136,551	180,664	149,931	90,600	53,598	980'99	60,695	74097	92703	86422
OVP	641,816	644,253	717,973	726303	797,957	969,641	1,149,227	320,897	375,968	420,402	363,878	429297	513145	556477
TB Cases	13,740	12,559	20,241	61132	17,439	82,703	13,978	9,317	8,935	16,214	41,350	11091	80153	10652
ANC	154,349	146,981	193,795	151561	182,478	199,232	199,353	136,134	126,559	174,690	133,853	159010	167187	172832
PLHIV	23,907	21,637	33,511	42091	41,822	43,276	44,401							

- Company	Number of	Number of positive detected	ted					Number of F	IIV +ve cases	Number of HIV +ve cases linked to ART Centre	Centre			
ypology	2017-18	2018-19	2019-20	2020-21	2021-22	2022-23	2023-24	2017-18	2018-19	2019-20	2020-21	2021-22	2022-23	2023-24
FSW	72	110	132	113	158	203	166	64	103	127	109	148	200	158
nai	41	107	178	123	298	926	265	30	62	163	113	260	865	242
MSM	18	18	43	37	51	62	62	15	17	40	35	43	61	09
H/TG	8	8	2	7	2	26	21	9	2	5	7	2	18	18
Migrant	477	200	494	372	463	814	623	442	467	463	347	444	789	615
Trucker	72	88	117	79	116	178	150	69	82	110	71	107	172	146
OVP	514	719	915	583	859	1242	1141	469	640	838	541	813	1232	1142
TB Cases	23	22	51	12	25	29	52	21	49	31	=	19	21	23
ANC	72	92	94	89	108	136	115	99	63	06	84	106	132	115



MANAGEMENT OF SEXUALLY TRANSMITTED INFECTIONS AND REPRODUCTIVE TRACT INFECTIONS

6.1. Background


Sexually transmitted infections which are mainly spread through sexual contact and are caused by bacteria, viruses and parasites. There are more than 30 different bacteria, viruses and parasites which are known to be transmitted through sexual route. A sexually transmitted infection which is spread from one person to another through sexual routes and is carried in blood, semen, vaginal and other bodily fluids. There are some pathogens of STIs which can be transmitted through mother to child during pregnancy, childbirth and breastfeeding.

The reproductive tract infections (RTI) refer to any infection in the reproductive tract of a person. These infections may or may not transmit through sexual route. STIs can increase the risk of HIV infection and is one of the major routes of transmission of HIV infection. STIs cause a serious

threat leading to sexual and reproductive morbidity such as pelvic inflammatory diseases, infertility and can also lead to cancers. Mother and child transmission of STIs can result in stillbirth, neonatal deaths, low birth weights, prematurity, sepsis, neonatal conjunctivitis and congenital deformities. Hence, the prevention, management, and control of STI and RTI is important to prevent HIV transmission and ensure sound sexual-reproductive health and wellbeing.

The National AIDS and STD Control Programme is committed to work towards strengthening STI/RTI services in India. The NACP-V aims to ensure universal access to quality STI/RTI services for at-risk and vulnerable populations and attainment of dual elimination of vertical transmission HIV and Syphilis in the country.

Figure 6.1. STI/RTI Service Delivery Model under NACP



GC: General Clients; KP: Key Populations; PLHIV: People living with HIV. *Screening & Referrals of PLHIV for STI/RTI services

6.2. STI/RTI Service Delivery Model under NACP

The STI/RTI services in the country are provided through 1,127 Designated STI/RTI Clinics (DSRCs) branded as Suraksha Clinics which are based at District Hospitals and Medical Colleges under the National AIDS and STD Control Programme. The services below district level are provided through National Health Mission (NHM) at various levels of Community Health Centre (CHCs), Primary Health Centre (PHCs) and Sub-centres (SCs). The STI/RTI services are provisioned for key and Bridge populations through 1,577 Targeted Interventions (TI) clinics and 155 LWS in coordination with the general health system. The STI/RTI services are also included as essential package of services under Sampoorna Suraksha Strategy (SSS) to cater to the needs of 'at-risk HIV Negative' population.

The syndromic treatment of STIs using colour coded drug kits has been considered as the

backbone of services provided at DSRCs. The patients are provided on-site screening and diagnostic services through co-located CTCs and laboratories under district hospital/medical colleges. The services provided at STI/RTI Clinics are counselling, promotion of condoms, screening of STIs, management of STIs through syndromic colour coded drug kits, referral for resistant & failure cases and referral to ICTC for screening of HIV and syphilis. All the patients who have visited DSRC's and are HIV negative are referred to Sampoorna Suraksha Kendra so that they could be provided the cyclical preventive services and thus they remained HIV-ve throughout their life.

Out of 1,127 DSRCs operational under NACP across the country, more than 75% of DSRCs are located in 15 states – Uttar Pradesh (115), Tamil Nadu (106), Maharashtra (80), Gujarat (60), Madhya Pradesh (66), Andhra Pradesh (55), Karnataka (54), Rajasthan (53), Telangana (50), West Bengal (48), Bihar (44), Odisha (40), Chhattisgarh (31), Haryana (31) and Punjab (31).





Figure 6.2. Number of DSRCs operational in States/UTs under NACP-V

6.3. Clinic visit for STI/RTI services

The total number of STI/RTI client managed under NACP in the year 2023-24 is 104.8 lakh which includes the clients managed at DSRC, Targeted Interventions sites and in prison and other closed settings. Out of 104.8 Lakhs clients, the total number of STI/RTI patients visited at DSRC in the

year 2023-24 is 68.94 lakhs. Out of these 68.94 lakhs clients, 26.4 lakhs were male clients, 42 lakh were female clients and 0.4 lakhs were TG clients. The percentage wise distribution is presented at figure 6.3.

Figure 6.3. Gender-wise distribution of STI/RTI Client managed at DSRC in FY 2023-24



Out of the total client visited, 3/4th of the clients were reported from Uttar Pradesh (18%), Tamil Nadu (12%), Maharashtra (11%), Madhya Pradesh (7%), Bihar (7%), Andhra Pradesh (6%), Karnataka (5%), Rajasthan and West Bengal (4%).

6.4. Average number of clients visit per day per DSRC

The average number of STI/RTI clients managed per day per DSRC across the country in the FY 2023-24 is 20 clients. 9 States/UT have reported

higher number of clients managed per day against the National figure. These States are Uttar Pradesh and Bihar (36) each, Maharashtra (31), Tamil Nadu, Madhya Pradesh and Andhra Pradesh (25) each, Puducherry (24), Punjab (23), Chhattisgarh (22). On the contrary, States/UT who have reported less than 10 clients visits per day per DSRC are Assam (9), Uttarakhand (8), Meghalaya (7), Tripura (7), Chandigarh (6), Kerala (6), J&K (5), Jharkhand (5), Mizoram (5), DNH&DD (4), Manipur (4), Nagaland (3), Arunachal Pradesh and Sikkim (1). State/UTs wise number of STI/RTI client visited per DSRC is depicted in figure no. 6.4.




Figure 6.4. Number of Client visits per day per DSRC in FY 2023-24

6.5. Syndromic Case Management

STI/RTI syndrome is defined as a group of common symptoms and signs caused by one or more than one sexually transmitted organism. The STI/RTI syndromes reported in males are – urethral discharge (UD), anorectal discharge (ARD), genital ulcer disease – non herpetic (GUD – NH), genital ulcer disease – herpetic (GUD – H), painful scrotal swelling (PSS) and inguinal bubo (IB). The clients accessing STI/RTI services at

DSRC are also screened for genital warts and other STI/RTI. In 2023-24, around 3.15 lakh syndromes were reported among males. Among the total number of syndromes reported, the highest number of syndromes diagnosed are Urethral Discharge (59%) followed by Genital Ulcer Disease Herpetic (15%) and Genital Ulcer Disease Non-Herpetic (12%). Additionally, 5.1 lakh other STI's and 0.23 lakh cases of Genital Warts were also reported. The distribution of syndromes reported in males is depicted in figure 6.5.

Genital Ulcer Disease
(GUD) - Herpetic, 15%

Genital Ulcer (GUD) Non Herpetic, 12%
Painful Scrotal
Swelling (PSS), 9%

Inguinal Bubo (IB),
2% Ano-rectal Discharge
(ARD), 3%


Figure 6.5. STI/RTI Syndromes diagnosed at DSRC among Males in FY 2023-24

The STI/RTI syndromes reported in females are – Vagino cervical discharge (VCD), anorectal discharge (ARD), genital ulcer disease – non herpetic (GUD – NH), genital ulcer disease – herpetic (GUD – H), lower abdominal pain (LAP) and inguinal bubo (IB).

More than 17 lakh syndromes were reported among females accessing STI/RTI services at

DSRC. The predominant syndrome reported was VCD (60%), followed by LAP (37%). Additionally, 4.1 lakhs other STI/RTI including 0.14 lakh cases of genital warts were reported among females. The distribution of syndromes reported in females is depicted in figure 6.6.


Figure 6.6. STI/RTI Syndromes diagnosed at DSRC among females in FY 2023-24



Urethral Discharge remained the major syndrome diagnosed in male clients at DSRC. The States /UT reporting highest proportion of Urethral Discharge were DNH&DD (85%), Jammu & Kashmir (84%), Arunachal Pradesh (81%), Jharkhand (80%) and Madhya Pradesh (76%). However, the States/UT reporting GUD-H as predominant syndrome were Chandigarh (77%)


and Delhi (41%). Moreover, West Bengal (29%) and Kerala (27%) reported GUD-NH as the predominant syndrome among males. Painful Scrotal Swelling was reported to be in highest proportion in Assam (50%) followed by Andaman & Nicobar Islands (25%) and West Bengal (20%). (See figure 6.7)

Figure 6.7. States/UT wise distribution of STI/RTI Syndromes (%) among males (2023-24)



Vagino Cervical Discharge has remained the predominant syndrome diagnosed females attending DSRC. The states reporting highest proportion of VCD were Mizoram (79%), Goa (78%), Maharashtra (75%), Gujarat (74%) and Assam (72%), and Andhra Pradesh (71%). The States/UT reporting high proportion of LAP were Haryana (49%), Uttarakhand (49%) Uttar Pradesh Puducherry (46%), Manipur (43%).Himachal (43%), Delhi (43%). State/UT-wise distribution of various syndromes(%) in females for FY 2023-24 is demonstrated in figure 6.8.

Figure 6.8. States/UT wise distribution of STI/RTI Syndromes (%) among females (2023-24)



3.5%

6.6. Laboratory Diagnosis at DSRC

A total number of 41.4 lakhs RPR tests were conducted for screening of syphilis among DSRC clients (excluding pregnant women). Among them the total screening done among male, female and H/TG were 17.4 lakh, 23.9 lakh and 0.2 lakh. The test positivity was reported to be 1.4%, 0.4% and

among males, females, population respectively (see Table 6.1). The total Syphilis positives identified in 2023-24 are 35,785 cases with overall test positivity for India reported to be 0.9% for DSRC attendees. The trend for test positivity of syphilis at DSRC continues to rise in 2023-24 when compared with test positivity reported in 2022-23 (0.7%) and 2021-22 (0.60%).

and H/TG

Table 6.1. Syphilis Screening at DSRC, 2023-24

Indicator	Males	Females	H/TG	Total
Total number of RPR tests conducted	17,38,273	23,85,323	24,287	41,47,883
Total number of tests reactive	24,943	9,988	854	35,785
% Test positivity	1.4%	0.4%	3.5%	0.9%

The States/UT reporting test positivity > 1% were Sikkim (9.4%), Arunachal Pradesh (6.7%), Meghalaya (6.3%), Kerala (5.3%), Andaman & Nicobar Islands (2.7%), Chandigarh (2.7%), Assam

(2.2%), Mizoram (2.0%), Gujarat (2.0%), Nagaland (1.8%), West Bengal (1.6%), Goa (1.6%), Delhi (1.6%), Odisha (1.4%), Manipur (1.2%), DNH&DD (1.0%). (See Table 6.2).

Table 6.2. Syphilis Screening at DSRC, 2023-24

States/UT	Male	Female	H/TG
A & N Islands	4.3%	1.2%	100.0%
Andhra Pradesh	0.7%	0.1%	1.2%
Arunachal Pradesh	6.9%	6.6%	66.7%
Assam	4.0%	0.9%	19.9%
Bihar	1.0%	0.7%	0.4%
Chandigarh	9.4%	0.8%	100.0%
Chhattisgarh	0.8%	0.3%	2.7%
DNHDD	1.6%	0.5%	0.0%
Delhi	3.4%	0.5%	4.3%
Goa	2.1%	0.7%	0.0%
Gujarat	3.5%	0.9%	14.3%
Haryana	1.6%	0.2%	7.4%
Himachal Pradesh	0.5%	0.1%	33.3%
Jammu and Kashmir	1.8%	0.0%	0.0%
Jharkhand	1.3%	0.3%	28.6%
Karnataka	0.9%	0.2%	1.3%
Kerala	8.3%	2.0%	21.5%
Madhya Pradesh	1.6%	0.5%	7.4%
Maharashtra	1.3%	0.4%	9.8%
Manipur	4.3%	0.3%	17.6%
Meghalaya	6.8%	5.9%	33.3%
Mizoram	2.1%	2.0%	0.0%
Nagaland	2.0%	1.5%	0.0%
Odisha	2.0%	0.6%	4.9%
Puducherry	1.2%	0.2%	5.0%
Punjab	1.4%	0.4%	4.1%
Rajasthan	1.6%	0.3%	4.0%
Sikkim	18.1%	5.2%	0.0%
Tamil Nadu	0.7%	0.2%	1.6%
Telangana	1.4%	0.4%	3.2%
Tripura	0.3%	0.1%	2.9%
Uttar Pradesh	0.8%	0.2%	1.3%
Uttarakhand	2.8%	0.3%	9.7%
West Bengal	3.2%	0.6%	9.1%
India	1.4%	0.4%	3.5%



HIV COUNSELLING AND TESTING SERVICES

7.1. Background

HIV Counselling and Testing Services (HCTS) is a crucial element of the National AIDS and STD Control Programme (NACP) in India, designed to provide comprehensive counselling for HIV and prevention, early HIV screening confirmation, ensuring prompt linkage to the and care cascade. establishment in 1997, HCTS has served as the primary entry point for HIV and STI prevention, diagnosis, treatment, and care. Clients receive pre-test counselling, undergo HIV and STI screening, and access post-test support in a confidential environment. Those HIV-negative are counselled on risk reduction, while those who test positive receive psychosocial support and are linked to treatment services. NACO's current strategy under NACP-V targets an 80% reduction in new HIV infections, focusing on tailored strategies for high-risk, at-risk, and low-risk groups.

Priority populations under HCTS include individuals in closed settings, self-walk-in clients, Social and sexual networks, sexual partners of people living with HIV, clients motivated from National AIDS helpline 1097/ IEC material/ virtual outreach and vulnerable adolescent/youth.

Central to the newer initiative under HCTS is the Sampoorna Suraksha Strategy (SSS). SSS integrates various health services and emphasizes community engagement for at-risk negative populations to keep them negative by providing various cyclical preventive services. This approach not only improves access to testing and treatment but also incorporates education, prevention, and referral services, fostering a collaborative environment among stakeholders across health and social sectors.

By addressing the needs of diverse populations, including those with high-risk behaviour who may not identify as high-risk, HCTS aims to reduce stigma and encourage proactive health-seeking behaviour, ultimately contributing to the goal of ending the AIDS epidemic as public health threat in India. Regular screenings at every six months

are recommended to facilitate early diagnosis, which is essential for better health outcomes and aligns with the global 95-95-95 targets aimed at improving HIV management and reducing new infections.

7. 2. HIV Counselling and Testing Service (HCTS) Facilities

The HIV Counselling and Testing Service (HCTS) facilities established under the NACP aims to enhance the accessibility and quality of HIV services. While HIV confirmation services are primarily available at the district level, the National Health Mission (NHM) extends these services to sub-district facilities, promoting a decentralized approach to HIV and STI screening. The guiding principles of HCTS facilities emphasize resource optimization, collaboration with NHM, and integration with other health programs, ensuring a comprehensive and effective approach to HIV and STI counselling and testing. The collaboration between NACP and NHM is critical for scaling up preventive and testing services while optimally utilizing the existing NHM resources up to the level of Village Health Sanitation and Nutrition Day (VHSND) camps. This strategy allows for decentralization of testing services through the general health system approach while alleviating the congestion at Integrated Counselling and Testing Centres (ICTCs) and thus give necessary focus on preventive care for at-risk clients at ICTCs, while ensuring they remain HIV-negative.

ICTCs serve as essential confirmatory facilities, strategically located within government healthcare systems, including medical colleges, hospitals, and community health centers. These centers implement the Test & Treat policy, facilitating immediate linkage to treatment upon confirmation. In addition, HIV screening sites are established across various health settings, employing rapid testing using dual RDT kits/HIV whole blood finger prick test (WBFPT) to enhance accessibility. As of March 2024, there were more

than 34 thousand HCTS testing/screening facilities across the country, including 4,488 confirmatory ICTC, conducting over 3.33 crore tests for pregnant women and 3.85 crore tests for clients other than pregnant women. All the facilities providing HIV and STI testing including ICTC report in HMIS. However, ICTC (Confirmatory Sites) also reports in SOCH.

7.3. HCTS Uptake

HIV testing services under the NACP are provided to two main groups: pregnant women and clients other than pregnant women. While the latter group (clients other than pregnant women) is discussed in this section, and the content on the pregnant women is covered in the chapter

pertaining to EVTHS. The seven-year trend analysis of HIV testing (depicted in Figure 7.1) and HIV-positive detection (Figure 7.2) shows a steady increase in testing uptake and a corresponding improvement in identifying HIV-positive clients. However, the sero-positivity rate has shown gradual decline over the years. The total number of HIV positive cases identified has shown a decline compared to year 2019-20 and before. This suggests that while testing coverage has improved, efforts to reach at risk individuals for early detection and higher yield require further strengthening to reach the global targets of first 95.

Figure 7.1. Trend in HIV testing (in crore) in last seven years





Figure 7.2 Trend in identification of HIV positive clients and sero-positivity in last seven years



At the ICTCs, testing services are prioritized for high-risk groups (HRGs), at-risk populations, and self-referred clients (walk-in). These clients receive targeted counselling and testing, with those testing positive linked to ART Centre to provide the treatment for HIV and prevent further morbidity, mortality and further HIV transmission as a result of viral load suppression. At screening sites, most clients are referred by healthcare providers. State-wise analysis (Figure 7.3) reveals that approximately 40% of HIV tests were conducted at screening sites, while the remaining 60% occurred at ICTCs, with 16% of tests administered to walk-in clients. Importantly, achieving the testing target of 2.7 crore tests for FY 2023-24 reflects a significant over-achievement in testing but highlights the need for a more focused approach to reach priority clients.

To address gaps in targeted testing, states are encouraged to implement strategies from the HCTS Guidelines 2024, such as index testing, social networking approaches, and mobile outreach initiatives. These methods aim to reach high-risk populations, including sex workers and their clients, men who have sex with men (MSM), transgender individuals, PWID, truck drivers, migrant workers, and partners/children of PLHIV. HIV prevalence in these groups remains higher than in the general population, necessitating tailored intervention strategies.

Figure 7.3. States/UT-wise breakup of HIV testing for FY 2023-24.




Table 7.1. States/UT wise HCTS uptake 2023-24.

			AIII	Trans J /Const	To a						IN Design			Desired in	
			≥	MIV lested / screened	peu			rercentage			HIV POSITIVE			Positivity	
S.No	States/UTs	Walk in Clients at ICTC	Provider Referred clients at ICTC	Total ICTC	Clients at Screening Sites	Grand Total	Walk in Clients at ICTC	Provider Referred clients at ICTC	Clients at Screening Sites	Walk in Clients at ICTC	Provider Referred clients at ICTC	Total	Walk in Clients at ICTC	Provider Referred clients at ICTC	Total
-	Andaman & Nicobar	3,841	16,871	20,712	5,325	26,037	15%	%29	20%	8	35	43	0.21	0.21	0.17
2	Andhra Pradesh	2,50,270	9,15,417	11,65,687	6,37,756	18,03,443	14%	51%	35%	3,690	10,327	14,017	1.47	1.13	0.78
3	Arunachal Pradesh	5,231	14,828	20,059	37,630	27,689	%6	26%	%29	328	266	894	6.27	3.82	1.55
4	Assam	860'99	1,91,960	2,58,053	70,614	3,28,667	20%	28%	21%	3,876	3,184	090'2	5.86	1.66	2.15
2	Bihar	3,20,476	5,28,785	8,49,261	7,05,299	15,54,560	21%	34%	45%	5,129	4,230	6'326	1.60	0.80	09.0
9	Chandigarh	1,963	93,911	95,874	က	95,877	2%	%86	%0	155	588	743	7.90	0.63	0.77
7	Chhattisgarh	1,08,304	3,60,145	4,68,449	1,36,946	6,05,395	18%	26%	23%	1,104	1,750	2,854	1.02	0.49	0.47
8	Dadra & Nagar Haveli	1,016	25,790	26,806	6,568	33,374	3%	77%	20%	12	40	52	1.18	0.16	0.16
6	Daman & Diu	1,515	6,934	8,449	3,485	11,934	13%	28%	29%	6	23	32	0.59	0.33	0.27
10	Delhi	1,48,126	4,53,345	6,01,471	34,563	6,36,034	23%	71%	2%	2,682	3,453	6,135	1.81	0.76	96.0
11	Goa	21,011	42,627	63,638	49,699	1,13,337	19%	38%	44%	85	177	262	0.40	0.42	0.23
12	Gujarat	2,82,033	8,68,536	11,50,569	5,98,079	17,48,648	16%	20%	34%	3,606	4,049	7,655	1.28	0.47	0.44
13	Haryana	2,15,837	5,73,935	7,89,772	93,091	8,82,863	24%	%59	11%	2,482	3,621	6,103	1.15	0.63	69.0
14	Himachal Pradesh	84,321	1,81,608	2,65,929	1,42,536	4,08,465	21%	44%	35%	200	424	624	0.24	0.23	0.15
15	Jammu & Kashmir	9,447	1,28,955	1,38,402	2,98,079	4,36,481	2%	30%	%89	87	278	365	0.92	0.22	0.08
16	Jharkhand	72,802	1,60,743	2,33,545	1,84,655	4,18,200	17%	38%	44%	999	1,081	1,746	0.91	79.0	0.42
17	Kamataka	4,65,600	18,32,272	22,97,872	16,83,726	39,81,598	12%	46%	42%	2,428	10,754	13,182	0.52	0.59	0.33
18	Kerala	81,603	4,66,309	5,47,912	11,65,460	17,13,372	2%	27%	%89	370	865	1,235	0.45	0.19	0.07
19	Ladak	30	4,582	4,612	1,327	5,939	1%	77%	22%	0	5	2	0.00	0.11	0.08
20	Lakshadweep	0	207	207	2,998	3,205	%0	%9	94%	0	0	0	0.00	0.00	0.00
21	Madhya Pradesh	2,93,089	7,06,562	9,99,651	9,57,767	19,57,418	15%	36%	46%	1,900	4,178	8/0/9	0.65	0.59	0.31
22	Maharashtra	13,51,540	15,40,364	28,91,904	14,91,420	43,83,324	31%	35%	34%	8,303	5,419	13,722	0.61	0.35	0.31
23	Mumbai	1,13,741	3,24,859	4,38,600	600'08	5,18,609	22%	%89	15%	1,694	1,605	3,299	1.49	0.49	0.64
24	Manipur	18,666	65,430	84,096	24,596	1,08,692	17%	%09	23%	305	435	740	1.63	99.0	89.0
25	Meghalaya	13,328	55,869	69,197	18,628	87,825	15%	64%	21%	393	958	1,351	2.95	1.71	1.54
26	Mizoram	23,622	39,353	62,975	20,236	83,211	28%	47%	24%	831	1,269	2,100	3.52	3.22	2.52
27	Nagaland	19,290	63,517	82,807	78,847	1,61,654	12%	36%	49%	409	1,379	1,986	3.15	2.17	1.23
28	Odisha	1,43,192	7,92,872	9,36,064	4,92,238	14,28,302	10%	26%	34%	701	2,815	3,516	0.49	0.36	0.25
29	Puducherry	62,713	88,559	1,51,272	77,117	2,28,389	27%	36%	34%	92	131	196	0.10	0.15	0.09
30	Punjab	24,022	7,21,821	7,45,843	2,54,836	10,00,679	2%	72%	25%	1,555	11,587	13,142	6.47	1.61	1.31
31	Rajasthan	1,08,842	9,36,551	10,45,393	14,18,541	24,63,934	4%	38%	58%	2,179	4,777	936'9	2.00	0.51	0.28
32	Sikkim	1,558	20,436	21,994	9,591	31,585	2%	%59	30%	11	50	61	0.71	0.24	0.19
33	Tamil Nadu	7,18,833	18,01,766	25,20,599	6,43,480	31,64,079	23%	21%	20%	2,942	4,396	7,338	0.41	0.24	0.23
34	Telangana	2,47,359	5,48,343	7,95,702	3,99,464	11,95,166	21%	46%	33%	4,055	669'9	10,754	1.64	1.22	0.90
35	Tripura	28,177	56,774	84,951	50,318	1,35,269	21%	42%	37%	870	884	1,754	3.09	1.56	1.30
36	Uttar Pradesh	3,76,691	14,05,453	17,82,144	18,53,568	36,35,712	10%	36%	51%	7,028	8,665	15,693	1.87	0.62	0.43
37	Uttarakhand	9,333	1,40,926	1,50,259	2,57,138	4,07,397	2%	35%	63%	363	1,079	1,442	3.89	0.77	0.35
38	West Bengal	4,30,393	8,85,850	13,16,243	13,32,778	26,49,021	16%	33%	20%	2,760		8/9/9	0.64	0.44	0.25
	India	61,23,908		1,70,63,065 2,31,86,973	1,53,18,411	3,85,05,384	14%	20%	36%	63,478	1,05,694	1,69,172	1.04	0.62	0.44

Table 7.1 provides the States/UT wise uptake of HCTS. The contribution of testing conducted for walk-in-clients varies from 0% in Lakshadweep to 31% in Maharashtra with national average of 15%. Similarly, the HIV testing at screening site varies from 0% in Chandigarh to 94% in Lakshadweep. It is important that states disseminate the HIV and STI IEC material widely, so that the clients who are at risk of HIV and STI reach to ICTC for counselling and testing services. It is also important that States/UT envisage fast tracking of clients based on HCTS Guideline 2024, so that those clients who are not at risk of HIV but are referred for HIV screening are fast tracked for immediate screening test. The screening for such kind of patients can be decentralized by establishing more number of screening sites in the health system where the concerned health care personal can undertake the role of providing the HIV counselling and testing while maintaining the effective cold chain, recording and reporting. The counsellors at ICTC thus can provide focussed counselling to the at-risk clients. The risk assessment tool plays a critical role for the identification of the at risk client accessing the ICTC.

7.4. Risk assessment

Risk assessment is a critical step in prioritizing clients for HCTS and preventive services. Counsellors at ICTC use a standardized risk assessment questionnaire consisting of seven key questions that evaluate an individual's risk based on sexual behavior, needle-sharing, and STI symptoms. Special attention is given to discordant couples, where one partner is HIV-positive and the other is not. In such cases, the HIV-negative spouse/partner is considered "at-risk" prioritized for regular follow-up and preventive interventions, including HIV education, condom distribution, and STI care. During FY 2023-24, in the programme, 31,45,725 clients were assessed for risk by six risk assessment questions. A total 6,92,858 clients responded with at least one risk behaviour.

7.5. HIV Sero-positives and Yield trends

Although HIV testing among at-risk clients reached an all-time high during FY 2023-24, the yield in terms of newly identified HIV-positive cases remains lower than pre-COVID-19 levels. A total of 1,69,172 HIV-positive clients were identified, with a national sero-positivity rate of 0.44%. This lower yield is expected as the country moves closer to achieving the first 95% target, where identifying each new case requires additional efforts and more targeted approaches. Understanding this, NACO has directed States /UT on various key strategies/activities such as Integrated Health Campaign, Intensified IEC Campaign, campaign in prison and other close settings, index testing campaign etc.

Assam demonstrated the most significant increase in HIV detection, rising from 3,767 cases in FY 2022-23 to 7,060 cases in FY 2023-24, attributed to focused testing during the integrated health campaign. This suggests that increasing overall HIV testing volumes may not be essential to improve positive detection rates. Figures 7.4 and 7.5 illustrate the States/UT wise distribution of HIV testing and HIV detection for FY 2023-24, respectively. States/UT-wise data significant variations in HIV detection, with the top 10 states accounting for 68% of newly identified cases, including Maharashtra (10%), Uttar Pradesh (9%), Andhra Pradesh (8%), Karnataka (8%), Punjab (8%), Telangana (6%), Bihar (6%), Gujarat (5%), Tamil Nadu (4%), and Assam (4%).





Figure 7.4. Distribution of HIV Testing in FY 2023-24

Figure 7.5. Distribution of HIV detection in FY 2023-24



As indicated in Table 7.1, the national HIV sero-positivity rate stands at 0.44%, with state-level rates varying widely. The lowest positivity rate was reported in Lakshadweep (0%), while Mizoram had the highest at 2.52%. States/UT exceeding the national average include Mizoram (2.52%), Assam (2.15%), Arunachal Pradesh (1.55%), Meghalaya (1.54%), Punjab (1.31%), Tripura (1.29%), Nagaland (1.23%), Delhi (0.96%), Telangana (0.90%), Andhra Pradesh (0.78%), Chandigarh (0.70%), Haryana (0.69%), Manipur (0.68%), Mumbai (0.64%), Bihar (0.60%), and Chhattisgarh (0.47%).

7.6. Gender difference in HIV testing:


In FY 2023-24, of total approximately 45% of HIV tests were conducted on women, while a very small percentage (0.003%) were conducted on transgender individuals figure (7.6 a). of the 1,69,172 HIV-positive cases identified, 55% were male, 45% female, and 0.003% transgender, with sero-positivity rates of 0.55% for men, 0.30% for women, and 1.10% for transgender individuals figure (7.6 b). This disparity in sero-positivity highlights the need for targeted outreach and testing for HRG/At-risk populations, where HIV prevalence remains significantly higher compared to the general population.

a) HIV Testing

TS/TG 1,22,443
0%

Male 2,12,04,432
55%

Figure 7.6. Gender wise distribution of HIV testing and HIV detection in FY 2023-24.



7.7. Spouse/Partner testing among HIV positive detected

Spouse/partner testing is an essential strategy in breaking the chain of transmission cycle for HIV infection. This involves testing of all sexual or injection sharing partners and biological children of individuals diagnosed with HIV (index cases) and linking HIV-positive people to further treatment and care cascade. Those tested negative are provided with prevention services, including HIV education, condoms, STI care, and harm reduction strategies. During FY 2023-24, the coverage of spouse/partner testing decreased from 54% to 36%, and the proportion of sero-positivity among partners was 43%, down from 47% in the previous year. However, interstate variations remain significant. The figure 7.7 explains States/UTs wise distribution of Spouse/partner testing and sero positivity for the period of 2023-24. Andhra Pradesh (78%), Manipur (52%), Goa (51%), West Bengal (47%), DD (44%), Delhi (41%), Telangana (40%), DNH (39%), Jharkhand (39%), Uttar Pradesh and J&K (37%) reported higher coverage than national average.

State/UTs reported higher positivity among spouse /partner testing than national average of Meghalaya (66%), Bihar (61%), Rajasthan (57%), Nagaland (54%), Delhi (54%), Chhattisgarh (51%), Mizoram (51%), Uttar Pradesh (51%), Goa (50%), Jharkhand (49%), MP (47%), Karnataka (47%), Maharashtra (46%), and Mumbai (45%).

To close these gaps, NACO has relaunched index testing in a campaign mode, with the aim of covering all eligible PLHIV as per the updated HCTS Guidelines 2024. The campaign envisages to scale up the high yielding index testing strategy in the country with further institutionalization of the approach in the existing HCTS ecosystem.





Figure 7.7. HIV sero-positivity among partner tested

7.8. Sampoorna Suraksha Kendra


Many individuals engaging in behaviours that increase their vulnerability to HIV and STIs may not consider themselves HRGs. To effectively reach these clients, NACO has rolled out the Sampoorna Suraksha Kendra (SSK) as an immersion learning model at 150 selected facilities (ICTCs/DSRCs) in 150 districts of 20 States. By integrating STI services into the ICTC framework and vis-a-vis, a holistic approach has been used to provide sexual health and preventive services.

Through the strategic roles of ICTCs and DSRCs, NACP implements a comprehensive and inclusive Sampoorna Suraksha Strategy. This approach not only addresses immediate health needs but also fosters a supportive environment individuals feel empowered to seek help and adopt safer practices. By prioritizing these initiatives, it is envisaged ultimately to reduce the burden of HIV and STIs in India. During FY 2023-24, 1,04,911 at-risk negative clients were successfully enrolled for comprehensive prevention packages at these facilities.

Figure 7.8. States/UT-wise distribution of SSK and client registration.



HIV	Counsel	llina	and	Testina	Services



INITIATION AND **RETENTION ON ART**



8.1. Background

Initiation and retention on antiretroviral therapy (ART) are essential for achieving long-term viral suppression and improved health outcomes. Early initiation of ART has been demonstrated to reduce HIV-related morbidity and mortality, prevent the progression of HIV to AIDS, and significantly lower the risk of transmitting the virus to others.

Given the evidences, care, support, and treatment (CST) services have been central to India's response to the AIDS epidemic since the Phase-II of the NACP. Over the years, CST services under NACP has expanded exponentially with PLHIV having access to free diagnostic services, first-line, second line, and third-line ART, as well as comprehensive services for the prevention, diagnosis, and management of opportunistic infections, including tuberculosis (TB) through a single-window approach. The "test and treat" policy, adopted under NACP in 2017, emphasizes the immediate initiation of ART upon HIV

Reducing AIDS-related deaths is a key goal of NACP Phase-V. This phase focusses on fasttracking ART initiation for all PLHIV, focusing on lifelong retention and consistent viral load suppression. The program emphasizes integrated service delivery and links with other national health programs, especially for managing non-communicable diseases (NCDs).

8.2 Facilities

Expanding access through a robust network of ART centres has been crucial in increasing uptake of CST services under NACP. Supported by the provisions under National Medical Commission (NMC), each Medical College now has an ART centre. The ART network grew from 25 centres in March 2005 to 775 by March 2024. In comparisons, there were 553 ART centres in March 2020, showing significant growth in last 4 years with establishment of over 200 new centres. These ART centres are strategically linked with 18 Centres of Excellence, including 11 for adults and 7 for paediatric care, ensuring tailored support (Figure 8.1 and 8.2).

diagnosis, regardless of CD4 count or disease stage, ensuring that PLHIV receive timely treatment.

CoE (18) ART Center (775) LAC and LAC Plus (1307)

CSC (320)

Figure 8.1. ART service delivery mechanism under NACP, March 2024

The decentralization of services is supported by the establishment of 1,307 Link ART Centers and Care and Support Centers. As on March 2024, there were 1,307 LACs (including LAC plus) and 320 CSC, including 9 funded by the State Government and 83 supported through the domestic budget. This extensive network improves access to critical services, enhancing treatment adherence and reducing stigma and discrimination related to HIV care. By fostering a more inclusive and accessible healthcare environment, the NACP aims to promote better health outcomes for PLHIV nationwide.


8.3. On-ART PLHIV

As on March 2024, around 17.95 lakh PLHIV were on-ART including of around 16.89 lakh PLHIV taking ART from 775 centres under NACP. Besides, around 1.06 lakh PLHIV are estimated to be taking ART from private health care sector. On-ART PLHIV number in March 2024 is almost 1.15 lakh higher than the number in March 2023 (Table 8.1, Figure 8.2).

Around 16.89 lakh on-ART PLHIV at NACP supported ART centres included around 8.77 lakh males, 8.05 lakh females, and 0.07 lakh H/TG people. Maharashtra has the highest number of on-ART PLHIV (2.80 lakh), followed by Andhra Pradesh (2.22 lakh), Karnataka (1.90 lakh), Tamil Nadu (1.32 lakh), Uttar Pradesh (1.16 lakh), and Telangana (1.04 lakh). Bihar ranks seventh with 0.86 lakh on-ART PLHIV, followed by Gujarat (0.85 lakh), Punjab (0.64 lakh), Rajasthan (0.61 lakh), and West Bengal (0.56 lakh). These eleven states account for nearly 83% of the total on-ART PLHIV at NACO-supported ART centres.

Nationally, the number of PLHIV on ART per centre was 2,179 in March 2024, compared to 2,211 in March 2023 (Figure 8.3). Notably, the ART centres in the States of Telangana and Andhra Pradesh remain the most crowded in the nation, with an average of 3,849 and 3,768 PLHIV on ART per centre, respectively. Delhi follows with an average of 3,258 PLHIV on ART per centre. Bihar (2,954), Maharashtra (2,721), Punjab (2,648),

Figure 8.2. Scale-up of ART facilities and PLHIV on ART at NACP facilities, from year 2005 to March 2024



Chandigarh (2,560), Chhattisgarh (2,520), and Karnataka (2,342) were other States/UTs with 'on-ART' PLHIV per ART centre higher than the national average. West Bengal (2,160) and Uttar Pradesh (2,041) were other two States with more than 2000 on-ART PLHIV per center. Both had average on-ART PLHIV in the range of 1,900 - <2000 in March'23. Himachal Pradesh (806), Uttarakhand (605), Arunachal Pradesh (586), Dadra and Nagar Haveli and Daman and Diu (424), Sikkim (333) and Andaman & Nicobar Islands (207) had less than 1,000 on-ART PLHIV per centre.

The number of on-ART PLHIV per center decreased in 10 States/UTs: Andhra Pradesh, Chandigarh, Haryana, Himachal Pradesh, Karnataka, Maharashtra, Manipur, Tamil Nadu, Telangana, and Uttarakhand. In Chandigarh, this decrease aligns with the transfer of on-ART PLHIV to their native States. The data for Manipur should be interpreted cautiously, as the number of on-ART PLHIV dropped from 14,492 in March 2023 to 14,335 in March 2024, possibly due to a reporting issue given the State's situation. In the remaining States/UTs, the decline might result

from an increase in ART centers per NMC directives, rather than an actual rationalization of distribution of PLHIV.

In 24 States/UT, the average number of on-ART PLHIV per ART center increased. In Assam, this number rose from 1,330 in March 2023 to 1,707 per center in March 2024. Similarly, in Tripura, it increased from 1,450 to 1,796. Punjab saw an increase from 2,356 to 2,648, while in Meghalaya, the number grew from 1,216 to 1,491. These States are witnessing a rapid increase in detection of HIV positive cases because of both epidemiological and programmatic reasons.

Bihar, Chhattisgarh, and Delhi, each with at least 2,300 PLHIV on ART, also experienced an increase of at least 100 units in average number of on-ART PLHIV per ART center. Andaman & Nicobar Islands, Arunachal Pradesh, Dadra and Nagar Haveli and Daman and Diu, Goa, Jammu & Kashmir and Ladakh, Jharkhand, Kerala, Madhya Pradesh, Puducherry, and Sikkim were other States/UTs where average number of on-ART PLHIV per ART center increased.




Figure 8.3. States/UTs wise average PLHIV per ART centre, March 2024

8.4. ART initiation and retention

The initiation and retention on ART for HIV-infected persons is of paramount importance in the India's fight against HIV/AIDS. Rapid initiation of ART, ideally on the same day of is crucial for preventing the diagnosis, deterioration of the immune system and reducing likelihood of opportunistic infections. Sustained adherence to ART not only helps in maintaining viral suppression, which is vital for the health and longevity of the person living with HIV, but also plays a significant role in preventing the transmission of the virus to others. Effective ART programs thus contribute to both individual health outcomes and broader public health goals. Ensuring that individuals remain engaged and adherent to their treatment regimens requires concerted efforts and supportive healthcare systems.

Under NACP Phase-V, the focus remains on quick ART initiation, adherence, and retention to enhance care quality. Progress on these aspects is measured by indicators: (i) ART initiation per 100 detections in ICTC centres, (ii) 12-month retention among PLHIV (%), and (iii) lost-to-follow-up (LFU) per 100 PLHIV 'Alive and on-ART'.

8.4.1. ART initiation

In 2023-24, for every 100 new detections of HIV infected persons made at co lower than in previous years and may be attributed to either linkage loss or repeat testing among HIV-positive individuals. Achieving at least 95% performance on these indicators is crucial, as any significant linkage loss would adversely affect the progress of the national AIDS response across all three key targets.




Figure 8.4. ART initiation, retention and LFU; from FY 2017-18 to 2023-24

The initiation of ART exhibited significant variation across genders. Among males, 92 PLHIV were newly initiated on ART for every 100 detections, whereas this figure was as high as 95 among females. In the year 2023-24, a total of 1,334 H/TG individuals were newly diagnosed while

1,081 H/TG persons were newly initiated on ART. This indicates that 81 PLHIV were newly initiated on ART for every 100 detections among H/TG individuals, which is notably lower than the initiation rate observed among males or females.




Figure 8.5. Gender-wise new ART initiation per 100 new detections, FY 2023-24

State/UT-wise, ART initiation per 100 detections varied from 130 in Arunachal Pradesh to 47 in Puducherry (Figure 8.6). The higher number of PLHIV initiating ART compared to detections in Arunachal Pradesh may be due to a reporting issue or because new HIV-positive cases from neighboring States are registering for ART services in the State. In Assam, a neighboring State of Arunachal Pradesh, ART initiation for

every 100 new detections was 76. Himachal Pradesh (75), Delhi (73), Sikkim (73), and Chandigarh (64) were other States/UTs where ART initiation per 100 detections was below 80. In Chhattisgarh, Gujarat, Odisha, Jammu and Kashmir and Ladakh, Dadra and Nagar Haveli and Daman and Diu, Meghalaya, Andaman Nicobar Islands, and Kerala, ART initiation per 100 detections ranged between 81 and 90.




Figure 8.6. States/UT-wise new ART initiation per 100 new detections, FY 2023-24

8.4.2. On-ART retention

High retention rates, as measured by the 12-month on-ART retention indicator, are important for effective HIV infection management, including achieving viral suppression, reducing mortality, and improving quality of life for people living with HIV (PLHIV). This indicator represents the percentage of HIV-infected individuals who continue treatment after one year. The 12-month on-ART retention rate was recorded at 93% in 2023-24, continuing an upward trend since 2020-21 (Figure 8.4).

Retention rate varied widely by State/UT. In 8 States/UT, retention was less than 90 with lowest retention rate being noted in the State of Tripura (54%). Arunachal Pradesh, Assam, Chhattisgarh,

Manipur and Odisha were other States where retention rate ranged between 73% and 85% (Figure 8.7).

Mizoram's retention rate increased from 90% to 98%, and Uttarakhand improved from 79% to 98%. Jharkhand also saw growth, improving from 78% to 97%, while Andhra Pradesh rose from 86% to 96%. However, Andaman and Nicobar Islands' retention rate dropped from 100% to 93%, and Tripura fell from 70% to 54%, indicating service delivery issues. Manipur slightly decreased from 78% to 76%, raising concerns about PLHIV engagement. Arunachal Pradesh improved its low retention rate from 41% to 73%.




Figure 8.7. States/UT-wise Retention Rate, FY 2023-24

8.4.3. Lost-to-follow up (LFU)

As of March 2024, there were approximately 1.69 lakh LFU nationally, about 11 thousand fewer than in March 2023. This equates to 10 LFU PLHIV for every 100 on-ART PLHIV, continuing the declining trend since 2021-22 (Figure 8.4). The rate varied by gender, ranging from 8.6 for females to 20.3 among H/TG person (Figure 8.8).

Fifteen States/UTs had higher figures of LFU for every 100 on-ART PLHIV. In Delhi, this figure was as high as 39.9, followed by 31.5 in Assam, 25.4 in Arunachal Pradesh, 22.9 in Chhattisgarh, and 20.6 in Uttarakhand. In Meghalaya, Nagaland and Tripura, this ranged between 19 - <20 (Figure 8.9).






Figure 8.8. Gender-wise LFU PLHIV per 100 on-ART PLHIV, 2023-24





Nationally, the number of LFU PLHIV decreased by about 6% from March 2023 to March 2024. This declining trend was observed in 21 States/UTs (Figure 8.10). However, 12 States/UTs saw an increase. Arunachal Pradesh had over five times more LFU PLHIV in March 2024 compared

to March 2023, while Tripura had twice as many. Assam reported a 65% increase, Punjab 34%, Manipur 16%, and Chhattisgarh 12%. Delhi, Kerala, Uttar Pradesh, Andhra Pradesh, Meghalaya, and Goa saw increases between 3% and 7%.




Figure 8.10. States/UT-wise change in LFU number between March 2023 and March 2024


8.5. Differentiated Care Model

Differentiated care is a patient-focused approach that simplifies HIV care to meet the specific needs of PLHIV while reducing strain on healthcare systems. It adjusts care based on a patient's clinical condition, the population group they belong to, and the context of their living environment. The goal is to improve the patient experience and achieve better treatment outcomes, ensuring care remains both medically sound and efficient. Models like Multi-Month

Dispensing (MMD), Linkage ART Clinics (LAC), and Community ART Refill Groups (CARG) are being expanded under NACP Phase V to bring services closer to PLHIV, ease the burden on ART centres, and enhance treatment adherence. These models empower patients to take more control of their care, improve access to treatment, and help achieve viral load suppression.

Table 8.1. States/UT-wise key CST indicators at NACO's supported ART centres, FY 2023-24

State/UT	ART Centre (March 2024)	On-ART PLHIV (March 2024)	Average on -ART PLHIV per ARTC (March 2024)	LFU PLHIV (March 2024)	ART initiation per 100 new detections	12-month Retention among PLHIV (In %)	LFU per 100 on -ART PLHIV (March 2024)
ANI	_	207	207	11	83.7	92.6	5.3
Andhra Pradesh	59	2,22,338	3,768	11,002	97.4	96.5	4.9
Arunachal Pradesh	2	1,171	286	298	130.5	73.2	25.4
Assam	6	15,367	1,707	4,845	76.4	80.9	31.5
Bihar	29	85,675	2,954	4,894	7.79	93.3	5.7
Chhattisgarh	8	20,161	2,520	4,616	6.68	82.2	22.9
Chandigarh	2	5,120	2,560	384	64.2	95.3	7.5
Delhi	12	39,094	3,258	15,614	73.5	94.9	39.9
DNHⅅ	_	424	424	4	86.7	16	0.9
Goa	2	3,409	1,705	458	91.5	93.9	13.4
Gujarat	47	84,577	1,800	8,991	89.8	66	10.6
Haryana	27	34,535	1,279	1,893	97.3	92.3	5.5
Himachal Pradesh	7	5,640	908	269	74.8	94.1	4.8
Jharkhand	13	15,770	1,213	643	6.96	97.1	4.1
Karnataka	81	1,89,680	2,342	13,749	95.5	63	7.2
Kerala	15	16,631	1,109	699	81.2	95.3	4
Maharashtra	103	2,80,278	2,721	41,433	97.2	93.8	14.8
Manipur	13	14,335	1,103	1,218	94	75.7	8.5
Meghalaya	4	5,963	1,491	1,183	85.4	96.1	19.8
Mizoram	14	16,217	1,158	633	97.3	98.4	3.9
Madhya Pradesh	33	41,668	1,263	3,883	91.7	92.9	9.3
J&K and Ladakh	8	3,646	1,215	325	87	96.1	8.9
Nagaland	12	13,722	1,144	2,687	91.2	87.5	19.6
Odisha	19	26,713	1,406	2,906	88.7	85.1	10.9
Pondicherry	1	1,413	1,413	46	46.7	100	3.3
Punjab	24	63,554	2,648	10,118	94.6	86.8	15.9
Rajasthan	36	90,535	1,682	3,593	92.6	93.2	5.9
Sikkim	1	333	333	6	73	96.4	2.7
Telangana	27	1,03,933	3,849	12,373	66	93.6	11.9
Tamil Nadu	73	1,32,301	1,812	3,254	93.2	95.2	2.5
Tripura	3	5,388	1,796	1,031	95.4	54.3	19.1
Uttar Pradesh	57	1,16,357	2,041	5,177	92.2	93.7	4.4
Uttarakhand	11	6,654	909	1,373	97.3	97.5	20.6
West Bengal	26	56,156	2,160	9,216	91.7	93.2	16.4
India	775	16,88,965	2,179	1,68,798	93	93	10



HIV-TB CO-INFECTION MANAGEMENT

9.1. Background

Tuberculosis is an airborne infection caused by the bacilli, Mycobacterium tuberculosis (MTB). TB is the commonest opportunistic infection (OI) among People Living with HIV (PLHIV). The combination of both HIV and TB, if untreated leads to mortality. Latent TB infection (LTBI) is an asymptomatic condition while active TB disease is a symptomatic illness requiring TB treatment. Active TB disease may be confined to the lung parenchyma and airways (pulmonary TB), or may involve organs other than the lungs (extra pulmonary TB) e.g., pleura, lymph nodes, abdomen, central nervous system, bone, joints, skin, etc.

To mitigate the dual burden of HIV and TB coinfection and to ensure seamless access to quality services, the NACP and the National Tuberculosis Elimination Programme (NTEP) of the Government of India introduced single window services in December 2016 for prevention and management of HIV-TB coinfection at ART centres. The approach undertaken under single window services is to ensure that PLHIV attending ART centre are screened for TB with fast tracking of all presumptive TB cases to the co-located TB diagnosis centre for early TB diagnosis and identification of drug resistance. Those PLHIV found TB positive are immediately initiated on six-month ATT at ART centre while drug resistance cases are initiated at NTEP sites. After ruling out active TB and contraindications for TPT, PLHIV are provided TB Preventive Treatment (TPT). NACP and NTEP officials coordinate in synergy on monthly basis to ensure that all the PLHIV are offered the required package of services with a common objective to reduce mortality rates.

9.2. TB Screening and Referral

To ensure implementation of Intensified Case Finding (ICF) at ART centre, all PLHIV attending ART centre are screened for TB for four symptoms (4S) every month. The ART centre staff looks for 4-symptom complex - current cough, fever, weight loss and night sweat among adult PLHIV while among Children living with HIV (CLHIV), the 4S consists of current cough, fever, poor weight gain and history of contact with TB case. The percentage of PLHIV screened for TB has hovered around 97% in last three years as depicted in figure 9.2. Except for Nagaland which was 78% in last year, has now improved to 96% while Uttarakhand which was >95% last year has plummeted to 91% in current financial year. 4S screening of less than 95% was observed in seven States/UT including Meghalaya (93%), Puducherry (93%), Telangana (92%), Uttarakhand (91%), Chhattisgarh (91%), Delhi (91%) and Goa (89%) as shown in figure 9.1

Presumptive cases are ascertained by the Medical Officer at the ART centre and referred for TB diagnosis and identification of drug resistance. Both the programme staff coordinate and ensure that PLHIV who are referred reach the TB testing site are tested as recommended in the national guidelines. The diagnosis rate among those tested hovered around 7% in 2021-22 and 2022-23 and currently stand at 6% in 2023-24 as shown in figure 9.2





Figure 9.1. States/UT-wise total PLHIV screening in FY 2023-24

Figure 9.2. Total PLHIV screened, tested for TB and diagnosed as TB positive in last three years (%)



9.3. Pulmonary and Extra-Pulmonary TB cases

Active TB disease may be confined to the lung parenchyma and airways (pulmonary TB), or may involve organs other than the lungs (extra pulmonary TB) e.g., pleura, lymph nodes, abdomen, central nervous system, bone, joints, skin, etc. As shown in figure 9.3 it is observed that 72% of the TB cases diagnosed by ART centre from April 23 to March 24 were confined to the lung parenchyma and airways (pulmonary TB) while the rest of 28% were extra pulmonary cases.

These are the cases which were referred by ART centre to co-located TB diagnosis centre. Further, it is also observed that >60 % of the pulmonary cases were microbiologically confirmed while >60% of the extra pulmonary cases were clinically confirmed as shown in figure 9.4.

Figure 9.3. Anatomical Site of TB disease – (%)





Figure 9.4. Microbiologically and Clinically Diagnosed Cases (%)




9.4. HIV-TB Co-infection management

Emphasis is also given to early ART initiation for co-infected PLHIV. Combined use of ART and anti-TB treatment (ATT) reduces the impact of active TB among PLHIV significantly. The National Guidelines for HIV Care and Treatment (2021) recommends that ART should be started among PLHIV as soon as possible within two weeks of initiating TB treatment, regardless of CD4 cell count (except among PLHIV with TB meningitis).

In 2023-24, out of those PLHIV who were registered (34,595) in the HIV-TB register, almost all (99%) were initiated on anti-TB treatment (ATT), 95% on CPT and ART (Figure 9.5). Treatment initiation of >95 for ATT, ART and CPT has remained constant in last three years reflecting commitment of the programme to reduce AIDS related deaths by 80%.


Figure 9.5. States/UTs-wise total PLHIV screening, tested for TB and diagnosed as TB positive as on March 2024



In the year April 2023 to March 2024 there were 14% of co-infected PLHIV registered in Maharashtra (including Mumbai) followed by Andhra Pradesh (11%), Karnataka (11%), Uttar Pradesh

(9%), Tamil Nadu (7%), Gujarat (7%), Bihar (5%) while the remaining States/UTs contributed to 37% as shown in Figure 9.6

Figure 9.6. Percentagewise States contributing to total number of co-infected PLHIV registered at ART Centre from April 23 – March 2024



In April 23-March 2024, there were 69.7 % male co-infected PLHIV registered at the ART centre while the rest were female (29.3) with Transgender (0.3%) as shown in table 9.1. The percentage of


female co-infected PLHIV registering at the ART centre has remained between the range of 29 – 32% as shown in the table.

Table 9.1. Gender-wise distribution (in %) of total co-infected PLHIV registered at ART Centre, 2021-22 to 2023-24

Year	Male	% Male	Female	% Female	TG	% TG
2021-22	23,692	68.2	10960	31.6	80	0.2
2022-23	25,469	73.3	11285	32.5	93	0.3
2023-24	24,320	69.7	10185	29.3	90	0.3


A total of 34,595 co-infected PLHIV were registered at the ART centre from April 2023-March 2024 of which around 65% were diagnosed by the ART centre while the rest of 35% were already reported to ART centre as TB diagnosed case. This trend has remained constant in last two years as depicted in figure 9.7. There were 34,114 PLHIV who were initiated on ATT (99%) out of

Figure 9.7. Percentage of co-infected PLHIV diagnosed by ARTC out of total registered at ARTC



those co-infected PLHIV registered from April 2023- March 2024. There were >98% PLHIV in last three years who were initiated at the government facility. The Government facility is either the ART centre or the NTEP facility designated for treatment initiation. The rest of the PLHIV were initiated at the private institution as shown in figure 9.8

Figure 9.8. Percentage of Co-infected PLHIV initiated n TB treatment at Government and Private institution out of registered



9.5. TB preventive Therapy among PLHIV

To prevent the progression of latent TB infection to active TB disease among PLHIV, TB Preventive Therapy (TPT) is provided, after ruling out active TB, through ART centers under the National AIDS & STD Control Programme (NACP), in alignment with National TB Elimination Programme (NTEP) guidelines and recommendations of Technical Resource Group on ART. Guidance on TPT for PLHIV have been updated recently in view of availability of shorter and more effective TPT regimens under NTEP. Till March 2024, overall, ≥ 95% of PLHIV in active care at NACO's ART centres were initiated on TB preventive treatment since the inception of single window services at ART centres.

There were 18 States /UTs such as of West Bengal, Andhra Pradesh, Chandigarh, Goa, Gujarat, Himachal Pradesh, J&K, Jharkhand, Karnataka, Maharashtra, Odisha, Pondicherry, Punjab, Rajasthan, Tamil Nadu, Telangana, Uttar Pradesh and Madhya Pradesh where TPT has been provided to >95% of PLHIV (Figure 9.9). However, there are states like Chhattisgarh, Mizoram, Kerala, Haryana, Meghalaya, Assam, Tripura, Uttarakhand, Bihar, Sikkim, Dadar & Nagar Haveli and Arunachal Pradesh where the TPT uptake was <80 % as on March 2024.





Figure 9.9. State/UT-wise TPT initiation, as on March 2024 since inception of single window services at ARTC

An integrated package of services keeping beneficiaries and communities in the centre is the first guiding principle of NACP Phase-V. Hence, both NACP and NTEP work in synergy to ensure

that PLHIV get free and quality ubiquitous services in line with national guidelines are provided to ameliorate the quality of life of PLHIV.



LABORATORY SERVICES



10.1. Background

NACP Phase V (2021-2026) emphasises to :1) optimize the use of programme laboratories for viral load (VL) testing and 2) maintain and expand laboratory quality assurance covered under Goal 2 of NACP V (Reduce AIDS-related mortalities by 80%) for which NACO is committed and has taken several steps explained in detail in the chapter below.


10.2. Viral load testing

In order to optimize the use of non-programme public sector viral load laboratories, apart from the existing 64 viral load laboratories, NACO has roped in 12 high throughput viral load machines installed by ICMR (Indian Council for Medical Research) during COVID -19, of which two VL machines have become functional and have started VL testing. Additionally, States like Mizoram and Nagaland have installed viral load

machines on a reagent rental basis and have initiated testing. These laboratories were thoroughly assessed on quality parameters before utilising them under the programme. At present, 68 viral load machines are functional. These laboratories were optimized through systematic mapping and linkages with all ARTCs. All the States have hired sample transportation agency and samples are being transported to their linked viral load lab in cold chain within the timeline.

The below figure 10.1 shows the distribution of viral load labs across India. As part of the scale-up, all the ART lab technicians were trained on viral load sample collection, separation of plasma, packaging and transporting to their linked viral load labs. Also, the laboratory staff from VL labs other than the programme labs were given three-day hands-on training.

Figure 10.1. Distribution of viral load laboratories, March 2024



Around 54.4 lakh viral load tests were done cumulatively between 2018-19 and 2023-24 under NACP (figure 10.2). In 2018-19, around 2.4 lakh viral load tests were done. As is evident from figure 10.2, the number of VL tests conducted are increasing every year. In 2021-22, around 10.3 lakh viral load tests were conducted while in FY' 2022-23, 12.3 lakh tests were conducted including the number of tests done through public-private

partnership (PPP) model. In FY 2023-24, viral load through PPP model was phased out, while programme and non-programme labs were utilized to further scale up testing. In total, approximately 13.78 lakh tests were conducted in 2023-24 through both programmatic and non-programmatic viral load laboratories. States/UTs-wise viral load tests conducted in 2023-24 is shown is table 10.1

16.00 lakh) 14.00 Viral load tests (in I 12.00 10.00 6.84 4.08 8.00 13.78 6.00 4.00 6.25 2.00 0.00 2018-19 2019-20 2020-21 2021- 22 2022-23 2023-24 ■Through PPP Model ■Through Programme and Non-Programme Labs

Figure 10.2. Scale up of the Viral load tests (in lakh) under NACP, from FY 2018-19 to 2023-24

10.3. CD4 testing

The programme is continuing CD4 testing in order to determine the baseline immune status of the PLHIV, to monitor the treatment failure especially in case of HIV-2, to initiate prophylaxis for Opportunistic Infections (Ols), and as per discretion of Medical Officers (MO).

As per the current testing guidelines, CD4 monitoring can be discontinued for any patient (except children aged <5 yrs.), if CD4 count is more than 350 cells/cu mm and viral load count is less than 1000 copies/mL (when both tests are conducted at the same time). However, CD4 testing can be initiated if the patient has been switched to a different regimen due to treatment failure (Plasma Viral Load ≥1000 copies/ml) or when deemed necessary for clinical management by the MO at any point in time.

There are 460 functional CD4 testing machines (including both laboratory-based and point of care) under NACP of which 150 CD4 machines are newly procured under the buyback offer replacing the old CD4 machines.

Figure 10.3 shows the CD4 testing over the last five years. CD4 testing has a declining trend since 2019-20. This is due to focus of the programme on routine viral load monitoring as it provides an early and more accurate indication of treatment failure and the need to switch from first-line ART to second-line drugs. Overall, around 18.8 lakh tests were done in 2019-20 vis-à-vis around 8.7 lakh CD4 tests done in 2023-24. States/UT-wise CD4 tests conducted in 2023-24 is shown in Table 10.1.




Figure 10.3: CD4 tests (in lakh) under NACP, from FY 2019-20 to 2023-24

Table 10.1. States/UT-wise CD4 and viral load tests conducted, 2023-24

S.No	States/UTs	CD4 tests	Viral Load test
1	Andaman & Nicobar Islands	64	177
2	Andhra Pradesh	1,22,433	2,03,454
3	Arunachal Pradesh	91	240
4	Assam	6,899	9,676
5	Bihar	14,924	26,004
6	Chandigarh	4,981	5,799
7	Chhattisgarh	1,820	16,302
8	Dadra & Nagar Haveli and Daman and Diu	-	349
9	Delhi	25,527	34,677
10	Goa	1,798	3,481
11	Gujarat	42,112	71,236
12	Haryana	15,750	20,834
13	Himachal Pradesh	3,334	5,607
14	Jammu & Kashmir	3,322	2,389
15	Ladakh	3,322	2,307
16	Jharkhand	3,645	13,086
17	Karnataka	1,34,623	1,54,713
18	Kerala	2,491	17,099
19	Madhya Pradesh	29,160	40,282
20	Maharashtra	1,42,461	2,57,120
21	Manipur	1,417	9,270
22	Meghalaya	796	4,867
23	Mizoram	6,072	13,945
24	Nagaland	6,680	10,473
25	Odisha	6,586	9,961
26	Puducherry	903	1,134
27	Punjab	25,559	33,703
28	Rajasthan	34,696	48,318
29	Sikkim	495	381
30	Tamil Nadu	1,07,753	1,37,322
31	Telangana	44,036	86,595
32	Tripura	1,384	1,642
33	Uttar Pradesh	48,984	91,501
34	Uttaranchal	3,824	5,048
35	West Bengal	23,036	41,577
	India	8,67,656	13,78,262

10.4. Quality Management under NACP

Quality in a medical laboratory is the most essential element to ensure reliable testing. In order to warrant and maintain quality at all levels, a robust external quality assessment (EQA) system and process of accreditation/ certification is in place under NACP.


NACP Phase-V continues to have a four-tiered structure for EQA for HIV serology. The process of administering EQA for HIV serology is done through two ways as depicted in the Figure 10.4 and the process is explained below

The laboratories are categorized into four tiers, as follows:

- Apex Laboratory (First tier) National Institute of Translational Virology and AIDS Research (NITVAR), (Formerly NARI), Pune
- 13 National Reference Laboratories (NRLs) (Second tier) including ICMR-NITVAR
- 117 State Reference Laboratories (SRLs) (Third tier), and
- Stand-Alone ICTC (SA-ICTC) (Fourth tier)

ICMR-NITVAR is the Apex laboratory for providing EQA panels which are indigenously prepared for HIV Serology, CD4 testing labs, and Viral load testing labs.

Figure 10.4. EQA system for HIV Serology under NACP



10.4.1. EQA For HIV Serology

Panel testing, and retesting/reverse testing are the two mechanisms followed to check and ensure the quality of test result, handling of lab technicians putting up the test and to check the quality of test kit.

a. Panel Testing (PT): Well characterized blinded panels are sent biannually from the Apex lab to NRL (8-member panel), NRL to SRL (8-member panel) and SRL to SA-ICTC (4-member panel). In the year 2023, 100% NRL participated in panel testing with 100% concordance results.


Participation of SRL and SA-ICTC in panel testing in last four years is depicted in Figure 10.5 below. As evident, participation of SRL and ICTC have improved in the year 2023 as compared to the year 2022. Participation of SRL in the year 2023

was 97.8% and that of ICTC was 93.2%. Both SRL and ICTCs that participated in panel testing showed a concordance result of 99.6%. The data for the panel testing has also been uploaded on NACO Prayogshala.

b. Re-testing/reverse testing is a process where SA - ICTCs send already tested 20% positive and 5% negative samples received in first seven working days of each quarter (April, July, October, January) to their linked SRL for re-confirmation/ re-checking of the results. The participation as well as performance of ICTCs in re-testing/reverse testing has improved in FY 2023-24 as compared to that of last year (Table 10.2).

Figure 10.5. Participation in panel testing and concordance results, 2019 to 2023

a. SRL and ICTC participation in panel testing (in %)



b. Concordance at SRL & ICTC (in %)




Table 10.2. Participation of ICTC in re-testing and discordant results, 2019-20 to 2023-24

Year	% Participation	% Discordance
2019-20	88	0.03
2020-21	77	0.1
2021-22	84	0.1
2022-23	91	0.05
2023-24	94	0.03

Besides HIV serology, ICMR- NITVAR-Pune is the apex laboratory for EQA for approx. 350 CD4 labs and 64 viral load labs.


10.4.2. EQA For CD4

NACO established CD4 EQA for the laboratories linked to ART centers in 2005. The EQA round is conducted twice in a year (once in every six months), mostly in the month of February-March and October-November. Each CD4 EQA panel contains two samples (of different levels). The labs

are supposed to test the samples within the defined timelines and submit the report to the Apex lab for analysis. This is being reported through NACO Prayogshala. In addition to CD4 EQA, the 'Good Laboratory Practice' training for the ART center laboratory technicians are also conducted every year.

Around 62.4% of laboratories having CD4 machines participated in EQA in the year 2024 with an average performance of 66% (Figure 10.6).

Figure 10.6. CD4 EQA % participation & Performance, from year 2019 to 2024



10.4.3. EQA For Viral Load

ICMR-NITVAR-Pune conducts viral load EQA for all 64 VL laboratories under the national programme. In the year 2024 two additional non-programme VL labs (Kohima in Nagaland and Aizawl in Mizoram) also participated in the EQA. As per the procedure defined five member panels were sent to the labs. The labs tested the PT

samples within the defined time frame and uploaded the results on 'NACO Prayogshala' portal for further analysis.

In 2023 and 2024, only one round was conducted and 64 out of 66 laboratories secured satisfactory result (Figure 10.7).




Figure 10. 7. Participation and performance of viral load laboratories in EQA

10.5. Accreditation

In order to ensure the quality and accuracy of all tests conducted under NACP, it is important to maintain international quality standards across all testing facilities under the programme. Recognizing this important aspect, NACO has been implementing Quality Management Systems (QMS) in HIV testing reference laboratories since 2010 and have been providing technical

assistance to all the laboratories for the development and implementation of a Quality Management System. These efforts have led to notable achievements and 92% of the laboratories are accredited as per ISO 15189:2012 Standard. The table 10.3 below shows the accreditation status of all testing labs under NACP

Table 10.3. Accreditation status of laboratories under NACP

S.No	Type of Lab	Number of Lab	Number accredited
1	National Reference Laboratories	13	13
2	State Reference Laboratories	117	110
3	Viral Load (programme labs)	64	54
4	Early Infant Diagnosis	6	6

10.6. Certificate of Excellence to ICTCs

With increasing number of HIV tests being performed across the country, it is important to standardize and measure implementation of Quality Management Systems (QMS). In order to establish QMS at ICTCs, NACO has developed the QMS ICTC tool for measuring optimum quality standards at ICTCs. This tool assesses quality standards at ICTCs in the areas of counselling & testing and facilitate necessary corrective actions for Continuous Quality Improvement (CQI).

The checklist has four "Domains" – Operations, Technical, Monitoring and Evaluation (M&E) and

Logistics. Each of these domains has two or more sub elements, which are termed as "attributes" and there are a total of 14 attributes. The maximum overall score an ICTC can obtain is 246 and the Operations domain accounts for 78; Technical, 90; M&E, 50 and Logistics 28. On a score of >90%, the ICTC is eligible for Certification and SACS would recommend to NACO for 'Certificate of Excellence'

As on date, 649 SA-ICTCs (Table 10.4) have been approved by NACO for "Certification of Excellence" who have achieved grade 5 or more than 90% score during the final assessment

Table 10.4. State-wise status of Certificate of Excellence to ICTCs

S. No	States/UTs	No. of ICTCs	ICTCs recommended for Certificate of Excellence
1	Andhra Pradesh	218	60
2	Bihar	186	5
3	Delhi	85	6
4	Goa	12	10
5	Haryana	104	2
6	Jammu & Kashmir	34	6
7	Ladakh	0.	
8	Karnataka	432	135
9	Kerala	88	25
10	Madhya Pradesh	250	2
11	Maharashtra	544	85
12	Manipur	49	24
13	Meghalaya	35	8
14	Mizoram	41	29
15	Nagaland	63	57
16	Odisha	166	3
17	Puducherry	12	10
18	Punjab	110	1
19	Sikkim	13	9
20	Tamil Nadu	295	19
21	Telangana	118	70
22	Uttar Pradesh	397	43
23	Uttarakhand	41	5
24	West Bengal	314	35
	Total	3,607	649

10.7. Early Infant Diagnosis (EID)

The Government of India initiated the implementation of EID services under the NACP in 2010 with an objective to diagnose HIV-1 infection in infants and children aged <18 months. HIV exposed infants cannot be tested using standard HIV antibody tests due to the presence of maternal antibodies (transferred during pregnancy or breast feeding) and absence of self-generated antibodies early in life.

Thus, in infants below 18 months, direct detection tests for the virus must be conducted. The current test of choice is the HIV Total nucleic acid-polymerase chain reaction (TNA-PCR) for which a network of six laboratories has been strengthened for the purpose. Additionally, NACP

has approved two additional labs- Kohima in Nagaland and Nellore in Andhra Pradesh to cater to excess load at six labs which in turn will reduce the turnaround time (TAT). Currently, there are a total of eight EID labs in the country.

All six old EID Laboratories (AIIMS-New Delhi, ICMR-NITVAR-Pune, NIMHANS-Bengaluru, NIRT-Chennai, Kasturba-Mumbai, and NICED- Kolkata) successfully participated in EQA. This is a biannual activity. The labs test the results within the defined time and submit the report on the portal. For the new labs EQA will be introduced in FY' 2024-25. The number of EID tests conducted over last five years is represented in Figure 10.8.




Figure 10.8. Number of EID tests done, 2019-20 to 2023-24


10.8. Sexually Transmitted Infection (STI)

Sexually transmitted infections (STIs) significant morbidity worldwide and are associated with increased risk for HIV transmission. It disproportionately affects key populations including FSW, MSM, H/TG persons, and PWID. To achieve the 95-95-95 targets and end the AIDS epidemic as a public health threat by 2030, in accordance with Sustainable Development Goal (SDG), NACP phase-V emphasizes universal access to quality Sexually

Transmitted Infections/Reproductive Tract Infections (STI/RTI) services, particularly for high risk and vulnerable populations, as well as the elimination of vertical transmission of HIV and Syphilis.

The STI laboratory network consists of an APEX laboratory, 10 (including Apex lab) Regional STI Training, Research & Reference Laboratories (RSTRRLs) which act as a referral, 45 linked State STI training and Reference Laboratory (SRC) and around 1,127 designated STI/RTI clinics situated at government healthcare facilities at district level and above as shown in Figure 10.9.


Figure 10.9. Laboratory network under National AIDS and STD Control Programme




Considering the importance of RSTRRLs and SRCs laboratory network in the country and efforts to improve the access to and quality of STI services in the country, assessment was carried out between June 2023 to October 2023. The RSTR-RLs and SRCs were assessed using a checklist to understand current operational capacities, linkages, participation in EQA and surveillance

programs. Figure-10.10 indicates the geography of the RSTRRLs and the linked SRCs. The check list focused on eight technical areas such as Infrastructure, human resource, equipment, core functions, quality assurance, safety, documentation and reporting, supply and inventory. Additionally, it also concentrated on the Process control area in RSTRRLs.

Figure-10.10. indicates the geography of the RSTRRLs and the linked SRCs





ELIMINATION OF VERTICAL TRANSMISSION OF HIV & SYPHILIS (EVTHS)



11.1. Background

India has made notable progress since the inception of the Prevention of Parent-to-Child Transmission (PPTCT) initiative addressing vertical transmission of HIV and syphilis through various phases of the National AIDS and STD Control Programme (NACP). The focus has sharpened on eliminating vertical transmission of these infections as a Goal 3 of the NACP Phase-V. To support this ambition, NACO has taken a strong step by setting up task force to revise EVTHS guidelines in 2022 and parallel planning a phase-wise implementation of EVTHS interventions. The First phase implementation was rolled out in seven high priority States viz Bihar, Karnataka, Maharashtra, Mizoram, Nagaland, Rajasthan and Uttar Pradesh as an immersion learning model in April 2023 in close collaboration with NHM.

The first phase demonstrated significant improvements in EVTHS care cascade in FY 2023-24, including better screening, identification, and care for infected pregnant women and exposed infants, validating the program's potential for broader impact as described in subsequent sections of this chapter. Having successfully completed its initial phase in seven high-priority States, the same has been expanded nationwide starting from April 1, 2024. This expansion underscores India's commitment to achieving the goal of eliminating vertical transmission by 2025.

The chapter is divided into three sections

- Coverage of ANC registration, HIV Testing and Syphilis Testing among pregnant women
- HIV and Syphilis Treatment Coverage among infected pregnant women
- Care of Exposed infants.

To measure progress towards EVTHS, NACO monitors various impact and process indicators. The States/UTs wise summary of key indicators is provided in Table 11.1.

11.2. ANC registration, HIV and Syphilis Testing

In the realm of EVTHS, access to critical health services such as antenatal care (ANC) registration, HIV testing, and syphilis testing is of paramount importance for identifying and managing infections in pregnant women. Early identification of these conditions enables timely interventions that can significantly reduce vertical transmission and improve maternal and neonatal health outcomes. To evaluate the effectiveness of these services, it is essential to analyse current trends in ANC registration (First 95) and testing for HIV and syphilis (Second 95). The trends over the past seven years, as illustrated in Figure 11.1.

and syphilis screening services increasingly accessible across a range of public and private healthcare facilities, as well as through outreach programs such as Village Health Sanitation and Nutrition Days (VHSND). In collaboration with the National Health Mission (NHM), numerous States have initiated the procurement of HIV-syphilis dual rapid diagnostic test (RDT) kits using NHM budget allocations through PIP of respective States. This strategic approach aims to facilitate the distribution of these testing kits to healthcare facilities and sites, thereby enhancing comprehensive screening of pregnant women for these critical infections.


The implementation of dual RDT kits has led to a notable improvement in HIV and syphilis testing

rates among pregnant women. The coverage of testing has demonstrated substantial improvement over the past few years, as illustrated in Figure 11.1. In the fiscal year 2023-24, HIV testing among pregnant women increased to 87% (this factor in the duplication in

HIV testing in the pregnant women), while syphilis testing reached 85%. This trend reflects enhanced efforts in EVTHS initiatives aimed at increasing the accessibility and uptake of testing services among pregnant women.

	Syphilis Treatment Coverage	100%	100%	72%	22%	%68	100%	%26	100%	95%	91%	95%	%96	%88	83%	%26	100%	100%	100%	%0	100%	%26	100%	%82	%26	%26	%86	100%	%66	85%	73%	100%	%26	75%	72%	%92	93%	%98	
		3 100											162 96	7 88	5 83	162 97	206 10	80 10	2 10	0		395 97					336 98		232 96			_							
	Syphilis Treated									`											1,293			-														7,739	
	Syphilis Reactive	3	63	278	565	113	27	211	6	174	7	717	168	8	9	167	207	8	2	'	1,293	407	9	930	61	147	342	7	234	1,019	44	216	64	16	957	34	451	9,037	
	% ANC Syphilis Tested Against Estimated	%06	107%	75%	37%	72%	91%	28%	%68	%68	192%	95%	%66	71%	%8	%68	110%	87%	%0	110%	%//	132%	81%	105%	112%	%68	88%	135%	%96	103%	%69	%66	134%	91%	84%	110%	%86	85%	
	Syphilis Tested	4,366	9,91,103	21,565	3,03,655	8,90,803	16,643	4,12,296	26,610	3,21,346	42,409	13,88,741	6,75,571	91,850	17,862	8,43,841	13,26,204	4,48,887	2	1,169	17,49,582	27,92,471	42,803	85,096	21,645	26,784	8,26,315	33,821	4,71,545	21,49,560	8,108	11,76,007	9,20,424	53,797	55,89,895	2,38,907	15,91,709	2,56,03,392	SS
	ART Coverage (Population Level Denominator)	100%	95%	64%	94%	54%	312%	%06	125%	%96	%68	%86	108%	88%	83%	88%	91%	%92		-	%86	%86	72%	%96	102%	82%	%26	20%	83%	%06	10%	93%	94%	74%	91%	%62	%66	%06	Report Submitted by SACS
24	ART Coverage (Facility Level Denominator)	100%	100%	%9/	94%	%88	%86	93%	111%	%98	109%	%26	100%	91%	104%	%56	102%	%86			%26	%86	83%	%26	93%	%26	%26	100%	94%	102%	33%	101%	101%	%9/	100%	%29	104%	%26	Report Su
2023-	Initiated On ART	4	1,647	16	247	985	53	389	10	391	22	1,099	223	30	25	296	1,515	78	•	'	804	2,102	112	287	298	236	363	7	096	888	1	606	1,048	48	1,910	63	286	17,985	
for FY	PW	4	1,640	21	264	1,120	54	419	6	453	23	1,152	554	33	24	312	1,490	80	•	'	827	2,141	135	296	322	248	373	7	1,025	873	က	868	1,040	63	1,905	98	561	18,463	
cators	EMTCT	4	1,797	25	264	1,823	17	430	8	408	28	1,121	513	34	30	335	1,662	102	•	'	817	2,144	155	536	292	288	394	14	1,027	992	10	926	1,118	92	2,097	8	592	19,961	
ss indi	% ANC tested against Estimated	78%	101%	64%	%62	72%	100%	71%	71%	95.6%	152%	%98	%98	%6/	111%	73%	%26	%89	51%	%88	73%	105%	%99	%98	107%	72%	72%	114%	81%	85%	64%	%62	120%	%62	100%	87%	%98	%28	
HS proce	HIV Tested	3.766	9,34,393	18,397	6,50,937	25,34,071	18,202	5,05,624	21,019	2,75,926	33,672	12,90,038	5,86,987	1,01,522	2,40,204	6,96,009	11.46.331	3,54,621	2,376	929	16.57.621	22,20,309	34,617	69,872	20,613	21,500	6,74,520	28,715	3,99,251	17,83,149	7,438	9,40,896	8,23,246	46,765	66,36,132	1,90,004	14,01,302	2,63,70,974	
of EVT	% ANC Covered against Estimated	104%	%68	94%	73%	%96	165%	%88	41%	124%	85%	%06	81%	%08	127%	106%	%96	81%	100%	%86	81%	104%	113%	126%	108%	%68	%69	71%	87%	85%	63%	%08	113%	91%	106%	87%	91%	94%	
summar)	HMIS ANC regn.	5.049	8.24,603	27,029	5,97,564	33,71,766	29,970	6,30,453	12,297	4,46,052	18,850	13,61,625	5,55,715	1,03,035	2.73.541	10,12,846	11.59.827	4.20,170	4.651	1,040	18.38.843	21,92,924	59,589	1,02,139	20,870	26,660	6,44,760	17,832	4,28,047	17,66,228	7,323	9,56,988	7.79.736	53,849	70.61.380	1.88.546	14,83,441	2,84,85,238	HMIS
/UT wise	Estimated # of Annual Pregnancies	4.840	9.23.200	28,900	8,23,820	35,30,140	18,190	7,12,470	29,790	3,60,500	22,110	15,05,120	6.84,080	1,29,270	2.15.790	9.51,600	12,05,060	5.17.840	4.670	1,060	22.58.620	21,15,690	52,850	80,810	19,270	29,970	9,34,720	25,120	4,91,800	20,88,490	11,700	11.88.940	6,87,530	29,090	66.41.050	2,17,250	16,24,780	3,01,96,130	
Table 11.1. States/UT wise summary of EVTHS process indicators for FY 2023-24	States/UTs	ANI	Andhra Pradesh	Arunachal Pradesh	Assam	Bihar	Chandigarh	Chhattisgarh	DNH & DD	Delhi	Goa	Gujarat	Harvana	Himachal Pradesh	Jammu & Kashmir	Jharkhand	Kamataka	Kerala	Ladak	Lakshadweep	Madhva Pradesh	Maharashtra	Manipur	Meghalaya	Mizoram	Nagaland	Odisha	Pondicherry	Punjab	Raiasthan	Sikkim	Tamil Nadu	Telandana	Tribura	Uttar Pradesh	Uttarakhand	West Bengal	India	*Source
Table	S.S.	,	2				9	7	∞	10	7	12	13	14	15	16	17	18	19	20	2	22	24	25	26	27	28	59	30	33	32	33	34	35	36	37	38		

Figure 11.1. EVTHS Process Indicators (%)




11.2.1. ANC Registration

In the FY 2023-24, ANC registration rate in India stands at 94%, as reported by the Health Management Information System (HMIS). ANC registration was consistently above 94% since FY 2017-18 (except for FY 2019-20 which was affected by pandemic). A total of twenty States and union territories have reported ANC registration rates less than the national average of 94% in FY 2023-24. These States/UT are DNH & (41%),Sikkim (63%), Odisha Pondicherry (71%), Assam (73%), Himachal Pradesh (80%), Tamil Nadu (80%), Kerala (81%), Haryana (81%), Madhya Pradesh (81%), Rajasthan (85%), Goa (85%), Uttarakhand (87%), Punjab (87%), Chhattisgarh (88%), Nagaland (89%), Andhra Pradesh (89%), Gujarat (90%), Tripura (91%), and West Bengal (91%).

11.2.2. HIV Testing among Pregnant Women

The HIV testing has improved to 87% in FY 2023-24 (after factor in 21% duplication in HIV testing in pregnant women). Twenty-four States/UTs reported lower HIV testing than the national average of 87%. Ladak (51%), Sikkim (64%), Arunachal Pradesh (64%), Manipur (66%), Kerala (68%), DNH & DD (71%), Chhattisgarh (71%), Nagaland (72%), Bihar (72%), Odisha (72%), Jharkhand (73%), Madhya Pradesh (73%), Delhi (77%), Andaman & Nicobar Islands (78%), Himachal Pradesh (79%), Assam (79%), Tamil Nadu (79%), Tripura (79%), Punjab (81%), Rajasthan (85%), Gujarat (86%), Haryana (86%), West Bengal (86%), and Meghalaya (86%).

Figure 11.2. HIV Sero-Positivity in FY 2023-24



In FY 2023-24, out of approximately 2.6 crore HIV tests conducted, 8,122 HIV-positive pregnant women were detected as HIV positive, resulting in a national sero-positivity rate of 0.03%. However, significant regional disparities exist, with Nagaland reporting the highest rate at 0.72%. eighteen States and union territories exceeded

the national average, as shown in Figure 11.2. Various interventions have been designed under the programs to ensure primary prevention. Successful implementation of the EVTHS guidelines, along with other prevention strategies, is expected to further reduce positivity rates.


11.2.3. Syphilis testing among pregnant women

The EVTHS guidelines 2024 recommends syphilis screening using HIV and Syphilis dual rapid diagnostic testing (Dual RDT) kits. However, when Dual RDT is not available, Rapid Plasma Reagin (RPR) or Venereal disease research laboratory (VDRL) test for Syphilis can be used . Dual RDT as mentioned earlier, are provided through NHM PIP for ANC screening at screening facilities whereas the RPR kits are provided for testing by NACP at NACP facilities.

Eleven States and Union Territories (UTs) reported syphilis testing rates below the national average of 85%. These include Ladakh (0%), Jammu & Kashmir (8%), Bihar (25%), Assam (37%), Chhattisgarh (58%), Sikkim (69%), Himachal Pradesh (71%), Arunachal Pradesh (75%), Madhya Pradesh (77%), Manipur (81%), and Uttar Pradesh (84%).

As illustrated in Figure 11.3, syphilis positivity rates varied significantly across regions, ranging from 0.00% in Lakshadweep to 1.29% in Arunachal Pradesh, with a national average of 0.04%. Notably, fifteen States and UTs reported syphilis positivity rates exceeding this national average. States with higher positivity rates include Arunachal Pradesh (1.29%), Meghalaya (1.09%), Nagaland (0.55%), Sikkim (0.54%), Mizoram (0.28%), Assam (0.19%), Chandigarh (0.16%), Andaman & Nicobar Islands (0.07%), Madhya Pradesh (0.07%), Chhattisgarh (0.05%), Delhi (0.05%), Gujarat (0.05%), Punjab (0.05%), and Rajasthan (0.05%).

Figure 11.3. Syphilis Sero-Positivity in FY 2023-24



11.3. Treatment Coverage among infected pregnant women

Ensuring comprehensive treatment coverage for pregnant women infected with HIV and/or syphilis is critical for safeguarding maternal and infant health. The infected pregnant women are promptly initiated on treatment at the nearest health facility providing the treatment services. These pregnant women are also covered as 'high risk pregnancy' under Extended- PMSMA initiative for priority care.

11.3.1. Identification of pregnant WLHIV

During FY 2023-24, the program successfully enrolled 10,341 pregnant WLHIV who were aware of their HIV status prior to pregnancy, referred to as 'Known pregnant WLHIV.' Additionally, 8,122 newly diagnosed pregnant WLHIV were identified. As illustrated in Figure 11.4, there has been a progressive increase in the proportion of 'Known pregnant WLHIV,' rising from 33% in FY 2017-18 to 56% in FY 2023-24.





Figure 11.4. Proportion of Newly detected and Known Pregnant WLHIV FY 2017-18 to FY 2023-24

Figure 11.5 shows the breakdown of known and newly diagnosed pregnant WLHIV cases by state and UT. States/UTs such Andaman & Nicobar Islands (100%), Pondicherry (86%), Tamil Nadu (75%), Manipur (71%), Jammu & Kashmir (71%), Andhra Pradesh (70%), Maharashtra (67%),

Karnataka (66%), Goa (65%), Kerala (65%), Chandigarh (65%), Mizoram (64%), Himachal Pradesh (64%), and Telangana (58%), reported proportions of Known pregnant WLHIV that exceed the national average of 55%

Figure 11.5. States/UTs wise Newly Diagnosed and Known Pregnant WLHIV (percentage distribution), FY 2023-24



Program could provide the services to 18,463 (92%) pregnant WLHIV out of estimated 19,961 (as per India Estimate 2023) the pregnant women who may be need of EVTHS interventions for HIV.

The first phase of EVTHS implementation in Uttar Pradesh, Mizoram and Bihar during the FY 2023-2024 has demonstrated significant results in the identification of pregnant WLHIV, with an increase of around 25%. In Uttar Pradesh, a total of 1,905 pregnant WLHIV were identified in FY 2023-2024, marking a substantial rise from 1,508 identified in the previous fiscal year. Similarly, Mizoram reported an increase from 256 to 322 identified cases, while Bihar reported a rise from 911 to 1,120 cases. This increase underscores the effectiveness of the implemented strategies aimed at improving screening and support for this vulnerable population.


However, several States such as Kerala, Jammu & Kashmir, Goa, Arunachal Pradesh, Nagaland, Manipur, Rajasthan, Karnataka, Uttar Pradesh, Andhra Pradesh, Tamil Nadu, Telangana, and Jharkhand need to enhance their efforts to improve early identification, as evidenced by lower identification rates compared to estimations, as indicated in Table 11.1.

Additionally, 593 WLHIV were diagnosed with HIV in their post-natal care period after the child birth or during breastfeeding. It accounts for 7.3 cases per 100 newly diagnosed pregnant WLHIV. This can be a sign of undiagnosed cases during pregnancy or new infections cases during breastfeeding period and hence, programmatically significant to understand the missed opportunity of the interventions under EVTHS. However, under the program, these

women and their children are also provided with EVTHS service packages to eliminate risk of HIV transmission through breast milk, if the child is not already infected. The States contributing to these 593 cases include Uttar Pradesh (17%), Madhya

Pradesh (10%), Bihar (9%), Punjab (8%), Rajasthan (7%), West Bengal (6%), Karnataka (5%), Haryana (5%), Odisha (4%), Delhi (4%), and with the remaining States accounting for 25% of the total.

Figure 11.6. Distribution of WLHIV cases diagnosed in post-natal period after the childbirth and during breastfeeding



11.3.2. Treatment coverage for pregnant WLHIV

The program focuses on rapid initiation of ART, achieving optimal adherence for achieving optimal plasma viral load suppression. ART prevents vertical transmission of HIV by reducing the maternal viral load, loading the foetus with Anti-retroviral drugs that prevent the transmitted virions from replicating and improving overall health of mother.

In the FY 2023-24, 17,985 (97%) of identified pregnant WLHIV were on ART, an increase from 94% the previous year. However, certain States, Including Sikkim (33%), Uttarakhand (67%), Arunachal Pradesh (76%), Tripura (76%), Manipur (83%), Delhi (86%), Bihar (88%), Himachal Pradesh (91%), Mizoram (93%), Chhattisgarh (93%), Assam (94%), and Punjab (94%), show significant room for improvement in ART initiation. It is important to consolidate the efforts for prompt ART initiation in pregnant WLHIV to achieving viral suppression before delivery, which will reduce the risk of HIV transmission to the child.

11.3.3. Identification of Syphilis Infected Pregnant Women

Syphilis screening services are available across various public and private facilities as well as provided through outreach services such as community-based screening. There has been a progressive increase in the reporting of syphilis-infected pregnant women. As illustrated in Figure 11.7, during fiscal year 2023-24, a total of 9,037 syphilis-infected pregnant women were reported across various States, compared to 5,228 in FY 2021-22. Ongoing efforts, such as continuous training for both NACP and non-NACP staff on syphilis screening and reporting in HMIS have contributed to a gradual improvement in the identification and reporting of infected pregnant women.




Figure 11.7. Trend in identification of syphilis infected pregnant women in last three years

Ten States accounted for 77% of the reported syphilis cases, as shown in Figure 11.8. Madhya Pradesh (14%), Rajasthan (11%), and Uttar Pradesh (11%) were the leading States in reporting. Other notable contributors included Meghalaya (10%), Gujarat (8%), Assam (6%), West Bengal (5%), Maharashtra (5%), Odisha (4%), and Arunachal

Pradesh (3%). To improve overall outcomes, the remaining States need to enhance their implementation strategies to ensure that pregnant women are effectively screened for syphilis and that those who test reactive are promptly linked to appropriate treatment.

Rest of the states, 2,078, 23%

Arunachal Pradesh, 278, 3%

Odisha, 342, 4%

Maharashtra, 407, 5%

West Bengal, 451, 5%

Assam, 565, 6%

Gujarat, 717, 8%

Madhya Pradesh, 1,293 14%

Rajasthan, 1,019 11%

West Bengal, 451, 5%

Assam, 565, 6%

Gujarat, 717, 8%

Figure 11.8. Top 10 States/UTs reporting syphilis infected pregnant women in FY 2023-24

11.3.4. Identification and treatment of Syphilis Infected Pregnant Women

The "Test & Treat" policy for syphilis, implemented under EVTHS, ensures that all pregnant women who screen reactive for syphilis receive at least one dose of Benzathine Penicillin G (BPG) as an on-the- spot treatment. This single dose is effective in preventing vertical transmission of syphilis, irrespective of the syphilis stage. However, complete treatment as per the stage of infection is necessary for the complete management of sero-reactive pregnant women. Out of the 9,037 identified cases, 7,739 women

(86%), received treatment (at least one dose of BPG) for syphilis. While this figure reflects a commendable effort in managing the infection, treatment coverage varied significantly across States/UTs. For instance, as shown in Table 11.1, States/UTs like Madhya Pradesh, Kerala and Andhra Pradesh, Chandigarh, DNH & DD, Pondicherry, Manipur, Andaman & Nicobar Islands, and demonstrated 100% treatment rates, yet others, such as Assam (22%), reported alarmingly low coverage.

11.4. Management of Babies exposed to HIV and/ or Syphilis infection

The term "exposed babies" is used to refer to the babies born to infected mothers, until infection can be reliably excluded or confirmed in them. HIV and syphilis-exposed infants are at a higher risk of morbidity and mortality and hence require specialized care and close follow up.

11.4.1. Management of HIV-Exposed babies

Under the EVTHS services, various interventions are provided to the HIV exposed babies such as ARV prophylaxis, OI prophylaxis, EID at defined intervals, close monitoring of Infant feeding and Growth & Development and early initiation of treatment to the children identified of having HIV infection. Two critical interventions are administration of ARV prophylaxis and Early Infant Diagnosis are discussed below.

11.4.2. ARV Prophylaxis

Postnatal antiretroviral drugs (either single or dual based on maternal plasma viral load) are provided to all infants exposed to HIV to reduce the risk of perinatal HIV transmission. In FY 2023-24, out of 14,672 live births, 14,561 infants (99%) received ARV prophylaxis. ARV prophylaxis coverage has significantly improved, rising from 85% in FY 2020-21 to 99% in FY 2023-24, underscoring the program's success in protecting at-risk new-borns.

11.4.3. Early Infant Diagnosis (EID)

Early infant diagnosis (EID) of HIV is an integral component of the EVTHS under NACP, ensuring follow up care of HIV exposed Infants/children (born to HIV positive mother) for early detection of infection and timely access to antiretroviral treatment. The services are offered through all stand-alone ICTCs. EID is conducted at 6 weeks, 6 months, 12 months and 18 months or 3 months after cession of breastfeeding whichever is later as per the EID algorithm provide in national guidelines. Linkage between EID and HIV care cascade and the proportion of children tested TNA positive who initiated on ART have improved significantly over the last few years.

11.4.4. First EID (6 weeks-2 months)

The first Early Infant Diagnosis (EID) of HIV, conducted at 6 weeks to 2 months of age, serves as a critical indicator of perinatal transmission rates. In the 2023-24 period, a total of 14,512 infants were eligible for testing, with 14,509 (~100%) undergoing the first EID at 42 days. Among these, 66 infants were diagnosed as HIV positive, resulting in a national positivity rate of 0.46%. Of those diagnosed, 44 infants (66%) were successfully linked to antiretroviral therapy (ART). The State-wise distribution of testing, positivity rates, and ART initiation is illustrated in Figure 11.9.




Figure 11.9. First EID at 6 weeks: Testing, positivity and ART initiation (%)

Notably, certain regions such as Ladakh and Lakshadweep reported zero eligible HIV-exposed infants, while several States/UTs, including Himachal Pradesh, Manipur, Goa, Mizoram, A&N, Arunachal Pradesh, J&K, Meghalaya, Odisha, Puducherry, Sikkim, Tripura, Bihar, Kerala, Haryana, Delhi, Uttarakhand, DNH & DD, and Chandigarh, recorded no positive cases at the 6-week mark.

The positivity rates exhibited significant variation across States, with Assam presenting the highest rate at 6.81% and Madhya Pradesh at 1.52%. In contrast, States such as Rajasthan and Punjab reported notably lower positivity rates of 0.14% and 0.12%, respectively, highlighting disparities in perinatal transmission risk across the country. Karnataka, despite having a higher number of pregnant women living with HIV (WLHIV), managed to maintain a lower positivity rate of 0.17%.

In addition to the initial testing at 6 weeks, 2,288 infants who were not tested at this time subsequently underwent EID testing within 6 months. Among these later tests, 41 infants (1.79%) were identified as positive, and 35 (85%) were linked to treatment. The higher positivity observed among infants tested beyond the recommended 6-week window suggests a potential correlation with maternal non-adherence to follow-up protocols. This underscores the necessity for enhanced counselling and support to improve treatment adherence among mothers and their infants, as timely intervention is essential for reducing transmission rates and ensuring better health outcomes.

11.4.5. Second EID (6 months-12 months) and Third EID (12 months-18 months)

The second and third Early Infant Diagnosis (EID) tests are recommended for infants at six months and twelve months of age, respectively. To ensure timely testing, parents receive counselling on the importance of adhering to these recommended intervals. However, the health system remains flexible, allowing parents to bring their child for EID testing whenever they seek medical care. During these two testing phases, infants undergo three parallel antibody tests, and if any test turns a reactive result, the sample is forwarded for a confirmatory TNA-PCR test.

In 2023-24, a total of 13,038 infants were eligible for the second EID test between six and twelve months. Out of these, 12,360 infants (95%) were tested using the antibody test, resulting in 60 infants (0.77%) being confirmed positive through the TNA-PCR diagnosis. Of the positive cases, 57 infants (95%) were initiated on antiretroviral therapy (ART). Notably, Jammu and Kashmir exhibited a higher positivity rate of 4.17%, which can be attributed to the smaller sample size of only 24 tested infants, with one case result positive.

For the third EID testing, out of 10,764 eligible infants, 9,978 (93%) were tested via the antibody test, with 54 infants (0.54%) receiving a positive diagnosis from TNA-PCR. All 54 infants were also started on ART. Figure 11.10 illustrates the state-wise positivity rates for both the second and third EID tests conducted during FY 2023-24.




Figure 11.10. States/UT wise positivity at second and third EID FY 2023-24

States/UTs such as Delhi, Haryana, Madhya Pradesh, Jharkhand, Odisha, and Gujarat ranked among the top ten for higher positivity rates in both testing phases, suggesting a need for further investigation into the factors contributing to these results.

The overall high uptake of the second and third EID tests, coupled with low positivity rates, indicates a successful retention of mother-baby pairs within the care cascade. The latest EVTHS guidelines

emphasize the importance of coordinating maternal ART refills and follow-up appointments with EID to ensure comprehensive HIV care for both mothers and infants. This alignment enables healthcare professionals at ART centres and ICTC facilities to provide essential support to these families.

11.4.6. Final EID at 18 months or 3 months after cessation of breastfeeding whichever is later

The HIV status of an HIV-exposed child is confirmed at 18 months of age or three months after the complete cessation of breastfeeding, whichever is later. Figure 11.11 illustrates the trend in 18-month testing, showing a noticeable increase in overall testing rates, which can be attributed to improved coverage. Additionally, the data indicates a decline in positivity rates, despite a relatively constant number of positive

cases among children. This suggests that the provision of care is improving, leading to better health outcomes for HIV-exposed infants. In FY 2023-24, there has been a significant increase in the uptake of the 18-month Early Infant Diagnosis (EID), with 11,509 infants tested compared to 8,765 the previous year. This stability suggests that while testing has increased, the rate of new infections among infants has not escalated.




Figure 11.11. The trend in 18 months EID in last seven years

Nationally, there were 12,027 eligible infants for 18 months testing during FY 2023-24. Out of these, 11,509 (96%) of the eligible HIV-exposed children underwent the antibody test at 18 months. Among them, 306 infants (2.7%) were

confirmed to be HIV positive. Out of 306 confirmed HIV positive, there were 297 of those (97%) initiated antiretroviral therapy (ART). The overall positivity rate reported was 2.58




Figure 11.12. Number of children tested and found positive at 18 month

11.4.7. Summary of EID

The summary of EID conducted at 6 weeks, 6 months, 12 months and 18 months is provided in Table 11.2. The total 50,649 EID test were conducted which led to identification of 528 (1.04%) positive children and 487 (92%) children were initiated to ART in FY 2023-24.

However, at 18 months all the children are tested for EID irrespective of their earlier EID status. Hence the positive reported may include children diagnose positive on earlier EID

Table 11.2. Summary of EID testing FY 2023-24

Visit of Babies	Tested	Positive	Positivity (%)	Initiated On ART	ART Initiation (%)
First Visit (at 6 week)	14,514	67	0.46%	44	66%
First Visit (2 Months -6months)	2,288	41	1.79%	35	85%
Second Visit (6 Months to 12 Months)	12,360	60	0.49%	57	95%
Third Visit (12 Months to 18 Months)	9,978	54	0.54%	54	100%
Fourth Visit (18 Months or later)	11,509	306	2.66%	297	97%
Total EID test	50,649	528	1.04%	487	92%

11.4.8. Management of Syphilis-Exposed Babies

Syphilis exposed require regular follow-up, including clinical evaluations and serological tests, to monitor for potential complications. Diagnosis of congenital syphilis relies on clinical examination and follow-up tests. In FY 2023-24, 1,763 of syphilis-exposed infants received treatment. Infants diagnosed with congenital syphilis should receive appropriate treatment immediately. Benzathine penicillin G is the first-line treatment,

with dosages depending on the infant's age and severity of the infection.

The EVTHS guidelines 2024 recommended follow up of syphilis exposed babies at SNCU at birth followed by paediatric care at 14 weeks and later. The integration of services with general health system will improve postnatal care of exposed babies.

Table 11.3. States-UT wise congenital syphilis treatment FY 2020-21 to FY 2023-24 (Source HMIS)

										1	,	1	
ON O	Tillocators	Number of pables		Found Congenital Sypnilis	ai sypnilis		umber or Ba	Number of Bables I reated		Perc	Percentage of Bables Treated	sables Trea	red
9.NO	orates/01	2020- 2021	2021- 2022	2022- 2023	2023- 2024	2020- 2021	2021- 2022	2022- 2023	2023- 2024	2020- 2021	2021- 2022	2022- 2023	2023- 2024
-	Andaman & Nicobar Islands	0	0	0	0	0	0	0	0	%0	%0	%0	%0
2	Andhra Pradesh	29	125	9	48	29	75	9	15	100%	%09	100%	31%
3	Arunachal Pradesh	22	0	1	9	0	1	0	16	%0	%0	%0	267%
4	Assam	1	_	15	4	1	_	15	31	100%	100%	100%	%5//
2	Bihar	125	7	108	42	125	0	86	86	100%	%0	91%	205%
9	Chandigarh	3	3	0	1	1	3	0	1	33%	100%	%0	100%
7	Chhattisgarh	75	156	65	31	22	48	14	48	78%	31%	22%	155%
8	Dadra & Nagar Haveli	44	4	0	0	0	4	0	0	%0	100%	%0	%0
6	Daman & Diu	0	0	0	0	0	0	0	0	%0	%0	%0	%0
10	Delhi	2	20	9	10	0	17	2	89	%0	85%	83%	%068
11	Goa	1	0	0	4	1	0	0	4	100%	%0	%0	100%
12	Gujarat	1,135	473	602	208	376	348	559	151	33%	74%	%86	73%
13	Haryana	0	29	65	80	0	29	34	5	%0	100%	52%	%9
14	Himachal Pradesh	3	2	0	2	3	2	2	2	100%	100%	%0	100%
15	Jammu and Kashmir	0	1	0	0	0	1	0	20	%0	100%	%0	%0
16	Jharkhand	6	0	1	0	6	0	1	0	100%	%0	100%	%0
17	Karnataka	228	384	417	933	26	293	217	347	43%	%92	25%	37%
18	Kerala	3	3	7	8	2	3	9	5	%29	100%	%98	%89
19	Ladakh	0	0	0	0	0	0	0	0	%0	%0	%0	%0
20	Lakshadweep	0	0	0	0	0	0	0	0	%0	%0	%0	%0
21	Madhya Pradesh	19	48	18	102	11	23	8	67	%89	48%	44%	%99
22	Maharashtra	477	17	399	836	476	14	375	194	100%	82%	94%	23%
23	Mumbai	0	0	0		0	0	0		%0	%0	%0	%0
24	Manipur	1	0	0	0	1	0	0	0	100%	%0	%0	%0
25	Meghalaya	74	114	80	131	89	06	73	95	%76	%62	91%	73%
26	Mizoram	0	30	2	8	0	3	2	20	%0	10%	100%	250%
27	Nagaland	0	_	2	14	0	_	_	15	%0	100%	20%	107%
28	Odisha	4	6	2	35	1	8	4	31	25%	89%	%08	86%
29	Puducherry	0	0	0	0	0	0	0	0	%0	%0	%0	%0
30	Punjab	5	2	2	12	5	0	5	8	100%	%0	100%	%29
31	Rajasthan	1,104	461	477	186	1,104	373	263	90	100%	81%	22%	48%
32	Sikkim	1	0	0	0	0	0	0	1	%0	%0	%0	%0
33	Tamil Nadu	14	20	2	009	14	2	2	111	100%	25%	40%	19%
34	Telangana	38	155	99	199	32	21	99	361	84%	14%	100%	181%
35	Tripura	1	0	1	1	1	0	1	1	100%	%0	100%	100%
36	Uttar Pradesh	1,143	327	302	17	478	11	172	6	42%	3%	21%	23%
37	Uttarakhand	0	8	3	2	0	2	0	0	%0	63%	%0	%0
38	West Bengal	12	58	403	59	12	10	403	146	100%	17%	100%	247%
	India	4,644	2,458	3,061	3,579	2,907	1,389	2,332	1,969	63%	21%	%9 2	25%

The EVTHS guidelines 2024 recommended follow up of syphilis exposed babies at SNCU at birth followed by paediatric care at 14 weeks and later. The integration of services with general health system will improve postnatal care of exposed babies.

The way forward

State AIDS Control Societies (SACS) are guided to collaborate closely with the state National Health Mission (NHM) to achieve 100% coverage for HIV and syphilis testing among pregnant women, linkages of infected women to EVTHS interventions and care of exposed infants. This partnership aims to streamline efforts and resources to ensure comprehensive care is integrated into NACP-NHM interventions.

Additionally, India's current initiative to integrate the HMIS with the Reproductive and Child Health (RCH) program and the SOCH will further enhance reporting of care cascade of EVTHS. This integration is designed to improve data collection and reporting, allowing for better identification of gaps in service provision and ensuring that all women have access to necessary screening. By focusing on these collaborative efforts and enhanced reporting mechanisms, the initiative seeks to bolster maternal and child health outcomes and effectively address the dual burden of HIV and syphilis among pregnant women.



SCORECARD



12.1. Background

The "Scorecard of SACS" offers a comprehensive overview of each state's performance in implementing the NACP across all facilities. It serves as a valuable tool for identifying areas that require additional efforts to achieve the NACP targets in the respective financial year.

The Scorecard of SACS is a quarterly activity within a financial year. The Scorecard of SACS is dynamic and the indicators are scrutinised and modified, if necessary, in consultation with each division on the basis of the programme need before the first scorecard of each financial year is prepared. Within each financial year, the

indicators of the scorecard remain the same. The scorecard of the financial year 2023-24 was prepared using a set of 44 indicators, based on the data and other relevant information as on March 31st, 2024. The details are provided in the subsequent section.

12.2. Methodology

Each indicator was based on the programme data and other relevant information for the financial year 2023-24, to which weights were assigned based on recommendations of programme divisions and approval of competent authority. Details of the indicators are provided in Table 12.1.

Table 12.1. Details of the Indicators across different service categories under NACP

S. N.	Indicator	Numerator	Denominator	Weight points
1	First 95	Total PLHIV in Active care	Estimated PLHIV	3
2	Second 95	Total PLHIV alive and on ART	Total PLHIV in Active care	2
3	Third 95	Out of test conducted no. of Viral Load suppressed	No. of Viral Load test conducted in the state	2
4	Average Frequency of Social Media updates	-	-	1
5	Status of AEP integration in state school curriculum	-	-	1
6	Status of SCA	-	-	1
7	Status of state rules	-	-	1
8	Status of ombudsman	-	-	1
9	TI/LWS onboarding	No. of Facilities onboarded	Approved in AAP (TI, LWS)	2
10	OST onboarding	No. of Facilities onboarded	Approved in AAP (OST)	2
4.4	C (UDC :	Total HRG coverage	MARCE	4
11	Coverage of HRG against estimates	(TI+LWS)	p-MPSE mapping estimates	1
12	HIV testing among HRG	HRG tested for HIV	Total active HRG population	1
13	HIV testing among prisoners	HIV testing among prisoners	Total estimation of prisoners in states	1
14	Clinic visit of HRGs at TI-Clinics	Number of HRGs visited TI-clinics	Total active HRG population	1
15	Percentage of HRGs screened for Syphilis	Number of HRGs screened for Syphilis at TI	Total active HRG population	1
16	IDU on OST	Active client on OST	50% of active IDU coverage in TI	1
17	Percentage of fund released to TI	Funds transferred to TIs	Total funds transferred to states	1
18	Number of TIs trained by Kshmata Kendra (KK) against the AAP targets	Total number of TIs trained	Number of TIs to be trained through Kshamta Kendra (KK) as per AAP target	1

S. N.	Indicator	Numerator	Denominator	Weight points
19	HIV testing against Target-at risk	No. of HIV tests done among at risk clients in the FY	Target for HIV testing among at risk clients in the FY	1
20	HIV testing against target-PW	No. of HIV tests done among PW in the FY	Target for HIV testing among PW in the FY	1
21	Percentage of pregnant women screened for Syphilis	Total number of PW tested for Syphilis	Target for syphilis screening among PW in the FY	1
22	Treatment provided to Syphilis reactive pregnant women	Number of pregnant women provided treatment	Total number of PW tested reactive for Syphilis	2
23	Index testing among newly detected HIV positive clients	Number of index testing conducted	Number of newly detected PLHIV*1.5	3
24	Percentage of 6 weeks - <2 months EID testing against live birth	Number of 6 weeks - <2 months EID testing	Number of live births	1
25	Clients managed at DSRC against the target	Number of Clients managed at DSRC	Target for the FY	1
26	STI attendees screened for HIV	Number of STI attendees screened for HIV	Number of STI attendees	1
27	STI attendees screened for Syphilis	Number of STI attendees screened for Syphilis	Number of STI attendees	1
28	Percentage of pregnant women who initiated ART	No. of HIV Positive pregnant women initiated on ART (MPR data)	Total no of HIV Positive pregnant women reported (incl. Known Positive)	1
29	Proportion of LFU-PLHIV, out of those initiated on ART in FY 2023-24	Out of newly initiated, LFU in FY 2023- 24	PLHIV Initiated on ART in FY 2023- 24	3
30	Proportion of PLHIV initiated on ART, out of those registered in FY 2023-24	Out of newly registered, PLHIV initiated on ART in FY 2023-24	PLHIV registered in FY 2023-24	2
31	Proportion of reported died, out of those initiated on ART in FY 2023-24	Out of newly initiated, PLHIV reported died in FY 2023-24	PLHIV initiated on ART in FY 2023- 24	1
32	Percentage of SRL accredited	No. of SRL accredited	No. of SRL in the state	1
33	Percentage participation of ICTCs in re - testing	No. of ICTC participated in the state	Total no. of ICTC in the state	1
34	Number of abstracts selected from studies conducted in FY21-22	Number of abstracts selected from studies conducted in FY 2021-22	Number of Studies Undertaken	2
35	Number of ongoing studies from FY22-23	Number of ongoing studies from FY 2022-23	Number of approved studies from FY 2022-23	1
36	Submission of research proposals from FY23-24 to NACO	#Submission of research proposals from FY23-24 to NACO	2 research studies to be undertaken	1
37	Secondary Data Analysis by SACS	Plan/ number of secondary data analyses submitted to NACO in the FY 2023-24	Two secondary data analyses plan by SACS in the FY 2023-24	1
38	Expenditure with respect to funds released during FY 2022-23	Expenditure in the FY 2022-23	Funds release in FY 2022-23	1

No. of research proposals from FY 23-24 summited to NACO

S. N.	Indicator	Numerator	Denominator	Weight points
39	Submission of Provisional Utilization Certificate (UC) in GFR 12A for the FY 2022-23	Date of receipt of requisite report/ document	by 30-Apr-2023	1
40	Submission of audited UC in GFR 12A for the FY 2022-23	Date of receipt of requisite report/ document	by 30-Jun-2023	1
41	Submission of EC/ GB ratification for approval of Expenditure incurred during FY 2021-22	Date of receipt of requisite report/ document	30-Jun-22	1
42	Timely Submission of CST-SCM Report	No. of formats reported during the period	Total no. of formats to be reported in the period	2
43	Format Adherence to CST-SCM Report	No. of correct formats reported during the period	Total no. of formats to be reported in the period	1
44	Timely Submission of BSD & STI-SCM Report	No. of formats reported during the period	Total no. of formats to be reported in the period	2

Performance on individual indicators were divided into 4 categories as described in the below table [Good (Green, 3 Marks), Average (Yellow, 2 Marks), Poor (Red, 1 Mark), Not Applicable (No

colour- No score added in denominator)]. Indicator wise details of performance categories are given in the Table 12.2

Table 12.2. Categorisation of performance of indicators

SI. No.	Indicator Name	Zone for ranking				
31. 140.	Indicator Name	Green	Yellow	Red		
1	First 95	≥95%	≥80% to <95%	<80%		
2	Second 95	≥95%	≥80% to <95%	<80%		
3	Third 95	≥95%	≥80% to <95%	<80%		
4	Average Frequency of Social Media updates	If the average number of social media updates of SACS is over 45 per quarter during the FY, including original content, reposts, retweets, and shares	If the average number of social media update of SACS falls between 40 and 44 per quarter in the FY.	If the average number of social media update of SACS falls below 40 per quarter in the FY.		
5	Status of AEP integration in state school curriculum	Yes		No		
6	Status of SCA	At least one meeting held since 2020		No meeting held		
7	Status of state rules	Notified		Not notified		
8	Status of ombudsman	Appointed		Not appointed		
9	TI/LWS onboarding	≥95%	≥90% to <95%	<90%		
10	OST onboarding	≥95%	≥90% to <95%	<90%		
11	Coverage of HRG against estimates	≥90%	≥80% to <90%	<80%		
12	HIV testing among HRG	≥95%	≥90% to <95%	<90%		

CL No	Indicator Name			
SI. No.	Indicator Name	Green	Yellow	Red
13	HIV testing among prisoners	≥50%	≥40% to <50%	<40%
14	Clinic visit of HRGs at TI-Clinics	≥90%	≥75% to <90%	<75%
15	Percentage of HRGs screened for Syphilis	≥90%	≥75% to <90%	<75%
16	IDU on OST	≥50%	≥30% to <50%	<30%
17	Percentage of fund released to TI	≥50%	≥45% to <50%	<45%
18	Number of TIs trained by Kshamta Kendra (KK) against the AAP targets	≥75%	≥70% to <75%	<70%
19	HIV testing against Target-at risk	≥95%	≥80% to <95%	<80%
20	HIV testing against target-PW	≥95%	≥80% to <95%	<80%
21	Percentage of pregnant women screened for Syphilis	≥95%	≥80% to <95%	<80%
22	Treatment provided to Syphilis reactive pregnant women	≥95%	≥80% to <95%	<80%
23	Index testing among newly detected HIV positive clients	≥95%	≥80% to <95%	<80%
24	Percentage of 6 weeks - <2 months EID testing against live birth	≥95%	≥80% to <95%	<80%
25	Clients managed at DSRC against the target	≥90%	≥75% to <90%	<75%
26	STI attendees screened for HIV	>75%	≥50% to ≤75%	<50%
27	STI attendees screened for Syphilis	>75%	≥50% to ≤75%	<50%
28	Percentage of pregnant women who initiated ART	≥95%	≥80% to <95%	<80%
29	Proportion of LFU-PLHIV, out of those initiated on ART in FY 2023-24	<2%	≥ 2% to <5%	≥5%
30	Proportion of PLHIV initiated on ART, out of those registered in FY 2023-24	≥98%	≥95% to <98%	<95%
31	Proportion of reported died, out of those initiated on ART in FY 2023-24	<2%	≥ 2% to <5%	≥5%
32	Percentage of SRL accredited	100	≥80% to <100%	<80%
33	Percentage participation of ICTCs in re-testing	≥95%	≥85% to <95%	<85%
34	Number of abstracts selected from studies conducted in FY21-22	100	>25% to <100%	≤25%
35	Number of ongoing studies from FY22-23	100	>25% to <100%	≤25%
36	Submission of research proposals from FY23-24 to NACO	100	>25% to <100%	≤25%
37	Secondary Data Analysis by SACS	2	1	0

SI. No.	Indicator Name		Zone for ranking	
31. NO.	indicator Name	Green	Yellow	Red
38	Expenditure with respect to funds released during FY 2022-23	≥90%	≥85% to <90%	<85%
39	Submission of Provisional Utilization Certificate (UC) in GFR 12A for the FY 2022-23	By 30-Apr-2023	By 31- May-2023	After 31-May-2023
40	Submission of audited UC in GFR 12A for the FY 2022-23	By 30-Jun-2023	By 30-Sep-2023	After 30-Sep-2023
41	Submission of EC/ GB ratification for approval of Expenditure incurred during FY 2021-22	By 30-Jun-2022	By 30-Sept-2022	After 30-Sept-2022
42	Timely Submission of CST-SCM Report	≥95%	≥80% to <95%	<80%
43	Format Adherence to CST-SCM Report	≥95%	≥80% to <95%	<80%
44	Timely Submission of BSD & STI-SCM Report	≥90%	≥75% to <90%	<75%

12.3. Performance of SACS in Programme Implementation

A. Comparison of performance of SACS based on the scorecards of FY 2022-23 and FY 2023-24

Among the 35 SACS, 17 SACS improved their ranks between the annual scorecards of FY

2022-23 and FY 2023-24, while 3 SACS maintained their previous ranks. The table below provides the changes in SACS ranking between the scorecard of FY 2022-23 and FY 2023-24:

Table 12.3. Change in overall ranks of SACS between the scorecard of FY 2022-23 and FY 2023-24

Improved Rank	Retained Rank	Deteriorated Rank
Karnataka (3-2), Mumbai (6-5), Tripura (24-23), Bihar (34-33), Punjab (9-7), Meghalaya (14-12), Arunachal Pradesh (35-32), West Bengal (11-7), Madhya Pradesh (24-20), Delhi (30-26), Nagaland (19-14), Himachal Pradesh (22-17), Rajasthan (27-17), Maharashtra (17-6), Mizoram (19-7), Telangana (31-17), Jharkhand (29-14)	Chandigarh (1-1), Tamil Nadu (4-4) J&K & Ladakh (33-33)	Puducherry (2-3), Andhra Pradesh (5-7), Chhattisgarh (28-31), Gujarat (9-12), Goa (8-11), Odisha (31-35), Andaman and Nicobar Islands (16-21), Kerala (11-16), Assam (24-30), DNH ⅅ (23-29), Uttar Pradesh (19-28), Haryana (14-23), Manipur (17-27), Uttarakhand (11-22), Sikkim (7-23)

Figure 12.1. Performance of SACS for each indicator





Figure 12.2. States/UT wise obtained score (in percentage), FY 2023-24 $\,$








1. Status of HIV/AIDS Epidemic A. Epidemic Estimates (2023) Male Indicator Female Total 1. IPR 2.69 2. IMR 1.15 3. Adult (15-49 yrs) HIV Prevalence (%) 0.19 0.20 0.22 4. Estimated people living with HIV 13,92,268 11,52,097 25,44,365 5. ART coverage (%) 66.84 74.39 70.54 6. Estimated children living with HIV 33,074 29,970 63,044 7. Annual new HIV infections 40,293 28,164 68,457 8. Annual AIDS-related deaths (ARD) 23,977 11,885 35,862 9. Change in annual new HIV infections since 2010 (%) -45.73 -44.23 -43.12 10. Change in annual ARD since 2010(%) -82.25 -79.26 -77.37 11. EMTCT need 19,961 19,961

B. High risk population size (2020-22), safe practices (2021) and prevalence (2021/2023)

Population Group	Estimates Size	Condom Use (%)	New Needle/ Syringe use (%)	HIV Prevalence (%)
1. Female Sex Workers	9,95,499	97.80	78.70	1.85
2. Men who have sex with men	3,51,020	94.60	78.80	3.26
3. Injecting Drug Users	2,88,717	-	91.30	9.03
4. Hijra/Transgender People	96,193	98.30	-	3.78
5. Migrants	72,00,000	53.60	57.10	0.89
6. Truckers	20,00,000	70.70	50.00	1.00
7. Prison inmates	22,55,799	62.90	65.00	1.99

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general	population (2019	9-21)	
Indicator	Male	Female	Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)	30.70	21.60	-
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	28.50	20.10	-
3. Adults willing to care for a relative with HIV/AIDS in own home (%)	74.30	70.90	-
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	69.20	64.30	-
5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)	3.80	0.50	-
5.1 Condom use during last higher-risk intercourse (%)	60.00	57.40	-
6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)	6.39	0.83	-
6.1 Condom use during last higher-risk intercourse (%)	60.58	62.80	-

2. Progress on 95-95-95 (2023-24)



Indicators	Male	Female	Total*
1. Estimated PLHIV size (2023)	13,92,268	11,52,097	25,44,365
2. PLHIV who know their HIV Status	10,89,318	9,50,610	20,48,730
3. PLHIV who know their HIV status and are on ART	9,29,930	8,57,798	17,94,692
4. PLHIV who are on ART and tested for their viral load	5,52,903	5,49,960	11,06,398
4.1 PLHIV who are virally suppressed	5,37,311	5,37,096	10,77,875

^{*} Including of H/TG PLHIV

3. Prevention of new HIV infections among general population

A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2023-24
Schools with operational Adolescent Education Program (AEP)	68,848
2. Colleges with operational Red Ribbon Clubs (RRC)	14,270
3. Persons trained under mainstreaming	5,70,249
4. No. of calls received at helpline	4,76,660

B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management under NACP

Indicator		202	3-24	
1. NACO Supported Designated STI/RTI				1127
Clinics (DSRC)	Male	Female	TG	Total
2. Clients managed				1,04,88,581
3. RPR Tests conducted at DSRC	17,38,273	23,85,323	24,287	41,47,883
4. Syphilis seropositivity (%) at DSRC	1.43	0.42	3.52	0.86

4. Prevention of new HIV infections among highrisk group and bridge population

A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

Indicator	2023-24
1. Targeted Interventions	1,577
2. OST centres (Excluding Satellite OST centres)	263

B. Female Sex Workers

C. Men who have sex with men

D. I ellidie Sex Workers	
Indicator	2023-24
1. Estimated size	9,95,498
2. Coverage (%)	>=95
3. Condoms distributed	14,49,40,020
4. Tested for HIV (April 2023-September 2023)	6,93,099
4.1. HIV sero-positive (%)	0.14
4.1.1. Linked to ART	853
5. Tested for HIV (October 2023 -March 2024)	8,40,911
5.1. HIV sero-positive (%)	0.13
5.1.1. Linked to ART	973
6. Clinic Visits	30,81,696
7. STI/RTI treated	46,041
8. Presumptive treatment	1,72,542

Indicator 2023-24 1. Estimated size 3,51,019 2. Coverage (%) >=95 4,70,79,001 3. Condoms distributed 4. Tested for HIV (April 2023-September 2023) 2,31,658 4.1. HIV sero-positive (%) 0.43 4.1.1. Linked to ART 855 5. Tested for HIV (October 2023 -March 2024) 2,93,148 5.1. HIV sero-positive (%) 0.35 5.1.1. Linked to ART 922

10,60,908

9,412

54,291

D. Injecting arug users	
Indicator	2023-24
1. Estimated size	2,88,717
2. Coverage (%)	90
3. Needles distributed	5,45,82,749
4. Syringes distributed	4,03,05,876
5. On OST	54,210
6. Tested for HIV (April 2023 -September 2023)	1,51,673
6.1. HIV sero-positive (%)	2.09
6.1.1 Linked to ART	2,602
7. Tested for HIV (October 2023 -March 2024)	1,87,396
7.1. HIV sero-positive (%)	1.25
7.1.1. Linked to ART	1,760

E. Hijra/Transgender people	
Indicator	2023-24
1. Estimated size	96,192
2. Coverage (%)	90
3. Condoms distributed	1,34,07,437
4. Tested for HIV (April 2023-September 2023)	55,105
4.1. HIV sero-positive (%)	0.50
4.1.1. Linked to ART	241
5. Tested for HIV (October 2023 -March 2024)	70,903
5.1. HIV sero-positive (%)	0.34
5.1.1. Put on ART	208
6. Clinic Visits	2,55,197
7. STI/RTI treated	3,056
8. Presumptive treatment	13,713

F. Migrants	
Indicator	2023-24
1. Estimated size	72,00,000
2. Coverage (%)	>=95
3. Tested for HIV	9,13,220
3.1. HIV sero-positive (%)	0.14
3.2. Linked to ART	1,130

G. Truckers	
Indicator	2023-24
1. Estimated size	20,00,000
2. Coverage (%)	56
3. Tested for HIV	3,11,052
3.1. HIV sero-positive (%)	0.14
3.2. On ART	327

H. Prison inmates		
Indicator	2023-24	
1. Total prisons	1319	
2. Prisons covered under programme	1262	
3. Total inmates admitted	22,55,799	
4. Inmates Covered (%)	61	
5. Tested for HIV	13,72,205	
5.1. HIV sero-positive (%)	0.48	
5.2. On ART (%)	89.48	

I. Link Worker Scheme	
Indicator	2023-24
Districts covered under scheme	191
Vulnerable population covered	25,34,108
3. Tested for HIV	12,80,469
3.1. HIV sero-positive (%)	0.20
3.2. Linked to ART (%)	97.08

6. Clinic Visits

7. STI/RTI treated

8. Presumptive treatment

J. Opioid Substitution Therapy	
Indicator	2023-24
1. OST Centres	263
1.1. OSTC in Public Health Settings	214
1.2. OSTC in NGO Settings	49
1.3 No. of Satellite OST Centres	164
2. IDU on OST	54,210

5. Early detection of HIV infected people		
A. HIV counselling and testing services (HCTS)		
Indicator	2023-24	
1. HCTC confirmatory facilities	4,657	
2. Sampoorna Suraksha Kendras	150	

B. HIV testing among vulnerable population (excluding pregnant women)

Indicator	2023-24				
	Male	Female	TG	Total	
1. Tested for HIV	2,12,04,600	1,71,78,365	1,22,443	3,85,05,408	
1.1 HIV Positives	1,15,825	52,013	1,334	1,69,172	
1.2 HIV sero -positivity (%)	0.55	0.30	1.09	0.44	
2. Spouse/sexual partner of HIV positive people tested	66,893	57,352	766	1,25,011	
2.1 HIV Positives	22,181	19,711	171	42,063	
2.2 HIV sero -positivity (%)	33	34	22	33.65	
3. No. of contacts with 'at-risk' population through 'Sampoorna Suraksha'	-	-	-	1,04,911	

6. Initiation and retention on ART of HIV infected

A. Treatment facilities

Indicator	2023-24
1. ART Centres	775
2.Centre of Excellence	
2.1. Centre of Excellence (Adult)	11
2.2 Centre of Excellent (Paediatric)	7
3. Link ART Centres	1,307
4. Care Support Centres	320

B. Treatment uptake

Indicator	2023-24					
	Male	Female	TG	Total		
HIV positive cases diagnosed (At ICTC)	1,15,825	60,728	1,334	1,77,887		
New PLHIV Registered at ART center	1,10,231	59,100	1,116	1,70,447		
2.1 Initiated on ART	1,06,457	57,810	1,081	1,65,348		
3. PLHIV alive and on ART	9,29,930	8,57,798	6,964	17,94,692		
4. 12 months retention on ART (%)				93.0		
5. Lost to follow-up cases	1,06,406	61,043	1,349	1,68,798		

A. Laboratory facilities and service uptake	
Indicator	2023-2
Viral load laboratories (programme and non- programme labs)	6
 1.1 Accredited Viral load laboratories (out of 64 VL labs) 	5
2. Viral load tests conducted	13,78,26
2.1. Virally suppressed (%)	94.
3. National reference laboratories (NRL)	1
3.1 Accredited NRL	1
4. State reference laboratories (SRL)	11
4.1 Accredited SRL	10
5. CD4 machines	46
5.1 CD4 tests conducted	8,67,59
6. External Quality Assurance of ICTC	
6.1 Average Participation (%)	9
6.2. Average Discordance (%)	0.0
7. "Certificate of Excellence" by NACO	
7.1 No. of ICTCs received "Certificate of Excellence"	64

HIV & Syphilis

A. HIV	
Indicator	2023-24
1. Estimated pregnant women (PW)	3,01,96,130
2. HIV testing among PW	2,63,70,973
3. HIV sero-positivity (%) among tested	0.03
4. HIV Positive PW (old + new detections)	19,056
4.1 On life-long ART	17,985
5. Live births among HIV positive PW	14,672
5.1 Babies given ARV Prophylaxis (%)	>=95
6. Babies tested HIV (6 week- 6 month)	14,514
6.1 Babies confirmed HIV Positive (6 week- 6 month)	67
7. HIV testing among exposed babies at 18 months	
7.1 HIV exposed babies tested at 18 months	11,509
7.2 Babies confirmed HIV positive at 18 months	306
8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months)	528
9. HIV positive babies initiated on ART	487

B. Syphilis	
Indicator	2023-24
1. Syphilis testing among PW	2,56,03,392
2.Sero-positivity (%) among tested	0.04
3. Put on treatment	7,739


9. Elimination of HIV/AIDS related Stigma and Discrimination 2023-24 Indicator 1. State rules notified for HIV/AIDS Prevention and Control Act (2017) 28 29

2. State designated/appointed ombudsman

10. HIV-TB Co-m	orbidities							
A. HRG and Bridge	e Population							
Indicator								2023-24
	Quarter	FSW	MSM	IDU	TG	Migrants	Truckers	Total
	Quarter 1	9,74,624	3,11,190	1,39,345	71,750	4,63,690	2,53,574	22,14,173
C LC TD	Quarter 2	10,03,123	3,24,727	1,59,930	71,951	5,26,058	2,68,268	23,54,057
Screened for TB	Quarter 3	10,18,635	3,23,540	1,66,984	77,548	5,70,880	3,04,372	24,61,959
	Quarter 4	10,57,035	3,45,874	1,77,323	80,947	6,07,622	3,23,751	25,92,552
	Quarter 1	11,688	4,429	2,209	840	2,707	867	22,740
T . I(TD	Quarter 2	13,399	5,387	3,323	1,156	3,693	946	27,904
Tested for TB	Quarter 3	14,367	5,678	3,880	1,091	3,279	918	29,213
	Quarter 4	15,213	5,623	3,853	1,277	3,760	1,127	30,853
	Quarter 1	124	44	49	7	79	7	310
D: 1 11 TD	Quarter 2	131	64	90	13	90	11	399
Diagnosed with TB	Quarter 3	109	54	56	9	115	10	353
	Quarter 4	116	48	75	11	59	5	314
	Quarter 1	117	47	42	7	72	3	288
Initiated on TB	Quarter 2	118	54	81	11	86	9	359
treatment	Quarter 3	95	46	34	7	115	6	303
	Quarter 4	103	36	64	7	54	4	268

B. HIV-TB Coinfed	ted at ART Ce	entre						
Indicator								2023-24
Moths	PLHIV attending ART Centre	PLHIV underwent 4S screening	PLHIV with presumptive TB	PLHIV tested for TB	PLHIV diagnosed with TB	PLHIV initiated on IPT	Co-Infected enrolled at ARTc	Co-infected initiated on ART
Apr - 23	10,01,711	9,75,221	35,434	33,681	2,339	10,421		
May - 23	10,50,788	10,25,432	42,283	35,322	2,588	13,119		
Jun - 23	10,25,661	9,99,740	41,884	36,908	2,430	12,962		
Jul - 23	10,44,274	10,11,294	44,337	37,983	2,331	12,853		
Aug - 23	10,65,063	10,32,168	44,802	39,009	2,170	12,203		
Sep - 23	10,63,882	10,32,963	41,475	37,704	1,937	10,145		
Oct - 23	10,93,185	10,62,405	41,750	38,077	2,045	9,782		
Nov - 23	11,50,340	11,11,473	45,698	36,879	1,978	9,344		
Dec - 23	12,47,839	12,12,209	45,826	39,260	1,991	10,742		
Jan - 24	12,73,005	12,33,416	45,059	40,896	2,090	11,436		
Feb - 24	11,92,183	11,56,692	48,482	41,675	2,301	11,097		
Mar - 24	11,88,846	11,52,245	43,687	41,252	2,357	11,176		
April 2023- March 2024							34,595	32,792

FACT SHEET STATES/UTs




ANDAMAN & NICOBAR ISLANDS

1. Status of HIV/AIDS Epidemic			
A. Epidemic Estimates (2023)			
Indicator	Male	Female	Total
1. IPR	-	-	3.90
2. IMR	-	-	1.67
3. Adult (15-49 yrs) HIV Prevalence (%)	0.19	0.14	0.16
4. Estimated people living with HIV	307	206	513
5. ART coverage (%)	42.10	42.64	42.32
6. Estimated children living with HIV	8	8	16
7. Annual new HIV infections	12	8	20
8. Annual AIDS-related deaths (ARD)	6	4	10
9. Change in annual new HIV infections since 2010 (%)	-55.56	-52.94	-53.49
10. Change in annual ARD since 2010(%)	-45.45	-42.86	-44.44
11. EMTCT need	-	4	4

B. High risk population size (2020-22), safe practices (2021) and prevalence (2021/2023) Condom Use New Needle/ **HIV Prevalence** Population Group **Estimates Size** (%) Syringe use (%) 1. Female Sex Workers 2. Men who have sex with men 3. Injecting Drug Users 4. Hijra/Transgender People 5. Migrants 6. Truckers 7. Prison inmates 903

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)						
Indicator	Male	Female	Total			
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)	34.70	14.90	-			
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	37.00	14.80	-			
3. Adults willing to care for a relative with HIV/AIDS in own home (%)	59.90	66.50	-			
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	64.40	72.90	-			
5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)	3.80	0.10	-			
5.1 Condom use during last higher-risk intercourse (%)	84.10	0.00	-			
6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)	5.88	0.00	-			
6.1 Condom use during last higher-risk intercourse (%)	100.00	NA	-			

2. Progress on 95-95-95 (2023-24)



Indicators	Male	Female	Total*
1. Estimated PLHIV size (2023)	307	206	513
2. PLHIV who know their HIV Status	133	87	220
3. PLHIV who know their HIV status and are on ART	124	83	207
4. PLHIV who are on ART and tested for their viral load	86	70	156
4.1 PLHIV who are virally suppressed	83	66	149

^{*} Including of H/TG PLHIV

3. Prevention of new HIV infections among general population

A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2023-24
Schools with operational Adolescent Education Program (AEP)	122
2. Colleges with operational Red Ribbon Clubs (RRC)	14
3. Persons trained under mainstreaming	2,832
4. No. of calls received at helpline	-

B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management under NACP

Indicator	2023-24			
1. NACO Supported Designated STI/RTI	1			
Clinics (DSRC)	Male	Female	TG	Total
2. Clients managed				5,070
3. RPR Tests conducted at DSRC	2,083	2,258	2	4,343
4. Syphilis seropositivity (%) at DSRC	4.27	1.15	100.00	2.69

4. Prevention of new HIV infections among highrisk group and bridge population

A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

Indicator	2023-24
1. Targeted Interventions	1
2. OST centres (Excluding Satellite OST centres)	0

B. Female Sex Workers	
Indicator	2023-24
1. Estimated size	-
2. Coverage (%)	-
3. Condoms distributed	815
4. Tested for HIV (April 2023-September 2023)	469
4.1. HIV sero-positive (%)	0.00
4.1.1. Linked to ART	-
5. Tested for HIV (October 2023 -March 2024)	1,594
5.1. HIV sero-positive (%)	0.00
5.1.1. Linked to ART	-
6. Clinic Visits	-
7. STI/RTI treated	-
8. Presumptive treatment	-

C. Men who have sex with men	
Indicator	2023-24
1. Estimated size	-
2. Coverage (%)	-
3. Condoms distributed	-
4. Tested for HIV (April 2023-September 2023)	-
4.1. HIV sero-positive (%)	-
4.1.1. Linked to ART	-
5. Tested for HIV (October 2023 -March 2024)	-
5.1. HIV sero-positive (%)	-
5.1.1. Linked to ART	-
6. Clinic Visits	-
7. STI/RTI treated	-
8. Presumptive treatment	_

D. Injecting drug users	
Indicator	2023-24
1. Estimated size	-
2. Coverage (%)	-
3. Needles distributed	-
4. Syringes distributed	-
5. On OST	-
6. Tested for HIV (April 2023 -September 2023)	-
6.1. HIV sero-positive (%)	-
6.1.1 Linked to ART	-
7. Tested for HIV (October 2023 -March 2024)	-
7.1. HIV sero-positive (%)	-
7.1.1. Linked to ART	-

E. Hijra/Transgender people	
Indicator	2023-24
1. Estimated size	-
2. Coverage (%)	-
3. Condoms distributed	-
4. Tested for HIV (April 2023-September 2023)	-
4.1. HIV sero-positive (%)	-
4.1.1. Linked to ART	-
5. Tested for HIV (October 2023 -March 2024)	-
5.1. HIV sero-positive (%)	-
5.1.1. Put on ART	-
6. Clinic Visits	-
7. STI/RTI treated	-
8. Presumptive treatment	-

F. Migrants	
Indicator	2023-24
1. Estimated size	-
2. Coverage (%)	0
3. Tested for HIV	412
3.1. HIV sero-positive (%)	0.00
3.2. Linked to ART	0

G. Truckers	
Indicator	2023-24
1. Estimated size	-
2. Coverage (%)	-
3. Tested for HIV	184
3.1. HIV sero-positive (%)	0.54
3.2. On ART	1

H. Prison inmates		
Indicator	2023-24	
1. Total prisons	4	
2. Prisons covered under programme	2	
3. Total inmates admitted	903	
4. Inmates Covered (%)	79	
5. Tested for HIV	712	
5.1. HIV sero-positive (%)	0.14	
5.2. On ART (%)	>=95%	

I. Link Worker Scheme	
Indicator	2023-24
Districts covered under scheme	-
Vulnerable population covered	-
3. Tested for HIV	-
3.1. HIV sero-positive (%)	-
3.2. Linked to ART (%)	-

J. Opioid Substitution Therapy	
Indicator	2023-24
1. OST Centres	-
1.1. OSTC in Public Health Settings	-
1.2. OSTC in NGO Settings	-
1.3 No. of Satellite OST Centres	-
2. IDU on OST	-

5. Early detection of HIV infected people

A. HIV counselling and testing services (HCTS)

The state of the s	,
Indicator	2023-24
1. HCTC confirmatory facilities	14
2. Sampoorna Suraksha Kendras	_

B. HIV testing among vulnerable population (excluding pregnant women)

Indicator	2023-24			
	Male	Female	TG	Total
1. Tested for HIV	15,289	10,748	-	26,037
1.1 HIV Positives	33	10	-	43
1.2 HIV sero -positivity (%)	0.22	0.09	-	0.17
Spouse/sexual partner of HIV positive people tested	16	18	-	34
2.1 HIV Positives	5	1	-	6
2.2 HIV sero -positivity (%)	31	6	-	17.65
No. of contacts with 'at- risk' population through 'Sampoorna Suraksha'	-	-	-	-

6. Initiation and retention on ART of HIV infected people

A. Treatment facilities

A. Heatiliett facilities	
Indicator	2023-24
1. ART Centres	1
2.Centre of Excellence	
2.1. Centre of Excellence (Adult)	-
2.2 Centre of Excellent (Paediatric)	-
3. Link ART Centres	-
4. Care Support Centres	-

B. Treatment uptake

Indicator	2023-24			
	Male	Female	TG	Total
HIV positive cases diagnosed (At ICTC)	33	10		43
New PLHIV Registered at ART center	30	9		39
2.1 Initiated on ART	28	8		36
3. PLHIV alive and on ART	124	83		207
4. 12 months retention on ART (%)				92.6
5. Lost to follow-up cases	8	3		11

A. Laboratory facilities and service uptake	
Indicator	2023-2
Viral load laboratories (programme and non- programme labs)	
1.1 Accredited Viral load laboratories (out of 64 VL labs)	
2. Viral load tests conducted	17
2.1. Virally suppressed (%)	86
3. National reference laboratories (NRL)	
3.1 Accredited NRL	
4. State reference laboratories (SRL)	
4.1 Accredited SRL	
5. CD4 machines	
5.1 CD4 tests conducted	
6. External Quality Assurance of ICTC	
6.1 Average Participation (%)	10
6.2. Average Discordance (%)	0.0
7. "Certificate of Excellence" by NACO	
7.1 No. of ICTCs received "Certificate of Excellence"	

HIV & Syphilis

A• 111¥	
Indicator	2023-24
1. Estimated pregnant women (PW)	4,840
2. HIV testing among PW	3,766
3. HIV sero-positivity (%) among tested	-
4. HIV Positive PW (old + new detections)	4
4.1 On life-long ART	4
5. Live births among HIV positive PW	2
5.1 Babies given ARV Prophylaxis (%)	>=95
6. Babies tested HIV (6 week- 6 month)	2
6.1 Babies confirmed HIV Positive (6 week- 6 month)	-
7. HIV testing among exposed babies at 18 months	
7.1 HIV exposed babies tested at 18 months	-
7.2 Babies confirmed HIV positive at 18 months	-
8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months)	-
9. HIV positive babies initiated on ART	-

B. Syphilis	
Indicator	2023-24
1. Syphilis testing among PW	4,366
2.Sero-positivity (%) among tested	0.07
3. Put on treatment	3

9. Elimination of HIV/AIDS related Stigma and Discrimination Indicator

Indicator	2023-24
1. State rules notified for HIV/AIDS Prevention and Control Act (2017)	Yes
2. State designated/appointed ombudsman	Yes


10. HIV-TB Co-morbidities								
A. HRG and Bridge Population								
Indicator 2023-24								
	Quarter	FSW	MSM	IDU	TG	Migrants	Truckers	Total
	Quarter 1	0	0	0	0	0	0	0
C II TD	Quarter 2	0	1	0	0	0	0	1
Screened for TB	Quarter 3	28	24	0	4	124	105	285
	Quarter 4	0	0	0	0	288	79	367
	Quarter 1	0	0	0	0	0	0	0
Tested for TB	Quarter 2	0	0	0	0	0	0	0
lested for TB	Quarter 3	0	1	0	0	0	1	2
	Quarter 4	0	0	0	0	0	0	0
	Quarter 1	0	0	0	0	0	0	0
Diamana da itala TD	Quarter 2	0	0	0	0	0	0	0
Diagnosed with TB	Quarter 3	0	0	0	0	0	0	0
	Quarter 4	0	0	0	0	0	0	0
	Quarter 1	0	0	0	0	0	0	0
Initiated on TB	Quarter 2	0	0	0	0	0	0	0
treatment	Quarter 3	0	0	0	0	0	0	0
	Quarter 4	0	0	0	0	0	0	0

B. HIV-TB Coinfected at ART Centre Indicator 2023-24 PLHIV with presumptive TB Co-infected enrolled at ARTC PLHIV PLHIV PLHIV PLHIV Co-infected initiated on ART PLHIV tested for TB diagnosed with TB initiated on IPT Moths attending underwent ART Centre 4S screening Apr - 23 103 103 2 92 92 1 1 May - 23 2 Jun - 23 107 107 Jul - 23 95 95 4 2 117 117 Aug - 23 2 3 Sep - 23 112 112 2 Oct - 23 116 4 116 107 3 107 Nov - 23 2 5 Dec - 23 125 125 2 Jan - 24 113 113 95 95 Feb - 24 6 Mar - 24 121 121 1 1 3 April 2023-4 March 2024

NATIONAL AIDS & STD CONTROL PROGRAMME STATE/UT SCORECARD, FY 2023-24

		States/UTs	Andaman & Nicobar Islands
	I .	Ranks	21
SI.	Maximum Mai		168
lo.	Obtained Mar		118 (70%)
1	First 95 (G:≥9	43	
2	•	≥95%, Y: 80-94%, R:<80%)	94
3	·	P5%, Y: 80-94%, R:<80%)	>=95
4	Average Freque	uency of Social Media updates (G: ≥ 45, Y:40- 44, R:<40 indigenous posts) of Q1,	104
5	Status of AEP	integration in state school curriculum (G:Yes, R:No)	Yes
6	Status of SCA	(G: At least one meeting held since 2020, R: other than G)	No Meeting held
7	Status of State	Rules (G: Notified, R: Not notified)	Notified
8	Status of Omb	oudsman (G: Appointed, R: Not appointed)	Appointed
9	TI/LWS onboa	rding (G: ≥95%, Y: 90-<95%, R:<90%)	100
0	OST onboardi	ng (G: ≥95%, Y: 90-<95%, R:<90%)	NA
1	Coverage of F	IRG against estimates (G: ≥90%, Y: 80-<90%, R:<80%)	29
2	HIV testing an	nong HRG (G: ≥95%, Y: 90-<95%, R:<90%)	49
3	HIV testing an	nong prisoners (G: ≥50%, Y: 40% to <50%, R:<40%)	64
4		HRGs at TI-Clinics (G: ≥90%, Y: 75-89%, R:<75%)	2
5		HRGs screened for Syphilis (G: ≥90%, Y: 75-89%, R:<75%)	49
6		G: ≥50%, Y: 30% to <50%, R:<30%)	NA
7	-	fund released to TI (G: ≥50%, Y: 45-<50%, R:<45%)	50
8		TIs trained by Kshmata Kendra (KK) against the AAP targets (G: ≥75%, Y: 70-<75%,	0
9	-	ainst Target-at risk % (G: ≥95%, Y: 80-94%, R:<80%)	157
0		ainst target-PW (G: ≥95%, Y: 80-94%, R:<80%)	78
1	0 0	pregnant women screened for Syphilis (G: ≥95%, Y: 8094%, R:<80%)	90
	_	<u> </u>	
2	Treatment pro	ovided to Syphilis reactive pregnant women (G: ≥95%, Y: 80-94%, R:<80%)	67
3	Index testing	among newly detected HIV positive clients (G: ≥95%, Y: 8094%, R:<80%)	25
4	Percentage of	100	
5	Clients manag	90	
6	STI attendees	screened for HIV (G: >75%, Y: 50-75%, R:<50%)	100
7	STI attendees	screened for Syphilis (G: >75%, Y: 50-75%, R:<50%)	99
8	% of pregnant	women who initiated ART (G: ≥95%, Y: 80-94%, R:<80%)	80
9	Proportion of	LFU-PLHIV, out of those initiated on ART in FY 2023-24 (G:<2%, Y: 2 to 5%, R:>5%)	0
0	Proportion of R:<95%)	PLHIV initiated on ART, out of those registered in FY 202324 (G:>98%, Y: 95 to 98%,	92
1	Proportion of Y: 2 to 5 %, R:	reported died, out of those initiated on ART in FY 2023-24 (G:<2%, >5 %)	0
2	% of SRL accre	edited (G:100%, Y: 80-99%, R:<80%)	0
3	% participatio	n of ICTCs in re-testing (G: ≥95%, Y: 85-94, R:<85%)	100
4		stracts selected from studies conducted in FY21-22 (G:100%, Y: >25 to <100%, R:	0
5	Number of on	going studies from FY22-23 (G:100%, Y: >25 to <100%, R: ≤25%)	1
6	Submission of >25 to <100%	research proposals from FY23-24 to NACO (G:100%, Y: b. R: ≤25%)	2
7		ta Analysis by SACS (G:2, Y: 1, R: No Secondary Data Analysis Plan Submitted)	2
8		ith respect to funds released during FY 2022-23 (G: ≥90%, Y: 85 to <90%, R: <85%)	97
9	Submission of	Provisional Utilization Certificate (UC) in GFR 12A for the FY 2022-23 (G: by 30-Apr-1-May-2023, R: after 31-May2023)	
0	Submission of	audited UC in GFR 12A for the FY 2022-23 (G : by 30-Jun2023, Y : by 30-Sep-2023,	28-08-2023
1		P-2023) EC/ GB ratification for approval of Expenditure incurred during FY 2021-22 (G: by Y: by 30-Sept-2022, R: after 30Sept-2022)	01-08-2023
2	-	ssion of CST-SCM Report (G:>95%, Y: 80-95%, R:<80%)	96
3		ence to CST-SCM Report (G:>95%, Y: 80-95%, R:<80%)	94
4	Timely Submi	ssion of BSD & STI-SCM Report (G: ≥90%, Y: 75-<90%, R:<75%)	92
	Green=3 Marks	Yellow=2Marks Red=1 Mark No Color	ır=Not Applicable
Veiç	ght points	Indicator SI. No.	<u> </u>
	3	1, 23, 29	
	2	1, 3, 9, 10, 22, 30, 34, 42, 44	
	2		

HIV testing against target-at risk (SI. No. 19): over-achievements above 120% are marked in red







1. Status of HIV/AIDS Epidemic			
A. Epidemic Estimates (2023)			
Indicator	Male	Female	Total
1. IPR	-	-	1.10
2. IMR	-	-	0.41
3. Adult (15-49 yrs) HIV Prevalence (%)	0.63	0.61	0.62
4. Estimated people living with HIV	1,61,081	1,59,141	3,20,222
5. ART coverage (%)	65.75	81.76	73.96
6. Estimated children living with HIV	2,699	2,510	5,209
7. Annual new HIV infections	1,983	1,526	3,509
8. Annual AIDS-related deaths (ARD)	3,854	1,456	5,310
9. Change in annual new HIV infections since 2010 (%)	-75.94	-76.25	-76.08
10. Change in annual ARD since 2010(%)	-83.59	-90.39	-86.26
11. EMTCT need	-	1,797	1,797

B. High risk population size (2020-22), safe practices (2021) and prevalence (2021/2023)

Population Group	Estimates Size	Condom Use (%)	New Needle/ Syringe use (%)	HIV Prevalence (%)
1. Female Sex Workers	1,19,367	99.60	-	1.78
2. Men who have sex with men	22,060	98.30	-	2.06
3. Injecting Drug Users	1,332	-	98.50	1.32
4. Hijra/Transgender People	5,364	-	-	4.61
5. Migrants	1,99,533	76.40	-	0.93
6. Truckers	52,345	95.50	96.80	0.60
7. Prison inmates	90,819	90.70	71.40	2.58

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21) Male Female Total 1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%) 38.60 24.60 2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%) 38.10 27.20 3. Adults willing to care for a relative with HIV/AIDS in own home (%) 66.40 64.10 4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) 72.10 64.30 3.80 0.10 5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%) 5.1 Condom use during last higher-risk intercourse (%) 31.30 0.00 6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%) 5.17 0.00 6.1 Condom use during last higher-risk intercourse (%) 42.86

2. Progress on 95-95-95 (2023-24)



Indicators	Male	Female	Total*
1. Estimated PLHIV size (2023)	1,61,081	1,59,141	3,20,222
2. PLHIV who know their HIV Status	1,24,809	1,45,584	2,71,363
3. PLHIV who know their HIV status and are on ART	1,01,855	1,25,093	2,27,721
4. PLHIV who are on ART and tested for their viral load	77,033	96,202	1,73,725
4.1 PLHIV who are virally suppressed	74,230	93,206	1,67,898

^{*} Including of H/TG PLHIV

3. Prevention of new HIV infections among general population

A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2023-24
Schools with operational Adolescent Education Program (AEP)	1,770
2. Colleges with operational Red Ribbon Clubs (RRC)	457
3. Persons trained under mainstreaming	80
4. No. of calls received at helpline	_

B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management

Indicator	2023-24			
1. NACO Supported Designated STI/RTI	55			
Clinics (DSRC)	Male	Female	TG	Total
2. Clients managed				7,71,128
3. RPR Tests conducted at DSRC	59,453	1,41,888	1,419	2,02,760
4. Syphilis seropositivity (%) at DSRC	0.74	0.14	1.20	0.32

4. Prevention of new HIV infections among highrisk group and bridge population

A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

Indicator	2023-24
1. Targeted Interventions	96
2. OST centres (Excluding Satellite OST centres)	2

B. Female Sex Workers 2023-24 Indicator 1. Estimated size 1,19,367 2. Coverage (%) >=95 2,45,71,702 3. Condoms distributed 4. Tested for HIV (April 2023-September 2023) 1,17,627 4.1. HIV sero-positive (%) 0.03 4.1.1. Linked to ART 26 5. Tested for HIV (October 2023 -March 2024) 1,28,992 5.1. HIV sero-positive (%) 0.03 5.1.1. Linked to ART 29 6. Clinic Visits 4,88,653 7. STI/RTI treated 2,043 27,170 8. Presumptive treatment

C. Men who have sex with men	
Indicator	2023-24
1. Estimated size	22,059
2. Coverage (%)	>=95
3. Condoms distributed	52,98,430
4. Tested for HIV (April 2023-September 2023)	23,818
4.1. HIV sero-positive (%)	0.09
4.1.1. Linked to ART	14
5. Tested for HIV (October 2023 -March 2024)	26,753
5.1. HIV sero-positive (%)	0.10
5.1.1. Linked to ART	19
6. Clinic Visits	99,432
7. STI/RTI treated	174
8. Presumptive treatment	5,138

D. Injecting drug users	
Indicator	2023-24
1. Estimated size	1,332
2. Coverage (%)	>=95
3. Needles distributed	3,93,867
4. Syringes distributed	3,94,263
5. On OST	453
6. Tested for HIV (April 2023 -September 2023)	1,907
6.1. HIV sero-positive (%)	0.05
6.1.1 Linked to ART	1
7. Tested for HIV (October 2023 -March 2024)	2,195
7.1. HIV sero-positive (%)	0.09
7.1.1. Linked to ART	2

E. Hijra/Transgender people	
Indicator	2023-24
1. Estimated size	5,363
2. Coverage (%)	>=95
3. Condoms distributed	10,21,306
4. Tested for HIV (April 2023-September 2023)	4,073
4.1. HIV sero-positive (%)	0.32
4.1.1. Linked to ART	5
5. Tested for HIV (October 2023 -March 2024)	4,360
5.1. HIV sero-positive (%)	0.37
5.1.1. Put on ART	11
6. Clinic Visits	17,086
7. STI/RTI treated	38
8. Presumptive treatment	963

F. Migrants	
Indicator	2023-24
1. Estimated size	1,99,533
2. Coverage (%)	46
3. Tested for HIV	34,112
3.1. HIV sero-positive (%)	0.06
3.2. Linked to ART	14

G. Truckers	
Indicator	2023-24
1. Estimated size	52,345
2. Coverage (%)	58
3. Tested for HIV	15,548
3.1. HIV sero-positive (%)	0.06
3.2. On ART	6

H. Prison inmates	
Indicator	2023-24
1. Total prisons	106
2. Prisons covered under programme	83
3. Total inmates admitted	90,819
4. Inmates Covered (%)	49
5. Tested for HIV	44,432
5.1. HIV sero-positive (%)	0.17
5.2. On ART (%)	92.00

I. Link Worker Scheme	
Indicator	2023-24
Districts covered under scheme	13
Vulnerable population covered	2,05,938
3. Tested for HIV	1,06,855
3.1. HIV sero-positive (%)	0.19
3.2. Linked to ART (%)	99.49

J. Opioid Substitution Therapy	
Indicator	2023-24
1. OST Centres	2
1.1. OSTC in Public Health Settings	2
1.2. OSTC in NGO Settings	-
1.3 No. of Satellite OST Centres	1
2. IDU on OST	453

5. Early detection of HIV infected people

A. HIV counselling and testing services (HCTS)

At the counseling and costing services (11019)				
Indicator	2023-24			
1. HCTC confirmatory facilities	252			
2. Sampoorna Suraksha Kendras	12			

B. HIV testing among vulnerable population (excluding pregnant women)

Indicator	2023-24			
	Male	Female	TG	Total
1. Tested for HIV	9,00,296	8,95,892	7,255	18,03,443
1.1 HIV Positives	7,784	6,114	119	14,017
1.2 HIV sero -positivity (%)	0.86	0.68	1.64	0.78
Spouse/sexual partner of HIV positive people tested	7,560	5,940	119	13,619
2.1 HIV Positives	2,835	2,900	24	5,759
2.2 HIV sero -positivity (%)	38	49	20	42.29
3. No. of contacts with 'at- risk' population through 'Sampoorna Suraksha'	-	-	-	10,383

6. Initiation and retention on ART of HIV infected people

A. Treatment facilities

Indicator	2023-24
1. ART Centres	59
2.Centre of Excellence	
2.1. Centre of Excellence (Adult)	1
2.2 Centre of Excellent (Paediatric)	-
3. Link ART Centres	154
4. Care Support Centres	23

B. Treatment uptake

Indicator	2023-24			
	Male	Female	TG	Total
HIV positive cases diagnosed (At ICTC)	7,784	6,612	119	14,515
New PLHIV Registered at ART center	7,693	6,485	79	14,257
2.1 Initiated on ART	7,617	6,444	78	14,139
3. PLHIV alive and on ART	1,01,855	1,25,093	774	2,27,721
4. 12 months retention on ART (%)				>=95
5. Lost to follow-up cases	6,055	4,850	97	11,002

7. Viral Suppression and laboratories	
A. Laboratory facilities and service uptake	
Indicator	2023-2
Viral load laboratories (programme and non- programme labs)	1
1.1 Accredited Viral load laboratories (out of 64 VL labs)	1
2. Viral load tests conducted	2,03,45
2.1. Virally suppressed (%)	93.
3. National reference laboratories (NRL)	
3.1 Accredited NRL	
4. State reference laboratories (SRL)	
4.1 Accredited SRL	
5. CD4 machines	3
5.1 CD4 tests conducted	1,22,43
6. External Quality Assurance of ICTC	
6.1 Average Participation (%)	9
6.2. Average Discordance (%)	0.0
7. "Certificate of Excellence" by NACO	
7.1 No. of ICTCs received "Certificate of Excellence"	6
8. Elimination of mother to child trans HIV & Syphilis	mission of
A. HIV Indicator	2023-2
Estimated pregnant women (PW)	9,23,20
2. HIV testing among PW	9,34,39
3. HIV sero-positivity (%) among tested	0.0
4. HIV Positive PW (old + new detections)	1,65
4.1 On life-long ART	1,64
5. Live births among HIV positive PW	1,12
5.1 Babies given ARV Prophylaxis (%)	>=9
6. Babies tested HIV (6 week- 6 month)	1,24
6.1 Babies confirmed HIV Positive (6 week- 6 month)	,

B. Syphilis	
Indicator	2023-24
1. Syphilis testing among PW	9,91,103
2.Sero-positivity (%) among tested	0.01
3. Put on treatment	63

7. HIV testing among exposed babies at 18 months

7.1 HIV exposed babies tested at 18 months

7.2 Babies confirmed HIV positive at 18 months

8. Total Babies Identified HIV Positive (6 weeks to

9. HIV positive babies initiated on ART

2. State designated/appointed ombudsman

upto 18 Months)

9. Elimination of HIV/AIDS related Stigma and Discrimination Indicator 2023-24 1. State rules notified for HIV/AIDS Prevention and Control Act (2017)

No

1,132

12 22

18

10. HIV-TB Co-morbidities								
A. HRG and Bridge Population								
Indicator								2023-24
	Quarter	FSW	MSM	IDU	TG	Migrants	Truckers	Total
Screened for TB	Quarter 1	1,68,463	37,140	1,870	5,456	13,167	5,214	2,31,310
	Quarter 2	1,71,968	36,127	1,926	5,677	10,803	5,436	2,31,937
	Quarter 3	1,78,035	36,762	2,007	5,704	12,415	5,477	2,40,400
	Quarter 4	1,83,707	39,142	1,826	6,016	15,407	5,554	2,51,652
Tested for TB	Quarter 1	1,525	175	58	27	68	2	1,855
	Quarter 2	1,594	190	20	19	52	5	1,880
	Quarter 3	1,458	152	29	17	96	-	1,752
	Quarter 4	1,685	255	23	32	179	4	2,178
	Quarter 1	2	0	0	0	1	0	3
	Quarter 2	3	1	0	0	0	0	4
Diagnosed with TB	Quarter 3	2	2	0	0	2	0	6
	Quarter 4	0	1	1	1	0	0	3
Initiated on TB treatment	Quarter 1	2	0	0	0	1	0	3
	Quarter 2	1	0	0	0	0	0	1
	Quarter 3	2	2	0	0	2	0	6
	Quarter 4	0	1	1	1	0	0	3

C. HIV-TB Coinfected at ART Centre Indicator 2023-24 PLHIV PLHIV PLHIV with PLHIV Co-infected enrolled at Co-infected initiated on ART PLHIV PLHIV tested for TB presumptive TB diagnosed with TB initiated on IPT Moths attending underwent ART Centre 4S screening ARTC 1,58,139 Apr - 23 1,56,636 3,507 3,500 174 675 4,695 246 547 May - 23 1,65,258 1,63,347 4,690 Jun - 23 1,57,727 1,54,943 4,792 4,788 214 567 Jul - 23 1,59,400 1,56,948 5,027 5,019 221 398 5,406 224 Aug - 23 1,58,617 1,56,309 5,389 333 Sep - 23 1,57,372 1,54,825 5,374 5,368 207 251 1,50,966 189 Oct - 23 1,53,388 5,100 5,085 316 1,55,581 5,278 196 295 Nov - 23 1,57,708 5,272 Dec - 23 1,62,229 1,59,990 5,144 5,139 166 689 Jan - 24 1,75,906 1,73,628 6,269 6,267 200 754 Feb - 24 1,62,775 1,61,204 5,802 5,797 216 707 Mar - 24 1,60,971 1,58,724 5,387 5,384 231 793 April 2023-3,731 3,672 March 2024

		States/UTs	Andhra Pradesh
CL NI-	N4	Ranks	7
SI. No.	Maximur		177
	Obtained		135 (76%)
1		G:≥95%, Y: 80-94%, R:<80%)	85
2		P5 (G:≥95%, Y: 80-94%, R:<80%)	84
3		(G:≥95%, Y: 80-94%, R:<80%)	>=95
4		Frequency of Social Media updates (G: ≥ 45, Y:40- 44, R:<40 indigenous posts) 2, Q3 & Q4	12
5	Status of	AEP integration in state school curriculum (G:Yes, R:No)	Yes
6		SCA (G: At least one meeting held since 2020, R: other than G)	Not constituted
7	Status of	State Rules (G: Notified, R: Not notified)	Notified
8	Status of	Ombudsman (G: Appointed, R: Not appointed)	Appointed
9	TI/LWS c	onboarding (G: ≥95%, Y: 90-<95%, R:<90%)	100
10	OST onb	oarding (G: ≥95%, Y: 90-<95%, R:<90%)	100
11	Coverag	e of HRG against estimates (G: ≥90%, Y: 80-<90%, R:<80%)	133
12	HIV testi	ng among HRG (G: ≥95%, Y: 90-<95%, R:<90%)	94
13	HIV testi	ng among prisoners (G: ≥50%, Y: 40% to <50%, R:<40%)	28
14	Clinic vis	it of HRGs at TI-Clinics (G: ≥90%, Y: 75-89%, R:<75%)	93
15	Percenta	ge of HRGs screened for Syphilis (G: ≥90%, Y: 75-89%, R:<75%)	89
16	IDU on C	DST (G: ≥50%, Y: 30% to <50%, R:<30%)	41
17	Percenta	ge of fund released to TI (G: ≥50%, Y: 45-<50%, R:<45%)	94
18	Percenta	ge of TIs trained by Kshmata Kendra (KK) against the AAP targets (G: ≥75%, Y: 5, R:<70%)	0
19		ng against Target-at risk % (G: ≥95%, Y: 80-94%, R:<80%)	115
20		ng against target-PW (G: ≥95%, Y: 80-94%, R:<80%)	101
21		ge of pregnant women screened for Syphilis (G: ≥95%, Y: 80-94%, R:<80%)	107
22			100
		nt provided to Syphilis reactive pregnant women (G: ≥95%, Y: 80-94%, R:<80%)	
23	Index tes	sting among newly detected HIV positive clients (G: ≥95%, Y: 80-94%, R:<80%)	76
24	Percenta R:<80%)	ge of 6 weeks - <2 months EID testing against live birth (G: ≥95%, Y: 80-94%,	98
25	Clients m	nanaged at DSRC against the target (G: ≥90%, Y: 75-89%, R:<75%)	99
26	STI atten	dees screened for HIV (G: >75%, Y: 50-75%, R:<50%)	41
27	STI atten	dees screened for Syphilis (G: >75%, Y: 50-75%, R:<50%)	50
28	% of pre	gnant women who initiated ART (G: ≥95%, Y: 80-94%, R:<80%)	100
29		on of LFU-PLHIV, out of those initiated on ART in FY 202324 (G:<2%, Y: 2 to 5%,	3
30		on of PLHIV initiated on ART, out of those registered in FY 2023-24 (G:>98%, Y: %, R:<95%)	99
31	Proportion 5 %, R:>	on of reported died, out of those initiated on ART in FY 2023-24 (G:<2%, Y: 2 to 5 %)	6
32		accredited (G:100%, Y: 80-99%, R:<80%)	100
33		pation of ICTCs in re-testing (G: ≥95%, Y: 85-94, R:<85%)	94
34	'	of abstracts selected from studies conducted in FY21-22	1
	(G:100%	, Y: >25 to <100%, R: ≤25%)	
35		of ongoing studies from FY22-23 (G:100%, Y: >25 to	3
24		R: ≤25%) on of research proposals from EV22 24 to NACO	1
36		on of research proposals from FY23-24 to NACO , Y: >25 to <100%, R: ≤25%)	1
37		, Y: >25 to < 100%, R: ≤25%) ry Data Analysis by SACS (G:2, Y: 1, R: No Secondary Data Analysis Plan	2
3/	Seconda		2
38		cure with respect to funds released during FY 2022-23 (G:	148
		: 85 to <90%, R: <85%)	
39	Submissi	on of Provisional Utilization Certificate (UC) in GFR 12A for the FY 2022-23 (G: or-2023, Y: by 31-May-2023, R: after 31-May-2023)	27-07-2023
40		on of audited UC in GFR 12A for the FY 2022-23 (G : by 30-Jun-2023, Y : by 30-	27-07-2023
	Sep-202	3, R : after 30-Sep-2023)	
41	Submission of EC/ GB ratification for approval of Expenditure incurred during FY 2021-22 (G: by 30-Jun-2022, Y: by 30-Sept-2022, R: after 30-Sept-2022)		20-12-2023
42		ubmission of CST-SCM Report (G:>95%, Y: 80-95%, R:<80%)	100
43			91
44		ubmission of BSD & STI-SCM Report (G: ≥90%, Y: 75<90%, R:<75%)	100
	_	·	
	en=3 Marks		ur=Not Applicable
Weight p		Indicator SI. No.	
3		1, 23, 29	
3		2, 3, 9, 10, 22, 30, 34, 42, 44	







1. Status of HIV/AIDS Epidemic A. Epidemic Estimates (2023)				
1. IPR	-	-	14.56	
2. IMR	-	-	12.82	
3. Adult (15-49 yrs) HIV Prevalence (%)	0.35	0.15	0.25	
4. Estimated people living with HIV	1,743	722	2,465	
5. ART coverage (%)	57.04	25.66	48.05	
6. Estimated children living with HIV	27	26	53	
7. Annual new HIV infections	256	104	360	
8. Annual AIDS-related deaths (ARD)	11	10	21	
9. Change in annual new HIV infections since 2010 (%)	468.89	477.78	469.84	
10. Change in annual ARD since 2010(%)	120.00	400.00	214.29	
11. EMTCT need	-	25	25	

B. High risk population size (2020-22), safe practices (2021) and prevalence (2021/2023) Condom Use New Needle/ **HIV Prevalence** Population Group Estimates Size (%) Syringe use (%) (%) 1. Female Sex Workers 65.50 0.27 6,941 901 2. Men who have sex with men 5,143 36.00 1.60 3. Injecting Drug Users 4. Hijra/Transgender People 140 5. Migrants 40,500 6. Truckers 7. Prison inmates 960

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)			
Indicator	Male	Female	Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)	33.40	12.30	-
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	35.40	15.50	-
3. Adults willing to care for a relative with HIV/AIDS in own home (%)	67.90	56.70	-
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	59.30	50.30	-
5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)	7.40	2.00	-
5.1 Condom use during last higher-risk intercourse (%)	75.80	58.50	-
6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)	12.35	3.96	-
6.1 Condom use during last higher-risk intercourse (%)	80.00	62.16	-

2. Progress on 95-95-95 (2023-24) PLHIV who know their HIV status (%) PLHIV who know their HIV status and are on ART and virially suppressed ART (%) 2018-19 2019-20 2020-21 20201-22 2020-23 2023-24

Indicators	Male	Female	Total*
1. Estimated PLHIV size (2023)	1,743	722	2,465
2. PLHIV who know their HIV Status	1,340	257	1,606
3. PLHIV who know their HIV status and are on ART	990	182	1,177
4. PLHIV who are on ART and tested for their viral load	84	25	109
4.1 PLHIV who are virally suppressed	83	24	107

^{*} Including of H/TG PLHIV

A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2023-24
Schools with operational Adolescent Education Program (AEP)	310
2. Colleges with operational Red Ribbon Clubs (RRC)	57
3. Persons trained under mainstreaming	8,426
4. No. of calls received at helpline	-

B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management

Indicator	2023-24				
1. NACO Supported Designated STI/RTI	18				
Clinics (DSRC)	Men	Female	H/TG	Total	
2. Clients managed				33,947	
3. RPR Tests conducted at DSRC	5,206	6,171	3	11,380	
4. Syphilis seropositivity (%) at DSRC	6.90	6.58	66.67	6.74	

4. Prevention of new HIV infections among high-risk group and bridge population

A. Targeted Intervention (TI) Projects and Opioid Substitution Therapy (OST)

Indicator	2023-24
1. Targeted Intervention (TI) Projects	31
2. OST centres (Excluding Satellite OST centres)	4

B. Female Sex Workers			
Indicator	2023-24		
1. Estimated size	6,940		
2. Coverage (%)	88.71		
3. Condoms distributed	6,23,092		
4. Tested for HIV (April 2022-September 2022)	3,766		
4.1. HIV sero-positive (%)	0.08		
4.1.1. Linked to ART	3		
5. Tested for HIV (October 2022 -March 2023)	5,509		
5.1. HIV sero-positive (%)	0.11		
5.1.1. Linked to ART	3		
6. Clinic Visits	15,019		
7. STI/RTI treated	154		
8. Presumptive treatment	1,750		

C. Men who have Sex with Men			
Indicator	2023-24		
1. Estimated size	900		
2. Coverage (%)	>=95		
3. Condoms distributed	69,510		
4. Tested for HIV (April 2022-September 2022)	363		
4.1. HIV sero-positive (%)	0.28		
4.1.1. Linked to ART	1		
5. Tested for HIV (October 2022 -March 2023)	798		
5.1. HIV sero-positive (%)	2.51		
5.1.1. Linked to ART	20		
6. Clinic Visits	1,796		
7. STI/RTI treated	24		
8. Presumptive treatment	103		

D. Injecting Drug Users			
Indicator	2023-24		
1. Estimated size	5,142		
2. Coverage (%)	>=95		
3. Needles distributed	4,87,105		
4. Syringes distributed	4,87,016		
5. On OST	775		
6. Tested for HIV (April 2022 -September 2022)	3,487		
6.1. HIV sero-positive (%)	5.42		
6.1.1 Linked to ART	173		
7. Tested for HIV (October 2022 -March 2023)	5,239		
7.1. HIV sero-positive (%)	2.25		
7.1.1. Linked to ART	94		

E. Hijra/Transgender person			
Indicator	2023-24		
1. Estimated size	139		
2. Coverage (%)	>=95		
3. Condoms distributed	13,119		
4. Tested for HIV (April 2022-September 2022)	73		
4.1. HIV sero-positive (%)	1.37		
4.1.1. Linked to ART	1		
5. Tested for HIV (October 2022 -March 2023)	144		
5.1. HIV sero-positive (%)	2.08		
5.1.1. Linked to ART	3		
6. Clinic Visits	370		
7. STI/RTI treated	4		
8. Presumptive treatment	32		

F. Migrants			
Indicator	2023-24		
1. Estimated size	40,500		
2. Coverage (%)	>=95		
3. Tested for HIV	15,132		
3.1. HIV sero-positive (%)	0.14		
3.2. Linked to ART	17		

G. Truckers	
Indicator	2023-24
1. Estimated size	-
2. Coverage (%)	-
3. Tested for HIV	-
3.1. HIV sero-positive (%)	-
3.2. On ART	-

H. Prison Inmates	
Indicator	2023-24
1. Total prisons	2
2. Prisons covered under programme	12
3. Total inmates admitted	960
4. Inmates Covered (%)	63
5. Tested for HIV	600
5.1. HIV sero-positive (%)	4.17
5.2. On ART (%)	16.00

I. Link Worker Scheme	
Indicator	2023-24
Districts covered under scheme	-
Vulnerable population covered	-
3. Tested for HIV	-
3.1. HIV sero-positive (%)	-
3.2. Linked to ART (%)	-

J. Opioid Substitution Therapy		
Indicator	2023-24	
1. OST Centres	4	
1.1. OSTC in Public Health Settings	4	
1.2. OSTC in NGO Settings	-	
1.3. No. of Satellite OST Centres	15	
2. IDU on OST	775	

5. Early detection of HIV infected people

A. HIV counselling and testing services (HCTS)

3 · · · · · 3 · · · · · · ,	•
Indicator	2023-24
1. HCTC confirmatory facilities	33
2. Sampoorna Suraksha Kendras	-

B. HIV testing among vulnerable population (excluding pregnant women)

Indicator	2023-24			
	Male	Female	TG	Total
1. Tested for HIV	34,362	23,071	256	57,689
1.1 HIV Positives	816	75	3	894
1.2 HIV sero -positivity (%)	2.37	0.33	1.17	1.55
Spouse/sexual partner of HIV positive people tested	579	281	20	880
2.1 HIV Positives	37	24	-	61
2.2 HIV sero -positivity (%)	6	9	-	6.93
No. of contacts with 'at- risk' population through 'Sampoorna Suraksha'	-	-	-	-

6. Initiation and retention on ART of HIV infected people

A. Treatment facilities

Indicator	2023-24
1. ART Centres	2
2. Centre of Excellence	
2.1. Centre of Excellence (Adult)	-
2.2. Centre of Excellent (Paediatric)	-
3. Link ART Centres	5
4. Care Support Centres	-

B. Treatment uptake

Indicator	2023-24			
	Male	Female	TG	Total
HIV positive cases diagnosed (At ICTC)	816	86	3	905
New PLHIV Registered at ART centre	1,077	119	8	1,204
2.1 Initiated on ART	1,058	115	8	1,181
3. PLHIV alive and on ART	990	182	5	1,177
4. 12 months retention on ART (%)				73.2
5. Lost to follow-up cases	263	33	2	298

7. Viral Suppression and laboratories	
A. Laboratory facilities and service uptake	
Indicator	2023-24
Viral load laboratories (programme and non- programme labs)	0
1.1 Accredited Viral load laboratories (out of 64 VL labs)	0
2. Viral load tests conducted	240
2.1. Virally suppressed (%)	94.6
3. National reference laboratories (NRL)	-
3.1 Accredited NRL	-
4. State reference laboratories (SRL)	1
4.1 Accredited SRL	1
5. CD4 machines	1
5.1 CD4 tests conducted	91
6. External Quality Assurance of ICTC	
6.1 Average Participation (%)	94
6.2. Average Discordance (%)	0.00
7. "Certificate of Excellence" by NACO	
7.1 No. of ICTCs received "Certificate of Excellence"	-
8. Elimination of mother to child transm HIV & Syphilis	nission of
A. HIV	
Indicator	2023-24
1 Estimated pregnant women (PM)	28 900

niv & Sypnilis	
A. HIV	
Indicator	2023-24
1. Estimated pregnant women (PW)	28,900
2. HIV testing among PW	18,397
3. HIV sero-positivity (%) among tested	0.06
4. HIV Positive PW (old + new detections)	21
4.1 On life-long ART	16
5. Live births among HIV positive PW	12
5.1 Babies given ARV Prophylaxis (%)	>=95
6 Rabies tested HIV (6 week- 6 month)	10

o. bables tested filv (o week- o month)	10
6.1 Babies confirmed HIV Positive (6 week- 6 month)	-
7. HIV testing among exposed babies at 18 months	
7.1 HIV exposed babies tested at 18 months	5
7.2 Babies confirmed HIV positive at 18 months	-
8. Total Babies Identified HIV Positive (6 weeks to	-

B. Syphilis	
Indicator	2023-24
1. Syphilis testing among PW	21,565

2. Sero-positivity (%) among tested 1.29
3. Put on treatment 201

9. Elimination of HIV/AIDS related Stigma and Discrimination

9. HIV positive babies initiated on ART

Indicator	2023-24
1. State rules notified for HIV/AIDS Prevention a Control Act (2017)	nd Yes
2. State designated/appointed ombudsman	Yes

10. HIV-TB Co-morbidities								
A. HRG and Bridge Population								
Indicator	Indicator 2023-24							
	Quarter	FSW	MSM	IDU	TG	Migrants	Truckers	Total
	Quarter 1	2,599	315	2,317	58	13,763	-	19,052
Screened for TB	Quarter 2	3,144	375	2,491	85	14,814	-	20,909
Screened for TB	Quarter 3	3,480	471	3,067	74	13,791	-	20,883
	Quarter 4	4,037	566	3,360	115	12,313	-	20,391
	Quarter 1	10	0	75	0	5	-	90
Tested for TB	Quarter 2	10	0	46	0	2	-	58
lested for TB	Quarter 3	30	4	58	2	0	-	94
	Quarter 4	106	7	30	0	5	-	148
	Quarter 1	0	0	1	0	0	-	1
Diagnosed with TB	Quarter 2	0	0	2	0	0	-	2
Diagnosed with 16	Quarter 3	0	0	0	0	0	-	0
	Quarter 4	1	0	0	0	0	-	1
	Quarter 1	0	0	1	0	0	-	1
Initiated on TB	Quarter 2	0	0	2	0	0	-	2
treatment	Quarter 3	0	0	0	0	0	-	0
	Quarter 4	1	0	0	0	0	-	1

B. HIV-TB Coinfected at ART Centre Indicator 2023-24 PLHIV with presumptive TB Co-infected enrolled at ARTC PLHIV PLHIV PLHIV PLHIV Co-infected initiated on ART PLHIV tested for TB diagnosed with TB initiated on IPT Moths attending underwent ART Centre 4S screening Apr - 23 May - 23 Jun - 23 Jul - 23 _ Aug - 23 Sep - 23 Oct - 23 Nov - 23 Dec - 23 Jan - 24 Feb - 24 Mar - 24 April 2023-March 2024

		State/UT	Arunachal Pradesh
CI		Rank	32
SI. No.	Maximum Ma		177 114 (64%)
1		5%, Y: 80-94%, R:<80%)	65
2		:≥95%, Y: 80-94%, R:<80%)	73
3		95%, Y: 80-94%, R:<80%)	>=95
4	•	uency of Social Media updates (G: ≥ 45, Y:40- 44, R:<40 indigenous posts) of	18
	Q1, Q2, Q3 8		
5	Status of AEP	integration in state school curriculum (G:Yes, R:No)	Yes
6	Status of SCA	(G: At least one meeting held since 2020, R: other than G)	Meeting held in 2017
7	Status of State	Rules (G: Notified, R: Not notified)	Notified
8	Status of Omb	oudsman (G: Appointed, R: Not appointed)	Appointed
9	TI/LWS onboa	arding (G: ≥95%, Y: 90-<95%, R:<90%)	100
10	OST onboard	ing (G: ≥95%, Y: 90-<95%, R:<90%)	95
11	Coverage of I	HRG against estimates (G: ≥90%, Y: 80-<90%, R:<80%)	115
12	HIV testing ar	nong HRG (G: ≥95%, Y: 90-<95%, R:<90%)	71
13		nong prisoners (G: ≥50%, Y: 40% to <50%, R:<40%)	75
14		HRGs at TI-Clinics (G: ≥90%, Y: 75-89%, R:<75%)	54
15		f HRGs screened for Syphilis (G: ≥90%, Y: 75-89%, R:<75%)	71
16		G: ≥50%, Y: 30% to <50%, R:<30%)	20
17		fund released to TI (G: ≥50%, Y: 45-<50%, R:<45%)	113
18	<pre>Percentage of <75%, R:<709</pre>	f TIs trained by Kshmata Kendra (KK) against the AAP targets (G: ≥75%, Y: 70- ‰	100
19		₉ gainst Target-at risk % (G: ≥95%, Y: 80-94%, R:<80%)	124
20)	gainst target-PW (G: ≥95%, Y: 80-94%, R:<80%)	64
21		pregnant women screened for Syphilis (G: ≥95%, Y: 80-94%, R:<80%)	76
22		ovided to Syphilis reactive pregnant women (G: ≥95%, Y: 80-94%, R:<80%)	98
23	·	among newly detected HIV positive clients (G: ≥95%, Y: 80-94%, R:<80%)	17
24)	f 6 weeks - <2 months EID testing against live birth (G: ≥95%, Y: 80-94%,	100
	R:<80%)		
25		ged at DSRC against the target (G: ≥90%, Y: 75-89%, R:<75%)	144
26		screened for HIV (G: >75%, Y: 50-75%, R:<50%)	63
27		screened for Syphilis (G: >75%, Y: 50-75%, R:<50%)	99
28		t women who initiated ART (G: ≥95%, Y: 80-94%, R:<80%)	76
29	Proportion of R:>5%)	LFU-PLHIV, out of those initiated on ART in FY 2023-24 (G:<2%, Y: 2 to 5%,	21
30	Proportion of to 98%, R:<95	PLHIV initiated on ART, out of those registered in FY 2023-24 (G:>98%, Y: 95%)	98
31	Proportion of R:>5 %)	reported died, out of those initiated on ART in FY 202324 (G:<2%, Y: 2 to 5 %,	1
32		edited (G:100%, Y: 80-99%, R:<80%)	100
33	% participatio	n of ICTCs in re-testing (G: ≥95%, Y: 85-94, R:<85%)	88
34		stracts selected from studies conducted in FY21-22	1
2.5		25 to <100%, R: ≤25%)	
35		ngoing studies from FY22-23 (G:100%, Y: >25 to <100%, R: ≤25%)	0
36		f research proposals from FY23-24 to NACO (G:100%, 0%, R: ≤25%)	2
37		ta Analysis by SACS (G:2, Y: 1, R: No Secondary Data Analysis Plan Submitted)	2
38	Expenditure v	with respect to funds released during FY 2022-23 (G:	98
39	Submission of	o <90%, R: <85%) Frovisional Utilization Certificate (UC) in GFR 12A for the FY 2022-23 (G : by Y : by 31-May-2023, R : after	18-05-2023
40		f audited UC in GFR 12A for the FY 2022-23 (G : by 30Jun-2023, Y : by 30-Sep-30-Sep-2023)	05-01-2024
41	Submission of	FEC/ GB ratification for approval of Expenditure incurred during FY 2021-22 -2022, Y: by 30-Sept-2022,	20-07-2023
42		ssion of CST-SCM Report (G:>95%, Y: 80-95%, R:<80%)	89
43	Format Adher	rence to CST-SCM Report (G:>95%, Y: 80-95%, R:<80%)	98
44	Timely Submi	ssion of BSD & STI-SCM Report (G: ≥90%, Y: 75- -7 75%)	67
	Green=3 Marks		Colour=Not Applicable
	tht points	Indicator SI. No.	22.341 TOTAPPHOADIE
. ,	3		
	2	1, 23, 29 2, 3, 9, 10, 22, 30, 34, 42, 44	
	_	4, 5, 6, 7, 8, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 24, 25, 26, 27, 28, 31, 32	22 25 27 27 20 20 40





1. Status of HIV/AIDS Epidemic			
A. Epidemic Estimates (2023)			
Indicator	Male	Female	Total
1. IPR	-	-	6.31
2. IMR	-	-	3.95
3. Adult (15-49 yrs) HIV Prevalence (%)	0.17	0.08	0.13
4. Estimated people living with HIV	21,721	10,311	32,032
5. ART coverage (%)	50.33	48.43	49.85
6. Estimated children living with HIV	329	306	635
7. Annual new HIV infections	1,418	603	2,021
8. Annual AIDS-related deaths (ARD)	209	128	337
9. Change in annual new HIV infections since 2010 (%)	22.24	21.82	22.11
10. Change in annual ARD since 2010(%)	-44.71	-8.57	-34.94
11. EMTCT need	-	264	264

B. High risk population size (2020-22), safe practices (2021) and prevalence (2021/2023)				
Population Group	Estimates Size	Condom Use (%)	New Needle/ Syringe use (%)	HIV Prevalence (%)
1. Female Sex Workers	39,721	99.00	69.60	1.65
2. Men who have sex with men	16,667	77.80	-	3.61
3. Injecting Drug Users	26,156	-	92.80	11.24
4. Hijra/Transgender People	2,481	-	-	-
5. Migrants	20,000	33.50	-	3.21
6. Truckers	25,000	94.60	-	2.12
7. Prison inmates	48,070	17.60	47.70	4.17

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)				
Indicator	Male	Female	Total	
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)	25.30	19.20	-	
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	27.40	19.00	-	
3. Adults willing to care for a relative with HIV/AIDS in own home (%)	75.60	76.10	-	
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	69.10	72.40	-	
5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)	1.10	0.30	-	
5.1 Condom use during last higher-risk intercourse (%)	62.60	40.00	-	
6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)	1.79	0.49	-	
6.1 Condom use during last higher-risk intercourse (%)	69.23	25.00	-	

2. Progress on 95-95-95 (2023-24) PLHIV who know their HIV status (%) PLHIV who know their HIV status and are on ART and virily suppressed ART (%) 2018-19 2019-20 2020-21 2021-22 2022-23 2023-24

Indicators	Male	Female	Total*
1. Estimated PLHIV size (2023)	21,721	10,311	32,032
2. PLHIV who know their HIV Status	15,322	6,209	21,592
3. PLHIV who know their HIV status and are on ART	10,757	4,871	15,668
4. PLHIV who are on ART and tested for their viral load	5,359	3,200	8,573
4.1 PLHIV who are virally suppressed	5,207	3,100	8,321

^{*} Including of H/TG PLHIV

A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2023-24
Schools with operational Adolescent Education Program (AEP)	500
2. Colleges with operational Red Ribbon Clubs (RRC)	300
3. Persons trained under mainstreaming	12,834
4. No. of calls received at helpline	-

B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management under NACP

Indicator	2023-24			
NACO Supported Designated STI/	28			
RTI Clinics (DSRC)	Male	Female	TG	Total
2. Total STI/RTI Clients managed				1,47,065
3. RPR Tests conducted	20,658	32,481	181	53,320
4. Syphilis seropositivity (%)	3.95	0.95	19.89	2.17

4. Prevention of new HIV infections among highrisk group and bridge population

A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

Indicator	2023-24
1. Targeted Interventions	52
2. OST centres (Excluding Satellite OST centres)	6

B. Female Sex Workers

D. Lettigle Sex AAOLKEL2	
Indicator	2023-24
1. Estimated size	39,720
2. Coverage (%)	38.94
3. Condoms distributed	20,60,753
4. Tested for HIV (April 2023-September 2023)	9,482
4.1. HIV sero-positive (%)	0.27
4.1.1. Linked to ART	22
5. Tested for HIV (October 2023 -March 2024)	11,116
5.1. HIV sero-positive (%)	0.22
5.1.1. Linked to ART	23
6. Clinic Visits	46,787
7. STI/RTI treated	688
8. Presumptive treatment	2,594

C. Men who have sex with men

Or more time have sex than men	
Indicator	2023-24
1. Estimated size	16,666
2. Coverage (%)	36
3. Condoms distributed	6,33,992
4. Tested for HIV (April 2023-September 2023)	3,900
4.1. HIV sero-positive (%)	1.38
4.1.1. Linked to ART	48
5. Tested for HIV (October 2023 -March 2024)	4,645
5.1. HIV sero-positive (%)	0.97
5.1.1. Linked to ART	35
6. Clinic Visits	18,899
7. STI/RTI treated	160
8. Presumptive treatment	1,236

D. Injecting Drug Users	
Indicator	2023-24
1. Estimated size	26,155
2. Coverage (%)	65
3. Needles distributed	33,36,181
4. Syringes distributed	33,88,130
5. On OST	3,329
6. Tested for HIV (April 2023 -September 2023)	8,852
6.1. HIV sero-positive (%)	13.69
6.1.1 Linked to ART	1,028
7. Tested for HIV (October 2023 -March 2024)	10,900
7.1. HIV sero-positive (%)	7.22
7.1.1. Linked to ART	544

E. Hijra/Transgender person	
Indicator	2023-24
1. Estimated size	2,481
2. Coverage (%)	37
3. Condoms distributed	1,10,154
4. Tested for HIV (April 2023-September 2023)	569
4.1. HIV sero-positive (%)	0.00
4.1.1. Linked to ART	3
5. Tested for HIV (October 2023 -March 2024)	686
5.1. HIV sero-positive (%)	0.00
5.1.1. Put on ART	1
6. Clinic Visits	3,074
7. STI/RTI treated	39
8. Presumptive treatment	193

F. Migrants	
Indicator	2023-24
1. Estimated size	20,000
2. Coverage (%)	88
3. Tested for HIV	4,682
3.1. HIV sero-positive (%)	0.98
3.2. Linked to ART	29

G. Truckers	
Indicator	2023-24
1. Estimated size	25,000
2. Coverage (%)	>=95
3. Tested for HIV	5,377
3.1. HIV sero-positive (%)	0.35
3.2. On ART	11

H. Prison Inmates		
Indicator	2023-24	
1. Total prisons	31	
2. Prisons covered under programme	32	
3. Total inmates admitted	48,070	
4. Inmates Covered (%)	55	
5. Tested for HIV	26,282	
5.1. HIV sero-positive (%)	2.87	
5.2. On ART (%)	79.42	

I. Link Worker Scheme		
Indicator	2023-24	
1. Districts covered under scheme	1	
2. Vulnerable population covered	6,381	
3. Tested for HIV	1,146	
3.1. HIV sero-positive (%)	1.48	
3.2. Linked to ART (%)	76.47	

J. Opioid Substitution Therapy	
Indicator	2023-24
1. OST Centres	6
1.1. OSTC in Public Health Settings	6
1.2. OSTC in NGO Settings	-
1.3 No. of Satellite OST Centres	12
2. IDU on OST	3,329

5. Early detection of HIV infected people

A. HIV counselling and testing services (HCTS)

,	
Indicator	2023-24
1. HCTC confirmatory facilities	107
2. Sampoorna Suraksha Kendras	1

B. HIV testing among vulnerable population (excluding pregnant women)

Indicator	2023-24			
	Male	Female	TG	Total
1. Tested for HIV	1,95,021	1,33,415	231	3,28,667
1.1 HIV Positives	6,384	649	27	7,060
1.2 HIV sero -positivity (%)	3.27	0.49	11.69	2.15
Spouse/sexual partner of HIV positive people tested	922	850	9	1,781
2.1 HIV Positives	329	217	6	552
2.2 HIV sero -positivity (%)	36	26	67	30.99
No. of contacts with 'at- risk' population through 'Sampoorna Suraksha'	-	-	-	855

6. Initiation and retention on ART of HIV infected people

A. Treatment facilities

Indicator	2023-24
1. ART Centres	9
2.Centre of Excellence	
2.1. Centre of Excellence (Adult)	-
2.2 Centre of Excellent (Paediatric)	-
3. Link ART Centres	8
4. Care Support Centres	3

B. Treatment uptake

Indicator				2023-24
	Male	Female	TG	Total
HIV positive cases diagnosed (At ICTC)	6,384	865	27	7,276
New PLHIV Registered at ART center	5,190	786	20	5,996
2.1 Initiated on ART	4,804	739	18	5,561
3. PLHIV alive and on ART	10,757	4,871	40	15,668
4. 12 months retention on ART (%)				80.9
5. Lost to follow-up cases	3,823	1,006	16	4,845

7. Viral Suppression and laboratories	
A. Laboratory facilities and service uptake	
Indicator	2023-24
Viral load laboratories (programme and non- programme labs)	0
1.1 Accredited Viral load laboratories (out of 64 VL labs)	0
2. Viral load tests conducted	9,676
2.1. Virally suppressed (%)	95.2
3. National reference laboratories (NRL)	-
3.1 Accredited NRL	-
4. State reference laboratories (SRL)	3
4.1 Accredited SRL	3
5. CD4 machines	5
5.1 CD4 tests conducted	6,899
6. External Quality Assurance of ICTC	
6.1 Average Participation (%)	>=95
6.2. Average Discordance (%)	0.00
7. "Certificate of Excellence" by NACO	
7.1 No. of ICTCs received "Certificate of Excellence"	-
8. Elimination of mother to child transr HIV & Syphilis	mission of
A. HIV	
Indicator	2023-24
1 Fating at a display and a support a support (D) AA	0 22 020

Indicator	2023-24
1. Estimated pregnant women (PW)	8,23,820
2. HIV testing among PW	6,50,937
3. HIV sero-positivity (%) among tested	0.03
4. HIV Positive PW (old + new detections)	276
4.1 On life-long ART	247
5. Live births among HIV positive PW	171
5.1 Babies given ARV Prophylaxis (%)	52.63
6. Babies tested HIV (6 week- 6 month)	235
6.1 Babies confirmed HIV Positive (6 week- 6 month)	16
7. HIV testing among exposed babies at 18 months	
7.1 HIV exposed babies tested at 18 months	182
7.2 Babies confirmed HIV positive at 18 months	12
8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months)	31
9. HIV positive babies initiated on ART	30

B. Syphilis	
Indicator	2023-24
1. Syphilis testing among PW	3,03,655
2.Sero-positivity (%) among tested	0.19
3. Put on treatment	126

9. Elimination of HIV/AIDS related Stigma and Discrimination

Indicator	2023-24
1. State rules notified for HIV/AIDS Prevention and Control Act (2017)	Yes
2. State designated/appointed ombudsman	Yes

10. HIV-TB Co-m	orbidities							
A. HRG and Bridge	e Population							
Indicator				202	3-24			
	Quarter	FSW	MSM	IDU	TG	Migrants	Truckers	Total
	Quarter 1	12,138	4,563	8,227	864	2,725	3,313	31,830
Screened for TB	Quarter 2	13,052	5,203	12,386	896	2,487	4,222	38,246
Screened for TB	Quarter 3	12,696	5,270	13,310	917	3,910	5,464	41,567
	Quarter 4	13,160	5,942	12,933	952	4,179	4,770	41,936
	Quarter 1	61	6	263	-	52	76	458
T . I(TD	Quarter 2	62	14	352	-	78	110	616
Tested for TB	Quarter 3	6	11	217	-	60	-	294
	Quarter 4	6	13	145	-	4	41	209
	Quarter 1	5	-	-	-	-	-	5
D: 1 :: TD	Quarter 2	-	6	21	-	-	-	27
Diagnosed with TB	Quarter 3	-	1	6	-	-	-	7
	Quarter 4	1	-	1	-	-	-	2
Initiated on TB treatment	Quarter 1	6	-	-	-	-	-	6
	Quarter 2	-	5	14	-	-	-	19
	Quarter 3	-	1	2	-	-	-	3
	Quarter 4	-	-	2	-	-	-	2

B. HIV-TB Coinfected at ART Centre 2023-24 Indicator Co-infected enrolled at PLHIV with presumptive TB PLHIV PLHIV PLHIV PLHIV Co-infected initiated on ART PLHIV tested for TB attending diagnosed with TB initiated on IPT Moths underwent ART Centre 4S screening ARTC 4,485 4,485 303 7 Apr - 23 41 21 4,979 5,084 183 353 38 14 May - 23 Jun - 23 5,019 5,018 102 66 33 780 Jul - 23 6,567 6,567 92 72 20 729 7,228 7,228 83 72 25 476 Aug - 23 17 Sep - 23 6,991 6,991 90 60 394 Oct - 23 6,957 6,837 125 95 14 268 74 8,374 8,282 45 16 212 Nov - 23 Dec - 23 8,374 8,282 74 45 16 212 Jan - 24 9,268 123 85 145 9,166 11 135 91 17 Feb - 24 6,681 6,614 113 Mar - 24 6,779 6,779 92 50 15 112 April 2023-406 321 March 2024

National Marks			State/UT	Assam
No. Detained Marks 114 (66%) 2 Second St (Grap9St, Yr. 80.948), R-80%) 73 3 Third 95 (Grap9St, Yr. 80.948), R-80% 75 4 Avarage Frequency of Social Media updates (Gr. a 45, Y-40. 44, R-<40 indigenous posts) of O1, O2, O3 & O4 1199 5 Status of AEP Integration in state school curriculum (Gr.Yes, RNo) Yes 6 Status of Status Rules (Gr. Northerl, R. Not northerly) Meeting held in 2024 7 Status of Othorderm (Gr. 19%), Y. 90-495%, R. e-9073 Moothing (Gr. 19%), Y. 90-495%, R. e-9073 9 TIV LWO onboarding (Gr. 19%), Y. 90-495%, R. e-9078 100 11 Coverage of HIKG against estimates (Gr. 20%), Y. 40%, to 20%, R. e-8080 40 12 TIV tecting among TIRG (Gr. 29%), Y. 40%, to 20%, R. e-9078, R. e-9780 40 13 TWY testing among TIRG (Gr. 29%), Y. 40%, to 20%, R. e-8080 40 14 TWY testing among TIRG (Gr. 29%), Y. 40%, to 20%, R. e-8090 41 15 Percentage of HIKG against (Gr. 29%), Y. 40%, to 20%, R. e-8090 42 16 DUI on OST (Gr. 29%), Y. 90 - 90%, R. e-8090 42 17 Percentage of Files (Gr. 20%), Y. 90%, Y. 80 - 90%, R. e-8090 <t< th=""><th></th><th>_</th><th>Rank</th><th></th></t<>		_	Rank	
1				
2 Second 95 (3:5998, Y. 80-948, R. +80%) 3 Third 95 (3:5998, Y. 80-948, R. +80%) 4 Average Frequency of Social Modal updates (G: a 45, Y-40-44, R-<40 indigenous posts) of Q1, Q2, Q3 8 C34 5 Status of AEP integration in state school curriculum (G1Yes, RNo)				
A Norrigon Frequency of Scala Media updates (S. s. 45, Y.40 - 44, R40 indigenous posts) of O.1, O.2, O.3 & O.4 1999 19				
A varrage Frequency of Social Media updates (Si = 45, Y.40 - 44, R.<40 incligenous posts) of C1, C2, C3 & C4 C1, C2, C3 & C4 C2, C3 & C4 C3 C3 C4 C4 C4 C4 C4		J		
Sestus of SCA (G. Alz least one maceting held since 2020, R. other than C) Status of SCA (G. Alz least one maceting held since 2020, R. other than C) Status of Star Rules (G. Notified, R. Not notified) Status of Ornbudman (G. Appointed, R. Not appointed) 7 ITUMS obheadeding (G. 295%, Y. 90 - 95%, R. e-90%) 10 OST onboarding (G. 295%, Y. 90 - 95%, R. e-90%) 10 OST onboarding (G. 295%, Y. 90 - 95%, R. e-90%) 11 Coverage of HRG against estimates (G. 390%, Y. 90 - 95%, R. e-90%) 12 IVI testing among pisnoner (G. 250%, Y. 90 - 95%, R. e-90%) 13 IVI testing among pisnoner (G. 250%, Y. 90 - 95%, R. e-75%) 14 Clinic vist of HRGs at Ti-Clinics (G. 295%, Y. 90 - 95%, R. e-75%) 15 Percentage of HRG separated for Syphilic (G. 296%, Y. 75 - 97%, R. e-75%) 16 DU on OST (G. 250%, Y. 30% to e-30%, Y. 75 - 97%, R. e-75%) 17 Percentage of Filt for trained by Kshmata Kandra (G. 2004, Y. 75 - 87%, R. e-75%) 18 Percentage of filt of trained by Kshmata Kandra (G. 2004, Y. 75 - 87%, R. e-80%) 19 IVI testing against Target-at risk % (G. 95%, Y. 80 - 94%, R. e-80%) 10 IVI testing against Target-at risk % (G. 95%, Y. 80 - 94%, R. e-80%) 11 IVI testing against Target-at risk % (G. 95%, Y. 80 - 94%, R. e-80%) 12 Percentage of Irgen provided to Syphilis (G. 295%, Y. 80 - 94%, R. e-80%) 13 Taratman provided to Syphilis (G. 295%, Y. 80 - 94%, R. e-80%) 14 Percentage of pregnant women screened for Syphilis (G. 295%, Y. 80 - 94%, R. e-80%) 15 Clinits managed at DSRC against the target (G. 295%, Y. 80 - 94%, R. e-80%) 16 Clinits managed at DSRC against the target (G. 295%, Y. 80 - 94%, R. e-80%) 17 Taratmandees screened for IIVI (G. 75%, Y. 80 - 94%, R. e-80%) 18 Proportion of PLHIV initiated on ART, out of those initiated on ART in PY 2023 24 (G. e-98%, Y. 2 to 5 %, P. 3 to 5				
6 Status of SCA (S.A fleast one meeting hold since 2020, R. other than G) 7 Status of State Rules (Si Nortfield, R. Not nortified) 8 Status of Ornbuddhran (G. Appointed, R. Not appointed) 9 TrUMS onbabarding (G: ≥95%, Y: 90-≥95%, R:>90%) 10 OST onbabarding (G: ≥95%, Y: 90-≥95%, R:>90%) 10 OST onbabarding (G: ≥95%, Y: 90-≥95%, R:>90%) 11 Coverage of HRG againet estimates (G: ≥90%, R:>900%) 12 If IV testing among prisoners (G: ≥90%, Y: 90-≥95%, R:>90%) 13 If IV testing among prisoners (G: ≥90%, Y: 90-≥95%, R:>90%) 14 Clinic visit of IRIGs at TLClinics (G: ≥90%, Y: 93-≥95%, R:>50%) 15 Percentage of IRIG series (G: ≥90%, Y: 93-≥95%, R:>50%) 16 IDU on OST (G: ≥50%, Y: 30% to ≤90%, R:<50%) 17 Percentage of IRIG series of the IRIG (S: ≥90%, Y: 93-≥95%, R:>45 ≥90%, R:>45 ≥90% 18 Percentage of IRIG series of the IRIG (S: ≥90%, Y: 93-≥95%, R:>45 ≥90%, R:>45 ≥90% 19 IIIV testing against Target at risk % (G: ≥95%, Y: 90-94%, R:>40%) 10 IIV testing against Target by Kin-vision (G: ≥95%, Y: 90-94%, R:>80%) 11 Percentage of Irig regional women screened for Syphilia (G: ≥95%, Y: 80-94%, R:>80%) 12 Percentage of pregnant women screened for Syphilia (G: ≥95%, Y: 80-94%, R:>80%) 13 Indiax testing among newly detected HIV positive clients (G: ≥95%, Y: 80-94%, R:>80%) 14 Percentage of oregnant women screened for Syphilia (G: ≥95%, Y: 80-94%, R:>80%) 15 Clinics managed at DSRC against the target (G: ≥90%, Y: 75-89%, R:>90% 16 Percentage of oregnant women screened for Syphilia (G: ≥95%, Y: 80-94%, R:>80%) 17 STI attendees screened for HIV (G: ≥95%, Y: 90-94%, R:>80%) 18 Percentage of every attended the Irig (G: ≥95%, Y: 90-94%, R:>80%) 19 Robert testing among newly detected HIV positive clients (G: ≥95%, Y: 80-94%, R:>80%) 20 Clients managed at DSRC against the target (G: ≥95%, Y: 80-94%, R:>80%) 21 Percentage of every attended the Syphilia (G: ≥95%, Y: 80-94%, R:>80%) 22 Clients managed at DSRC against the target (G: ≥95%, Y: 80-94%, R:>95%) 23 No of SRC, Regnant women who initiated on ART in PY 2022-24	7		· · · · · · · · · · · · · · · · · · ·	107
2 Satuse of State Rules (G. Notified, R. Not notified) Satus of Chmbudames (G. Appointed, R. Not sappointed) Appointed	5	Status of AEP	integration in state school curriculum (G:Yes, R:No)	Yes
8 Status of Combustinans (G. Appointed, R. Not appointed) 9 TUMMS chobaciding (G. ±95%, Y. 90-45%, R. +90%) 10 00T onboarding (G. ±95%, Y. 90-45%, R. +90%) 11 Coverage of HRG against estimates (G. ±95%, R. +90%) 12 HTV testing among HRG (G. ±95%, Y. 90-45%, R. +90%) 13 HTV testing among prisoners (G. ±95%, Y. 90-45%, R. +90%) 14 Clinic visit of HRG at TiClinics (G. ±90%, Y. 80-45%, R. +20%) 15 Percentage of HRG asceneed for Syphilia (G. ±90%, Y. 80-45%, R. +25%) 16 DiO on CST (G. ±50%, Y. 30% to ±50%, R. +30%) 17 Percentage of HRG asceneed for Syphilia (G. ±90%, Y. 58-89%, R. +25%) 18 Percentage of HRG asceneed for Syphilia (G. ±90%, Y. 58-89%, R. +45%) 19 Percentage of Tis rained by Kishnata Kandra (KG) against the AAP targets (G: ≠75%, Y. 70-45%, R. +20%) 19 HIV testing against Target-at risk % (G: ≠95%, Y. 80-94%, R. +80%) 20 HIV testing against target-PW (G: ±95%, Y. 80-94%, R. +80%) 21 Percentage of pregnant vomens recreased for Syphilia (G: 525%, Y. 80-94%, R. +80%) 22 Treatment provided to Syphilia reactive pregnant vomen (G: ±95%, Y. 80-94%, R. +80%) 23 Index testing among newly detected HIV positive clients (G: ±95%, Y. 80-94%, R. +80%) 24 Percentage of oweeks − <2 months EID testing against live birth (G: ±95%, Y. 80-94%, R. +80%) 25 Clients managed at DSRC against the target (G: ±90%, Y. 80-94%, R. +80%) 26 STI attendees screened for HIV (G: ±75%, Y. 50-75%, R. +50%) 27 STI attendees screened for HIV (G: ±75%, Y. 50-75%, R. +50%) 28 % of pregnant women with initiated Ant (G: ±95%, Y. 80-94%, R. +80%) 29 Proportion of EIHV initiated on ART, out of those initiated on ART in FY 2023-24 (G: <2%, Y. 2 to 5%, R. ±95%) 30 Proportion of FPI-HIV, out of those initiated on ART in FY 2023-24 (G: <2%, Y. 2 to 5%, R. ±95%) 31 Number of abstracts selected from studies conducted in FY21-22 32 (G:100%, Y. ±25 to ±100%, R. ±25%) 34 Number of ongoing studies from FY23-24 to NACO (G:100%, Y. ±25 to ±100%, R. ±25%) 35 Submission of Fesseric proposals from FY23-24 to NACO (G:100%, Y. ±25 to ±100%, R. ±25%) 36 Submission	6	Status of SCA	(G: At least one meeting held since 2020, R: other than G)	Meeting held in 2024
7 TYLWS enbearding (G: 95%, Y; 90~95%, R:-90%) 100 0 OST notocrding (G: 95%, Y; 90~95%, R:-90%) 100 10 OST notocrding (G: 95%, Y; 90~95%, R:-90%) 40 11 Coverage of HRG against estimates (G: 290%, Y; 80.40%, R:-80%) 40 12 HIV resting among Prisoners (G: 250%, Y; 40% to 450%, R:-40%) 41 13 HIV resting among prisoners (G: 250%, Y; 40% to 450%, R:-40%) 118 14 Citine value of HRGs at Trichine (G: 290%, Y; 75-89%, R:-40%) 22 15 Percentage of HRGs screened for Syphilis (G: 290%, Y; 75-89%, R:-45%) 27 16 Citine value of HRGs at Trichine (G: 290%, Y; 75-89%, R:-45%) 29 17 Percentage of Find released to Ti (G: 250%, Y; 30% to 45%, R:-40%) 98 18 Reventage of Find released to Ti (G: 250%, Y; 45-40%, R:-40%) 99 19 HIV resting against target-at risk X (G: 255%, Y; 80.44%, R:-80%) 199 19 HIV resting against target-PW (G: 295%, Y; 80.44%, R:-80%) 199 10 HIV resting against target-PW (G: 295%, Y; 80.44%, R:-80%) 199 11 Percentage of Find released to Ti (G: 255%, Y; 80.44%, R:-80%) 199 12 Percentage of Find released to Ti (G: 255%, Y; 80.44%, R:-80%) 199 13 Percentage of Find released to Ti (G: 255%, Y; 80.44%, R:-80%) 199 14 Westing against target-PW (G: 295%, Y; 80.44%, R:-80%) 199 15 Percentage of Find released to Ti (G: 255%, Y; 80.44%, R:-80%) 199 16 Percentage of Find released to Ti (G: 255%, Y; 80.44%, R:-80%) 199 17 Percentage of Find released to Ti (G: 255%, Y; 80.44%, R:-80%) 199 18 Westing against target-PW (G: 255%, Y; 80.44%, R:-80%) 199 19 Percentage of Find released to Ti (G: 255%, Y; 80.44%, R:-80%) 199 10 Percentage of Find released to Ti (G: 255%, Y; 80.44%, R:-80%) 199 11 Percentage of Find released to Ti (G: 255%, Y; 80.44%, R:-80%) 199 12 Percentage of Find released to Ti (G: 255%, Y; 80.44%, R:-80%) 199 13 Percentage of Versels2 months EID testing against Here brith (G: 255%, Y; 80.94%, R:-80%)	7	Status of State	e Rules (G: Notified, R: Not notified)	Notified
OST onboarding (G: =95%, Y. 9095%, R: >90%) 100	8			Appointed
11 Coverage of HRG against estimates (G: 90%, Y: 80 < 90%, Re-80%)				
HV testing among HRG (G: 295%, Y. 90-495%, R:-60%) 18			-	
13				
Clinic visit of HRGs at Tr-Clinics (G: 2005), Y: 75-89%, R:<75%) 73				
15 Percentage of HRGs screened for Syphilis (G: 290%, Y: 75-89%, R:<75%) 37				
16 IDU on CST (G: ≥50%, Y. 30% to <50%, R: <50%, P. <50%, P. <50%, P. <50%, P. <50% 98 7 Percentage of fund released to TI (G: ≥50%, Y. 45.~50%, R: <45%) 98 8 Percentage of Tis trained by Kshmata Kendra (KK) against the AAP targets (G: ≥75%, Y. 70.				
Percentage of Turn released to Til (G: \$50%, Y-45×60%, Rr-45%)				
Percentage of Tis trained by Kahmata Kendra (KK) against the AAP targets (G: ≥75%, Y: 70- ≤75%, K: 70%)				
- (75%, R:<070%) 19				
HIV testing against target-PW (G: ≥95%, Y: 80-94%, R:<80%)		_		
21 Percentage of pregnant women screened for Syphilis (G: ≥95%, Y: 80-94%, R:<80%)	19	HIV testing ag	ainst Target-at risk % (G: ≥95%, Y: 80-94%, R:<80%)	159
Treatment provided to Syphilis reactive pregnant women (G; ≥95%, Y; 80-94%, R:-80%) 76				
23 Index testing among newly detected HIV positive clients (G; ≥95%, Y; 80-94%, R; <80%)			, -	
24 Percentage of 6 weeks - <2 months EID testing against live birth (G: ≥95%, Y: 80-94%, R:<80%) Clients managed at DSRC against the target (G: ≥90%, Y: 75-89%, R:<75%) 25 Clients managed at DSRC against the target (G: ≥90%, Y: 75-89%, R:<75%) 26 STI attendees screened for FIIV (G: ≥75%, Y: 50-75%, R:<50%) 27 STI attendees screened for FIIV (G: ≥75%, Y: 50-75%, R:<50%) 28 % of pregnant women who initiated ART (G: ≥95%, Y: 80-94%, R:<80%) 29 Proportion of LFU-PLHIV, out of those initiated on ART in FY 2023-24 (G:<2%, Y: 2 to 5%, R:>5%) 30 Proportion of PLHIV initiated on ART, out of those registered in FY 2023-24 (G:<2%, Y: 2 to 5%, R:>5%) 31 Proportion of PLHIV initiated on ART, out of those registered in FY 2023-24 (G:<2%, Y: 2 to 5%, R:>5%) 32 % of SRL accredited (G: 100%, Y: 80-99%, R:<80%) 33 % participation of ICTCs in re-testing (G: ≥95%, Y: 85-94, R:<85%) 34 Number of abstracts selected from studies conducted in FY21-22 (G:100%, Y: >25 to <100%, R: ≤25%) 35 Number of abstracts selected from studies conducted in FY21-22 (G:100%, Y: >25 to <100%, R: ≤25%) 36 Submission of research proposals from FY23-24 to NACO (G:100%, Y: >25 to <100%, R: ≤25%) 37 Secondary Data Analysis by SACS (G:2, Y: 1, R: No Secondary Data Analysis Plan Submitted) 2 Submission of Provisional Utilization Certificate (UC) in GFR 12A for the FY 2022-23 (G: by 30-40-2023, Y: 39 1-May-2023, R: after 30-Sept-2023) 40 Submission of Provisional Utilization Certificate (UC) in GFR 12A for the FY 2022-23 (G: by 30-40-2023, Y: 39 3-Sep-2023) 41 Submission of SC GG Bratification for approval of Expenditure incurred during FY 2021-22 (G: by 30-40-2022, Y: by 30-Sept-2022) 42 Timely Submission of CST-SCM Report (G:>95%, Y: 80-95%, R:<80%) 3		· ·		
R:<80%				
25 Clients managed at DSRC against the target (G: ≥90%, Y: 75-89%, R:<75%) 26 STI attendees screened for HIV (G: >75%, Y: 50.75%, R:<50%) 27 STI attendees screened for FIHV (G: >75%, Y: 50.75%, R:<50%) 28 % of pregnant women who initiated ART (G: ≥95%, Y: 80-94%, R:<50%) 29 Proportion of LFU-PLHIV, out of those initiated on ART in FY 2023-24 (G: <2%, Y: 2 to 5%, R:>5%) 30 Proportion of PLHIV initiated an ART, out of those registered in FY 2023-24 (G: <2%, Y: 2 to 5%, R:>5%) 31 Proportion of PLHIV initiated on ART, out of those registered in FY 2023-24 (G: <2%, Y: 2 to 5%, R:>5%) 32 % of SRL accredited (G: 100%, Y: 80-99%, R:<80%) 33 % participation of ICTCs in re-testing (G: ≥95%, Y: 85-94, R:<85%) 34 Number of abstracts selected from studies conducted in FY21-22 35 (G:100%, Y: >25 to <100%, R: ≤25%) 35 Number of abstracts selected from studies conducted in FY21-22 36 Submission of research proposals from FY22-23 (G:100%, Y: >25 to <100%, R: ≤25%) 37 Secondary Data Analysis by SACS (G:2, Y: 1, R: No Secondary Data Analysis Plan Submitted) 38 Expenditure with respect to funds released during FY 2022-23 (G: 20, Y: 2, R: sfer 30-5ep-2023) 40 Submission of Provisional Utilization Certificate (UC) in GFR 12A for the FY 2022-23 (G: by 30-Jun-2023, Y: by 31-May-2023, R: after 30-5ep-2023) 41 Submission of GCG GB ratification for approval of Expenditure incurred during FY 2021-22 42 Timely Submission of GST-SCM Report (G:>95%, Y: 80-95%, R:<80%) 43 Format Adherence to CST-SCM Report (G:>95%, Y: 80-95%, R:<80%) 44 Timely Submission of GSD & STI-SCM Report (G:>95%, Y: 80-95%, R:<80%) 5	24	_	f 6 weeks - <2 months EID testing against live birth (G: ≥95%, Y: 80-94%,	100
26 STI attendees screened for HIV (G: >75%, Y: 50.75%, R:<50%) 27 STI attendees screened for FIV (G: >75%, Y: 50.75%, R:<50%) 28 % of pregnant women who initiated ART (G: >75%, Y: 50.75%, R:<50%) 30 Proportion of LFU-PLHIV, out of those initiated on ART in FY 2023-24 (G:<2%, Y: 2 to 5%, 22 ks.55%) 31 Proportion of PLHIV initiated on ART, out of those registered in FY 2023-24 (G:<2%, Y: 2 to 5%, 2 ks.55%) 32 % of SRL accredited (G: 100%, Y: 80.99%, R:<80%) 33 % participation of ICTCs in re-testing (G: ≥95%, Y: 85.94, R:<85%) 34 Number of abstracts selected from studies conducted in FY21-22 2 2 2 (G: 100%, Y: ≥25 to <100%, R: ≤25%) 35 Number of ongoing studies from FY22-23 (G: 100%, Y: >25 to <100%, R: ≤25%) 36 Submission of research proposals from FY23-24 to NACO (G:100%, Y: >25 to <100%, R: ≤25%) 37 Secondary Data Analysis by SACS (G:2, Y: 1, R: No Secondary Data Analysis Plan Submitted) 38 Expenditure with respect to funds released during FY 2022-23 (G: 290%, Y: by 31-May-2023) 39 Submission of Provisional Utilization Certificate (UC) in GFR 12A for the FY 2022-23 (G: by 30-Apr-2023, Y: by 31-May-2023, R: after 30-Sept-2022; R: a	25	•		1.1
27 STI attendees screened for Syphilis (G: >75%, Y: 50-75%, R:<50%)				
28 % of pregnant women who initiated ART (G: ≥95%, Y: 80-94%, R.<80%) 29 Proportion of LFU-PLHIV, out of those initiated on ART in FY 2023-24 (G:<2%, Y: 2 to 5%, R:>5%) 30 Proportion of PLHIV initiated on ART, out of those registered in FY 2023-24 (G:<2%, Y: 2 to 5%, to 98%, R:<95%) 31 Proportion of reported died, out of those initiated on ART in FY 2023-24 (G:<2%, Y: 2 to 5%, R:>5 %) 32 % of SRI. accredited (G:100%, Y: 80-99%, R:<80%) 33 % participation of ICTCs in re-testing (G: ≥95%, Y: 85-94, R:<85%) 34 Number of abstracts selected from studies conducted in FY21-22 2 (G:100%, Y: >25 to <100%, R: ≥25%) 35 Number of ongoing studies from FY22-23 (G:100%, Y: >25 to <100%, R: ≥25%) 36 Submission of research proposals from FY23-24 to NACO (G:100%, Y: >25 to <100%, R: ≥25%) 37 Secondary Data Analysis by SACS (G:2, Y: 1, R: No Secondary Data Analysis Plan Submitted) 38 Expenditure with respect to funds released during FY 2022-23 (G: 290%, Y: 85 to <90%, R: <25%) 39 Submission of Provisional Utilization Certificate (UC) in GFR 12A for the FY 2022-23 (G: by 30-Apr-2023, Y: by 31-May-2023, R: after 30-Sept-2022, R:				
29				
30 Proportion of PLHIV initiated on ART, out of those registered in FY 2023-24 (G:>98%, R:<55%)				22
10 98%, R:<95%) 11 Proportion of reported died, out of those initiated on ART in FY 202324 (G:<2%, Y: 2 to 5 %, R:>5 %) 12		R:>5%)		
Proportion of reported died, out of those initiated on ART in FY 202324 (G:<2%, Y: 2 to 5 %, R:>5 %) 2	30			93
R:>5 %) 100 32 % of SRL accredited (G:100%, Y: 80-99%, R:<80%)				
32 % of SRL accredited (G:100%, Y: 80-99%, R:<80%) 33 % participation of ICTCs in re-testing (G: ≥95%, Y: 85-94, R:<85%) 34 Number of abstracts selected from studies conducted in FY21-22 (G:100%, Y: >25 to <100%, R: ≤25%) 35 Number of ongoing studies from FY22-23 (G:100%, Y: >25 to <100%, R: ≤25%) 36 Submission of research proposals from FY23-24 to NACO (G:100%, Y: >25 to <100%, R: ≤25%) 37 Secondary Data Analysis by SACS (G:2, Y: 1, R: No Secondary Data Analysis Plan Submitted) 2 Expenditure with respect to funds released during FY 2022-23 (G: 290%, Y: 85 to <90%, R: <85%) 39 Submission of Provisional Utilization Certificate (UC) in GFR 12A for the FY 2022-23 (G: by 30-Apr-2023, Y: by 31-May-2023, R: after 31-May-2023) 40 Submission of audited UC in GFR 12A for the FY 2022-23 (G: by 30-Jun-2023, Y: by 30-Sept-2023, R: after 30-Sept-2023) 41 Submission of EC/ GB ratification for approval of Expenditure incurred during FY 2021-22 (G: by 30-Jun-2022, Y: by 30-Sept-2022, R: after 30-Sept-2022) 42 Timely Submission of CST-SCM Report (G:>95%, Y: 80-95%, R:<80%) 43 Format Adherence to CST-SCM Report (G:>95%, Y: 80-95%, R:<80%) 44 Timely Submission of BSD & STI-SCM Report (G:>95%, Y: 80-95%, R:<80%) 45 Pormat Adherence to CST-SCM Report (G:>90%, Y: 75-90%, R:<75%) 46 Points Indicator SI. No. 3 1, 23, 29 2 2, 3, 9, 10, 22, 30, 34, 42, 44 4, 5, 6, 7, 8, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 24, 25, 26, 27, 28, 31, 32, 33, 35, 36, 37, 38, 39, 40, 41	31		reported died, out of those initiated on ART in FY 202324 (G:<2%, Y: 2 to 5 %,	2
33 % participation of ICTCs in re-testing (G: ≥95%, Y: 85-94, R:<85%) 34 Number of abstracts selected from studies conducted in FY21-22 (G:100%, Y: >25 to <100%, R: ≤25%) 35 Number of ongoing studies from FY22-23 (G:100%, Y: >25 to <100%, R: ≤25%) 36 Submission of research proposals from FY23-24 to NACO (G:100%, Y: >25 to <100%, R: ≤25%) 37 Secondary Data Analysis by SACS (G:2, Y: 1, R: No Secondary Data Analysis Plan Submitted) 2 Expenditure with respect to funds released during FY 2022-23 (G: ≥90%, Y: 85 to <90%, R: <85%) 39 Submission of Provisional Utilization Certificate (UC) in GFR 12A for the FY 2022-23 (G: by 30-Apr-2023, Y: by 31-May-2023, R: after 31-May-2023) 40 Submission of audited UC in GFR 12A for the FY 2022-23 (G: by 30-Jun-2023, Y: by 30-Sep-2023, R: after 30-Sep-2023) 41 Submission of EC/ GB ratification for approval of Expenditure incurred during FY 2021-22 (G: by 30-Jun-2022, Y: by 30-Sept-2022, R: after 30-Sept-2022) 42 Timely Submission of CST-SCM Report (G: >95%, Y: 80-95%, R:<80%) 43 Format Adherence to CST-SCM Report (G: >95%, Y: 80-95%, R:<80%) 44 Timely Submission of BSD & STI-SCM Report (G: ≥90%, Y: 75-	32		edited (G:100% Y: 80-99% R:<80%)	100
34 Number of abstracts selected from studies conducted in FY21-22 (G:100%, Y: >25 to <100%, R: ≥25%)				
Number of ongoing studies from FY22-23 (G:100%, Y: >25 to <100%, R: ≤25%) 2	34			2
R: ≤25%) 36 Submission of research proposals from FY23-24 to NACO (G:100%, Y: >25 to <100%, R: ≤25%)		(G:100%, Y: >	25 to <100%, R: ≤25%)	
36 Submission of research proposals from FY23-24 to NACO (G:100%, Y: >25 to <100%, R: ≤25%) 37 Secondary Data Analysis by SACS (G:2, Y: 1, R: No Secondary Data Analysis Plan Submitted) 28 Expenditure with respect to funds released during FY 2022-23 (G: ≥90%, Y: 85 to <90%, R: <85%) 39 Submission of Provisional Utilization Certificate (UC) in GFR 12A for the FY 2022-23 (G: by 30-Apr-2023, Y: by 31-May-2023, R: after 31-May-2023) 40 Submission of audited UC in GFR 12A for the FY 2022-23 (G: by 30Jun-2023, Y: by 30-Sep-2023, R: after 30-Sep-2023) 41 Submission of EC/ GB ratification for approval of Expenditure incurred during FY 2021-22 (G: by 30-Jun-2022, Y: by 30-Sept-2022) 42 Timely Submission of CST-SCM Report (G:>95%, Y: 80-95%, R:<80%) 43 Format Adherence to CST-SCM Report (G:>95%, Y: 80-95%, R:<80%) 44 Timely Submission of BSD & STI-SCM Report (G:>95%, Y: 75- 45 Yellow=2Marks 46 No Colour=Not Applicable Weight points 47 Indicator SI. No. 3 1, 23, 29 2 2, 3, 9, 10, 22, 30, 34, 42, 44 4, 5, 6, 7, 8, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 24, 25, 26, 27, 28, 31, 32, 33, 35, 36, 37, 38, 39, 40, 41	35		ngoing studies from FY22-23 (G:100%, Y: >25 to <100%,	2
Y: >25 to <100%, R: ≤25%) Y: >25 to <100%, R: ≤25%) 37 Secondary Data Analysis by SACS (G:2, Y: 1, R: No Secondary Data Analysis Plan Submitted) 2 38 Expenditure with respect to funds released during FY 2022-23 (G: ≥70%, Y: 85 to <90%, R: <85%)	2.		5 - L C - EVO2 04 - NV 22 /2 /22/	
37 Secondary Data Analysis by SACS (G:2, Y: 1, R: No Secondary Data Analysis Plan Submitted) 28 Expenditure with respect to funds released during FY 2022-23 (G: ≥90%, Y: 85 to <90%, R: <85%) 39 Submission of Provisional Utilization Certificate (UC) in GFR 12A for the FY 2022-23 (G: by 30-Apr-2023, Y: by 31-May-2023, R: after 31-May-2023) 40 Submission of audited UC in GFR 12A for the FY 2022-23 (G: by 30-Jun-2023, Y: by 30-Sep-2023, R: after 30-Sep-2023) 41 Submission of EC/ GB ratification for approval of Expenditure incurred during FY 2021-22 (G: by 30-Jun-2022, Y: by 30-Sept-2022, R: after 30-Sept-2022) 42 Timely Submission of CST-SCM Report (G:>95%, Y: 80-95%, R:<80%) 43 Format Adherence to CST-SCM Report (G:>95%, Y: 80-95%, R:<80%) 44 Timely Submission of BSD & STI-SCM Report (G: ≥90%, Y: 75-	36			2
38 Expenditure with respect to funds released during FY 2022-23 (G: >90%, Y: 85 to <90%, R: <85%)	37	l		2
≥90%, Y: 85 to <90%, R: <85%) 39 Submission of Provisional Utilization Certificate (UC) in GFR 12A for the FY 2022-23 (G: by 30-Apr-2023, Y: by 31-May-2023, R: after 31-May-2023) 40 Submission of audited UC in GFR 12A for the FY 2022-23 (G: by 30Jun-2023, Y: by 30-Sep-2023, R: after 30-Sep-2023) 41 Submission of EC/ GB ratification for approval of Expenditure incurred during FY 2021-22 (G: by 30-Jun-2022, Y: by 30-Sept-2022, R: after 30-Sept-2022) 42 Timely Submission of CST-SCM Report (G:>95%, Y: 80-95%, R:<80%) 43 Format Adherence to CST-SCM Report (G:>95%, Y: 80-95%, R:<80%) 44 Timely Submission of BSD & STI-SCM Report (G:≥90%, Y: 75-		_		
39 Submission of Provisional Utilization Certificate (UC) in GFR 12A for the FY 2022-23 (G : by 30-Apr-2023, Y : by 31-May-2023, R : after 31-May-2023) 40 Submission of audited UC in GFR 12A for the FY 2022-23 (G : by 30Jun-2023, Y : by 30-Sep-2023, R : after 30-Sep-2023) 41 Submission of EC/ GB ratification for approval of Expenditure incurred during FY 2021-22 (G: by 30-Jun-2022, Y: by 30-Sept-2022, R: after 30-Sept-2022) 42 Timely Submission of CST-SCM Report (G:>95%, Y: 80-95%, R:<80%) 43 Format Adherence to CST-SCM Report (G:>95%, Y: 80-95%, R:<80%) 44 Timely Submission of BSD & STI-SCM Report (G: ≥90%, Y: 75-90%, R:<75%) 45 Green=3 Marks 46 Yellow=2Marks 47 Fellow=2Marks 48 No Colour=Not Applicable Weight points 49 Indicator Sl. No. 3 1, 23, 29 2 2, 3, 9, 10, 22, 30, 34, 42, 44 4, 5, 6, 7, 8, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 24, 25, 26, 27, 28, 31, 32, 33, 35, 36, 37, 38, 39, 40, 41	ఎ ర		·	131
30-Apr-2023, Y: by 31-May-2023, R: after 31-May-2023] 40 Submission of audited UC in GFR 12A for the FY 2022-23 (G: by 30Jun-2023, Y: by 30-Sep-2023, R: after 30-Sep-2023) 41 Submission of EC/ GB ratification for approval of Expenditure incurred during FY 2021-22 (G: by 30-Jun-2022, Y: by 30-Sept-2022, R: after 30-Sept-2022) 42 Timely Submission of CST-SCM Report (G:>95%, Y: 80-95%, R:<80%) 43 Format Adherence to CST-SCM Report (G:>95%, Y: 80-95%, R:<80%) 44 Timely Submission of BSD & STI-SCM Report (G: ≥90%, Y: 75-90%, R:<75%) 45 Green=3 Marks 46 Yellow=2Marks 47 Ferent Mark 48 No Colour=Not Applicable Weight points 49 Indicator Sl. No. 40 Indicator Sl. No. 41 Indicator Sl. No. 42 Indicator Sl. No.	39			03-05-2023
40 Submission of audited UC in GFR 12A for the FY 2022-23 (G: by 30Jun-2023, Y: by 30-Sep-2023, R: after 30-Sep-2023) 41 Submission of EC/ GB ratification for approval of Expenditure incurred during FY 2021-22 (G: by 30-Jun-2022, Y: by 30-Sept-2022, R: after 30-Sept-2022) 42 Timely Submission of CST-SCM Report (G:>95%, Y: 80-95%, R:<80%) 43 Format Adherence to CST-SCM Report (G:>95%, Y: 80-95%, R:<80%) 44 Timely Submission of BSD & STI-SCM Report (G:≥90%, Y: 75- 490%, R:<75%) 40 Green=3 Marks 41 Yellow=2Marks 42 Vellow=2Marks 43 Format Adherence to CST-SCM Report (G:≥90%, Y: 75- 44 Submission of BSD & STI-SCM Report (G:≥90%, Y: 75- 45 Yellow=2Marks 46 No Colour=Not Applicable 47 Vellow=2Marks 48 No Colour=Not Applicable 49 Veight points 40 Indicator SI. No. 41 Vellow=2Marks 40 Veight points 41 Vellow=2Marks 41 Vellow=2Marks 42 Vellow=2Marks 43 Vellow=2Marks 44 Vellow=2Marks 45 Vellow=2Marks 46 Vellow=2Marks 47 Vellow=2Marks 48 Vellow=2Marks 49 Vellow=2Marks 40 Vellow=2Marks 40 Vellow=2Marks 41 Vellow=2Marks 41 Vellow=2Marks 42 Vellow=2Marks 43 Vellow=2Marks 44 Vellow=2Marks 45 Vellow=2Marks 46 Vellow=2Marks 47 Vellow=2Marks 48 Vellow=2Marks 49 Vellow=2Marks 40 Vellow=2Marks 40 Vellow=2Marks 41 Vellow=2Marks 41 Vellow=2Marks 42 Vellow=2Marks 43 Vellow=2Marks 44 Vellow=2Marks 45 Vellow=2Marks 46 Vellow=2Marks 47 Vellow=2Marks 48 Vellow=2Marks 49 Vellow=2Marks 49 Vellow=2Marks 40 Vellow=2Marks 40 Vellow=2Marks 40 Vellow=2Marks 41 Vellow=2Marks 41 Vellow=2Marks 42 Vellow=2Marks 43 Vellow=2Marks 44 Vellow=2Marks 44 Vellow=2Marks 45 Vellow=2Marks 46 Vellow=2Marks 47 Vellow=2Marks 47 Vellow=2Marks 48 Vellow=2Marks 49 Vellow=2Marks 40 Vellow=2Marks 40 Vellow=2Marks 40 Vellow=2Marks 40 Vellow=2Marks 41 Vellow=2Marks 41 Vellow=2Marks 42 Vellow=2Marks 43 Vellow=2Marks 44 Vellow=2Marks 44 Vellow=2Marks 45 Vellow=2Marks 46 Vellow=2Marks 47 Vellow=2Marks 47 Vellow=2Marks 48 Vel		30-Apr-2023,	Y : by 31-May-2023, R : after	
2023, R : after 30-Sep-2023) 41 Submission of EC/ GB ratification for approval of Expenditure incurred during FY 2021-22 (G: by 30-Jun-2022, Y: by 30-Sept-2022, R: after 30-Sept-2022) 42 Timely Submission of CST-SCM Report (G:>95%, Y: 80-95%, R:<80%) 43 Format Adherence to CST-SCM Report (G:>95%, Y: 80-95%, R:<80%) 44 Timely Submission of BSD & STI-SCM Report (G: ≥90%, Y: 75- 290%, R:<75%) 48 Yellow=2Marks Red=1 Mark No Colour=Not Applicable Weight points Indicator SI. No. 3 1, 23, 29 2 2, 3, 9, 10, 22, 30, 34, 42, 44 4, 5, 6, 7, 8, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 24, 25, 26, 27, 28, 31, 32, 33, 35, 36, 37, 38, 39, 40, 41	4.0	-		00.04.000
41 Submission of EC/ GB ratification for approval of Expenditure incurred during FY 2021-22 (G: by 30-Jun-2022, Y: by 30-Sept-2022, R: after 30-Sept-2022) 42 Timely Submission of CST-SCM Report (G:>95%, Y: 80-95%, R:<80%) 43 Format Adherence to CST-SCM Report (G:>95%, Y: 80-95%, R:<80%) 44 Timely Submission of BSD & STI-SCM Report (G: ≥90%, Y: 75- 490%, R:<75%) 49 Green=3 Marks 40 Yellow=2Marks 41 Vision Provided P	40			02-01-2024
(G: by 30-Jun-2022, Y: by 30-Sept-2022) R: after 30-Sept-2022) 42 Timely Submission of CST-SCM Report (G:>95%, Y: 80-95%, R:<80%) 91 43 Format Adherence to CST-SCM Report (G:>95%, Y: 80-95%, R:<80%) 93 44 Timely Submission of BSD & STI-SCM Report (G: ≥90%, Y: 75-	41		1 '	29-11-2022
42 Timely Submission of CST-SCM Report (G:>95%, Y: 80-95%, R:<80%)				
43 Format Adherence to CST-SCM Report (G:>95%, Y: 80-95%, R:<80%) 44 Timely Submission of BSD & STI-SCM Report (G: ≥90%, Y: 75- 290%, R:<75%) Foreign Submission of BSD & STI-SCM Report (G: ≥90%, Y: 75- 290%, R:<75%) Foreign Submission of BSD & STI-SCM Report (G: ≥90%, Y: 75- 290%, R:<75%) Foreign Submission of BSD & STI-SCM Report (G: ≥90%, Y: 75- 290%, R:<75%) Foreign Submission of BSD & STI-SCM Report (G: ≥90%, Y: 75- 290%, R:<75%) Foreign Submission of BSD & STI-SCM Report (G: ≥90%, Y: 75- 290%, R:<75%) Foreign Submission of BSD & STI-SCM Report (G: ≥90%, Y: 75- 292 290%, R:<75%) Foreign Submission of BSD & STI-SCM Report (G: ≥90%, Y: 75- 292 290%, R:<75%) Foreign Submission of BSD & STI-SCM Report (G: ≥90%, Y: 75- 292 290%, R:<75%) Foreign Submission of BSD & STI-SCM Report (G: ≥90%, Y: 75- 292 290%, R:<75%) Foreign Submission of BSD & STI-SCM Report (G: ≥90%, Y: 75- 292 290%, R:<75%) Foreign Submission of BSD & STI-SCM Report (G: ≥90%, Y: 75- 292 290%, R:<75%) Foreign Submission of BSD & STI-SCM Report (G: ≥90%, Y: 75- 292 290%, R:<75%) Foreign Submission of BSD & STI-SCM Report (G: ≥90%, Y: 75- 292 290%, R:<75%) Foreign Submission of BSD & STI-SCM Report (G: ≥90%, Y: 75- 292 290%, R:<75%) Foreign Submission of BSD & STI-SCM Report (G: ≥90%, Y: 75- 292 290%, R:<75%) Foreign Submission of BSD & STI-SCM Report (G: ≥90%, Y: 75- 292 290%, R:<75%) Foreign Submission of BSD & STI-SCM Report (G: ≥90%, Y: 75- 292 290%, R:<75%) Foreign Submission of BSD & STI-SCM Report (G: ≥90%, Y: 75- 292 290%, R:<75%) Foreign Submission of BSD & STI-SCM Report (G: ≥90%, Y: 75- 292 290%, R:<75%) Foreign Submission of BSD & STI-SCM Report (G: ≥90%, Y: 75- 292 290%, R:<75%) Foreign Submission of BSD & STI-SCM Report (G: ≥90%, Y: 75- 292 290%, R:<75%) Foreign Submission of BSD & STI-SCM Report (G: ≥90%, Y: 75- 292 290%, R:<75%) Foreign Submission of BSD & STI-SCM Report (G: ≥90%, Y: 75- 292 290%, R:<75%) Foreign Submission of BSD & STI-SCM Report (G: ≥90%, Y: 75- 292 290%, R:<75%) Foreign Submission of BSD				
44 Timely Submission of BSD & STI-SCM Report (G: ≥90%, Y: 75-		-	· · · · · · · · · · · · · · · · · · ·	
Green=3 Marks Yellow=2Marks Red=1 Mark No Colour=Not Applicable Weight points Indicator SI. No. 3 1, 23, 29 2 2, 3, 9, 10, 22, 30, 34, 42, 44 4, 5, 6, 7, 8, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 24, 25, 26, 27, 28, 31, 32, 33, 35, 36, 37, 38, 39, 40, 41	43	Format Adher	rence to CST-SCM Report (G:>95%, Y: 80-95%, R:<80%)	93
Green=3 Marks Yellow=2Marks Red=1 Mark No Colour=Not Applicable Weight points Indicator SI. No. 3 1, 23, 29 2 2, 3, 9, 10, 22, 30, 34, 42, 44 4, 5, 6, 7, 8, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 24, 25, 26, 27, 28, 31, 32, 33, 35, 36, 37, 38, 39, 40, 41	44			92
Weight points Indicator SI. No. 3 1, 23, 29 2 2, 3, 9, 10, 22, 30, 34, 42, 44 4, 5, 6, 7, 8, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 24, 25, 26, 27, 28, 31, 32, 33, 35, 36, 37, 38, 39, 40, 41				
3 1, 23, 29 2 2, 3, 9, 10, 22, 30, 34, 42, 44 4, 5, 6, 7, 8, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 24, 25, 26, 27, 28, 31, 32, 33, 35, 36, 37, 38, 39, 40, 41				Colour=Not Applicable
2 2, 3, 9, 10, 22, 30, 34, 42, 44 4, 5, 6, 7, 8, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 24, 25, 26, 27, 28, 31, 32, 33, 35, 36, 37, 38, 39, 40, 41	Weig			
4, 5, 6, 7, 8, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 24, 25, 26, 27, 28, 31, 32, 33, 35, 36, 37, 38, 39, 40, 41				
		2		
43		1		2, 33, 35, 36, 37, 38, 39, 40, 41,





1. Status of HIV/AIDS Epidemic			
A. Epidemic Estimates (2023)			
Indicator	Male	Female	Total
1. IPR	-	-	5.31
2. IMR	-	-	2.71
3. Adult (15-49 yrs) HIV Prevalence (%)	0.18	0.14	0.16
4. Estimated people living with HIV	89,732	65,914	1,55,646
5. ART coverage (%)	54.79	62.50	58.15
6. Estimated children living with HIV	3,298	3,035	6,333
7. Annual new HIV infections	4,901	3,371	8,272
8. Annual AIDS-related deaths (ARD)	1,230	609	1,839
9. Change in annual new HIV infections since 2010 (%)	-9.29	-9.77	-9.50
10. Change in annual ARD since 2010(%)	-49.30	-67.93	-57.50
11. EMTCT need	-	1,823	1,823

B. High-risk population size (2021-22), safe practices (2015) and prevalence (2021/2023)					
Population Group	Estimates Size	Condom Use (%)	New Needle/ Syringe use (%)	HIV Prevalence (%)	
1. Female Sex Workers	11,682	97.50	-	0.62	
2. Men who have sex with men	2,376	99.30	-	0.41	
3. Injecting Drug Users	4,585	-	84.70	2.86	
4. Hijra/Transgender People	846	-	-	-	
5. Migrants	-	-	-	-	
6. Truckers	15,000	-	-	-	
7. Prison inmates	3,38,024	45.50	68.80	0.17	

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)			
Indicator	Male	Female	Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)	25.10	10.30	-
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	25.30	10.10	-
3. Adults willing to care for a relative with HIV/AIDS in own home (%)	81.50	76.70	-
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	65.20	68.60	-
5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)	5.00	0.40	-
5.1 Condom use during last higher-risk intercourse (%)	50.90	23.40	-
6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)	9.04	0.56	-
6.1 Condom use during last higher-risk intercourse (%)	51.45	33.33	-

2. Progress on 95-95-95 (2023-24) PLHIV who know their HIV status (%) PLHIV who know their HIV status and are on ART and virally suppressed ART (%) 2018-19 2019-20 2020-21 2021-22 2022-23 2023-24

Indicators	Male	Female	Total*
1. Estimated PLHIV size (2023)	89,732	65,914	1,55,646
2. PLHIV who know their HIV Status	51,736	42,658	94,556
3. PLHIV who know their HIV status and are on ART	47,037	39,365	86,544
4. PLHIV who are on ART and tested for their viral load	4,053	3,396	7,459
4.1 PLHIV who are virally suppressed	3,892	3,257	7,159

^{*} Including of H/TG PLHIV

A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2023-24
Schools with operational Adolescent Education Program (AEP)	560
2. Colleges with operational Red Ribbon Clubs (RRC)	456
3. Persons trained under mainstreaming	2,343
4. No. of calls received at helpline	-

B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management

Indicator				2023-24
NACO Supported Designated STI/	44			
Designated STI/ RTI Clinics (DSRC)	Male	Female	TG	Total
2. Clients managed				5,61,928
3. RPR Tests conducted at DSRC	64,300	90,666	1,366	1,56,332
4. Syphilis seropositivity (%) at DSRC	1.01	0.70	0.37	0.83

4. Prevention of new HIV infections among highrisk group and bridge population

A. Targeted Interventions (TI) and Opioid Substitution Therapy (OST)

Indicator	2023-24
1. Targeted Interventions	13
2. OST centres (Excluding Satellite OST centres)	2

B. Female Sex Workers	
Indicator	2023-24
1. Estimated size	11,681
2. Coverage (%)	55.98
3. Condoms distributed	11,83,805
4. Tested for HIV (April 2023-September 2023)	4,859
4.1. HIV sero-positive (%)	0.19
4.1.1. Linked to ART	9
5. Tested for HIV (October 2023 -March 2024)	5,104
5.1. HIV sero-positive (%)	0.18
5.1.1. Linked to ART	9
6. Clinic Visits	19,475
7. STI/RTI treated	174
8. Presumptive treatment	785

2023-24
2,376
60
1,90,898
922
0.65
6
1,054
0.28
2
3,862
18
141

D. Injecting drug users	
Indicator	2023-24
1. Estimated size	4,585
2. Coverage (%)	66
3. Needles distributed	13,27,870
4. Syringes distributed	8,21,780
5. On OST	227
6. Tested for HIV (April 2023 -September 2023)	2,798
6.1. HIV sero-positive (%)	0.39
6.1.1 Linked to ART	9
7. Tested for HIV (October 2023 -March 2024)	2,805
7.1. HIV sero-positive (%)	0.32
7.1.1. Linked to ART	11

E. Hijra/Transgender people	
Indicator	2023-24
1. Estimated size	846
2. Coverage (%)	0
3. Condoms distributed	-
4. Tested for HIV (April 2023-September 2023)	0
4.1. HIV sero-positive (%)	-
4.1.1. Linked to ART	-
5. Tested for HIV (October 2023 -March 2024)	0
5.1. HIV sero-positive (%)	-
5.1.1. Put on ART	-
6. Clinic Visits	0
7. STI/RTI treated	0
8. Presumptive treatment	0

F. Migrants	
Indicator	2023-24
1. Estimated size	-
2. Coverage (%)	-
3. Tested for HIV	-
3.1. HIV sero-positive (%)	-
3.2. Linked to ART	-

G. Truckers	
Indicator	2023-24
1. Estimated size	15,000
2. Coverage (%)	67
3. Tested for HIV	2,176
3.1. HIV sero-positive (%)	0.60
3.2. On ART	13

H. Prison Inmates	
Indicator	2023-24
1. Total prisons	59
2. Prisons covered under programme	59
3. Total inmates admitted	3,38,024
4. Inmates Covered (%)	47
5. Tested for HIV	1,57,697
5.1. HIV sero-positive (%)	0.42
5.2. On ART (%)	59.82

I. Link Worker Scheme	
Indicator	2023-24
1. Districts covered under scheme	3
Vulnerable population covered	2,05,605
3. Tested for HIV	48,677
3.1. HIV sero-positive (%)	0.10
3.2. Linked to ART (%)	102.04

1,176

J. Opioid Substitution Therapy	
Indicator	2023-24
1. OST Centres	2
1.1. OSTC in Public Health Settings	2
1.2. OSTC in NGO Settings	-
1.3. No. of Satellite OST Centres	-
2. IDU on OST	227

5. Early detection of HIV infected people

A. HIV counselling and testing services (HCTS)

, a rin to dialogning and teoding services (11010)		
Indicator	2023-24	
1. HCTC confirmatory facilities	197	
2. Sampoorna Suraksha Kendras	8	

2022 24

B. HIV testing among vulnerable population (excluding pregnant women)

Indicator		202	3-24	
	Male	Female	TG	Total
1. Tested for HIV	8,31,565	7,15,225	7,770	15,54,560
1.1 HIV Positives	6,078	3,211	70	9,359
1.2 HIV sero -positivity (%)	0.73	0.45	0.90	0.60
Spouse/sexual partner of HIV positive people tested	3,516	2,863	34	6,413
2.1 HIV Positives	1,753	1,526	9	3,288
2.2 HIV sero -positivity (%)	50	53	26	51.27
No. of contacts with 'at- risk' population through 'Sampoorna Suraksha'	-	-	-	5,205

6. Initiation and retention on ART of HIV infected people

A. Treatment facilities

Indicator

Indicator	2023-24
1. ART Centres	29
2.Centre of Excellence	
2.1. Centre of Excellence (Adult)	-
2.2 Centre of Excellent (Paediatric)	-
3. Link ART Centres	6
4. Care Support Centres	15

B. Treatment uptake

Indicator	2023-24				
	Male	Female	TG	Total	
HIV positive cases diagnosed (At ICTC)	6,078	3,852	70	10,000	
New PLHIV Registered at ART center	6,098	3,891	41	10,030	
2.1 Initiated on ART	5,908	3,826	37	9,771	
3. PLHIV alive and on ART	47,037	39,365	142	86,544	
4. 12 months retention on ART (%)				93.3	
5. Lost to follow-up cases	2,951	1,927	16	4,894	

7. Viral Suppression and laboratories	
A. Laboratory facilities and service uptake	0000
Indicator	2023-2
Viral load laboratories (programme and non- programme labs)	
1.1 Accredited Viral load laboratories (out of 64 VL labs)	
2. Viral load tests conducted	26,00
2.1. Virally suppressed (%)	94
3. National reference laboratories (NRL)	
3.1 Accredited NRL	
4. State reference laboratories (SRL)	
4.1 Accredited SRL	
5. CD4 machines	1
5.1 CD4 tests conducted	14,92
6. External Quality Assurance of ICTC	
6.1 Average Participation (%)	3
6.2. Average Discordance (%)	0.0
7. "Certificate of Excellence" by NACO	
7.1 No. of ICTCs received "Certificate of Excellence"	
8. Elimination of mother to child transi HIV & Syphilis	mission of
A. HIV	
Indicator	2023-2
1. Estimated pregnant women (PW)	35,30,14
2. HIV testing among PW	25,34,07

A. IIIV	
Indicator	2023-24
1. Estimated pregnant women (PW)	35,30,140
2. HIV testing among PW	25,34,071
3. HIV sero-positivity (%) among tested	0.03

985 4.1 On life-long ART 1,208 5. Live births among HIV positive PW >=95 5.1 Babies given ARV Prophylaxis (%) 6. Babies tested HIV (6 week- 6 month) 1,109

4. HIV Positive PW (old + new detections)

6.1 Babies confirmed HIV Positive (6 week- 6 month) 7. HIV testing among exposed babies at 18 months 7.1 HIV exposed babies tested at 18 months 630 7.2 Babies confirmed HIV positive at 18 months 13 21 8. Total Babies Identified HIV Positive (6 weeks to

upto 18 Months) 21 9. HIV positive babies initiated on ART

B. Syphilis	
Indicator	2023-24
1. Syphilis testing among PW	8,90,803
2.Sero-positivity (%) among tested	0.01
3. Put on treatment	101

9. Elimination of HIV/AIDS related Stigma and Discrimination

Indicator	2023-24
1. State rules notified for HIV/AIDS Prevention and Control Act (2017)	Yes
2. State designated/appointed ombudsman	Yes

10. HIV-TB Co-m	orbidities							
A. HRG and Bridge Population								
Indicator	ndicator 2023-24							
	Quarter	FSW	MSM	IDU	TG	Migrants	Truckers	Total
	Quarter 1	4,327	915	2,542	-	-	1,826	9,610
Screened for TB	Quarter 2	4,922	1,021	2,701	-	-	2,334	10,978
Screened for TB	Quarter 3	5,127	1,030	2,645	-	-	2,402	11,204
	Quarter 4	5,022	1,226	2,759	-	-	2,562	11,569
	Quarter 1	37	8	27	-	-	-	72
Tested for TB	Quarter 2	50	15	156	-	-	-	221
rested for 16	Quarter 3	42	11	131	-	-	1	185
	Quarter 4	52	16	228	-	-	1	297
	Quarter 1	1	-	2	-	-	-	3
Diagrapas duvith TD	Quarter 2	5	-	2	-	-	-	7
Diagnosed with TB	Quarter 3	1	-	1	-	-	-	2
	Quarter 4	3	-	1	-	-	-	4
	Quarter 1	1	-	2	-	-	-	3
Initiated on TB	Quarter 2	5	-	2	-	-	-	7
treatment	Quarter 3	1	-	1	-	-	-	2
	Quarter 4	3	-	-	-	-	-	3

B. HIV-TB Coinfected at ART Centre Indicator 2023-24 Co-infected enrolled at PLHIV with presumptive TB PLHIV PLHIV PLHIV PLHIV Co-infected initiated on ART PLHIV tested for TB diagnosed with TB initiated on IPT Moths attending underwent ART Centre 4S screening ARTC 43,926 42,599 1,038 293 Apr - 23 616 135 135 44,753 43,301 1,064 657 356 May - 23 Jun - 23 46,123 44,529 940 596 123 367 1,129 Jul - 23 45,305 44,476 621 136 205 45,116 44,434 986 563 121 279 Aug - 23 Sep - 23 49,955 48,988 969 567 106 303 50,587 49,645 959 503 101 248 Oct - 23 95 54,773 52,290 647 402 283 Nov - 23 Dec - 23 64,591 61,701 824 495 94 252 Jan - 24 58,927 583 479 98 61,726 86 Feb - 24 59,489 57,267 796 675 110 391 Mar - 24 60,562 57,884 852 736 105 219 April 2023-1,588 1,381 March 2024

		State/UT	Bihar
	1	Rank	33
SI. No.	Maximum Mark		177
	Obtained Marks		113 (64%)
2		%, Y: 80-94%, R:<80%) .95%, Y: 80-94%, R:<80%)	92
3		5%, Y: 80-94%, R:<80%)	>=95
4		ency of Social Media updates (G: ≥ 45, Y:40- 44, R:<40 indigenous posts) of	228
	Q1, Q2, Q3 & C	· · · · · · · · · · · · · · · · · · ·	
5	Status of AEP in	ntegration in state school curriculum (G:Yes, R:No)	Yes
6	Status of SCA (0	G: At least one meeting held since 2020, R: other than G)	No Meeting held
7		Rules (G: Notified, R: Not notified)	Notified
8		ldsman (G: Appointed, R: Not appointed) ding (G: ≥95%, Y: 90-<95%, R:<90%)	Appointed
10		g (G: ≥95%, Y: 90-<95%, R:<90%)	43 100
11		RG against estimates (G: ≥90%, Y: 80-<90%, R:<80%)	54
12	-	ong HRG (G: ≥95%, Y: 90-<95%, R:<90%)	96
13		ong prisoners (G: ≥50%, Y: 40% to <50%, R:<40%)	48
14	Clinic visit of HF	RGs at TI-Clinics (G: ≥90%, Y: 75-89%, R:<75%)	94
15	Percentage of H	HRGs screened for Syphilis (G: ≥90%, Y: 75-89%, R:<75%)	91
16		≥50%, Y: 30% to <50%, R:<30%)	15
17		und released to TI (G: ≥50%, Y: 45-<50%, R:<45%)	49
18	_	Ts trained by Kshmata Kendra (KK) against the AAP targets (G: ≥75%, Y: 70-	92
19	<75%, R:<70%)	inst Target-at risk % (G: ≥95%, Y: 80-94%, R:<80%)	213
20		inst Target-at risk % (G: ≥95%, Y: 80-94%, K:<80%) inst target-PW (G: ≥95%, Y: 80-94%, R:<80%)	72
21		pregnant women screened for Syphilis (G: ≥95%, Y: 80-94%, R:<80%)	25
22		ided to Syphilis reactive pregnant women (G: ≥95%, Y: 80-94%, R:<80%)	89
23		mong newly detected HIV positive clients (G: ≥75%, Y: 80-94%, R:<80%)	36
24	_	weeks - <2 months EID testing against live birth (G: ≥95%, Y: 80-94%,	99
	R:<80%)		
25	Clients manage	d at DSRC against the target (G: ≥90%, Y: 75-89%, R:<75%)	77
26	STI attendees s	creened for HIV (G: >75%, Y: 50-75%, R:<50%)	46
27		creened for Syphilis (G: >75%, Y: 50-75%, R:<50%)	32
28 29		women who initiated ART (G: ≥95%, Y: 80-94%, R:<80%)	1
	R:>5%)	FU-PLHIV, out of those initiated on ART in FY 2023-24 (G:<2%, Y: 2 to 5%,	
30	Proportion of Pl to 98%, R:<95%	LHIV initiated on ART, out of those registered in FY 2023-24 (G:>98%, Y: 95 6)	97
31	Proportion of re R:>5 %)	eported died, out of those initiated on ART in FY 202324 (G:<2%, Y: 2 to 5 %,	5
32	% of SRL accred	dited (G:100%, Y: 80-99%, R:<80%)	0
33	% participation	of ICTCs in re-testing (G: ≥95%, Y: 85-94, R:<85%)	35
34	Number of abst R: ≤25%)	tracts selected from studies conducted in FY21-22 (G:100%, Y: >25 to <100%	0
35	_	oing studies from FY22-23 (G:100%, Y: >25 to <100%,	0
36	R: ≤25%) Submission of r	esearch proposals from FY23-24 to NACO (G:100%,	2
30	Y: >25 to <100°		
37	Secondary Data	Analysis by SACS (G:2, Y: 1, R: No Secondary Data Analysis Plan Submitted)	0
38	Expenditure wit	th respect to funds released during FY 2022-23 (G:	76
		<90%, R: <85%)	
39	30-Apr-2023, Y	Provisional Utilization Certificate (UC) in GFR 12A for the FY 2022-23 (G : by : by 31-May-2023, R : after	26-05-2023
40		nudited UC in GFR 12A for the FY 2022-23 (G : by 30Jun-2023, Y : by 30-Sep-	25-01-2024
	2023, R : after 3	· · · · · · · · · · · · · · · · · · ·	
41		EC/ GB ratification for approval of Expenditure incurred during FY 2021-22 (G g, Y: by 30-Sept-2022, R: after 30-Sept-2022)	10-11-2023
42	-	ion of CST-SCM Report (G:>95%, Y: 80-95%, R:<80%)	96
43	_	nce to CST-SCM Report (G:>95%, Y: 80-95%, R:<80%)	93
44	Timely Submiss	ion of BSD & STI-SCM Report (G: ≥90%, Y: 75- '5%)	75
	Green=3 Marks		Colour=Not Applicable
Weig		Indicator SI. No.	
	3	1, 23, 29	
	2	2, 3, 9, 10, 22, 30, 34, 42, 44	
	1	4, 5, 6, 7, 8, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 24, 25, 26, 27, 28, 31, 3	2, 33, 35, 36, 37, 38, 39, 40, 41,
	1	43	





CHANDIGARH

1. Status of HIV/AIDS Epidemic					
A. Epidemic Estimates (2023)					
Indicator	Male	Female	Total		
1. IPR	-	-	3.12		
2. IMR	-	-	2.45		
3. Adult (15-49 yrs) HIV Prevalence (%)	0.32	0.19	0.26		
4. Estimated people living with HIV	1,726	870	2,596		
5. ART coverage (%)	211.71	221.74	216.15		
6. Estimated children living with HIV	26	23	49		
7. Annual new HIV infections	56	26	82		
8. Annual AIDS-related deaths (ARD)	11	6	17		
9. Change in annual new HIV infections since 2010 (%)	-52.94	-51.85	-53.18		
10. Change in annual ARD since 2010(%)	-52.17	-45.45	-50.00		
11. EMTCT need	-	17	17		

B. High risk population size (2020-22), safe practices (2021) and prevalence (2021/2023) Condom Use New Needle/ **HIV Prevalence** Estimates Size Population Group (%) Syringe use (%) (%) 90.50 1. Female Sex Workers 75.80 0.80 3,333 90.30 2. Men who have sex with men 2,569 1.61 3. Injecting Drug Users 1,908 95.20 2.80 4. Hijra/Transgender People 164 5. Migrants 25,000 68.90 0.40 6. Truckers 15,330

3,223

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)				
Indicator	Male	Female	Total	
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)	54.10	20.30	-	
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	43.20	21.00	-	
3. Adults willing to care for a relative with HIV/AIDS in own home (%)	88.40	65.80	-	
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	76.00	48.40	-	
5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)	1.80	0.00	-	
5.1 Condom use during last higher-risk intercourse (%)	46.50	NA	-	
6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)	5.00	0.00	-	
6.1 Condom use during last higher-risk intercourse (%)	50.00	NA	-	

2. Progress on 95-95-95 (2023-24) 295 295 295 295 295 295 B1 88 88 88 82 85 89 PLHIV who know their HIV status (%) HIV status and are on ART and virially suppressed ART (%) 2018-19 2018-19 2019-20 2020-21 2021-22 2022-23 2023-24

7. Prison inmates

Indicators	Male	Female	Total*
1. Estimated PLHIV size (2023)	1,726	870	2,596
2. PLHIV who know their HIV Status	3,837	1,911	5,780
3. PLHIV who know their HIV status and are on ART	3,341	1,753	5,120
4. PLHIV who are on ART and tested for their viral load	1,454	759	2,217
4.1 PLHIV who are virally suppressed	1,425	743	2,172

77.80

89.70

3.25

^{*} Including of H/TG PLHIV

A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2023-24
Schools with operational Adolescent Education Program (AEP)	150
2. Colleges with operational Red Ribbon Clubs (RRC)	25
3. Persons trained under mainstreaming	4,526
4. No. of calls received at helpline	-

B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management

Indicator	2023-24				
NACO Supported Designated STI/					
RTI Clinics (DSRC)	Male	Female	TG	Total	
2. Total STI/RTI Clients managed				28,090	
3. RPR Tests conducted	2,074	7,503	1	9,578	
4. Syphilis seropositivity (%)	9.40	0.81	100.00	2.68	

4. Prevention of new HIV infections among high-risk group and bridge population

A. Targeted Intervention (TI) Projects and Opioid Substitution Therapy (OST)

Indicator	2023-24
1. Targeted Intervention (TI) Projects	12
2. OST centres (Excluding Satellite OST centres)	4

B. Female Sex Workers

Indicator	2023-24
1. Estimated size	3,333
2. Coverage (%)	>=95
3. Condoms distributed	11,76,982
4. Tested for HIV (April 2022-September 2022)	3,113
4.1. HIV sero-positive (%)	0.10
4.1.1. Linked to ART	3
5. Tested for HIV (October 2022 -March 2023)	3,047
5.1. HIV sero-positive (%)	0.23
5.1.1. Linked to ART	7
6. Clinic Visits	12,343
7. STI/RTI treated	147
8. Presumptive treatment	530

C. Men who have Sex with Men

C. Well wild have Sex with Men				
Indicatort	2023-24			
1. Estimated size	2,569			
2. Coverage (%)	>=95			
3. Condoms distributed	7,16,838			
4. Tested for HIV (April 2022-September 2022)	2,311			
4.1. HIV sero-positive (%)	0.35			
4.1.1. Linked to ART	7			
5. Tested for HIV (October 2022 -March 2023)	2,523			
5.1. HIV sero-positive (%)	0.55			
5.1.1. Linked to ART	13			
6. Clinic Visits	9,592			
7. STI/RTI treated	60			
8. Presumptive treatment	696			

D. Injecting Drug Users	
Indicator	2023-24
1. Estimated size	1,908
2. Coverage (%)	>=95
3. Needles distributed	7,00,586
4. Syringes distributed	4,04,144
5. On OST	909
6. Tested for HIV (April 2022 -September 2022)	1,757
6.1. HIV sero-positive (%)	0.06
6.1.1 Linked to ART	1
7. Tested for HIV (October 2022 -March 2023)	2,137
7.1. HIV sero-positive (%)	0.14
7.1.1. Linked to ART	2

E. Hijra/Transgender person	
Indicator	2023-24
1. Estimated size	164
2. Coverage (%)	>=95
3. Condoms distributed	55,575
4. Tested for HIV (April 2022-September 2022)	148
4.1. HIV sero-positive (%)	0.00
4.1.1. Linked to ART	0
5. Tested for HIV (October 2022 -March 2023)	165
5.1. HIV sero-positive (%)	0.00
5.1.1. Linked to ART	0
6. Clinic Visits	625
7. STI/RTI treated	2
8. Presumptive treatment	36

F. Migrants	
Indicator	2023-24
1. Estimated size	25,000
2. Coverage (%)	>=95
3. Tested for HIV	8,737
3.1. HIV sero-positive (%)	0.06
3.2. Linked to ART	5

G. Truckers	
Indicator	2023-24
1. Estimated size	15,330
2. Coverage (%)	65
3. Tested for HIV	3,418
3.1. HIV sero-positive (%)	0.09
3.2. On ART	2

H. Prison Inmates	
Indicator	2023-24
1. Total prisons	1
2. Prisons covered under programme	1
3. Total inmates admitted	3,223
4. Inmates Covered (%)	64
5. Tested for HIV	2,073
5.1. HIV sero-positive (%)	0.48
5.2. On ART (%)	50.00

I. Link Worker Scheme	
Indicator	2023-24
Districts covered under scheme	-
Vulnerable population covered	-
3. Tested for HIV	-
3.1. HIV sero-positive (%)	-
3.2. Linked to ART (%)	-

J. Opioid Substitution Therapy	
Indicator	2023-24
1. OST Centres	4
1.1. OSTC in Public Health Settings	-
1.2. OSTC in NGO Settings	4
1.3. No. of Satellite OST Centres	-
2. IDU on OST	909

5. Early detection of HIV infected people

A. HIV counselling and testing services (HCTS)

70 THY Counselling and testing services (The	3.3,
Indicator	2023-24
1. HCTC confirmatory facilities	14
2. Sampoorna Suraksha Kendras	1

B. HIV testing among vulnerable population (excluding pregnant women)

Indicator	2023-24			
	Male	Female	TG	Total
1. Tested for HIV	56,098	39,513	266	95,877
1.1 HIV Positives	601	141	1	743
1.2 HIV sero -positivity (%)	1.07	0.36	0.38	0.77
Spouse/sexual partner of HIV positive people tested	71	213	-	284
2.1 HIV Positives	39	55	-	94
2.2 HIV sero -positivity (%)	55	26	-	33.10
No. of contacts with 'at- risk' population through 'Sampoorna Suraksha'	-	-	-	378

6. Initiation and retention on ART of HIV infected people

A. Treatment facilities

Indicator	2023-24
1. ART Centres	2
2.Centre of Excellence	
2.1. Centre of Excellence (Adult)	1
2.2 Centre of Excellent (Paediatric)	-
3. Link ART Centres	3
4. Care Support Centres	1

B. Treatment uptake

Indicator	2023-24			
	Male	Female	TG	Total
HIV positive cases diagnosed (At ICTC)	601	161	1	763
New PLHIV Registered at ART center	431	125	6	562
2.1 Initiated on ART	371	114	5	490
3. PLHIV alive and on ART	3,341	1,753	26	5,120
4. 12 months retention on ART (%)				>=95
5. Lost to follow-up cases	302	79	3	384

7. Viral Suppression and laboratories	
A. Laboratory facilities and service uptake	
Indicator	2023-2
Viral load laboratories (programme and non- programme labs)	
1.1 Accredited Viral load laboratories (out of 64 VL labs)	
2. Viral load tests conducted	5,79
2.1. Virally suppressed (%)	94.
3. National reference laboratories (NRL)	
3.1 Accredited NRL	
4. State reference laboratories (SRL)	
4.1 Accredited SRL	
5. CD4 machines	
5.1 CD4 tests conducted	4,98
6. External Quality Assurance of ICTC	
6.1 Average Participation (%)	>=9
6.2. Average Discordance (%)	0.0
7. "Certificate of Excellence" by NACO	
7.1 No. of ICTCs received "Certificate of Excellence"	
8. Elimination of mother to child trans HIV & Syphilis	mission of
A. HIV	
Indicator	2023-2
1. Estimated pregnant women (PW)	18,19
2. HIV testing among PW	18,20
3. HIV sero-positivity (%) among tested	0.1
4. HIV Positive PW (old + new detections)	5
4.1 On life-long ART	5
5. Live births among HIV positive PW	3
5.1 Babies given ARV Prophylaxis (%)	>=9
6. Babies tested HIV (6 week- 6 month)	2
6.1 Babies confirmed HIV Positive (6 week- 6 month)	
7. HIV testing among exposed babies at 18 months	
7.1 HIV exposed babies tested at 18 months	4
7.2 Babies confirmed HIV positive at 18 months	
8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months)	
9. HIV positive babies initiated on ART	
B. Syphilis	
Indicator	2023-2
1. Syphilis testing among PW	16,64
2.Sero-positivity (%) among tested	0.1
3. Put on treatment	2
9. Elimination of HIV/AIDS related Stigma and Discrimination	
Indicator	2023-2
State rules notified for HIV/AIDS Prevention and Control Act (2017)	Ye
2. State designated/appointed ombudsman	Ye
<u> </u>	

10. HIV-TB Co-morbidities A. HRG and Bridge Population Indicator 2023-24 Quarter FSW MSM IDU TG Migrants Truckers Total 2,687 Quarter 1 2,881 2,135 1,844 141 2,472 12,160 Quarter 2 3,121 2,403 1,922 153 2,788 2,548 12,935 Screened for TB Quarter 3 3,146 2,484 2,069 162 2,970 2,479 13,310 2,563 Quarter 4 3,098 2,167 169 2,769 2,566 13,332 Quarter 1 3 13 15 18 2 10 5 30 Quarter 2 13 Tested for TB Quarter 3 3 12 3 17 35 Quarter 4 5 12 11 10 38 1 Quarter 1 1 2 2 Quarter 2 Diagnosed with TB Quarter 3 1 2 Quarter 4 1 1 Quarter 1 1 1 2 2 Quarter 2 Initiated on TB treatment Quarter 3 1 1 2 Quarter 4 1

B. HIV-TB Coinfected at ART Centre Indicator 2023-24 Co-infected initiated on PLHIV PLHIV PLHIV with PLHIV **PLHIV** Co-infected PLHIV tested for TB presumptive TB diagnosed with TB Moths initiated on enrolled at attending underwent ART Centre 4S screening IPT ARTC ART Apr - 23 2,214 2,214 32 25 19 2,416 10 40 37 31 May - 23 2,416 Jun - 23 2,487 2,487 30 26 5 66 Jul - 23 2,500 2,500 28 26 5 16 2,603 30 19 5 31 Aug - 23 2,603 Sep - 23 2,919 2,919 32 23 5 38 Oct - 23 2,689 2,689 29 10 4 41 7 19 2,980 39 Nov - 23 2,980 15 Dec - 23 3,742 3,742 17 12 4 52 5 Jan - 24 2.900 2.900 31 25 34 9 Feb - 24 2,659 2,659 36 18 46 Mar - 24 2,702 2,702 33 22 13 43 April 2023-153 137 March 2024

		State/UT	Chandigarh
	T	Rank	1
SI.	Maximum Ma	****	177
No.	Obtained Ma		149 (84%)
1		75%, Y: 80-94%, R:<80%)	>=95
2		:≥95%, Y: 80-94%, R:<80%)	89
3		95%, Y: 80-94%, R:<80%)	>=95
4	Average Freq Q1, Q2, Q3 8	quency of Social Media updates (G: \geq 45, Y:40- 44, R:<40 indigenous posts) & Q4	of 19
5	Status of AEP	integration in state school curriculum (G:Yes, R:No)	Yes
6	Status of SCA	(G: At least one meeting held since 2020, R: other than G)	Meeting held in 2023
7	Status of State	e Rules (G: Notified, R: Not notified)	Notified
8	Status of Oml	budsman (G: Appointed, R: Not appointed)	Appointed
9	TI/LWS onbox	arding (G: ≥95%, Y: 90-<95%, R:<90%)	100
10	OST onboard	ling (G: ≥95%, Y: 90-<95%, R:<90%)	100
11	Coverage of I	HRG against estimates (G: ≥90%, Y: 80-<90%, R:<80%)	140
12	HIV testing ar	mong HRG (G: ≥95%, Y: 90-<95%, R:<90%)	104
3	HIV testing ar	mong prisoners (G: ≥50%, Y: 40% to <50%, R:<40%)	78
4	Clinic visit of	HRGs at TI-Clinics (G: ≥90%, Y: 75-89%, R:<75%)	97
5	Percentage o	f HRGs screened for Syphilis (G: ≥90%, Y: 75-89%, R:<75%)	99
6	IDU on OST (G: ≥50%, Y: 30% to <50%, R:<30%)	84
7		f fund released to TI (G: ≥50%, Y: 45-<50%, R:<45%)	104
8		f TIs trained by Kshmata Kendra (KK) against the AAP targets (G: ≥75%, Y: 7	0- 100
9		gainst Target-at risk % (G: ≥95%, Y: 80-94%, R:<80%)	90
0		gainst target-RW (G: ≥95%, Y: 80-94%, R:<80%)	115
1		f pregnant women screened for Syphilis (G: ≥95%, Y: 80-94%, R:<80%)	106
2		ovided to Syphilis reactive pregnant women (G: ≥95%, Y: 80-94%, R:<80%)	100
4	Percentage o	among newly detected HIV positive clients (G: ≥95%, Y: 80-94%, R:<80%) f 6 weeks - <2 months EID testing against live birth (G: ≥95%, Y: 80-94%,	25 86
5	R:<80%)		108
		ged at DSRC against the target (G: ≥90%, Y: 75-89%, R:<75%)	
6		s screened for HIV (G: >75%, Y: 50-75%, R:<50%)	98
7		s screened for Syphilis (G: >75%, Y: 50-75%, R:<50%)	100
8 9	Proportion of	t women who initiated ART (G: ≥95%, Y: 80-94%, R:<80%) LFU-PLHIV, out of those initiated on ART in FY 2023-24 (G:<2%, Y: 2 to 5%,	96
	R:>5%)		
0	to 98%, R:<9!	PLHIV initiated on ART, out of those registered in FY 2023-24 (G:>98%, Y: 9 5%)	P5 87
1	Proportion of R:>5 %)	reported died, out of those initiated on ART in FY 202324 (G:<2%, Y: 2 to 5	6%,
2	% of SRL accr	redited (G:100%, Y: 80-99%, R:<80%)	100
3	% participation	on of ICTCs in re-testing (G: ≥95%, Y: 85-94, R:<85%)	100
4		ostracts selected from studies conducted in FY21-22 •25 to <100%, R: ≤25%)	3
5	ļ	ngoing studies from FY22-23 (G:100%, Y: >25 to <100%,	4
	R: ≤25%)		
6	Y: >25 to <10	f research proposals from FY23-24 to NACO (G:100%,)0%, R: ≤25%)	2
7	Secondary Da	ata Analysis by SACS (G:2, Y: 1, R: No Secondary Data Analysis Plan Submitt	ed) 2
8		with respect to funds released during FY 2022-23 (G: to <90%, R: <85%)	104
9	Submission o	f Provisional Utilization Certificate (UC) in GFR 12A for the FY 2022-23 (G : b Y : by 31-May-2023, R : after	y 22-05-2023
Ю	Submission o	, f audited UC in GFR 12A for the FY 2022-23 (G : by 30Jun-2023, Y : by 30-S r 30-Sep-2023)	ep- 06-11-2023
1	Submission o	FEC/ GB ratification for approval of Expenditure incurred during FY 2021-22 22, Y: by 30-Sept-2022, R: after 30-Sept-2022)	? (G: 27-07-2023
2		ission of CST-SCM Report (G:>95%, Y: 80-95%, R:<80%)	96
3	-	rence to CST-SCM Report (G:>95%, Y: 80-95%, R:<80%)	96
.4		ission of BSD & STI-SCM Report (G: ≥90%, Y: 75-	100
	Green=3 Mark		No Colour=Not Applicable
۸/-:		Indicator SI. No.	140 Coloui – 140t Applicable
veić	ght points		
	3	1, 23, 29	
	2	2, 3, 9, 10, 22, 30, 34, 42, 44	
		4, 5, 6, 7, 8, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 24, 25, 26, 27, 28, 3	1, 32, 33, 35, 36, 37, 38, 39, 40



CHHATTISGARH

1. Status of HIV/AIDS Epidemic			
A. Epidemic Estimates (2023)			
Indicator	Male	Female	Total
1. IPR	-	-	3.12
2. IMR	-	-	0.93
3. Adult (15-49 yrs) HIV Prevalence (%)	0.17	0.16	0.16
4. Estimated people living with HIV	21,330	18,840	40,170
5. ART coverage (%)	54.65	50.48	53.08
6. Estimated children living with HIV	859	816	1,675
7. Annual new HIV infections	627	625	1,252
8. Annual AIDS-related deaths (ARD)	468	516	984
9. Change in annual new HIV infections since 2010 (%)	-62.94	-58.42	-60.81
10. Change in annual ARD since 2010(%)	-69.96	-59.14	-65.12
11. EMTCT need	-	430	430

B. High risk population size (2020-22), safe practices (2021) and prevalence (2021/2023)				
Population Group	Estimates Size	Condom Use (%)	New Needle/ Syringe use (%)	HIV Prevalence (%)
1. Female Sex Workers	18,375	93.30	-	1.92
2. Men who have sex with men	2,889	87.50	-	4.01
3. Injecting Drug Users	3,923	-	98.80	7.20
4. Hijra/Transgender People	1,118	-	-	6.00
5. Migrants	2,31,000	76.40	-	1.20
6. Truckers	62,000	48.90	57.10	2.00
7. Prison inmates	71,148	48.30	82.60	1.07

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)				
Indicator	Male	Female	Total	
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)	30.70	23.00	-	
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	29.90	22.00	-	
3. Adults willing to care for a relative with HIV/AIDS in own home (%)	77.70	79.40	-	
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	74.50	72.40	-	
5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)	5.00	0.50	-	
5.1 Condom use during last higher-risk intercourse (%)	56.00	21.20	-	
6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)	9.08	0.40	-	
6.1 Condom use during last higher-risk intercourse (%)	54.84	16.67	-	

2. Progress on 95-95-95 (2023-24) PLHIV who know their HIV status (%) PLHIV who know their HIV status (%) PLHIV who know their HIV status and are on ART (%) 2022-23 2023-24

Indicators	Male	Female	Total*
1. Estimated PLHIV size (2023)	21,330	18,840	40,170
2. PLHIV who know their HIV Status	15,311	11,806	27,289
3. PLHIV who know their HIV status and are on ART	11,747	9,586	21,488
4. PLHIV who are on ART and tested for their viral load	954	784	1,750
4.1 PLHIV who are virally suppressed	886	752	1,649

^{*} Including of H/TG PLHIV

A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2023-24
Schools with operational Adolescent Education Program (AEP)	436
2. Colleges with operational Red Ribbon Clubs (RRC)	225
3. Persons trained under mainstreaming	5,812
4. No. of calls received at helpline	-

B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management

Indicator	2023-24			
NACO Supported Designated STI/	31			
RTI Clinics (DSRC)	Male	Female	TG	Total
2. Total STI/RTI Clients managed				2,74,590
3. RPR Tests conducted	62,217	89,239	993	1,52,449
4. Syphilis seropositivity (%)	0.77	0.30	2.72	0.51

4. Prevention of new HIV infections among high-risk group and bridge population

A. Targeted Intervention (TI) Projects and Opioid Substitution Therapy (OST)

Indicator	2023-24
1. Targeted Intervention (TI) Projects	44
2. OST centres (Excluding Satellite OST centres)	6

B. Female Sex Workers

Indicator	2023-24
1. Estimated size	18,375
2. Coverage (%)	>=95
3. Condoms distributed	52,59,850
4. Tested for HIV (April 2022-September 2022)	16,563
4.1. HIV sero-positive (%)	0.00
4.1.1. Linked to ART	21
5. Tested for HIV (October 2022 -March 2023)	21,106
5.1. HIV sero-positive (%)	0.00
5.1.1. Linked to ART	51
6. Clinic Visits	72,722
7. STI/RTI treated	2,649
8. Presumptive treatment	4,763

C. Men who have Sex with Men

or men une nave out man men	
Indicatort	2023-24
1. Estimated size	2,888
2. Coverage (%)	>=95
3. Condoms distributed	11,21,767
4. Tested for HIV (April 2022-September 2022)	3,000
4.1. HIV sero-positive (%)	0.00
4.1.1. Linked to ART	30
5. Tested for HIV (October 2022 -March 2023)	4,254
5.1. HIV sero-positive (%)	0.00
5.1.1. Linked to ART	27
6. Clinic Visits	14,363
7. STI/RTI treated	420
8. Presumptive treatment	1,081

D. Injecting Drug Users	
Indicator	2023-24
1. Estimated size	3,922
2. Coverage (%)	>=95
3. Needles distributed	6,99,871
4. Syringes distributed	6,26,853
5. On OST	1,218
6. Tested for HIV (April 2022 -September 2022)	3,129
6.1. HIV sero-positive (%)	0.00
6.1.1 Linked to ART	1
7. Tested for HIV (October 2022 -March 2023)	3,971
7.1. HIV sero-positive (%)	0.00
7.1.1. Linked to ART	5

E. Hijra/Transgender person	
Indicator	2023-24
1. Estimated size	1,118
2. Coverage (%)	>=95
3. Condoms distributed	4,00,562
4. Tested for HIV (April 2022-September 2022)	903
4.1. HIV sero-positive (%)	-
4.1.1. Linked to ART	3
5. Tested for HIV (October 2022 -March 2023)	1,155
5.1. HIV sero-positive (%)	-
5.1.1. Linked to ART	4
6. Clinic Visits	4,343
7. STI/RTI treated	169
8. Presumptive treatment	173

F. Migrants	
Indicator	2023-24
1. Estimated size	2,31,000
2. Coverage (%)	>=95
3. Tested for HIV	44,166
3.1. HIV sero-positive (%)	0.07
3.2. Linked to ART	24

G. Truckers	
Indicator	2023-24
1. Estimated size	62,000
2. Coverage (%)	>=95
3. Tested for HIV	35,220
3.1. HIV sero-positive (%)	0.09
3.2. On ART	20

H. Prison Inmates	
Indicator	2023-24
1. Total prisons	33
2. Prisons covered under programme	33
3. Total inmates admitted	71,148
4. Inmates Covered (%)	45
5. Tested for HIV	32,305
5.1. HIV sero-positive (%)	0.12
5.2. On ART (%)	90.00

I. Link Worker Scheme	
Indicator	2023-24
Districts covered under scheme	6
Vulnerable population covered	1,24,245
3. Tested for HIV	89,201
3.1. HIV sero-positive (%)	0.16
3.2. Linked to ART (%)	>=95

J. Opioid Substitution Therapy	
Indicator	2023-24
1. OST Centres	6
1.1. OSTC in Public Health Settings	6
1.2. OSTC in NGO Settings	-
1.3. No. of Satellite OST Centres	-
2. IDU on OST	1,218

5. Early detection of HIV infected people

A. HIV counselling and testing services (HCTS)

The first country and cooming continues (,
Indicator	2023-24
1. HCTC confirmatory facilities	143
2. Sampoorna Suraksha Kendras	-

B. HIV testing among vulnerable population (excluding pregnant women)

Indicator	2023-24			
	Male	Female	TG	Total
1. Tested for HIV	3,02,681	3,00,936	1,778	6,05,395
1.1 HIV Positives	1,865	949	40	2,854
1.2 HIV sero -positivity (%)	0.62	0.32	2.25	0.47
Spouse/sexual partner of HIV positive people tested	636	899	20	1,555
2.1 HIV Positives	339	367	1	707
2.2 HIV sero -positivity (%)	53	41	5	45.47
No. of contacts with 'at- risk' population through 'Sampoorna Suraksha'	-	-	-	-

6. Initiation and retention on ART of HIV infected people

A. Treatment facilities

Indicator	2023-24
1. ART Centres	8
2.Centre of Excellence	
2.1. Centre of Excellence (Adult)	-
2.2 Centre of Excellent (Paediatric)	-
3. Link ART Centres	17
4. Care Support Centres	3

B. Treatment uptake

Indicator	2023-24			
	Male	Female	TG	Total
HIV positive cases diagnosed (At ICTC)	1,865	1,177	40	3,082
New PLHIV Registered at ART center	1,842	1,154	21	3,017
2.1 Initiated on ART	1,667	1,082	21	2,770
3. PLHIV alive and on ART	11,747	9,586	155	21,488
4. 12 months retention on ART (%)				82.2
5. Lost to follow-up cases	2,753	1,847	16	4,616

7. Viral Suppression and laboratories	
A. Laboratory facilities and service uptake	
Indicator	2023-2
Viral load laboratories (programme and non- programme labs)	
1.1 Accredited Viral load laboratories (out of 64 VL labs)	
2. Viral load tests conducted	16,30
2.1. Virally suppressed (%)	94.
3. National reference laboratories (NRL)	
3.1 Accredited NRL	
4. State reference laboratories (SRL)	
4.1 Accredited SRL	
5. CD4 machines	
5.1 CD4 tests conducted	1,82
6. External Quality Assurance of ICTC	
6.1 Average Participation (%)	7
6.2. Average Discordance (%)	0.0
7. "Certificate of Excellence" by NACO	
7.1 No. of ICTCs received "Certificate of Excellence"	
 Elimination of mother to child trans HIV & Syphilis HIV 	mission ot
Indicator	2023-2
Estimated pregnant women (PW)	7,12,47
2. HIV testing among PW	5,05,62
3. HIV sero-positivity (%) among tested	0.0
4. HIV Positive PW (old + new detections)	42
4.1 On life-long ART	38
5. Live births among HIV positive PW	33
5.1 Babies given ARV Prophylaxis (%)	>=9
6. Babies tested HIV (6 week- 6 month)	30
6.1 Babies confirmed HIV Positive (6 week- 6 month)	
7. HIV testing among exposed babies at 18 months	
7.1 HIV exposed babies tested at 18 months	26
7.2 Babies confirmed HIV positive at 18 months	
8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months)	
9. HIV positive babies initiated on ART	
B. Syphilis	
Indicator	2023-2
1. Syphilis testing among PW	4,12,29
2.Sero-positivity (%) among tested	0.0
3. Put on treatment	20
9. Elimination of HIV/AIDS related Stigma and Discrimination	
Indicator	2023-2
Indicator 1. State rules notified for HIV/AIDS Prevention and Control Act (2017)	2023-2 Ye


2. State designated/appointed ombudsman

Yes

10. HIV-TB Co-me	orbidities							
A. HRG and Bridge Population								
Indicator	Indicator 2023-24							
	Quarter	FSW	MSM	IDU	TG	Migrants	Truckers	Total
	Quarter 1	16,009	3,145	3,075	1,099	20,591	15,881	59,800
C IC TD	Quarter 2	16,861	3,559	3,256	1,135	15,832	16,131	56,774
Screened for TB	Quarter 3	17,891	3,750	3,510	1,187	16,778	17,111	60,227
	Quarter 4	20,021	4,513	3,736	1,312	26,388	23,485	79,455
	Quarter 1	195	37	12	21	127	74	466
T . I(TD	Quarter 2	315	61	65	43	51	62	597
Tested for TB	Quarter 3	523	78	116	36	147	88	988
	Quarter 4	672	176	114	63	147	77	1,249
	Quarter 1	8	1	3	-	-	-	12
D: 1 ::1 TD	Quarter 2	8	2	-	-	-	-	10
Diagnosed with TB	Quarter 3	12	3	-	-	1	-	16
	Quarter 4	27	1	-	1	1	-	30
	Quarter 1	8	1	3	-	-	-	12
Initiated on TB	Quarter 2	8	2	-	-	-	-	10
treatment	Quarter 3	12	3	-	-	1	-	16
	Quarter 4	27	1	-	1	1	-	30

B. HIV-TB Coinfected at ART Centre Indicator 2023-24 PLHIV with presumptive TB PLHIV PLHIV PLHIV PLHIV Co-infected enrolled at Co-infected initiated on ART PLHIV tested for TB diagnosed with TB initiated on IPT Moths attending underwent ART Centre 4S screening ARTC 10,295 9,536 274 33 Apr - 23 342 41 13 11,816 10,856 356 272 May - 23 Jun - 23 11,442 10,523 330 246 54 6 8,682 Jul - 23 10,364 145 116 16 12,191 10,533 341 259 32 16 Aug - 23 Sep - 23 10,989 9,396 320 220 28 28 11,722 11,299 335 269 30 56 Oct - 23 25 13,007 327 190 6 Nov - 23 11,402 Dec - 23 13,163 11,006 389 317 30 39 Jan - 24 12,709 12,335 472 229 31 31 25 Feb - 24 11,676 11,283 868 725 46 Mar - 24 12,036 11,465 981 854 23 19 April 2023-410 365 March 2024

		State/UT	Chhattisgarh
		Rank	31
SI.	Maximum Ma	rks	177
No.	Obtained Ma	rks	115 (65%)
1		25%, Y: 80-94%, R:<80%)	68
2		:≥95%, Y: 80-94%, R:<80%)	79
3	•	95%, Y: 80-95%, R:<80%)*	94
4		juency of Social Media updates (G: ≥ 45, Y:40- 44, R:<40 indigenous posts) of	66
	Q1, Q2, Q3 8		
5		integration in state school curriculum (G:Yes, R:No)	Yes
6		(G: At least one meeting held since 2020, R: other than G)	Meeting held in 2023
7		e Rules (G: Notified, R: Not notified)	Notified
8		budsman (G: Appointed, R: Not appointed)	Appointed
9		arding (G: ≥95%, Y: 90-<95%, R:<90%)	100
10		ling (G: ≥95%, Y: 90-<95%, R:<90%)	100
11	_	HRG against estimates (G: ≥90%, Y: 80-<90%, R:<80%)	130
12		mong HRG (G: ≥95%, Y: 90-<95%, R:<90%) mong prisoners (G: ≥50%, Y: 40% to <50%, R:<40%)	85
13		39	
14		HRGs at TI-Clinics (G: ≥90%, Y: 75-89%, R:<75%)	84
15		f HRGs screened for Syphilis (G: ≥90%, Y: 75-89%, R:<75%)	80
16		G: ≥50%, Y: 30% to <50%, R:<30%)	56
17		f fund released to TI (G: ≥50%, Y: 45-<50%, R:<45%)	89
18	_	f TIs trained by Kshmata Kendra (KK) against the AAP targets (G: ≥75%, Y: 70-	80
16	<75%, R:<70°		
19		gainst Target-at risk % (G: ≥95%, Y: 80-94%, R:<80%)	191
20		gainst target-PW (G: ≥95%, Y: 80-94%, R:<80%)	71
21		f pregnant women screened for Syphilis (G: ≥95%, Y: 80-94%, R:<80%)	58
22	Treatment pro	ovided to Syphilis reactive pregnant women (G: ≥95%, Y: 80-94%, R:<80%)	97
23	Index testing	among newly detected HIV positive clients (G: ≥95%, Y: 80-94%, R:<80%)	30
24	Percentage o R:<80%)	f 6 weeks - <2 months EID testing against live birth (G: ≥95%, Y: 80-94%,	97
25	Clients manag	ged at DSRC against the target (G: ≥90%, Y: 75-89%, R:<75%)	136
26		s screened for HIV (G: >75%, Y: 50-75%, R:<50%)	34
27		s screened for Syphilis (G: >75%, Y: 50-75%, R:<50%)	75
28		t women who initiated ART (G: ≥95%, Y: 80-94%, R:<80%)	90
29		LFU-PLHIV, out of those initiated on ART in FY 2023-24 (G:<2%, Y: 2 to 5%,	6
30	,	PLHIV initiated on ART, out of those registered in FY 2023-24 (G:>98%, Y: 955%)	92
31		reported died, out of those initiated on ART in FY 202324 (G:<2%, Y: 2 to 5 %	, 5
32		redited (G:100%, Y: 80-99%, R:<80%)	0
33		on of ICTCs in re-testing (G: ≥95%, Y: 85-94, R:<85%)	79
34	· · ·	ostracts selected from studies conducted in FY21-22	0
J-1		≥25 to <100%, R: ≤25%)	
35	Number of or R: ≤25%)	ngoing studies from FY22-23 (G:100%, Y: >25 to <100%,	4
36		f research proposals from FY23-24 to NACO (G:100%,	2
		00%, R: ≤25%)	
37		ata Analysis by SACS (G:2, Y: 1, R: No Secondary Data Analysis Plan Submitted	
38	· ·	with respect to funds released during FY 2022-23 (G:	114
39	Submission o	to <90%, R: <85%) f Provisional Utilization Certificate (UC) in GFR 12A for the FY 2022-23 (G : by Y: by 31-May-2023, R: after	17-05-2023
40	31-May-2023		- 24-04-2024
41		r 30-Sep-2023) f EC/ GB ratification for approval of Expenditure incurred during FY 2021-22 (C	i: 08-12-2022
41	by 30-Jun-20	22, Y: by 30-Sept-2022, R: after 30-Sept-2022)	91
	-	ission of CST-SCM Report (G:>95%, Y: 80-95%, R:<80%)	
44	Timely Submi	rence to CST-SCM Report (G:>95%, Y: 80-95%, R:<80%) ission of BSD & STI-SCM Report (G: ≥90%, Y: 75-	94 83
	<90%, R:<		Color National States
	Green=3 Mark		Colour=Not Applicable
Weig	ght points	Indicator SI. No.	
	3	1, 23, 29	
		2, 3, 9, 10, 22, 30, 34, 42, 44	
	2	<u> </u>	



DADRA AND NAGAR HAVELI AND DAMAN AND DIU

1. Status of HIV/AIDS Epidemic			
A. Epidemic Estimates (2023)			
Indicator	Male	Female	Total
1. IPR	-	-	5.08
2. IMR	-	-	4.94
3. Adult (15-49 yrs) HIV Prevalence (%)	0.19	0.14	0.18
4. Estimated people living with HIV	1,284	468	1,752
5. ART coverage (%)	87.67	127.64	98.34
6. Estimated children living with HIV	17	12	29
7. Annual new HIV infections	66	24	90
8. Annual AIDS-related deaths (ARD)	7	4	11
9. Change in annual new HIV infections since 2010 (%)	88.57	33.33	67.92
10. Change in annual ARD since 2010(%)	-81.58	-80.00	-79.31
11. EMTCT need	_	8	8

B. High risk population size (2020-22), safe practices (2021) and prevalence (2021/2023)						
Population Group	Estimates Size	Condom Use (%)	New Needle/ Syringe use (%)	HIV Prevalence (%)		
1. Female Sex Workers	-	-	-	ı		
2. Men who have sex with men	-	-	-	-		
3. Injecting Drug Users	-	-	-	-		
4. Hijra/Transgender People	-	-	-	-		
5. Migrants	-	-	-	-		
6. Truckers	-	-	-	-		
7. Prison inmates	485	-	-	-		

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)				
Indicator	Male	Female	Total	
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)	28.10	25.30	-	
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	31.10	24.60	-	
3. Adults willing to care for a relative with HIV/AIDS in own home (%)	55.70	82.30	-	
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	77.40	73.50	-	
5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)	7.30	0.00	-	
5.1 Condom use during last higher-risk intercourse (%)	84.00	-	-	
6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)	6.48	0.00	-	
6.1 Condom use during last higher-risk intercourse (%)	100.00	-	-	

2. Progress on 95-95-95 (2023-24) PLHIV who know their HIV status (%) PLHIV who know their HIV status and are on ART and virally suppressed (%) 2018-19 ■ 2019-20 ■ 2020-21 ■ 2021-22 ■ 2022-23 ■ 2023-24

Indicators	Male	Female	Total*
1. Estimated PLHIV size (2023)	1,284	468	1,752
2. PLHIV who know their HIV Status	1,186	642	1,828
3. PLHIV who know their HIV status and are on ART	1,126	597	1,723
4. PLHIV who are on ART and tested for their viral load	189	133	322
4.1 PLHIV who are virally suppressed	185	130	315

^{*} Including of H/TG PLHIV

A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2023-24
Schools with operational Adolescent Education Program (AEP)	90
2. Colleges with operational Red Ribbon Clubs (RRC)	24
3. Persons trained under mainstreaming	6,380
4. No. of calls received at helpline	-

B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management

Indicator	2023-24			
NACO Supported Designated STI/	4			
RTI Clinics (DSRC)	Male	Female	TG	Total
2. Total STI/RTI Clients managed				5,492
3. RPR Tests conducted	2,314	2,405	-	4,719
4. Syphilis seropositivity (%)	1.56	0.50	-	1.02

4. Prevention of new HIV infections among high-risk group and bridge population

A. Targeted Intervention (TI) Projects and Opioid Substitution Therapy (OST)

Indicator	2023-24
1. Targeted Intervention (TI) Projects	-
2. OST centres (Excluding Satellite OST centres)	_

B. Female Sex Workers

20 1 01114110 0010 110111010	
Indicator	2023-24
1. Estimated size	-
2. Coverage (%)	-
3. Condoms distributed	-
4. Tested for HIV (April 2022-September 2022)	-
4.1. HIV sero-positive (%)	-
4.1.1. Linked to ART	-
5. Tested for HIV (October 2022 -March 2023)	-
5.1. HIV sero-positive (%)	-
5.1.1. Linked to ART	-
6. Clinic Visits	-
7. STI/RTI treated	-
8. Presumptive treatment	-

C. Men who have Sex with Men	
Indicatort	2023-24
1. Estimated size	-
2. Coverage (%)	-
3. Condoms distributed	-
4. Tested for HIV (April 2022-September 2022)	-
4.1. HIV sero-positive (%)	-
4.1.1. Linked to ART	-
5. Tested for HIV (October 2022 -March 2023)	-
5.1. HIV sero-positive (%)	-
5.1.1. Linked to ART	-
6. Clinic Visits	-
7. STI/RTI treated	-
8. Presumptive treatment	-

D. Injecting Drug Users	
Indicator	2023-24
1. Estimated size	-
2. Coverage (%)	-
3. Needles distributed	-
4. Syringes distributed	-
5. On OST	-
6. Tested for HIV (April 2022 -September 2022)	-
6.1. HIV sero-positive (%)	-
6.1.1 Linked to ART	-
7. Tested for HIV (October 2022 -March 2023)	-
7.1. HIV sero-positive (%)	-
7.1.1. Linked to ART	-

E. Hijra/Transgender person	
Indicator	2023-24
1. Estimated size	-
2. Coverage (%)	-
3. Condoms distributed	-
4. Tested for HIV (April 2022-September 2022)	-
4.1. HIV sero-positive (%)	-
4.1.1. Linked to ART	-
5. Tested for HIV (October 2022 -March 2023)	-
5.1. HIV sero-positive (%)	-
5.1.1. Linked to ART	-
6. Clinic Visits	-
7. STI/RTI treated	-
8. Presumptive treatment	-

F. Migrants	
Indicator	2023-24
1. Estimated size	-
2. Coverage (%)	-
3. Tested for HIV	-
3.1. HIV sero-positive (%)	-
3.2. Linked to ART	-

G. Truckers	
Indicator	2023-24
1. Estimated size	-
2. Coverage (%)	-
3. Tested for HIV	-
3.1. HIV sero-positive (%)	-
3.2. On ART	-

H. Prison Inmates	
Indicator	2023-24
1. Total prisons	-
2. Prisons covered under programme	-
3. Total inmates admitted	-
4. Inmates Covered (%)	-
5. Tested for HIV	-
5.1. HIV sero-positive (%)	-
5.2. On ART (%)	-

I. Link Worker Scheme	
Indicator	2023-24
Districts covered under scheme	-
Vulnerable population covered	-
3. Tested for HIV	-
3.1. HIV sero-positive (%)	-
3.2. Linked to ART (%)	-

J. Opioid Substitution Therapy	
Indicator	2023-24
1. OST Centres	-
1.1. OSTC in Public Health Settings	-
1.2. OSTC in NGO Settings	-
1.3. No. of Satellite OST Centres	-
2. IDU on OST	-

5. Early detection of HIV infected people

A. HIV counselling and testing services (HCTS)

, a riiv counselling and testing services (rivie,	
Indicator	2023-24
HCTC confirmatory facilities	3
2. Sampoorna Suraksha Kendras	-

2023-24

B. HIV testing among vulnerable population (excluding pregnant women)

	Male	Female	TG	Total
1. Tested for HIV	26,023	19,285	-	45,308
1.1 HIV Positives	56	28	-	84
1.2 HIV sero -positivity (%)	0.22	0.15	-	0.19
Spouse/sexual partner of HIV positive people tested	43	31	-	74
2.1 HIV Positives	10	7	-	17
2.2 HIV sero -positivity (%)	23	23	-	22.97
No. of contacts with 'at- risk' population through 'Sampoorna Suraksha'	-	-	-	-

6. Initiation and retention on ART of HIV infected people

A. Treatment facilities

Indicator

Indicator	2023-24
1. ART Centres	1
2.Centre of Excellence	
2.1. Centre of Excellence (Adult)	-
2.2 Centre of Excellent (Paediatric)	-
3. Link ART Centres	1
4. Care Support Centres	-

B. Treatment uptake

Indicator	2023-24			
	Male	Female	TG	Total
HIV positive cases diagnosed (At ICTC)	56	34		90
New PLHIV Registered at ART center	50	28		78
2.1 Initiated on ART	50	28		78
3. PLHIV alive and on ART	1,126	597		1,723
4. 12 months retention on ART (%)				91.0
5. Lost to follow-up cases	1	3		4

A. Laboratory facilities and service uptake Indicator 1. Viral load laboratories (programme and non-programme labs) 1.1 Accredited Viral load laboratories (out of 64 VL labs) 2. Viral load tests conducted 2.1. Virally suppressed (%) 3. National reference laboratories (NRL) 3.1 Accredited NRL 4. State reference laboratories (SRL) 4.1 Accredited SRL 5. CD4 machines 5.1 CD4 tests conducted 6. External Quality Assurance of ICTC 6.1 Average Participation (%) 6.2. Average Discordance (%) 7. "Certificate of Excellence" by NACO 7.1 No. of ICTCs received "Certificate of Excellence" 8. Elimination of mother to child transmission of HIV & Syphilis A. HIV Indicator 1. Estimated pregnant women (PW) 29,75 2. HIV testing among PW 21,01 3. HIV sero-positivity (%) among tested 4. HIV Positive PW (old + new detections) 4.1 On life-long ART 5. Live births among HIV positive PW 5.1 Babies given ARV Prophylaxis (%) 6. Babies tested HIV (6 week- 6 month) 6.1 Babies confirmed HIV Positive (6 weeks to upto 18 Months) 7. HIV testing among exposed babies at 18 months 7. HIV exposed babies lested at 18 months 7. Babies confirmed HIV Positive (6 weeks to upto 18 Months) 9. HIV positive babies initiated on ART 8. Syphilis Indicator 2023-2 1. Syphilis Indicator 2023-2 1. Syphilis Lesting among PW 2. Sero-positivity (%) among tested 3. Put on treatment 9. Elimination of HIV/AIDS related Stigma and Discrimination Indicator 1. Sysphilis Lesting among PW 2. Sero-positivity (%) among tested 3. Put on treatment 9. Elimination of HIV/AIDS related Stigma and Discrimination Indicator 1. Sysphilis Lesting among PW 2. Sero-positivity (%) among tested 3. Put on treatment	7. Viral Suppression and laboratories	
Indicator 1. Viral load laboratories (programme and non-programme labs) 1.1 Accredited Viral load laboratories (out of 64 VL labs) 2. Viral load tests conducted 2.1. Virally suppressed (%) 3. National reference laboratories (NRL) 3.1 Accredited NRL 4. State reference laboratories (SRL) 4.1 Accredited SRL 5. CD4 machines 5.1 CD4 tests conducted 6. External Quality Assurance of ICTC 6.1 Average Participation (%) 6.2. Average Discordance (%) 7. "Certificate of Excellence" by NACO 7.1 No. of ICTCs received "Certificate of Excellence" 8. Elimination of mother to child transmission of HIV & Syphilis A. HIV Indicator 1. Estimated pregnant women (PW) 29,75 2. HIV testing among PW 3. HIV sero-positivity (%) among tested 4. HIV Positive PW (old + new detections) 4.1 On life-long ART 5. Live births among HIV positive PW 5.1 Babies given ARV Prophylaxis (%) 6. Babies tested HIV (6 week- 6 month) 6.1 Babies confirmed HIV Positive (6 weeks to upto 18 Months) 7. HIV testing among exposed babies at 18 months 7. 2 Babies confirmed HIV Positive at 18 months 7. 2 Babies confirmed HIV Positive (6 weeks to upto 18 Months) 9. HIV positive babies initiated on ART 8. Syphilis Indicator 1. Syphilis lesting among PW 2. Sero-positivity (%) among tested 3. Put on treatment 9. Elimination of HIV/AIDS related Stigma and Discrimination Indicator 1. State rules notified for HIV/AIDS Prevention and		
1.1 Accredited Viral load laboratories (out of 64 VL labs) 2. Viral load tests conducted 2.1. Virally suppressed (%) 3. National reference laboratories (NRL) 3.1 Accredited NRL 4. State reference laboratories (SRL) 4.1 Accredited SRL 5. CD4 machines 5.1 CD4 tests conducted 6. External Quality Assurance of ICTC 6.1 Average Participation (%) 6.2. Average Discordance (%) 7. "Certificate of Excellence" by NACO 7.1 No. of ICTCs received "Certificate of Excellence" 8. Elimination of mother to child transmission of HIV & Syphilis A. HIV Indicator 1. Estimated pregnant women (PW) 29,75 2. HIV testing among PW 2. HIV resiting among PW 3. HIV sero-positivity (%) among tested 4. HIV Positive PW (old + new detections) 4.1 On life-long ART 5. Live births among HIV positive PW 5.1 Babies given ARV Prophylaxis (%) 6. Babies tested HIV (6 week- 6 month) 6.1 Babies confirmed HIV Positive (6 week- 6 month) 7. HIV exposed babies at 18 months 7.1 HIV exposed babies tested at 18 months 7.1 HIV exposed babies tested at 18 months 7.1 Babies confirmed HIV Positive (6 weeks to upto 18 Months) 9. HIV positive babies initiated on ART 8. Syphilis Indicator 2023-2 1. Syphilis Indicator 2023-2 2. Sero-positivity (%) among tested 3. Put on treatment 9. Elimination of HIV/AIDS related Stigma and Discrimination Indicator 1. State rules notified for HIV/AIDS Prevention and		
2. Viral load tests conducted 2.1. Virally suppressed (%) 3. National reference laboratories (NRL) 3.1 Accredited NRL 4. State reference laboratories (SRL) 4.1 Accredited SRL 5. CD4 machines 5.1 CD4 tests conducted 6. External Quality Assurance of ICTC 6.1 Average Participation (%) 6.2. Average Discordance (%) 7. "Certificate of Excellence" by NACO 7.1 No. of ICTCs received "Certificate of Excellence" 8. Elimination of mother to child transmission of HIV & Syphilis A. HIV Indicator 1. Estimated pregnant women (PW) 29,75 2. HIV testing among PW 3. HIV sero-positivity (%) among tested 4. HIV Positive PW (old + new detections) 4.1 On life-long ART 5. Live births among HIV positive PW 5.1 Babies given ARV Prophylaxis (%) 6. Babies tested HIV (6 week- 6 month) 6.1 Babies confirmed HIV Positive (6 weeks to upto 18 Months) 7. HIV testing among exposed babies at 18 months 7.1 HIV exposed babies tested at 18 months 7.2 Babies confirmed HIV Positive at 18 months 7.2 Babies confirmed HIV Positive (6 weeks to upto 18 Months) 9. HIV positive babies initiated on ART B. Syphilis Indicator 2023-2 1. Syphilis testing among PW 2.6,61 2. Sero-positivity (%) among tested 0.00 3. Put on treatment 9. Elimination of HIV/AIDS related Stigma and Discrimination Indicator 2023-2 1. State rules notified for HIV/AIDS Prevention and		
2.1. Virally suppressed (%) 3. National reference laboratories (NRL) 3.1 Accredited NRL 4. State reference laboratories (SRL) 4.1 Accredited SRL 5. CD4 machines 5.1 CD4 tests conducted 6. External Quality Assurance of ICTC 6.1 Average Participation (%) 6.2. Average Discordance (%) 7. "Certificate of Excellence" by NACO 7.1 No. of ICTCs received "Certificate of Excellence" 8. Elimination of mother to child transmission of HIV & Syphilis A. HIV Indicator 1. Estimated pregnant women (PW) 29,75 2. HIV testing among PW 2.1,01 3. HIV sero-positivity (%) among tested 4. HIV Positive PW (old + new detections) 4.1 On life-long ART 5. Live births among HIV positive PW 5.1 Babies given ARV Prophylaxis (%) 6. Babies tested HIV (6 week- 6 month) 6.1 Babies confirmed HIV Positive (6 week- 6 month) 7. HIV testing among exposed babies at 18 months 7.1 HIV exposed babies tested at 18 months 7.2 Babies confirmed HIV positive (6 weeks to upto 18 Months) 9. HIV positive babies initiated on ART B. Syphilis Indicator 1. Syphilis lindicator 2023-2 2. Sero-positivity (%) among tested 3. Put on treatment 9. Elimination of HIV/AIDS related Stigma and Discrimination Indicator 1. State rules notified for HIV/AIDS Prevention and		
3. National reference laboratories (NRL) 3.1 Accredited NRL 4. State reference laboratories (SRL) 4.1 Accredited SRL 5. CD4 machines 5.1 CD4 tests conducted 6. External Quality Assurance of ICTC 6.1 Average Participation (%) 6.2. Average Discordance (%) 7. "Certificate of Excellence" by NACO 7.1 No. of ICTCs received "Certificate of Excellence" 8. Elimination of mother to child transmission of HIV & Syphilis A. HIV Indicator 1. Estimated pregnant women (PW) 29,75 2. HIV testing among PW 21,01 3. HIV sero-positivity (%) among tested 4. HIV Positive PW (old + new detections) 4.1 On life-long ART 5. Live births among HIV positive PW 5.1 Babies given ARV Prophylaxis (%) 6. Babies tested HIV (6 week- 6 month) 6.1 Babies confirmed HIV Positive (6 week- 6 month) 7. HIV testing among exposed babies at 18 months 7.1 HIV exposed babies tested at 18 months 7.2 Babies confirmed HIV positive (6 weeks to upto 18 Months) 9. HIV positive babies initiated on ART B. Syphilis Indicator 1. Syphilis lindicator 1. Syphilis testing among PW 2. Sero-positivity (%) among tested 3. Put on treatment 9. Elimination of HIV/AIDS related Stigma and Discrimination Indicator 1. State rules notified for HIV/AIDS Prevention and	2. Viral load tests conducted	34
3.1 Accredited NRL 4. State reference laboratories (SRL) 4.1 Accredited SRL 5. CD4 machines 5.1 CD4 tests conducted 6. External Quality Assurance of ICTC 6.1 Average Participation (%) 6.2. Average Discordance (%) 7. "Certificate of Excellence" by NACO 7.1 No. of ICTCs received "Certificate of Excellence" 8. Elimination of mother to child transmission of HIV & Syphilis A. HIV Indicator 1. Estimated pregnant women (PW) 29,75 2. HIV testing among PW 21,01 3. HIV sero-positivity (%) among tested 4. HIV Positive PW (old + new detections) 4.1 On life-long ART 5. Live births among HIV positive PW 5.1 Babies given ARV Prophylaxis (%) 6. Babies tested HIV (6 week-6 month) 6.1 Babies confirmed HIV Positive (6 week-6 month) 7. HIV testing among exposed babies at 18 months 7.1 HIV exposed babies tested at 18 months 7.2 Babies confirmed HIV positive at 18 months 8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months) 9. HIV positive babies initiated on ART 8. Syphilis Indicator 1. Syphilis testing among PW 2.6,61 2. Sero-positivity (%) among tested 3. Put on treatment 9. Elimination of HIV/AIDS related Stigma and Discrimination Indicator 1. State rules notified for HIV/AIDS Prevention and	2.1. Virally suppressed (%)	94
4. State reference laboratories (SRL) 4.1 Accredited SRL 5. CD4 machines 5.1 CD4 tests conducted 6. External Quality Assurance of ICTC 6.1 Average Participation (%) 6.2. Average Discordance (%) 7. "Certificate of Excellence" by NACO 7.1 No. of ICTCs received "Certificate of Excellence" 8. Elimination of mother to child transmission of HIV & Syphilis A. HIV Indicator 1. Estimated pregnant women (PW) 29,75 2. HIV testing among PW 21,01 3. HIV sero-positivity (%) among tested 0.00 4. HIV Positive PW (old + new detections) 4. 1 On life-long ART 5. Live births among HIV positive PW 5.1 Babies given ARV Prophylaxis (%) 6. Babies tested HIV (6 week- 6 month) 6.1 Babies confirmed HIV Positive (6 week-6 month) 7. HIV testing among exposed babies at 18 months 7.1 HIV exposed babies tested at 18 months 7.2 Babies Identified HIV Positive (6 weeks to upto 18 Months) 9. HIV positive babies initiated on ART 8. Syphilis Indicator 2023-2 1. Syphilis testing among PW 2.6,61 2. Sero-positivity (%) among tested 3. Put on treatment 9. Elimination of HIV/AIDS related Stigma and Discrimination Indicator 1. State rules notified for HIV/AIDS Prevention and	3. National reference laboratories (NRL)	
4.1 Accredited SRL 5. CD4 machines 5.1 CD4 tests conducted 6. External Quality Assurance of ICTC 6.1 Average Participation (%) 6.2. Average Discordance (%) 7. "Certificate of Excellence" by NACO 7.1 No. of ICTCs received "Certificate of Excellence" 8. Elimination of mother to child transmission of HIV & Syphilis A. HIV Indicator 1. Estimated pregnant women (PW) 29,75 2. HIV testing among PW 2. HIV sero-positivity (%) among tested 4. HIV Positive PW (old + new detections) 4. 1 On life-long ART 5. Live births among HIV positive PW 5.1 Babies given ARV Prophylaxis (%) 6. Babies tested HIV (6 week- 6 month) 6.1 Babies confirmed HIV Positive (6 week- 6 month) 7. HIV testing among exposed babies at 18 months 7.1 HIV exposed babies tested at 18 months 7.2 Babies confirmed HIV Positive 18 months 7.2 Babies confirmed HIV Positive (6 weeks to upto 18 Months) 9. HIV positive babies initiated on ART B. Syphilis Indicator 2023-2 2. Sero-positivity (%) among tested 3. Put on treatment 9. Elimination of HIV/AIDS related Stigma and Discrimination Indicator 2023-2 1. Systate rules notified for HIV/AIDS Prevention and	3.1 Accredited NRL	
5. CD4 machines 5.1 CD4 tests conducted 6. External Quality Assurance of ICTC 6.1 Average Participation (%) 6.2. Average Discordance (%) 7. "Certificate of Excellence" by NACO 7.1 No. of ICTCs received "Certificate of Excellence" 8. Elimination of mother to child transmission of HIV & Syphilis A. HIV Indicator 1. Estimated pregnant women (PW) 29,75 2. HIV testing among PW 21,01 3. HIV sero-positivity (%) among tested 4. HIV Positive PW (old + new detections) 4.1 On life-long ART 5. Live births among HIV positive PW 5.1 Babies given ARV Prophylaxis (%) 6. Babies tested HIV (6 week- 6 month) 6.1 Babies confirmed HIV Positive (6 week- 6 month) 7. HIV testing among exposed babies at 18 months 7.1 HIV exposed babies tested at 18 months 7.2 Babies confirmed HIV Positive at 18 months 7.2 Babies confirmed HIV Positive (6 weeks to upto 18 Months) 9. HIV positive babies initiated on ART B. Syphilis Indicator 2023-2 2. Sero-positivity (%) among tested 3. Put on treatment 9. Elimination of HIV/AIDS related Stigma and Discrimination Indicator 2023-2 1. State rules notified for HIV/AIDS Prevention and	4. State reference laboratories (SRL)	
5.1 CD4 tests conducted 6. External Quality Assurance of ICTC 6.1 Average Participation (%) 6.2. Average Discordance (%) 7. "Certificate of Excellence" by NACO 7.1 No. of ICTCs received "Certificate of Excellence" 8. Elimination of mother to child transmission of HIV & Syphilis A. HIV Indicator 1. Estimated pregnant women (PW) 29,75 2. HIV testing among PW 21,01 3. HIV sero-positivity (%) among tested 4. HIV Positive PW (old + new detections) 4.1 On life-long ART 5. Live births among HIV positive PW 5.1 Babies given ARV Prophylaxis (%) 6. Babies tested HIV (6 week- 6 month) 6.1 Babies confirmed HIV Positive (6 week- 6 month) 7. HIV testing among exposed babies at 18 months 7.1 HIV exposed babies tested at 18 months 8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months) 9. HIV positive babies initiated on ART 8. Syphilis Indicator 2023-2 1. Syphilis testing among PW 2. Sero-positivity (%) among tested 3. Put on treatment 9. Elimination of HIV/AIDS related Stigma and Discrimination Indicator 1. State rules notified for HIV/AIDS Prevention and	4.1 Accredited SRL	
6. External Quality Assurance of ICTC 6.1 Average Participation (%) 6.2. Average Discordance (%) 7. "Certificate of Excellence" by NACO 7.1 No. of ICTCs received "Certificate of Excellence" 8. Elimination of mother to child transmission of HIV & Syphilis A. HIV Indicator 1. Estimated pregnant women (PW) 2. HIV testing among PW 2. HIV sero-positivity (%) among tested 4. HIV Positive PW (old + new detections) 4.1 On life-long ART 5. Live births among HIV positive PW 5.1 Babies given ARV Prophylaxis (%) 6. Babies tested HIV (6 week- 6 month) 6.1 Babies confirmed HIV Positive (6 week- 6 month) 7. HIV testing among exposed babies at 18 months 7.1 HIV exposed babies tested at 18 months 7.2 Babies confirmed HIV positive (6 weeks to upto 18 Months) 9. HIV positive babies initiated on ART 8. Syphilis Indicator 1. Syphilis testing among PW 2. Sero-positivity (%) among tested 3. Put on treatment 9. Elimination of HIV/AIDS related Stigma and Discrimination Indicator 2023-2 1. State rules notified for HIV/AIDS Prevention and	5. CD4 machines	
6.1 Average Participation (%) 6.2. Average Discordance (%) 7. "Certificate of Excellence" by NACO 7.1 No. of ICTCs received "Certificate of Excellence" 8. Elimination of mother to child transmission of HIV & Syphilis A. HIV Indicator 2023-2 1. Estimated pregnant women (PW) 29,79 2. HIV testing among PW 21,01 3. HIV sero-positivity (%) among tested 4. HIV Positive PW (old + new detections) 4.1 On life-long ART 5. Live births among HIV positive PW 5.1 Babies given ARV Prophylaxis (%) 6. Babies tested HIV (6 week- 6 month) 6.1 Babies confirmed HIV Positive (6 week- 6 month) 7. HIV testing among exposed babies at 18 months 7.1 HIV exposed babies tested at 18 months 7.2 Babies confirmed HIV Positive at 18 months 8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months) 9. HIV positive babies initiated on ART 8. Syphilis Indicator 2023-2 1. Syphilis testing among PW 26,61 2. Sero-positivity (%) among tested 3. Put on treatment 9. Elimination of HIV/AIDS related Stigma and Discrimination Indicator 1. State rules notified for HIV/AIDS Prevention and	5.1 CD4 tests conducted	
6.2. Average Discordance (%) 7. "Certificate of Excellence" by NACO 7.1 No. of ICTCs received "Certificate of Excellence" 8. Elimination of mother to child transmission of HIV & Syphilis A. HIV Indicator 2023-2 1. Estimated pregnant women (PW) 29,75 2. HIV testing among PW 21,01 3. HIV sero-positivity (%) among tested 4. HIV Positive PW (old + new detections) 4.1 On life-long ART 5. Live births among HIV positive PW 5.1 Babies given ARV Prophylaxis (%) 6. Babies tested HIV (6 week- 6 month) 6.1 Babies confirmed HIV Positive (6 week- 6 month) 7. HIV testing among exposed babies at 18 months 7.1 HIV exposed babies tested at 18 months 7.2 Babies confirmed HIV Positive (6 weeks to upto 18 Months) 9. HIV positive babies initiated on ART B. Syphilis Indicator 2023-2 1. Syphilis testing among PW 2.6,61 2. Sero-positivity (%) among tested 3. Put on treatment 9. Elimination of HIV/AIDS related Stigma and Discrimination Indicator 1. State rules notified for HIV/AIDS Prevention and	6. External Quality Assurance of ICTC	
7. "Certificate of Excellence" by NACO 7.1 No. of ICTCs received "Certificate of Excellence" 8. Elimination of mother to child transmission of HIV & Syphilis A. HIV Indicator 2023-2 1. Estimated pregnant women (PW) 29,79 2. HIV testing among PW 21,01 3. HIV sero-positivity (%) among tested 4. HIV Positive PW (old + new detections) 4.1 On life-long ART 5. Live births among HIV positive PW 5.1 Babies given ARV Prophylaxis (%) 6. Babies tested HIV (6 week- 6 month) 6.1 Babies confirmed HIV Positive (6 week- 6 month) 7. HIV testing among exposed babies at 18 months 7.1 HIV exposed babies tested at 18 months 7.2 Babies confirmed HIV Positive (6 weeks to upto 18 Months) 9. HIV positive babies initiated on ART 8. Syphilis Indicator 1. Syphilis testing among PW 2.6,61 2. Sero-positivity (%) among tested 3. Put on treatment 9. Elimination of HIV/AIDS related Stigma and Discrimination Indicator 1. State rules notified for HIV/AIDS Prevention and	6.1 Average Participation (%)	
7.1 No. of ICTCs received "Certificate of Excellence" 8. Elimination of mother to child transmission of HIV & Syphilis A. HIV Indicator 1. Estimated pregnant women (PW) 2. HIV testing among PW 2. HIV sero-positivity (%) among tested 4. HIV Positive PW (old + new detections) 4. 1 On life-long ART 5. Live births among HIV positive PW 5.1 Babies given ARV Prophylaxis (%) 6. Babies tested HIV (6 week- 6 month) 6.1 Babies confirmed HIV Positive (6 week- 6 month) 7. HIV testing among exposed babies at 18 months 7.1 HIV exposed babies tested at 18 months 7.2 Babies confirmed HIV positive (6 weeks to upto 18 Months) 9. HIV positive babies initiated on ART 8. Syphilis Indicator 1. Syphilis testing among PW 2. Sero-positivity (%) among tested 3. Put on treatment 9. Elimination of HIV/AIDS related Stigma and Discrimination Indicator 1. State rules notified for HIV/AIDS Prevention and	6.2. Average Discordance (%)	
8. Elimination of mother to child transmission of HIV & Syphilis A. HIV Indicator 1. Estimated pregnant women (PW) 29,79 2. HIV testing among PW 21,01 3. HIV sero-positivity (%) among tested 4. HIV Positive PW (old + new detections) 4.1 On life-long ART 5. Live births among HIV positive PW 5.1 Babies given ARV Prophylaxis (%) 6. Babies tested HIV (6 week- 6 month) 6.1 Babies confirmed HIV Positive (6 week- 6 month) 7. HIV testing among exposed babies at 18 months 7.2 Babies confirmed HIV positive at 18 months 8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months) 9. HIV positive babies initiated on ART B. Syphilis Indicator 2023-2 1. Syphilis testing among PW 2. Sero-positivity (%) among tested 3. Put on treatment 9. Elimination of HIV/AIDS related Stigma and Discrimination Indicator 1. State rules notified for HIV/AIDS Prevention and	7. "Certificate of Excellence" by NACO	
HIV & Syphilis A. HIV Indicator 1. Estimated pregnant women (PW) 29,79 2. HIV testing among PW 3. HIV sero-positivity (%) among tested 4. HIV Positive PW (old + new detections) 4.1 On life-long ART 5. Live births among HIV positive PW 5.1 Babies given ARV Prophylaxis (%) 6. Babies tested HIV (6 week- 6 month) 6.1 Babies confirmed HIV Positive (6 week- 6 month) 7. HIV testing among exposed babies at 18 months 7.1 HIV exposed babies tested at 18 months 7.2 Babies confirmed HIV Positive (6 weeks to upto 18 Months) 9. HIV positive babies initiated on ART B. Syphilis Indicator 1. Syphilis testing among PW 2. Sero-positivity (%) among tested 3. Put on treatment 9. Elimination of HIV/AIDS related Stigma and Discrimination Indicator 1. State rules notified for HIV/AIDS Prevention and		
A. HIV Indicator 1. Estimated pregnant women (PW) 2. HIV testing among PW 2. HIV sero-positivity (%) among tested 4. HIV Positive PW (old + new detections) 4.1 On life-long ART 5. Live births among HIV positive PW 5.1 Babies given ARV Prophylaxis (%) 6. Babies tested HIV (6 week- 6 month) 6.1 Babies confirmed HIV Positive (6 week- 6 month) 7. HIV testing among exposed babies at 18 months 7.2 Babies confirmed HIV positive at 18 months 8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months) 9. HIV positive babies initiated on ART B. Syphilis Indicator 2023-2 1. Syphilis testing among PW 2. Sero-positivity (%) among tested 3. Put on treatment 9. Elimination of HIV/AIDS related Stigma and Discrimination Indicator 1. State rules notified for HIV/AIDS Prevention and		mission of
1. Estimated pregnant women (PW) 29,75 2. HIV testing among PW 21,01 3. HIV sero-positivity (%) among tested 4. HIV Positive PW (old + new detections) 4.1 On life-long ART 5. Live births among HIV positive PW 5.1 Babies given ARV Prophylaxis (%) 6. Babies tested HIV (6 week- 6 month) 6.1 Babies confirmed HIV Positive (6 week- 6 month) 7. HIV testing among exposed babies at 18 months 7.1 HIV exposed babies tested at 18 months 7.2 Babies confirmed HIV positive at 18 months 8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months) 9. HIV positive babies initiated on ART B. Syphilis Indicator 1. Syphilis testing among PW 2. Sero-positivity (%) among tested 3. Put on treatment 9. Elimination of HIV/AIDS related Stigma and Discrimination Indicator 2023-2 1. State rules notified for HIV/AIDS Prevention and		
2. HIV testing among PW 2. HIV sero-positivity (%) among tested 4. HIV Positive PW (old + new detections) 4.1 On life-long ART 5. Live births among HIV positive PW 5.1 Babies given ARV Prophylaxis (%) 6. Babies tested HIV (6 week- 6 month) 6.1 Babies confirmed HIV Positive (6 week- 6 month) 7. HIV testing among exposed babies at 18 months 7.1 HIV exposed babies tested at 18 months 7.2 Babies confirmed HIV positive at 18 months 8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months) 9. HIV positive babies initiated on ART B. Syphilis Indicator 1. Syphilis testing among PW 2. Sero-positivity (%) among tested 3. Put on treatment 9. Elimination of HIV/AIDS related Stigma and Discrimination Indicator 2023-2 1. State rules notified for HIV/AIDS Prevention and	Indicator	2023-2
3. HIV sero-positivity (%) among tested 4. HIV Positive PW (old + new detections) 4.1 On life-long ART 5. Live births among HIV positive PW 5.1 Babies given ARV Prophylaxis (%) 6. Babies tested HIV (6 week- 6 month) 6.1 Babies confirmed HIV Positive (6 week- 6 month) 7. HIV testing among exposed babies at 18 months 7.1 HIV exposed babies tested at 18 months 7.2 Babies confirmed HIV positive at 18 months 8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months) 9. HIV positive babies initiated on ART 8. Syphilis Indicator 2023-2 1. Syphilis testing among PW 2. Sero-positivity (%) among tested 3. Put on treatment 9. Elimination of HIV/AIDS related Stigma and Discrimination Indicator 2023-2 1. State rules notified for HIV/AIDS Prevention and	1. Estimated pregnant women (PW)	29,79
4. HIV Positive PW (old + new detections) 4.1 On life-long ART 5. Live births among HIV positive PW 5.1 Babies given ARV Prophylaxis (%) 6. Babies tested HIV (6 week- 6 month) 6.1 Babies confirmed HIV Positive (6 week- 6 month) 7. HIV testing among exposed babies at 18 months 7.1 HIV exposed babies tested at 18 months 7.2 Babies confirmed HIV positive at 18 months 8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months) 9. HIV positive babies initiated on ART B. Syphilis Indicator 1. Syphilis testing among PW 2. Sero-positivity (%) among tested 3. Put on treatment 9. Elimination of HIV/AIDS related Stigma and Discrimination Indicator 2023-2 1. State rules notified for HIV/AIDS Prevention and	2. HIV testing among PW	21,01
4.1 On life-long ART 5. Live births among HIV positive PW 5.1 Babies given ARV Prophylaxis (%) 6. Babies tested HIV (6 week- 6 month) 6.1 Babies confirmed HIV Positive	3. HIV sero-positivity (%) among tested	0.0
5. Live births among HIV positive PW 5.1 Babies given ARV Prophylaxis (%) 6. Babies tested HIV (6 week- 6 month) 6.1 Babies confirmed HIV Positive (6 week- 6 month) 7. HIV testing among exposed babies at 18 months 7.1 HIV exposed babies tested at 18 months 7.2 Babies confirmed HIV positive at 18 months 8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months) 9. HIV positive babies initiated on ART B. Syphilis Indicator 1. Syphilis testing among PW 2. Sero-positivity (%) among tested 3. Put on treatment 9. Elimination of HIV/AIDS related Stigma and Discrimination Indicator 2023-2 1. State rules notified for HIV/AIDS Prevention and	4. HIV Positive PW (old + new detections)	
5.1 Babies given ARV Prophylaxis (%) 6. Babies tested HIV (6 week- 6 month) 6.1 Babies confirmed HIV Positive	4.1 On life-long ART	
6. Babies tested HIV (6 week- 6 month) 6.1 Babies confirmed HIV Positive (6 week- 6 month) 7. HIV testing among exposed babies at 18 months 7.1 HIV exposed babies tested at 18 months 7.2 Babies confirmed HIV positive at 18 months 8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months) 9. HIV positive babies initiated on ART B. Syphilis Indicator 2023-2 1. Syphilis testing among PW 2. Sero-positivity (%) among tested 3. Put on treatment 9. Elimination of HIV/AIDS related Stigma and Discrimination Indicator 2023-2 1. State rules notified for HIV/AIDS Prevention and	5. Live births among HIV positive PW	
6.1 Babies confirmed HIV Positive (6 week- 6 month) 7. HIV testing among exposed babies at 18 months 7.1 HIV exposed babies tested at 18 months 7.2 Babies confirmed HIV positive at 18 months 8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months) 9. HIV positive babies initiated on ART B. Syphilis Indicator 2023-2 1. Syphilis testing among PW 2. Sero-positivity (%) among tested 3. Put on treatment 9. Elimination of HIV/AIDS related Stigma and Discrimination Indicator 2023-2 1. State rules notified for HIV/AIDS Prevention and	5.1 Babies given ARV Prophylaxis (%)	>=9
(6 week- 6 month) 7. HIV testing among exposed babies at 18 months 7.1 HIV exposed babies tested at 18 months 7.2 Babies confirmed HIV positive at 18 months 8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months) 9. HIV positive babies initiated on ART B. Syphilis Indicator 1. Syphilis testing among PW 2. Sero-positivity (%) among tested 3. Put on treatment 9. Elimination of HIV/AIDS related Stigma and Discrimination Indicator 2023-2 1. State rules notified for HIV/AIDS Prevention and	6. Babies tested HIV (6 week- 6 month)	
7.1 HIV exposed babies tested at 18 months 7.2 Babies confirmed HIV positive at 18 months 8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months) 9. HIV positive babies initiated on ART B. Syphilis Indicator 1. Syphilis testing among PW 2. Sero-positivity (%) among tested 3. Put on treatment 9. Elimination of HIV/AIDS related Stigma and Discrimination Indicator 2023-2 1. State rules notified for HIV/AIDS Prevention and		
7.1 HIV exposed babies tested at 18 months 7.2 Babies confirmed HIV positive at 18 months 8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months) 9. HIV positive babies initiated on ART B. Syphilis Indicator 1. Syphilis testing among PW 2. Sero-positivity (%) among tested 3. Put on treatment 9. Elimination of HIV/AIDS related Stigma and Discrimination Indicator 2023-2 1. State rules notified for HIV/AIDS Prevention and	7. HIV testing among exposed babies at 18 months	
7.2 Babies confirmed HIV positive at 18 months 8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months) 9. HIV positive babies initiated on ART B. Syphilis Indicator 1. Syphilis testing among PW 2. Sero-positivity (%) among tested 3. Put on treatment 9. Elimination of HIV/AIDS related Stigma and Discrimination Indicator 2023-2 1. State rules notified for HIV/AIDS Prevention and	7.1 HIV exposed babies tested at 18 months	
8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months) 9. HIV positive babies initiated on ART B. Syphilis Indicator 1. Syphilis testing among PW 2. Sero-positivity (%) among tested 3. Put on treatment 9. Elimination of HIV/AIDS related Stigma and Discrimination Indicator 2023-2 1. State rules notified for HIV/AIDS Prevention and	7.2 Babies confirmed HIV positive at 18 months	
9. HIV positive babies initiated on ART B. Syphilis Indicator 2023-2 1. Syphilis testing among PW 2. Sero-positivity (%) among tested 3. Put on treatment 9. Elimination of HIV/AIDS related Stigma and Discrimination Indicator 2023-2 1. State rules notified for HIV/AIDS Prevention and	8. Total Babies Identified HIV Positive (6 weeks to	
Indicator 1. Syphilis testing among PW 26,61 2. Sero-positivity (%) among tested 3. Put on treatment 9. Elimination of HIV/AIDS related Stigma and Discrimination Indicator 2023-2 1. State rules notified for HIV/AIDS Prevention and	·	
Syphilis testing among PW 26,61 2.Sero-positivity (%) among tested 3. Put on treatment Elimination of HIV/AIDS related Stigma and Discrimination Indicator 2023-2 State rules notified for HIV/AIDS Prevention and	B. Syphilis	
2.Sero-positivity (%) among tested 3. Put on treatment 9. Elimination of HIV/AIDS related Stigma and Discrimination Indicator 2023-2 1. State rules notified for HIV/AIDS Prevention and	Indicator	2023-2
3. Put on treatment 9. Elimination of HIV/AIDS related Stigma and Discrimination Indicator 2023-2 1. State rules notified for HIV/AIDS Prevention and	1. Syphilis testing among PW	26,61
9. Elimination of HIV/AIDS related Stigma and Discrimination Indicator 2023-2 1. State rules notified for HIV/AIDS Prevention and	2.Sero-positivity (%) among tested	0.0
and Discrimination Indicator 2023-2 1. State rules notified for HIV/AIDS Prevention and		
State rules notified for HIV/AIDS Prevention and	•	
	Indicator	2023-2
		N

2. State designated/appointed ombudsman

Yes

10. HIV-TB Co-morbidities A. HRG and Bridge Population											
	Quarter	FSW	MSM	IDU	TG	Migrants	Truckers	Total			
Screened for TB	Quarter 1	-	-	-	-	-	-				
	Quarter 2	-	-	-	-	1	-				
	Quarter 3	-	-	-	-	-	-				
	Quarter 4	-	-	-	-	-	-				
Tested for TB	Quarter 1	-	-	-	-	-	-				
	Quarter 2	-	-	-	-	-	-				
	Quarter 3	-	-	-	-	-	-				
	Quarter 4	-	-	-	-	-	-				
Diagnosed with TB	Quarter 1	-	-	-	-	-	-				
	Quarter 2	-	-	-	-	-	-				
	Quarter 3	-	-	-	-	-	-				
	Quarter 4	-	-	-	-	-	-				
Initiated on TB treatment	Quarter 1	-	-	-	-	-	-				
	Quarter 2	-	-	-	-	-	-				
	Quarter 3	-	-	-	-	-	-				
	Quarter 4	_	_	_	_	-	-				

								l			
B. HIV-TB Coinfected at ART Centre											
Indicator								2023-24			
Moths	PLHIV attending ART Centre	PLHIV underwent 4S screening	PLHIV with presumptive TB	PLHIV tested for TB	PLHIV diagnosed with TB	PLHIV initiated on IPT	Co-infected enrolled at ARTC	Co-infected initiated on ART			
Apr - 23	244	244	12	12	-	15					
May - 23	258	258	4	4	-	9					
Jun - 23	273	273	6	6	-	14					
Jul - 23	285	285	14	14	-	3					
Aug - 23	275	275	6	6	-	-					
Sep - 23	296	296	10	10	1	17					
Oct - 23	239	239	11	11	-	2					
Nov - 23	93	93	7	7	2	3					
Dec - 23	198	198	6	6	1	3					
Jan - 24	284	284	4	4	-	6					
Feb - 24	269	269	5	5	-	4					
Mar - 24	266	266	6	6	3	8					
April 2023- March 2024							10	10			

		State/UT	DNH & DD
		Rank	29
SI.	Maximum Ma		147
۷٥.	Obtained Mai		98 (67%)
1	J	5%, Y: 80-94%, R:<80%)	>=95
2		:≥95%, Y: 80-94%, R:<80%)	94
3	•	95%, Y: 80-94%, R:<80%)	>=95
4		uency of Social Media updates (G: ≥ 45, Y:40- 44, R:<40 indigenous posts) of	225
_	Q1, Q2, Q3 8		V
5		integration in state school curriculum (G:Yes, R:No)	Yes No Meeting held
7		(G: At least one meeting held since 2020, R: other than G) e Rules (G: Notified, R: Not notified)	Not Notified
8		oudsman (G: Appointed, R: Not appointed)	Appointed
9		arding (G: ≥95%, Y: 90-<95%, R:<90%)	0
10		ing (G: ≥95%, Y: 90-<95%, R:<90%)	NA
11		HRG against estimates (G: ≥90%, Y: 80-<90%, R:<80%)	NA
12		nong HRG (G: ≥95%, Y: 90-<95%, R:<90%)	NA
13		nong prisoners (G: ≥50%, Y: 40% to <50%, R:<40%)	32
14		HRGs at TI-Clinics (G: ≥90%, Y: 75-89%, R:<75%)	NA
15		f HRGs screened for Syphilis (G: ≥90%, Y: 75-89%, R:<75%)	NA
16		G: ≥50%, Y: 30% to <50%, R:<30%)	NA
17		f fund released to TI (G: ≥50%, Y: 45-<50%, R:<45%)	0
18		f TIs trained by Kshmata Kendra (KK) against the AAP targets (G: ≥75%, Y: 70-	NA NA
	<75%, R:<70%		1375
19		gainst Target-at risk % (G: ≥95%, Y: 80-94%, R:<80%)	123
20		gainst target at hisk /6 (81. ± / 61. 61. 51. 66. 7 / 76. 166. 166. 7 / 76. 166. 166. 166. 166. 166. 166. 166.	71
21		f pregnant women screened for Syphilis (G: ≥95%, Y: 80-94%, R:<80%)	89
22		ovided to Syphilis reactive pregnant women (G: ≥95%, Y: 80-94%, R:<80%)	100
23	·	among newly detected HIV positive clients (G: ≥95%, Y: 80-94%, R:<80%)	41
24		f 6 weeks - <2 months EID testing against live birth (G: ≥95%, Y: 80-94%,	86
24	R:<80%)	1 o weeks - <2 months EID testing against live birth (G: 295%, 1: 60-94%,	
25	Clients manag	ged at DSRC against the target (G: ≥90%, Y: 75-89%, R:<75%)	79
26	STI attendees	screened for HIV (G: >75%, Y: 50-75%, R:<50%)	55
27	STI attendees	screened for Syphilis (G: >75%, Y: 50-75%, R:<50%)	89
28		t women who initiated ART (G: ≥95%, Y: 80-94%, R:<80%)	71
29	Proportion of R:>5%)	LFU-PLHIV, out of those initiated on ART in FY 2023-24 (G:<2%, Y: 2 to 5%,	0
30	Proportion of to 98%, R:<95	PLHIV initiated on ART, out of those registered in FY 2023-24 (G:>98%, Y: 95 5%)	100
31	Proportion of R:>5 %)	reported died, out of those initiated on ART in FY 202324 (G:<2%, Y: 2 to 5 %,	1
32	% of SRL accr	edited (G:100%, Y: 80-99%, R:<80%)	NA
33		on of ICTCs in re-testing (G: ≥95%, Y: 85-94, R:<85%)	NA
34		ostracts selected from studies conducted in FY21-22 25 to <100%, R: ≤25%)	0
35		ngoing studies from FY22-23 (G:100%, Y: >25 to <100%,	O
	R: ≤25%)		
36	Submission of Y: >25 to <10	f research proposals from FY23-24 to NACO (G:100%, 10%, R: ≤25%)	2
37	Secondary Da	nta Analysis by SACS (G:2, Y: 1, R: No Secondary Data Analysis Plan Submitted)	2
38		with respect to funds released during FY 2022-23 (G: o <90%, R: <85%)	68
39	Submission of	f Provisional Utilization Certificate (UC) in GFR 12A for the FY 2022-23 (G : by Y : by 31-May-2023, R : after	21-06-2023
40	Submission of	f audited UC in GFR 12A for the FY 2022-23 (G : by 30Jun-2023, Y : by 30-Sep- - 30-Sep-2023)	05-01-2024
41	Submission of	FEC/ GB ratification for approval of Expenditure incurred during FY 2021-22 (G:	23-03-2024
42		22, Y: by 30-Sept-2022, R: after 30-Sept-2022) ssion of CST-SCM Report (G:>95%, Y: 80-95%, R:<80%)	98
	_	·	
43 44		rence to CST-SCM Report (G:>95%, Y: 80-95%, R:<80%) ssion of BSD & STI-SCM Report (G: ≥90%, Y: 75-	89 67
-+-+	<90%, R:<	75%)	
	Green=3 Marks		ur=Not Applicable
Weig	ght points	Indicator SI. No.	
	3	1, 23, 29	
	2	2, 3, 9, 10, 22, 30, 34, 42, 44	
			3, 35, 36, 37, 38, 39, 40,





DELHI

1. Status of HIV/AIDS Epidemic					
A. Epidemic Estimates (2023)					
Indicator	Male	Female	Total		
1. IPR	-	-	4.60		
2. IMR	-	-	2.01		
3. Adult (15-49 yrs) HIV Prevalence (%)	0.36	0.25	0.31		
4. Estimated people living with HIV	36,588	22,281	58,869		
5. ART coverage (%)	73.30	64.34	70.64		
6. Estimated children living with HIV	733	622	1,355		
7. Annual new HIV infections	1,626	1,085	2,711		
8. Annual AIDS-related deaths (ARD)	480	546	1,026		
9. Change in annual new HIV infections since 2010 (%)	-25.48	-15.56	-21.83		
10. Change in annual ARD since 2010(%)	-17.10	67.48	13.37		
11. EMTCT need	-	408	408		


B. High risk population size (2020-22), safe practices (2021) and prevalence (2021/2023) Population Group Condom Use N

Population Group	Estimates Size	Condom Use (%)	New Needle/ Syringe use (%)	HIV Prevalence (%)
1. Female Sex Workers	88,399	96.60	-	0.81
2. Men who have sex with men	27,026	79.30	80.30	2.59
3. Injecting Drug Users	32,481	-	90.10	15.87
4. Hijra/Transgender People	17,907	-	-	3.60
5. Migrants	2,77,822	-	-	0.75
6. Truckers	60,000	80.00	31.60	0.80
7. Prison inmates	65,412	5.90	20.20	2.63

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

Indicator	Male	Female	Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)	43.80	29.50	-
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	36.30	25.10	-
3. Adults willing to care for a relative with HIV/AIDS in own home (%)	85.90	80.00	-
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	80.30	73.20	-
5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)	7.20	0.60	-
5.1 Condom use during last higher-risk intercourse (%)	72.80	86.50	-
6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)	11.36	0.75	-
6.1 Condom use during last higher-risk intercourse (%)	70.00	100.00	-

2. Progress on 95-95-95 (2023-24)



Indicators	Male	Female	Total*
1. Estimated PLHIV size (2023)	36,588	22,281	58,869
2. PLHIV who know their HIV Status	38,990	18,038	57,714
3. PLHIV who know their HIV status and are on ART	27,249	14,577	42,262
4. PLHIV who are on ART and tested for their viral load	17,658	10,097	28,007
4.1 PLHIV who are virally suppressed	17,360	9,962	27,568

^{*} Including of H/TG PLHIV

3. Prevention of new HIV infections among general population

A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2023-24
Schools with operational Adolescent Education Program (AEP)	290
2. Colleges with operational Red Ribbon Clubs (RRC)	85
3. Persons trained under mainstreaming	9,743
4. No. of calls received at helpline	_

B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management

Indicator	2023-24				
1. NACO Supported Designated STI/	28				
RTI Clinics (DSRC)	Male	Female	TG	Total	
2. Total STI/RTI Clients managed				3,63,606	
3. RPR Tests conducted	25,240	47,399	649	73,288	
4. Syphilis seropositivity (%)	3.40	0.54	4.31	1.56	

4. Prevention of new HIV infections among high-risk group and bridge population

A. Targeted Intervention (TI) Projects and Opioid Substitution Therapy (OST)

Indicator	2023-24
1. Targeted Intervention (TI) Projects	79
2. OST centres (Excluding Satellite OST centres)	12

B. Female Sex Workers Indicator

Indicator	2023-24
1. Estimated size	88,399
2. Coverage (%)	78.10
3. Condoms distributed	31,30,619
4. Tested for HIV (April 2022-September 2022)	34,089
4.1. HIV sero-positive (%)	0.16
4.1.1. Linked to ART	46
5. Tested for HIV (October 2022 -March 2023)	55,990
5.1. HIV sero-positive (%)	0.08
5.1.1. Linked to ART	41
6. Clinic Visits	2,13,947
7. STI/RTI treated	3,521
8. Presumptive treatment	18,999

C. Men who have Sex with Men Indicatort 2023-24 1. Estimated size 27,026 2. Coverage (%) >=95 3. Condoms distributed 16,84,089 4. Tested for HIV (April 2022-September 2022) 8,826 4.1. HIV sero-positive (%) 0.61 4.1.1. Linked to ART 5. Tested for HIV (October 2022 -March 2023) 18,106 5.1. HIV sero-positive (%) 0.28 5.1.1. Linked to ART 43 6. Clinic Visits 80,511 7. STI/RTI treated 286 8. Presumptive treatment 5,767

D. Injecting Drug Users	
Indicator	2023-24
1. Estimated size	32,481
2. Coverage (%)	57
3. Needles distributed	82,71,940
4. Syringes distributed	42,71,024
5. On OST	0
6. Tested for HIV (April 2022 -September 2022)	8,210
6.1. HIV sero-positive (%)	2.00
6.1.1 Linked to ART	116
7. Tested for HIV (October 2022 -March 2023)	15,357
7.1. HIV sero-positive (%)	0.64
7.1.1. Linked to ART	73

E. Hijra/Transgender person				
Indicator	2023-24			
1. Estimated size	17,906			
2. Coverage (%)	87			
3. Condoms distributed	13,61,648			
4. Tested for HIV (April 2022-September 2022)	7,654			
4.1. HIV sero-positive (%)	0.29			
4.1.1. Linked to ART	20			
5. Tested for HIV (October 2022 -March 2023)	11,966			
5.1. HIV sero-positive (%)	0.21			
5.1.1. Linked to ART	24			
6. Clinic Visits	49,075			
7. STI/RTI treated	285			
8. Presumptive treatment	2,191			

F. Migrants	
Indicator	2023-24
1. Estimated size	2,77,822
2. Coverage (%)	>=95
3. Tested for HIV	37,428
3.1. HIV sero-positive (%)	0.29
3.2. Linked to ART	87

G. Truckers	
Indicator	2023-24
1. Estimated size	60,000
2. Coverage (%)	67
3. Tested for HIV	5,825
3.1. HIV sero-positive (%)	0.26
3.2. On ART	10

H. Prison Inmates	
Indicator	2023-24
1. Total prisons	16
2. Prisons covered under programme	16
3. Total inmates admitted	65,412
4. Inmates Covered (%)	17
5. Tested for HIV	11,077
5.1. HIV sero-positive (%)	1.57
5.2. On ART (%)	>=95

I. Link Worker Scheme	
Indicator	2023-24
Districts covered under scheme	-
Vulnerable population covered	-
3. Tested for HIV	-
3.1. HIV sero-positive (%)	-
3.2. Linked to ART (%)	-

J. Opioid Substitution Therapy	
Indicator	2023-24
1. OST Centres	12
1.1. OSTC in Public Health Settings	8
1.2. OSTC in NGO Settings	4
1.3. No. of Satellite OST Centres	-
2. IDU on OST	2,793

5. Early detection of HIV infected people

A. HIV counselling and testing services (HCTS)

The same commissioning continues	(,
Indicator	2023-24
1. HCTC confirmatory facilities	87
2. Sampoorna Suraksha Kendras	5

B. HIV testing among vulnerable population (excluding pregnant women)

Indicator	2023-24			
	Male	Female	TG	Total
1. Tested for HIV	3,40,766	2,86,585	8,683	6,36,034
1.1 HIV Positives	4,867	1,205	63	6,135
1.2 HIV sero -positivity (%)	1.43	0.42	0.73	0.96
Spouse/sexual partner of HIV positive people tested	3,849	921	42	4,812
2.1 HIV Positives	1,741	371	22	2,134
2.2 HIV sero -positivity (%)	45	40	52	44.35
No. of contacts with 'at- risk' population through 'Sampoorna Suraksha'	-	-	-	3,845

6. Initiation and retention on ART of HIV infected people

A. Treatment facilities

Indicator	2023-24
1. ART Centres	12
2.Centre of Excellence	
2.1. Centre of Excellence (Adult)	1
2.2 Centre of Excellent (Paediatric)	1
3. Link ART Centres	-
4. Care Support Centres	5

B. Treatment uptake

Indicator	2023-24			
	Male	Female	TG	Total
HIV positive cases diagnosed (At ICTC)	4,867	1,466	63	6,396
New PLHIV Registered at ART center	3,846	1,197	42	5,085
2.1 Initiated on ART	3,535	1,127	39	4,701
3. PLHIV alive and on ART	27,249	14,577	437	42,262
4. 12 months retention on ART (%)				94.9
5. Lost to follow-up cases	11,657	3,697	260	15,614

7. Viral Suppression and laboratories	
A. Laboratory facilities and service uptake	
Indicator	2023-2
Viral load laboratories (programme and non- programme labs)	
1.1 Accredited Viral load laboratories (out of 64 VL labs)	
2. Viral load tests conducted	34,67
2.1. Virally suppressed (%)	>=9
3. National reference laboratories (NRL)	
3.1 Accredited NRL	
4. State reference laboratories (SRL)	
4.1 Accredited SRL	
5. CD4 machines	
5.1 CD4 tests conducted	25,52
6. External Quality Assurance of ICTC	
6.1 Average Participation (%)	>=9
6.2. Average Discordance (%)	0.0
7. "Certificate of Excellence" by NACO	
7.1 No. of ICTCs received "Certificate of Excellence"	
8. Elimination of mother to child trans HIV & SyphilisA. HIV	mission of
Indicator	2023-2
Estimated pregnant women (PW)	3,60,50
2. HIV testing among PW	2,75,92
3. HIV sero-positivity (%) among tested	0.0
4. HIV Positive PW (old + new detections)	47
4.1 On life-long ART	39
5. Live births among HIV positive PW	34
5.1 Babies given ARV Prophylaxis (%)	>=9
6. Babies tested HIV (6 week- 6 month)	32
6.1 Babies confirmed HIV Positive (6 week- 6 month)	
7. HIV testing among exposed babies at 18 months	
7.1 HIV exposed babies tested at 18 months	22
7.2 Babies confirmed HIV positive at 18 months	1
8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months)	2
9. HIV positive babies initiated on ART	2
B. Syphilis	
Indicator	2023-2
1. Syphilis testing among PW	3,21,34
2.Sero-positivity (%) among tested	0.0
3. Put on treatment	16
9. Elimination of HIV/AIDS related Stigma and Discrimination	
Indicator	2023-2
State rules notified for HIV/AIDS Prevention and	2023 2 Ye
Control Act (2017)	

2. State designated/appointed ombudsman

Yes

10. HIV-TB Co-morbidities									
A. HRG and Bridge Population									
Indicator 2023-24									
	Quarter	FSW	MSM	IDU	TG	Migrants	Truckers	Total	
	Quarter 1	46,117	18,338	13,185	11,239	28,971	4,929	1,22,779	
C II TD	Quarter 2	54,420	21,653	16,116	14,859	32,137	5,496	1,44,68	
Screened for TB	Quarter 3	58,165	23,863	16,621	14,374	33,960	5,450	1,52,433	
	Quarter 4	59,022	23,930	16,068	14,952	36,200	5,857	1,56,029	
	Quarter 1	376	140	62	19	83	41	721	
To the olders TD	Quarter 2	455	45	61	8	71	38	678	
Tested for TB	Quarter 3	577	55	75	15	75	42	839	
	Quarter 4	575	57	110	19	56	31	848	
	Quarter 1	38	-	2	1	16	-	57	
Diamana daniah TD	Quarter 2	38	2	4	1	9	1	55	
Diagnosed with TB	Quarter 3	31	2	2	-	9	1	45	
	Quarter 4	18	1	9	1	3	1	33	
	Quarter 1	37	1	2	1	16	-	57	
Initiated on TB treatment	Quarter 2	37	2	4	1	9	1	54	
	Quarter 3	27	2	2	-	9	1	41	
	Quarter 4	17	1	9	1	2	1	3′	

B. HIV-TB Coinfected at ART Centre Indicator 2023-24 PLHIV with presumptive TB PLHIV PLHIV PLHIV PLHIV Co-infected enrolled at Co-infected initiated on ART PLHIV tested for TB diagnosed with TB initiated on IPT Moths attending underwent ART Centre 4S screening ARTC 22,517 21,009 278 Apr - 23 427 336 282 119 221 24,113 22,533 394 May - 23 Jun - 23 23,656 21,922 437 280 95 125 Jul - 23 25,174 20,373 536 272 104 99 25,713 24,106 449 295 80 59 Aug - 23 Sep - 23 21,190 17,744 407 281 64 42 Oct - 23 24,093 22,316 391 70 12 293 43 24,424 22,673 413 271 63 Nov - 23 Dec - 23 28,047 25,824 417 244 68 51 74 Jan - 24 31,579 28,846 480 125 293 93 Feb - 24 26,967 24,968 543 389 74 Mar - 24 25,548 23,706 445 358 101 52 April 2023-1,340 1,282 March 2024

		State/UT	Delhi				
		Rank	26				
SI.	Maximum Ma		177				
No.	Obtained Mar		121 (68%)				
2		5%, Y: 80-94%, R:<80%) :≥95%, Y: 80-94%, R:<80%)	>=95 73				
3		?5%, Y: 80-94%, R:<80%)	>=95				
4		uency of Social Media updates (G: ≥ 45, Y:40- 44, R:<40 indigenous posts) of	3				
	Q1, Q2, Q3 &	· · · · · · · · · · · · · · · · · · ·					
5	Status of AEP	integration in state school curriculum (G:Yes, R:No)	Yes				
6		(G: At least one meeting held since 2020, R: other than G)	Meeting held in 2011				
7		e Rules (G: Notified, R: Not notified)	Notified				
8		oudsman (G: Appointed, R: Not appointed)	Appointed				
9		ing (G: ≥95%, Y: 90-<95%, R:<90%) ing (G: ≥95%, Y: 90-<95%, R:<90%)	94 100				
11		HRG against estimates (G: ≥90%, Y: 80-<90%, R:<80%)	80				
12		nong HRG (G: ≥95%, Y: 90-<95%, R:<90%)	73				
13		nong prisoners (G: ≥50%, Y: 40% to <50%, R:<40%)	14				
14		HRGs at TI-Clinics (G: ≥90%, Y: 75-89%, R:<75%)	82				
15	Percentage of	HRGs screened for Syphilis (G: ≥90%, Y: 75-89%, R:<75%)	72				
16	IDU on OST (0	G: ≥50%, Y: 30% to <50%, R:<30%)	30				
17		fund released to TI (G: ≥50%, Y: 45-<50%, R:<45%)	72				
18	<75%, R:<70%		100				
19		ainst Target-at risk % (G: ≥95%, Y: 80-94%, R:<80%)	53				
20		painst target-PW (G: ≥95%, Y: 80-94%, R:<80%)	77				
21	_	pregnant women screened for Syphilis (G: ≥95%, Y: 80-94%, R:<80%)	89				
22	•	ovided to Syphilis reactive pregnant women (G: ≥95%, Y: 80-94%, R:<80%)	95				
23	_	among newly detected HIV positive clients (G: ≥95%, Y: 80-94%, R:<80%)	41				
24	Percentage of R:<80%)	6 weeks - <2 months EID testing against live birth (G: ≥95%, Y: 80-94%,	97				
25		ged at DSRC against the target (G: ≥90%, Y: 75-89%, R:<75%)	101				
26		screened for HIV (G: >75%, Y: 50-75%, R:<50%)	37				
27		screened for Syphilis (G: >75%, Y: 50-75%, R:<50%)	48				
28	% of pregnant women who initiated ART (G: ≥95%, Y: 80-94%, R:<80%) 82						
30	R:>5%)						
	to 98%, R:<95	·	3				
31	R:>5 %)	reported died, out of those initiated on ART in FY 202324 (G:<2%, Y: 2 to 5 %,	3				
32		edited (G:100%, Y: 80-99%, R:<80%)	100				
33	% participatio	n of ICTCs in re-testing (G: ≥95%, Y: 85-94, R:<85%)	98				
34		stracts selected from studies conducted in FY21-22	4				
25		25 to <100%, R: ≤25%)					
35	R: ≤25%)	going studies from FY22-23 (G:100%, Y: >25 to <100%,	3				
36	Submission of Y: >25 to <10	research proposals from FY23-24 to NACO (G:100%, 0%, R: ≤25%)	1				
37	Secondary Da	ta Analysis by SACS (G:2, Y: 1, R: No Secondary Data Analysis Plan Submitted)	2				
38		vith respect to funds released during FY 2022-23 (G: o <90%, R: <85%)	106				
39		Provisional Utilization Certificate (UC) in GFR 12A for the FY 2022-23 (G : by Y : by 31-May-2023, R : after	03-05-2023				
40	Submission of	audited UC in GFR 12A for the FY 2022-23 (G : by 30Jun-2023, Y : by 30-Sep-30-Sep-2023)	07-07-2023				
41							
40	R: after 30-Se		0.4				
42	_	ssion of CST-SCM Report (G:>95%, Y: 80-95%, R:<80%)	91				
43		rence to CST-SCM Report (G:>95%, Y: 80-95%, R:<80%) ssion of BSD & STI-SCM Report (G: ≥90%, Y: 75- 175%)	96 58				
	Green=3 Marks		Colour=Not Applicable				
Weig	ght points	Indicator SI. No.	··				
	3	1, 23, 29					
	2	2, 3, 9, 10, 22, 30, 34, 42, 44					
	1	4, 5, 6, 7, 8, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 24, 25, 26, 27, 28, 31, 32	2, 33, 35, 36, 37, 38, 39, 40, 41,				
		43					







1. Status of HIV/AIDS Epidemic			
A. Epidemic Estimates (2023)			
Indicator	Male	Female	Total
1. IPR	-	-	2.15
2. IMR	-	-	1.60
3. Adult (15-49 yrs) HIV Prevalence (%)	0.30	0.28	0.29
4. Estimated people living with HIV	2,373	2,101	4,474
5. ART coverage (%)	78.73	84.06	81.35
6. Estimated children living with HIV	44	42	86
7. Annual new HIV infections	49	47	96
8. Annual AIDS-related deaths (ARD)	20	13	33
9. Change in annual new HIV infections since 2010 (%)	-10.91	4.44	-4.95
10. Change in annual ARD since 2010(%)	-93.31	-93.12	-93.24
11. EMTCT need	-	28	28

B. High risk population size (2020-22), sate practices (2021) and prevalence (2021/2023)				
Population Group	Estimates Size	Condom Use (%)	New Needle/ Syringe use (%)	HIV Prevalence (%)
1. Female Sex Workers	5,040	99.20	-	0.60
2. Men who have sex with men	3,339	89.70	-	2.40
3. Injecting Drug Users	302	-	100.00	0.00
4. Hijra/Transgender People	132	-	-	-
5. Migrants	35,000	-	-	-
6. Truckers	23,000	-	-	-
7. Prison inmates	1,856	-	-	_

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)			
Indicator	Male	Female	Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)	67.20	49.00	-
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	72.80	52.90	-
3. Adults willing to care for a relative with HIV/AIDS in own home (%)	79.80	80.10	-
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	83.00	79.80	-
5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)	8.80	5.20	-
5.1 Condom use during last higher-risk intercourse (%)	96.60	100.00	-
6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)	15.12	2.82	-
6.1 Condom use during last higher-risk intercourse (%)	92.31	100.00	-

2. Progress on	75-75-75 (20	23-24)
77 79 80 84 87 91	84 85 84 84 83 84	79 86 86 89 ≥95≥95
PLHIV who know their HIV status (%)	PLHIV who know their HIV status and are on ART (%)	PLHIV who are on ART and virally suppressed (%)
2018-19 2019-20	■ 2020-21 ■ 2021-22	■ 2022-23 ■ 2023-2 4

Indicators	Male	Female	Total*
1. Estimated PLHIV size (2023)	2,373	2,101	4,474
2. PLHIV who know their HIV Status	2,171	1,899	4,078
3. PLHIV who know their HIV status and are on ART	1,753	1,651	3,409
4. PLHIV who are on ART and tested for their viral load	1,474	1,427	2,902
4.1 PLHIV who are virally suppressed	1,466	1,424	2,891

^{*} Including of H/TG PLHIV

3. Prevention of new HIV infections among general population

A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2023-24
Schools with operational Adolescent Education Program (AEP)	528
2. Colleges with operational Red Ribbon Clubs (RRC)	170
3. Persons trained under mainstreaming	1,712
4. No. of calls received at helpline	-

B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management

Indicator	2023-24			
NACO Supported Designated STI/		4	4	
RTI Clinics (DSRC)	Male	Female	TG	Total
2. Total STI/RTI Clients managed				39,211
3. RPR Tests conducted	6,253	3,224	-	9,477
4. Syphilis seropositivity (%)	2.08	0.74	-	1.62

4. Prevention of new HIV infections among high-risk group and bridge population

A. Targeted Intervention (TI) Projects and Opioid Substitution Therapy (OST)

Indicator	2023-24
1. Targeted Intervention (TI) Projects	16
2. OST centres (Excluding Satellite OST centres)	1

B. Female Sex Workers

Indicator	2023-24
1. Estimated size	5,040
2. Coverage (%)	>=95
3. Condoms distributed	19,84,603
4. Tested for HIV (April 2022-September 2022)	5,285
4.1. HIV sero-positive (%)	0.02
4.1.1. Linked to ART	0
5. Tested for HIV (October 2022 -March 2023)	6,384
5.1. HIV sero-positive (%)	0.02
5.1.1. Linked to ART	0
6. Clinic Visits	22,954
7. STI/RTI treated	246
8. Presumptive treatment	710

C. Men who have Sex with Men	
Indicatort	2023-24
1. Estimated size	3,338
2. Coverage (%)	>=95
3. Condoms distributed	9,32,463
4. Tested for HIV (April 2022-September 2022)	3,629
4.1. HIV sero-positive (%)	0.22
4.1.1. Linked to ART	8
5. Tested for HIV (October 2022 -March 2023)	4,177
5.1. HIV sero-positive (%)	0.14
5.1.1. Linked to ART	2
6. Clinic Visits	15,206
7. STI/RTI treated	160
8. Presumptive treatment	337

D. Injecting Drug Users	
Indicator	2023-24
1. Estimated size	301
2. Coverage (%)	>=95
3. Needles distributed	95,739
4. Syringes distributed	95,739
5. On OST	126
6. Tested for HIV (April 2022 -September 2022)	653
6.1. HIV sero-positive (%)	0.00
6.1.1 Linked to ART	0
7. Tested for HIV (October 2022 -March 2023)	870
7.1. HIV sero-positive (%)	0.00
7.1.1. Linked to ART	0

E. Hijra/Transgender person	
Indicator	2023-24
1. Estimated size	131
2. Coverage (%)	>=95
3. Condoms distributed	33,992
4. Tested for HIV (April 2022-September 2022)	121
4.1. HIV sero-positive (%)	0.83
4.1.1. Linked to ART	1
5. Tested for HIV (October 2022 -March 2023)	180
5.1. HIV sero-positive (%)	0.56
5.1.1. Linked to ART	0
6. Clinic Visits	558
7. STI/RTI treated	17
8. Presumptive treatment	18

F. Migrants	
Indicator	2023-24
1. Estimated size	35,000
2. Coverage (%)	>=95
3. Tested for HIV	11,769
3.1. HIV sero-positive (%)	0.08
3.2. Linked to ART	7

G. Truckers	
Indicator	2023-24
1. Estimated size	23,000
2. Coverage (%)	43
3. Tested for HIV	2,578
3.1. HIV sero-positive (%)	0.08
3.2. On ART	2

H. Prison Inmates	
Indicator	2023-24
1. Total prisons	1
2. Prisons covered under programme	1
3. Total inmates admitted	1,856
4. Inmates Covered (%)	35
5. Tested for HIV	651
5.1. HIV sero-positive (%)	0.46
5.2. On ART (%)	>=95

I. Link Worker Scheme	
Indicator	2023-24
Districts covered under scheme	-
Vulnerable population covered	-
3. Tested for HIV	-
3.1. HIV sero-positive (%)	-
3.2. Linked to ART (%)	-

J. Opioid Substitution Therapy	
Indicator	2023-24
1. OST Centres	1
1.1. OSTC in Public Health Settings	-
1.2. OSTC in NGO Settings	1
1.3. No. of Satellite OST Centres	-
2. IDU on OST	126

5. Early detection of HIV infected people

A. HIV counselling and testing services (HCTS)

J	
Indicator	2023-24
1. HCTC confirmatory facilities	13
2. Sampoorna Suraksha Kendras	-

B. HIV testing among vulnerable population (excluding pregnant women)

Indicator	2023-24			
	Male	Female	TG	Total
1. Tested for HIV	68,583	44,542	212	1,13,337
1.1 HIV Positives	183	77	2	262
1.2 HIV sero -positivity (%)	0.27	0.17	0.94	0.23
Spouse/sexual partner of HIV positive people tested	138	112	3	253
2.1 HIV Positives	65	35	3	103
2.2 HIV sero -positivity (%)	47	31	100	40.7
No. of contacts with 'atrisk' population through 'Sampoorna Suraksha'	-	-	-	-

6. Initiation and retention on ART of HIV infected people

A. Treatment facilities

Indicator	2023-24
1. ART Centres	2
2.Centre of Excellence	
2.1. Centre of Excellence (Adult)	-
2.2 Centre of Excellent (Paediatric)	-
3. Link ART Centres	3
4. Care Support Centres	1

B. Treatment uptake

Indicator	2023-24			
	Male	Female	TG	Total
HIV positive cases diagnosed (At ICTC)	183	85	2	270
New PLHIV Registered at ART center	178	85	2	265
2.1 Initiated on ART	169	77	1	247
3. PLHIV alive and on ART	1,753	1,651	5	3,409
4. 12 months retention on ART (%)				93.9
5. Lost to follow-up cases	299	156	3	458

7. Viral Suppression and laboratories	
A. Laboratory facilities and service uptake	0000 0
Indicator 1. Viral load laboratories (programme and non-	2023-2
programme labs)	
1.1 Accredited Viral load laboratories (out of 64 VL labs)	
2. Viral load tests conducted	3,48
2.1. Virally suppressed (%)	>=9
3. National reference laboratories (NRL)	
3.1 Accredited NRL	
4. State reference laboratories (SRL)	
4.1 Accredited SRL	
5. CD4 machines	
5.1 CD4 tests conducted	1,79
6. External Quality Assurance of ICTC	
6.1 Average Participation (%)	10
6.2. Average Discordance (%)	0.0
7. "Certificate of Excellence" by NACO	
7.1 No. of ICTCs received "Certificate of Excellence"	1
8. Elimination of mother to child transi HIV & Syphilis	nission of
A. HIV	
Indicator	2023-2
1. Estimated pregnant women (PW)	22,11
2. HIV testing among PW	33,67
3. HIV sero-positivity (%) among tested	0.0
4. HIV Positive PW (old + new detections)	2
4.1 On life-long ART	2
5. Live births among HIV positive PW	1
5.1 Babies given ARV Prophylaxis (%)	>=9
6. Babies tested HIV (6 week- 6 month)	1
6.1 Babies confirmed HIV Positive	
(6 week- 6 month)	
7. HIV testing among exposed babies at 18 months	
7.1 HIV exposed babies tested at 18 months	1
7.2 Babies confirmed HIV positive at 18 months	
8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months)	
9. HIV positive babies initiated on ART	
B. Syphilis	
Indicator	2023-2
1. Syphilis testing among PW	42,40
2.Sero-positivity (%) among tested	0.0
3. Put on treatment	
9. Elimination of HIV/AIDS related Stigma	
9. Elimination of HIV/AIDS related Stigma and Discrimination	1
9. Elimination of HIV/AIDS related Stigma	2023-2

2. State designated/appointed ombudsman

10. HIV-TB Co-morbidities A. HRG and Bridge Population Indicator 2023-24 IDU Quarter FSW MSM TG Migrants Truckers Total 2,799 2,379 Quarter 1 4,682 3,256 512 98 13,726 Quarter 2 5,450 3,681 551 121 2,696 2,269 14,768 Screened for TB Quarter 3 5,891 3,928 607 141 2,469 2,471 15,507 4,114 4,072 Quarter 4 6,168 672 162 2,397 17,585 Quarter 1 1 1 6 21 5 43 Quarter 2 11 Tested for TB 7 Quarter 3 1 88 159 6 261 Quarter 4 32 138 4 4 2 180 Quarter 1 1 Quarter 2 1 Diagnosed with TB Quarter 3 Quarter 4 Quarter 1 1 1 Quarter 2 Initiated on TB treatment Quarter 3

B. HIV-TB Coinfected at ART Centre Indicator 2023-24 Co-infected initiated on PLHIV with PLHIV PLHIV PLHIV **PLHIV** Co-infected PLHIV tested for TB presumptive TB diagnosed with TB Moths initiated on enrolled at attending underwent ART Centre 4S screening IPT ARTC ART Apr - 23 2,492 2,216 23 6 1,971 7 11 34 May - 23 2,267 Jun - 23 2,416 2,213 14 7 31 Jul - 23 2,417 2,188 30 18 21 38 31 2 20 Aug - 23 2,321 2,001 Sep - 23 2,352 2,201 19 19 1 16 2 Oct - 23 2,538 2,231 19 18 14 1 13 Nov - 23 2,583 2,263 13 11 Dec - 23 2,851 2,454 13 10 18 Jan - 24 3,095 2.745 15 7 18 2 Feb - 24 2,244 1,946 16 16 16 Mar - 24 2,475 2,207 19 14 2 12 April 2023-45 March 2024

Quarter 4

	State/UT Rank	Goa 11
SI.	Maximum Marks	11
No.	Obtained Marks	132 (75%)
1	First 95 (G:≥95%, Y: 80-94%, R:<80%)	91
2	Second 95 (G:≥95%, Y: 80-94%, R:<80%)	84
3	Third 95 (G:≥95%, Y: 80-94%, R:<80%)	>=95
4	Average Frequency of Social Media updates (G: ≥ 45, Y:40- 44, R:<40 indigenous posts) of	49
	Q1, Q2, Q3 & Q4	
5	Status of AEP integration in state school curriculum (G:Yes, R:No)	Yes
6	Status of SCA (G: At least one meeting held since 2020, R: other than G)	Meeting held in 2024
7	Status of State Rules (G: Notified, R: Not notified)	Notified
8	Status of Ombudsman (G: Appointed, R: Not appointed)	Appointed
9	TI/LWS onboarding (G: ≥95%, Y: 90-<95%, R:<90%)	100
10	OST onboarding (G: ≥95%, Y: 90-<95%, R:<90%)	100
11	Coverage of HRG against estimates (G: ≥90%, Y: 80-<90%, R:<80%)	144
12	HIV testing among HRG (G: ≥95%, Y: 90-<95%, R:<90%)	92
13	HIV testing among prisoners (G: ≥50%, Y: 40% to <50%, R:<40%)	34
14	Clinic visit of HRGs at TI-Clinics (G: ≥90%, Y: 75-89%, R:<75%)	88
15	Percentage of HRGs screened for Syphilis (G: ≥90%, Y: 75-89%, R:<75%)	86
16	IDU on OST (G: ≥50%, Y: 30% to <50%, R:<30%)	33
17	Percentage of fund released to TI (G: ≥50%, Y: 45-<50%, R:<45%)	98
18	Percentage of TIs trained by Kshmata Kendra (KK) against the AAP targets (G: ≥75%, Y: 70-	100
1.0	<75%, R:<70%)	
19	HIV testing against Target-at risk % (G: ≥95%, Y: 80-94%, R:<80%)	67
20	HIV testing against target-PW (G: ≥95%, Y: 80-94%, R:<80%)	152
21	Percentage of pregnant women screened for Syphilis (G: ≥95%, Y: 80-94%, R:<80%)	192
22	Treatment provided to Syphilis reactive pregnant women (G: ≥95%, Y: 80-94%, R:<80%)	91
23	Index testing among newly detected HIV positive clients (G: ≥95%, Y: 80-94%, R:<80%)	51
24	Percentage of 6 weeks - <2 months EID testing against live birth (G: ≥95%, Y: 80-94%, R:<80%)	100
25	Clients managed at DSRC against the target (G: ≥90%, Y: 75-89%, R:<75%)	143
26	STI attendees screened for HIV (G: >75%, Y: 50-75%, R:<50%)	11
27	STI attendees screened for Syphilis (G: >75%, Y: 50-75%, R:<50%)	57
28 29	% of pregnant women who initiated ART (G: ≥95%, Y: 80-94%, R:<80%) Proportion of LFU-PLHIV, out of those initiated on ART in FY 2023-24 (G:<2%, Y: 2 to 5%,	109 6
20	R:>5%)	00
30	Proportion of PLHIV initiated on ART, out of those registered in FY 2023-24 (G:>98%, Y: 95 to 98%, R:<95%)	93
31	Proportion of reported died, out of those initiated on ART in FY 202324 (G:<2%, Y: 2 to 5 %, R:>5 %)	5
32	% of SRL accredited (G:100%, Y: 80-99%, R:<80%)	100
33	% participation of ICTCs in re-testing (G: ≥95%, Y: 85-94, R:<85%)	100
34	Number of abstracts selected from studies conducted in FY21-22	2
	(G:100%, Y: >25 to <100%, R: ≤25%)	
35	Number of ongoing studies from FY22-23 (G:100%, Y: >25 to <100%, R: \leq 25%)	2
36	Submission of research proposals from FY23-24 to NACO (G:100%,	1
27	Y: >25 to <100%, R: ≤25%)	
37	Secondary Data Analysis by SACS (G:2, Y: 1, R: No Secondary Data Analysis Plan Submitted)	2
38	Expenditure with respect to funds released during FY 2022-23 (G: ≥90%, Y: 85 to <90%, R: <85%)	119
39	Submission of Provisional Utilization Certificate (UC) in GFR 12A for the FY 2022-23 (G: by 30-Apr-2023, Y: by 31-May-2023, R: after 31-May-2023)	07-06-2023
40	Submission of audited UC in GFR 12A for the FY 2022-23 (G : by 30Jun-2023, Y : by 30-Sep-2023, R : after 30-Sep-2023)	16-02-2024
41	Submission of EC/ GB ratification for approval of Expenditure incurred during FY 2021-22 (G: by 30-Jun-2022, Y: by 30-Sept-2022, R: after 30-Sept-2022)	09-08-2023
42	Timely Submission of CST-SCM Report (G:>95%, Y: 80-95%, R:<80%)	91
43	Format Adherence to CST-SCM Report (G:>95%, Y: 80-95%, R:<80%)	89
44	Timely Submission of BSD & STI-SCM Report (G: ≥90%, Y: 75-<90%, R:<75%)	100
Green	n=3 Marks Yellow=2Marks Red=1 Mark No Colour=No	ot Applicable
	tht points Indicator SI. No.	
.,		
	3 1, 23, 29 2 2, 3, 9, 10, 22, 30, 34, 42, 44	
	4, 5, 6, 7, 8, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 24, 25, 26, 27, 28, 31, 3	





GUJARAT

1. Status of HIV/AIDS Epidemic				
A. Epidemic Estimates (2023)				
Indicator	Male	Female	Total	
1. IPR	-	-	2.22	
2. IMR	-	-	1.37	
3. Adult (15-49 yrs) HIV Prevalence (%)	0.20	0.17	0.19	
4. Estimated people living with HIV	68,926	51,386	1,20,312	
5. ART coverage (%)	76.08	69.79	73.73	
6. Estimated children living with HIV	1,818	1,554	3,372	
7. Annual new HIV infections	1,439	1,232	2,671	
8. Annual AIDS-related deaths (ARD)	370	430	800	
9. Change in annual new HIV infections since 2010 (%)	-57.89	-55.59	-56.86	
10. Change in annual ARD since 2010(%)	-71.60	-60.22	-66.44	
11. EMTCT need	_	1.121	1.121	

B. High risk population size (2020-22), safe practices (2021) and prevalence (2021/2023) Condom Use New Needle/ HIV Prevalence Population Group Estimates Size (%) Syringe use (%) (%) 1. Female Sex Workers 37,118 98.80 1.34 34,299 99.30 4.61 2. Men who have sex with men 98.40 2.00 3. Injecting Drug Users 779 4. Hijra/Transgender People 2,605 3.60 5. Migrants 13,14,462 62.00 0.13 6. Truckers 1,20,000 52.70 0.30 7. Prison inmates 83,285 91.90 94.70 0.50

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)			
Indicator	Male	Female	Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)	35.70	28.50	-
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	33.40	27.20	-
3. Adults willing to care for a relative with HIV/AIDS in own home (%)	87.90	86.30	-
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	72.40	70.40	-
5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)	5.50	0.70	-
5.1 Condom use during last higher-risk intercourse (%)	42.90	51.20	-
6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)	8.72	1.45	-
6.1 Condom use during last higher-risk intercourse (%)	45.52	52.17	-

2. Progress on 95-95-95 (2023-24)			
74 78 79 82 84	87 86 84 84 86 87	86 85 84 93 ≥95 72 84 95 95	
PLHIV who know their HIV status (%)	PLHIV who know their HIV status and are on ART (%)	PLHIV who are on ART and virally suppressed (%)	
■ 2018-19 ■ 2019-20	■ 2020-21 ■ 2021-22	■ 2022-23 ■ 2023-2 4	

Indicators	Male	Female	Total*
1. Estimated PLHIV size (2023)	68,926	51,386	1,20,312
2. PLHIV who know their HIV Status	59,957	40,290	1,00,721
3. PLHIV who know their HIV status and are on ART	51,780	35,412	87,581
4. PLHIV who are on ART and tested for their viral load	35,806	25,203	61,207
4.1 PLHIV who are virally suppressed	34,894	24,512	59,604

^{*} Including of H/TG PLHIV

3. Prevention of new HIV infections among general population

A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2023-24
Schools with operational Adolescent Education Program (AEP)	20,258
2. Colleges with operational Red Ribbon Clubs (RRC)	451
3. Persons trained under mainstreaming	23,723
4. No. of calls received at helpline	-

B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management

Indicator		202	23-24	
NACO Supported Designated STI/		6	0	
RTI Clinics (DSRC)	Male	Female	TG	Total
2. Total STI/RTI Clients managed				3,35,026
3. RPR Tests conducted	59,267	83,888	154	1,43,309
4. Syphilis seropositivity (%)	3.51	0.92	14.29	2.01

4. Prevention of new HIV infections among high-risk group and bridge population

A. Targeted Intervention (TI) Projects and Opioid Substitution Therapy (OST)

Indicator	2023-24
1. Targeted Intervention (TI) Projects	>=95
2. OST centres (Excluding Satellite OST centres)	2

B. Female Sex Workers

Indicator	2023-24
1. Estimated size	37,118
2. Coverage (%)	90.76
3. Condoms distributed	1,23,21,121
4. Tested for HIV (April 2022-September 2022)	27,873
4.1. HIV sero-positive (%)	0.07
4.1.1. Linked to ART	20
5. Tested for HIV (October 2022 -March 2023)	30,294
5.1. HIV sero-positive (%)	0.03
5.1.1. Linked to ART	9
6. Clinic Visits	1,19,723
7. STI/RTI treated	1,885
8. Presumptive treatment	4,876

C. Men who have Sex with Men		
Indicatort	2023-24	
1. Estimated size	34,299	
2. Coverage (%)	93	
3. Condoms distributed	81,72,817	
4. Tested for HIV (April 2022-September 2022)	25,316	
4.1. HIV sero-positive (%)	0.23	
4.1.1. Linked to ART	50	
5. Tested for HIV (October 2022 -March 2023)	28,063	
5.1. HIV sero-positive (%)	0.15	
5.1.1. Linked to ART	40	
6. Clinic Visits	1,13,759	
7. STI/RTI treated	1,173	
8. Presumptive treatment	4,374	

D. Injecting Drug Users	
Indicator	2023-24
1. Estimated size	778
2. Coverage (%)	>=95
3. Needles distributed	1,44,428
4. Syringes distributed	1,44,428
5. On OST	36
6. Tested for HIV (April 2022 -September 2022)	719
6.1. HIV sero-positive (%)	0.00
6.1.1 Linked to ART	-
7. Tested for HIV (October 2022 -March 2023)	875
7.1. HIV sero-positive (%)	0.11
7.1.1. Linked to ART	1

E. Hijra/Transgender person	
Indicator	2023-24
1. Estimated size	2,604
2. Coverage (%)	74
3. Condoms distributed	3,88,370
4. Tested for HIV (April 2022-September 2022)	1,612
4.1. HIV sero-positive (%)	0.19
4.1.1. Linked to ART	2
5. Tested for HIV (October 2022 -March 2023)	1,767
5.1. HIV sero-positive (%)	0.06
5.1.1. Linked to ART	1
6. Clinic Visits	7,020
7. STI/RTI treated	49
8. Presumptive treatment	233

F. Migrants	
Indicator	2023-24
1. Estimated size	13,14,462
2. Coverage (%)	66
3. Tested for HIV	56,328
3.1. HIV sero-positive (%)	0.12
3.2. Linked to ART	66

G. Truckers	
Indicator	2023-24
1. Estimated size	1,20,000
2. Coverage (%)	46
3. Tested for HIV	8,979
3.1. HIV sero-positive (%)	0.13
3.2. On ART	9

H. Prison Inmates			
Indicator	2023-24		
1. Total prisons	32		
2. Prisons covered under programme	39		
3. Total inmates admitted	83,285		
4. Inmates Covered (%)	31		
5. Tested for HIV	26,213		
5.1. HIV sero-positive (%)	0.20		
5.2. On ART (%)	84.62		

I. Link Worker Scheme	
Indicator	2023-24
Districts covered under scheme	16
Vulnerable population covered	1,36,335
3. Tested for HIV	47,481
3.1. HIV sero-positive (%)	0.13
3.2. Linked to ART (%)	92.19

J. Opioid Substitution Therapy	
Indicator	2023-24
1. OST Centres	2
1.1. OSTC in Public Health Settings	2
1.2. OSTC in NGO Settings	-
1.3. No. of Satellite OST Centres	-
2. IDU on OST	88

5. Early detection of HIV infected people

A. HIV counselling and testing services (HCTS)

Indicator	2023-24
1. HCTC confirmatory facilities	261
2. Sampoorna Suraksha Kendras	13

B. HIV testing among vulnerable population (excluding pregnant women)

Indicator	2023-24			
	Male	Female	TG	Total
1. Tested for HIV	9,63,623	7,81,311	3,714	17,48,648
1.1 HIV Positives	5,357	2,268	30	7,655
1.2 HIV sero -positivity (%)	0.56	0.29	0.81	0.44
Spouse/sexual partner of HIV positive people tested	2,101	4,986	11	7,098
2.1 HIV Positives	706	946	2	1,654
2.2 HIV sero -positivity (%)	34	19	18	23.30
3. No. of contacts with 'at- risk' population through 'Sampoorna Suraksha'	-	-	-	5,415

6. Initiation and retention on ART of HIV infected people

A. Treatment facilities

Indicator	2023-24
1. ART Centres	47
2.Centre of Excellence	
2.1. Centre of Excellence (Adult)	1
2.2 Centre of Excellent (Paediatric)	-
3. Link ART Centres	61
4. Care Support Centres	25

B. Treatment uptake

Indicator	2023-24			
	Male	Female	TG	Total
HIV positive cases diagnosed (At ICTC)	5,357	2,831	30	8,218
New PLHIV Registered at ART center	5,002	2,674	33	7,709
2.1 Initiated on ART	4,762	2,582	33	7,377
3. PLHIV alive and on ART	51,780	35,412	390	87,581
4. 12 months retention on ART (%)				>=95
5. Lost to follow-up cases	5,723	3,191	77	8,991

7. Viral Suppression and laboratories	
A. Laboratory facilities and service uptake	
Indicator	2023-2
Viral load laboratories (programme and non- programme labs)	
1.1 Accredited Viral load laboratories (out of 64 VL labs)	
2. Viral load tests conducted	71,23
2.1. Virally suppressed (%)	92.
3. National reference laboratories (NRL)	
3.1 Accredited NRL	
4. State reference laboratories (SRL)	
4.1 Accredited SRL	
5. CD4 machines	2
5.1 CD4 tests conducted	42,11
6. External Quality Assurance of ICTC	
6.1 Average Participation (%)	>=9
6.2. Average Discordance (%)	0.0
7. "Certificate of Excellence" by NACO	
7.1 No. of ICTCs received "Certificate of Excellence"	
8. Elimination of mother to child trans HIV & SyphilisA. HIV	mission of
Indicator	2023-2
1. Estimated pregnant women (PW)	15,05,12
2. HIV testing among PW	12,90,03
3. HIV sero-positivity (%) among tested	0.0
4. HIV Positive PW (old + new detections)	1,17
4.1 On life-long ART	1,09
5. Live births among HIV positive PW	86
5.1 Babies given ARV Prophylaxis (%)	>=9
6. Babies tested HIV (6 week- 6 month)	89
6.1 Babies confirmed HIV Positive (6 week- 6 month)	
7. HIV testing among exposed babies at 18 months	
7.1 HIV exposed babies tested at 18 months	71
7.2 Babies confirmed HIV positive at 18 months	
8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months)	3
9. HIV positive babies initiated on ART	2
B. Syphilis	
Indicator	2023-2
Syphilis testing among PW	13,88,74
	0.0
2.Sero-positivity (%) among tested	
Sero-positivity (%) among tested Put on treatment	
3. Put on treatment 9. Elimination of HIV/AIDS related Stigma	2023-2
3. Put on treatment 9. Elimination of HIV/AIDS related Stigma and Discrimination	68

2. State designated/appointed ombudsman

Yes

10. HIV-TB Co-m	orbidities							
A. HRG and Bridge	e Population							
Indicator				202	3-24			
	Quarter	FSW	MSM	IDU	TG	Migrants	Truckers	Total
	Quarter 1	26,547	25,590	815	2,278	30,037	12,706	97,973
Screened for TB	Quarter 2	27,081	25,698	978	2,506	36,261	12,636	1,05,160
Screened for 1B	Quarter 3	26,478	25,268	957	2,646	41,059	12,609	1,09,017
	Quarter 4	27,355	25,690	924	2,604	43,570	13,292	1,13,435
	Quarter 1	738	1,371	20	147	586	107	2,969
Tarkerd for TD	Quarter 2	1,041	1,330	42	175	386	102	3,076
Tested for TB	Quarter 3	977	1,256	32	209	366	78	2,918
	Quarter 4	862	1,142	28	160	439	84	2,715
	Quarter 1	4	4	2	-	10	2	22
Diamana davida TD	Quarter 2	2	12	-	-	6	-	20
Diagnosed with TB	Quarter 3	3	5	-	-	16	-	24
	Quarter 4	2	5	-	1	14	-	22
	Quarter 1	4	6	2	-	9	-	21
Initiated on TB	Quarter 2	2	12	-	-	7	-	21
treatment	Quarter 3	3	5	-	-	16	-	24
	Quarter 4	2	4	-	1	14	-	21

B. HIV-TB Coinfected at ART Centre Indicator 2023-24 PLHIV with presumptive TB PLHIV PLHIV PLHIV PLHIV Co-infected enrolled at Co-infected initiated on ART PLHIV tested for TB diagnosed with TB initiated on IPT Moths attending underwent ART Centre 4S screening ARTC 51,984 3,025 Apr - 23 51,153 3,015 182 411 177 51,954 51,041 3,073 3,051 483 May - 23 Jun - 23 49,680 48,789 2,952 2,932 175 399 Jul - 23 50,472 49,551 3,065 3,044 151 353 52,490 51,915 3,183 160 390 Aug - 23 3,149 Sep - 23 51,394 50,780 2,998 2,953 157 309 52,274 51,691 3,071 324 Oct - 23 3,028 167 2,909 129 Nov - 23 55,165 54,347 2,850 366 Dec - 23 61,241 60,645 3,069 3,009 153 371 Jan - 24 60,275 3,328 3,270 61,102 135 422 3,257 Feb - 24 60,615 60,101 3,191 153 359 Mar - 24 57,873 57,293 3,191 3,133 184 338 April 2023-51,984 51,153 March 2024

	State/UT	Gujarat
CI	Rank	12
SI. No.	Maximum Marks	177
1	Obtained Marks	131 (74%) 84
2	First 95 (G:≥95%, Y: 80-94%, R:<80%) Second 95 (G:≥95%, Y: 80-94%, R:<80%)	87
3	Third 95 (G:≥95%, Y: 80-94%, R:<80%)	>=95
4	Average Frequency of Social Media updates (G: ≥ 45, Y:40- 44, R:<40 indigenous posts) of	1
	Q1, Q2, Q3 & Q4	
5	Status of AEP integration in state school curriculum (G:Yes, R:No)	Yes
6	Status of SCA (G: At least one meeting held since 2020, R: other than G)	Meeting held in 2010
7	Status of State Rules (G: Notified, R: Not notified)	Notified
8	Status of Ombudsman (G: Appointed, R: Not appointed)	Appointed
9	TI/LWS onboarding (G: ≥95%, Y: 90-<95%, R:<90%)	100
10	OST onboarding (G: ≥95%, Y: 90-<95%, R:<90%)	100
11	Coverage of HRG against estimates (G: ≥90%, Y: 80-<90%, R:<80%)	92
12	HIV testing among HRG (G: ≥95%, Y: 90-<95%, R:<90%)	87
13	HIV testing among prisoners (G: ≥50%, Y: 40% to <50%, R:<40%)	27
14	Clinic visit of HRGs at TI-Clinics (G: ≥90%, Y: 75-89%, R:<75%)	91
15	Percentage of HRGs screened for Syphilis (G: ≥90%, Y: 75-89%, R:<75%)	88
16 17	IDU on OST (G: ≥50%, Y: 30% to <50%, R:<30%) Percentage of fund released to TI (G: ≥50%, Y: 45-<50%, R:<45%)	17 100
18	Percentage of Tls trained by Kshmata Kendra (KK) against the AAP targets (G: ≥75%, Y: 70-	100
	ercentage of this trained by Ashmata Kendra (KK) against the AAF targets (d. 275%, 1: 70- <75%, R:<70%)	100
19	HIV testing against Target-at risk % (G: ≥95%, Y: 80-94%, R:<80%)	187
20	HIV testing against target-PW (G: ≥95%, Y: 80-94%, R:<80%)	86
21	Percentage of pregnant women screened for Syphilis (G: ≥95%, Y: 80-94%, R:<80%)	92
22	Treatment provided to Syphilis reactive pregnant women (G: ≥95%, Y: 80-94%, R:<80%)	95
23	Index testing among newly detected HIV positive clients (G: ≥95%, Y: 80-94%, R:<80%)	35
24	Percentage of 6 weeks - <2 months EID testing against live birth (G: ≥95%, Y: 80-94%,	100
	R:<80%)	
25	Clients managed at DSRC against the target (G: ≥90%, Y: 75-89%, R:<75%)	55
26	STI attendees screened for HIV (G: >75%, Y: 50-75%, R:<50%)	96
27	STI attendees screened for Syphilis (G: >75%, Y: 50-75%, R:<50%)	82
28	% of pregnant women who initiated ART (G: ≥95%, Y: 80-94%, R:<80%)	87
29	Proportion of LFU-PLHIV, out of those initiated on ART in FY 2023-24 (G:<2%, Y: 2 to 5%, R:>5%)	4
30	Proportion of PLHIV initiated on ART, out of those registered in FY 2023-24 (G:>98%, Y: 95 to 98%, R:<95%)	96
31	Proportion of reported died, out of those initiated on ART in FY 202324 (G:<2%, Y: 2 to 5 %, R:>5 %)	6
32	% of SRL accredited (G:100%, Y: 80-99%, R:<80%)	100
33	% participation of ICTCs in re-testing (G: ≥95%, Y: 85-94, R:<85%)	96
34	Number of abstracts selected from studies conducted in FY21- 1 (G:100%, Y: >25 to <100%, R: \leq 25%)	2
35	Number of ongoing studies from FY22-23 (G:100%, Y: >25 to <100%, R: ≤25%)	5
36	Submission of research proposals from FY23-24 to NACO (G:100%, Y: >25 to <100%, R: ≤25%)	2
37	Secondary Data Analysis by SACS (G:2, Y: 1, R: No Secondary Data Analysis Plan Submitted)	2
38	Expenditure with respect to funds released during FY 2022-23 (G:	111
39	≥90%, Y: 85 to <90%, R: <85%) Submission of Provisional Utilization Certificate (UC) in GFR 12A for the FY 2022-23 (G: by 30-Apr-2023, Y: by 31-May-2023, R: after	06-06-2023
40	31-May-2023, 1 : By 31-May-2023, 1 : alter 31-May-2023) Submission of audited UC in GFR 12A for the FY 2022-23 (G : by 30Jun-2023, Y : by 30-Sep-	13-02-2024
41	2023, R : after 30-Sep-2023) Submission of EC/ GB ratification for approval of Expenditure incurred during FY 2021-22 (G:	09-05-2023
40	by 30-Jun-2022, Y: by 30-Sept-2022, R: after 30-Sept-2022)	0/-
42	Timely Submission of CST-SCM Report (G:>95%, Y: 80-95%, R:<80%)	96
43 44	Format Adherence to CST-SCM Report (G:>95%, Y: 80-95%, R:<80%)	100 75
-+-+	Timely Submission of BSD & STI-SCM Report (G: ≥90%, Y: 75-<90%, R:<75%)	
)A/ :		Colour=Not Applicable
vveig	ht points Indicator SI. No. 3 1, 23, 29	
	2 2, 3, 9, 10, 22, 30, 34, 42, 44	





HARYANA

1. Status of HIV/AIDS Epidemic			
A. Epidemic Estimates (2023)			
Indicator	Male	Female	Total
1. IPR	-	-	5.12
2. IMR	-	-	3.74
3. Adult (15-49 yrs) HIV Prevalence (%)	0.28	0.17	0.23
4. Estimated people living with HIV	36,310	20,268	56,578
5. ART coverage (%)	61.21	66.22	63.20
6. Estimated children living with HIV	752	628	1,380
7. Annual new HIV infections	1,932	965	2,897
8. Annual AIDS-related deaths (ARD)	208	97	305
9. Change in annual new HIV infections since 2010 (%)	-23.82	-25.19	-24.26
10. Change in annual ARD since 2010(%)	-79.43	-79.23	-79.36
11. EMTCT need	-	513	513

B. High risk population size (2020-22), safe practices (2021) and prevalence (2021/2023) Condom Use New Needle/ HIV Prevalence Estimates Size Population Group (%) Syringe use (%) (%) 97.00 1. Female Sex Workers 17,668 1.33 99.20 8,022 6.89 2. Men who have sex with men 3. Injecting Drug Users 19,025 97.60 9.24 4. Hijra/Transgender People 1,435 5. Migrants 1,31,755 6. Truckers 15,000 7. Prison inmates 90,701 59.30 77.30 2.75

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)					
Indicator	Male	Female	Total		
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)	36.40	19.70	-		
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	31.70	17.50	-		
3. Adults willing to care for a relative with HIV/AIDS in own home (%)	84.50	75.20	-		
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	78.90	64.30	-		
5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)	6.70	0.20	-		
5.1 Condom use during last higher-risk intercourse (%)	70.10	35.00	-		
6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)	10.94	0.38	-		
6.1 Condom use during last higher-risk intercourse (%)	65.29	20.00	-		

2. Progress on	95-95-95 (202	23-24)
34 43 47 54 63 69	79 73 81 89 92	82 78 87 94
PLHIV who know their HIV status (%)	PLHIV who know their HIV status and are on ART (%)	PLHIV who are on ART and virally suppressed (%)
■ 2018-19 ■ 2019-20	■ 2020-21 ■ 2021-22	■ 2022-23 ■ 2023-2 4

Indicators	Male	Female	Total*
1. Estimated PLHIV size (2023)	36,310	20,268	56,578
2. PLHIV who know their HIV Status	24,366	14,697	39,182
3. PLHIV who know their HIV status and are on ART	22,446	13,588	36,148
4. PLHIV who are on ART and tested for their viral load	8,896	6,540	15,480
4.1 PLHIV who are virally suppressed	8,359	6,203	14,607

^{*} Including of H/TG PLHIV

3. Prevention of new HIV infections among general population

A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2023-24
Schools with operational Adolescent Education Program (AEP)	3,397
2. Colleges with operational Red Ribbon Clubs (RRC)	429
3. Persons trained under mainstreaming	35,098
4. No. of calls received at helpline	_

B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management

Indicator	2023-24			
NACO Supported Designated STI/	31			
RTI Clinics (DSRC)	Male	Female	TG	Total
2. Total STI/RTI Clients managed				2,20,036
3. RPR Tests conducted	37,863	90,427	68	1,28,358
4. Syphilis seropositivity (%)	1.56	0.21	7.35	0.61

4. Prevention of new HIV infections among high-risk group and bridge population

A. Targeted Intervention (TI) Projects and Opioid Substitution Therapy (OST)

Indicator	2023-24
1. Targeted Intervention (TI) Projects	35
2. OST centres (Excluding Satellite OST centres)	13

B. Female Sex Workers

Indicator	2023-24
1. Estimated size	17,667
2. Coverage (%)	92.97
3. Condoms distributed	22,02,726
4. Tested for HIV (April 2022-September 2022)	9,003
4.1. HIV sero-positive (%)	0.34
4.1.1. Linked to ART	25
5. Tested for HIV (October 2022 -March 2023)	10,865
5.1. HIV sero-positive (%)	0.34
5.1.1. Linked to ART	19
6. Clinic Visits	41,731
7. STI/RTI treated	1,024
8. Presumptive treatment	1,674

C. Men who have Sex with Men

Indicatort	2023-24
1. Estimated size	8,022
2. Coverage (%)	76
3. Condoms distributed	7,48,356
4. Tested for HIV (April 2022-September 2022)	4,002
4.1. HIV sero-positive (%)	1.47
4.1.1. Linked to ART	43
5. Tested for HIV (October 2022 -March 2023)	4,762
5.1. HIV sero-positive (%)	0.86
5.1.1. Linked to ART	30
6. Clinic Visits	19,051
7. STI/RTI treated	273
8. Presumptive treatment	675

D. Injecting Drug Users	
Indicator	2023-24
1. Estimated size	19,024
2. Coverage (%)	51
3. Needles distributed	18,55,641
4. Syringes distributed	11,90,809
5. On OST	2,094
6. Tested for HIV (April 2022 -September 2022)	4,504
6.1. HIV sero-positive (%)	4.06
6.1.1 Linked to ART	137
7. Tested for HIV (October 2022 -March 2023)	6,496
7.1. HIV sero-positive (%)	3.17
7.1.1. Linked to ART	125

E. Hijra/Transgender person	
Indicator	2023-24
1. Estimated size	1,434
2. Coverage (%)	35
3. Condoms distributed	39,055
4. Tested for HIV (April 2022-September 2022)	287
4.1. HIV sero-positive (%)	0.70
4.1.1. Linked to ART	2
5. Tested for HIV (October 2022 -March 2023)	475
5.1. HIV sero-positive (%)	0.63
5.1.1. Linked to ART	2
6. Clinic Visits	1,474
7. STI/RTI treated	13
8. Presumptive treatment	90

F. Migrants	
Indicator	2023-24
1. Estimated size	1,31,755
2. Coverage (%)	>=95
3. Tested for HIV	14,722
3.1. HIV sero-positive (%)	0.21
3.2. Linked to ART	30

G. Truckers	
Indicator	2023-24
1. Estimated size	15,000
2. Coverage (%)	>=95
3. Tested for HIV	6,787
3.1. HIV sero-positive (%)	0.72
3.2. On ART	45

H. Prison Inmates	
Indicator	2023-24
1. Total prisons	19
2. Prisons covered under programme	20
3. Total inmates admitted	90,701
4. Inmates Covered (%)	46
5. Tested for HIV	41,952
5.1. HIV sero-positive (%)	1.13
5.2. On ART (%)	>=95

I. Link Worker Scheme	
Indicator	2023-24
Districts covered under scheme	-
Vulnerable population covered	-
3. Tested for HIV	-
3.1. HIV sero-positive (%)	-
3.2. Linked to ART (%)	-

J. Opioid Substitution Therapy	
Indicator	2023-24
1. OST Centres	13
1.1. OSTC in Public Health Settings	13
1.2. OSTC in NGO Settings	-
1.3. No. of Satellite OST Centres	2
2. IDU on OST	2,094

5. Early detection of HIV infected people A. HIV counselling and testing services (HCTS)

	*
Indicator	2023-24
1. HCTC confirmatory facilities	104
2. Sampoorna Suraksha Kendras	3

B. HIV testing among vulnerable population (excluding pregnant women)

Indicator	2023-24			
	Male	Female	TG	Total
1. Tested for HIV	4,89,298	3,92,655	910	8,82,863
1.1 HIV Positives	4,683	1,386	34	6,103
1.2 HIV sero -positivity (%)	0.96	0.35	3.74	0.69
Spouse/sexual partner of HIV positive people tested	1,877	2,106	14	3,997
2.1 HIV Positives	566	574	4	1,144
2.2 HIV sero -positivity (%)	30	27	29	28.62
3. No. of contacts with 'at- risk' population through 'Sampoorna Suraksha'	-	-	-	1,946

6. Initiation and retention on ART of HIV infected people

A. Treatment facilities

Indicator	2023-24
1. ART Centres	27
2.Centre of Excellence	
2.1. Centre of Excellence (Adult)	-
2.2 Centre of Excellent (Paediatric)	-
3. Link ART Centres	6
4. Care Support Centres	1

B. Treatment uptake


Indicator	2023-24				
	Male	Female	TG	Total	
HIV positive cases diagnosed (At ICTC)	4,683	1,749	34	6,466	
New PLHIV Registered at ART center	4,566	1,811	28	6,405	
2.1 Initiated on ART	4,483	1,781	28	6,292	
3. PLHIV alive and on ART	22,446	13,588	114	36,148	
4. 12 months retention on ART (%)				92.3	
5. Lost to follow-up cases	1,236	651	6	1,893	

A. Laboratory facilities and service linear	•
A. Laboratory facilities and service uptake Indicator	- 2023-2
Viral load laboratories (programme and non- programme labs)	
1.1 Accredited Viral load laboratories (out of 64 VL labs)	
2. Viral load tests conducted	20,83
2.1. Virally suppressed (%)	93
3. National reference laboratories (NRL)	
3.1 Accredited NRL	
4. State reference laboratories (SRL)	
4.1 Accredited SRL	
5. CD4 machines	
5.1 CD4 tests conducted	15,75
6. External Quality Assurance of ICTC	
6.1 Average Participation (%)	· ·
6.2. Average Discordance (%)	0.0
7. "Certificate of Excellence" by NACO	
7.1 No. of ICTCs received "Certificate of Excellence"	
8. Elimination of mother to child trans HIV & Syphilis	smission of
A. HIV	
Indicator	2023-2
Estimated pregnant women (PW)	6,84,08
2. HIV testing among PW	5,86,98
3. HIV sero-positivity (%) among tested	0.0
4. HIV Positive PW (old + new detections)	58
4.1 On life-long ART	55
5. Live births among HIV positive PW	57
5.1 Babies given ARV Prophylaxis (%)	>=9
6. Babies tested HIV (6 week- 6 month)	5
6.1 Babies confirmed HIV Positive (6 week- 6 month)	
7. HIV testing among exposed babies at 18 months	
7.1 HIV exposed babies tested at 18 months	43
7.2 Babies confirmed HIV positive at 18 months	
8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months)	
9. HIV positive babies initiated on ART	
B. Syphilis	
Indicator	2023-2
1. Syphilis testing among PW	6,75,57
2.Sero-positivity (%) among tested	0.0
3. Put on treatment	10
Elimination of HIV/AIDS related Stigma and Discrimination	1
Indicator	2023-2
1. State rules notified for HIV/AIDS Prevention and Control Act (2017)	N

10. HIV-TB Co-morbidities								
A. HRG and Bridge Population								
Indicator 2023-24								
	Quarter	FSW	MSM	IDU	TG	Migrants	Truckers	Total
	Quarter 1	9,981	4,453	4,224	192	12,399	12,316	43,565
C II TD	Quarter 2	9,902	4,746	4,276	358	11,786	13,529	44,597
Screened for TB	Quarter 3	10,140	4,926	5,509	661	13,502	13,945	48,683
	Quarter 4	10,474	4,833	6,214	496	13,256	11,390	46,663
	Quarter 1	9	6	28	-	31	19	93
Tested for TB	Quarter 2	30	10	189	-	19	18	266
rested for TB	Quarter 3	48	10	305	3	18	8	392
	Quarter 4	122	25	425	-	14	91	677
	Quarter 1	1	1	3	-	-	1	6
Diamana da ida TD	Quarter 2	1	2	6	-	1	3	13
Diagnosed with TB	Quarter 3	3	3	3	-	-	-	9
	Quarter 4	2	3	16	-	-	2	23
	Quarter 1	1	1	3	-	-	1	6
Initiated on TB	Quarter 2	1	2	5	-	1	3	12
treatment	Quarter 3	2	1	1	-	-	-	4
	Quarter 4	1	1	12	-	-	2	16

B. HIV-TB Coinfected at ART Centre Indicator 2023-24 Co-infected enrolled at PLHIV with presumptive TB PLHIV PLHIV PLHIV PLHIV Co-infected initiated on ART PLHIV tested for TB diagnosed with TB initiated on IPT Moths attending underwent ART Centre 4S screening ARTC 13,230 13,230 579 Apr - 23 340 340 56 394 504 13,903 13,903 394 64 May - 23 Jun - 23 13,430 13,430 377 377 41 Jul - 23 13,389 11,918 827 441 42 388 11,962 11,960 1,228 497 63 397 Aug - 23 Sep - 23 11,450 10,659 1,201 427 53 364 Oct - 23 11,614 11,614 986 460 34 467 1,197 41 412 Nov - 23 11,861 11,861 426 Dec - 23 13,412 13,412 1,203 420 39 425 Jan - 24 13,355 458 580 13,730 451 46 Feb - 24 13,279 12,691 360 348 46 569 Mar - 24 13,966 13,315 389 389 65 566 April 2023-657 616 March 2024

		State/UT	Haryana
-1		Rank	23
SI. Io.	Maximum Ma		177
1	Obtained Ma		123 (69%)
2	-	95%, Y: 80-94%, R:<80%) 5:≥95%, Y: 80-94%, R:<80%)	92
3	4	:95%, Y: 80-94%, R:<80%)	94
4		quency of Social Media updates (G: ≥ 45, Y:40- 44, R:<40 indigenous posts) of	121
•	Q1, Q2, Q3 8		121
5	Status of AEF	P integration in state school curriculum (G:Yes, R:No)	Yes
5		A (G: At least one meeting held since 2020, R: other than G)	No Meeting held
7		te Rules (G: Notified, R: Not notified)	Not Notified
3	Status of Om	budsman (G: Appointed, R: Not appointed)	Appointed
7	TI/LWS onbo	arding (G: ≥95%, Y: 90-<95%, R:<90%)	81
C	OST onboard	ding (G: ≥95%, Y: 90-<95%, R:<90%)	100
1	Coverage of	HRG against estimates (G: ≥90%, Y: 80-<90%, R:<80%)	70
2	HIV testing a	mong HRG (G: ≥95%, Y: 90-<95%, R:<90%)	78
3	HIV testing a	mong prisoners (G: ≥50%, Y: 40% to <50%, R:<40%)	59
1	Clinic visit of	HRGs at TI-Clinics (G: ≥90%, Y: 75-89%, R:<75%)	76
5	Percentage o	of HRGs screened for Syphilis (G: ≥90%, Y: 75-89%, R:<75%)	70
5		(G: ≥50%, Y: 30% to <50%, R:<30%)	45
7	9	of fund released to TI (G: ≥50%, Y: 45-<50%, R:<45%)	82
3	<75%, R:<70	·	100
7		gainst Target-at risk % (G: ≥95%, Y: 80-94%, R:<80%)	222
)		gainst target-PW (G: ≥95%, Y: 80-94%, R:<80%)	86
1		of pregnant women screened for Syphilis (G: ≥95%, Y: 80-94%, R:<80%)	99
2		ovided to Syphilis reactive pregnant women (G: ≥95%, Y: 80-94%, R:<80%)	96
3	Index testing	among newly detected HIV positive clients (G: ≥95%, Y: 80-94%, R:<80%)	34
4	Percentage of R:<80%)	of 6 weeks - <2 months EID testing against live birth (G: ≥95%, Y: 80-94%,	97
5	Clients mana	ged at DSRC against the target (G: ≥90%, Y: 75-89%, R:<75%)	87
6	STI attendees	s screened for HIV (G: >75%, Y: 50-75%, R:<50%)	72
7	STI attendees	s screened for Syphilis (G: >75%, Y: 50-75%, R:<50%)	80
3	% of pregnan	nt women who initiated ART (G: ≥95%, Y: 80-94%, R:<80%)	70
9	Proportion of R:>5%)	f LFU-PLHIV, out of those initiated on ART in FY 2023-24 (G:<2%, Y: 2 to 5%,	3
0	Proportion of to 98%, R:<9	FPLHIV initiated on ART, out of those registered in FY 2023-24 (G:>98%, Y: 955%)	98
1	Proportion of R:>5 %)	f reported died, out of those initiated on ART in FY 202324 (G:<2%, Y: 2 to 5 %,	2
2	% of SRL acci	redited (G:100%, Y: 80-99%, R:<80%)	100
3	% participation	on of ICTCs in re-testing (G: ≥95%, Y: 85-94, R:<85%)	93
4		bstracts selected from studies conducted in FY21-22	2
	(G:100%, Y: >	>25 to <100%, R: ≤25%)	
5	Number of o R: ≤25%)	ngoing studies from FY22-23 (G:100%, Y: >25 to <100%,	4
6		of research proposals from FY23-1 to NACO (G:100%,	2
	Y: >25 to <10	00%, R: ≤25%)	
7	Secondary D	ata Analysis by SACS (G:2, Y: 1, R: No Secondary Data Analysis Plan Submitted)	2
3		with respect to funds released during FY 2022-23 (G:	113
		to <90%, R: <85%)	
9		of Provisional Utilization Certificate (UC) in GFR 12A for the FY 2022-23 (G : by ,Y : by 31-May-2023, R : after	03-07-2023
0	Submission o	of audited UC in GFR 12A for the FY 2022-23 (G : by 30Jun-2023, Y : by 30-Sep-	19-01-2024
_		er 30-Sep-2023)	
1		of EC/ GB ratification for approval of Expenditure incurred during FY 2021-22 n-2022, Y: by 30-Sept-2022, ent-2022)	19-01-2024
2		ission of CST-SCM Report (G:>95%, Y: 80-95%, R:<80%)	94
3		erence to CST-SCM Report (G:>95%, Y: 80-95%, R:<80%)	96
4		ission of BSD & STI-SCM Report (G: ≥90%, Y: 75-	100
	Green=3 Mark		Colour=Not Applicable
/ei	ght points	Indicator SI. No.	11.00. Hot Applicable
· e 1	•		
	2	1, 23, 29	
		2, 3, 9, 10, 22, 30, 34, 42, 44	22 22 25 27 22 22 22
	1	4, 5, 6, 7, 8, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 24, 25, 26, 27, 28, 31, 3	,2, ,3, ,3, ,0, 3/, 38, 39, 40







1. Status of HIV/AIDS Epidemic				
A. Epidemic Estimates (2023)				
Indicator	Male	Female	Total	
1. IPR	-	-	2.65	
2. IMR	-	-	1.49	
3. Adult (15-49 yrs) HIV Prevalence (%)	0.13	0.10	0.11	
4. Estimated people living with HIV	4,434	3,449	7,883	
5. ART coverage (%)	71.56	81.57	76.01	
6. Estimated children living with HIV	79	70	149	
7. Annual new HIV infections	118	91	209	
8. Annual AIDS-related deaths (ARD)	46	19	65	
9. Change in annual new HIV infections since 2010 (%)	-64.46	-55.39	-61.01	
10. Change in annual ARD since 2010(%)	-85.71	-79.57	-84.58	
11. EMTCT need	-	34	34	

B. High risk population size (2020-22), safe practices (2021) and prevalence (2021/2023) Condom Use New Needle/ **HIV Prevalence** Estimates Size Population Group (%) Syringe use (%) (%) 97.60 1. Female Sex Workers 13,210 0.55 98.80 2. Men who have sex with men 1,252 1.56 3. Injecting Drug Users 3,662 99.60 4.40 4. Hijra/Transgender People 258 5. Migrants 1,45,880 39.40 0.00 6. Truckers 14,000 8,441 63.20 73.30 0.00 7. Prison inmates

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)					
Indicator	Male	Female	Total		
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)	40.80	36.20	-		
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	37.30	34.00	-		
3. Adults willing to care for a relative with HIV/AIDS in own home (%)	87.10	89.70	-		
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	85.20	80.70	-		
5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)	5.90	0.20	-		
5.1 Condom use during last higher-risk intercourse (%)	76.20	28.80	-		
6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)	8.07	0.67	-		
6.1 Condom use during last higher-risk intercourse (%)	66.67	33.33	-		

2. Progress on	75-75-75 (20	23-24)
62 65 68 71 75 80	87 89 86 87 88 90	81 84 82 56 81 84 82
PLHIV who know their HIV status (%)	PLHIV who know their HIV status and are on ART (%)	PLHIV who are on ART and virally suppressed (%)
■ 2018-19 ■ 2019-20	■ 2020-21 ■ 2021-22	■ 2022-23 ■ 2023-2 4

Indicators	Male	Female	Total*
1. Estimated PLHIV size (2023)	4,434	3,449	7,883
2. PLHIV who know their HIV Status	3,422	2,852	6,279
3. PLHIV who know their HIV status and are on ART	2,997	2,638	5,640
4. PLHIV who are on ART and tested for their viral load	2,641	2,346	4,991
4.1 PLHIV who are virally suppressed	2,597	2,304	4,905

^{*} Including of H/TG PLHIV

3. Prevention of new HIV infections among general population

A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2023-24
Schools with operational Adolescent Education Program (AEP)	1,971
2. Colleges with operational Red Ribbon Clubs (RRC)	309
3. Persons trained under mainstreaming	12,215
4. No. of calls received at helpline	_

B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management

Indicator		202	23-24	
1. NACO Supported		2	0	
Designated STI/ RTI Clinics (DSRC)	Male	Female	TG	Total
2. Total STI/RTI Clients managed				1,16,958
3. RPR Tests conducted	31,359	41,251	3	72,613
4. Syphilis seropositivity (%)	0.51	0.11	33.33	0.29

4. Prevention of new HIV infections among high-risk group and bridge population

A. Targeted Intervention (TI) Projects and Opioid Substitution Therapy (OST)

Indicator	2023-24
1. Targeted Intervention (TI) Projects	17
2. OST centres (Excluding Satellite OST centres)	1

B. Female Sex Workers

Indicator	2023-24
1. Estimated size	13,210
2. Coverage (%)	59.04
3. Condoms distributed	10,62,518
4. Tested for HIV (April 2022-September 2022)	5,690
4.1. HIV sero-positive (%)	0.05
4.1.1. Linked to ART	3
5. Tested for HIV (October 2022 -March 2023)	7,174
5.1. HIV sero-positive (%)	0.04
5.1.1. Linked to ART	3
6. Clinic Visits	24,114
7. STI/RTI treated	921
8. Presumptive treatment	1,106

C. Men who have Sex with Men	
Indicatort	2023-24
1. Estimated size	1,251
2. Coverage (%)	>=95
3. Condoms distributed	1,83,072
4. Tested for HIV (April 2022-September 2022)	920
4.1. HIV sero-positive (%)	0.98
4.1.1. Linked to ART	9
5. Tested for HIV (October 2022 -March 2023)	1,287
5.1. HIV sero-positive (%)	0.39
5.1.1. Linked to ART	4
6. Clinic Visits	4,125
7. STI/RTI treated	154
8. Presumptive treatment	383

D. Injecting Drug Users	
Indicator	2023-24
1. Estimated size	3,661
2. Coverage (%)	86
3. Needles distributed	5,18,668
4. Syringes distributed	4,07,345
5. On OST	214
6. Tested for HIV (April 2022 -September 2022)	1,710
6.1. HIV sero-positive (%)	0.82
6.1.1 Linked to ART	9
7. Tested for HIV (October 2022 -March 2023)	3,098
7.1. HIV sero-positive (%)	0.68
7.1.1. Linked to ART	19

E. Hijra/Transgender person	
Indicator	2023-24
1. Estimated size	257
2. Coverage (%)	20
3. Condoms distributed	5,481
4. Tested for HIV (April 2022-September 2022)	49
4.1. HIV sero-positive (%)	0.00
4.1.1. Linked to ART	-
5. Tested for HIV (October 2022 -March 2023)	49
5.1. HIV sero-positive (%)	0.00
5.1.1. Linked to ART	-
6. Clinic Visits	144
7. STI/RTI treated	-
8. Presumptive treatment	1

F. Migrants	
Indicator	2023-24
1. Estimated size	1,45,880
2. Coverage (%)	67
3. Tested for HIV	10,375
3.1. HIV sero-positive (%)	0.11
3.2. Linked to ART	10

G. Truckers	
Indicator	2023-24
1. Estimated size	14,000
2. Coverage (%)	71
3. Tested for HIV	2,676
3.1. HIV sero-positive (%)	0.07
3.2. On ART	0

H. Prison Inmates	
Indicator	2023-24
1. Total prisons	16
2. Prisons covered under programme	14
3. Total inmates admitted	8,441
4. Inmates Covered (%)	83
5. Tested for HIV	6,985
5.1. HIV sero-positive (%)	0.30
5.2. On ART (%)	>=95

I. Link Worker Scheme	
Indicator	2023-24
Districts covered under scheme	-
Vulnerable population covered	-
3. Tested for HIV	-
3.1. HIV sero-positive (%)	-
3.2. Linked to ART (%)	-

J. Opioid Substitution Therapy	
Indicator	2023-24
1. OST Centres	1
1.1. OSTC in Public Health Settings	1
1.2. OSTC in NGO Settings	-
1.3. No. of Satellite OST Centres	2
2. IDU on OST	214

5. Early detection of HIV infected people

A. HIV counselling and testing services (HCTS)

A. The Counselling and testing services (FIC13)		
Indicator	2023-24	
1. HCTC confirmatory facilities	59	
2. Sampoorna Suraksha Kendras	-	

B. HIV testing among vulnerable population (excluding pregnant women)

Indicator	2023-24			
	Male	Female	TG	Total
1. Tested for HIV	2,34,205	1,74,198	62	4,08,465
1.1 HIV Positives	492	131	1	624
1.2 HIV sero -positivity (%)	0.21	0.08	1.61	0.15
Spouse/sexual partner of HIV positive people tested	172	176	5	353
2.1 HIV Positives	83	53	-	136
2.2 HIV sero -positivity (%)	48	30	-	38.53
No. of contacts with 'at- risk' population through 'Sampoorna Suraksha'	-	-	-	-

6. Initiation and retention on ART of HIV infected people

A. Treatment facilities

Indicator	2023-24
1. ART Centres	7
2.Centre of Excellence	
2.1. Centre of Excellence (Adult)	-
2.2 Centre of Excellent (Paediatric)	-
3. Link ART Centres	1
4. Care Support Centres	2

B. Treatment uptake

Indicator	2023-24			
	Male	Female	TG	Total
HIV positive cases diagnosed (At ICTC)	492	143	1	636
New PLHIV Registered at ART center	389	121	-	510
2.1 Initiated on ART	364	112	-	476
3. PLHIV alive and on ART	2,997	2,638	5	5,640
4. 12 months retention on ART (%)				94.1
5. Lost to follow-up cases	198	71	-	269

A. Laboratory facilities and service uptake Indicator	
	2023-2
Viral load laboratories (programme and non- programme labs)	2023-2
1.1 Accredited Viral load laboratories (out of 64 VL labs)	
2. Viral load tests conducted	5,60
2.1. Virally suppressed (%)	94.
3. National reference laboratories (NRL)	
3.1 Accredited NRL	
4. State reference laboratories (SRL)	
4.1 Accredited SRL	
5. CD4 machines	
5.1 CD4 tests conducted	3,33
6. External Quality Assurance of ICTC	
6.1 Average Participation (%)	>=9
6.2. Average Discordance (%)	0.0
7. "Certificate of Excellence" by NACO	
7.1 No. of ICTCs received "Certificate of Excellence"	
8. Elimination of mother to child transm HIV & Syphilis	ission of
A. HIV	
Indicator	2023-2
1. Estimated pregnant women (PW)	1,29,27
2. HIV testing among PW	1,01,52
3. HIV sero-positivity (%) among tested	0.0
4. HIV Positive PW (old + new detections)	3
4.1 On life-long ART	3
5. Live births among HIV positive PW	1
5.1 Babies given ARV Prophylaxis (%)	>=9
6. Babies tested HIV (6 week- 6 month)	1
6.1 Babies confirmed HIV Positive (6 week- 6 month)	
7. HIV testing among exposed babies at 18 months	
7.1 HIV exposed babies tested at 18 months	2
7.2 Babies confirmed HIV positive at 18 months	
8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months)	
9. HIV positive babies initiated on ART	
B. Syphilis	
Indicator	2023-2
Syphilis testing among PW	91,85
	0.0
2.Sero-positivity (%) among tested	
2.Sero-positivity (%) among tested 3. Put on treatment	
1 1	
3. Put on treatment 9. Elimination of HIV/AIDS related Stigma	2023-2

2. State designated/appointed ombudsman

Yes


Quarter 4

10. HIV-TB Co-morbidities A. HRG and Bridge Population Indicator 2023-24 Migrants Quarter FSW MSM IDU TG Truckers Total 9,511 Quarter 1 5,670 852 1,682 35 1,739 19,489 Quarter 2 5,548 976 1,871 36 11,375 1,694 21,500 Screened for TB 6,194 Quarter 3 1,053 1,770 22 11,799 1,780 22,618 1,400 Quarter 4 7,109 2,645 51 10,343 2,324 23,872 Quarter 1 90 23 13 8 134 176 9 46 20 9 260 Quarter 2 Tested for TB Quarter 3 157 39 36 44 4 280 Quarter 4 124 24 73 42 7 270 2 Quarter 1 1 1 2 Quarter 2 1 1 4 Diagnosed with TB Quarter 3 1 2 4 2 Quarter 4 1 1 2 Quarter 1 1 1 1 3 Quarter 2 1 1 Initiated on TB treatment Quarter 3 1 1 2 4

B. HIV-TB Coinfected at ART Centre Indicator 2023-24 Co-infected initiated on PLHIV PLHIV PLHIV with PLHIV **PLHIV** Co-infected PLHIV tested for TB presumptive TB diagnosed with TB Moths initiated on enrolled at attending underwent ART Centre 4S screening IPT ARTC ART Apr - 23 2,157 2,143 48 48 38 2,206 50 5 2,194 50 45 May - 23 Jun - 23 2,264 2,253 50 50 3 28 Jul - 23 2,229 2,225 42 42 6 26 2,452 47 47 39 Aug - 23 2,447 Sep - 23 2,872 2,864 51 51 2 34 Oct - 23 2,548 2,538 44 44 3 45 4 3,193 41 28 Nov - 23 3,185 41 Dec - 23 4,197 4,187 51 51 5 40 3 Jan - 24 3.952 3,941 32 32 33 Feb - 24 3,826 3,816 38 38 6 33 Mar - 24 3,819 3,806 475 46 5 36 April 2023-100 95 March 2024

2

		State/UT	Himachal Pradesh
		Rank	17
SI.	Maximum Ma	arks	177
۱o.	Obtained Ma	arks	127 (72%)
1	First 95 (G:≥	95%, Y: 80-94%, R:<80%)	80
2	Second 95 (C	G:≥95%, Y: 80-94%, R:<80%)	90
3	Third 95 (G:≥	e95%, Y: 80-94%, R:<80%)	>=95
4		quency of Social Media updates (G: ≥ 45, Y:40- 44, R:<40 indigenous posts) of	142
	Q1, Q2, Q3	& Q4	
5		integration in state school curriculum (G:Yes, R:No)	Yes
6		A (G: At least one meeting held since 2020, R: other than G)	Meeting held in 2022
7		te Rules (G: Notified, R: Not notified)	Notified
8		budsman (G: Appointed, R: Not appointed)	Appointed
9		oarding (G: ≥95%, Y: 90-<95%, R:<90%)	100
10		ding (G: ≥95%, Y: 90-<95%, R:<90%)	100
11		HRG against estimates (G: ≥90%, Y: 80-<90%, R:<80%)	68
12		mong HRG (G: ≥95%, Y: 90-<95%, R:<90%)	84
13		mong prisoners (G: ≥50%, Y: 40% to <50%, R:<40%)	76
14	Clinic visit of	HRGs at TI-Clinics (G: ≥90%, Y: 75-89%, R:<75%)	75
5	Percentage o	of HRGs screened for Syphilis (G: ≥90%, Y: 75-89%, R:<75%)	83
6		(G: ≥50%, Y: 30% to <50%, R:<30%)	14
7	Percentage o	of fund released to TI (G: ≥50%, Y: 45-<50%, R:<45%)	103
8	_	of TIs trained by Kshmata Kendra (KK) against the AAP targets (G: ≥75%, Y: 70-	88
_	<75%, R:<70		
9		gainst Target-at risk % (G: ≥95%, Y: 80-94%, R:<80%)	24
0		gainst target-PW (G: ≥95%, Y: 80-94%, R:<80%)	79
1		of pregnant women screened for Syphilis (G: ≥95%, Y: 80-94%, R:<80%)	71
22	Treatment pr	rovided to Syphilis reactive pregnant women (G: ≥95%, Y: 80-94%, R:<80%)	88
23	Index testing	among newly detected HIV positive clients (G: ≥95%, Y: 80-94%, R:<80%)	32
24	Percentage of R:<80%)	of 6 weeks - <2 months EID testing against live birth (G: ≥95%, Y: 80-94%,	92
25	Clients mana	ged at DSRC against the target (G: ≥90%, Y: 75-89%, R:<75%)	112
26		s screened for HIV (G: >75%, Y: 50-75%, R:<50%)	52
27		s screened for Syphilis (G: >75%, Y: 50-75%, R:<50%)	83
28		nt women who initiated ART (G: ≥95%, Y: 80-94%, R:<80%)	91
29		f LFU-PLHIV, out of those initiated on ART in FY 2023-24 (G:<2%, Y: 2 to 5%,	2
30		f PLHIV initiated on ART, out of those registered in FY 2023-24 (G:>98%, Y: 95	93
31		f reported died, out of those initiated on ART in FY 202324 (G:<2%, Y: 2 to 5 %,	2
32		redited (G:100%, Y: 80-99%, R:<80%)	100
3		on of ICTCs in re-testing (G: ≥95%, Y: 85-94, R:<85%)	99
4		bstracts selected from studies conducted in FY21-22	1
		>25 to <100%, R: ≤25%)	
5		ngoing studies from FY22-23 (G:100%, Y: >25 to <100%,	4
	R: ≤25%)		
6		of research proposals from FY23-24 to NACO (G:100%, 00%, R: ≤25%)	2
7	Secondary D	ata Analysis by SACS (G:2, Y: 1, R: No Secondary Data Analysis Plan Submitted)	2
8	Expenditure	with respect to funds released during FY 2022-23 (G:	104
		to <90%, R: <85%)	
39		of Provisional Utilization Certificate (UC) in GFR 12A for the FY 2022-23 (G : by , Y : by 31-May-2023, R : after	07-06-2023
Ю	-	of audited UC in GFR 12A for the FY 2022-23 (G : by 30Jun-2023, Y : by 30-Sep-	15-02-2024
		er 30-Sep-2023)	
1		of EC/ GB ratification for approval of Expenditure incurred during FY 2021-22 n-2022, Y: by 30-Sept-2022, ept-2022)	22-08-2023
2		ission of CST-SCM Report (G:>95%, Y: 80-95%, R:<80%)	91
3	,	erence to CST-SCM Report (G:>95%, Y: 80-95%, R:<80%)	96
		<u>`</u>	
4	<90%, R:		83
	Green=3 Mark		Colour=Not Applicable
Veiç	ght points	Indicator SI. No.	
	3	1, 23, 29	
	2	2, 3, 9, 10, 22, 30, 34, 42, 44	22 25 27 27 22 25 :-
		4, 5, 6, 7, 8, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 24, 25, 26, 27, 28, 31, 32	2, 33, 35, 36, 37, 38, 39, 40



JAMMU & KASHMIR, AND LADAKH

1. Status of HIV/AIDS Epidemic			
A. Epidemic Estimates (2023)			
Indicator	Male	Female	Total
1. IPR	-	-	2.62
2. IMR	-	-	0.96
3. Adult (15-49 yrs) HIV Prevalence (%)	0.07	0.04	0.06
4. Estimated people living with HIV	4,433	2,256	6,689
5. ART coverage (%)	51.16	70.37	57.85
6. Estimated children living with HIV	68	61	129
7. Annual new HIV infections	126	49	175
8. Annual AIDS-related deaths (ARD)	113	24	137
9. Change in annual new HIV infections since 2010 (%)	-75.15	-75.00	-75.11
10. Change in annual ARD since 2010(%)	-50.87	-61.29	-52.92
11. EMTCT need	-	30	30

B. High risk population size (2020-22), safe practices (2021) and prevalence (2021/2023)				
Population Group	Estimates Size	Condom Use (%)	New Needle/ Syringe use (%)	HIV Prevalence (%)
1. Female Sex Workers	4,634	98.00	ı	0.40
2. Men who have sex with men	677	-	ı	-
3. Injecting Drug Users	10,162	-	94.90	0.50
4. Hijra/Transgender People	614	-	ı	-
5. Migrants	25,000	-	-	-
6. Truckers	20,000	-	-	-
7. Prison inmates	14,123	-	-	-

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)			
Indicator	Male	Female	Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)	33.60	15.80	-
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	33.80	17.20	-
3. Adults willing to care for a relative with HIV/AIDS in own home (%)	66.20	59.80	-
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	74.60	65.00	-
5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)	0.60	0.00	-
5.1 Condom use during last higher-risk intercourse (%)	66.10	-	-
6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)	0.45	0.00	-
6.1 Condom use during last higher-risk intercourse (%)	66.67	-	-

2. Progress on 95-95-95 (2023-24)				
48 55 55 56 62 63	77 74 77 80 81 86	76 84 90 90 93 94		
PLHIV who know their HIV status (%)	PLHIV who know their HIV status and are on ART (%)	PLHIV who are on ART and virally suppressed (%)		
■ 2018-19 ■ 2019-20	■ 2020-21 ■ 2021-22	■ 2022-23 ■ 2023-24		

Indicators	Male	Female	Total*
1. Estimated PLHIV size (2023)	4,433	2,256	6,689
2. PLHIV who know their HIV Status	2,539	1,677	4,232
3. PLHIV who know their HIV status and are on ART	2,141	1,492	3,646
4. PLHIV who are on ART and tested for their viral load	839	599	1,441
4.1 PLHIV who are virally suppressed	793	564	1,360

^{*} Including of H/TG PLHIV

3. Prevention of new HIV infections among general population

A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2023-24
Schools with operational Adolescent Education Program (AEP)	950
2. Colleges with operational Red Ribbon Clubs (RRC)	332
3. Persons trained under mainstreaming	2,692
4. No. of calls received at helpline	-

B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management

Indicator		202	23-24	
NACO Supported Designated STI/	6			
RTI Clinics (DSRC)	Male	Female	TG	Total
2. Total STI/RTI Clients managed				26,165
3. RPR Tests conducted	1,474	4,562	-	6,036
4. Syphilis seropositivity (%)	1.83	0.02	-	0.46

4. Prevention of new HIV infections among high-risk group and bridge population

A. Targeted Intervention (TI) Projects and Opioid Substitution Therapy (OST)

Indicator	2023-24
1. Targeted Intervention (TI) Projects	23
2. OST centres (Excluding Satellite OST centres)	6

2023-24

4,633

527

B. Female Sex Workers Indicator 1. Estimated size

	,
2. Coverage (%)	62.65
3. Condoms distributed	45,390
4. Tested for HIV (April 2022-September 2022)	1,662
4.1. HIV sero-positive (%)	0.00
4.1.1. Linked to ART	-
5. Tested for HIV (October 2022 -March 2023)	2,712
5.1. HIV sero-positive (%)	0.00
5.1.1. Linked to ART	-
6. Clinic Visits	9,430
7. STI/RTI treated	926

Indicatort 1. Estimated size 2. Coverage (%) 3. Condoms distributed 4. Tested for HIV (April 2022-September 2022) 4.1. HIV sero-positive (%) 4.1.1. Linked to ART 5. Tested for HIV (October 2022 - March 2023)	2023-24 676
2. Coverage (%) 3. Condoms distributed 4. Tested for HIV (April 2022-September 2022) 4.1. HIV sero-positive (%) 4.1.1. Linked to ART	676
3. Condoms distributed 4. Tested for HIV (April 2022-September 2022) 4.1. HIV sero-positive (%) 4.1.1. Linked to ART	070
4. Tested for HIV (April 2022-September 2022) 4.1. HIV sero-positive (%) 4.1.1. Linked to ART	>=95
4.1. HIV sero-positive (%) 4.1.1. Linked to ART	16,567
4.1.1. Linked to ART	574
	0.00
5. Tested for HIV (October 2022 -March 2023)	-
	636
5.1. HIV sero-positive (%)	0.00
5.1.1. Linked to ART	-
6. Clinic Visits	2,524
7. STI/RTI treated	86
8. Presumptive treatment	172

D. Injecting Drug Users	
Indicator	2023-24
1. Estimated size	10,162
2. Coverage (%)	58
3. Needles distributed	13,57,553
4. Syringes distributed	8,39,208
5. On OST	841
6. Tested for HIV (April 2022 -September 2022)	3,178
6.1. HIV sero-positive (%)	0.16
6.1.1 Linked to ART	5
7. Tested for HIV (October 2022 -March 2023)	5,528
7.1. HIV sero-positive (%)	0.09
7.1.1. Linked to ART	5

E. Hijra/Transgender person	
Indicator	2023-24
1. Estimated size	613
2. Coverage (%)	-
3. Condoms distributed	-
4. Tested for HIV (April 2022-September 2022)	-
4.1. HIV sero-positive (%)	-
4.1.1. Linked to ART	-
5. Tested for HIV (October 2022 -March 2023)	-
5.1. HIV sero-positive (%)	-
5.1.1. Linked to ART	-
6. Clinic Visits	-
7. STI/RTI treated	-
8. Presumptive treatment	-

F. Migrants	
Indicator	2023-24
1. Estimated size	25,000
2. Coverage (%)	>=95
3. Tested for HIV	5,332
3.1. HIV sero-positive (%)	0.06
3.2. Linked to ART	3

G. Truckers	
Indicator	2023-24
1. Estimated size	20,000
2. Coverage (%)	>=95
3. Tested for HIV	4,252
3.1. HIV sero-positive (%)	0.09
3.2. On ART	0

H. Prison Inmates	
Indicator	2023-24
1. Total prisons	16
2. Prisons covered under programme	15
3. Total inmates admitted	14,123
4. Inmates Covered (%)	49
5. Tested for HIV	6,895
5.1. HIV sero-positive (%)	0.09
5.2. On ART (%)	83.33

I. Link Worker Scheme	
Indicator	2023-24
Districts covered under scheme	-
2. Vulnerable population covered	-
3. Tested for HIV	-
3.1. HIV sero-positive (%)	-
3.2. Linked to ART (%)	-

8. Presumptive treatment

J. Opioid Substitution Therapy	
Indicator	2023-24
1. OST Centres	6
1.1. OSTC in Public Health Settings	6
1.2. OSTC in NGO Settings	-
1.3. No. of Satellite OST Centres	-
2. IDU on OST	841

5. Early detection of HIV infected people

A HIV counselling and testing services (HCTS)

A. HIV counselling and testing services (HC13)		
Indicator	2023-24	
1. HCTC confirmatory facilities	35	
2. Sampoorna Suraksha Kendras	-	

B. HIV testing among vulnerable population (excluding pregnant women)

Indicator	2023-24			
	Male	Female	TG	Total
1. Tested for HIV	2,60,551	1,81,821	48	4,42,420
1.1 HIV Positives	270	97	3	370
1.2 HIV sero -positivity (%)	0.10	0.05	6.25	0.08
Spouse/sexual partner of HIV positive people tested	41	163	-	204
2.1 HIV Positives	9	20	-	29
2.2 HIV sero -positivity (%)	22	12	-	14.22
No. of contacts with 'at- risk' population through 'Sampoorna Suraksha'	-	-	-	-

6. Initiation and retention on ART of HIV infected people

A. Treatment facilities

Indicator	2023-24
1. ART Centres	3
2.Centre of Excellence	
2.1. Centre of Excellence (Adult)	-
2.2 Centre of Excellent (Paediatric)	-
3. Link ART Centres	3
4. Care Support Centres	1

B. Treatment uptake

Indicator	2023-24			
	Male	Female	TG	Total
HIV positive cases diagnosed (At ICTC)	270	104	3	377
New PLHIV Registered at ART center	245	92	1	338
2.1 Initiated on ART	236	91	1	328
3. PLHIV alive and on ART	2,141	1,492	13	3,646
4. 12 months retention on ART (%)				>=95
5. Lost to follow-up cases	238	85	2	325

7. Viral Suppression and laboratories	
A. Laboratory facilities and service uptake	ļ
Indicator	2023-24
Viral load laboratories (programme and non- programme labs)	C
1.1 Accredited Viral load laboratories (out of 64 VL labs)	C
2. Viral load tests conducted	2,389
2.1. Virally suppressed (%)	93.6
3. National reference laboratories (NRL)	
3.1 Accredited NRL	
4. State reference laboratories (SRL)	2
4.1 Accredited SRL	2
5. CD4 machines	2
5.1 CD4 tests conducted	3,322
6. External Quality Assurance of ICTC	
6.1 Average Participation (%)	94
6.2. Average Discordance (%)	0.00
7. "Certificate of Excellence" by NACO	
7.1 No. of ICTCs received "Certificate of Excellence"	6
8. Elimination of mother to child trans HIV & Syphilis	mission of
A. HIV	
Indicator	2023-24
1. Estimated pregnant women (PW)	2,20,460
2. HIV testing among PW	2,42,581
3. HIV sero-positivity (%) among tested	0.00
4. HIV Positive PW (old + new detections)	24
4.1 On life-long ART	24
5. Live births among HIV positive PW	23
5.1 Babies given ARV Prophylaxis (%)	>=95
6. Babies tested HIV (6 week- 6 month)	22
6.1 Babies confirmed HIV Positive	
(6 week- 6 month)	
7. HIV testing among exposed babies at 18 months	
7.1 HIV exposed babies tested at 18 months	10
7.2 Babies confirmed HIV positive at 18 months	
8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months)	1
9. HIV positive babies initiated on ART	1
D. C	
B. Syphilis Indicator	2022.24
Syphilis testing among PW	2023-2 4 17,864
2.Sero-positivity (%) among tested	0.04
3. Put on treatment	0.0-
9. Elimination of HIV/AIDS related Stigma	
and Discrimination	
Indicator	2023-24
1. State rules notified for HIV/AIDS Prevention and Control Act (2017)	Yes

2. State designated/appointed ombudsman

Yes

10. HIV-TB Co-morbidities								
A. HRG and Bridge Population								
Indicator	2023-24							
	Quarter	FSW	MSM	IDU	TG	Migrants	Truckers	Total
Screened for TB	Quarter 1	1,034	586	2,485	-	906	515	5,526
	Quarter 2	1,422	757	3,016	-	2,369	1,337	8,901
	Quarter 3	1,807	758	3,259	-	3,109	1,474	10,407
	Quarter 4	2,332	1,842	5,894	-	5,126	1,340	16,534
Tested for TB	Quarter 1	36	-	72	-	-	9	117
	Quarter 2	79	-	176	-	-	-	255
	Quarter 3	106	-	169	-	2	-	277
	Quarter 4	16	-	104	-	14	12	146
Diagnosed with TB	Quarter 1	-	-	1	-	-	-	1
	Quarter 2	-	-	-	-	-	-	-
	Quarter 3	-	-	-	-	-	-	-
	Quarter 4	-	-	-	-	-	-	-
Initiated on TB treatment	Quarter 1	-	-	1	-	-	-	1
	Quarter 2	-	-	-	-	-	-	-
	Quarter 3	-	-	-	-	-	-	-
	Quarter 4	-	-	-	-	-	-	-

B. HIV-TB Coinfected at ART Centre Indicator 2023-24 PLHIV with presumptive TB PLHIV PLHIV PLHIV PLHIV Co-infected enrolled at Co-infected initiated on ART PLHIV tested for TB diagnosed with TB initiated on IPT Moths attending underwent ART Centre 4S screening ARTC 2,334 2,334 Apr - 23 14 14 26 2 11 11 26 2,723 2,723 May - 23 Jun - 23 2,609 2,609 24 24 4 38 2,746 Jul - 23 2,746 16 16 4 37 5 2,689 2,689 19 19 15 Aug - 23 3 Sep - 23 2,678 2,402 12 12 35 2,621 2,340 9 9 5 24 Oct - 23 1 25 2,721 18 18 Nov - 23 2,465 Dec - 23 3,050 2,745 9 9 1 12 Jan - 24 3,091 3,091 5 20 11 11 5 8 15 Feb - 24 2,971 2,971 8 Mar - 24 2,964 2,964 12 12 3 28 April 2023-51 March 2024

	State/UT	J&K & Ladakh
	Rank	33
SI. Io.	Maximum Marks	177
	Obtained Marks	113 (64%)
1	First 95 (G:≥95%, Y: 80-94%, R:<80%)	63
2	Second 95 (G:≥95%, Y: 80-94%, R:<80%)	86
3	Third 95 (G:≥95%, Y: 80-94%, R:<80%)	94
4	Average Frequency of Social Media updates (G: ≥ 45, Y:40- 44, R:<40 indigenous posts) of	17
_	Q1, Q2, Q3 & Q4	
5	Status of AEP integration in state school curriculum (G:Yes, R:No)	Yes
6	Status of SCA (G: At least one meeting held since 2020, R: other than G)	Dissolved
7	Status of State Rules (G: Notified, R: Not notified)	Notified
8	Status of Ombudsman (G: Appointed, R: Not appointed)	Not Appointed
9	TI/LWS onboarding (G: ≥95%, Y: 90-<95%, R:<90%)	88
10	OST onboarding (G: ≥95%, Y: 90-<95%, R:<90%)	100
1	Coverage of HRG against estimates (G: ≥90%, Y: 80-<90%, R:<80%)	59
2	HIV testing among HRG (G: ≥95%, Y: 90-<95%, R:<90%)	76
3	HIV testing among prisoners (G: ≥50%, Y: 40% to <50%, R:<40%)	16
4	Clinic visit of HRGs at TI-Clinics (G: ≥90%, Y: 75-89%, R:<75%)	77
5	Percentage of HRGs screened for Syphilis (G: ≥90%, Y: 75-89%, R:<75%)	41
6	IDU on OST (G: ≥50%, Y: 30% to <50%, R:<30%)	29
7	Percentage of fund released to TI (G: ≥50%, Y: 45-<50%, R:<45%)	87
8	Percentage of TIs trained by Kshmata Kendra (KK) against the AAP targets (G: ≥75%, Y: 70-	87
	<75%, R:<70%)	
9	HIV testing against Target-at risk % (G: ≥95%, Y: 80-94%, R:<80%)	80
20	HIV testing against target-PW (G: ≥95%, Y: 80-94%, R:<80%)	110
21	Percentage of pregnant women screened for Syphilis (G: ≥95%, Y: 80-94%, R:<80%)	8
22	Treatment provided to Syphilis reactive pregnant women (G: ≥95%, Y: 80-94%, R:<80%)	88
23	Index testing among newly detected HIV positive clients (G: ≥95%, Y: 80-94%, R:<80%)	36
24	Percentage of 6 weeks - <2 months EID testing against live birth (G: ≥95%, Y: 80-94%,	100
	R:<80%)	
25	Clients managed at DSRC against the target (G: ≥90%, Y: 75-89%, R:<75%)	14
26	STI attendees screened for HIV (G: >75%, Y: 50-75%, R:<50%)	28
27	STI attendees screened for Syphilis (G: >75%, Y: 50-75%, R:<50%)	65
28	% of pregnant women who initiated ART (G: ≥95%, Y: 80-94%, R:<80%)	104
	· -	
29	Proportion of LFU-PLHIV, out of those initiated on ART in FY 2023-24 (G:<2%, Y: 2 to 5%,	3
20	R:>5%)	
30	Proportion of PLHIV initiated on ART, out of those registered in FY 2023-24 (G:>98%, Y: 95 to 98%, R:<95%)	97
31		4
) I	Proportion of reported died, out of those initiated on ART in FY 202324 (G:<2%, Y: 2 to 5 %, R:>5 %)	4
32	% of SRL accredited (G:100%, Y: 80-99%, R:<80%)	100
33	% participation of ICTCs in re-testing (G: ≥95%, Y: 85-94, R:<85%)	94
34	Number of abstracts selected from studies conducted in FY21-22 (G:100%, Y: >25 to <100%,	
>4	R: <25%)	3
35	Number of ongoing studies from FY22-23 (G:100%, Y: >25 to <100%,	0
55	R: ≤25%)	U
36	R: ≤25%) Submission of research proposals from FY23-24 to NACO (G:100%,	2
,,,	Y: >25 to <100%, R: ≤25%)	2
37	Secondary Data Analysis by SACS (G:2, Y: 1, R: No Secondary Data Analysis Plan Submitted)	2
88	Expenditure with respect to funds released during FY 2022-23 (G:	118
20	≥90%, Y: 85 to <90%, R: <85%)	10.05.0000
39	Submission of Provisional Utilization Certificate (UC) in GFR 12A for the FY 2022-23 (G: by 30-Apr-2023, Y: by 31-May-2023, R: after 31-May-2023)	18-05-2023
40	Submission of audited UC in GFR 12A for the FY 2022-23 (G : by 30Jun-2023, Y : by 30-Sep-	07-02-2024
	2023, R : after 30-Sep-2023)	07-02-2024
11	Submission of EC/ GB ratification for approval of Expenditure incurred during FY 2021-22	20-07-2023
	(G: by 30-Jun-2022, Y: by 30-Sept-2022, R: after 30-Sept-2022)	25 67 2626
2	Timely Submission of CST-SCM Report (G:>95%, Y: 80-95%, R:<80%)	96
13	Format Adherence to CST-SCM Report (G:>95%, Y: 80-95%, R:<80%)	89
14	Timely Submission of BSD & STI-SCM Report (G: ≥90%, Y: 75-	100
~~	11mely Submission of BSD & STI-SCM Report (G: ≥90%, Y: 75-	100
	•	Colour=Not Applicable
		2010til – Not Applicable
vveiç	ght points Indicator SI. No.	
	3 1, 23, 29	
	2 2, 3, 9, 10, 22, 30, 34, 42, 44	





JHARKHAND

1. Status of HIV/AIDS Epidemic			
A. Epidemic Estimates (2023)			
Indicator	Male	Female	Total
1. IPR	-	-	3.13
2. IMR	-	-	1.85
3. Adult (15-49 yrs) HIV Prevalence (%)	0.08	0.07	0.07
4. Estimated people living with HIV	12,894	10,900	23,794
5. ART coverage (%)	67.56	72.58	70.16
6. Estimated children living with HIV	583	546	1,129
7. Annual new HIV infections	392	351	743
8. Annual AIDS-related deaths (ARD)	125	69	194
9. Change in annual new HIV infections since 2010 (%)	-60.32	-55.00	-57.94
10. Change in annual ARD since 2010(%)	-59.81	-71.37	-64.79
11. EMTCT need	-	335	335

B. High risk population size (2020-22), safe practices (2021) and prevalence (2021/2023) Condom Use New Needle/ HIV Prevalence Estimates Size Population Group (%) Syringe use (%) (%) 99.90 0.55 1. Female Sex Workers 11,860 98.20 6.68 2. Men who have sex with men 1,742 3. Injecting Drug Users 779 4. Hijra/Transgender People 483 5. Migrants 20,000 6. Truckers 35,000 98.30 0.00 62,551 28.60 33.30 0.38 7. Prison inmates

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)			
Indicator	Male	Female	Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)	31.10	13.80	-
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	28.40	15.20	-
3. Adults willing to care for a relative with HIV/AIDS in own home (%)	86.20	77.20	-
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	75.30	67.50	-
5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)	3.60	0.40	-
5.1 Condom use during last higher-risk intercourse (%)	38.30	23.10	-
6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)	5.71	0.68	-
6.1 Condom use during last higher-risk intercourse (%)	35.59	30.00	-

2. Progress on 95-95-95 (2023-24)				
62 61 64 67 71 76	80 88 84 86 88 88	83 83 ≥95 74 83 87 77 86		
PLHIV who know their HIV status (%)	PLHIV who know their HIV status and are on ART (%)	PLHIV who are on ART and virally suppressed (%)		
■ 2018-19 ■ 2019-20	■ 2020-21 ■ 2021-22	2 2022-23 2023-24		

Indicators	Male	Female	Total*
1. Estimated PLHIV size (2023)	12,894	10,900	23,794
2. PLHIV who know their HIV Status	9,544	8,434	18,057
3. PLHIV who know their HIV status and are on ART	8,337	7,553	15,960
4. PLHIV who are on ART and tested for their viral load	4,288	3,910	8,226
4.1 PLHIV who are virally suppressed	4,087	3,758	7,872

^{*} Including of H/TG PLHIV

A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2023-24
Schools with operational Adolescent Education Program (AEP)	2,126
2. Colleges with operational Red Ribbon Clubs (RRC)	321
3. Persons trained under mainstreaming	2,557
4. No. of calls received at helpline	-

B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management

Indicator	2023-24			
NACO Supported Designated STI/	28			
RTI Clinics (DSRC)	Male	Female	TG	Total
2. Total STI/RTI Clients managed				94,096
3. RPR Tests conducted	9,149	14,230	7	23,386
4. Syphilis seropositivity (%)	1.30	0.27	28.57	0.68

4. Prevention of new HIV infections among high-risk group and bridge population

A. Targeted Intervention (TI) Projects and Opioid Substitution Therapy (OST)

Indicator	2023-24
1. Targeted Intervention (TI) Projects	30
2. OST centres (Excluding Satellite OST centres)	3

B. Female Sex Workers

Indicator	2023-24
1. Estimated size	11,860
2. Coverage (%)	>=95
3. Condoms distributed	27,06,469
4. Tested for HIV (April 2022-September 2022)	12,535
4.1. HIV sero-positive (%)	0.02
4.1.1. Linked to ART	3
5. Tested for HIV (October 2022 -March 2023)	15,975
5.1. HIV sero-positive (%)	0.08
5.1.1. Linked to ART	11
6. Clinic Visits	61,400
7. STI/RTI treated	700
8. Presumptive treatment	2,046

C. Men who have Sex with Men Indicatort 2023-24 1. Estimated size 1,742 2. Coverage (%) >=95 3,55,578 3. Condoms distributed 4. Tested for HIV (April 2022-September 2022) 2,150 4.1. HIV sero-positive (%) 0.47 4.1.1. Linked to ART 10 5. Tested for HIV (October 2022 -March 2023) 2,505 5.1. HIV sero-positive (%) 0.24 5.1.1. Linked to ART 6 6. Clinic Visits 9,160 7. STI/RTI treated 60 8. Presumptive treatment 320

D. Injecting Drug Users	
Indicator	2023-24
1. Estimated size	778
2. Coverage (%)	>=95
3. Needles distributed	4,06,100
4. Syringes distributed	3,72,945
5. On OST	124
6. Tested for HIV (April 2022 -September 2022)	1,034
6.1. HIV sero-positive (%)	0.00
6.1.1 Linked to ART	-
7. Tested for HIV (October 2022 -March 2023)	1,374
7.1. HIV sero-positive (%)	0.29
7.1.1. Linked to ART	3

E. Hijra/Transgender person	
Indicator	2023-24
1. Estimated size	482
2. Coverage (%)	>=95
3. Condoms distributed	81,797
4. Tested for HIV (April 2022-September 2022)	499
4.1. HIV sero-positive (%)	0.00
4.1.1. Linked to ART	-
5. Tested for HIV (October 2022 -March 2023)	697
5.1. HIV sero-positive (%)	0.14
5.1.1. Linked to ART	1
6. Clinic Visits	2,460
7. STI/RTI treated	4
8. Presumptive treatment	168

F. Migrants	
Indicator	2023-24
1. Estimated size	20,000
2. Coverage (%)	>=95
3. Tested for HIV	8,445
3.1. HIV sero-positive (%)	0.05
3.2. Linked to ART	4

G. Truckers	
Indicator	2023-24
1. Estimated size	35,000
2. Coverage (%)	93
3. Tested for HIV	6,485
3.1. HIV sero-positive (%)	0.08
3.2. On ART	4

H. Prison Inmates	
Indicator	2023-24
1. Total prisons	32
2. Prisons covered under programme	32
3. Total inmates admitted	62,551
4. Inmates Covered (%)	59
5. Tested for HIV	37,069
5.1. HIV sero-positive (%)	0.06
5.2. On ART (%)	>=95

I. Link Worker Scheme	
Indicator	2023-24
Districts covered under scheme	-
Vulnerable population covered	-
3. Tested for HIV	-
3.1. HIV sero-positive (%)	-
3.2. Linked to ART (%)	-

J. Opioid Substitution Therapy	
Indicator	2023-24
1. OST Centres	3
1.1. OSTC in Public Health Settings	3
1.2. OSTC in NGO Settings	-
1.3. No. of Satellite OST Centres	-
2. IDU on OST	124

A. HIV counselling and testing services (HCTS)

7 10 1 11 1 1 COMMISSION 19 COMMISSION (1 1	,
Indicator	2023-24
1. HCTC confirmatory facilities	71
2. Sampoorna Suraksha Kendras	1

B. HIV testing among vulnerable population (excluding pregnant women)

Indicator	2023-24				
	Male	Female	TG	Total	
1. Tested for HIV	2,25,676	1,91,651	873	4,18,200	
1.1 HIV Positives	1,132	578	36	1,746	
1.2 HIV sero -positivity (%)	0.50	0.30	4.12	0.42	
Spouse/sexual partner of HIV positive people tested	601	579	40	1,220	
2.1 HIV Positives	305	223	12	540	
2.2 HIV sero -positivity (%)	51	39	30	44.26	
No. of contacts with 'at- risk' population through 'Sampoorna Suraksha'	-	-	-	545	

6. Initiation and retention on ART of HIV infected people

A. Treatment facilities

Indicator	2023-24
1. ART Centres	13
2.Centre of Excellence	
2.1. Centre of Excellence (Adult)	-
2.2 Centre of Excellent (Paediatric)	-
3. Link ART Centres	6
4. Care Support Centres	5

B. Treatment uptake

Indicator	2023-24			
	Male	Female	TG	Total
HIV positive cases diagnosed (At ICTC)	1,132	741	36	1,909
2. New PLHIV Registered at ART center	1,116	729	33	1,878
2.1 Initiated on ART	1,100	718	32	1,850
3. PLHIV alive and on ART	8,337	7,553	70	15,960
4. 12 months retention on ART (%)				>=95
5. Lost to follow-up cases	396	240	7	643

7. Viral Suppression and laboratories	
A. Laboratory facilities and service uptake	
Indicator	2023-2
Viral load laboratories (programme and non- programme labs)	
1.1 Accredited Viral load laboratories (out of 64 VL labs)	
2. Viral load tests conducted	13,08
2.1. Virally suppressed (%)	94.
3. National reference laboratories (NRL)	
3.1 Accredited NRL	
4. State reference laboratories (SRL)	
4.1 Accredited SRL	
5. CD4 machines	
5.1 CD4 tests conducted	3,64
6. External Quality Assurance of ICTC	
6.1 Average Participation (%)	>=9
6.2. Average Discordance (%)	0.0
7. "Certificate of Excellence" by NACO	
7.1 No. of ICTCs received "Certificate of Excellence"	
 Elimination of mother to child trans HIV & Syphilis HIV 	mission of
Indicator	2023-2
Estimated pregnant women (PW)	9,51,60
2. HIV testing among PW	6,96,00
3. HIV sero-positivity (%) among tested	0.0
4. HIV Positive PW (old + new detections)	33
4.1 On life-long ART	29
5. Live births among HIV positive PW	25
5.1 Babies given ARV Prophylaxis (%)	>=9
6. Babies tested HIV (6 week- 6 month)	20
6.1 Babies confirmed HIV Positive (6 week- 6 month)	
7. HIV testing among exposed babies at 18 months	
7.1 HIV exposed babies tested at 18 months	18
7.2 Babies confirmed HIV positive at 18 months	
8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months)	1
9. HIV positive babies initiated on ART	1
B. Syphilis	
Indicator	2023-2
Syphilis testing among PW	8,43,84
2.Sero-positivity (%) among tested	0.0
3. Put on treatment	16
9. Elimination of HIV/AIDS related Stigma and Discrimination	
Indicator	2023-2
State rules notified for HIV/AIDS Prevention and Control Act (2017)	Ye
· ·	

2. State designated/appointed ombudsman

Yes

10. HIV-TB Co-morbidities								
A. HRG and Bridge Population								
Indicator	Indicator 2023-24							
	Quarter	FSW	MSM	IDU	TG	Migrants	Truckers	Total
	Quarter 1	14,042	2,091	1,081	511	6,309	6,014	30,048
Screened for TB	Quarter 2	15,314	2,258	1,232	602	6,193	4,086	29,685
Screened for TB	Quarter 3	15,927	2,346	1,328	651	5,949	6,112	32,313
	Quarter 4	16,164	2,461	1,418	702	5,932	6,691	33,368
	Quarter 1	56	2	-	-	-	-	58
Tested for TB	Quarter 2	33	1	-	-	-	-	34
lested for 1B	Quarter 3	36	-	-	-	-	-	36
	Quarter 4	57	1	-	-	-	3	61
	Quarter 1	1	1	-	-	-	-	2
Diagraph of with TD	Quarter 2	-	-	-	-	-	-	-
Diagnosed with TB	Quarter 3	-	-	-	-	-	-	-
	Quarter 4	-	1	-	-	-	-	1
Initiated on TB	Quarter 1	1	1	-	-	-	-	2
	Quarter 2	-	-	-	-	-	-	-
treatment	Quarter 3	-	-	-	-	-	-	-
	Quarter 4	-	1	-	-	-	-	1

B. HIV-TB Coinfected at ART Centre Indicator 2023-24 PLHIV with presumptive TB PLHIV PLHIV PLHIV PLHIV Co-infected enrolled at Co-infected initiated on ART PLHIV tested for TB diagnosed with TB initiated on IPT Moths attending underwent ART Centre 4S screening ARTC 10,651 10,397 Apr - 23 302 235 24 109 404 17 180 10,243 9,973 329 May - 23 Jun - 23 10,360 9,852 414 326 30 178 Jul - 23 10,992 10,840 407 311 25 112 11,806 11,765 274 21 Aug - 23 366 136 Sep - 23 11,681 11,504 355 326 20 119 11,406 11,297 353 269 23 98 Oct - 23 22 11,295 11,201 284 148 Nov - 23 416 Dec - 23 12,535 12,441 343 325 28 106 Jan - 24 12,682 12,520 310 108 286 24 26 Feb - 24 11,460 11,385 661 333 102 Mar - 24 11,547 11,467 386 341 17 83 April 2023-369 354 March 2024

	State/UT	Jharkhand
	Rank	14
SI.	Maximum Marks	177
No.	Obtained Marks	130 (73%)
1	First 95 (G:≥95%, Y: 80-94%, R:<80%)	76
2	Second 95 (G:≥95%, Y: 80-94%, R:<80%)	88
3	Third 95 (G:≥95%, Y: 80-94%, R:<80%)	>=95
4	Average Frequency of Social Media updates (G: \geq 45, Y:40- 44, R:<40 indigenous posts) of Q1, Q2, Q3 & Q4	287
5	Status of AEP integration in state school curriculum (G:Yes, R:No)	Yes
6	Status of SCA (G: At least one meeting held since 2020, R: other than G)	Meeting held in 2023
7	Status of State Rules (G: Notified, R: Not notified)	Notified
8	Status of Ombudsman (G: Appointed, R: Not appointed)	Appointed
9	TI/LWS onboarding (G: ≥95%, Y: 90-<95%, R:<90%)	91
10	OST onboarding (G: ≥95%, Y: 90-<95%, R:<90%)	100
11	Coverage of HRG against estimates (G: ≥90%, Y: 80-<90%, R:<80%)	157
12	HIV testing among HRG (G: ≥95%, Y: 90-<95%, R:<90%)	81
13	HIV testing among prisoners (G: ≥50%, Y: 40% to <50%, R:<40%)	40
14	Clinic visit of HRGs at TI-Clinics (G: ≥90%, Y: 75-89%, R:<75%)	86
15	Percentage of HRGs screened for Syphilis (G: ≥90%, Y: 75-89%, R:<75%)	81
16	IDU on OST (G: ≥50%, Y: 30% to <50%, R:<30%)	17
17	Percentage of fund released to TI (G: ≥50%, Y: 45-<50%, R:<45%)	82
18	Percentage of TIs trained by Kshmata Kendra (KK) against the AAP targets (G: ≥75%, Y: 70-<75%, R:<70%)	100
19	HIV testing against Target-at risk % (G: ≥95%, Y: 80-94%, R:<80%)	55
20	HIV testing against target-PW (G: ≥95%, Y: 80-94%, R:<80%)	73
21	Percentage of pregnant women screened for Syphilis (G: ≥95%, Y: 80-94%, R:<80%)	89
22	Treatment provided to Syphilis reactive pregnant women (G: ≥95%, Y: 80-94%, R:<80%)	97
23	Index testing among newly detected HIV positive clients (G: ≥95%, Y: 80-94%, R:<80%)	39
24	Percentage of 6 weeks - <2 months EID testing against live birth (G: ≥95%, Y: 80-94%,	99
25	R:<80%) Clients managed at DSRC against the target (G: ≥90%, Y: 75-89%, R:<75%)	22
26	STI attendees screened for HIV (G: >75%, Y: 50-75%, R:<50%)	56
27	STI attendees screened for Syphilis (G: >75%, Y: 50-75%, R:<50%)	56
28	% of pregnant women who initiated ART (G: ≥95%, Y: 80-94%, R:<80%)	89
29	Proportion of LFU-PLHIV, out of those initiated on ART in FY 2023-24 (G:<2%, Y: 2 to 5%,	3
30	R:>5%) Proportion of PLHIV initiated on ART, out of those registered in FY 2023-24 (G:>98%, Y: 95	99
31	to 98%, R:<95%) Proportion of reported died, out of those initiated on ART in FY 202324 (G:<2%, Y: 2 to 5 %,	6
22	R:>5 %)	// 7
32	% of SRL accredited (G:100%, Y: 80-99%, R:<80%)	66.7
33	% participation of ICTCs in re-testing (G: ≥95%, Y: 85-94, R:<85%) Number of abstracts selected from studies conducted in FY21-22	98 4
34	(G:100%, Y: >25 to <100%, R: ≤25%)	4
35	Number of ongoing studies from FY22-23 (G:100%, Y: >25 to <100%, R: ≤25%)	4
36	Submission of research proposals from FY23-24 to NACO (G:100%, Y: >25 to <100%, R: ≤25%)	2
37	Secondary Data Analysis by SACS (G:2, Y: 1, R: No Secondary Data Analysis Plan Submitted)	2
38	Expenditure with respect to funds released during FY 2022-23 (G:	126
	≥90%, Y: 85 to <90%, R: <85%)	
39	Submission of Provisional Utilization Certificate (UC) in GFR 12A for the FY 2022-23 (G : by $^1\!\!$ Apr-2023, Y : by 31-May-2023, R : after 31-May-2023)	29-05-2023
40	Submission of audited UC in GFR 12A for the FY 2022-23 (G : by 30Jun-2023, Y : by 30-Sep-2023, R : after 30-Sep-2023)	03-01-2024
41	Submission of EC/ GB ratification for approval of Expenditure incurred during FY 2021-22 (G: by 30-Jun-2022, Y: by 30-Sept-2022,	09-10-2023
42	R: after 30-Sept-2022) Timely Submission of CST-SCM Report (G:>95%, Y: 80-95%, R:<80%)	87
43	Format Adherence to CST-SCM Report (G:>95%, Y: 80-95%, R:<80%)	96
44	Timely Submission of BSD & STI-SCM Report (G: ≥90%, Y: 75- <90%, R:<75%)	100
		Colour=Not Applicable
Weig	ht points Indicator SI. No.	
	3 1, 23, 29	
	2 2, 3, 9, 10, 22, 30, 34, 42, 44	
	4, 5, 6, 7, 8, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 24, 25, 26, 27, 28, 31, 32	2, 33, 35, 36, 37, 38, 39, 40, 41
	1 43	





KARNATAKA

1. Status of HIV/AIDS Epidemic			
A. Epidemic Estimates (2023)			
Indicator	Male	Female	Total
1. IPR	-	-	1.13
2. IMR	-	-	0.37
3. Adult (15-49 yrs) HIV Prevalence (%)	0.40	0.45	0.42
4. Estimated people living with HIV	1,33,456	1,47,041	2,80,497
5. ART coverage (%)	67.90	75.75	72.24
6. Estimated children living with HIV	2,900	2,686	5,586
7. Annual new HIV infections	1,606	1,569	3,175
8. Annual AIDS-related deaths (ARD)	3,450	2,149	5,599
9. Change in annual new HIV infections since 2010 (%)	-70.22	-70.17	-70.19
10. Change in annual ARD since 2010(%)	-79.25	-84.57	-81.68
11. EMTCT need	_	1,662	1,662

B. High risk population size (2020-22), safe practices (2021) and prevalence (2021/2023) **HIV Prevalence** Condom Use New Needle/ Estimates Size Population Group (%) Syringe use (%) (%) 97.60 1. Female Sex Workers 1,53,337 86.50 3.01 96.70 99.60 2. Men who have sex with men 45,631 2.81 3. Injecting Drug Users 4,331 96.80 0.00 4. Hijra/Transgender People 10,926 3.20 5. Migrants 2,10,000 0.20 6. Truckers 85,000 67.50 1.20

71,889

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)			
Indicator	Male	Female	Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)	26.60	24.50	-
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	24.40	26.80	-
3. Adults willing to care for a relative with HIV/AIDS in own home (%)	78.80	73.70	-
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	74.80	69.50	-
5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)	2.80	0.40	-
5.1 Condom use during last higher-risk intercourse (%)	59.20	74.60	-
6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)	4.23	0.08	-
6.1 Condom use during last higher-risk intercourse (%)	56.86	100.00	-

2. Progress on	95-95-95 (20	23-24)
68 70 72 75 78 81	83 85 83 83 85 87	93 ≥95 79 81 81
PLHIV who know their HIV status (%)	PLHIV who know their HIV status and are on ART (%)	PLHIV who are on ART and virally suppressed (%)
2018-19 2019-20	■ 2020-21 ■ 2021-22	■ 2022-23 ■ 2023-24

7. Prison inmates

Indicators	Male	Female	Total*
1. Estimated PLHIV size (2023)	1,33,456	1,47,041	2,80,497
2. PLHIV who know their HIV Status	1,04,428	1,22,265	2,27,463
3. PLHIV who know their HIV status and are on ART	88,791	1,09,124	1,98,523
4. PLHIV who are on ART and tested for their viral load	58,566	72,575	1,31,474
4.1 PLHIV who are virally suppressed	57,025	71,151	1,28,521

69.70

64.00

1.03

^{*} Including of H/TG PLHIV

A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2023-24
Schools with operational Adolescent Education Program (AEP)	7,700
2. Colleges with operational Red Ribbon Clubs (RRC)	1,736
3. Persons trained under mainstreaming	3,29,679
4. No. of calls received at helpline	_

B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management

Indicator	2023-24			
NACO Supported Designated STI/	54			
RTI Clinics (DSRC)	Male	Female	TG	Total
2. Total STI/RTI Clients managed				6,99,508
3. RPR Tests conducted	79,709	1,27,515	2,001	2,09,225
4. Syphilis seropositivity (%)	0.86	0.23	1.35	0.48

4. Prevention of new HIV infections among high-risk group and bridge population

A. Targeted Intervention (TI) Projects and Opioid Substitution Therapy (OST)

Indicator	2023-24
1. Targeted Intervention (TI) Projects	75
2. OST centres (Excluding Satellite OST centres)	2

B. Female Sex Workers

C. Men who have Sex with Men

Indicator	2023-24
1. Estimated size	1,53,336
2. Coverage (%)	>=95
3. Condoms distributed	73,59,848
4. Tested for HIV (April 2022-September 2022)	87,505
4.1. HIV sero-positive (%)	0.07
4.1.1. Linked to ART	54
5. Tested for HIV (October 2022 -March 2023)	1,19,625
5.1. HIV sero-positive (%)	0.12
5.1.1. Linked to ART	136
6. Clinic Visits	4,43,325
7. STI/RTI treated	4,173
8. Presumptive treatment	29,233

Indicatort 2023-24 1. Estimated size 45,630 2. Coverage (%) >=95 3. Condoms distributed 35,34,991 4. Tested for HIV (April 2022-September 2022) 27,748 4.1. HIV sero-positive (%) 0.24 4.1.1. Linked to ART 5. Tested for HIV (October 2022 -March 2023) 42,114 0.34 5.1. HIV sero-positive (%) 5.1.1. Linked to ART 140 6. Clinic Visits 1,42,485

623

7,589

D. Injecting Drug Users	
Indicator	2023-24
1. Estimated size	4,330
2. Coverage (%)	61
3. Needles distributed	5,75,390
4. Syringes distributed	3,47,445
5. On OST	141
6. Tested for HIV (April 2022 -September 2022)	914
6.1. HIV sero-positive (%)	0.11
6.1.1 Linked to ART	1
7. Tested for HIV (October 2022 -March 2023)	3,501
7.1. HIV sero-positive (%)	0.09
7.1.1. Linked to ART	3

E. Hijra/Transgender person	
Indicator	2023-24
1. Estimated size	10,926
2. Coverage (%)	>=95
3. Condoms distributed	10,05,179
4. Tested for HIV (April 2022-September 2022)	6,754
4.1. HIV sero-positive (%)	0.38
4.1.1. Linked to ART	26
5. Tested for HIV (October 2022 -March 2023)	8,713
5.1. HIV sero-positive (%)	0.34
5.1.1. Linked to ART	27
6. Clinic Visits	34,286
7. STI/RTI treated	221
8. Presumptive treatment	1,254

F. Migrants	
Indicator	2023-24
1. Estimated size	2,10,000
2. Coverage (%)	>=95
3. Tested for HIV	64,015
3.1. HIV sero-positive (%)	0.11
3.2. Linked to ART	66

G. Truckers	
Indicator	2023-24
1. Estimated size	85,000
2. Coverage (%)	>=95
3. Tested for HIV	15,524
3.1. HIV sero-positive (%)	0.15
3.2. On ART	18

H. Prison Inmates	
Indicator	2023-24
1. Total prisons	57
2. Prisons covered under programme	54
3. Total inmates admitted	71,889
4. Inmates Covered (%)	70
5. Tested for HIV	50,529
5.1. HIV sero-positive (%)	0.19
5.2. On ART (%)	87.76

I. Link Worker Scheme	
Indicator	2023-24
1. Districts covered under scheme	29
Vulnerable population covered	1,51,001
3. Tested for HIV	88,015
3.1. HIV sero-positive (%)	0.31
3.2. Linked to ART (%)	>=95

7. STI/RTI treated

8. Presumptive treatment

J. Opioid Substitution Therapy	
Indicator	2023-24
1. OST Centres	2
1.1. OSTC in Public Health Settings	2
1.2. OSTC in NGO Settings	-
1.3. No. of Satellite OST Centres	-
2. IDU on OST	141

A. HIV counselling and testing services (HCTS)

Indicator	2023-24
1. HCTC confirmatory facilities	443
2. Sampoorna Suraksha Kendras	7

B. HIV testing among vulnerable population (excluding pregnant women)

Indicator	2023-24			
	Male	Female	TG	Total
1. Tested for HIV	20,87,576	18,71,583	22,439	39,81,598
1.1 HIV Positives	7,684	5,391	107	13,182
1.2 HIV sero -positivity (%)	0.37	0.29	0.48	0.33
Spouse/sexual partner of HIV positive people tested	2,911	4,179	44	7,134
2.1 HIV Positives	1,360	1,554	14	2,928
2.2 HIV sero -positivity (%)	47	37	32	41.04
3. No. of contacts with 'at- risk' population through 'Sampoorna Suraksha'	-	-	-	2,424

6. Initiation and retention on ART of HIV infected people

A. Treatment facilities

Indicator	2023-24
1. ART Centres	81
2.Centre of Excellence	
2.1. Centre of Excellence (Adult)	1
2.2 Centre of Excellent (Paediatric)	1
3. Link ART Centres	308
4. Care Support Centres	36

B. Treatment uptake

Indicator	2023-24			
	Male	Female	TG	Total
HIV positive cases diagnosed (At ICTC)	7,684	5,933	107	13,724
New PLHIV Registered at ART center	7,402	5,781	74	13,257
2.1 Initiated on ART	7,309	5,727	73	13,109
3. PLHIV alive and on ART	88,791	1,98,523	607	1,98,523
4. 12 months retention on ART (%)				93.0
5. Lost to follow-up cases	7,356	6,283	110	13,749

7. Viral Suppression and laboratories	
A. Laboratory facilities and service uptake	
Indicator	2023-2
Viral load laboratories (programme and non- programme labs)	
1.1 Accredited Viral load laboratories (out of 64 VL labs)	
2. Viral load tests conducted	1,54,71
2.1. Virally suppressed (%)	93.
3. National reference laboratories (NRL)	
3.1 Accredited NRL	
4. State reference laboratories (SRL)	1
4.1 Accredited SRL	1
5. CD4 machines	5
5.1 CD4 tests conducted	1,34,62
6. External Quality Assurance of ICTC	
6.1 Average Participation (%)	>=9
6.2. Average Discordance (%)	0.0
7. "Certificate of Excellence" by NACO	
7.1 No. of ICTCs received "Certificate of Excellence"	13
8. Elimination of mother to child trans HIV & SyphilisA. HIV	mission ot
Indicator	2023-2
1. Estimated pregnant women (PW)	12,05,06
2. HIV testing among PW	11,46,33
3. HIV sero-positivity (%) among tested	0.0
4. HIV Positive PW (old + new detections)	1,52
4.1 On life-long ART	1,51
5. Live births among HIV positive PW	1,15
5.1 Babies given ARV Prophylaxis (%)	>=9
6. Babies tested HIV (6 week- 6 month)	1,15
6.1 Babies confirmed HIV Positive (6 week- 6 month)	
7. HIV testing among exposed babies at 18 months	
7.1 HIV exposed babies tested at 18 months	97
7.2 Babies confirmed HIV positive at 18 months	2
8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months)	4
9. HIV positive babies initiated on ART	4
B. Syphilis	
Indicator	2023-2
Syphilis testing among PW	13,26,20
2.Sero-positivity (%) among tested	0.0
3. Put on treatment	20
9. Elimination of HIV/AIDS related Stigma and Discrimination	
Indicator	2023-2
State rules notified for HIV/AIDS Prevention and Control Act (2017)	Ye

2. State designated/appointed ombudsman

Yes

10. HIV-TB Co-m	orbidities							
A. HRG and Bridge	e Population							
Indicator	2023-24							
	Quarter	FSW	MSM	IDU	TG	Migrants	Truckers	Total
	Quarter 1	2,04,111	60,263	885	17,063	26,707	13,022	3,22,051
Screened for TB	Quarter 2	2,05,672	61,486	840	7,889	35,241	18,001	3,29,129
Screened for 1B	Quarter 3	2,03,126	56,535	1,524	13,038	51,612	23,200	3,49,035
	Quarter 4	2,15,035	62,716	1,810	13,544	48,540	24,070	3,65,715
	Quarter 1	1,927	629	3	99	191	-	2,849
Tested for TB	Quarter 2	1,702	685	3	75	359	-	2,824
rested for 1B	Quarter 3	2,157	808	3	78	320	11	3,377
	Quarter 4	2,161	694	3	104	378	33	3,373
	Quarter 1	4	3	-	-	1	-	8
D: 1 11 TD	Quarter 2	7	4	-	-	-	-	11
Diagnosed with TB	Quarter 3	5	7	-	1	-	1	14
	Quarter 4	14	12	-	4	1	1	32
	Quarter 1	4	3	-	-	2	-	9
Initiated on TB	Quarter 2	3	2	-	-	-	-	5
treatment	Quarter 3	1	5	-	-	-	-	6
	Quarter 4	5	5	-	-	-	-	10

B. HIV-TB Coinfected at ART Centre Indicator 2023-24 PLHIV PLHIV PLHIV with PLHIV PLHIV Co-infected enrolled at Co-infected initiated on ART PLHIV tested for TB presumptive TB diagnosed with TB initiated on IPT Moths attending underwent ART Centre 4S screening ARTC 1,31,542 1,28,274 Apr - 23 5,164 4,982 278 724 1,673 1,33,596 7,892 304 May - 23 1,36,848 5,169 Jun - 23 1,37,243 1,33,851 8,640 5,992 305 1,353 Jul - 23 1,43,362 1,39,053 8,834 6,085 256 1,379 1,38,743 6,717 223 2,371 Aug - 23 1,45,592 6,503 Sep - 23 1,39,981 1,36,351 5,676 5,567 228 1,183 1,44,992 1,39,917 5,581 1,225 Oct - 23 5,231 218 8,954 208 1,070 Nov - 23 1,40,011 1,35,535 4,774 Dec - 23 1,45,283 1,41,412 5,972 5,793 217 1,425 1,512 1,49,094 1,44,117 5,601 Jan - 24 5,445 227 Feb - 24 1,44,320 1,40,407 5,052 4,943 206 984 Mar - 24 1,46,993 1,43,374 5,262 5,174 236 1,064 April 2023-3,708 3,586 March 2024

ond 95 (G:: od 95 (G::≥9 orage Frequ Q2, Q3 & cus of AEP i cus of SCA cus of State cus of Omb WS onboar if onboardin testing am testing am testing am testing am fic visit of H centage of on OST (G centage of centage of sy, R:<70% testing ag	s, Y: 80-94%, R:<80%) 295%, Y: 80-94%, R:<80%) 5%, Y: 80-94%, R:<80%) 6%, Y: 80-94%, R:<80%) 6mcy of Social Media updates (G: ≥ 45, Y:40- 44, R:<40 in Q4 6. At least one meeting held since 2020, R: other than G) 6. At least one meeting held since 2020, R: other than G) 6. Rules (G: Notified, R: Not notified) 6. Appointed, R: Not appointed) 6. Appointed, R: Not ap	b) ets (G: ≥75%, Y: 70- 4%, R:<80%) 30-94%, R:<80%)	2 177 147 (83%) 81 87 >=95 119 Yes Meeting held in 2022 Notified Appointed 91 100 98 81 65 86 82 11 97 100 111 95 110				
tained Mark t 95 (G:≥95 ond 95 (AE) o	s, Y: 80-94%, R:<80%) 295%, Y: 80-94%, R:<80%) 5%, Y: 80-94%, R:<80%) 6%, Y: 80-94%, R:<80%) 6mcy of Social Media updates (G: ≥ 45, Y:40- 44, R:<40 in Q4 6. At least one meeting held since 2020, R: other than G) 6. At least one meeting held since 2020, R: other than G) 6. Rules (G: Notified, R: Not notified) 6. Appointed, R: Not appointed) 6. Appointed, R: Not ap	b) ets (G: ≥75%, Y: 70- 4%, R:<80%) 30-94%, R:<80%)	147 (83%) 81 87 >=95 119 Yes Meeting held in 2022 Notified Appointed 91 100 98 81 65 86 82 11 97 100 111				
t 95 (G:≥95 ond 95 (G:)95 ond	%, Y: 80-94%, R:<80%) 295%, Y: 80-94%, R:<80%) 5%, Y: 80-94%, R:<80%) ency of Social Media updates (G: ≥ 45, Y:40- 44, R:<40 in Q4 Integration in state school curriculum (G:Yes, R:No) G: At least one meeting held since 2020, R: other than G) Rules (G: Notified, R: Not notified) udsman (G: Appointed, R: Not appointed) ding (G: ≥95%, Y: 90-<95%, R:<90%) Ig (G: ≥95%, Y: 90-<95%, R:<90%) RG against estimates (G: ≥90%, Y: 80-<90%, R:<80%) Ing HRG (G: ≥95%, Y: 90-<95%, R:<90%) RGs at TI-Clinics (G: ≥90%, Y: 75-89%, R:<75%) HRGs screened for Syphilis (G: ≥90%, Y: 75-89%, R:<75%) ind released to TI (G: ≥50%, Y: 45-<50%, R:<45%) Tils trained by Kshmata Kendra (KK) against the AAP targe of the property of the propert	b) ets (G: ≥75%, Y: 70- 4%, R:<80%) 30-94%, R:<80%)	81 87 >=95 119 Yes Meeting held in 2022 Notified Appointed 91 100 98 81 65 86 82 11 97 100				
ond 95 (G:: od 95 (G::≥9 orage Frequ Q2, Q3 & cus of AEP i cus of SCA cus of State cus of Omb WS onboar if onboardin testing am testing am testing am testing am fic visit of H centage of on OST (G centage of centage of sy, R:<70% testing ag	295%, Y: 80-94%, R:<80%) 5%, Y: 80-94%, R:<80%) ency of Social Media updates (G: ≥ 45, Y:40- 44, R:<40 in Q4 integration in state school curriculum (G:Yes, R:No) G: At least one meeting held since 2020, R: other than G) Rules (G: Notified, R: Not notified) udsman (G: Appointed, R: Not appointed) ding (G: ≥95%, Y: 90-<95%, R:<90%) Ig (G: ≥95%, Y: 90-<95%, R:<90%) RG against estimates (G: ≥90%, Y: 80-<90%, R:<80%) Ing HRG (G: ≥95%, Y: 90-<95%, R:<90%) RGs at TI-Clinics (G: ≥90%, Y: 40% to <50%, R:<40%) RGs at TI-Clinics (G: ≥90%, Y: 75-89%, R:<75%) HRGs screened for Syphilis (G: ≥90%, Y: 75-89%, R:<75%) ind released to TI (G: ≥50%, Y: 45-<50%, R:<45%) TIs trained by Kshmata Kendra (KK) against the AAP targe of the property of	b) ets (G: ≥75%, Y: 70- 4%, R:<80%) 30-94%, R:<80%)	87 >=95 119 Yes Meeting held in 2022 Notified Appointed 91 100 98 81 65 86 82 11 97 100 111				
d 95 (G:≥9 arage Frequence Q2, Q3 & cus of AEP is cus of SCA cus of State cus of Omb WS onboard in testing am testing am testing am testing am testing am testing are centage of on OST (Gentage of S%, R:<70% testing agreement property te	5%, Y: 80-94%, R:<80%) ency of Social Media updates (G: ≥ 45, Y:40- 44, R:<40 in Q4 Integration in state school curriculum (G:Yes, R:No) G: At least one meeting held since 2020, R: other than G) Rules (G: Notified, R: Not notified) udsman (G: Appointed, R: Not appointed) ding (G: ≥95%, Y: 90-<95%, R:<90%) Integration in state school curriculum (G:Yes, R:No) G: ≥95%, Y: 90-<95%, R:<90%) Integration in state school curriculum (G:Yes, R:<80%) Integration in state school curriculum (G:Yes, R:<80%) Integration in state school curriculum (G: ≥90%, Y: 80-<90%, R:<80%) Integration in state school curriculum (G: ≥90%, R:<80%) Integration in state school curriculum (G: ≥90%, R:<80%) Integration in state school curriculum (G: ≥90%, R:<40%) Integration in state school curriculum (G: ≥90%, R:<40%) Integration in state school curriculum (G: ≥90%, R:<40%) Integration in state school curriculum (G: ≥95%, Y: 80-94%, R:<80%) Integration in state school curriculum (G: ≥95%, Y: 80-94%, R:<80%) Integration in state school curriculum (G: ≥95%, Y: 80-94%, R:<80%) Integration in state school curriculum (G: ≥95%, Y: 80-94%, R:<80%) Integration in state school curriculum (G: ≥95%, Y: 80-94%, R:<80%) Integration in state school curriculum (G: ≥95%, Y: 80-94%, R:<80%) Integration in state school curriculum (G: ≥95%, Y: 80-94%, R:<80%) Integration in state school curriculum (G: ≥95%, Y: 80-94%, R:<80%) Integration in state school curriculum (G: ≥95%, Y: 80-94%, R:<80%) Integration in state school curriculum (G: ≥95%, Y: 80-94%, R:<80%) Integration in state school curriculum (G: ≥95%, Y: 80-94%, R:<80%) Integration in state school curriculum (G: ≥95%, Y: 80-94%, R:<80%) Integration in state school curriculum (G: ≥95%, Y: 80-94%, R:<80%) Integration in state school curriculum (G: ≥95%, Y: 80-94%, R:<80%)	b) ets (G: ≥75%, Y: 70- 4%, R:<80%) 30-94%, R:<80%)	>=95 119 Yes Meeting held in 2022 Notified Appointed 91 100 98 81 65 86 82 11 97 100 111				
rage Frequency 2, Q3 & cus of AEP is cus of SCA cus of State cus of Omb was on board in testing am testing again	ency of Social Media updates (G: ≥ 45, Y:40- 44, R:<40 in Q4 Integration in state school curriculum (G:Yes, R:No) G: At least one meeting held since 2020, R: other than G) Rules (G: Notified, R: Not notified) Judsman (G: Appointed, R: Not appointed) ding (G: ≥95%, Y: 90-<95%, R:<90%) Integration (G: ≥90%, Y: 80-<90%, R:<40%) Integration (G: ≥90%, Y: 75-89%, R:<75%) Integration (G: ≥90%, Y: 75-89%, R:<75%) Integration (G: ≥50%, R:<30%) Integration (G: ≥50%, Y: 45-<50%, R:<45%) Integration (G: ≥50%, Y: 80-94%, R:<80%) Integration (G: ≥95%, Y: 80-94%, R:<80%)	b) ets (G: ≥75%, Y: 70- 4%, R:<80%) 30-94%, R:<80%)	119 Yes Meeting held in 2022 Notified Appointed 91 100 98 81 65 86 82 11 97 100 111				
Q2, Q3 & tus of AEP is tus of SCA tus of SCA tus of State tus of Omb. WS onboal Tonboardin testing am testing am tic visit of Honor of Control of SCA tus	ntegration in state school curriculum (G:Yes, R:No) G: At least one meeting held since 2020, R: other than G) Rules (G: Notified, R: Not notified) Judsman (G: Appointed, R: Not appointed) ding (G: ≥95%, Y: 90-<95%, R:<90%) Ig (G: ≥95%, Y: 90-<95%, R:<90%) RG against estimates (G: ≥90%, Y: 80-<90%, R:<80%) Jong HRG (G: ≥95%, Y: 90-<95%, R:<90%) RGs at TI-Clinics (G: ≥90%, Y: 75-89%, R:<75%) HRGs screened for Syphilis (G: ≥90%, Y: 75-89%, R:<75%) Lind released to TI (G: ≥50%, R:<30%) Judy Hard (B: ≥95%, Y: 90-<95%, R:<90%) Linds target-at risk % (G: ≥95%, Y: 80-94%, R:<80%) Linist target-PW (G: ≥95%, Y: 80-94%, R:	b) ets (G: ≥75%, Y: 70- 4%, R:<80%) 30-94%, R:<80%)	Yes Meeting held in 2022 Notified Appointed 91 100 98 81 65 86 82 11 97 100 111				
cus of AEP is tus of SCA cus of State cus of Omb WS onboar Tonboardin verage of H testing am testing am testing am tic visit of H centage of on OST (Goentage of SW, R:<70% testing agreement project te	ntegration in state school curriculum (G:Yes, R:No) G: At least one meeting held since 2020, R: other than G: Rules (G: Notified, R: Not notified) Idsman (G: Appointed, R: Not appointed) Iding (G: ≥95%, Y: 90-<95%, R:<90%) Ing (G: ≥95%, Y: 90-<95%, R:<90%) Ing (G: ≥95%, Y: 90-<95%, R:<90%) Ing HRG (G: ≥95%, Y: 90-<95%, R:<90%) Ing HRG (G: ≥95%, Y: 90-<95%, R:<90%) Ing HRG (G: ≥95%, Y: 40% to <50%, R:<40%) Ing Prisoners (G: ≥50%, Y: 40% to <50%, R:<40%) Ing Screened for Syphilis (G: ≥90%, Y: 75-89%, R:<75%) Ing Screened for Syphilis (G: ≥90%, Y: 75-89%, R:<75%) In trained by Kshmata Kendra (KK) against the AAP targe of the AAP	6) ets (G: ≥75%, Y: 70- 4%, R:<80%) 30-94%, R:<80%)	Meeting held in 2022 Notified Appointed 91 100 98 81 65 86 82 11 97 100 111				
cus of SCA cus of State cus of Omb WS onboar T onboardin verage of H testing am testing am ic visit of H centage of on OST (G centage of	G: At least one meeting held since 2020, R: other than G) Rules (G: Notified, R: Not notified) Idsman (G: Appointed, R: Not appointed) Iding (G: ≥95%, Y: 90-<95%, R:<90%) Ig (G: ≥95%, Y: 90-<95%, R:<90%) Ig (G: ≥95%, Y: 90-<95%, R:<90%) In HRG (G: ≥95%, Y: 90-<95%, R:<90%) In HRG (G: ≥95%, Y: 90-<95%, R:<90%) In HRG (G: ≥95%, Y: 40% to <50%, R:<40%) In HRGs screened for Syphilis (G: ≥90%, Y: 75-89%, R:<75%) If It rained by Kshmata Kendra (KK) against the AAP targe (I) In this transpet is the AAP targe (I) In this target is the AAP targe (I) In	6) ets (G: ≥75%, Y: 70- 4%, R:<80%) 30-94%, R:<80%)	Notified Appointed 91 100 98 81 65 86 82 11 97 100				
cus of Omboarding verage of Historical amiliar visit of Hi	Idsman (G: Appointed, R: Not appointed) Iding (G: ≥95%, Y: 90-<95%, R:<90%) Iding HRG (G: ≥95%, Y: 90-<95%, R:<90%) Iding Prisoners (G: ≥50%, Y: 40% to <50%, R:<40%) Iding RGs at TI-Clinics (G: ≥90%, Y: 75-89%, R:<75%) Iding Screened for Syphilis (G: ≥90%, Y: 75-89%, R:<75%) Iding Iding Screened for Syphilis (G: ≥90%, Y: 75-89%, R:<75%) Iding Teleased to TI (G: ≥50%, Y: 45-<50%, R:<45%) It strained by Kshmata Kendra (KK) against the AAP targe of the AAP tar	ets (G: ≥75%, Y: 70- 4%, R:<80%) 30-94%, R:<80%)	Appointed 91 100 98 81 65 86 82 11 97 100				
cus of Omboarding verage of Historical amiliar visit of Hi	Idsman (G: Appointed, R: Not appointed) Iding (G: ≥95%, Y: 90-<95%, R:<90%) Iding HRG (G: ≥95%, Y: 90-<95%, R:<90%) Iding Prisoners (G: ≥50%, Y: 40% to <50%, R:<40%) Iding RGs at TI-Clinics (G: ≥90%, Y: 75-89%, R:<75%) Iding Screened for Syphilis (G: ≥90%, Y: 75-89%, R:<75%) Iding Iding Screened for Syphilis (G: ≥90%, Y: 75-89%, R:<75%) Iding Teleased to TI (G: ≥50%, Y: 45-<50%, R:<45%) It strained by Kshmata Kendra (KK) against the AAP targe of the AAP tar	ets (G: ≥75%, Y: 70- 4%, R:<80%) 30-94%, R:<80%)	Appointed 91 100 98 81 65 86 82 11 97 100				
WS onboal Tonboarding rerage of H testing am testing am tic visit of H centage of on OST (Ci centage of centage of testing ag	ding (G: ≥95%, Y: 90-<95%, R:<90%) In (G: ≥95%, Y: 40% to <50%, R:<40%) In (G: ≥90%, Y: 75-89%, R:<75%) In (G: ≥90%, Y: 75-89%, R:<75%) In (G: ≥50%, Y: 30% to <50%, R:<30%) In (G: ≥50%, Y: 45-<50%, R:<45%) In (G: ≥50%, Y: 45-<50%, R:<45%) In (G: ≥50%, Y: 80-94%, R:<80%) In (G: ≥95%, Y: 80-94%, R:<80%)	ets (G: ≥75%, Y: 70- 4%, R:<80%) 30-94%, R:<80%)	91 100 98 81 65 86 82 11 97 100				
r onboardii verage of H testing am testing am iic visit of H centage of on OST (C centage of centage of centage of testing ag testing ag centage of atment pro ex testing a centage of extentage of extentage of extentage of	g (G: ≥95%, Y: 90-<95%, R:<90%) RG against estimates (G: ≥90%, Y: 80-<90%, R:<80%) ong HRG (G: ≥95%, Y: 90-<95%, R:<90%) ong prisoners (G: ≥50%, Y: 40% to <50%, R:<40%) RGs at TI-Clinics (G: ≥90%, Y: 75-89%, R:<75%) HRGs screened for Syphilis (G: ≥90%, Y: 75-89%, R:<75%) : ≥50%, Y: 30% to <50%, R:<30%) fund released to TI (G: ≥50%, Y: 45-<50%, R:<45%) Its trained by Kshmata Kendra (KK) against the AAP targe tinst Target-at risk % (G: ≥95%, Y: 80-94%, R:<80%) oregnant women screened for Syphilis (G: ≥95%, Y: 80-94%, R:<80%) fixed to Syphilis reactive pregnant women (G: ≥95%, Y: 80-94%, R:<80%) mong newly detected HIV positive clients (G: ≥95%, Y: 80-95%, Y: 80-95	ets (G: ≥75%, Y: 70- 4%, R:<80%) 30-94%, R:<80%)	98 81 65 86 82 11 97 100				
testing am testing am testing am testing am tic visit of Homeon OST (Grentage of Sw., R:<70% testing agreement properties of atment properties of sw., and testing agreement properties of sw., and testi	RG against estimates (G: ≥90%, Y: 80-<90%, R:<80%) ong HRG (G: ≥95%, Y: 90-<95%, R:<90%) ong prisoners (G: ≥50%, Y: 40% to <50%, R:<40%) RGs at TI-Clinics (G: ≥90%, Y: 75-89%, R:<75%) HRGs screened for Syphilis (G: ≥90%, Y: 75-89%, R:<75%) : ≥50%, Y: 30% to <50%, R:<30%) fund released to TI (G: ≥50%, Y: 45-<50%, R:<45%) FIs trained by Kshmata Kendra (KK) against the AAP targe olinist Target-at risk % (G: ≥95%, Y: 80-94%, R:<80%) oregnant women screened for Syphilis (G: ≥95%, Y: 80-94%, R:<80%) rided to Syphilis reactive pregnant women (G: ≥95%, Y: 80-94%, R:<80%) mong newly detected HIV positive clients (G: ≥95%, Y: 80-95%, Y: 80	ets (G: ≥75%, Y: 70- 4%, R:<80%) 30-94%, R:<80%)	81 65 86 82 11 97 100				
testing amic visit of Hocentage of on OST (Contage of centage of testing agreement properties). The centage of testing agreement properties testing agreement properties (Contage of testing agreement properties).	ong prisoners (G: ≥50%, Y: 40% to <50%, R:<40%) RGs at TI-Clinics (G: ≥90%, Y: 75-89%, R:<75%) HRGs screened for Syphilis (G: ≥90%, Y: 75-89%, R:<75%) ⇒50%, Y: 30% to <50%, R:<30%) Fund released to TI (G: ≥50%, Y: 45-<50%, R:<45%) Fis trained by Kshmata Kendra (KK) against the AAP targe inist Target-at risk % (G: ≥95%, Y: 80-94%, R:<80%) circular target-PW (G: ≥95%, Y: 80-94%, R:<80%) oregnant women screened for Syphilis (G: ≥95%, Y: 80-94%) mong newly detected HIV positive clients (G: ≥95%, Y: 80-95%,	ets (G: ≥75%, Y: 70- 4%, R:<80%) 30-94%, R:<80%)	65 86 82 11 97 100 111 95				
ic visit of Hocentage of on OST (Contage of centage of centage of testing agreement properties). The centage of atment properties of testing agreement properties (Contage of Section 2014).	RGs at TI-Clinics (G: ≥90%, Y: 75-89%, R:<75%) HRGs screened for Syphilis (G: ≥90%, Y: 75-89%, R:<75%): ≥50%, Y: 30% to <50%, R:<30%) Fund released to TI (G: ≥50%, Y: 45-<50%, R:<45%) FIs trained by Kshmata Kendra (KK) against the AAP targe inist Target-at risk % (G: ≥95%, Y: 80-94%, R:<80%) inist target-PW (G: ≥95%, Y: 80-94%, R:<80%) oregnant women screened for Syphilis (G: ≥95%, Y: 80-94%) iniong newly detected HIV positive clients (G: ≥95%, Y: 80-95%, Y: 8	ets (G: ≥75%, Y: 70- 4%, R:<80%) 30-94%, R:<80%)	86 82 11 97 100 111 95				
centage of on OST (Greentage of centage of secting agreement properties). The centage of atment properties are testing agreement properties (Contage of Section 2006).	HRGs screened for Syphilis (G: ≥90%, Y: 75-89%, R:<75%; ≥50%, Y: 30% to <50%, R:<30%) Fund released to TI (G: ≥50%, Y: 45-<50%, R:<45%) Fis trained by Kshmata Kendra (KK) against the AAP targe (a) Finist Target-at risk % (G: ≥95%, Y: 80-94%, R:<80%) Finist target-PW (G: ≥95%, Y: 80-94%, R:<80%) Foregnant women screened for Syphilis (G: ≥95%, Y: 80-94%) Finist target-PW (G: ≥95%, Y: 80-94%, R:<80%) Foregnant women screened for Syphilis (G: ≥95%, Y: 80-94%) Finist target-PW (G: ≥95%, Y: 80-94%, R:<80%)	ets (G: ≥75%, Y: 70- 4%, R:<80%) 30-94%, R:<80%)	82 11 97 100 111 95				
on OST (G centage of centage of (%, R:<70% testing ag- testing ag- centage of atment pro ex testing a centage of 80%)	: ≥50%, Y: 30% to <50%, R:<30%) Fund released to TI (G: ≥50%, Y: 45-<50%, R:<45%) Fis trained by Kshmata Kendra (KK) against the AAP targe ininst Target-at risk % (G: ≥95%, Y: 80-94%, R:<80%) ininst target-PW (G: ≥95%, Y: 80-94%, R:<80%) pregnant women screened for Syphilis (G: ≥95%, Y: 80-94%) rided to Syphilis reactive pregnant women (G: ≥95%, Y: 80-94%) mong newly detected HIV positive clients (G: ≥95%, Y: 80-94%)	ets (G: ≥75%, Y: 70- 4%, R:<80%) 30-94%, R:<80%)	11 97 100 111 95				
centage of centage of sentage of setting against testing against testing against testing against testing at testing at testing acceptage of setting acceptag	Fund released to TI (G: ≥50%, Y: 45-<50%, R:<45%) Fils trained by Kshmata Kendra (KK) against the AAP targe inst Target-at risk % (G: ≥95%, Y: 80-94%, R:<80%) inst target-PW (G: ≥95%, Y: 80-94%, R:<80%) bregnant women screened for Syphilis (G: ≥95%, Y: 80-94%, R:<80%) rided to Syphilis reactive pregnant women (G: ≥95%, Y: 80-94%, R:<80%)	4%, R:<80%) 30-94%, R:<80%)	97 100 111 95				
centage of 6%, R:<70% testing agitesting agicentage of atment properties testing accentage of eatment grows testing accentage of 80%)	Fils trained by Kshmata Kendra (KK) against the AAP targe) linst Target-at risk % (G: ≥95%, Y: 80-94%, R:<80%) linst target-PW (G: ≥95%, Y: 80-94%, R:<80%) pregnant women screened for Syphilis (G: ≥95%, Y: 80-94 vided to Syphilis reactive pregnant women (G: ≥95%, Y: 80-94 mong newly detected HIV positive clients (G: ≥95%, Y: 80-94)	4%, R:<80%) 30-94%, R:<80%)	100 111 95				
testing again testing again testing again testing again testing at the testing at	ninst Target-at risk % (G: ≥95%, Y: 80-94%, R:<80%) inst target-PW (G: ≥95%, Y: 80-94%, R:<80%) pregnant women screened for Syphilis (G: ≥95%, Y: 80-94 ided to Syphilis reactive pregnant women (G: ≥95%, Y: 80-94 mong newly detected HIV positive clients (G: ≥95%, Y: 80-94	4%, R:<80%) 30-94%, R:<80%)	111 95				
testing aga testing aga centage of atment pro ex testing a centage of 80%)	inst Target-at risk % (G: ≥95%, Y: 80-94%, R:<80%) inst target-PW (G: ≥95%, Y: 80-94%, R:<80%) bregnant women screened for Syphilis (G: ≥95%, Y: 80-94 ided to Syphilis reactive pregnant women (G: ≥95%, Y: 80 mong newly detected HIV positive clients (G: ≥95%, Y: 80	80-94%, R:<80%)	95				
testing aga centage of atment pro ex testing a centage of 80%)	inst target-PW (G: ≥95%, Y: 80-94%, R:<80%) pregnant women screened for Syphilis (G: ≥95%, Y: 80-94 yided to Syphilis reactive pregnant women (G: ≥95%, Y: 80 mong newly detected HIV positive clients (G: ≥95%, Y: 80	80-94%, R:<80%)	95				
centage of atment pro ex testing a centage of 80%)	oregnant women screened for Syphilis (G: ≥95%, Y: 80-94 vided to Syphilis reactive pregnant women (G: ≥95%, Y: 8 mong newly detected HIV positive clients (G: ≥95%, Y: 80	80-94%, R:<80%)					
atment pro ex testing a centage of 80%)	vided to Syphilis reactive pregnant women (G: ≥95%, Y: 8 mong newly detected HIV positive clients (G: ≥95%, Y: 80	80-94%, R:<80%)	110				
ex testing a centage of 80%)	mong newly detected HIV positive clients (G: ≥95%, Y: 80						
centage of 80%)	•	0-94%, R:<80%)	99				
80%)	5 weeks - <2 months EID testing against live birth (G: ≥95	Index testing among newly detected HIV positive clients (G: ≥95%, Y: 80-94%, R:<80%)					
nts manag	Percentage of 6 weeks - <2 months EID testing against live birth (G: ≥95%, Y: 80-94%, R:<80%)						
	ed at DSRC against the target (G: ≥90%, Y: 75-89%, R:<7!	5%)	98				
attendees :	screened for HIV (G: >75%, Y: 50-75%, R:<50%)		78				
	creened for Syphilis (G: >75%, Y: 50-75%, R:<50%)		64				
f pregnant	women who initiated ART (G: ≥95%, Y: 80-94%, R:<80%)		100				
portion of l 5%)	FU-PLHIV, out of those initiated on ART in FY 2023-24 (G	:<2%, Y: 2 to 5%,	2				
portion of F 98%, R:<95	LHIV initiated on ART, out of those registered in FY 2023 %)	-24 (G:>98%, Y: 95	99				
portion of r 5 %)	eported died, out of those initiated on ART in FY 202324	(G:<2%, Y: 2 to 5 %,	7				
	dited (G:100%, Y: 80-99%, R:<80%)		100				
	of ICTCs in re-testing (G: ≥95%, Y: 85-94, R:<85%)		97				
	tracts selected from studies conducted in FY21-22 5 to <100%, R: ≤25%)		4				
	going studies from FY22-23 (G:100%, Y: >25 to <100%,		3				
mission of	research proposals from FY23-24 to NACO (G:100%, %, R: ≤25%)		2				
	a Analysis by SACS (G:2, Y: 1, R: No Secondary Data Anal	lysis Plan Submitted)	2				
	th respect to funds released during FY 2022-23 (G:	-	172				
	<90%, R: <85%)		1/2				
mission of	Provisional Utilization Certificate (UC) in GFR 12A for the F : by 31-May-2023, R : after	FY 2022-23 (G : by	16-05-2023				
mission of	audited UC in GFR 12A for the FY 2022-23 (G : by 30Jun- 30-Sep-2023)	-2023, Y : by 30-Sep-	03-10-2023				
mission of	EC/ GB ratification for approval of Expenditure incurred d 2022, Y: by 30-Sept-2022,	during FY 2021-22	20-07-2023				
	sion of CST-SCM Report (G:>95%, Y: 80-95%, R:<80%)		98				
ery submis	<u> </u>		94				
	sion of BSD & STI-SCM Report (G: ≥90%, Y: 75-		100				
mat Adhere		rk Nio C	Colour=Not Applicable				
mat Adhere ely Submis 0%, R:<		INO	2010at – Mot Applicable				
mat Adhere ely Submis 0%, R:< n=3 Marks							
mat Adhere ely Submis 0%, R:< n=3 Marks pints							
mat Adhere ely Submis 0%, R:< n=3 Marks	1, 23, 29						
	nat Adhere ely Submiss)%, R:<7 n=3 Marks	nat Adherence to CST-SCM Report (G:>95%, Y: 80-95%, R:<80%) ely Submission of BSD & STI-SCM Report (G: ≥90%, Y: 75- 0%, R:<75%) Yellow=2Marks Red-1 Maints Indicator SI. No.	nat Adherence to CST-SCM Report (G:>95%, Y: 80-95%, R:<80%) sely Submission of BSD & STI-SCM Report (G: ≥90%, Y: 75- 10%, R:<75%) 3 Marks				





1. Status of HIV/AIDS Epidemic					
A. Epidemic Estimates (2023)					
Indicator	Male	Female	Total		
1. IPR	-	-	1.33		
2. IMR	-	-	0.63		
3. Adult (15-49 yrs) HIV Prevalence (%)	0.08	0.06	0.07		
4. Estimated people living with HIV	12,990	11,427	24,417		
5. ART coverage (%)	75.19	69.61	72.71		
6. Estimated children living with HIV	261	249	510		
7. Annual new HIV infections	171	154	325		
8. Annual AIDS-related deaths (ARD)	115	173	288		
9. Change in annual new HIV infections since 2010 (%)	-74.25	-74.50	-74.39		
10. Change in annual ARD since 2010(%)	-76.19	-67.36	-71.54		
11. EMTCT need	-	102	102		

B. High risk population size (2020-22), safe practices (2021) and prevalence (2021/2023) Condom Use New Needle/ **HIV Prevalence** Estimates Size Population Group (%) Syringe use (%) (%) 16,623 97.50 1. Female Sex Workers 0.44 98.10 0.35 2. Men who have sex with men 13,836 3. Injecting Drug Users 3,276 99.10 0.40 0.56 4. Hijra/Transgender People 2,604 5. Migrants 1,50,000 0.00 6. Truckers 20,000 92.30 1.20 52,686 35.00 82.80 0.25 7. Prison inmates

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)					
Indicator	Male	Female	Total		
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)	45.20	34.80	-		
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	40.60	30.20	-		
3. Adults willing to care for a relative with HIV/AIDS in own home (%)	65.30	71.00	-		
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	78.90	71.70	-		
5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)	0.50	0.00	-		
5.1 Condom use during last higher-risk intercourse (%)	47.90	-	-		
6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)	0.51	0.00	-		
6.1 Condom use during last higher-risk intercourse (%)	0.00	-	-		

2. Progress on	95-95-95 (20	23-24)
64 64 66 67 72 76	295 295 295 295 295	83 89 91 92 <u>295 295</u>
PLHIV who know their HIV status (%)	PLHIV who know their HIV status and are on ART (%)	PLHIV who are on ART and virally suppressed (%)
2018-19 2019-20	2020-21 2021-22	■ 2022-23 ■ 2023-24

Indicators	Male	Female	Total*
1. Estimated PLHIV size (2023)	12,990	11,427	24,417
2. PLHIV who know their HIV Status	10,479	8,016	18,530
3. PLHIV who know their HIV status and are on ART	9,836	8,014	17,881
4. PLHIV who are on ART and tested for their viral load	8,377	7,026	15,417
4.1 PLHIV who are virally suppressed	8,354	7,001	15,369

^{*} Including of H/TG PLHIV

A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2023-24
Schools with operational Adolescent Education Program (AEP)	1,500
2. Colleges with operational Red Ribbon Clubs (RRC)	293
3. Persons trained under mainstreaming	2,229
4. No. of calls received at helpline	_

B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management

Indicator	2023-24					
NACO Supported Designated STI/	23			23		
RTI Clinics (DSRC)	Male	Female	TG	Total		
2. Total STI/RTI Clients managed				99,545		
3. RPR Tests conducted	11,519	11,133	130	22,782		
4. Syphilis seropositivity (%)	8.32	1.98	21.54	5.29		

4. Prevention of new HIV infections among high-risk group and bridge population

A. Targeted Intervention (TI) Projects and Opioid Substitution Therapy (OST)

Indicator	2023-24
1. Targeted Intervention (TI) Projects	64
2. OST centres (Excluding Satellite OST centres)	10

B. Female Sex Workers

Di l'elliale Dex Workers	
Indicator	2023-24
1. Estimated size	16,623
2. Coverage (%)	>=95
3. Condoms distributed	20,88,228
4. Tested for HIV (April 2022-September 2022)	14,894
4.1. HIV sero-positive (%)	0.00
4.1.1. Linked to ART	0
5. Tested for HIV (October 2022 -March 2023)	16,912
5.1. HIV sero-positive (%)	0.02
5.1.1. Linked to ART	3
6. Clinic Visits	58,731
7. STI/RTI treated	573
8. Presumptive treatment	2,444

C. Men who have Sex with Men

Comment with the state of the s	
Indicatort	2023-24
1. Estimated size	13,836
2. Coverage (%)	>=95
3. Condoms distributed	13,23,298
4. Tested for HIV (April 2022-September 2022)	10,495
4.1. HIV sero-positive (%)	0.11
4.1.1. Linked to ART	10
5. Tested for HIV (October 2022 -March 2023)	11,963
5.1. HIV sero-positive (%)	0.18
5.1.1. Linked to ART	17
6. Clinic Visits	43,968
7. STI/RTI treated	365
8. Presumptive treatment	1,810

D. Injecting Drug Users	
Indicator	2023-24
1. Estimated size	3,276
2. Coverage (%)	>=95
3. Needles distributed	5,83,237
4. Syringes distributed	2,90,136
5. On OST	549
6. Tested for HIV (April 2022 -September 2022)	2,498
6.1. HIV sero-positive (%)	0.00
6.1.1 Linked to ART	-
7. Tested for HIV (October 2022 -March 2023)	2,719
7.1. HIV sero-positive (%)	0.00
7.1.1. Linked to ART	-

E. Hijra/Transgender person	
Indicator	2023-24
1. Estimated size	2,604
2. Coverage (%)	>=95
3. Condoms distributed	3,48,867
4. Tested for HIV (April 2022-September 2022)	2,539
4.1. HIV sero-positive (%)	0.12
4.1.1. Linked to ART	2
5. Tested for HIV (October 2022 -March 2023)	2,959
5.1. HIV sero-positive (%)	0.14
5.1.1. Linked to ART	4
6. Clinic Visits	8,954
7. STI/RTI treated	65
8. Presumptive treatment	439

F. Migrants	
Indicator	2023-24
1. Estimated size	1,50,000
2. Coverage (%)	82
3. Tested for HIV	44,259
3.1. HIV sero-positive (%)	0.18
3.2. Linked to ART	62

G. Truckers	
Indicator	2023-24
1. Estimated size	20,000
2. Coverage (%)	>=95
3. Tested for HIV	10,431
3.1. HIV sero-positive (%)	0.17
3.2. On ART	4

H. Prison Inmates	
Indicator	2023-24
1. Total prisons	56
2. Prisons covered under programme	56
3. Total inmates admitted	52,686
4. Inmates Covered (%)	56
5. Tested for HIV	29,505
5.1. HIV sero-positive (%)	0.21
5.2. On ART (%)	68.25

I. Link Worker Scheme	
Indicator	2023-24
Districts covered under scheme	-
Vulnerable population covered	-
3. Tested for HIV	-
3.1. HIV sero-positive (%)	-
3.2. Linked to ART (%)	-

J. Opioid Substitution Therapy	
Indicator	2023-24
1. OST Centres	10
1.1. OSTC in Public Health Settings	7
1.2. OSTC in NGO Settings	3
1.3. No. of Satellite OST Centres	1
2. IDU on OST	549

A. HIV counselling and testing services (HCTS)

Indicator	2023-24
1. HCTC confirmatory facilities	90
2. Sampoorna Suraksha Kendras	-

B. HIV testing among vulnerable population (excluding pregnant women)

Indicator	2023-24			
	Male	Female	TG	Total
1. Tested for HIV	8,97,532	8,12,729	3,111	17,13,372
1.1 HIV Positives	970	254	11	1,235
1.2 HIV sero -positivity (%)	0.11	0.03	0.35	0.07
Spouse/sexual partner of HIV positive people tested	219	451	6	676
2.1 HIV Positives	48	78	3	129
2.2 HIV sero -positivity (%)	22	17	50	19.08
No. of contacts with 'at- risk' population through 'Sampoorna Suraksha'	-	-	-	-

6. Initiation and retention on ART of HIV infected people

A. Treatment facilities

Indicator	2023-24
1. ART Centres	15
2.Centre of Excellence	
2.1. Centre of Excellence (Adult)	-
2.2 Centre of Excellent (Paediatric)	-
3. Link ART Centres	10
4. Care Support Centres	7

B. Treatment uptake

Indicator	2023-24			
	Male	Female	TG	Total
HIV positive cases diagnosed (At ICTC)	970	282	11	1,263
New PLHIV Registered at ART center	897	273	9	1,179
2.1 Initiated on ART	778	239	8	1,025
3. PLHIV alive and on ART	9,836	8,014	31	17,881
4. 12 months retention on ART (%)				>=95
5. Lost to follow-up cases	556	111	2	669

7. Viral Suppression and laboratories	
A. Laboratory facilities and service uptake	
Indicator	2023-24
Viral load laboratories (programme and non- programme labs)	1
1.1 Accredited Viral load laboratories (out of 64 VL labs)	1
2. Viral load tests conducted	17,099
2.1. Virally suppressed (%)	>=95
3. National reference laboratories (NRL)	(
3.1 Accredited NRL	(
4. State reference laboratories (SRL)	
4.1 Accredited SRL	Ę
5. CD4 machines	ç
5.1 CD4 tests conducted	2,491
6. External Quality Assurance of ICTC	
6.1 Average Participation (%)	100
6.2. Average Discordance (%)	0.00
7. "Certificate of Excellence" by NACO	
7.1 No. of ICTCs received "Certificate of Excellence"	25
8. Elimination of mother to child trans HIV & Syphilis	mission of
A. HIV	
Indicator	2023-24
1. Estimated pregnant women (PW)	5,17,840
2. HIV testing among PW	3,54,621
3. HIV sero-positivity (%) among tested	0.01
4. HIV Positive PW (old + new detections)	80
4.1 On life-long ART	78
5. Live births among HIV positive PW	60
5.1 Babies given ARV Prophylaxis (%)	>=95
6. Babies tested HIV (6 week- 6 month)	68
6.1 Babies confirmed HIV Positive	
(6 week- 6 month)	
7. HIV testing among exposed babies at 18 months	
7.1 HIV exposed babies tested at 18 months	48
7.2 Babies confirmed HIV positive at 18 months	
8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months)	1
HIV positive babies initiated on ART	,
D. C L. W.	
B. Syphilis	2022 24
Indicator 1. Syphilis testing among PW	2023-2 4 4,48,887
2.Sero-positivity (%) among tested	0.02
Put on treatment Elimination of HIV/AIDS related Stigma	80
and Discrimination	
Indicator	2023-24
1. State rules notified for HIV/AIDS Prevention and Control Act (2017)	Yes


2. State designated/appointed ombudsman

Yes

10. HIV-TB Co-morbidities								
A. HRG and Bridge Population								
Indicator	Indicator 2023-24							
	Quarter	FSW	MSM	IDU	TG	Migrants	Truckers	Total
	Quarter 1	16,019	12,274	2,675	2,108	18,337	5,069	56,482
Screened for TB	Quarter 2	19,286	15,123	2,767	2,709	26,998	4,767	71,650
Screened for TB	Quarter 3	20,163	13,822	2,628	2,596	26,413	4,657	70,279
	Quarter 4	18,711	12,031	2,858	2,534	22,471	4,067	62,672
	Quarter 1	54	2	15	1	20	-	92
Tested for TB	Quarter 2	78	15	9	3	77	-	182
rested for 16	Quarter 3	86	7	11	19	95	-	218
	Quarter 4	11	16	8	5	14	-	54
	Quarter 1	-	-	1	-	-	-	1
Diagnosed with TB	Quarter 2	1	-	-	-	1	-	2
Diagnosed with 16	Quarter 3	1	1	1	-	-	-	3
	Quarter 4	1	1	-	-	-	-	2
	Quarter 1	-	-	1	-	-	-	1
Initiated on TB	Quarter 2	-	-	-	-	-	-	-
treatment	Quarter 3	1	1	1	-	-	-	3
	Quarter 4	1	1	-	-	-	-	2

B. HIV-TB Coinfected at ART Centre Indicator 2023-24 PLHIV with presumptive TB PLHIV PLHIV PLHIV PLHIV Co-infected enrolled at Co-infected initiated on ART PLHIV tested for TB diagnosed with TB initiated on IPT Moths attending underwent ART Centre 4S screening ARTC 8,575 8,575 Apr - 23 125 115 8 63 9,581 13 124 9,568 161 155 May - 23 Jun - 23 9,438 9,417 188 175 16 61 Jul - 23 9,348 9,336 170 160 6 70 9,136 9,127 141 142 8 Aug - 23 66 Sep - 23 9,227 9,143 174 170 11 42 Oct - 23 9,454 9,442 195 14 69 176 19 57 11,808 11,786 212 191 Nov - 23 Dec - 23 13,456 13,441 215 199 20 47 Jan - 24 10,634 10,448 205 23 192 56 13 Feb - 24 8,687 8,553 182 179 76 Mar - 24 9,298 9,298 182 179 14 57 April 2023-225 198 March 2024

	State/UT	Kerala
	Rank	16
SI. No.	Maximum Marks	177
	Obtained Marks	128 (72%)
1	First 95 (G:≥95%, Y: 80-94%, R:<80%)	76
2	Second 95 (G:≥95%, Y: 80-94%, R:<80%)	>=95
3	Third 95 (G:≥95%, Y: 80-94%, R:<80%)	>=95
4	Average Frequency of Social Media updates (G: \geq 45, Y:40- 44, R:<40 indigenous posts) of Q1, Q2, Q3 & Q4	111
5	Status of AEP integration in state school curriculum (G:Yes, R:No)	Yes
6	Status of SCA (G: At least one meeting held since 2020, R: other than G)	No Meeting held
7	Status of State Rules (G: Notified, R: Not notified)	Notified
8	Status of Ombudsman (G: Appointed, R: Not appointed)	Appointed
9	TI/LWS onboarding (G: ≥95%, Y: 90-<95%, R:<90%)	100
10	OST onboarding (G: ≥95%, Y: 90-<95%, R:<90%)	100
11	Coverage of HRG against estimates (G: ≥90%, Y: 80-<90%, R:<80%)	166
12	HIV testing among HRG (G: ≥95%, Y: 90-<95%, R:<90%)	70
13	HIV testing among prisoners (G: ≥50%, Y: 40% to <50%, R:<40%)	39
14	Clinic visit of HRGs at TI-Clinics (G: ≥90%, Y: 75-89%, R:<75%)	66
15	Percentage of HRGs screened for Syphilis (G: ≥90%, Y: 75-89%, R:<75%)	50
16		33
	IDU on OST (G: ≥50%, Y: 30% to <50%, R:<30%) Percentage of fixed colored to TI (G:>50%, V: 45 <50%, P:<45%)	
7	Percentage of fund released to TI (G: ≥50%, Y: 45-<50%, R:<45%)	96
18	Percentage of TIs trained by Kshmata Kendra (KK) against the AAP targets (G: ≥75%, Y: 70-<75%, R:<70%)	100
19	HIV testing against Target-at risk % (G: ≥95%, Y: 80-94%, R:<80%)	334
20	HIV testing against target-PW (G: ≥95%, Y: 80-94%, R:<80%)	68
21	Percentage of pregnant women screened for Syphilis (G: ≥95%, Y: 80-94%, R:<80%)	87
22	Treatment provided to Syphilis reactive pregnant women (G: ≥95%, Y: 80-94%, R:<80%)	100
23	Index testing among newly detected HIV positive clients (G: ≥95%, Y: 80-94%, R:<80%)	27
24	Percentage of 6 weeks - <2 months EID testing against live birth (G: ≥95%, Y: 80-94%, R:<80%)	99
25	Clients managed at DSRC against the target (G: ≥90%, Y: 75-89%, R:<75%)	24
26	STI attendees screened for HIV (G: >75%, Y: 50-75%, R:<50%)	99
27	STI attendees screened for Syphilis (G: >75%, Y: 50-75%, R:<50%)	57
28	% of pregnant women who initiated ART (G: ≥95%, Y: 80-94%, R:<80%)	88
29	<u> </u>	
29	Proportion of LFU-PLHIV, out of those initiated on ART in FY 2023-24 (G:<2%, Y: 2 to 5%, R:>5%)	4
30	Proportion of PLHIV initiated on ART, out of those registered in FY 2023-24 (G:>98%, Y: 95 to 98%, R:<95%)	87
31	Proportion of reported died, out of those initiated on ART in FY 202324 (G:<2%, Y: 2 to 5 % R:>5 %)	4
32	% of SRL accredited (G:100%, Y: 80-99%, R:<80%)	100
33	% participation of ICTCs in re-testing (G: ≥95%, Y: 85-94, R:<85%)	100
34	Number of abstracts selected from studies conducted in FY21-22	4
	(G:100%, Y: >25 to <100%, R: ≤25%)	
35	Number of ongoing studies from FY22-23 (G:100%, Y: >25 to <100%,	O
	R: ≤25%)	
36	Submission of research proposals from FY23-24 to NACO (G:100%,	2
	Y: >25 to <100%, R: ≤25%)	
37	Secondary Data Analysis by SACS (G:2, Y: 1, R: No Secondary Data Analysis Plan Submitted) 2
38	Expenditure with respect to funds released during FY 2022-23 (G: ≥90%, Y: 85 to <90%, R: <85%)	100
39	Submission of Provisional Utilization Certificate (UC) in GFR 12A for the FY 2022-23 (G: by	17-05-2023
<i>.,</i>	30-Apr-2023, Y: by 31-May-2023, R: after 31-May-2023)	17-03-2023
40	1	16.01.2024
+0	Submission of audited UC in GFR 12A for the FY 2022-23 (G: by 30Jun-2023, Y: by 30-Sep 2023, R: after 30-Sep-2023)	16-01-2024
41	Submission of EC/ GB ratification for approval of Expenditure incurred during FY 2021-22	12.05.3033
+ 1	Submission of EC/ GB ratification for approval of Expenditure incurred during FY 2021-22 (G: by 30-Jun-2022, Y: by 30-Sept-2022, R: after 30-Sept-2022)	12-05-2023
2	R: aπer 30-Sept-2022) Timely Submission of CST-SCM Report (G:>95%, Y: 80-95%, R:<80%)	96
13	Format Adherence to CST-SCM Report (G:>95%, Y: 80-95%, R:<80%)	93
14	Timely Submission of BSD & STI-SCM Report (G: ≥90%, Y: 75-	83
	<90%, R:<75%) Green=3 Marks Yellow=2Marks Red=1 Mark No.	o Colour=Not Applicable
No:	ght points Indicator SI. No.	
vvei	- '	
	3 1, 23, 29	
	2 2, 3, 9, 10, 22, 30, 34, 42, 44	
	4, 5, 6, 7, 8, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 24, 25, 26, 27, 28, 31,	



MADHYA PRADESH

1. Status of HIV/AIDS Epidemic			
A. Epidemic Estimates (2023)			
Indicator	Male	Female	Total
1. IPR	-	-	2.16
2. IMR	-	-	0.87
3. Adult (15-49 yrs) HIV Prevalence (%)	0.11	0.09	0.10
4. Estimated people living with HIV	39,194	30,976	70,170
5. ART coverage (%)	63.92	60.51	62.61
6. Estimated children living with HIV	1,260	1,164	2,424
7. Annual new HIV infections	824	692	1,516
8. Annual AIDS-related deaths (ARD)	574	508	1,082
9. Change in annual new HIV infections since 2010 (%)	-69.52	-67.05	-68.46
10. Change in annual ARD since 2010(%)	-82.23	-75.58	-79.63
11. EMTCT need	-	817	817

B. High risk population siz	B. High risk population size (2020-22), safe practices (2021) and prevalence (2021/2023)				
Population Group	Estimates Size	Condom Use (%)	New Needle/ Syringe use (%)	HIV Prevalence (%)	
1. Female Sex Workers	53,455	95.50	-	0.75	
2. Men who have sex with men	18,085	98.90	-	1.84	
3. Injecting Drug Users	11,919	-	89.00	2.96	
4. Hijra/Transgender People	1,614	-	-	-	
5. Migrants	1,25,834	78.90	76.70	0.78	
6. Truckers	85,000	67.30	-	0.00	
7. Prison inmates	1,68,350	65.20	78.30	1.42	

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)					
Indicator	Male	Female	Total		
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)	26.20	18.70	-		
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	23.70	17.30			
3. Adults willing to care for a relative with HIV/AIDS in own home (%)	73.90	71.50	-		
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	60.70	59.60	-		
5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)	5.50	0.50	-		
5.1 Condom use during last higher-risk intercourse (%)	56.90	40.50	-		
6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)	10.20	0.97			
6.1 Condom use during last higher-risk intercourse (%)	51.57	50.00	-		

2. Progress on 95-95-95 (2023-24)				
48 55 58 61 66 72	77 77 78 80 84	81 81 77 88 88 88 88 88 88 88 88 88 88 88 88		
PLHIV who know their HIV status (%)	PLHIV who know their HIV status and are on ART (%)	PLHIV who are on ART and virally suppressed (%)		
■ 2018-19 ■ 2019-20	■ 2020-21 ■ 2021-22	■ 2022-23 ■ 2023-24		

Indicators	Male	Female	Total*
1. Estimated PLHIV size (2023)	39,194	30,976	70,170
2. PLHIV who know their HIV Status	29,061	21,255	50,491
3. PLHIV who know their HIV status and are on ART	24,133	18,017	42,284
4. PLHIV who are on ART and tested for their viral load	6,583	5,256	11,863
4.1 PLHIV who are virally suppressed	6,288	5,029	11,342

^{*} Including of H/TG PLHIV

A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2023-24
Schools with operational Adolescent Education Program (AEP)	-
2. Colleges with operational Red Ribbon Clubs (RRC)	700
3. Persons trained under mainstreaming	10,113
4. No. of calls received at helpline	-

B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management

Indicator	2023-24			
NACO Supported Designated STI/	66			
RTI Clinics (DSRC)	Male	Female	TG	Total
2. Total STI/RTI Clients managed				7,82,350
3. RPR Tests conducted	94,448	1,63,643	336	2,58,427
4. Syphilis seropositivity (%)	1.60	0.49	7.44	0.90

4. Prevention of new HIV infections among high-risk group and bridge population

A. Targeted Intervention (TI) Projects and Opioid Substitution Therapy (OST)

Indicator	2023-24
1. Targeted Intervention (TI) Projects	72
2. OST centres (Excluding Satellite OST centres)	17

B. Female Sex Workers

C. Men who have Sex with Men

Indicator	2023-24
1. Estimated size	53,454
2. Coverage (%)	>=95
3. Condoms distributed	46,99,465
4. Tested for HIV (April 2022-September 2022)	40,114
4.1. HIV sero-positive (%)	0.09
4.1.1. Linked to ART	34
5. Tested for HIV (October 2022 -March 2023)	41,447
5.1. HIV sero-positive (%)	0.08
5.1.1. Linked to ART	30
6. Clinic Visits	1,57,915
7. STI/RTI treated	3,575
8. Presumptive treatment	7,083

Indicatort 2023-24 1. Estimated size 18,084 2. Coverage (%) >=95 3. Condoms distributed 12,43,379 4. Tested for HIV (April 2022-September 2022) 14,806 4.1. HIV sero-positive (%) 0.41 4.1.1. Linked to ART 5. Tested for HIV (October 2022 -March 2023) 15,885 5.1. HIV sero-positive (%) 0.32 5.1.1. Linked to ART 50 6. Clinic Visits 59,767 7. STI/RTI treated 752

2,855

D. Injecting Drug Users	
Indicator	2023-24
1. Estimated size	11,918
2. Coverage (%)	>=95
3. Needles distributed	14,70,412
4. Syringes distributed	14,69,938
5. On OST	1,854
6. Tested for HIV (April 2022 -September 2022)	8,573
6.1. HIV sero-positive (%)	0.58
6.1.1 Linked to ART	33
7. Tested for HIV (October 2022 -March 2023)	9,146
7.1. HIV sero-positive (%)	0.56
7.1.1. Linked to ART	44

E. Hijra/Transgender person	
Indicator	2023-24
1. Estimated size	1,613
2. Coverage (%)	66
3. Condoms distributed	60,781
4. Tested for HIV (April 2022-September 2022)	792
4.1. HIV sero-positive (%)	0.25
4.1.1. Linked to ART	2
5. Tested for HIV (October 2022 -March 2023)	861
5.1. HIV sero-positive (%)	0.58
5.1.1. Linked to ART	4
6. Clinic Visits	3,286
7. STI/RTI treated	23
8. Presumptive treatment	362

F. Migrants	
Indicator	2023-24
1. Estimated size	1,25,834
2. Coverage (%)	>=95
3. Tested for HIV	33,694
3.1. HIV sero-positive (%)	0.06
3.2. Linked to ART	20

G. Truckers	
Indicator	2023-24
1. Estimated size	85,000
2. Coverage (%)	88
3. Tested for HIV	42,691
3.1. HIV sero-positive (%)	0.08
3.2. On ART	31

H. Prison Inmates	
Indicator	2023-24
1. Total prisons	131
2. Prisons covered under programme	130
3. Total inmates admitted	1,68,350
4. Inmates Covered (%)	>=95
5. Tested for HIV	1,77,275
5.1. HIV sero-positive (%)	0.12
5.2. On ART (%)	89.22

I. Link Worker Scheme	
Indicator	2023-24
1. Districts covered under scheme	10
Vulnerable population covered	1,07,527
3. Tested for HIV	1,00,587
3.1. HIV sero-positive (%)	0.10
3.2. Linked to ART (%)	>=95

8. Presumptive treatment

J. Opioid Substitution Therapy	
Indicator	2023-24
1. OST Centres	17
1.1. OSTC in Public Health Settings	13
1.2. OSTC in NGO Settings	4
1.3. No. of Satellite OST Centres	1
2. IDU on OST	1,854

A. HIV counselling and testing services (HCTS)

· ·	•
Indicator	2023-24
1. HCTC confirmatory facilities	214
2. Sampoorna Suraksha Kendras	16

2022 24

B. HIV testing among vulnerable population (excluding pregnant women)

indicator	2023-24				
	Male	Female	TG	Total	
1. Tested for HIV	10,60,211	8,95,413	1,794	19,57,418	
1.1 HIV Positives	4,191	1,850	37	6,078	
1.2 HIV sero -positivity (%)	0.40	0.21	2.06	0.31	
Spouse/sexual partner of HIV positive people tested	2,792	1,304	15	4,111	
2.1 HIV Positives	733	690	2	1,425	
2.2 HIV sero -positivity (%)	26	53	13	34.66	
No. of contacts with 'at- risk' population through 'Sampoorna Suraksha'	-	-	-	14,172	

6. Initiation and retention on ART of HIV infected people

A. Treatment facilities

Indicator	2023-24
1. ART Centres	33
2.Centre of Excellence	
2.1. Centre of Excellence (Adult)	-
2.2 Centre of Excellent (Paediatric)	-
3. Link ART Centres	28
4. Care Support Centres	11

B. Treatment uptake

Indicator	2023-24				
	Male	Female	TG	Total	
HIV positive cases diagnosed (At ICTC)	4,191	2,388	37	6,616	
New PLHIV Registered at ART center	3,956	2,186	38	6,180	
2.1 Initiated on ART	3,881	2,150	37	6,068	
3. PLHIV alive and on ART	24,133	18,017	134	42,284	
4. 12 months retention on ART (%)				92.9	
5. Lost to follow-up cases	2,398	1,462	23	3,883	

7. Viral Suppression and laboratories	
A Laboratory tacilities and convice untake	
A. Laboratory facilities and service uptake Indicator	2023-2
Viral load laboratories (programme and non- programme labs)	2020 2
1.1 Accredited Viral load laboratories (out of 64 VL labs)	
2. Viral load tests conducted	40,28
2.1. Virally suppressed (%)	91.
3. National reference laboratories (NRL)	
3.1 Accredited NRL	
4. State reference laboratories (SRL)	
4.1 Accredited SRL	
5. CD4 machines	1
5.1 CD4 tests conducted	29,16
6. External Quality Assurance of ICTC	
6.1 Average Participation (%)	8
6.2. Average Discordance (%)	0.1
7. "Certificate of Excellence" by NACO	
7.1 No. of ICTCs received "Certificate of Excellence"	
A. HIV Indicator	2023-2
Estimated pregnant women (PW)	22,58,62
2. HIV testing among PW	16,57,62
3. HIV sero-positivity (%) among tested	0.0
4. HIV Positive PW (old + new detections)	88
4.1 On life-long ART	80
5. Live births among HIV positive PW	61
5.1 Babies given ARV Prophylaxis (%)	>=9
6. Babies tested HIV (6 week- 6 month)	66
6.1 Babies confirmed HIV Positive (6 week- 6 month)	1
7. HIV testing among exposed babies at 18 months	
7.1 HIV exposed babies tested at 18 months	50
7.2 Babies confirmed HIV positive at 18 months	2
Total Babies Identified HIV Positive (6 weeks to upto 18 Months)	5
9. HIV positive babies initiated on ART	4
B. Syphilis	
Indicator	2023-2
Syphilis testing among PW	17,49,58
2.Sero-positivity (%) among tested	0.0
	1,29
3. Put on treatment	1,27
3. Put on treatment 9. Elimination of HIV/AIDS related Stigma	1,27
	1,27

1. State rules notified for HIV/AIDS Prevention and Control Act (2017)

2. State designated/appointed ombudsman

Yes

10. HIV-TB Co-morbidities A. HRG and Bridge Population								
Indicator	Indicator 2023-24							
	Quarter	FSW	MSM	IDU	TG	Migrants	Truckers	Total
	Quarter 1	37,737	13,744	8,890	878	17,600	18,598	97,447
C II TD	Quarter 2	41,021	15,437	9,247	973	22,529	23,062	1,12,269
Screened for TB	Quarter 3	39,754	14,925	9,761	1,179	20,361	22,562	1,08,542
	Quarter 4	42,245	16,615	9,824	1,375	22,393	23,405	1,15,857
	Quarter 1	356	255	344	6	32	27	1,020
Tested for TB	Quarter 2	419	329	353	-	518	46	1,665
	Quarter 3	592	487	496	16	107	82	1,780
	Quarter 4	1,388	631	473	8	59	57	2,616
	Quarter 1	13	4	7	-	-	-	24
D: L SLED	Quarter 2	10	6	7	-	17	-	40
Diagnosed with TB	Quarter 3	7	5	7	-	28	-	47
	Quarter 4	12	5	5	1	5	-	28
	Quarter 1	14	4	6	-	-	-	24
Initiated on TB	Quarter 2	9	6	10	-	17	-	42
treatment	Quarter 3	6	5	4	-	28	-	43
	Quarter 4	11	5	4	1	5	-	26

B. HIV-TB Coinfected at ART Centre Indicator 2023-24 PLHIV PLHIV PLHIV with PLHIV Co-infected enrolled at Co-infected initiated on ART PLHIV PLHIV tested for TB presumptive TB diagnosed with TB initiated on IPT Moths attending underwent ART Centre 4S screening ARTC 18,167 387 Apr - 23 18,167 732 657 75 71 299 18,727 18,727 1,524 674 May - 23 Jun - 23 18,629 18,588 868 775 89 401 Jul - 23 19,186 19,152 1,457 929 94 421 20,259 19,493 1,559 1,087 99 519 Aug - 23 Sep - 23 20,928 20,148 1,367 757 90 674 22,791 22,791 101 Oct - 23 964 936 561 1,914 838 Nov - 23 29,287 29,133 1,118 116 Dec - 23 28,249 27,698 2,200 1,284 121 1,161 Jan - 24 30,364 29,888 2,108 129 967 1,360 Feb - 24 26,706 26,435 4,293 1,283 146 831 Mar - 24 28,470 28,151 1,368 1,303 139 1,276 April 2023-1,460 1,387 March 2024

		State/UT	Madhya Pradesh
C1		Rank	20
SI. Vo.	Maximum Ma Obtained Ma		177 126 (71%)
1		785 75%, Y: 80-94%, R:<80%)	72
2		5/5, Y: 80-94%, R:<80%)	84
3		95%, Y: 80-95%, R:<80%)	>=95
4		quency of Social Media updates (G: ≥ 45, Y:40- 44, R:<40 indigenous posts) of	36
	Q1, Q2, Q3 8	k Q4	
5	Status of AEP	integration in state school curriculum (G:Yes, R:No)	Yes
6	Status of SCA	(G: At least one meeting held since 2020, R: other than G)	Not constituted
7		e Rules (G: Notified, R: Not notified)	Notified
8		budsman (G: Appointed, R: Not appointed)	Appointed
9		arding (G: ≥95%, Y: 90-<95%, R:<90%)	100
10		ling (G: ≥95%, Y: 90-<95%, R:<90%)	90 99
11 12	_	HRG against estimates (G: ≥90%, Y: 80-<90%, R:<80%)	92
13		mong HRG (G: ≥95%, Y: 90-<95%, R:<90%) mong prisoners (G: ≥50%, Y: 40% to <50%, R:<40%)	89
14		HRGs at TI-Clinics (G: ≥90%, Y: 75-89%, R:<75%)	90
15		f HRGs screened for Syphilis (G: ≥90%, Y: 75-89%, R:<75%)	91
16	_	G: ≥50%, Y: 30% to <50%, R:<30%)	32
17		f fund released to TI (G: ≥50%, Y: 45-<50%, R:<45%)	65
8		f TIs trained by Kshmata Kendra (KK) against the AAP targets (G: ≥75%, Y: 70-	100
	<75%, R:<70		
19	HIV testing a	gainst Target-at risk % (G: ≥95%, Y: 80-94%, R:<80%)	216
20	HIV testing a	gainst target-PW (G: ≥95%, Y: 80-94%, R:<80%)	73
21	Percentage o	f pregnant women screened for Syphilis (G: ≥95%, Y: 80-94%, R:<80%)	77
22	Treatment pr	ovided to Syphilis reactive pregnant women (G: ≥95%, Y: 80-94%, R:<80%)	97
23	Index testing	among newly detected HIV positive clients (G: ≥95%, Y: 80-94%, R:<80%)	30
24	Percentage o R:<80%)	f 6 weeks - <2 months EID testing against live birth (G: ≥95%, Y: 80-94%,	100
25		ged at DSRC against the target (G: ≥90%, Y: 75-89%, R:<75%)	115
26		s screened for HIV (G: >75%, Y: 50-75%, R:<50%)	22
27		s screened for Syphilis (G: >75%, Y: 50-75%, R:<50%)	53
28		t women who initiated ART (G: ≥95%, Y: 80-94%, R:<80%)	91
29	Proportion of	LFU-PLHIV, out of those initiated on ART in FY 2023-24 (G:<2%, Y: 2 to 5%,	2
30	R:>5%) Proportion of to 98%, R:<9	PLHIV initiated on ART, out of those registered in FY 2023-24 (G:>98%, Y: 95	98
31		reported died, out of those initiated on ART in FY 202324 (G:<2%, Y: 2 to 5 %,	5
32	-	redited (G:100%, Y: 80-99%, R:<80%)	100
33	% participation	on of ICTCs in re-testing (G: ≥95%, Y: 85-94, R:<85%)	88
34	Number of al	ostracts selected from studies conducted in FY21-22	1
		>25 to <100%, R: ≤25%)	
15	Number of o	ngoing studies from FY22-23 (G:100%, Y: >25 to <100%,	4
6		f research proposals from FY23-24 to NACO (G:100%, 00%, R: ≤25%)	2
37	Secondary Da	ata Analysis by SACS (G:2, Y: 1, R: No Secondary Data Analysis Plan Submitted)	2
88		with respect to funds released during FY 2022-23 (G:	103
9	Submission o	to <90%, R: <85%) f Provisional Utilization Certificate (UC) in GFR 12A for the FY 2022-23 (G: by Y: by 31-May-2023, R: after	21-06-2023
lO.	31-May-2023		23-01-2024
l 1	Submission o	r 30-Sep-2023) f EC/ GB ratification for approval of Expenditure incurred during FY 2021-22	08-02-2023
	(G: by 30-Jun-2022, Y: by 30-Sept-2022, R: after 30-Sept-2022)		
2	Timely Subm	ission of CST-SCM Report (G:>95%, Y: 80-95%, R:<80%)	93
3	Format Adhe	rence to CST-SCM Report (G:>95%, Y: 80-95%, R:<80%)	93
4	Timely Subm	ission of BSD & STI-SCM Report (G: ≥90%, Y: 75-	92
	<90%, R: Green=3 Mark		our=Not Applicable
	ght points	Indicator SI. No.	1.10 - 22.2.2
	3	1, 23, 29	
	2	2, 3, 9, 10, 22, 30, 34, 42, 44	



MAHARASHTRA

1. Status of HIV/AIDS Epidemic					
A. Epidemic Estimates (2023)					
Indicator	Male	Female	Total		
1. IPR	-	-	1.14		
2. IMR	-	-	0.40		
3. Adult (15-49 yrs) HIV Prevalence (%)	0.29	0.29	0.29		
4. Estimated people living with HIV	2,07,249	1,82,380	3,89,629		
5. ART coverage (%)	71.55	82.39	76.89		
6. Estimated children living with HIV	4,774	4,183	8,957		
7. Annual new HIV infections	2,331	2,113	4,444		
8. Annual AIDS-related deaths (ARD)	5,810	1,651	7,461		
9. Change in annual new HIV infections since 2010 (%)	-68.34	-64.64	-66.69		
10. Change in annual ARD since 2010(%)	-75.12	-85.64	-78.59		
11. EMTCT need	-	2,144	2,144		

B. High risk population size (2020-22), safe practices (2021) and prevalence (2021/2023) Condom Use New Needle/ **HIV Prevalence** Estimates Size Population Group (%) Syringe use (%) (%) 99.60 1. Female Sex Workers 95,351 2.54 99.40 40,187 2. Men who have sex with men 4.18 3. Injecting Drug Users 1,096 81.60 18.41 4. Hijra/Transgender People 10,323 6.00 97.40 5. Migrants 13,74,914 0.13 6. Truckers 2,05,000 99.20 0.40 1,41,478 88.10 87.50 1.13 7. Prison inmates

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)				
Indicator	Male	Female	Total	
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)	42.60	34.40	-	
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	37.20	35.20	-	
3. Adults willing to care for a relative with HIV/AIDS in own home (%)	78.80	75.40	-	
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	74.10	71.20	-	
5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)	4.40	0.40	-	
5.1 Condom use during last higher-risk intercourse (%)	86.30	88.70	-	
6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)	6.12	0.14	-	
6.1 Condom use during last higher-risk intercourse (%)	91.18	100.00	-	

2. Progress on 95-95-95 (2023-24)					
81 86 87 86 90 93	84 83 82 84 86 87	87 87 88 295 295 74			
PLHIV who know their HIV status (%)	PLHIV who know their HIV status and are on ART (%)	PLHIV who are on ART and virally suppressed (%)			

Indicators	Male	Female	Total*
1. Estimated PLHIV size (2023)	2,07,249	1,82,380	3,89,629
2. PLHIV who know their HIV Status	1,85,270	1,75,562	3,62,392
3. PLHIV who know their HIV status and are on ART	1,55,772	1,57,879	3,14,757
4. PLHIV who are on ART and tested for their viral load	1,02,184	1,04,072	2,06,878
4.1 PLHIV who are virally suppressed	1,00,682	1,02,575	2,03,872

^{*} Including of H/TG PLHIV

A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2023-24
Schools with operational Adolescent Education Program (AEP)	318
2. Colleges with operational Red Ribbon Clubs (RRC)	1,022
3. Persons trained under mainstreaming	27,456
4. No. of calls received at helpline	-

B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management

Indicator	2023-24			
NACO Supported Designated STI/	80			
Designated STI/ RTI Clinics (DSRC)	Male	Female	TG	Total
2. Total STI/RTI Clients managed				11,06,666
3. RPR Tests conducted	2,58,160	2,75,041	1,875	5,35,076
4. Syphilis seropositivity (%)	1.33	0.40	9.76	0.88

4. Prevention of new HIV infections among high-risk group and bridge population

A. Targeted Intervention (TI) Projects and Opioid Substitution Therapy (OST)

Indicator	2023-24
1. Targeted Intervention (TI) Projects	173
2. OST centres (Excluding Satellite OST centres)	3

B. Female Sex Workers

Indicator	2023-24
1. Estimated size	95,351
2. Coverage (%)	>=95
3. Condoms distributed	1,96,80,144
4. Tested for HIV (April 2022-September 2022)	66,476
4.1. HIV sero-positive (%)	0.13
4.1.1. Linked to ART	72
5. Tested for HIV (October 2022 -March 2023)	88,026
5.1. HIV sero-positive (%)	0.11
5.1.1. Linked to ART	74
6. Clinic Visits	3,29,602
7. STI/RTI treated	7,485
8. Presumptive treatment	17,719

C. Men who have Sex with Men Indicatort 2023-24 1. Estimated size 40,186 2. Coverage (%) 81 49,39,145 3. Condoms distributed 4. Tested for HIV (April 2022-September 2022) 19,853 4.1. HIV sero-positive (%) 0.43 4.1.1. Linked to ART 5. Tested for HIV (October 2022 -March 2023) 29,092 0.17 5.1. HIV sero-positive (%) 5.1.1. Linked to ART 35 6. Clinic Visits 1,13,873 7. STI/RTI treated 2,028 8. Presumptive treatment 4,224

D. Injecting Drug Users	
Indicator	2023-24
1. Estimated size	1,096
2. Coverage (%)	74
3. Needles distributed	51,643
4. Syringes distributed	29,726
5. On OST	199
6. Tested for HIV (April 2022 -September 2022)	560
6.1. HIV sero-positive (%)	0.54
6.1.1 Linked to ART	3
7. Tested for HIV (October 2022 -March 2023)	746
7.1. HIV sero-positive (%)	0.54
7.1.1. Linked to ART	4

E. Hijra/Transgender person			
Indicator	2023-24		
1. Estimated size	10,323		
2. Coverage (%)	>=95		
3. Condoms distributed	31,26,324		
4. Tested for HIV (April 2022-September 2022)	7,074		
4.1. HIV sero-positive (%)	0.79		
4.1.1. Linked to ART	49		
5. Tested for HIV (October 2022 -March 2023)	10,095		
5.1. HIV sero-positive (%)	0.31		
5.1.1. Linked to ART	27		
6. Clinic Visits	36,124		
7. STI/RTI treated	1,071		
8. Presumptive treatment	2,402		

F. Migrants	
Indicator	2023-24
1. Estimated size	13,74,914
2. Coverage (%)	>=95
3. Tested for HIV	3,06,872
3.1. HIV sero-positive (%)	0.16
3.2. Linked to ART	419

G. Truckers	
Indicator	2023-24
1. Estimated size	2,05,000
2. Coverage (%)	>=95
3. Tested for HIV	57,883
3.1. HIV sero-positive (%)	0.13
3.2. On ART	49

H. Prison Inmates	
Indicator	2023-24
1. Total prisons	64
2. Prisons covered under programme	58
3. Total inmates admitted	1,41,478
4. Inmates Covered (%)	55
5. Tested for HIV	77,333
5.1. HIV sero-positive (%)	0.33
5.2. On ART (%)	92.16

I. Link Worker Scheme	
Indicator	2023-24
Districts covered under scheme	21
Vulnerable population covered	4,93,916
3. Tested for HIV	3,68,524
3.1. HIV sero-positive (%)	0.15
3.2. Linked to ART (%)	100

J. Opioid Substitution Therapy			
Indicator	2023-24		
1. OST Centres	3		
1.1. OSTC in Public Health Settings	1		
1.2. OSTC in NGO Settings	2		
1.3. No. of Satellite OST Centres	-		
2. IDU on OST	199		

A. HIV counselling and testing services (HCTS)

A. HIV counselling and testing services (HC15)		
Indicator	2023-24	
1. HCTC confirmatory facilities	536	
2. Sampoorna Suraksha Kendras	8	

B. HIV testing among vulnerable population (excluding pregnant women)

Indicator	2023-24			
	Male	Female	TG	Total
1. Tested for HIV	27,16,219	21,66,044	19,670	49,01,933
1.1 HIV Positives	10,617	6,219	185	17,021
1.2 HIV sero -positivity (%)	0.39	0.29	0.94	0.35
Spouse/sexual partner of HIV positive people tested	10,064	6,160	174	16,398
2.1 HIV Positives	2,203	2,193	10	4,406
2.2 HIV sero -positivity (%)	22	36	6	26.87
No. of contacts with 'at- risk' population through 'Sampoorna Suraksha'	-	-	-	8,838

6. Initiation and retention on ART of HIV infected people

A. Treatment facilities

Indicator	2023-24
1. ART Centres	103
2.Centre of Excellence	
2.1. Centre of Excellence (Adult)	1
2.2 Centre of Excellent (Paediatric)	1
3. Link ART Centres	213
4. Care Support Centres	44

B. Treatment uptake

Indicator	2023-24			
	Male	Female	TG	Total
HIV positive cases diagnosed (At ICTC)	10,617	6,939	185	17,741
New PLHIV Registered at ART center	10,516	7,093	167	17,776
2.1 Initiated on ART	10,151	6,934	161	17,246
3. PLHIV alive and on ART	1,55,772	1,57,879	1,106	3,14,757
4. 12 months retention on ART (%)				93.8
5. Lost to follow-up cases	24,250	16,808	375	41,433

7. Viral Suppression and laboratories	
A. Laboratory facilities and service uptake	
Indicator	2023-2
Viral load laboratories (programme and non- programme labs)	1
1.1 Accredited Viral load laboratories (out of 64 VL labs)	1
2. Viral load tests conducted	2,57,12
2.1. Virally suppressed (%)	95.
3. National reference laboratories (NRL)	
3.1 Accredited NRL	
4. State reference laboratories (SRL)	1
4.1 Accredited SRL	1
5. CD4 machines	7
5.1 CD4 tests conducted	1,42,46
6. External Quality Assurance of ICTC	
6.1 Average Participation (%)	10
6.2. Average Discordance (%)	0.1
7. "Certificate of Excellence" by NACO	
7.1 No. of ICTCs received "Certificate of Excellence"	8
8. Elimination of mother to child trans HIV & Syphilis	mission of
A. HIV	
Indicator	2023-2
1. Estimated pregnant women (PW)	21,15,69
2. HIV testing among PW	22,20,30
3. HIV sero-positivity (%) among tested	0.0
4. HIV Positive PW (old + new detections)	2,15
4.1 On life-long ART	2,10
5. Live births among HIV positive PW	1,92
5.1 Babies given ARV Prophylaxis (%)	>=9
6. Babies tested HIV (6 week- 6 month)	1,70
6.1 Babies confirmed HIV Positive	1
(6 week- 6 month)	
7. HIV testing among exposed babies at 18 months	
7.1 HIV exposed babies tested at 18 months	1,47
7.2 Babies confirmed HIV positive at 18 months	3
8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months)	6
9. HIV positive babies initiated on ART	6
B. Syphilis	
Indicator	2023-2
1. Syphilis testing among PW	27,95,47
2.Sero-positivity (%) among tested	0.0
3. Put on treatment	39
Elimination of HIV/AIDS related Stigma and Discrimination	
Indicator	2023-2
State rules notified for HIV/AIDS Prevention and Control Act (2017)	Y∈

2. State designated/appointed ombudsman

10. HIV-TB Co-morbidities								
A. HRG and Bridge Population								
Indicator	Indicator 2023-24							
	Quarter	FSW	MSM	IDU	TG	Migrants	Truckers	Total
	Quarter 1	71,758	23,024	680	6,485	91,968	44,615	2,38,530
Screened for TB	Quarter 2	75,481	24,798	712	8,264	1,04,713	41,768	2,55,736
Screened for 1B	Quarter 3	81,443	25,076	703	8,457	1,10,138	41,773	2,67,590
	Quarter 4	83,163	26,869	704	9,011	1,29,159	47,506	2,96,412
	Quarter 1	1,369	459	-	75	748	424	3,075
Tested for TB	Quarter 2	1,610	586	6	203	855	436	3,696
rested for 16	Quarter 3	1,587	352	1	81	1,066	482	3,569
	Quarter 4	1,377	412	8	198	1,143	598	3,736
	Quarter 1	2	3	-	-	24	-	29
Diagnosed with TB	Quarter 2	6	3	4	2	22	1	38
Diagnosed with 16	Quarter 3	9	-	-	2	22	1	34
	Quarter 4	3	1	2	-	11	-	17
	Quarter 1	2	3	-	-	23	-	28
Initiated on TB	Quarter 2	5	3	3	2	21	1	35
treatment	Quarter 3	9	-	-	2	22	1	34
	Quarter 4	5	1	2	-	10	-	18

B. HIV-TB Coinfected at ART Centre Indicator 2023-24 PLHIV PLHIV PLHIV with PLHIV Co-infected enrolled at Co-infected initiated on ART PLHIV PLHIV tested for TB presumptive TB diagnosed with TB initiated on IPT Moths attending underwent ART Centre 4S screening ARTC 1,57,965 1,52,565 385 Apr - 23 9,206 9,034 2,311 336 1,52,572 9,573 3,229 May - 23 1,56,067 9,168 Jun - 23 1,58,336 1,55,049 9,900 9,495 305 2,226 Jul - 23 1,57,340 1,53,413 10,120 9,832 331 1,860 1,53,194 11,930 315 1,678 Aug - 23 1,58,297 9,486 Sep - 23 1,59,067 1,54,384 9,628 9,290 273 1,268 1,79,896 1,72,287 9,891 335 916 Oct - 23 9,592 1,97,550 1,87,902 10,179 308 1,064 Nov - 23 9,678 Dec - 23 2,16,472 2,10,373 12,027 9,888 306 1,400 2,19,169 335 2,057 Jan - 24 2,28,629 11,641 10,407 1,502 Feb - 24 2,19,943 2,10,762 10,952 10,783 362 Mar - 24 2,12,933 2,04,147 10,443 10,331 311 1,386 April 2023-4,851 4,672 March 2024

		State/UT	Maharashtra
-1	T.4 : .4	Rank	6
SI. Io.	Maximum Maximu		177
	Obtained Ma		137 (77%)
1		95%, Y: 80-94%, R:<80%)	93
2	_	5:≥95%, Y: 80-94%, R:<80%)	87
3		:95%, Y: 80-94%, R:<80%)	>=95
4	Average Fred Q1, Q2, Q3	quency of Social Media updates (G: ≥ 45, Y:40- 44, R:<40 indigenous pos & Q4	ts) of 48
5	Status of AEF	P integration in state school curriculum (G:Yes, R:No)	Yes
6	Status of SCA	A (G: At least one meeting held since 2020, R: other than G)	Not constituted
7	Status of Sta	te Rules (G: Notified, R: Not notified)	Notified
8	Status of Om	budsman (G: Appointed, R: Not appointed)	Appointed
9		oarding (G: ≥95%, Y: 90-<95%, R:<90%)	99
10	OST onboard	ding (G: ≥95%, Y: 90-<95%, R:<90%)	100
11	Coverage of	HRG against estimates (G: ≥90%, Y: 80-<90%, R:<80%)	99
12	HIV testing a	mong HRG (G: ≥95%, Y: 90-<95%, R:<90%)	83
13	HIV testing a	mong prisoners (G: ≥50%, Y: 40% to <50%, R:<40%)	50
14	Clinic visit of	HRGs at TI-Clinics (G: ≥90%, Y: 75-89%, R:<75%)	88
15	Percentage o	of HRGs screened for Syphilis (G: ≥90%, Y: 75-89%, R:<75%)	90
16	IDU on OST	(G: ≥50%, Y: 30% to <50%, R:<30%)	44
7		of fund released to TI (G: ≥50%, Y: 45-<50%, R:<45%)	75
8		of TIs trained by Kshmata Kendra (KK) against the AAP targets (G: ≥75%, \	
19	-	gainst Target-at risk % (G: ≥95%, Y: 80-94%, R:<80%)	250
20		gainst raiget-at risk % (G. ≥75%, 1. 30-74%, N. <80%) gainst target-PW (G: ≥95%, Y: 80-94%, R:<80%)	104
21		of pregnant women screened for Syphilis (G: ≥95%, Y: 80-94%, R:<80%)	131
22		rovided to Syphilis reactive pregnant women (G: ≥95%, Y: 80-94%, R:<80°	
23		among newly detected HIV positive clients (G: ≥95%, Y: 80-94%, R:<80%	
24	Percentage o	of 6 weeks - <2 months EID testing against live birth (G: ≥95%, Y: 80-94%,	
25	R:<80%)	ged at DSRC against the target (G: ≥90%, Y: 75-89%, R:<75%)	88
26		s screened for HIV (G: >75%, Y: 50-75%, R:<50%)	100
27		s screened for Syphilis (G: >75%, Y: 50-75%, R:<50%)	63
28		nt women who initiated ART (G: ≥95%, Y: 80-94%, R:<80%)	97
29	Proportion o	f LFU-PLHIV, out of those initiated on ART in FY 202324 (G:<2%, Y: 2 to 5	
30	R:>5%) Proportion of	f PLHIV initiated on ART, out of those registered in FY 2023-24 (G:>98%,	Y: 95 97
31	to 98%, R:<9	'5%) f reported died, out of those initiated on ART in FY 2023-24 (G:<2%, Y: 2	to 5
	%, R:>5 %)		
32	% of SRL acc	redited (G:100%, Y: 80-99%, R:<80%)	100
33	% participati	on of ICTCs in re-testing (G: ≥95%, Y: 85-94, R:<85%)	100
34		bstracts selected from studies conducted in FY21-22 >25 to <100%, R: ≤25%)	1
35	Number of o	ngoing studies from FY22-23 (G:100%, Y: >25 to	1
	<100%, R: ≤	25%)	
36		of research proposals from FY23-24 to NACO (G:100%, 00%, R: ≤25%)	2
37		ata Analysis by SACS (G:2, Y: 1, R: No Secondary Data Analysis Plan	2
38		with respect to funds released during FY 2022-23 (G: to <90%, R: <85%)	117
39	Submission of	of Provisional Utilization Certificate (UC) in GFR 12A for the FY 2022-23 (G , Y : by 31-May-2023, R : after 31-May-2023)	: by 18-05-2023
40	Submission of	f audited UC in GFR 12A for the FY 2022-23 (G : by 30-Jun-2023, Y : by 3 : after 30-Sep-2023)	21-02-2024
41	Submission of (G: by 30-Jun	. Grice 36 Sep 2020) of EC/ GB ratification for approval of Expenditure incurred during FY 2021 n-2022, Y: by 30-Sept- r 30-Sept-2022)	-22 24-05-2023
12		ission of CST-SCM Report (G:>95%, Y: 80-95%, R:<80%)	91
13		erence to CST-SCM Report (G:>95%, Y: 80-95%, R:<80%)	91
14		ission of BSD & STI-SCM Report (G: ≥90%, Y: 75-	83
-	Green=3 Marks		No Colour=Not Applicable
			140 Coloui – 1401 Applicable
veigl	ht points	Indicator SI. No.	
	3	1, 23, 29	
	2	2, 3, 9, 10, 22, 30, 34, 42, 44	
		4, 5, 6, 7, 8, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 24, 25, 26, 27, 28,	21 22 22 25 27 20 20 40





MANIPUR

1. Status of HIV/AIDS Epidemic			
A. Epidemic Estimates (2023)			
Indicator	Male	Female	Total
1. IPR	-	-	2.80
2. IMR	-	-	1.08
3. Adult (15-49 yrs) HIV Prevalence (%)	1.05	0.69	0.87
4. Estimated people living with HIV	14,576	9,896	24,472
5. ART coverage (%)	51.49	78.05	62.74
6. Estimated children living with HIV	367	351	718
7. Annual new HIV infections	473	213	686
8. Annual AIDS-related deaths (ARD)	423	67	490
9. Change in annual new HIV infections since 2010 (%)	-43.01	-45.80	-43.91
10. Change in annual ARD since 2010(%)	-64.09	-82.51	-68.63
11. EMTCT need	_	155	155

B. High risk population size (2020-22), safe practices (2021) and prevalence (2021/2023) Condom Use New Needle/ HIV Prevalence Population Group Estimates Size (%) Syringe use (%) 1. Female Sex Workers 5.662 99.60

1. Ferriale Sex Workers	3,002	77.00	-	1.13
2. Men who have sex with men	1,507	98.10	-	9.43
3. Injecting Drug Users	24,985	-	96.50	8.84
4. Hijra/Transgender People	468	-	-	-
5. Migrants	16,000	-	-	-
6. Truckers	-	-	-	-
7. Prison inmates	2,345	100.00	81.80	2.99

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)					
Indicator	Male	Female	Total		
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)	55.90	50.60	-		
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	48.40	48.70	-		
3. Adults willing to care for a relative with HIV/AIDS in own home (%)	87.00	82.00	-		
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	85.90	85.40	-		
5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)	3.00	0.10	-		
5.1 Condom use during last higher-risk intercourse (%)	24.80	0.00	-		
6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)	4.49	0.00	-		
6.1 Condom use during last higher-risk intercourse (%)	14.29	-	-		

2. Progress on	95-95-95 (20	23-24)
59 58 60 63 66 68	86 92 92 90 92 90	92 93 <u>>95 >95</u> >95
PLHIV who know their HIV status (%)	PLHIV who know their HIV status and are on ART (%)	PLHIV who are on ART and virally suppressed (%)
■ 2018-19 ■ 2019-20	2020-21 2021-22	■ 2022-23 ■ 2023-24

Indicators	Male	Female	Total*
1. Estimated PLHIV size (2023)	14,576	9,896	24,472
2. PLHIV who know their HIV Status	8,336	8,099	16,566
3. PLHIV who know their HIV status and are on ART	7,299	7,510	14,929
4. PLHIV who are on ART and tested for their viral load	3,911	4,071	8,049
4.1 PLHIV who are virally suppressed	3885	4064	8011

^{*} Including of H/TG PLHIV

(%)

A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2023-24
Schools with operational Adolescent Education Program (AEP)	175
2. Colleges with operational Red Ribbon Clubs (RRC)	61
3. Persons trained under mainstreaming	-
4. No. of calls received at helpline	-

B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management

Indicator	2023-24			
NACO Supported Designated STI/	10			
RTI Clinics (DSRC)	Male	Female	TG	Total
2. Total STI/RTI Clients managed				57,524
3. RPR Tests conducted	1,503	5,833	17	7,353
4. Syphilis seropositivity (%)	4.32	0.31	17.65	1.17

4. Prevention of new HIV infections among high-risk group and bridge population

A. Targeted Intervention (TI) Projects and Opioid Substitution Therapy (OST)

Indicator	2023-24
1. Targeted Intervention (TI) Projects	54
2. OST centres (Excluding Satellite OST centres)	26

B. Female Sex Workers

Indicator	2023-24
1. Estimated size	5,661
2. Coverage (%)	>=95
3. Condoms distributed	11,86,858
4. Tested for HIV (April 2022-September 2022)	2,322
4.1. HIV sero-positive (%)	0.09
4.1.1. Linked to ART	2
5. Tested for HIV (October 2022 -March 2023)	3,581
5.1. HIV sero-positive (%)	0.17
5.1.1. Linked to ART	6
6. Clinic Visits	17,266
7. STI/RTI treated	119
8. Presumptive treatment	885

C. Men who have Sex with Men			
Indicatort	2023-24		
1. Estimated size	1,506		
2. Coverage (%)	>=95		
3. Condoms distributed	2,11,567		
4. Tested for HIV (April 2022-September 2022)	829		
4.1. HIV sero-positive (%)	0.12		
4.1.1. Linked to ART	1		
5. Tested for HIV (October 2022 -March 2023)	885		
5.1. HIV sero-positive (%)	0.45		
5.1.1. Linked to ART	4		
6. Clinic Visits	3,549		
7. STI/RTI treated	4		
8. Presumptive treatment	125		

D. Injecting Drug Users	
Indicator	2023-24
1. Estimated size	24,984
2. Coverage (%)	>=95
3. Needles distributed	59,38,032
4. Syringes distributed	59,38,032
5. On OST	5,033
6. Tested for HIV (April 2022 -September 2022)	15,738
6.1. HIV sero-positive (%)	0.18
6.1.1 Linked to ART	19
7. Tested for HIV (October 2022 -March 2023)	20,181
7.1. HIV sero-positive (%)	0.23
7.1.1. Linked to ART	37

E. Hijra/Transgender person	
Indicator	2023-24
1. Estimated size	468
2. Coverage (%)	>=95
3. Condoms distributed	76,273
4. Tested for HIV (April 2022-September 2022)	324
4.1. HIV sero-positive (%)	0.62
4.1.1. Linked to ART	1
5. Tested for HIV (October 2022 -March 2023)	444
5.1. HIV sero-positive (%)	0.00
5.1.1. Linked to ART	-
6. Clinic Visits	1,553
7. STI/RTI treated	3
8. Presumptive treatment	31

F. Migrants	
Indicator	2023-24
1. Estimated size	16,000
2. Coverage (%)	30
3. Tested for HIV	747
3.1. HIV sero-positive (%)	0.27
3.2. Linked to ART	2

G. Truckers	
Indicator	2023-24
1. Estimated size	-
2. Coverage (%)	-
3. Tested for HIV	-
3.1. HIV sero-positive (%)	-
3.2. On ART	-

H. Prison Inmates	
Indicator	2023-24
1. Total prisons	5
2. Prisons covered under programme	2
3. Total inmates admitted	2,345
4. Inmates Covered (%)	22
5. Tested for HIV	514
5.1. HIV sero-positive (%)	0.39
5.2. On ART (%)	50.00

I. Link Worker Scheme	
Indicator	2023-24
1. Districts covered under scheme	9
Vulnerable population covered	27,008
3. Tested for HIV	14,517
3.1. HIV sero-positive (%)	0.13
3.2. Linked to ART (%)	>=95

J. Opioid Substitution Therapy	
Indicator	2023-24
1. OST Centres	26
1.1. OSTC in Public Health Settings	19
1.2. OSTC in NGO Settings	7
1.3. No. of Satellite OST Centres	32
2. IDU on OST	5,033

A. HIV counselling and testing services (HCTS)		
Indicator	2023-24	
1. HCTC confirmatory facilities	61	
2 Sampoorna Suraksha Kendras	_	

B. HIV testing among vulnerable population (excluding pregnant women)

Indicator	2023-24			
	Male	Female	TG	Total
1. Tested for HIV	67,626	39,609	1,457	1,08,692
1.1 HIV Positives	477	256	7	740
1.2 HIV sero -positivity (%)	0.71	0.65	0.48	0.68
Spouse/sexual partner of HIV positive people tested	337	347	4	688
2.1 HIV Positives	40	76	3	119
2.2 HIV sero -positivity (%)	12	22	75	17.30
3. No. of contacts with 'at- risk' population through 'Sampoorna Suraksha'	-	-	-	-

6. Initiation and retention on ART of HIV infected people

A. Treatment facilities

Indicator	2023-24
1. ART Centres	13
2.Centre of Excellence	
2.1. Centre of Excellence (Adult)	1
2.2 Centre of Excellent (Paediatric)	1
3. Link ART Centres	23
4. Care Support Centres	4

B. Treatment uptake

Indicator	2023-24			
	Male	Female	TG	Total
HIV positive cases diagnosed (At ICTC)	477	295	7	779
New PLHIV Registered at ART center	476	280	8	764
2.1 Initiated on ART	450	275	7	732
3. PLHIV alive and on ART	7,299	7,510	121	14,929
4. 12 months retention on ART (%)				75.7
5. Lost to follow-up cases	723	487	8	1,218

A. Laboratory facilities and service uptake	•
Indicator	2023-2
Viral load laboratories (programme and non- programme labs)	
1.1 Accredited Viral load laboratories (out of 64 VL labs)	
2. Viral load tests conducted	9,27
2.1. Virally suppressed (%)	>=9
3. National reference laboratories (NRL)	
3.1 Accredited NRL	
4. State reference laboratories (SRL)	
4.1 Accredited SRL	
5. CD4 machines	1
5.1 CD4 tests conducted	1,41
6. External Quality Assurance of ICTC	
6.1 Average Participation (%)	6
6.2. Average Discordance (%)	0.0
7. "Certificate of Excellence" by NACO	
7.1 No. of ICTCs received "Certificate of Excellence"	2
8. Elimination of mother to child trans HIV & Syphilis	mission of
A. HIV	
Indicator	2023-2
1. Estimated pregnant women (PW)	52,85
2. HIV testing among PW	34,61
3. HIV sero-positivity (%) among tested	0.1
4. HIV Positive PW (old + new detections)	13
4.1 On life-long ART	11
5. Live births among HIV positive PW	8
5.1 Babies given ARV Prophylaxis (%)	>=9
6. Babies tested HIV (6 week- 6 month)	4
6.1 Babies confirmed HIV Positive (6 week- 6 month)	
7. HIV testing among exposed babies at 18 months	
7.1 HIV exposed babies tested at 18 months	6
7.2 Babies confirmed HIV positive at 18 months	
8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months)	
9. HIV positive babies initiated on ART	
B. Syphilis	
Indicator	2023-2
1. Syphilis testing among PW	42,80
2.Sero-positivity (%) among tested	0.0
3. Put on treatment	
9. Elimination of HIV/AIDS related Stigma and Discrimination	
Indicator	2023-2

2. State designated/appointed ombudsman

Yes

Quarter 4

10. HIV-TB Co-morbidities										
A. HRG and Bridge Population										
Indicator	2023-24									
	Quarter	FSW	MSM	IDU	TG	Migrants	Truckers	Total		
Screened for TB	Quarter 1	2,249	624	7,337	202	1,172	-	11,584		
	Quarter 2	2,956	620	8,727	234	1,393	-	13,930		
	Quarter 3	3,492	675	8,935	245	1,598	-	14,945		
	Quarter 4	3,629	668	9,469	244	1,488	-	15,498		
Tested for TB	Quarter 1	49	18	58	-	1	-	126		
	Quarter 2	6	-	142	-	-	-	148		
	Quarter 3	9	1	163	-	-	-	173		
	Quarter 4	8	-	268	-	-	-	276		
Diagnosed with TB	Quarter 1	7	-	3	-	-	-	10		
	Quarter 2	1	-	2	-	-	-	3		
	Quarter 3	1	-	10	-	-	-	11		
	Quarter 4	-	-	4	-	-	-	4		
Initiated on TB treatment	Quarter 1	-	-	-	-	-	-	-		
	Quarter 2	1	-	1	-	-	-	2		
	Quarter 3	1	-	1	-	-	-	2		

B. HIV-TB Coinfected at ART Centre Indicator 2023-24 Co-infected enrolled at PLHIV with presumptive TB PLHIV PLHIV PLHIV PLHIV Co-infected initiated on ART PLHIV tested for TB attending diagnosed with TB initiated on IPT Moths underwent ART Centre 4S screening ARTC 8,064 7,932 44 Apr - 23 54 48 5 8,519 44 44 17 8,387 May - 23 Jun - 23 7,358 7,226 35 34 4 17 Jul - 23 7,391 7,391 18 18 4 4 7,422 7,422 33 32 4 Aug - 23 9 2 Sep - 23 7,130 6,985 32 29 Oct - 23 7,713 7,523 33 32 4 4 7 103 29 7,165 7,165 29 Nov - 23 4 Dec - 23 7,763 7,763 28 26 46 Jan - 24 8,605 8,605 17 4 16 16 5 30 30 Feb - 24 8,205 8,205 14 Mar - 24 8,992 8,992 48 47 13 13 April 2023-101 95 March 2024

		State/UT	Manipur
SI.	Maximum Ma	Rank	27 177
51. 10.	Obtained Ma		120 (68%)
1		75%, Y: 80-94%, R:<80%)	68
2	•	i:≥95%, Y: 80-94%, R:<80%)	90
3		95%, Y: 80-94%, R:<80%)	>=95
4		quency of Social Media updates (G: ≥ 45, Y:40- 44, R:<40 indigenous posts) of	
•	Q1, Q2, Q3 8		
5	Status of AEP	integration in state school curriculum (G:Yes, R:No)	Yes
6	Status of SCA	(G: At least one meeting held since 2020, R: other than G)	Meeting held in 2021
7	Status of Stat	e Rules (G: Notified, R: Not notified)	Notified
8	Status of Om	budsman (G: Appointed, R: Not appointed)	Appointed
9	TI/LWS onbo	arding (G: ≥95%, Y: 90-<95%, R:<90%)	92
10	OST onboard	ling (G: ≥95%, Y: 90-<95%, R:<90%)	95
11	Coverage of	HRG against estimates (G: ≥90%, Y: 80-<90%, R:<80%)	114
12	HIV testing ar	mong HRG (G: ≥95%, Y: 90-<95%, R:<90%)	68
13	HIV testing ar	mong prisoners (G: ≥50%, Y: 40% to <50%, R:<40%)	24
14	Clinic visit of	HRGs at TI-Clinics (G: ≥90%, Y: 75-89%, R:<75%)	75
15	Percentage o	f HRGs screened for Syphilis (G: ≥90%, Y: 75-89%, R:<75%)	71
16	IDU on OST (G: ≥50%, Y: 30% to <50%, R:<30%)	42
7	Percentage o	f fund released to TI (G: ≥50%, Y: 45-<50%, R:<45%)	92
8	_	f TIs trained by Kshmata Kendra (KK) against the AAP targets (G: ≥75%, Y: 70-	92
	<75%, R:<70°	·	
9		gainst Target-at risk % (G: ≥95%, Y: 80-94%, R:<80%)	11
0		gainst target-PW (G: ≥95%, Y: 80-94%, R:<80%)	66
1	_	f pregnant women screened for Syphilis (G: ≥95%, Y: 80-94%, R:<80%)	81
2	Treatment pr	ovided to Syphilis reactive pregnant women (G: ≥95%, Y: 80-94%, R:<80%)	100
:3	Index testing	among newly detected HIV positive clients (G: ≥95%, Y: 80-94%, R:<80%)	52
4	Percentage o R:<80%)	f 6 weeks - <2 months EID testing against live birth (G: ≥95%, Y: 80-94%,	98
:5	Clients manag	ged at DSRC against the target (G: ≥90%, Y: 75-89%, R:<75%)	64
:6	STI attendees	s screened for HIV (G: >75%, Y: 50-75%, R:<50%)	60
7	STI attendees	s screened for Syphilis (G: >75%, Y: 50-75%, R:<50%)	58
8	% of pregnan	t women who initiated ART (G: ≥95%, Y: 80-94%, R:<80%)	83
9		LFU-PLHIV, out of those initiated on ART in FY 2023-24 (G:<2%, Y: 2 to 5%,	4
	R:>5%)		
0	Proportion of to 98%, R:<9	PLHIV initiated on ART, out of those registered in FY 2023-24 (G:>98%, Y: 95 5%)	96
1	Proportion of R:>5 %)	reported died, out of those initiated on ART in FY 202324 (G:<2%, Y: 2 to 5 %	6,
2		redited (G:100%, Y: 80-99%, R:<80%)	100
3	' '	on of ICTCs in re-testing (G: ≥95%, Y: 85-94, R:<85%)	65
4		ostracts selected from studies conducted in FY21-22	4
		>25 to <100%, R: ≤25%)	
5		ngoing studies from FY22-23 (G:100%, Y: >25 to <100%,	0
4	R: ≤25%)	f receased proposals from EV22 24 to NIACO (C.1000)	
6		f research proposals from FY23-24 to NACO (G:100%, 20%, R: ≤25%)	2
7		JU%, R: ≤25%) ata Analysis by SACS (G:2, Y: 1, R: No Secondary Data Analysis Plan Submittec	2
	_		
8	≥90%, Y: 85 t	with respect to funds released during FY 2022-23 (G: to <90%, R: <85%)	136
9		f Provisional Utilization Certificate (UC) in GFR 12A for the FY 2022-23 (G : by Y : by 31-May-2023, R : after)	04-07-2023
0	Submission o	, f audited UC in GFR 12A for the FY 2022-23 (G : by 30Jun-2023, Y : by 30-Sep r 30-Sep-2023)	06-02-2024
1		f EC/ GB ratification for approval of Expenditure incurred during FY 2021-22 2-2022, Y: by 30-Sept-2022, ept-2022)	31-08-2023
2	Timely Subm	ission of CST-SCM Report (G:>95%, Y: 80-95%, R:<80%)	96
3	Format Adhe	rence to CST-SCM Report (G:>95%, Y: 80-95%, R:<80%)	91
4		ission of BSD & STI-SCM Report (G: ≥90%, Y: 75-	58
	Green=3 Mark	s Yellow=2Marks Red=1 Mark N	o Colour=Not Applicable
Veic	ht points	Indicator SI. No.	
	3	1, 23, 29	
	2	2, 3, 9, 10, 22, 30, 34, 42, 44	
		4, 5, 6, 7, 8, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 24, 25, 26, 27, 28, 31,	32 33 35 36 37 38 30 40
	1		





MEGHALAYA

1. Status of HIV/AIDS Epidemic					
A. Epidemic Estimates (2023)					
Indicator	Male	Female	Total		
1. IPR	-	-	9.77		
2. IMR	-	-	10.31		
3. Adult (15-49 yrs) HIV Prevalence (%)	0.45	0.41	0.43		
4. Estimated people living with HIV	4,962	4,539	9,501		
5. ART coverage (%)	57.64	73.46	65.20		
6. Estimated children living with HIV	183	180	363		
7. Annual new HIV infections	478	451	929		
8. Annual AIDS-related deaths (ARD)	29	23	52		
9. Change in annual new HIV infections since 2010 (%)	110.57	142.47	124.70		
10. Change in annual ARD since 2010(%)	-32.56	-25.81	-29.73		
11. EMTCT need	_	299	299		

B. High risk population size (2020-22), safe practices (2021) and prevalence (2021/2023) Condom Use New Needle/ **HIV Prevalence** Estimates Size Population Group (%) Syringe use (%) (%) 91.70 1. Female Sex Workers 3,297 10.92 89.20 9.09 2. Men who have sex with men 344 3. Injecting Drug Users 3,175 85.90 11.48 4. Hijra/Transgender People 110 5. Migrants 50,300

4,150 2,519

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)				
Indicator	Male	Female	Total	
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)	15.90	14.50	-	
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	14.30	13.40	-	
3. Adults willing to care for a relative with HIV/AIDS in own home (%)	67.20	64.50	-	
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	37.50	27.30	-	
5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)	2.60	1.10	-	
5.1 Condom use during last higher-risk intercourse (%)	40.20	45.30	-	
6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)	5.03	1.92	-	
6.1 Condom use during last higher-risk intercourse (%)	40.74	46.15	-	

2. Progress on 95-95-95 (2023-24)					
56 56 60 63 70 76	72 78 73 74 81 84	89 90 92 88			
PLHIV who know their HIV status (%) 2018-19 2019-20	PLHIV who know their HIV status and are on ART (%) 2020-21 2021-22	PLHIV who are on ART and virally suppressed (%) 2022-23 2023-24			

6. Truckers

7. Prison inmates

Indicators	Male	Female	Total*
1. Estimated PLHIV size (2023)	4,962	4,539	9,501
2. PLHIV who know their HIV Status	3,534	3,711	7,247
3. PLHIV who know their HIV status and are on ART	2,804	3,261	6,066
4. PLHIV who are on ART and tested for their viral load	1,884	2,447	4,331
4.1 PLHIV who are virally suppressed	1,777	2,363	4,140

33.30

66.70

5.50

^{*} Including of H/TG PLHIV

3. Prevention of new HIV infections among general population

A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2023-24
Schools with operational Adolescent Education Program (AEP)	250
2. Colleges with operational Red Ribbon Clubs (RRC)	83
3. Persons trained under mainstreaming	1,311
4. No. of calls received at helpline	-

B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management

Indicator	2023-24				
NACO Supported Designated STI/	10				
RTI Clinics (DSRC)	Male	Female	TG	Total	
2. Total STI/RTI Clients managed				31,369	
3. RPR Tests conducted	8,796	10,393	3	19,192	
4. Syphilis seropositivity (%)	6.79	5.95	33.33	6.34	

4. Prevention of new HIV infections among high-risk group and bridge population

A. Targeted Intervention (TI) Projects and Opioid Substitution Therapy (OST)

Indicator	2023-24
1. Targeted Intervention (TI) Projects	11
2. OST centres (Excluding Satellite OST centres)	6

B. Female Sex Workers

D. I Ciliaic Sex Workers	
Indicator	2023-24
1. Estimated size	3,296
2. Coverage (%)	69.68
3. Condoms distributed	3,67,843
4. Tested for HIV (April 2022-September 2022)	1,658
4.1. HIV sero-positive (%)	0.66
4.1.1. Linked to ART	9
5. Tested for HIV (October 2022 -March 2023)	1,685
5.1. HIV sero-positive (%)	0.47
5.1.1. Linked to ART	5
6. Clinic Visits	7,734
7. STI/RTI treated	304
8. Presumptive treatment	355

C. Men who have Sex with Men Indicatort 2023-24 1. Estimated size 343 2. Coverage (%) 3. Condoms distributed 33,004 4. Tested for HIV (April 2022-September 2022) 217 4.1. HIV sero-positive (%) 0.00 4.1.1. Linked to ART 0 5. Tested for HIV (October 2022 -March 2023) 141 0.71 5.1. HIV sero-positive (%) 5.1.1. Linked to ART 1 890 6. Clinic Visits 7. STI/RTI treated 0 8. Presumptive treatment 61

D. Injecting Drug Users				
Indicator	2023-24			
1. Estimated size	3,174			
2. Coverage (%)	86			
3. Needles distributed	3,16,821			
4. Syringes distributed	3,16,821			
5. On OST	1,117			
6. Tested for HIV (April 2022 -September 2022)	1,793			
6.1. HIV sero-positive (%)	2.23			
6.1.1 Linked to ART	26			
7. Tested for HIV (October 2022 -March 2023)	1,792			
7.1. HIV sero-positive (%)	0.67			
7.1.1. Linked to ART	8			

E. Hijra/Transgender person				
Indicator	2023-24			
1. Estimated size	109			
2. Coverage (%)	35			
3. Condoms distributed	7,349			
4. Tested for HIV (April 2022-September 2022)	24			
4.1. HIV sero-positive (%)	0.00			
4.1.1. Linked to ART	-			
5. Tested for HIV (October 2022 -March 2023)	25			
5.1. HIV sero-positive (%)	0.00			
5.1.1. Linked to ART	-			
6. Clinic Visits	112			
7. STI/RTI treated	0			
8. Presumptive treatment	11			

F. Migrants	
Indicator	2023-24
1. Estimated size	50,300
2. Coverage (%)	2
3. Tested for HIV	1,477
3.1. HIV sero-positive (%)	0.07
3.2. Linked to ART	0

G. Truckers	
Indicator	2023-24
1. Estimated size	4,150
2. Coverage (%)	-
3. Tested for HIV	-
3.1. HIV sero-positive (%)	-
3.2. On ART	-

H. Prison Inmates	
Indicator	2023-24
1. Total prisons	5
2. Prisons covered under programme	5
3. Total inmates admitted	2,519
4. Inmates Covered (%)	92
5. Tested for HIV	2,318
5.1. HIV sero-positive (%)	0.43
5.2. On ART (%)	>=95

I. Link Worker Scheme	
Indicator	2023-24
Districts covered under scheme	2
Vulnerable population covered	2,242
3. Tested for HIV	1,495
3.1. HIV sero-positive (%)	2.68
3.2. Linked to ART (%)	85.00

J. Opioid Substitution Therapy	
Indicator	2023-24
1. OST Centres	6
1.1. OSTC in Public Health Settings	3
1.2. OSTC in NGO Settings	3
1.3. No. of Satellite OST Centres	5
2. IDU on OST	1,117

A. HIV counselling and testing services (HC15)		
Indicator	2023-24	
1. HCTC confirmatory facilities	38	
2. Sampoorna Suraksha Kendras	-	

B. HIV testing among vulnerable population (excluding pregnant women)

Indicator	2023-24			
	Male	Female	TG	Total
1. Tested for HIV	41,385	46,436	4	87,825
1.1 HIV Positives	837	514	-	1,351
1.2 HIV sero -positivity (%)	2.02	1.11	0.00	1.54
Spouse/sexual partner of HIV positive people tested	297	367	1	665
2.1 HIV Positives	110	134	-	244
2.2 HIV sero -positivity (%)	37	37	-	36.69
No. of contacts with 'at- risk' population through 'Sampoorna Suraksha'	-	-	-	-

6. Initiation and retention on ART of HIV infected people

A. Treatment facilities

Indicator	2023-24
1. ART Centres	4
2.Centre of Excellence	
2.1. Centre of Excellence (Adult)	-
2.2 Centre of Excellent (Paediatric)	-
3. Link ART Centres	20
4. Care Support Centres	1

B. Treatment uptake

Indicator	2023-24			
	Male	Female	TG	Total
HIV positive cases diagnosed (At ICTC)	837	687		1,524
New PLHIV Registered at ART center	744	612		1,356
2.1 Initiated on ART	711	591		1,302
3. PLHIV alive and on ART	2,804	3,261	1	6,066
4. 12 months retention on ART (%)				>=95
5. Lost to follow-up cases	732	450	1	1,183

A. Laboratory facilities and service uptake	
Indicator	2023-2
Viral load laboratories (programme and non- programme labs)	
1.1 Accredited Viral load laboratories (out of 64 VL labs)	
2. Viral load tests conducted	4,86
2.1. Virally suppressed (%)	>=9
3. National reference laboratories (NRL)	
3.1 Accredited NRL	
4. State reference laboratories (SRL)	
4.1 Accredited SRL	
5. CD4 machines	
5.1 CD4 tests conducted	79
6. External Quality Assurance of ICTC	
6.1 Average Participation (%)	10
6.2. Average Discordance (%)	0.0
7. "Certificate of Excellence" by NACO	
7.1 No. of ICTCs received "Certificate of Excellence"	
8. Elimination of mother to child transn HIV & Syphilis	nission of
A. HIV	
Indicator	2023-2
Estimated pregnant women (PW)	80,81
2. HIV testing among PW	69,87
3. HIV sero-positivity (%) among tested	0.2
4. HIV Positive PW (old + new detections)	31
4.1 On life-long ART	28
5. Live births among HIV positive PW	28
5.1 Babies given ARV Prophylaxis (%)	>=9
6. Babies tested HIV (6 week- 6 month)	26
6.1 Babies confirmed HIV Positive (6 week- 6 month)	
7. HIV testing among exposed babies at 18 months	
7.1 HIV exposed babies tested at 18 months	20
7.2 Babies confirmed HIV positive at 18 months	1
8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months)	1
9. HIV positive babies initiated on ART	1
B. Syphilis Indicator	2022.2
1. Syphilis testing among PW	2023-2 85,09
2.Sero-positivity (%) among tested	1.0
3. Put on treatment	72
	72
9. Elimination of HIV/AIDS related Stigma	
9. Elimination of HIV/AIDS related Stigma and Discrimination	
	2023-2

2. State designated/appointed ombudsman

Yes

Quarter 4

10. HIV-TB Co-morbidities A. HRG and Bridge Population Indicator 2023-24 Quarter FSW MSM IDU TG Migrants Truckers Total 4,232 Quarter 1 1,710 196 2,228 28 70 Quarter 2 1,682 223 2,406 32 197 4,540 Screened for TB Quarter 3 1,847 243 2,791 29 1,091 6,001 20 109 Quarter 4 1,820 228 2,809 4,986 Quarter 1 23 131 154 17 79 Quarter 2 62 Tested for TB Quarter 3 24 142 166 Quarter 4 13 14 1 Quarter 1 1 1 Quarter 2 1 1 Diagnosed with TB Quarter 3 1 1 Quarter 4 1 1 Quarter 1 1 Quarter 2 1 Initiated on TB treatment Quarter 3 1 1

B. HIV-TB Coinfected at ART Centre Indicator 2023-24 Co-infected initiated on PLHIV PLHIV PLHIV with PLHIV **PLHIV** Co-infected PLHIV tested for TB presumptive TB diagnosed with TB Moths initiated on enrolled at attending underwent ART Centre 4S screening IPT ARTC ART Apr - 23 3,065 2,726 28 27 83 10 4,082 32 27 170 May - 23 3,199 Jun - 23 3,265 2,923 24 16 9 158 Jul - 23 3,656 3,258 194 19 2 170 25 5 154 Aug - 23 3,664 3,289 36 Sep - 23 3,560 3,151 16 13 3 72 Oct - 23 3,367 3,328 19 1 50 16 5 47 Nov - 23 3,268 3,233 11 Dec - 23 3,383 3,361 13 10 1 116 Jan - 24 3,599 3,578 21 10 3 102 3 69 Feb - 24 3,242 3,217 10 6 Mar - 24 3,277 3,258 20 18 4 55 April 2023-164 152 March 2024

1

	State/UT	Meghalaya
CI	Rank	12
SI.	Maximum Marks	177
No.	Obtained Marks	131 (74%)
1	First 95 (G:≥95%, Y: 80-94%, R:<80%)	76 84
3	Second 95 (G:≥95%, Y: 80-94%, R:<80%) Third 95 (G:≥95%, Y: 80-94%, R:<80%)	>=95
4		
4	Average Frequency of Social Media updates (G: ≥ 45, Y:40- 44, R:<40 indigenous posts) c Q1, Q2, Q3 & Q4	f 65
5	Status of AEP integration in state school curriculum (G:Yes, R:No)	Yes
6	Status of SCA (G: At least one meeting held since 2020, R: other than G)	Not constituted
7	Status of State Rules (G: Notified, R: Not notified)	Notified
8	Status of Ombudsman (G: Appointed, R: Not appointed)	Appointed
9	TI/LWS onboarding (G: ≥95%, Y: 90-<95%, R:<90%)	100
10	OST onboarding (G: ≥95%, Y: 90-<95%, R:<90%)	92
11	Coverage of HRG against estimates (G: ≥90%, Y: 80-<90%, R:<80%)	77
12	HIV testing among HRG (G: ≥95%, Y: 90-<95%, R:<90%)	69
13	HIV testing among prisoners (G: ≥50%, Y: 40% to <50%, R:<40%)	81
4	Clinic visit of HRGs at TI-Clinics (G: ≥90%, Y: 75-89%, R:<75%)	78
5	Percentage of HRGs screened for Syphilis (G: ≥90%, Y: 75-89%, R:<75%)	72
6	IDU on OST (G: ≥50%, Y: 30% to <50%, R:<30%)	81
7	Percentage of fund released to TI (G: ≥50%, Y: 45-<50%, R:<45%)	101
8	Percentage of TIs trained by Kshmata Kendra (KK) against the AAP targets (G: ≥75%, Y: 70)- 100
	<75%, R:<70%)	
19	HIV testing against Target-at risk % (G: ≥95%, Y: 80-94%, R:<80%)	3
20	HIV testing against target-PW (G: ≥95%, Y: 80-94%, R:<80%)	86
21	Percentage of pregnant women screened for Syphilis (G: ≥95%, Y: 80-94%, R:<80%)	105
22	Treatment provided to Syphilis reactive pregnant women (G: ≥95%, Y: 80-94%, R:<80%)	95
23	Index testing among newly detected HIV positive clients (G: ≥95%, Y: 80-94%, R:<80%)	16
24	Percentage of 6 weeks - <2 months EID testing against live birth (G: ≥95%, Y: 80-94%, R:<80%)	100
25	Clients managed at DSRC against the target (G: ≥90%, Y: 75-89%, R:<75%)	125
26	STI attendees screened for HIV (G: >75%, Y: 50-75%, R:<50%)	91
27	STI attendees screened for Syphilis (G: >75%, Y: 50-75%, R:<50%)	94
28	% of pregnant women who initiated ART (G: ≥95%, Y: 80-94%, R:<80%)	92
29	Proportion of LFU-PLHIV, out of those initiated on ART in FY 2023-24 (G:<2%, Y: 2 to 5%, R:>5%)	9
30	Proportion of PLHIV initiated on ART, out of those registered in FY 2023-24 (G:>98%, Y: 9 to 98%, R:<95%)	96
31	Proportion of reported died, out of those initiated on ART in FY 202324 (G:<2%, Y: 2 to 5 R:>5 %)	%, 2
32	% of SRL accredited (G:100%, Y: 80-99%, R:<80%)	100
33	% participation of ICTCs in re-testing (G: ≥95%, Y: 85-94, R:<85%)	100
34	Number of abstracts selected from studies conducted in FY21-22	1
	(G:100%, Y: >25 to <100%, R: ≤25%)	
35	Number of ongoing studies from FY22-23 (G:100%, Y: >25 to <100%,	2
36	R: ≤25%) Submission of research proposals from FY23-24 to NACO (G:100%,	2
_	Y: >25 to <100%, R: ≤25%)	
37	Secondary Data Analysis by SACS (G:2, Y: 1, R: No Secondary Data Analysis Plan Submittee	ed) 2
88	Expenditure with respect to funds released during FY 2022-23 (G:	117
	Expenditure with respect to lunds released during F1 2022-25 (G: ≥90%, Y: 85 to <90%, R: <85%)	
9	Submission of Provisional Utilization Certificate (UC) in GFR 12A for the FY 2022-23 (G:b) 30-Apr-2023, Y:by 31-May-2023, R: after	08-06-2023
10	31-May-2023)	07.00.000
10	Submission of audited UC in GFR 12A for the FY 2022-23 (G: by 30Jun-2023, Y: by 30-Se 2023, R: after 30-Sep-2023)	ep- 07-02-2024
1	Submission of EC/ GB ratification for approval of Expenditure incurred during FY 2021-22 (G: by 30-Jun-2022, Y: by 30-Sept-2022,	17-05-2023
2	(c. by 36-341-2022) R: after 30-Sept-2022) Timely Submission of CST-SCM Report (G:>95%, Y: 80-95%, R:<80%)	93
3	Format Adherence to CST-SCM Report (G:>95%, Y: 80-95%, R:<80%)	93
4	Timely Submission of BSD & STI-SCM Report (G: ≥90%, Y: 75- <90%, R:<75%)	92
		No Colour-Not Assissis
۸,		No Colour=Not Applicable
vei	ght points Indicator SI. No.	
	3 1, 23, 29	
	2 2, 3, 9, 10, 22, 30, 34, 42, 1	
	4, 5, 6, 7, 8, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 24, 25, 26, 27, 28, 3°	





MIZORAM

1. Status of HIV/AIDS Epidemic				
A. Epidemic Estimates (2023)				
Indicator	Male	Female	Total	
1. IPR	-	-	4.85	
2. IMR	-	-	4.13	
3. Adult (15-49 yrs) HIV Prevalence (%)	3.04	2.41	2.73	
4. Estimated people living with HIV	14,190	11,103	25,293	
5. ART coverage (%)	71.77	62.13	67.54	
6. Estimated children living with HIV	357	346	703	
7. Annual new HIV infections	704	523	1,227	
8. Annual AIDS-related deaths (ARD)	58	74	132	
9. Change in annual new HIV infections since 2010 (%)	-17.47	-16.98	-17.33	
10. Change in annual ARD since 2010(%)	-84.20	-67.83	-77.72	
11. EMTCT need	-	292	292	


B. High risk population size (2020-22), safe practices (2021) and prevalence (2021/2023)

Population Group	Estimates Size	Condom Use (%)	New Needle/ Syringe use (%)	HIV Prevalence (%)
1. Female Sex Workers	1,434	77.30	68.50	56.15
2. Men who have sex with men	841	100.00	-	12.80
3. Injecting Drug Users	10,397	-	80.10	32.08
4. Hijra/Transgender People	-	-	-	-
5. Migrants	50,300	50.00	-	4.80
6. Truckers	15,000	-	-	-
7. Prison inmates	6,500	-	69.70	21.50

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21) Indicator Male Female 1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%) 65.60 64.10

2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	60.00	68.90	-
3. Adults willing to care for a relative with HIV/AIDS in own home (%)	95.70	86.70	-
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	89.40	88.40	-
5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)	3.30	0.70	-
5.1 Condom use during last higher-risk intercourse (%)	29.00	7.10	-
6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)	2.44	0.69	-
6.1 Condom use during last higher-risk intercourse (%)	57.14	33.33	-

2. Progress on 95-95-95 (2023-24)



Indicators	Male	Female	Total*
1. Estimated PLHIV size (2023)	14,190	11,103	25,293
2. PLHIV who know their HIV Status	10,998	7,349	18,347
3. PLHIV who know their HIV status and are on ART	9,896	6,698	16,594
4. PLHIV who are on ART and tested for their viral load	6,841	4,937	11,778
4.1 PLHIV who are virally suppressed	6,772	4,926	11,698

Including of H/TG PLHIV

Total

3. Prevention of new HIV infections among general population

A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2023-24
Schools with operational Adolescent Education Program (AEP)	394
2. Colleges with operational Red Ribbon Clubs (RRC)	45
3. Persons trained under mainstreaming	556
4. No. of calls received at helpline	-

B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management

Indicator		202	23-24	
NACO Supported Designated STI/	10			
Designated STI/ RTI Clinics (DSRC)	Male	Female	TG	Total
2. Total STI/RTI Clients managed				40,956
3. RPR Tests conducted	7,361	5,760	-	13,121
4. Syphilis seropositivity (%)	2.09	1.96	-	2.03

4. Prevention of new HIV infections among high-risk group and bridge population

A. Targeted Intervention (TI) Projects and Opioid Substitution Therapy (OST)

Indicator	2023-24
1. Targeted Intervention (TI) Projects	36
2. OST centres (Excluding Satellite OST centres)	17

B. Female Sex Workers	
Indicator	2023-24
1. Estimated size	1,433
2. Coverage (%)	81.41
3. Condoms distributed	1,75,699
4. Tested for HIV (April 2022-September 2022)	606
4.1. HIV sero-positive (%)	1.82
4.1.1. Linked to ART	11
5. Tested for HIV (October 2022 -March 2023)	767
5.1. HIV sero-positive (%)	1.30
5.1.1. Linked to ART	10
6. Clinic Visits	3,616
7. STI/RTI treated	84
8. Presumptive treatment	221

2023-24 841
841
>=95
84,351
731
0.55
3
773
0.78
7
3,273
2
110

D. Injecting Drug Users	
Indicator	2023-24
1. Estimated size	10,397
2. Coverage (%)	>=95
3. Needles distributed	25,47,476
4. Syringes distributed	25,40,909
5. On OST	3,348
6. Tested for HIV (April 2022 -September 2022)	7,382
6.1. HIV sero-positive (%)	1.69
6.1.1 Linked to ART	106
7. Tested for HIV (October 2022 -March 2023)	7,310
7.1. HIV sero-positive (%)	1.11
7.1.1. Linked to ART	77

E. Hijra/Transgender person	
Indicator	2023-24
1. Estimated size	-
2. Coverage (%)	-
3. Condoms distributed	-
4. Tested for HIV (April 2022-September 2022)	-
4.1. HIV sero-positive (%)	-
4.1.1. Linked to ART	-
5. Tested for HIV (October 2022 -March 2023)	-
5.1. HIV sero-positive (%)	-
5.1.1. Linked to ART	-
6. Clinic Visits	-
7. STI/RTI treated	-
8. Presumptive treatment	-

F. Migrants	
Indicator	2023-24
1. Estimated size	50,300
2. Coverage (%)	>=95
3. Tested for HIV	10,826
3.1. HIV sero-positive (%)	0.25
3.2. Linked to ART	21

G. Truckers	
Indicator	2023-24
1. Estimated size	15,000
2. Coverage (%)	0
3. Tested for HIV	0
3.1. HIV sero-positive (%)	-
3.2. On ART	-

H. Prison Inmates	
Indicator	2023-24
1. Total prisons	10
2. Prisons covered under programme	9
3. Total inmates admitted	6,500
4. Inmates Covered (%)	50
5. Tested for HIV	3,235
5.1. HIV sero-positive (%)	3.18
5.2. On ART (%)	65.05

I. Link Worker Scheme	
Indicator	2023-24
Districts covered under scheme	8
Vulnerable population covered	18,871
3. Tested for HIV	15,117
3.1. HIV sero-positive (%)	0.61
3.2. Linked to ART (%)	93.48

J. Opioid Substitution Therapy	
Indicator	2023-24
1. OST Centres	17
1.1. OSTC in Public Health Settings	13
1.2. OSTC in NGO Settings	4
1.3. No. of Satellite OST Centres	44
2. IDU on OST	3,348

A. HIV counselling and testing services (HCTS)

Indicator	2023-24
1. HCTC confirmatory facilities	44
2. Sampoorna Suraksha Kendras	1

B. HIV testing among vulnerable population (excluding pregnant women)

Indicator	2023-24			
	Male	Female	TG	Total
1. Tested for HIV	50,922	32,289	-	83,211
1.1 HIV Positives	1,418	682	-	2,100
1.2 HIV sero -positivity (%)	2.78	2.11	-	2.52
Spouse/sexual partner of HIV positive people tested	894	1,033	-	1,927
2.1 HIV Positives	209	231	-	440
2.2 HIV sero -positivity (%)	23	22	-	22.83
3. No. of contacts with 'at- risk' population through 'Sampoorna Suraksha'	-	-	-	1,020

6. Initiation and retention on ART of HIV infected people

A. Treatment facilities

Indicator	2023-24
1. ART Centres	14
2.Centre of Excellence	
2.1. Centre of Excellence (Adult)	-
2.2 Centre of Excellent (Paediatric)	-
3. Link ART Centres	7
4. Care Support Centres	3

B. Treatment uptake

Indicator	2023-24			
	Male	Female	TG	Total
HIV positive cases diagnosed (At ICTC)	1,418	801		2,219
New PLHIV Registered at ART center	1,408	766		2,174
2.1 Initiated on ART	1,396	764		2,160
3. PLHIV alive and on ART	9,896	6,698		16,594
4. 12 months retention on ART (%)				>=95
5. Lost to follow-up cases	430	203	-	633

7. Viral Suppression and laboratories	
A. Laboratory facilities and service uptake	
Indicator	2023-2
Viral load laboratories (programme and non- programme labs)	
1.1 Accredited Viral load laboratories (out of 64 VL labs)	
2. Viral load tests conducted	13,94
2.1. Virally suppressed (%)	>=9
3. National reference laboratories (NRL)	
3.1 Accredited NRL	
4. State reference laboratories (SRL)	
4.1 Accredited SRL	
5. CD4 machines	
5.1 CD4 tests conducted	6,07
6. External Quality Assurance of ICTC	
6.1 Average Participation (%)	(
6.2. Average Discordance (%)	0.0
7. "Certificate of Excellence" by NACO	
7.1 No. of ICTCs received "Certificate of Excellence"	2
8. Elimination of mother to child trans HIV & Syphilis	mission of
A. HIV	
Indicator	2023-2
1. Estimated pregnant women (PW)	19,2
2. HIV testing among PW	20,6
3. HIV sero-positivity (%) among tested	0.!
4. HIV Positive PW (old + new detections)	32
4.1 On life-long ART	29
5. Live births among HIV positive PW	25
5.1 Babies given ARV Prophylaxis (%)	>=0
6. Babies tested HIV (6 week- 6 month)	27
6.1 Babies confirmed HIV Positive (6 week- 6 month)	
7. HIV testing among exposed babies at 18 months	
7.1 HIV exposed babies tested at 18 months	25
7.2 Babies confirmed HIV positive at 18 months	
8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months)	
9. HIV positive babies initiated on ART	
B. Syphilis	
Indicator	2023-2
1. Syphilis testing among PW	21,64
2.Sero-positivity (%) among tested	0.2
3. Put on treatment 9. Elimination of HIV/AIDS related Stigma	
and Discrimination	
Indicator	2023-2
State rules notified for HIV/AIDS Prevention and Control Act (2017)	Y

2. State designated/appointed ombudsman

Yes

10. HIV-TB Co-m	orbidities									
A. HRG and Bridge	Population									
Indicator				202	23-24					
	Quarter	Quarter FSW MSM IDU TG Migrants Truckers Total								
	Quarter 1	872	1,147	11,912	-	5,001	-	18,932		
Screened for TB	Quarter 2	883	786	12,115	-	4,221	-	18,005		
Screened for TB	Quarter 3	796	913	11,550	-	3,967	-	17,226		
	Quarter 4	814	1,010	11,910	-	3,513	-	17,247		
	Quarter 1	7	2	51	-	-	-	60		
Tested for TB	Quarter 2	9	-	34	-	-	-	43		
	Quarter 3	4	32	18	-	1	-	55		
	Quarter 4	10	-	10	-	2	-	22		
	Quarter 1	1	-	3	-	-	-	4		
Discussion of with TD	Quarter 2	-	-	3	-	-	-	3		
Diagnosed with TB	Quarter 3	-	-	1	-	-	-	1		
	Quarter 4	-	-	2	-	-	-	2		
	Quarter 1	1	-	3	-	-	-	4		
Initiated on TB	Quarter 2	-	-	3	-	-	-	3		
treatment	Quarter 3	-	-	1	-	-	-	1		
	Quarter 4	-	-	2	-	-	-	2		

B. HIV-TB Coinfected at ART Centre Indicator 2023-24 Co-infected enrolled at PLHIV with presumptive TB PLHIV PLHIV PLHIV PLHIV Co-infected initiated on ART PLHIV tested for TB diagnosed with TB initiated on IPT Moths attending underwent ART Centre 4S screening ARTC 7,172 31 Apr - 23 7,172 36 36 15 13 52 8,648 8,648 63 63 May - 23 Jun - 23 7,272 7,272 37 37 8 35 Jul - 23 7,708 7,708 55 53 13 72 58 8,800 8,800 71 10 192 Aug - 23 9 Sep - 23 7,666 7,666 53 46 133 Oct - 23 8,037 8,037 249 43 11 161 9 8,476 8,476 206 38 174 Nov - 23 9 Dec - 23 7,608 7,608 179 30 105 Jan - 24 7,915 7,915 94 8 36 124 9 Feb - 24 8,572 8,572 89 38 190 Mar - 24 8,215 8,215 76 39 13 246 April 2023-225 217 March 2024

	State/UT	Mizoram
SI.	Rank Maximum Marks	7 177
No.	Obtained Marks	135 (76%)
1	First 95 (G:≥95%, Y: 80-94%, R:<80%)	73
2	Second 95 (G:≥95%, Y: 80-94%, R:<80%)	90
3	Third 95 (G:≥95%, Y: 80-95%, R:<80%)	>=95
4	Average Frequency of Social Media updates (G: ≥ 45, Y:40- 44, R:<40 indigenous posts) of Q1, Q2, Q3 & Q4	26
5	Status of AEP integration in state school curriculum (G:Yes, R:No)	No
6	Status of SCA (G: At least one meeting held since 2020, R: other than G)	No Meeting held
7	Status of State Rules (G: Notified, R: Not notified)	Notified
8	Status of Ombudsman (G: Appointed, R: Not appointed)	Appointed
9	TI/LWS onboarding (G: ≥95%, Y: 90-<95%, R:<90%)	100
10	OST onboarding (G: ≥95%, Y: 90-<95%, R:<90%)	100
11	Coverage of HRG against estimates (G: ≥90%, Y: 80-<90%, R:<80%)	135
12	HIV testing among HRG (G: ≥95%, Y: 90-<95%, R:<90%)	59
13	HIV testing among prisoners (G: ≥50%, Y: 40% to <50%, R:<40%)	54
14	Clinic visit of HRGs at TI-Clinics (G: ≥90%, Y: 75-89%, R:<75%)	90
15	Percentage of HRGs screened for Syphilis (G: ≥90%, Y: 75-89%, R:<75%)	74
16	IDU on OST (G: ≥50%, Y: 30% to <50%, R:<30%)	51
17	Percentage of fund released to TI (G: ≥50%, Y: 45-<50%, R:<45%)	101
18	Percentage of TIs trained by Kshmata Kendra (KK) against the AAP targets (G: ≥75%, Y: 70-<75%, R:<70%)	100
19	HIV testing against Target-at risk % (G: ≥95%, Y: 80-94%, R:<80%)	36
20	HIV testing against target-PW (G: ≥95%, Y: 80-94%, R:<80%)	107
21	Percentage of pregnant women screened for Syphilis (G: ≥95%, Y: 80-94%, R:<80%)	112
22	Treatment provided to Syphilis reactive pregnant women (G: ≥95%, Y: 80-94%, R:<80%)	98
23	Index testing among newly detected HIV positive clients (G: ≥95%, Y: 80-94%, R:<80%)	26
24	Percentage of 6 weeks - <2 months EID testing against live birth (G: ≥95%, Y: 80-94%, R:<80%)	100
25	Clients managed at DSRC against the target (G: ≥90%, Y: 75-89%, R:<75%)	55
26	STI attendees screened for HIV (G: >75%, Y: 50-75%, R:<50%)	60
27	STI attendees screened for Syphilis (G: >75%, Y: 50-75%, R:<50%)	93
28	% of pregnant women who initiated ART (G: ≥95%, Y: 80-94%, R:<80%)	92
29	Proportion of LFU-PLHIV, out of those initiated on ART in FY 2023-24 (G:<2%, Y: 2 to 5%, R:>5%)	3
30	Proportion of PLHIV initiated on ART, out of those registered in FY 2023-24 (G:>98%, Y: 95 to 98%, R:<95%)	99
31	Proportion of reported died, out of those initiated on ART in FY 202324 (G:<2%, Y: 2 to 5 %, R:>5 %)	5
32	% of SRL accredited (G:100%, Y: 80-99%, R:<80%)	100
33	% participation of ICTCs in re-testing (G: ≥95%, Y: 85-94, R:<85%)	96
34	Number of abstracts selected from studies conducted in FY21-22	3
	(G:100%, Y: >25 to <100%, R: ≤25%)	
35	Number of ongoing studies from FY22-23 (G:100%, Y: >25 to <100%, R: ≤25%)	2
36	Submission of research proposals from FY23-24 to NACO (G:100%, Y: >25 to <100%, R: ≤25%)	2
37	Secondary Data Analysis by SACS (G:2, Y: 1, R: No Secondary Data Analysis Plan Submitted)	2
38	Expenditure with respect to funds released during FY 2022-23 (G: ≥90%, Y: 85 to <90%, R: <85%)	109
39	Submission of Provisional Utilization Certificate (UC) in GFR 12A for the FY 2022-23 (G: by 30-Apr-2023, Y: by 31-May-2023, R: after 31-May-2023)	03-05-2023
40	Submission of audited UC in GFR 12A for the FY 2022-23 (G : by 30Jun-2023, Y : by 30-Sep- 2023, R : after 30-Sep-2023)	06-09-2023
41	Submission of EC/ GB ratification for approval of Expenditure incurred during FY 2021-22 (G: by 30-Jun-2022, Y: by 30-Sept-2022, R: after 30-Sept-2022)	21-02-2023
42	Timely Submission of CST-SCM Report (G:>95%, Y: 80-95%, R:<80%)	94
43	Format Adherence to CST-SCM Report (G:>95%, Y: 80-95%, R:<80%)	93
44	Timely Submission of BSD & STI-SCM Report (G: ≥90%, Y: 75-<90%, R:<75%)	83
		olour=Not Applicable
	ht points Indicator SI. No.	
	3 1, 23, 29	
	2 2, 3, 9, 10, 22, 30, 34, 42, 44	
	4, 5, 6, 7, 8, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 24, 25, 26, 27, 28, 31, 32,	. 33, 35, 36, 37, 38, 39, 40, 41
	1 43	





NAGALAND

1. Status of HIV/AIDS Epidemic			
A. Epidemic Estimates (2023)			
Indicator	Male	Female	Total
1. IPR	-	-	4.37
2. IMR	-	-	2.86
3. Adult (15-49 yrs) HIV Prevalence (%)	1.39	1.34	1.37
4. Estimated people living with HIV	12,162	10,923	23,085
5. ART coverage (%)	59.07	66.77	62.77
6. Estimated children living with HIV	448	421	869
7. Annual new HIV infections	535	473	1,008
8. Annual AIDS-related deaths (ARD)	132	82	214
9. Change in annual new HIV infections since 2010 (%)	-39.20	-34.58	-37.08
10. Change in annual ARD since 2010(%)	-76.26	-76.16	-76.22
11. EMTCT need	-	288	288


B. High risk population size (2020-22), safe practices (2021) and prevalence (2021/2023)

Population Group	Estimates Size	Condom Use (%)	New Needle/ Syringe use (%)	HIV Prevalence (%)
1. Female Sex Workers	2,246	98.80	-	2.00
2. Men who have sex with men	1,239	97.40	ı	3.06
3. Injecting Drug Users	16,802	-	86.40	2.53
4. Hijra/Transgender People	82	-	ı	-
5. Migrants	5,000	-	-	-
6. Truckers	5,000	97.30	ı	1.20
7. Prison inmates	2,313	-	64.10	6.64

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

Indicator	Male	Female	Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)	40.10	25.60	-
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	31.90	21.10	-
3. Adults willing to care for a relative with HIV/AIDS in own home (%)	64.80	63.40	-
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	63.70	56.80	-
5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)	8.80	2.30	-
5.1 Condom use during last higher-risk intercourse (%)	59.50	11.60	-
6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)	7.46	3.38	-
6.1 Condom use during last higher-risk intercourse (%)	66.67	6.25	-

2. Progress on 95-95-95 (2023-24)



Indicators	Male	Female	Total*
1. Estimated PLHIV size (2023)	12,162	10,923	23,085
2. PLHIV who know their HIV Status	8,843	8,808	17,664
3. PLHIV who know their HIV status and are on ART	6,983	7,095	14,090
4. PLHIV who are on ART and tested for their viral load	4,217	4,750	8,979
4.1 PLHIV who are virally suppressed	4,118	4,698	8,827

3. Prevention of new HIV infections among general population

A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2023-24
Schools with operational Adolescent Education Program (AEP)	752
2. Colleges with operational Red Ribbon Clubs (RRC)	106
3. Persons trained under mainstreaming	3,938
4. No. of calls received at helpline	-

B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management

Indicator	2023-24			
NACO Supported Designated STI/	12			
RTI Clinics (DSRC)	Male	Female	TG	Total
2. Total STI/RTI Clients managed				62,858
3. RPR Tests conducted	5,361	4,302	-	9,663
4. Syphilis seropositivity (%)	2.03	1.53	-	1.81

4. Prevention of new HIV infections among high-risk group and bridge population

A. Targeted Intervention (TI) Projects and Opioid Substitution Therapy (OST)

Indicator	2023-24
1. Targeted Intervention (TI) Projects	46
2. OST centres (Excluding Satellite OST centres)	31

B. Female Sex Workers

Indicator	2023-24
1. Estimated size	2,245
2. Coverage (%)	>=95
3. Condoms distributed	7,26,117
4. Tested for HIV (April 2022-September 2022)	3,375
4.1. HIV sero-positive (%)	0.27
4.1.1. Linked to ART	5
5. Tested for HIV (October 2022 -March 2023)	3,634
5.1. HIV sero-positive (%)	0.28
5.1.1. Linked to ART	9
6. Clinic Visits	13,924
7. STI/RTI treated	70
8. Presumptive treatment	816

C. Men who have Sex with Men	
Indicatort	2023-24
1. Estimated size	1,238
2. Coverage (%)	>=95
3. Condoms distributed	5,37,692
4. Tested for HIV (April 2022-September 2022)	2,348
4.1. HIV sero-positive (%)	0.38
4.1.1. Linked to ART	9
5. Tested for HIV (October 2022 -March 2023)	2,059
5.1. HIV sero-positive (%)	0.29
5.1.1. Linked to ART	6
6. Clinic Visits	8,264
7. STI/RTI treated	19
8. Presumptive treatment	341

D. Injecting Drug Users	
Indicator	2023-24
1. Estimated size	16,802
2. Coverage (%)	>=95
3. Needles distributed	19,87,986
4. Syringes distributed	19,88,430
5. On OST	8,826
6. Tested for HIV (April 2022 -September 2022)	20,566
6.1. HIV sero-positive (%)	0.57
6.1.1 Linked to ART	98
7. Tested for HIV (October 2022 -March 2023)	18,950
7.1. HIV sero-positive (%)	0.40
7.1.1. Linked to ART	52

E. Hijra/Transgender person	
Indicator	2023-24
1. Estimated size	82
2. Coverage (%)	>=95
3. Condoms distributed	31,892
4. Tested for HIV (April 2022-September 2022)	117
4.1. HIV sero-positive (%)	0.00
4.1.1. Linked to ART	-
5. Tested for HIV (October 2022 -March 2023)	122
5.1. HIV sero-positive (%)	0.82
5.1.1. Linked to ART	1
6. Clinic Visits	582
7. STI/RTI treated	1
8. Presumptive treatment	49

F. Migrants	
Indicator	2023-24
1. Estimated size	5,000
2. Coverage (%)	>=95
3. Tested for HIV	3,660
3.1. HIV sero-positive (%)	0.16
3.2. Linked to ART	6

G. Truckers	
Indicator	2023-24
1. Estimated size	5,000
2. Coverage (%)	>=95
3. Tested for HIV	3,048
3.1. HIV sero-positive (%)	0.03
3.2. On ART	0

H. Prison Inmates	
Indicator	2023-24
1. Total prisons	11
2. Prisons covered under programme	12
3. Total inmates admitted	2,313
4. Inmates Covered (%)	51
5. Tested for HIV	1,171
5.1. HIV sero-positive (%)	3.59
5.2. On ART (%)	>=95

I. Link Worker Scheme	
Indicator	2023-24
1. Districts covered under scheme	6
Vulnerable population covered	1,45,786
3. Tested for HIV	14,490
3.1. HIV sero-positive (%)	0.32
3.2. Linked to ART (%)	93.48

J. Opioid Substitution Therapy	
Indicator	2023-24
1. OST Centres	31
1.1. OSTC in Public Health Settings	26
1.2. OSTC in NGO Settings	5
1.3. No. of Satellite OST Centres	26
2. IDU on OST	8,826

A. HIV counselling and testing services (HCTS)

At the counseling and testing services (11019)			
Indicator	2023-24		
1. HCTC confirmatory facilities	72		
2. Sampoorna Suraksha Kendras	1		

B. HIV testing among vulnerable population (excluding pregnant women)

Indicator	2023-24			
	Male	Female	TG	Total
1. Tested for HIV	96,526	65,126	2	1,61,654
1.1 HIV Positives	1,249	736	1	1,986
1.2 HIV sero -positivity (%)	1.29	1.13	50.00	1.23
Spouse/sexual partner of HIV positive people tested	976	669	1	1,646
2.1 HIV Positives	291	301	-	592
2.2 HIV sero -positivity (%)	30	45	-	35.97
3. No. of contacts with 'at- risk' population through 'Sampoorna Suraksha'	-	-	-	785

6. Initiation and retention on ART of HIV infected people

A. Treatment facilities

Indicator	2023-24
1. ART Centres	12
2.Centre of Excellence	
2.1. Centre of Excellence (Adult)	-
2.2 Centre of Excellent (Paediatric)	-
3. Link ART Centres	24
4. Care Support Centres	3

B. Treatment uptake

Indicator	2023-24			
	Male	Female	TG	Total
HIV positive cases diagnosed (At ICTC)	1,249	894	1	2,144
New PLHIV Registered at ART center	1,197	919	1	2,117
2.1 Initiated on ART	1,091	863	1	1,955
3. PLHIV alive and on ART	6,983	7,095	12	14,090
4. 12 months retention on ART (%)				87.5
5. Lost to follow-up cases	1,414	1,273		2,687

A. Laboratory facilities and service uptake	
Indicator	2023-2
Viral load laboratories (programme and non- programme labs)	
1.1 Accredited Viral load laboratories (out of 64 VL labs)	
2. Viral load tests conducted	10,47
2.1. Virally suppressed (%)	>=9
3. National reference laboratories (NRL)	
3.1 Accredited NRL	
4. State reference laboratories (SRL)	
4.1 Accredited SRL	
5. CD4 machines	1
5.1 CD4 tests conducted	6,68
6. External Quality Assurance of ICTC	
6.1 Average Participation (%)	10
6.2. Average Discordance (%)	0.0
7. "Certificate of Excellence" by NACO	
7.1 No. of ICTCs received "Certificate of Excellence"	5
Elimination of mother to child trans HIV & Syphilis	mission of
A. HIV	
Indicator	2023-2
1. Estimated pregnant women (PW)	29,97
2. HIV testing among PW	21,50
3. HIV sero-positivity (%) among tested	0.7
4. HIV Positive PW (old + new detections)	25
4.1 On life-long ART	23
5. Live births among HIV positive PW	33
5.1 Babies given ARV Prophylaxis (%)	>=9
6. Babies tested HIV (6 week- 6 month)	27
6.1 Babies confirmed HIV Positive (6 week- 6 month)	
7. HIV testing among exposed babies at 18 months	
7.1 HIV exposed babies tested at 18 months	16
7.2 Babies confirmed HIV positive at 18 months	
8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months)	
9. HIV positive babies initiated on ART	
B. Syphilis	
Indicator	2023-2
1. Syphilis testing among PW	26,78
0.6	0.5
2.Sero-positivity (%) among tested	
	14
3. Put on treatment	
2.Sero-positivity (%) among tested 3. Put on treatment 9. Elimination of HIV/AIDS related Stigma and Discrimination Indicator	2023-2

2. State designated/appointed ombudsman

Yes

10. HIV-TB Co-m	orbidities							
A. HRG and Bridge	e Population							
Indicator		2023-24						
	Quarter	FSW	MSM	IDU	TG	Migrants	Truckers	Total
	Quarter 1	1,529	939	6,999	123	590	93	10,27
c It TD	Quarter 2	1,910	1,275	9,063	147	621	76	13,09
Screened for TB	Quarter 3	1,809	1,310	8,711	95	452	52	12,42
	Quarter 4	2,178	1,121	8,659	103	300	63	12,42
	Quarter 1	32	4	67	-	1	-	10
	Quarter 2	47	2	95	-	-	-	14
Tested for TB	Quarter 3	40	-	73	-	1	-	11
	Quarter 4	62	2	81	-	-	-	14
	Quarter 1	-	1	4	-	-	-	!
D:	Quarter 2	-	-	3	-	-	-	
Diagnosed with TB	Quarter 3	1	-	-	-	1	-	:
	Quarter 4	-	-	3	-	-	-	
	Quarter 1	-	1	4	-	-	-	
Initiated on TB	Quarter 2	-	-	3	-	-	-	
treatment	Quarter 3	1	-	-	-	1	-	
	Quarter 4	_	_	2	_	_	-	

B. HIV-TB Coinfected at ART Centre Indicator 2023-24 Co-infected enrolled at PLHIV with presumptive TB PLHIV PLHIV PLHIV PLHIV Co-infected initiated on ART PLHIV tested for TB attending diagnosed with TB initiated on IPT Moths underwent ART Centre 4S screening ARTC 5,066 4,970 194 Apr - 23 96 87 34 103 91 28 5,882 5,799 133 May - 23 Jun - 23 6,040 5,919 63 59 22 128 Jul - 23 5,883 5,708 118 96 28 216 6,913 150 115 23 168 Aug - 23 6,630 Sep - 23 6,505 6,343 108 73 25 114 6,457 6,303 96 Oct - 23 61 26 111 27 79 6,997 102 Nov - 23 6,876 65 Dec - 23 6,594 6,393 110 58 22 88 Jan - 24 7,492 6,408 92 28 240 57 6,970 18 Feb - 24 7,611 113 50 319 Mar - 24 7,778 7,640 97 53 17 255 April 2023-341 297 March 2024

	State/UT	Nagaland
CI	Rank	14
SI. No.	Maximum Marks Obtained Marks	177
1	First 95 (G:≥95%, Y: 80-94%, R:<80%)	130 (73%) 77
2	Second 95 (G:≥95%, Y: 80-94%, R:<80%)	80
3	Third 95 (G:≥95%, Y: 80-94%, R:<80%)	>=95
4	Average Frequency of Social Media updates (G: ≥ 45, Y:40- 44, R:<40 indigenous posts) of	88
_	Q1, Q2, Q3 & Q4	
5	Status of AEP integration in state school curriculum (G:Yes, R:No)	Yes
6	Status of SCA (G: At least one meeting held since 2020, R: other than G)	No Meeting held
7	Status of State Rules (G: Notified, R: Not notified)	Notified
8	Status of Ombudsman (G: Appointed, R: Not appointed)	Appointed
9	TI/LWS onboarding (G: ≥95%, Y: 90-<95%, R:<90%)	100
10	OST onboarding (G: ≥95%, Y: 90-<95%, R:<90%)	100
11	Coverage of HRG against estimates (G: ≥90%, Y: 80-<90%, R:<80%)	190
12	HIV testing among HRG (G: ≥95%, Y: 90-<95%, R:<90%)	77
13	HIV testing among prisoners (G: ≥50%, Y: 40% to <50%, R:<40%)	42
14	Clinic visit of HRGs at TI-Clinics (G: ≥90%, Y: 75-89%, R:<75%)	78
15	Percentage of HRGs screened for Syphilis (G: ≥90%, Y: 75-89%, R:<75%)	74
16	IDU on OST (G: ≥50%, Y: 30% to <50%, R:<30%)	66
17	Percentage of fund released to TI (G: ≥50%, Y: 45-<50%, R:<45%)	93
18	Percentage of TIs trained by Kshmata Kendra (KK) against the AAP targets (G: ≥75%, Y: 70-	100
	<75%, R:<70%)	
19	HIV testing against Target-at risk % (G: ≥95%, Y: 80-94%, R:<80%)	102
20	HIV testing against target-PW (G: ≥95%, Y: 80-94%, R:<80%)	72
21	Percentage of pregnant women screened for Syphilis (G: ≥95%, Y: 80-94%, R:<80%)	89
22	Treatment provided to Syphilis reactive pregnant women (G: ≥95%, Y: 80-94%, R:<80%)	97
23	Index testing among newly detected HIV positive clients (G: ≥95%, Y: 80-94%, R:<80%)	34
24	Percentage of 6 weeks - <2 months EID testing against live birth (G: ≥95%, Y: 80-94%, R:<80%)	96
25	Clients managed at DSRC against the target (G: ≥90%, Y: 75-89%, R:<75%)	83
26	STI attendees screened for HIV (G: >75%, Y: 50-75%, R:<50%)	27
27	STI attendees screened for Syphilis (G: >75%, Y: 50-75%, R:<50%)	98
28	% of pregnant women who initiated ART (G: ≥95%, Y: 80-94%, R:<80%)	94
29	Proportion of LFU-PLHIV, out of those initiated on ART in FY 2023-24 (G:<2%, Y: 2 to 5%, R:>5%)	4
30	Proportion of PLHIV initiated on ART, out of those registered in FY 2023-24 (G:>98%, Y: 95 to 98%, R:<95%)	92
31	Proportion of reported died, out of those initiated on ART in FY 202324 (G:<2%, Y: 2 to 5 %, R:>5 %)	3
32	% of SRL accredited (G:100%, Y: 80-99%, R:<80%)	100
33	% participation of ICTCs in re-testing (G: ≥95%, Y: 85-94, R:<85%)	100
34	Number of abstracts selected from studies conducted in FY21-22 (G:100%, Y: >25 to <100%, R: ≤25%)	3
35	Number of ongoing studies from FY22-23 (G:100%, Y: >25 to <100%, R: ≤25%)	4
36	Submission of research proposals from FY23-24 to NACO (G:100%, Y: >25 to <100%, R: ≤25%)	2
37	Secondary Data Analysis by SACS (G:2, Y: 1, R: No Secondary Data Analysis Plan Submitted)	2
38	Expenditure with respect to funds released during FY 2022-23 (G: ≥90%, Y: 85 to <90%, R: <85%)	96
39	Submission of Provisional Utilization Certificate (UC) in GFR 12A for the FY 2022-23 (G: by 30-Apr-2023, Y: by 31-May-2023, R: after 31-May-2023)	09-05-2023
40	Submission of audited UC in GFR 12A for the FY 2022-23 (G : by 30Jun-2023, Y : by 30-Sep- 2023, R : after 30-Sep-2023)	26-06-2023
41	Submission of EC/ GB ratification for approval of Expenditure incurred during FY 2021-22 (G: by 30-Jun-2022, Y: by 30-Sept-2022, R: after 30-Sept-2022)	17-11-2022
42 43	Timely Submission of CST-SCM Report (G:>95%, Y: 80-95%, R:<80%) Format Adherence to CST-SCM Report (G:>95%, Y: 80-95%, R:<80%)	91 87
44	Format Agnerence to CS1-SCM Report (G: ≥95%, Y: 80-95%, R:<80%) Timely Submission of BSD & STI-SCM Report (G: ≥90%, Y: 75- <90%, R:<75%)	33
	Green=3 Marks Yellow=2Marks Red=1 Mark No C	olour=Not Applicable
Weig	ht points Indicator SI. No.	
	3 1, 23, 29	
	2 2, 3, 9, 10, 22, 30, 34, 42, 44	
	4, 5, 6, 7, 8, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 24, 25, 26, 27, 28, 31, 32	, 33, 35, 36, 37, 38, 39, 40, 41,
	1 43	





ODISHA

1. Status of HIV/AIDS Epidemic			
A. Epidemic Estimates (2023)			
Indicator	Male	Female	Total
1. IPR	-	-	2.39
2. IMR	-	-	0.79
3. Adult (15-49 yrs) HIV Prevalence (%)	0.13	0.11	0.12
4. Estimated people living with HIV	25,373	22,135	47,508
5. ART coverage (%)	62.23	54.52	59.71
6. Estimated children living with HIV	816	768	1,584
7. Annual new HIV infections	569	566	1,135
8. Annual AIDS-related deaths (ARD)	382	573	955
9. Change in annual new HIV infections since 2010 (%)	-71.87	-68.24	-70.17
10. Change in annual ARD since 2010(%)	-75.24	-50.98	-64.79
11. EMTCT need	-	394	394

B. High risk population size (2020-22), safe practices (2021) and prevalence (2021/2023) Condom Use **HIV Prevalence** New Needle/ Estimates Size Population Group (%) Syringe use (%) (%) 98.30 1. Female Sex Workers 24,620 0.65 100.00 1.20 2. Men who have sex with men 5,977 3. Injecting Drug Users 4,526 97.70 1.90 4. Hijra/Transgender People 7,209 1.49 5. Migrants 92,000 1.60 6. Truckers 15,607 72.20 2.00 7. Prison inmates 1,02,622 0.25

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)					
Indicator	Male	Female	Total		
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)	24.60	21.40	-		
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	22.10	18.10	-		
3. Adults willing to care for a relative with HIV/AIDS in own home (%)	77.50	71.30	-		
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	56.90	63.40	-		
5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)	1.10	0.20	-		
5.1 Condom use during last higher-risk intercourse (%)	39.30	2.70	-		
6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)	1.83	0.38	-		
6.1 Condom use during last higher-risk intercourse (%)	35.00	0.00	-		

2. Progress on 95-95-95 (2023-24)					
45 50 53 56 61 66	86 85 84 83 84 86	76 84 87 85 87 92			
PLHIV who know their HIV status (%) PLHIV who know their HIV status and are on ART (%) PLHIV who are on ART and virally suppressed (%)					
■ 2018-19 ■ 2019-20	2020-21 2021-22	■ 2022-23 ■ 2023-24			

Indicators	Male	Female	Total*
1. Estimated PLHIV size (2023)	25,373	22,135	47,508
2. PLHIV who know their HIV Status	17,633	13,008	31,270
3. PLHIV who know their HIV status and are on ART	14,930	11,360	26,777
4. PLHIV who are on ART and tested for their viral load	3,423	2,703	6,223
4.1 PLHIV who are virally suppressed	3,159	2,490	5,738

^{*} Including of H/TG PLHIV

3. Prevention of new HIV	infections among	general
population	_	_

A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2023-24
Schools with operational Adolescent Education Program (AEP)	464
2. Colleges with operational Red Ribbon Clubs (RRC)	640
3. Persons trained under mainstreaming	1,544
4. No. of calls received at helpline	_

B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management

Indicator	2023-24			
1. NACO Supported	40			
Designated STI/ RTI Clinics (DSRC)	Male	Female	TG	Total
2. Total STI/RTI Clients managed				3,04,178
3. RPR Tests conducted	70,413	63,143	3,477	1,37,033
4. Syphilis seropositivity (%)	1.95	0.60	4.92	1.40

4. Prevention of new HIV infections among high-risk group and bridge population

A. Targeted Intervention (TI) Projects and Opioid Substitution Therapy (OST)

Indicator	2023-24
1. Targeted Intervention (TI) Projects	52
2. OST centres (Excluding Satellite OST centres)	5

B. Female Sex Workers Indicator

Indicator	2023-24
1. Estimated size	24,620
2. Coverage (%)	72.77
3. Condoms distributed	19,56,748
4. Tested for HIV (April 2022-September 2022)	13,900
4.1. HIV sero-positive (%)	0.14
4.1.1. Linked to ART	17
5. Tested for HIV (October 2022 -March 2023)	14,483
5.1. HIV sero-positive (%)	0.12
5.1.1. Linked to ART	18
6. Clinic Visits	56,162
7. STI/RTI treated	2,269
8. Presumptive treatment	3,165

C. Men who have Sex with Men	
Indicatort	2023-24
1. Estimated size	5,977
2. Coverage (%)	74
3. Condoms distributed	4,36,842
4. Tested for HIV (April 2022-September 2022)	3,245
4.1. HIV sero-positive (%)	0.37
4.1.1. Linked to ART	11
5. Tested for HIV (October 2022 -March 2023)	3,398
5.1. HIV sero-positive (%)	0.62
5.1.1. Linked to ART	20
6. Clinic Visits	13,370
7. STI/RTI treated	380
8. Presumptive treatment	635

D. Injecting Drug Users	
Indicator	2023-24
1. Estimated size	4,525
2. Coverage (%)	80
3. Needles distributed	3,83,909
4. Syringes distributed	6,81,094
5. On OST	484
6. Tested for HIV (April 2022 -September 2022)	2,961
6.1. HIV sero-positive (%)	0.17
6.1.1 Linked to ART	4
7. Tested for HIV (October 2022 -March 2023)	3,061
7.1. HIV sero-positive (%)	0.33
7.1.1. Linked to ART	9

E. Hijra/Transgender person	
Indicator	2023-24
1. Estimated size	7,209
2. Coverage (%)	67
3. Condoms distributed	6,73,249
4. Tested for HIV (April 2022-September 2022)	3,793
4.1. HIV sero-positive (%)	1.00
4.1.1. Linked to ART	33
5. Tested for HIV (October 2022 -March 2023)	3,562
5.1. HIV sero-positive (%)	0.59
5.1.1. Linked to ART	20
6. Clinic Visits	15,384
7. STI/RTI treated	523
8. Presumptive treatment	1,035

F. Migrants	
Indicator	2023-24
1. Estimated size	92,000
2. Coverage (%)	>=95
3. Tested for HIV	43,494
3.1. HIV sero-positive (%)	0.13
3.2. Linked to ART	52

G. Truckers	
Indicator	2023-24
1. Estimated size	15,607
2. Coverage (%)	>=95
3. Tested for HIV	8,137
3.1. HIV sero-positive (%)	0.22
3.2. On ART	17

H. Prison Inmates	
Indicator	2023-24
1. Total prisons	92
2. Prisons covered under programme	85
3. Total inmates admitted	1,02,622
4. Inmates Covered (%)	55
5. Tested for HIV	56,825
5.1. HIV sero-positive (%)	0.17
5.2. On ART (%)	94.74

I. Link Worker Scheme	
Indicator	2023-24
Districts covered under scheme	7
Vulnerable population covered	1,94,777
3. Tested for HIV	57,402
3.1. HIV sero-positive (%)	0.13
3.2. Linked to ART (%)	>=95

J. Opioid Substitution Therapy	
Indicator	2023-24
1. OST Centres	5
1.1. OSTC in Public Health Settings	4
1.2. OSTC in NGO Settings	1
1.3. No. of Satellite OST Centres	1
2. IDU on OST	484

A. HIV counselling and testing services (HCTS)

, a rin a comiseining and testing services (11010)		
Indicator	2023-24	
1. HCTC confirmatory facilities	168	
2. Sampoorna Suraksha Kendras	3	

B. HIV testing among vulnerable population (excluding pregnant women)

Indicator	2023-24				
	Male	Female	TG	Total	
1. Tested for HIV	9,03,558	5,17,275	7,469	14,28,302	
1.1 HIV Positives	2,474	922	120	3,516	
1.2 HIV sero -positivity (%)	0.27	0.18	1.61	0.25	
Spouse/sexual partner of HIV positive people tested	649	891	29	1,569	
2.1 HIV Positives	289	313	12	614	
2.2 HIV sero -positivity (%)	45	35	41	39.13	
No. of contacts with 'at- risk' population through 'Sampoorna Suraksha'	-	-	-	1,369	

6. Initiation and retention on ART of HIV infected people

A. Treatment facilities

Indicator	2023-24
1. ART Centres	19
2.Centre of Excellence	
2.1. Centre of Excellence (Adult)	-
2.2 Centre of Excellent (Paediatric)	-
3. Link ART Centres	14
4. Care Support Centres	12

B. Treatment uptake

Indicator	2023-24			
	Male	Female	TG	Total
HIV positive cases diagnosed (At ICTC)	2,474	1,134	120	3,728
New PLHIV Registered at ART center	2,278	1,048	118	3,444
2.1 Initiated on ART	2,174	1,017	114	3,305
3. PLHIV alive and on ART	14,930	11,360	488	26,777
4. 12 months retention on ART (%)				85.1
5. Lost to follow-up cases	1,858	955	93	2,906


7. Viral Suppression and laboratories	
A. Laboratory facilities and service uptake Indicator	2023-24
Viral load laboratories (programme and non-programme labs)	0
1.1 Accredited Viral load laboratories (out of 64 VL labs)	0
2. Viral load tests conducted	9,961
2.1. Virally suppressed (%)	91.5
National reference laboratories (NRL)	-
3.1 Accredited NRL	-
4. State reference laboratories (SRL)	3
4.1 Accredited SRL	3
5. CD4 machines	12
5.1 CD4 tests conducted	6,586
6. External Quality Assurance of ICTC	
6.1 Average Participation (%)	>=95
6.2. Average Discordance (%)	0.00
7. "Certificate of Excellence" by NACO	
7.1 No. of ICTCs received "Certificate of Excellence"	3
8. Elimination of mother to child trans HIV & Syphilis	mission of
A. HIV	
Indicator	2023-24
1. Estimated pregnant women (PW)	9,34,720
2. HIV testing among PW	6,74,520
3. HIV sero-positivity (%) among tested	0.03
4. HIV Positive PW (old + new detections)	399
4.1 On life-long ART	363
5. Live births among HIV positive PW	290
5.1 Babies given ARV Prophylaxis (%)	>=95
6. Babies tested HIV (6 week- 6 month)	313
6.1 Babies confirmed HIV Positive (6 week- 6 month)	-
,	
7. HIV testing among exposed babies at 18 months	225
7.1 HIV exposed babies tested at 18 months	10
7.2 Babies confirmed HIV positive at 18 months 8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months)	13
9. HIV positive babies initiated on ART	13
B. Syphilis	
Indicator	2023-24
Syphilis testing among PW	8,26,315
2.Sero-positivity (%) among tested	0.04
3. Put on treatment	336
9. Elimination of HIV/AIDS related Stigma	
and Discrimination	
Indicator	2023-24
State rules notified for HIV/AIDS Prevention and Control Act (2017)	No

2. State designated/appointed ombudsman

10. HIV-TB Co-morbidities								
A. HRG and Bridge Population								
Indicator 2023-24								
	Quarter	FSW	MSM	IDU	TG	Migrants	Truckers	Total
	Quarter 1	12,194	3,108	2,727	2,951	18,052	4,536	43,568
Screened for TB	Quarter 2	14,137	3,356	3,603	3,333	17,702	3,959	46,090
Screened for 1B	Quarter 3	14,017	3,428	3,299	2,912	17,922	4,010	45,588
	Quarter 4	14,732	3,419	3,390	2,946	17,807	3,799	46,093
	Quarter 1	879	182	254	218	503	19	2,055
Tested for TB	Quarter 2	1,076	284	430	293	549	49	2,681
rested for 16	Quarter 3	1,077	224	301	271	398	23	2,294
	Quarter 4	1,127	205	384	259	429	22	2,426
	Quarter 1	4	-	-	2	2	-	8
Diagnosed with TB	Quarter 2	10	8	1	4	10	-	33
Diagnosed with 16	Quarter 3	6	1	-	-	3	-	10
	Quarter 4	4	1	-	1	2	-	8
	Quarter 1	4	-	-	2	2	-	8
Initiated on TB	Quarter 2	7	4	1	2	9	-	23
treatment	Quarter 3	6	1	-	-	4	-	11
	Quarter 4	5	1	-	1	2	-	9

B. HIV-TB Coinfected at ART Centre Indicator 2023-24 Co-infected enrolled at PLHIV with presumptive TB PLHIV PLHIV PLHIV PLHIV Co-infected initiated on ART PLHIV tested for TB diagnosed with TB initiated on IPT Moths attending underwent ART Centre 4S screening ARTC 8,694 8,246 531 Apr - 23 445 27 122 9,791 23 9,357 512 484 114 May - 23 Jun - 23 9,736 9,338 451 433 23 134 Jul - 23 9,943 9,394 515 502 24 261 10,461 9,995 571 563 25 281 Aug - 23 Sep - 23 11,016 10,719 567 554 28 225 10,488 10,206 552 548 202 Oct - 23 31 31 12,700 12,392 520 221 Nov - 23 486 Dec - 23 14,175 13,954 600 574 34 175 Jan - 24 15,896 15,752 532 532 28 109 16,079 30 Feb - 24 15,830 517 517 122 Mar - 24 15,970 15,394 554 551 32 53 April 2023-665 634 March 2024

	State/UT	Odisha
	Rank	35
SI.	Maximum Marks	177
No.	Obtained Marks	111 (63%)
1	First 95 (G:≥95%, Y: 80-94%, R:<80%)	66
2	Second 95 (G:≥95%, Y: 80-94%, R:<80%)	86
3	Third 95 (G:≥95%, Y: 80-94%, R:<80%)	92
4	Average Frequency of Social Media updates (G: ≥ 45, Y:40- 44, R:<40 indigenous posts) of Q1, Q2, Q3 & Q4	127
5	Status of AEP integration in state school curriculum (G:Yes, R:No)	Yes
6	Status of SCA (G: At least one meeting held since 2020, R: other than G)	Meeting held in 2012
7	Status of State Rules (G: Notified, R: Not notified)	Not Notified
8	Status of Ombudsman (G: Appointed, R: Not appointed)	Appointed
9	TI/LWS onboarding (G: ≥95%, Y: 90-<95%, R:<90%)	100
10	OST onboarding (G: ≥95%, Y: 90-<95%, R:<90%)	86
11	Coverage of HRG against estimates (G: ≥90%, Y: 80-<90%, R:<80%)	73
12	HIV testing among HRG (G: ≥95%, Y: 90-<95%, R:<90%)	87
13	HIV testing among prisoners (G: ≥50%, Y: 40% to <50%, R:<40%)	48
14	Clinic visit of HRGs at TI-Clinics (G: ≥90%, Y: 75-89%, R:<75%)	86
15	Percentage of HRGs screened for Syphilis (G: ≥90%, Y: 75-89%, R:<75%)	87
16	IDU on OST (G: ≥50%, Y: 30% to <50%, R:<30%)	27
17	Percentage of fund released to TI (G: ≥50%, Y: 45-<50%, R:<45%)	81
18	Percentage of TIs trained by Kshmata Kendra (KK) against the AAP targets (G: ≥75%, Y: 70-	79
19	<75%, R:<70%) HIV testing against Target-at risk % (G: ≥95%, Y: 80-94%, R:<80%)	131
20	HIV testing against Target-at risk % (G: ≥95%, Y: 80-94%, R:<80%) HIV testing against target-PW (G: ≥95%, Y: 80-94%, R:<80%)	131 72
21	Percentage of pregnant women screened for Syphilis (G: ≥95%, Y: 80-94%, R:<80%)	88
22		98
	Treatment provided to Syphilis reactive pregnant women (G: ≥95%, Y: 80-94%, R:<80%)	
23	Index testing among newly detected HIV positive clients (G: ≥95%, Y: 80-94%, R:<80%)	27
24	Percentage of 6 weeks - <2 months EID testing against live birth (G: ≥95%, Y: 80-94%,	100
	R:<80%)	
25	Clients managed at DSRC against the target (G: ≥90%, Y: 75-89%, R:<75%)	92
26	STI attendees screened for HIV (G: >75%, Y: 50-75%, R:<50%)	55
27	STI attendees screened for Syphilis (G: >75%, Y: 50-75%, R:<50%)	66 91
28	% of pregnant women who initiated ART (G: ≥95%, Y: 80-94%, R:<80%)	
29	Proportion of LFU-PLHIV, out of those initiated on ART in FY 2023-24 (G:<2%, Y: 2 to 5%, R:>5%)	5
30	Proportion of PLHIV initiated on ART, out of those registered in FY 2023-24 (G:>98%, Y: 95 to 98%, R:<95%)	96
31	Proportion of reported died, out of those initiated on ART in FY 202324 (G:<2%, Y: 2 to 5 %, R:>5 %)	5
32	% of SRL accredited (G:100%, Y: 80-99%, R:<80%)	66.7
33	% participation of ICTCs in re-testing (G: ≥95%, Y: 85-94, R:<85%)	98
34	Number of abstracts selected from studies conducted in FY21-22	0
	(G:100%, Y: >25 to <100%, R: ≤25%)	
35	Number of ongoing studies from FY22-23 (G:100%, Y: >25 to <100%,	0
	R: ≤25%)	
36	Submission of research proposals from FY23-24 to NACO (G:100%, Y: >25 to <100%, R: ≤25%)	0
37	Secondary Data Analysis by SACS (G:2, Y: 1, R: No Secondary Data Analysis Plan Submitted)	2
38	Expenditure with respect to funds released during FY 2022-23 (G: ≥90%, Y: 85 to <90%, R: <85%)	109
39	Submission of Provisional Utilization Certificate (UC) in GFR 12A for the FY 2022-23 (G: by	24-05-2023
37	30-Apr-2023, Y: by 31-May-2023, R: after	24 03-2023
	31-May-2023)	
40	Submission of audited UC in GFR 12A for the FY 2022-23 (G : by 30Jun-2023, Y : by 30-Sep-	12-02-2024
	2023, R : after 30-Sep-2023)	
41	Submission of EC/ GB ratification for approval of Expenditure incurred during FY 2021-22 (G:	15-11-2022
40	by 30-Jun-2022, Y: by 30-Sept-2022, R: after 30-Sept-2022)	0.1
42	Timely Submission of CST-SCM Report (G:>95%, Y: 80-95%, R:<80%)	91
43	Format Adherence to CST-SCM Report (G:>95%, Y: 80-95%, R:<80%)	93
44	Timely Submission of BSD & STI-SCM Report (G: ≥90%, Y: 75-	17
	<90%, R:<75%)	
		Colour=Not Applicable
vveig	ht points Indicator SI. No.	
	3 1, 23, 29	
	2 2, 3, 9, 10, 22, 30, 34, 42, 44	
	4, 5, 6, 7, 8, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 24, 25, 26, 27, 28, 31, 32	, 33, 35, 36, 37, 38, 39, 40, 41,





PUDUCHERRY

1. Status of HIV/AIDS Epidemic			
A. Epidemic Estimates (2023)			
Indicator	Male	Female	Total
1. IPR	-	-	3.19
2. IMR	-	-	1.19
3. Adult (15-49 yrs) HIV Prevalence (%)	0.19	0.17	0.18
4. Estimated people living with HIV	1,436	1,357	2,793
5. ART coverage (%)	52.87	54.82	54.01
6. Estimated children living with HIV	25	27	52
7. Annual new HIV infections	47	42	89
8. Annual AIDS-related deaths (ARD)	28	24	52
9. Change in annual new HIV infections since 2010 (%)	-14.55	-10.64	-12.75
10. Change in annual ARD since 2010(%)	-76.67	-69.62	-73.87
11. EMTCT need	-	14	14

B. High risk population size (2020-22), safe practices (2021) and prevalence (2021/2023) HIV Preva-Condom Use New Nee-dle/ Estimates Size Population Group (%) Syringe use (%) lence (%) 2,514 >=95 1. Female Sex Workers 0.50 0.00 2,489 >=95 2. Men who have sex with men 3. Injecting Drug Users 21 4. Hijra/Transgender People 203 0.00 5. Migrants 15,000 6. Truckers 2,230 7. Prison inmates

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)				
Indicator	Male	Female	Total	
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)	32.50	30.20	-	
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	32.30	25.40	-	
3. Adults willing to care for a relative with HIV/AIDS in own home (%)	76.40	67.40	-	
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	63.40	54.20	-	
5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)	2.40	0.10	-	
5.1 Condom use during last higher-risk intercourse (%)	60.50	0.00	-	
6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)	0.00	0.00	-	
6.1 Condom use during last higher-risk intercourse (%)	-	-	-	

2. Progress on 95-95-95 (2023-24)					
68 60 59 61 61 62	78 78 77 79 81 67	86, 86, 83			
PLHIV who know their HIV status (%) PLHIV who know their HIV status and are on ART (%) 2018-19 2019-20 2020-21 2021-22 2022-23 2023-24					

Indicators	Male	Female	Total*
1. Estimated PLHIV size (2023)	1,436	1,357	2,793
2. PLHIV who know their HIV Status	909	825	1,742
3. PLHIV who know their HIV status and are on ART	711	697	1,413
4. PLHIV who are on ART and tested for their viral load	471	534	1,011
4.1 PLHIV who are virally suppressed	471	524	1,000

^{*} Including of H/TG PLHIV

3. Prevention of new HIV infections among general population

A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2023-24
Schools with operational Adolescent Education Program (AEP)	325
2. Colleges with operational Red Ribbon Clubs (RRC)	80
3. Persons trained under mainstreaming	1,500
4. No. of calls received at helpline	-

B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management

Indicator	2023-24			
1. NACO Supported Designated STI/	5			
RTI Clinics (DSRC)	Male	Female	TG	Total
2. Total STI/RTI Clients managed				49,534
3. RPR Tests conducted	13,385	18,805	159	32,349
4. Syphilis seropositivity (%)	1.17	0.18	5.03	0.61

4. Prevention of new HIV infections among high-risk group and bridge population

A. Targeted Intervention (TI) Projects and Opioid Substitution Therapy (OST)

Indicator	2023-24
1. Targeted Intervention (TI) Projects	5
2. OST centres (Excluding Satellite OST centres)	0

B. Female Sex Workers

Indicator	2023-24
1. Estimated size	2,514
2. Coverage (%)	>=95
3. Condoms distributed	6,04,689
4. Tested for HIV (April 2022-September 2022)	2,332
4.1. HIV sero-positive (%)	0.00
4.1.1. Linked to ART	-
5. Tested for HIV (October 2022 -March 2023)	3,022
5.1. HIV sero-positive (%)	0.07
5.1.1. Linked to ART	2
6. Clinic Visits	10,041
7. STI/RTI treated	82
8. Presumptive treatment	496

C. Men who have Sex with Men Indicatort 2023-24 1. Estimated size 2,488 2. Coverage (%) >=95 6,69,914 3. Condoms distributed 4. Tested for HIV (April 2022-September 2022) 2,431 4.1. HIV sero-positive (%) 0.08 4.1.1. Linked to ART 5. Tested for HIV (October 2022 -March 2023) 2,985 0.17 5.1. HIV sero-positive (%) 5.1.1. Linked to ART 6. Clinic Visits 9,990 7. STI/RTI treated 31

509

D. Injecting Drug Users	
Indicator	2023-24
1. Estimated size	20
2. Coverage (%)	-
3. Needles distributed	-
4. Syringes distributed	-
5. On OST	-
6. Tested for HIV (April 2022 -September 2022)	-
6.1. HIV sero-positive (%)	-
6.1.1 Linked to ART	-
7. Tested for HIV (October 2022 -March 2023)	-
7.1. HIV sero-positive (%)	-
7.1.1. Linked to ART	-

E. Hijra/Transgender person	
Indicator	2023-24
1. Estimated size	203
2. Coverage (%)	>=95
3. Condoms distributed	71,203
4. Tested for HIV (April 2022-September 2022)	184
4.1. HIV sero-positive (%)	0.00
4.1.1. Linked to ART	-
5. Tested for HIV (October 2022 -March 2023)	227
5.1. HIV sero-positive (%)	0.44
5.1.1. Linked to ART	-
6. Clinic Visits	801
7. STI/RTI treated	1
8. Presumptive treatment	40

F. Migrants	
Indicator	2023-24
1. Estimated size	15,000
2. Coverage (%)	>=95
3. Tested for HIV	8,130
3.1. HIV sero-positive (%)	0.06
3.2. Linked to ART	5

G. Truckers	
Indicator	2023-24
1. Estimated size	-
2. Coverage (%)	-
3. Tested for HIV	-
3.1. HIV sero-positive (%)	-
3.2. On ART	-

H. Prison Inmates	
Indicator	2023-24
1. Total prisons	4
2. Prisons covered under programme	4
3. Total inmates admitted	2,230
4. Inmates Covered (%)	57
5. Tested for HIV	1,263
5.1. HIV sero-positive (%)	0.16
5.2. On ART (%)	100.00

I. Link Worker Scheme	
Indicator	2023-24
Districts covered under scheme	-
Vulnerable population covered	-
3. Tested for HIV	-
3.1. HIV sero-positive (%)	-
3.2. Linked to ART (%)	-

8. Presumptive treatment

J. Opioid Substitution Therapy	
Indicator	2023-24
1. OST Centres	-
1.1. OSTC in Public Health Settings	-
1.2. OSTC in NGO Settings	-
1.3. No. of Satellite OST Centres	-
2. IDU on OST	-
E Fault dataction of UIV infacted as	anla

A. HIV counselling and testing services (HCTS)

Indicator	2023-24
1. HCTC confirmatory facilities	12
2. Sampoorna Suraksha Kendras	-

B. HIV testing among vulnerable population (excluding pregnant women)

Indicator	2023-24				
	Male	Female	TG	Total	
1. Tested for HIV	1,31,531	96,483	375	2,28,389	
1.1 HIV Positives	128	68	-	196	
1.2 HIV sero -positivity (%)	0.10	0.07	0.00	0.09	
Spouse/sexual partner of HIV positive people tested	44	56	-	>=95	
2.1 HIV Positives	14	14	-	28	
2.2 HIV sero -positivity (%)	32	25	-	28.00	
3. No. of contacts with 'at- risk' population through 'Sampoorna Suraksha'	-	-	-	-	

6. Initiation and retention on ART of HIV infected people

A. Treatment facilities

Indicator	2023-24
1. ART Centres	1
2.Centre of Excellence	
2.1. Centre of Excellence (Adult)	-
2.2 Centre of Excellent (Paediatric)	-
3. Link ART Centres	1
4. Care Support Centres	1

B. Treatment uptake

Indicator	2023-24				
	Male	Female	TG	Total	
HIV positive cases diagnosed (At ICTC)	128	69	-	197	
New PLHIV Registered at ART center	67	26	-	93	
2.1 Initiated on ART	66	26	-	92	
3. PLHIV alive and on ART	711	697	5	1,413	
4. 12 months retention on ART (%)				>=95	
5. Lost to follow-up cases	28	18	-	46	

7. Viral Suppression and laboratories	
A. Laboratory facilities and service uptake	
Indicator	2023-2
Viral load laboratories (programme and non- programme labs)	
1.1 Accredited Viral load laboratories (out of 64 VL labs)	
2. Viral load tests conducted	1,13
2.1. Virally suppressed (%)	>=9
3. National reference laboratories (NRL)	
3.1 Accredited NRL	
4. State reference laboratories (SRL)	
4.1 Accredited SRL	
5. CD4 machines	
5.1 CD4 tests conducted	90
6. External Quality Assurance of ICTC	
6.1 Average Participation (%)	>=9
6.2. Average Discordance (%)	0.0
7. "Certificate of Excellence" by NACO	
7.1 No. of ICTCs received "Certificate of Excellence"	1
8. Elimination of mother to child trans HIV & SyphilisA. HIV	mission of
Indicator	2023-2
Estimated pregnant women (PW)	25,12
2. HIV testing among PW	28,71
3. HIV sero-positivity (%) among tested	0.0
4. HIV Positive PW (old + new detections)	
4.1 On life-long ART	
5. Live births among HIV positive PW	
5.1 Babies given ARV Prophylaxis (%)	>=9
6. Babies tested HIV (6 week- 6 month)	
6.1 Babies confirmed HIV Positive (6 week- 6 month)	
7. HIV testing among exposed babies at 18 months	
7.1 HIV exposed babies tested at 18 months	1
7.2 Babies confirmed HIV positive at 18 months	
8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months)	
9. HIV positive babies initiated on ART	
B. Syphilis	
Indicator	2023-2
1. Syphilis testing among PW	33,82
2.Sero-positivity (%) among tested	0.0
3. Put on treatment	
9. Elimination of HIV/AIDS related Stigma and Discrimination	
Indicator	2023-2
State rules notified for HIV/AIDS Prevention and Control Act (2017)	Ye


2. State designated/appointed ombudsman

Yes

10. HIV-TB Co-m	orbidities							
A. HRG and Bridge	e Population							
Indicator				202	3-24			
	Quarter	FSW	MSM	IDU	TG	Migrants	Truckers	Total
	Quarter 1	2,736	2,668	-	203	2,096	-	7,703
C L(TD	Quarter 2	2,863	2,825	-	234	2,579	-	8,501
Screened for TB	Quarter 3	2,994	2,940	-	234	3,046	-	9,214
	Quarter 4	3,085	3,044	-	245	4,378	-	10,752
	Quarter 1	37	31	-	1	-	-	69
T . I(TD	Quarter 2	22	6	-	-	1	-	29
Tested for TB	Quarter 3	22	7	-	1	1	-	30
	Quarter 4	14	10	-	1	-	-	25
	Quarter 1	1	-	-	-	-	-	1
D: :: TD	Quarter 2	-	-	-	-	-	-	
Diagnosed with TB	Quarter 3	1	1	-	-	-	-	2
	Quarter 4	-	-	-	-	-	-	
	Quarter 1	1	-	-	-	-	-	1
Initiated on TB	Quarter 2	-	-	-	-	-	-	
treatment	Quarter 3	1	1	-	-	-	-	2
	Quarter 4	-	-	-	-	-	-	

B. HIV-TB Coinfected at ART Centre 2023-24 Indicator Co-infected enrolled at PLHIV with presumptive TB PLHIV PLHIV PLHIV PLHIV Co-infected initiated on ART PLHIV tested for TB diagnosed with TB initiated on IPT Moths attending underwent ART Centre 4S screening ARTC Apr - 23 1,219 1,199 7 32 32 1,195 48 48 3 1,131 6 May - 23 Jun - 23 1,163 1,101 44 44 6 5 Jul - 23 1,195 1,114 43 43 3 4 1,178 1,060 42 42 6 Aug - 23 2 Sep - 23 1,193 1,067 45 45 27 Oct - 23 1,176 1,093 44 44 1 23 1 1,203 41 23 1,055 41 Nov - 23 2 7 Dec - 23 1,199 1,148 42 42 Jan - 24 1,204 1,121 44 44 1 3 5 8 Feb - 24 1,164 1,084 44 44 Mar - 24 1,144 1,034 39 39 2 5 April 2023-27 March 2024

	State/UT	Puducherry
CI	Rank	3
SI. Vo.	Maximum Marks Obtained Marks	168 139 (83%)
1	First 95 (G:≥95%, Y: 80-94%, R:<80%)	139 (63%)
2	Second 95 (G:≥95%, Y: 80-94%, R:<80%)	81
3	Third 95 (G:≥95%, Y: 80-94%, R:<80%)	>=95
4	Average Frequency of Social Media updates (G: ≥ 45, Y:40- 44, R:<40 indigenous posts) of Q1, Q2, Q3 & Q4	85
5	Status of AEP integration in state school curriculum (G:Yes, R:No)	Yes
6	Status of SCA (G: At least one meeting held since 2020, R: other than G)	Meeting held in 2022
7	Status of State Rules (G: Notified, R: Not notified)	Notified
8	Status of Ombudsman (G: Appointed, R: Not appointed)	Appointed
9	TI/LWS onboarding (G: ≥95%, Y: 90-<95%, R:<90%)	100
10	OST onboarding (G: ≥95%, Y: 90-<95%, R:<90%)	NA
11	Coverage of HRG against estimates (G: ≥90%, Y: 80-<90%, R:<80%)	125
12	HIV testing among HRG (G: ≥95%, Y: 90-<95%, R:<90%)	85
13	HIV testing among prisoners (G: ≥50%, Y: 40% to <50%, R:<40%)	64
14	Clinic visit of HRGs at TI-Clinics (G: ≥90%, Y: 75-89%, R:<75%)	80
15	Percentage of HRGs screened for Syphilis (G: ≥90%, Y: 75-89%, R:<75%)	86
16	IDU on OST (G: ≥50%, Y: 30% to <50%, R:<30%)	NA 100
17	Percentage of fund released to TI (G: ≥50%, Y: 45-<50%, R:<45%) Percentage of TIs trained by Kehmata Kondra (KK) against the AAR targets (G: >75%, X: 70.	100
18	Percentage of TIs trained by Kshmata Kendra (KK) against the AAP targets (G: ≥75%, Y: 70-<75%, R:<70%)	75
19	HIV testing against Target-at risk % (G: ≥95%, Y: 80-94%, R:<80%)	632
20	HIV testing against target-PW (G: ≥95%, Y: 80-94%, R:<80%)	114
21 22	Percentage of pregnant women screened for Syphilis (G: ≥95%, Y: 80-94%, R:<80%) Treatment provided to Syphilis reactive pregnant women (G: ≥95%, Y: 80-94%, R:<80%)	135 100
23	1 1 2	29
24	Index testing among newly detected HIV positive clients (G: ≥95%, Y: 80-94%, R:<80%) Percentage of 6 weeks - <2 months EID testing against live birth (G: ≥95%, Y: 80-94%, R:<80%)	100
25	Clients managed at DSRC against the target (G: ≥90%, Y: 75-89%, R:<75%)	191
26	STI attendees screened for HIV (G: >75%, Y: 50-75%, R:<50%)	90
27	STI attendees screened for Syphilis (G: >75%, Y: 50-75%, R:<50%)	90
28	% of pregnant women who initiated ART (G: ≥95%, Y: 80-94%, R:<80%)	100
29	Proportion of LFU-PLHIV, out of those initiated on ART in FY 2023-24 (G:<2%, Y: 2 to 5%, R:>5%)	2
30	Proportion of PLHIV initiated on ART, out of those registered in FY 2023-24 (G:>98%, Y: 95 to 98%, R:<95%)	99
31	Proportion of reported died, out of those initiated on ART in FY 202324 (G:<2%, Y: 2 to 5 %, R:>5 %)	11
32	% of SRL accredited (G:100%, Y: 80-99%, R:<80%)	100
33	% participation of ICTCs in re-testing (G: ≥95%, Y: 85-94, R:<85%)	100
34	Number of abstracts selected from studies conducted in FY21-22	4
35	(G:100%, Y: >25 to <100%, R: ≤25%) Number of ongoing studies from FY22-23 (G:100%, Y: >25 to <100%,	4
86	R: ≤25%) Submission of research proposals from FY23-24 to NACO (G:100%,	2
37	Y: >25 to <100%, R: ≤25%) Secondary Data Analysis by SACS (G:2, Y: 1, R: No Secondary Data Analysis Plan Submitted)	2
38	Expenditure with respect to funds released during FY 2022-23 (G: ≥90%, Y: 85 to <90%, R: <85%)	126
39	Submission of Provisional Utilization Certificate (UC) in GFR 12A for the FY 2022-23 (G:by 30-Apr-2023, Y:by 31-May-2023, R: after 31-May-2023)	15-05-2023
10	Submission of audited UC in GFR 12A for the FY 2022-23 (G : by 30Jun-2023, Y : by 30-Sep-2023, R : after 30-Sep-2023)	27-01-2024
11	Submission of EC/ GB ratification for approval of Expenditure incurred during FY 2021-22 (G: by 30-Jun-2022, Y: by 30-Sept-2022, R: after 30-Sept-2022)	
12	Timely Submission of CST-SCM Report (G:>95%, Y: 80-95%, R:<80%)	93
13	Format Adherence to CST-SCM Report (G:>95%, Y: 80-95%, R:<80%)	94
14	Timely Submission of BSD & STI-SCM Report (G: ≥90%, Y: 75- <90%, R:<75%)	92
	Green=3 Marks Yellow=2Marks Red=1 Mark No	Colour=Not Applicable
Wei	ght points Indicator Sl. No.	* *
	3 1, 23, 29	
	2 2, 3, 9, 10, 22, 30, 34, 42, 44	
		2, 33, 35, 36, 37, 38, 39, 40,





PUNJAB

1. Status of HIV/AIDS Epidemic					
A. Epidemic Estimates (2023)					
Indicator	Male	Female	Total		
1. IPR	-	-	8.60		
2. IMR	-	-	6.54		
3. Adult (15-49 yrs) HIV Prevalence (%)	0.47	0.35	0.42		
4. Estimated people living with HIV	63,102	42,688	1,05,790		
5. ART coverage (%)	73.31	47.25	62.98		
6. Estimated children living with HIV	1,033	891	1,924		
7. Annual new HIV infections	5,402	3,701	9,103		
8. Annual AIDS-related deaths (ARD)	179	387	566		
9. Change in annual new HIV infections since 2010 (%)	109.38	128.32	116.69		
10. Change in annual ARD since 2010(%)	-34.43	204.72	41.50		
11. EMTCT need	_	1.027	1.027		

B. High risk population size (2020-22), safe practices (2021) and prevalence (2021/2023) Condom Use HIV Preva-New Nee-dle/ Estimates Size Population Group (%) Syringe use (%) lence (%) 97.30 1. Female Sex Workers 27,304 40.00 3.38 95.40 2. Men who have sex with men 8,045 11.62 3. Injecting Drug Users 45,098 93.00 19.57 4. Hijra/Transgender People 1,316 5. Migrants 1,31,850 48.10 3.01 6. Truckers 86.20 2.33 89,182 35.70 59.50 9.25 7. Prison inmates

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)					
Indicator	Male	Female	Total		
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)	37.50	20.60	-		
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	33.30	17.50	-		
3. Adults willing to care for a relative with HIV/AIDS in own home (%)	79.80	77.20	-		
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	67.50	66.40	-		
5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)	5.90	0.30	-		
5.1 Condom use during last higher-risk intercourse (%)	56.90	30.10	-		
6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)	8.52	0.58	-		
6.1 Condom use during last higher-risk intercourse (%)	61.36	33.33	-		

2. Progress on 95-95-95 (2023-24)					
63 69 69 67 72 76	83 80 77 83 86 83	83 84 79 90 ≥95			
PLHIV who know their HIV status and are on ART (%) PLHIV who know their HIV status and are on ART (%) 2018-19 2019-20 2020-21 2021-22 2022-23 2023-24					

Indicators	Male	Female	Total*
1. Estimated PLHIV size (2023)	63,102	42,688	1,05,790
2. PLHIV who know their HIV Status	58,085	22,464	80,795
3. PLHIV who know their HIV status and are on ART	46,728	20,427	67,351
4. PLHIV who are on ART and tested for their viral load	13,460	8,787	22,297
4.1 PLHIV who are virally suppressed	12,942	8,540	21,528

^{*} Including of H/TG PLHIV

3. Prevention of new HIV infections among general population

A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2023-24
Schools with operational Adolescent Education Program (AEP)	6,337
2. Colleges with operational Red Ribbon Clubs (RRC)	700
3. Persons trained under mainstreaming	8,277
4. No. of calls received at helpline	-

B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management

Indicator	2023-24						
NACO Supported Designated STI/		31					
RTI Clinics (DSRC)	Male	Female	TG	Total			
2. Total STI/RTI Clients managed				3,50,975			
3. RPR Tests conducted	83,662	91,640	296	1,75,598			
4. Syphilis seropositivity (%)	1.39	0.35	4.05	0.85			

4. Prevention of new HIV infections among high-risk group and bridge population

A. Targeted Intervention (TI) Projects and Opioid Substitution Therapy (OST)

Indicator	2023-24
1. Targeted Intervention (TI) Projects	72
2. OST centres	35

B. Female Sex Workers

Indicator	2023-24
1. Estimated size	27,303
2. Coverage (%)	>=95
3. Condoms distributed	18,12,408
4. Tested for HIV (April 2022-September 2022)	13,324
4.1. HIV sero-positive (%)	0.32
4.1.1. Linked to ART	37
5. Tested for HIV (October 2022 -March 2023)	17,336
5.1. HIV sero-positive (%)	0.22
5.1.1. Linked to ART	28
6. Clinic Visits	60,076
7. STI/RTI treated	894
8. Presumptive treatment	2,404

Indicatort 1. Estimated size	2023-24 8,044
1. Estimated size	· · · · · · · · · · · · · · · · · · ·
2. Coverage (%)	78
3. Condoms distributed	5,01,407
4. Tested for HIV (April 2022-September 2022)	4,176
4.1. HIV sero-positive (%)	1.03
4.1.1. Linked to ART	35
5. Tested for HIV (October 2022 -March 2023)	5,362
5.1. HIV sero-positive (%)	0.69
5.1.1. Linked to ART	36
6. Clinic Visits	19,156
7. STI/RTI treated	209
8. Presumptive treatment	855

D. Injecting Drug Users	
Indicator	2023-24
1. Estimated size	45,098
2. Coverage (%)	70
3. Needles distributed	40,85,974
4. Syringes distributed	30,69,470
5. On OST	10,305
6. Tested for HIV (April 2022 -September 2022)	16,953
6.1. HIV sero-positive (%)	1.82
6.1.1 Linked to ART	255
7. Tested for HIV (October 2022 -March 2023)	23,419
7.1. HIV sero-positive (%)	1.61
7.1.1. Linked to ART	298

E. Hijra/Transgender person	
Indicator	2023-24
1. Estimated size	1,315
2. Coverage (%)	>=95
3. Condoms distributed	1,23,796
4. Tested for HIV (April 2022-September 2022)	1,077
4.1. HIV sero-positive (%)	0.46
4.1.1. Linked to ART	4
5. Tested for HIV (October 2022 -March 2023)	1,196
5.1. HIV sero-positive (%)	0.25
5.1.1. Linked to ART	3
6. Clinic Visits	4,783
7. STI/RTI treated	17
8. Presumptive treatment	207

F. Migrants	
Indicator	2023-24
1. Estimated size	1,31,850
2. Coverage (%)	71
3. Tested for HIV	9,255
3.1. HIV sero-positive (%)	0.10
3.2. Linked to ART	6

G. Truckers	
Indicator	2023-24
1. Estimated size	-
2. Coverage (%)	0
3. Tested for HIV	4,164
3.1. HIV sero-positive (%)	0.14
3.2. On ART	5

H. Prison Inmates	
Indicator	2023-24
1. Total prisons	26
2. Prisons covered under programme	25
3. Total inmates admitted	89,182
4. Inmates Covered (%)	72
5. Tested for HIV	64,324
5.1. HIV sero-positive (%)	2.63
5.2. On ART (%)	>=95

I. Link Worker Scheme	
Indicator	2023-24
Districts covered under scheme	8
Vulnerable population covered	20,989
3. Tested for HIV	8,927
3.1. HIV sero-positive (%)	2.77
3.2. Linked to ART (%)	93.12

J. Opioid Substitution Therapy	
Indicator	2023-24
1. OST Centres	35
1.1. OSTC in Public Health Settings	26
1.2. OSTC in NGO Settings	9
1.3. No. of Satellite OST Centres	8
2. IDU on OST	10,305

A. HIV counselling and testing services (HCTS)

3 · · · · · · 3 · · · · · · · · · · · · · · · · · · ·	
Indicator	2023-24
1. HCTC confirmatory facilities	115
2. Sampoorna Suraksha Kendras	6

B. HIV testing among vulnerable population (excluding pregnant women)

Indicator	2023-24			
	Male	Female	TG	Total
1. Tested for HIV	6,07,473	3,91,463	1,767	10,00,703
1.1 HIV Positives	11,350	1,756	36	13,142
1.2 HIV sero -positivity (%)	1.87	0.45	2.04	1.31
Spouse/sexual partner of HIV positive people tested	9,136	3,565	25	12,726
2.1 HIV Positives	1,445	824	15	2,284
2.2 HIV sero -positivity (%)	16	23	60	17.95
No. of contacts with 'at- risk' population through 'Sampoorna Suraksha'	-	-	-	4,461

6. Initiation and retention on ART of HIV infected people

A. Treatment facilities

Indicator	2023-24
1. ART Centres	24
2.Centre of Excellence	
2.1. Centre of Excellence (Adult)	-
2.2 Centre of Excellent (Paediatric)	-
3. Link ART Centres	16
4. Care Support Centres	8

B. Treatment uptake

Indicator	2023-24				
	Male	Female	TG	Total	
HIV positive cases diagnosed (At ICTC)	11,350	2,408	36	13,794	
New PLHIV Registered at ART center	10,793	2,309	21	13,123	
2.1 Initiated on ART	10,666	2,359	21	13,046	
3. PLHIV alive and on ART	46,728	20,427	196	67,351	
4. 12 months retention on ART (%)				89.8	
5. Lost to follow-up cases	8,492	1,605	21	10,118	

7. Viral Suppression and laboratories	
A. Laboratory facilities and service uptake	
Indicator	2023-2
Viral load laboratories (programme and non- programme labs)	
1.1 Accredited Viral load laboratories (out of 64 VL labs)	
2. Viral load tests conducted	33,70
2.1. Virally suppressed (%)	93.
3. National reference laboratories (NRL)	
3.1 Accredited NRL	
4. State reference laboratories (SRL)	
4.1 Accredited SRL	
5. CD4 machines	1
5.1 CD4 tests conducted	25,55
6. External Quality Assurance of ICTC	
6.1 Average Participation (%)	9
6.2. Average Discordance (%)	0.0
7. "Certificate of Excellence" by NACO	
7.1 No. of ICTCs received "Certificate of Excellence"	
 Elimination of mother to child trans HIV & Syphilis HIV 	mission of
Indicator	2023-2
Estimated pregnant women (PW)	4,91,80
2. HIV testing among PW	3,99,25
3. HIV sero-positivity (%) among tested	0.1
4. HIV Positive PW (old + new detections)	1,07
4.1 On life-long ART	96
5. Live births among HIV positive PW	74
5.1 Babies given ARV Prophylaxis (%)	>=9
6. Babies tested HIV (6 week- 6 month)	86
6.1 Babies confirmed HIV Positive (6 week- 6 month)	
7. HIV testing among exposed babies at 18 months	
7.1 HIV exposed babies tested at 18 months	52
7.2 Babies confirmed HIV positive at 18 months	
8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months)	1
9. HIV positive babies initiated on ART	1
B. Syphilis	
Indicator	2023-2
Syphilis testing among PW	4,71,54
2.Sero-positivity (%) among tested	0.0
3. Put on treatment	23
Elimination of HIV/AIDS related Stigma and Discrimination	
Indicator	2023-2
State rules notified for HIV/AIDS Prevention and Control Act (2017)	Ye
• •	

2. State designated/appointed ombudsman

Yes

10. HIV-TB Co-morbidities											
A. HRG and Bridge Population											
Indicator	2023-24										
	Quarter	FSW	MSM	IDU	TG	Migrants	Truckers	Total			
Screened for TB	Quarter 1	13,650	4,207	19,709	1,118	4,945	3,066	46,695			
	Quarter 2	13,350	4,565	20,921	1,177	4,346	3,664	48,023			
	Quarter 3	15,125	4,906	22,980	1,224	6,082	3,779	54,096			
	Quarter 4	17,892	5,421	26,430	1,266	6,668	4,456	62,133			
Tested for TB	Quarter 1	33	23	47	4	4	1	112			
	Quarter 2	35	33	287	5	5	1	366			
	Quarter 3	29	32	740	11	7	2	821			
	Quarter 4	32	34	540	6	6	1	619			
Diagnosed with TB	Quarter 1	1	-	7	-	-	-	8			
	Quarter 2	-	1	14	1	5	-	21			
	Quarter 3	-	-	8	-	3	-	11			
	Quarter 4	-	-	11	-	3	-	14			
Initiated on TB treatment	Quarter 1	1	-	7	-	-	-	8			
	Quarter 2	-	1	14	1	3	-	19			
	Quarter 3	-	-	7	-	3	-	10			
	Quarter 4	-	-	12	-	3	-	15			

B. HIV-TB Coinfected at ART Centre 2023-24 Indicator Co-infected enrolled at PLHIV with presumptive TB PLHIV PLHIV PLHIV PLHIV Co-infected initiated on ART PLHIV tested for TB diagnosed with TB initiated on IPT Moths attending underwent ART Centre 4S screening ARTC 32,501 32,501 489 Apr - 23 415 415 55 682 98 37,494 37,494 484 644 May - 23 Jun - 23 33,284 33,284 563 563 100 683 Jul - 23 30,850 30,850 528 528 95 934 488 37,061 37,061 488 67 961 Aug - 23 Sep - 23 40,817 40,817 833 830 74 865 42,273 42,273 802 79 534 Oct - 23 792 56 44,543 44,543 623 363 Nov - 23 613 Dec - 23 44,543 44,543 623 613 56 363 Jan - 24 47,245 47,245 1,010 630 1,069 66 1,431 89 Feb - 24 46,011 46,011 1,329 902 Mar - 24 46,317 46,317 1,618 1,618 108 843 April 2023-1,276 1,224 March 2024

	State/UT	Punjab
*1	Rank	7
SI. Io.	Maximum Marks	177
	Obtained Marks	135 (76%)
1	First 95 (G:≥95%, Y: 80-94%, R:<80%)	76
2	Second 95 (G:≥95%, Y: 80-94%, R:<80%)	83
3	Third 95 (G:≥95%, Y: 80-94%, R:<80%)	>=95
4	Average Frequency of Social Media updates (G: ≥ 45, Y:40- 44, R:<40 indigenous po Q1, Q2, Q3 & Q4	osts) of 101
5	Status of AEP integration in state school curriculum (G:Yes, R:No)	Yes
6	Status of SCA (G: At least one meeting held since 2020, R: other than G)	No Meeting held
7	Status of State Rules (G: Notified, R: Not notified)	Notified
8	Status of Ombudsman (G: Appointed, R: Not appointed)	Appointed
9	TI/LWS onboarding (G: ≥95%, Y: 90-<95%, R:<90%)	Appointed 99
10		80
	OST onboarding (G: ≥95%, Y: 90-<95%, R:<90%)	
11	Coverage of HRG against estimates (G: ≥90%, Y: 80-<90%, R:<80%)	82
12	HIV testing among HRG (G: ≥95%, Y: 90-<95%, R:<90%)	76
13	HIV testing among prisoners (G: ≥50%, Y: 40% to <50%, R:<40%)	61
4	Clinic visit of HRGs at TI-Clinics (G: ≥90%, Y: 75-89%, R:<75%)	80
5	Percentage of HRGs screened for Syphilis (G: ≥90%, Y: 75-89%, R:<75%)	68
6	IDU on OST (G: ≥50%, Y: 30% to <50%, R:<30%)	66
17	Percentage of fund released to TI (G: ≥50%, Y: 45-<50%, R:<45%)	81
8	Percentage of TIs trained by Kshmata Kendra (KK) against the AAP targets (G: ≥75%	, Y: 70-
	<75%, R:<70%)	
19	HIV testing against Target-at risk % (G: ≥95%, Y: 80-94%, R:<80%)	175
20	HIV testing against target-PW (G: ≥95%, Y: 80-94%, R:<80%)	81
21	Percentage of pregnant women screened for Syphilis (G: ≥95%, Y: 80-94%, R:<80%)	96
22	Treatment provided to Syphilis reactive pregnant women (G: ≥95%, Y: 80-94%, R:<8	30%) 99
23	Index testing among newly detected HIV positive clients (G: ≥95%, Y: 80-94%, R:<8	
24	Percentage of 6 weeks - <2 months EID testing against live birth (G: ≥95%, Y: 80-94 R:<80%)	
25	Clients managed at DSRC against the target (G: ≥90%, Y: 75-89%, R:<75%)	93
26	STI attendees screened for HIV (G: >75%, Y: 50-75%, R:<50%)	100
27	STI attendees screened for Syphilis (G: >75%, Y: 50-75%, R:<50%)	82
28	% of pregnant women who initiated ART (G: ≥95%, Y: 80-94%, R:<80%)	89
29	Proportion of LFU-PLHIV, out of those initiated on ART in FY 2023-24 (G:<2%, Y: 2 to R:>5%)	5 5%,
30	Proportion of PLHIV initiated on ART, out of those registered in FY 2023-24 (G:>98% to 98%, R:<95%)	5, Y: 95
31	Proportion of reported died, out of those initiated on ART in FY 202324 (G:<2%, Y: 7 R:>5 %)	2 to 5 %,
32	% of SRL accredited (G:100%, Y: 80-99%, R:<80%)	100
33	% participation of ICTCs in re-testing (G: ≥95%, Y: 85-94, R:<85%)	92
34	Number of abstracts selected from studies conducted in FY21-22 (G:100%, Y: >25 to	
-	R: ≤25%)	
35	Number of ongoing studies from FY22-23 (G:100%, Y: >25 to <100%,	3
	R: ≤25%)	
36	Submission of research proposals from FY23-24 to NACO (G:100%,	2
	Y: >25 to <100%, R: ≤25%)	
37	Secondary Data Analysis by SACS (G:2, Y: 1, R: No Secondary Data Analysis Plan Sul	omitted) 2
38	Expenditure with respect to funds released during FY 2022-23 (G:	95
	≥90%, Y: 85 to <90%, R: <85%)	75
39	Submission of Provisional Utilization Certificate (UC) in GFR 12A for the FY 2022-23 (30-Apr-2023, Y: by 31-May-2023, R: after 31-May-2023)	G : by 28-04-2023
40	Submission of audited UC in GFR 12A for the FY 2022-23 (G: by 30Jun-2023, Y: by	30-Sep- 28-07-2023
	2023, R: after 30-Sep-2023)	20-07-2025
11	Submission of EC/ GB ratification for approval of Expenditure incurred during FY 202	21-22 29-12-2022
	(G: by 30-Jun-2022, Y: by 30-Sept-2022, R: after 30-Sept-2022)	
2	Timely Submission of CST-SCM Report (G:>95%, Y: 80-95%, R:<80%)	94
3	Format Adherence to CST-SCM Report (G:>95%, Y: 80-95%, R:<80%)	91
14	Timely Submission of BSD & STI-SCM Report (G: ≥90%, Y: 75- <90%, R:<75%)	75
	Green=3 Marks Yellow=2Marks Red=1 Mark	No Colour=Not Applicable
۸/ ۰		140 Coloui - Not Applicable
vvei	ght points Indicator SI. No.	
	3 1, 23, 29	
	2 2 2 2 40 22 20 24 42 44	
	2 2, 3, 9, 10, 22, 30, 34, 42, 44	





RAJASTHAN

1. Status of HIV/AIDS Epidemic			
A. Epidemic Estimates (2023)			
Indicator	Male	Female	Total
1. IPR	-	-	4.07
2. IMR	-	-	2.80
3. Adult (15-49 yrs) HIV Prevalence (%)	0.15	0.10	0.12
4. Estimated people living with HIV	49,317	33,138	82,455
5. ART coverage (%)	70.22	88.55	77.72
6. Estimated children living with HIV	1,349	1,190	2,539
7. Annual new HIV infections	2,032	1,323	3,355
8. Annual AIDS-related deaths (ARD)	318	123	441
9. Change in annual new HIV infections since 2010 (%)	-26.08	-17.88	-23.07
10. Change in annual ARD since 2010(%)	-74.58	-76.70	-75.15
11. EMTCT need	-	992	992

B. High risk population size (2020-22), safe practices (2021) and prevalence (2021/2023)				
Population Group	Estimates Size	Condom Use (%)	New Nee-dle/ Syringe use (%)	HIV Preva- lence (%)
1. Female Sex Workers	21,034	99.80	-	2.75
2. Men who have sex with men	7,351	80.00	-	6.40
3. Injecting Drug Users	3,024	ı	-	-
4. Hijra/Transgender People	2,126	-	-	3.60
5. Migrants	1,10,000	20.70	70.00	0.39
6. Truckers	38,340	67.70	-	0.00
7. Prison inmates	1,42,473	59.50	67.30	1.58

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)				
Indicator	Male	Female	Total	
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)	36.00	26.80	-	
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	34.30	27.60	-	
3. Adults willing to care for a relative with HIV/AIDS in own home (%)	76.00	76.00	-	
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	78.20	72.40	-	
5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)	6.40	0.90	-	
5.1 Condom use during last higher-risk intercourse (%)	73.80	74.60	-	
6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)	11.59	2.07	-	
6.1 Condom use during last higher-risk intercourse (%)	74.23	76.47	-	

2. Progress on 95-95-95 (2023-24)					
71 75 76 77 79 83	87 86 84 86 89 91	82 83 85 91 59			
PLHIV who know their HIV status (%)	PLHIV who know their HIV status and are on ART (%)	PLHIV who are on ART and virally suppressed (%)			
2018-19 2019-20	■ 2020-21 ■ 2021-22	2022-23 2023-24			

Indicators	Male	Female	Total*
1. Estimated PLHIV size (2023)	49,317	33,138	82,455
2. PLHIV who know their HIV Status	37,112	31,136	68,368
3. PLHIV who know their HIV status and are on ART	33,639	28,455	62,197
4. PLHIV who are on ART and tested for their viral load	20,156	17,316	37,525
4.1 PLHIV who are virally suppressed	19,183	16,540	35,772

^{*} Including of H/TG PLHIV

A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2023-24
Schools with operational Adolescent Education Program (AEP)	500
2. Colleges with operational Red Ribbon Clubs (RRC)	755
3. Persons trained under mainstreaming	8,929
4. No. of calls received at helpline	-

B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management

Indicator	2023-24			
NACO Supported Designated STI/		5	3	
RTI Clinics (DSRC)	Male	Female	TG	Total
2. Total STI/RTI Clients managed				3,77,412
3. RPR Tests conducted	59,883	1,41,040	150	2,01,073
4. Syphilis seropositivity (%)	1.64	0.32	4.00	0.72

4. Prevention of new HIV infections among high-risk group and bridge population

A. Targeted Intervention (TI) Projects and Opioid Substitution Therapy (OST)

Indicator	2023-24
1. Targeted Intervention (TI) Projects	44
2. OST centres (Excluding Satellite OST centres)	3

B. Female Sex Workers

Indicator	2023-24
1. Estimated size	21,033
2. Coverage (%)	>=95
3. Condoms distributed	28,62,209
4. Tested for HIV (April 2022-September 2022)	13,858
4.1. HIV sero-positive (%)	0.06
4.1.1. Linked to ART	10
5. Tested for HIV (October 2022 -March 2023)	15,685
5.1. HIV sero-positive (%)	0.06
5.1.1. Linked to ART	7
6. Clinic Visits	64,479
7. STI/RTI treated	1,545
8. Presumptive treatment	3,177

C. Men who have Sex with Men Indicatort

Indicatort	2023-24
1. Estimated size	7,350
2. Coverage (%)	>=95
3. Condoms distributed	8,18,384
4. Tested for HIV (April 2022-September 2022)	4,954
4.1. HIV sero-positive (%)	0.00
4.1.1. Linked to ART	23
5. Tested for HIV (October 2022 -March 2023)	5,733
5.1. HIV sero-positive (%)	0.00
5.1.1. Linked to ART	26
6. Clinic Visits	24,302
7. STI/RTI treated	309
8. Presumptive treatment	1,226

D. Injecting Drug Users	
Indicator	2023-24
1. Estimated size	3,023
2. Coverage (%)	82
3. Needles distributed	7,85,658
4. Syringes distributed	5,55,959
5. On OST	342
6. Tested for HIV (April 2022 -September 2022)	1,392
6.1. HIV sero-positive (%)	1.36
6.1.1 Linked to ART	18
7. Tested for HIV (October 2022 -March 2023)	2,082
7.1. HIV sero-positive (%)	0.34
7.1.1 Linked to ART	5

2023-24
2,125
89
1,68,375
1,272
0.00
6
1,423
0.00
2
5,799
59
250

F. Migrants	
Indicator	2023-24
1. Estimated size	1,10,000
2. Coverage (%)	>=95
3. Tested for HIV	19,813
3.1. HIV sero-positive (%)	0.14
3.2. Linked to ART	24

G. Truckers	
Indicator	2023-24
1. Estimated size	38,340
2. Coverage (%)	52
3. Tested for HIV	2,669
3.1. HIV sero-positive (%)	0.07
3.2. On ART	2

H. Prison Inmates	
Indicator	2023-24
1. Total prisons	144
2. Prisons covered under programme	141
3. Total inmates admitted	1,42,473
4. Inmates Covered (%)	91
5. Tested for HIV	1,29,622
5.1. HIV sero-positive (%)	0.27
5.2. On ART (%)	91.50

I. Link Worker Scheme	
Indicator	2023-24
Districts covered under scheme	2
Vulnerable population covered	5,483
3. Tested for HIV	3,218
3.1. HIV sero-positive (%)	0.19
3.2. Linked to ART (%)	>=95

J. Opioid Substitution Therapy	
Indicator	2023-24
1. OST Centres	3
1.1. OSTC in Public Health Settings	3
1.2. OSTC in NGO Settings	-
1.3. No. of Satellite OST Centres	-
2. IDU on OST	342

A. HIV counselling and testing services (HCTS)

7. The counseling and testing services (The	3.3,
Indicator	2023-24
1. HCTC confirmatory facilities	165
2. Sampoorna Suraksha Kendras	15

B. HIV testing among vulnerable population (excluding pregnant women)

Indicator	2023-24			
	Male	Female	TG	Total
1. Tested for HIV	14,05,917	10,55,716	2,301	24,63,934
1.1 HIV Positives	4,775	2,158	23	6,956
1.2 HIV sero -positivity (%)	0.34	0.20	1.00	0.28
Spouse/sexual partner of HIV positive people tested	2,110	2,044	8	4,162
2.1 HIV Positives	942	939	1	1,882
2.2 HIV sero -positivity (%)	45	46	13	45.22
No. of contacts with 'at- risk' population through 'Sampoorna Suraksha'	-	-	-	5,541

6. Initiation and retention on ART of HIV infected people

A. Treatment facilities

Indicator	2023-24
1. ART Centres	36
2.Centre of Excellence	
2.1. Centre of Excellence (Adult)	-
2.2 Centre of Excellent (Paediatric)	-
3. Link ART Centres	21
4. Care Support Centres	17

B. Treatment uptake

Indicator	2023-24			
	Male	Female	TG	Total
HIV positive cases diagnosed (At ICTC)	4,775	2,612	23	7,410
New PLHIV Registered at ART center	4,505	2,501	21	7,027
2.1 Initiated on ART	4,386	2,456	20	6,862
3. PLHIV alive and on ART	33,639	28,455	103	62,197
4. 12 months retention on ART (%)				93.2
5. Lost to follow-up cases	2,130	1,451	12	3,593

A. Laboratory facilities and service uptake Indicator	
Indicator	2023-2
1. Viral load laboratories (programme and non- programme labs)	
1.1 Accredited Viral load laboratories (out of 64 VL labs)	
2. Viral load tests conducted	48,31
2.1. Virally suppressed (%)	92
3. National reference laboratories (NRL)	
3.1 Accredited NRL	
4. State reference laboratories (SRL)	
4.1 Accredited SRL	
5. CD4 machines	2
5.1 CD4 tests conducted	34,69
6. External Quality Assurance of ICTC	
6.1 Average Participation (%)	8
6.2. Average Discordance (%)	0.0
7. "Certificate of Excellence" by NACO	
7.1 No. of ICTCs received "Certificate of Excellence"	
8. Elimination of mother to child trans HIV & Syphilis	mission of
A. HIV	
Indicator	2023-2
Estimated pregnant women (PW)	20,88,49
2. HIV testing among PW	17,83,14
3. HIV sero-positivity (%) among tested	0.0
4. HIV Positive PW (old + new detections)	91
4.1 On life-long ART	88
5. Live births among HIV positive PW	76
5.1 Babies given ARV Prophylaxis (%)	>=9
6. Babies tested HIV (6 week- 6 month)	72
6.1 Babies confirmed HIV Positive (6 week- 6 month)	
7. HIV testing among exposed babies at 18 months	
7. HIV testing among exposed babies at 18 months 7.1 HIV exposed babies tested at 18 months	53
7.1 HIV exposed babies tested at 18 months	2
7.1 HIV exposed babies tested at 18 months 7.2 Babies confirmed HIV positive at 18 months 8. Total Babies Identified HIV Positive (6 weeks to	2
7.1 HIV exposed babies tested at 18 months 7.2 Babies confirmed HIV positive at 18 months 8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months)	2
7.1 HIV exposed babies tested at 18 months 7.2 Babies confirmed HIV positive at 18 months 8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months) 9. HIV positive babies initiated on ART	2 2
7.1 HIV exposed babies tested at 18 months 7.2 Babies confirmed HIV positive at 18 months 8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months) 9. HIV positive babies initiated on ART B. Syphilis	2023-2
7.1 HIV exposed babies tested at 18 months 7.2 Babies confirmed HIV positive at 18 months 8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months) 9. HIV positive babies initiated on ART B. Syphilis Indicator	2023-2 21,49,56
7.1 HIV exposed babies tested at 18 months 7.2 Babies confirmed HIV positive at 18 months 8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months) 9. HIV positive babies initiated on ART B. Syphilis Indicator 1. Syphilis testing among PW 2. Sero-positivity (%) among tested 3. Put on treatment	2023-2 21,49,56
7.1 HIV exposed babies tested at 18 months 7.2 Babies confirmed HIV positive at 18 months 8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months) 9. HIV positive babies initiated on ART B. Syphilis Indicator 1. Syphilis testing among PW 2. Sero-positivity (%) among tested	2023-2 21,49,56
7.1 HIV exposed babies tested at 18 months 7.2 Babies confirmed HIV positive at 18 months 8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months) 9. HIV positive babies initiated on ART B. Syphilis Indicator 1. Syphilis testing among PW 2.Sero-positivity (%) among tested 3. Put on treatment 9. Elimination of HIV/AIDS related Stigma	2023-2 21,49,56 0.0 87

2. State designated/appointed ombudsman

10. HIV-TB Co-m	orbidities							
A. HRG and Bridge Population								
Indicator	dicator 2023-24							
	Quarter	FSW	MSM	IDU	TG	Migrants	Truckers	Total
	Quarter 1	19,328	7,312	2,406	2,087	27,670	8,384	67,187
Screened for TB	Quarter 2	19,611	7,545	2,842	2,198	29,505	8,373	70,074
Screened for 1B	Quarter 3	20,518	8,113	3,223	2,402	28,940	8,797	71,993
	Quarter 4	20,967	8,760	3,484	2,432	28,416	9,042	73,101
	Quarter 1	25	19	2	-	47	4	97
Tested for TB	Quarter 2	72	32	1	6	121	6	238
lested for IB	Quarter 3	95	39	1	2	109	-	246
	Quarter 4	221	87	-	-	48	2	358
	Quarter 1	-	3	-	-	3	1	7
Diamana desith TD	Quarter 2	1	2	-	1	3	2	9
Diagnosed with TB	Quarter 3	1	2	1	1	1	-	6
	Quarter 4	-	-	-	-	-	-	-
	Quarter 1	-	3	-	-	3	1	7
Initiated on TB	Quarter 2	1	2	-	1	3	-	7
treatment	Quarter 3	1	1	1	1	1	-	5
	Quarter 4	-	-	-	-	-	-	-

B. HIV-TB Coinfected at ART Centre Indicator 2023-24 PLHIV PLHIV PLHIV with PLHIV PLHIV Co-infected enrolled at Co-infected initiated on ART PLHIV tested for TB presumptive TB diagnosed with TB initiated on IPT Moths attending underwent ART Centre 4S screening ARTC 30,245 30,083 Apr - 23 966 807 122 446 34,077 33,849 1,092 615 169 454 May - 23 Jun - 23 31,558 31,402 944 797 144 416 Jul - 23 30,953 30,747 1,009 855 125 469 1,008 847 110 492 Aug - 23 33,448 33,315 Sep - 23 33,760 33,608 919 771 79 496 32,511 32,245 99 488 Oct - 23 1,066 913 1,043 90 482 Nov - 23 37,973 36,651 887 Dec - 23 51,873 51,140 1,179 1,017 107 508 Jan - 24 42,313 42,152 1,079 110 432 929 37,902 Feb - 24 37,840 1,281 1,125 115 702 Mar - 24 35,124 35,034 1,248 1,106 130 510 April 2023-1,442 1,390 March 2024

		State/UT	Rajasthan
		Rank	17
SI.	Maximum Ma		177
lo.	Obtained Ma		127 (72%)
1		5%, Y: 80-94%, R:<80%)	83
2	•	:≥95%, Y: 80-94%, R:<80%)	91
3		95%, Y: 80-94%, R:<80%)	>=95
4	Q1, Q2, Q3 8	uency of Social Media updates (G: \geq 45, Y:40- 44, R:<40 indigenous posts) of ~ 0.4	of 68
5		integration in state school curriculum (G:Yes, R:No)	Yes
6		(G: At least one meeting held since 2020, R: other than G)	Not constituted
7		e Rules (G: Notified, R: Not notified)	Notified
8		oudsman (G: Appointed, R: Not appointed)	Appointed
9		arding (G: ≥95%, Y: 90-<95%, R:<90%)	100
0		ing (G: ≥95%, Y: 90-<95%, R:<90%)	100
1		HRG against estimates (G: ≥90%, Y: 80-<90%, R:<80%)	108
2		mong HRG (G: ≥95%, Y: 90-<95%, R:<90%)	83
3		mong prisoners (G: ≥50%, Y: 40% to <50%, R:<40%)	73
4		HRGs at TI-Clinics (G: ≥90%, Y: 75-89%, R:<75%)	90
5		f HRGs screened for Syphilis (G: ≥90%, Y: 75-89%, R:<75%)	48
6		G: ≥50%, Y: 30% to <50%, R:<30%)	29
7		f fund released to TI (G: ≥50%, Y: 45-<50%, R:<45%)	62
8		f TIs trained by Kshmata Kendra (KK) against the AAP targets (G: ≥75%, Y: 7-	
J	<75%, R:<709		31
9		gainst Target-at risk % (G: ≥95%, Y: 80-94%, R:<80%)	432
0		gainst target-RNS /8 (G. ≥73%, Y. 80-74%, N. <80%)	77
1		f pregnant women screened for Syphilis (G: ≥95%, Y: 80-94%, R:<80%)	86
2			86
		ovided to Syphilis reactive pregnant women (G: ≥95%, Y: 80-94%, R:<80%)	
3		among newly detected HIV positive clients (G: ≥95%, Y: 80-94%, R:<80%)	29
4	Percentage of R:<80%)	f 6 weeks - <2 months EID testing against live birth (G: ≥95%, Y: 80-94%,	100
5	Clients manag	ged at DSRC against the target (G: ≥90%, Y: 75-89%, R:<75%)	66
:6	STI attendees	screened for HIV (G: >75%, Y: 50-75%, R:<50%)	52
7	STI attendees	screened for Syphilis (G: >75%, Y: 50-75%, R:<50%)	76
8	% of pregnan	t women who initiated ART (G: ≥95%, Y: 80-94%, R:<80%)	97
9	Proportion of R:>5%)	LFU-PLHIV, out of those initiated on ART in FY 2023-24 (G:<2%, Y: 2 to 5%,	1
80	Proportion of to 98%, R:<95	PLHIV initiated on ART, out of those registered in FY 2023-24 (G:>98%, Y: 95%)	95 98
1	Proportion of R:>5 %)	reported died, out of those initiated on ART in FY 202324 (G:<2%, Y: 2 to 5	5
2	% of SRL accr	edited (G:100%, Y: 80-99%, R:<80%)	17
3	% participatio	on of ICTCs in re-testing (G: ≥95%, Y: 85-94, R:<85%)	89
4	Number of ab R: ≤25%)	ostracts selected from studies conducted in FY21-22 (G:100%, Y: >25 to <10	3
5	Number of or R: ≤25%)	ngoing studies from FY22-23 (G:100%, Y: >25 to <100%,	4
6		f research proposals from FY23-24 to NACO (G:100%, 10%, R: ≤25%)	2
7	Secondary Da	ata Analysis by SACS (G:2, Y: 1, R: No Secondary Data Analysis Plan Submitte	ed) 1
8		vith respect to funds released during FY 2022-23 (G: o <90%, R: <85%)	135
9		f Provisional Utilization Certificate (UC) in GFR 12A for the FY 2022-23 (G : b Y : by 31-May-2023, R : after)	у 23-06-2023
0		f audited UC in GFR 12A for the FY 2022-23 (G : by 30Jun-2023, Y : by 30-S $_{ m r}$ 30-Sep-2023)	ер-
1		f EC/ GB ratification for approval of Expenditure incurred during FY 2021-22 -2022, Y: by 30-Sept-2022, pt-2022)	20-12-2023
2	Timely Submi	ssion of CST-SCM Report (G:>95%, Y: 80-95%, R:<80%)	85
.3		rence to CST-SCM Report (G:>95%, Y: 80-95%, R:<80%)	96
4		ssion of BSD & STI-SCM Report (G: ≥90%, Y: 75-	67
	Green=3 Mark	·	No Colour=Not Applicable
		Indicator SI. No.	- Cologi – Not Applicable
veig	ht points		
	3	1, 23, 29	
	2	2, 3, 9, 10, 22, 30, 34, 42, 44	
		4, 5, 6, 7, 8, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 24, 25, 26, 27, 28, 3	1, 32, 33, 35, 36, 3/, 38, 39, 40





1. Status of HIV/AIDS Epidemic					
A. Epidemic Estimates (2023)					
Indicator	Male	Female	Total		
1. IPR	-	-	4.63		
2. IMR	-	-	3.11		
3. Adult (15-49 yrs) HIV Prevalence (%)	0.12	0.09	0.11		
4. Estimated people living with HIV	365	239	604		
5. ART coverage (%)	57.71	57.49	57.79		
6. Estimated children living with HIV	15	14	29		
7. Annual new HIV infections	17	11	28		
8. Annual AIDS-related deaths (ARD)	3	2	5		
9. Change in annual new HIV infections since 2010 (%)	-22.73	-21.43	-22.22		
10. Change in annual ARD since 2010(%)	0.00	100.00	25.00		
11. EMTCT need	-	10	10		

B. High risk population size (2020-22), safe practices (2021) and prevalence (2021/2023) Condom Use HIV Preva-New Nee-dle/ Population Group Estimates Size (%) Syringe use (%) lence (%) 93.50 1. Female Sex Workers 732 0.00 2. Men who have sex with men 3. Injecting Drug Users 821 89.40 0.20 4. Hijra/Transgender People 5. Migrants 6. Truckers 7. Prison inmates 816

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)			
Indicator	Male	Female	Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)	18.50	23.90	-
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	15.10	29.30	-
3. Adults willing to care for a relative with HIV/AIDS in own home (%)	64.10	74.40	-
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	67.40	73.10	-
5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)	12.80	3.60	-
5.1 Condom use during last higher-risk intercourse (%)	71.80	52.30	-
6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)	6.93	7.95	-
6.1 Condom use during last higher-risk intercourse (%)	42.86	58.33	-

2. Progress on 95-95-95 (2023-24)				
44 47 49 54 60 65	89 87 84 84 86 87	≥95 ≥95 86 87 89 91		
PLHIV who know their HIV status (%)	PLHIV who know their HIV status and are on ART (%)	PLHIV who are on ART and virally suppressed (%)		
■ 2018-19 ■ 2019-20	2020-21 2021-22	■ 2022-23 ■ 2023-2 4		

Indicators	Male	Female	Total*
1. Estimated PLHIV size (2023)	365	239	604
2. PLHIV who know their HIV Status	239	154	394
3. PLHIV who know their HIV status and are on ART	207	134	342
4. PLHIV who are on ART and tested for their viral load	187	125	313
4.1 PLHIV who are virally suppressed	183	130	314

^{*} Including of H/TG PLHIV

A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2023-24
Schools with operational Adolescent Education Program (AEP)	146
2. Colleges with operational Red Ribbon Clubs (RRC)	125
3. Persons trained under mainstreaming	1,610
4. No. of calls received at helpline	-

B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management

Indicator	2023-24				
NACO Supported Designated STI/	6				
RTI Clinics (DSRC)	Male	Female	TG	Total	
2. Total STI/RTI Clients managed				7,568	
3. RPR Tests conducted	675	1,394	1	2,070	
4. Syphilis seropositivity (%)	18.07	5.16	0.00	9.37	

4. Prevention of new HIV infections among high-risk group and bridge population

A. Targeted Intervention (TI) Projects and Opioid Substitution Therapy (OST)

Indicator	2023-24
1. Targeted Intervention (TI) Projects	6
2. OST centres (Excluding Satellite OST centres)	4

B. Female Sex Workers

D. I ellidie Sex Workers	
Indicator	2023-24
1. Estimated size	731
2. Coverage (%)	>=95
3. Condoms distributed	2,82,890
4. Tested for HIV (April 2022-September 2022)	915
4.1. HIV sero-positive (%)	0.00
4.1.1. Linked to ART	-
5. Tested for HIV (October 2022 -March 2023)	951
5.1. HIV sero-positive (%)	0.00
5.1.1. Linked to ART	-
6. Clinic Visits	3,346
7. STI/RTI treated	81
8. Presumptive treatment	117

C. Men who have Sex with Men	
Indicatort	2023-24
1. Estimated size	-
2. Coverage (%)	-
3. Condoms distributed	-
4. Tested for HIV (April 2022-September 2022)	-
4.1. HIV sero-positive (%)	-
4.1.1. Linked to ART	-
5. Tested for HIV (October 2022 -March 2023)	-
5.1. HIV sero-positive (%)	-
5.1.1. Linked to ART	-
6. Clinic Visits	-
7. STI/RTI treated	-
8. Presumptive treatment	-

D. Injecting Drug Users				
Indicator	2023-24			
1. Estimated size	821			
2. Coverage (%)	>=95			
3. Needles distributed	4,08,971			
4. Syringes distributed	4,08,971			
5. On OST	2,095			
6. Tested for HIV (April 2022 -September 2022)	1,004			
6.1. HIV sero-positive (%)	0.10			
6.1.1 Linked to ART	1			
7. Tested for HIV (October 2022 -March 2023)	1,440			
7.1. HIV sero-positive (%)	0.00			
7.1.1. Linked to ART	0			

E. Hijra/Transgender person				
Indicator	2023-24			
1. Estimated size	-			
2. Coverage (%)	-			
3. Condoms distributed	-			
4. Tested for HIV (April 2022-September 2022)	-			
4.1. HIV sero-positive (%)	-			
4.1.1. Linked to ART	-			
5. Tested for HIV (October 2022 -March 2023)	-			
5.1. HIV sero-positive (%)	-			
5.1.1. Linked to ART	-			
6. Clinic Visits	-			
7. STI/RTI treated	-			
8. Presumptive treatment	-			

F. Migrants	
Indicator	2023-24
1. Estimated size	-
2. Coverage (%)	-
3. Tested for HIV	-
3.1. HIV sero-positive (%)	-
3.2. Linked to ART	-

G. Truckers	
Indicator	2023-24
1. Estimated size	-
2. Coverage (%)	-
3. Tested for HIV	-
3.1. HIV sero-positive (%)	-
3.2. On ART	-

H. Prison Inmates	
Indicator	2023-24
1. Total prisons	2
2. Prisons covered under programme	2
3. Total inmates admitted	816
4. Inmates Covered (%)	74
5. Tested for HIV	602
5.1. HIV sero-positive (%)	0.17
5.2. On ART (%)	>=95

I. Link Worker Scheme	
Indicator	2023-24
Districts covered under scheme	-
Vulnerable population covered	-
3. Tested for HIV	-
3.1. HIV sero-positive (%)	-
3.2. Linked to ART (%)	-

J. Opioid Substitution Therapy	
Indicator	2023-24
1. OST Centres	4
1.1. OSTC in Public Health Settings	4
1.2. OSTC in NGO Settings	-
1.3. No. of Satellite OST Centres	3
2. IDU on OST	2,095

A. HIV counselling and testing services (HCTS)

7 to 1 in V to an isoming and to string ser vices (11010)		
Indicator	2023-24	
1. HCTC confirmatory facilities	14	
2. Sampoorna Suraksha Kendras	-	

B. HIV testing among vulnerable population (excluding pregnant women)

Indicator	2023-24			
	Male	Female	TG	Total
1. Tested for HIV	18,782	12,790	13	31,585
1.1 HIV Positives	45	14	2	61
1.2 HIV sero -positivity (%)	0.24	0.11	15.38	0.19
Spouse/sexual partner of HIV positive people tested	13	8	-	21
2.1 HIV Positives	-	1	-	1
2.2 HIV sero -positivity (%)	-	13	-	4.76
No. of contacts with 'at- risk' population through 'Sampoorna Suraksha'	-	-	-	-

6. Initiation and retention on ART of HIV infected people

A. Treatment facilities

Indicator	2023-24
1. ART Centres	1
2.Centre of Excellence	
2.1. Centre of Excellence (Adult)	-
2.2 Centre of Excellent (Paediatric)	-
3. Link ART Centres	1
4. Care Support Centres	-

B. Treatment uptake

Indicator	2023-24			
	Male	Female	TG	Total
HIV positive cases diagnosed (At ICTC)	45	16	2	63
New PLHIV Registered at ART center	38	12	1	51
2.1 Initiated on ART	34	11	1	46
3. PLHIV alive and on ART	207	134	1	342
4. 12 months retention on ART (%)				>=95
5. Lost to follow-up cases	6	3	-	9

7. Viral Suppression and laboratories	
A. Laboratory facilities and service uptake	
Indicator	2023-2
Viral load laboratories (programme and non- programme labs)	
1.1 Accredited Viral load laboratories (out of 64 VL labs)	
2. Viral load tests conducted	38
2.1. Virally suppressed (%)	94.
3. National reference laboratories (NRL)	
3.1 Accredited NRL	
4. State reference laboratories (SRL)	
4.1 Accredited SRL	
5. CD4 machines	
5.1 CD4 tests conducted	49
6. External Quality Assurance of ICTC	
6.1 Average Participation (%)	>=9
6.2. Average Discordance (%)	0.0
7. "Certificate of Excellence" by NACO	
7.1 No. of ICTCs received "Certificate of Excellence"	
8. Elimination of mother to child trans HIV & Syphilis	mission of
A. HIV	
Indicator	2023-2
1. Estimated pregnant women (PW)	11,70
2. HIV testing among PW	7,43
3. HIV sero-positivity (%) among tested	0.0
4. HIV Positive PW (old + new detections)	
4.1 On life-long ART	
5. Live births among HIV positive PW	
5.1 Babies given ARV Prophylaxis (%)	>=9
6. Babies tested HIV (6 week- 6 month)	
6.1 Babies confirmed HIV Positive (6 week- 6 month)	
7. HIV testing among exposed babies at 18 months	
7.1 HIV exposed babies tested at 18 months	
7.2 Babies confirmed HIV positive at 18 months	
8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months)	
9. HIV positive babies initiated on ART	
B. Syphilis	
Indicator	2023-2
1. Syphilis testing among PW	8,10
2.Sero-positivity (%) among tested	0.5
3. Put on treatment	3
9. Elimination of HIV/AIDS related Stigma and Discrimination	
Indicator	2023-2
State rules notified for HIV/AIDS Prevention and Control Act (2017)	Ye
State designated/appointed ombudsman	Y∈
appointed embadement	

10. HIV-TB Co-morbidities A. HRG and Bridge Population Indicator 2023-24 FSW MSM IDU Quarter TG Migrants Truckers Total 0 Quarter 1 557 394 951 Quarter 2 572 0 430 1,002 Screened for TB 0 Quarter 3 657 445 1,102 0 Quarter 4 637 447 1,084 Quarter 1 7 0 12 19 Quarter 2 0 18 24 6 Tested for TB Quarter 3 6 0 5 11 Quarter 4 5 0 8 13 1 0 0 Quarter 1 1 0 0 0 Quarter 2 0 Diagnosed with TB Quarter 3 0 0 0 0 0 0 0 0 Quarter 4 0 Quarter 1 1 0 1 0 0 0 0 Quarter 2 Initiated on TB treatment Quarter 3 0 0 0 0

B. HIV-TB Coinfected at ART Centre Indicator 2023-24 Co-infected initiated on PLHIV with PLHIV PLHIV PLHIV PLHIV Co-infected PLHIV tested for TB presumptive TB diagnosed with TB initiated on IPT Moths enrolled at attending underwent ART Centre 4S screening ARTC ART Apr - 23 158 158 2 2 1 1 1 157 157 16 May - 23 Jun - 23 166 166 15 Jul - 23 186 186 159 159 8 8 3 Aug - 23 Sep - 23 135 135 Oct - 23 132 132 11 172 1 Nov - 23 172 Dec - 23 141 141 Jan - 24 149 149 4 Feb - 24 150 150 4 Mar - 24 115 115 1 April 2023-8 March 2024

0

0

0

0

Quarter 4

	State/UT	Sikkim		
-	Rank	23		
SI. No.	Maximum Marks	177		
	Obtained Marks	123 (69%)		
2	First 95 (G:≥95%, Y: 80-94%, R:<80%) Second 95 (G:≥95%, Y: 80-94%, R:<80%)	65 87		
3	Third 95 (G:≥95%, Y: 80-94%, R:<80%)	>=95		
4	Average Frequency of Social Media updates (G: ≥ 45, Y:40- 44, R:			
-	Q1, Q2, Q3 & Q4	the margerious posts) of		
5	Status of AEP integration in state school curriculum (G:Yes, R:No)	Yes		
6	Status of SCA (G: At least one meeting held since 2020, R: other tl	han G) No Meeting held		
7	Status of State Rules (G: Notified, R: Not notified)	Notified		
8	Status of Ombudsman (G: Appointed, R: Not appointed)	Appointed		
9	TI/LWS onboarding (G: ≥95%, Y: 90-<95%, R:<90%)	100		
10	OST onboarding (G: ≥95%, Y: 90-<95%, R:<90%)	100		
11	Coverage of HRG against estimates (G: ≥90%, Y: 80-<90%, R:<80	%) 180		
12	HIV testing among HRG (G: ≥95%, Y: 90-<95%, R:<90%)	101		
13	HIV testing among prisoners (G: ≥50%, Y: 40% to <50%, R:<40%)	58		
14	Clinic visit of HRGs at TI-Clinics (G: ≥90%, Y: 75-89%, R:<75%)	88		
15	Percentage of HRGs screened for Syphilis (G: ≥90%, Y: 75-89%, R:	:<75%) 98		
16	IDU on OST (G: ≥50%, Y: 30% to <50%, R:<30%)	352		
17	Percentage of fund released to TI (G: ≥50%, Y: 45-<50%, R:<45%)			
18	Percentage of TIs trained by Kshmata Kendra (KK) against the AAF	P targets (G: ≥75%, Y: 70-		
	<75%, R:<70%)			
19	HIV testing against Target-at risk % (G: ≥95%, Y: 80-94%, R:<80%)			
20	HIV testing against target-PW (G: ≥95%, Y: 80-94%, R:<80%)	64		
21	Percentage of pregnant women screened for Syphilis (G: ≥95%, Y:			
22	Treatment provided to Syphilis reactive pregnant women (G: ≥959	%, Y: 80-94%, R:<80%) 73		
23	Index testing among newly detected HIV positive clients (G: ≥95%	5, Y: 80-94%, R:<80%)		
24	Percentage of 6 weeks - <2 months EID testing against live birth (0 R:<80%)	G: ≥95%, Y: 80-94%, 100		
25	Clients managed at DSRC against the target (G: ≥90%, Y: 75-89%,	, R:<75%) 66		
26	STI attendees screened for HIV (G: >75%, Y: 50-75%, R:<50%)	90		
27	STI attendees screened for Syphilis (G: >75%, Y: 50-75%, R:<50%)	91		
28	% of pregnant women who initiated ART (G: ≥95%, Y: 80-94%, R:<	<80%) 33		
29	Proportion of LFU-PLHIV, out of those initiated on ART in FY 2023. R:>5%)	-24 (G:<2%, Y: 2 to 5%,		
30	Proportion of PLHIV initiated on ART, out of those registered in FY to 98%, R:<95%)	/ 2023-24 (G:>98%, Y: 95		
31	Proportion of reported died, out of those initiated on ART in FY 20 R:>5 %)	02324 (G:<2%, Y: 2 to 5 %,		
32	% of SRL accredited (G:100%, Y: 80-99%, R:<80%)	100		
33	% participation of ICTCs in re-testing (G: ≥95%, Y: 85-94, R:<85%)	100		
34	Number of abstracts selected from studies conducted in FY21-22 R: ≤25%)	(G:100%, Y: >25 to <100%,		
35	Number of ongoing studies from FY22-23 (G:100%, Y: >25 to <10 R: \leq 25%)	00%,		
36	Submission of research proposals from FY23-24 to NACO (G:1009 Y: >25 to <100%, R: ≤25%)	1		
37	Secondary Data Analysis by SACS (G:2, Y: 1, R: No Secondary Dat	a Analysis Plan Submitted) 2		
38	Expenditure with respect to funds released during FY 2022-23 (G:	· · · · · · · · · · · · · · · · · · ·		
39	≥90%, Y: 85 to <90%, R: <85%) Submission of Provisional Utilization Certificate (UC) in GFR 12A for 2022 Y v by 21 May 2022 P v effect.	or the FY 2022-23 (G : by 02-05-2023		
10	30-Apr-2023, Y : by 31-May-2023, R : after 31-May-2023)	201 2022 V 1 20 C		
40	Submission of audited UC in GFR 12A for the FY 2022-23 (G: by 3 2023, R: after 30-Sep-2023)			
11	Submission of EC/ GB ratification for approval of Expenditure incurred during FY 2021-22 (G: by 30-Jun-2022, Y: by 30-Sept-2022, R: after 30-Sept-2022)			
12	Timely Submission of CST-SCM Report (G:>95%, Y: 80-95%, R:<80			
43	Format Adherence to CST-SCM Report (G:>95%, Y: 80-95%, R:<8	91		
14	Timely Submission of BSD & STI-SCM Report (G: ≥90%, Y: 75-<90%, R:<75%)	58		
	Green=3 Marks Yellow=2Marks Red=	=1 Mark No Colour=Not Applicable		
Weig	ight points Indicator Sl. No.			
	3 1, 23, 29			
	2 2, 3, 9, 10, 22, 30, 34, 42, 44			







1. Status of HIV/AIDS Epidemic			
A. Epidemic Estimates (2023)			
Indicator	Male	Female	Total
1. IPR	-	-	1.04
2. IMR	-	-	0.48
3. Adult (15-49 yrs) HIV Prevalence (%)	0.21	0.20	0.20
4. Estimated people living with HIV	86,786	82,107	1,68,893
5. ART coverage (%)	78.88	88.33	83.79
6. Estimated children living with HIV	1,583	1,468	3,051
7. Annual new HIV infections	961	800	1,761
8. Annual AIDS-related deaths (ARD)	1,257	610	1,867
9. Change in annual new HIV infections since 2010 (%)	-68.92	-69.16	-69.01
10. Change in annual ARD since 2010(%)	-82.99	-87.33	-84.70
11. EMTCT need	-	976	976

B. High risk population size (2020-22), safe practices (2021) and prevalence (2021/2023)				
Population Group	Estimates Size	Condom Use (%)	New Nee-dle/ Syringe use (%)	HIV Preva- lence (%)
1. Female Sex Workers	60,775	98.00	-	1.52
2. Men who have sex with men	38,284	94.70	-	2.07
3. Injecting Drug Users	115	-	-	-
4. Hijra/Transgender People	9,211	-	-	4.80
5. Migrants	1,95,127	93.50	-	0.00
6. Truckers	47,000	36.20	-	0.60
7. Prison inmates	1,23,083	58.20	86.60	0.81

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)			
Indicator	Male	Female	Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)	26.60	23.60	-
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	23.20	23.90	-
3. Adults willing to care for a relative with HIV/AIDS in own home (%)	65.70	56.40	-
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	52.20	41.50	-
5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)	0.80	0.00	-
5.1 Condom use during last higher-risk intercourse (%)	49.80	-	-
6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)	0.74	0.00	-
6.1 Condom use during last higher-risk intercourse (%)	16.67	-	-

2. Progress on	95-95-95 (20)	23-24)
81 82 83 85 88 92	84 86 85 85 86 88	85 85 86 93 ≥95
PLHIV who know their HIV status (%)	PLHIV who know their HIV status and are on ART (%)	PLHIV who are on ART and virally suppressed (%)
2018-19 2019-20	2020-21 2021-22	2022-23 2023-24

Indicators	Male	Female	Total*
1. Estimated PLHIV size (2023)	86,786	82,107	1,68,893
2. PLHIV who know their HIV Status	76,986	77,273	1,54,921
3. PLHIV who know their HIV status and are on ART	65,822	69,698	1,36,030
4. PLHIV who are on ART and tested for their viral load	56,052	61,149	1,17,570
4.1 PLHIV who are virally suppressed	54,263	60,070	1,14,692

^{*} Including of H/TG PLHIV

A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2023-24
Schools with operational Adolescent Education Program (AEP)	9,830
2. Colleges with operational Red Ribbon Clubs (RRC)	2,329
3. Persons trained under mainstreaming	12,551
4. No. of calls received at helpline	_

B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management

Indicator	2023-24			
1. NACO Supported	106			
Designated STI/ RTI Clinics (DSRC)	Male	Female	TG	Total
2. Total STI/RTI Clients managed				10,11,986
3. RPR Tests conducted	3,75,663	3,53,343	6,151	7,35,157
4. Syphilis seropositivity (%)	0.69	0.22	1.58	0.47

4. Prevention of new HIV infections among high-risk group and bridge population

A. Targeted Intervention (TI) Projects and Opioid Substitution Therapy (OST)

Indicator	2023-24
1. Targeted Intervention (TI) Projects	87
2. OST centres (Excluding Satellite OST centres)	1

B. Female Sex Workers

Indicator	2023-24
1. Estimated size	60,775
2. Coverage (%)	>=95
3. Condoms distributed	60,80,271
4. Tested for HIV (April 2022-September 2022)	26,949
4.1. HIV sero-positive (%)	0.10
4.1.1. Linked to ART	23
5. Tested for HIV (October 2022 -March 2023)	44,593
5.1. HIV sero-positive (%)	0.09
5.1.1. Linked to ART	34
6. Clinic Visits	1,09,552
7. STI/RTI treated	1,282
8. Presumptive treatment	7,813

C. Men who have Sex with Men Indicatort 2023-24 1. Estimated size 38,283 2. Coverage (%) >=95 43,29,891 3. Condoms distributed 4. Tested for HIV (April 2022-September 2022) 19,856 4.1. HIV sero-positive (%) 0.37 4.1.1. Linked to ART 5. Tested for HIV (October 2022 -March 2023) 29,910 0.30 5.1. HIV sero-positive (%) 5.1.1. Linked to ART 86 6. Clinic Visits 79,581

D. Injecting Drug Users	
Indicator	2023-24
1. Estimated size	115
2. Coverage (%)	>=95
3. Needles distributed	39,390
4. Syringes distributed	39,390
5. On OST	75
6. Tested for HIV (April 2022 -September 2022)	476
6.1. HIV sero-positive (%)	0.42
6.1.1 Linked to ART	2
7. Tested for HIV (October 2022 -March 2023)	521
7.1. HIV sero-positive (%)	0.19
7.1.1. Linked to ART	1

E. Hijra/Transgender person	
Indicator	2023-24
1. Estimated size	9,210
2. Coverage (%)	>=95
3. Condoms distributed	12,16,122
4. Tested for HIV (April 2022-September 2022)	4,789
4.1. HIV sero-positive (%)	0.46
4.1.1. Linked to ART	21
5. Tested for HIV (October 2022 -March 2023)	6,455
5.1. HIV sero-positive (%)	0.28
5.1.1. Linked to ART	18
6. Clinic Visits	16,952
7. STI/RTI treated	58
8. Presumptive treatment	1,245

F. Migrants	
Indicator	2023-24
1. Estimated size	1,95,127
2. Coverage (%)	34
3. Tested for HIV	21,316
3.1. HIV sero-positive (%)	0.13
3.2. Linked to ART	24

G. Truckers	
Indicator	2023-24
1. Estimated size	47,000
2. Coverage (%)	>=95
3. Tested for HIV	12,919
3.1. HIV sero-positive (%)	0.17
3.2. On ART	16

H. Prison Inmates	
Indicator	2023-24
1. Total prisons	142
2. Prisons covered under programme	128
3. Total inmates admitted	1,23,083
4. Inmates Covered (%)	55
5. Tested for HIV	68,184
5.1. HIV sero-positive (%)	0.15
5.2. On ART (%)	87.25

I. Link Worker Scheme	
Indicator	2023-24
Districts covered under scheme	17
Vulnerable population covered	2,02,807
3. Tested for HIV	93,573
3.1. HIV sero-positive (%)	0.04
3.2. Linked to ART (%)	108.11

380

6,343

7. STI/RTI treated

8. Presumptive treatment

J. Opioid Substitution Therapy	
Indicator	2023-24
1. OST Centres	1
1.1. OSTC in Public Health Settings	1
1.2. OSTC in NGO Settings	-
1.3. No. of Satellite OST Centres	-
2. IDU on OST	75
5 Farly detection of HIV infected nec	nle

A. HIV counselling and testing services (HCTS)

Indicator	2023-24
1. HCTC confirmatory facilities	346
2. Sampoorna Suraksha Kendras	-

B. HIV testing among vulnerable population (excluding pregnant women)

Indicator	2023-24			
	Male	Female	TG	Total
1. Tested for HIV	18,10,154	13,42,184	11,741	31,64,079
1.1 HIV Positives	4,543	2,736	59	7,338
1.2 HIV sero -positivity (%)	0.25	0.20	0.50	0.23
Spouse/sexual partner of HIV positive people tested	2,492	3,157	39	5,688
2.1 HIV Positives	544	668	1	1,213
2.2 HIV sero -positivity (%)	22	21	3	21.33
No. of contacts with 'at- risk' population through 'Sampoorna Suraksha'	-	-	-	-

6. Initiation and retention on ART of HIV infected people

A. Treatment facilities

Indicator	2023-24
1. ART Centres	73
2.Centre of Excellence	
2.1. Centre of Excellence (Adult)	1
2.2 Centre of Excellent (Paediatric)	1
3. Link ART Centres	173
4. Care Support Centres	32

B. Treatment uptake

Indicator	2023-24			
	Male	Female	TG	Total
HIV positive cases diagnosed (At ICTC)	4,543	2,982	59	7,584
New PLHIV Registered at ART center	4,446	2,892	59	7,397
2.1 Initiated on ART	4,233	2,775	57	7,065
3. PLHIV alive and on ART	65,822	69,698	510	1,36,030
4. 12 months retention on ART (%)				>=95
5. Lost to follow-up cases	2,050	1,164	40	3,254

A. Laboratory facilities and service uptake	
Indicator	2023-2
Viral load laboratories (programme and non- programme labs)	
1.1 Accredited Viral load laboratories (out of 64 VL labs)	
2. Viral load tests conducted	1,37,32
2.1. Virally suppressed (%)	92.
3. National reference laboratories (NRL)	
3.1 Accredited NRL	
4. State reference laboratories (SRL)	1
4.1 Accredited SRL	1
5. CD4 machines	4
5.1 CD4 tests conducted	1,07,75
6. External Quality Assurance of ICTC	
6.1 Average Participation (%)	>=9
6.2. Average Discordance (%)	0.0
7. "Certificate of Excellence" by NACO	
7.1 No. of ICTCs received "Certificate of Excellence"	1
8. Elimination of mother to child transm HIV & Syphilis	ission of
A. HIV	
Indicator	2023-2
Estimated pregnant women (PW)	11,88,94
2. HIV testing among PW	9,40,89
3. HIV sero-positivity (%) among tested	0.0
4. HIV Positive PW (old + new detections)	91
4.1 On life-long ART	90
5. Live births among HIV positive PW	67
5.1 Babies given ARV Prophylaxis (%)	>=9
6. Babies tested HIV (6 week- 6 month)	64
6.1 Babies confirmed HIV Positive (6 week- 6 month)	
7. HIV testing among exposed babies at 18 months	
7.1 HIV exposed babies tested at 18 months	55
7.2 Babies confirmed HIV positive at 18 months	1
8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months)	2
9. HIV positive babies initiated on ART	2
B. Syphilis	
D. Syprims	2023-2
Indicator	2023-2
Indicator 1. Syphilis testing among PW	11,76,00
1. Syphilis testing among PW	
Syphilis testing among PW Sero-positivity (%) among tested	0.0
1. Syphilis testing among PW	0.0
Syphilis testing among PW Sero-positivity (%) among tested Put on treatment	0.0
Syphilis testing among PW Sero-positivity (%) among tested Put on treatment Elimination of HIV/AIDS related Stigma	11,76,00 0.0 21 2023-2

2. State designated/appointed ombudsman

Yes

10. HIV-TB Co-morbidities								
A. HRG and Bridge Population								
Indicator 2023-24								
	Quarter	FSW	MSM	IDU	TG	Migrants	Truckers	Total
	Quarter 1	40,588	28,070	496	6,360	37,133	17,035	1,29,682
Screened for TB	Quarter 2	43,575	29,984	522	6,724	41,293	18,868	1,40,966
Screened for TB	Quarter 3	46,750	30,834	524	6,772	44,723	18,982	1,48,585
	Quarter 4	47,933	32,482	555	7,221	41,086	17,923	1,47,200
	Quarter 1	679	409	82	93	30	5	1,298
Tested for TB	Quarter 2	983	934	30	186	339	2	2,474
lested for TB	Quarter 3	1,115	945	5	176	36	20	2,297
	Quarter 4	1,104	1,002	1	277	5	1	2,390
	Quarter 1	-	1	-	-	-	1	2
Diagrapas duvida TD	Quarter 2	10	4	-	1	-	-	15
Diagnosed with TB	Quarter 3	1	3	-	3	-	3	10
	Quarter 4	2	6	-	-	2	-	10
	Quarter 1	-	1	-	-	-	-	1
Initiated on TB	Quarter 2	9	5	-	1	-	-	15
treatment	Quarter 3	-	3	-	3	-	-	6
	Quarter 4	3	4	-	-	-	-	7

B. HIV-TB Coinfected at ART Centre 2023-24 Indicator PLHIV with presumptive TB PLHIV PLHIV PLHIV PLHIV Co-infected enrolled at Co-infected initiated on ART PLHIV tested for TB diagnosed with TB initiated on IPT Moths attending underwent ART Centre 4S screening ARTC 87,013 83,436 4,728 574 Apr - 23 4,699 195 93,585 820 89,790 5,983 4,953 210 May - 23 Jun - 23 87,997 84,543 5,973 5,171 176 745 Jul - 23 92,956 88,934 6,122 5,164 184 643 196 92,938 88,764 5,990 5,212 706 Aug - 23 Sep - 23 91,693 87,623 5,931 5,072 158 604 1,00,399 96,263 6,536 5,442 742 Oct - 23 162 1,05,223 1,00,277 158 580 Nov - 23 6,469 5,281 Dec - 23 1,11,566 1,06,971 6,403 5,175 197 657 Jan - 24 1,09,122 1,04,198 5,866 5,037 187 625 Feb - 24 99,374 95,097 7,148 5,077 199 546 Mar - 24 97,781 93,912 5,833 4,992 201 545 April 2023-2,581 2,485 March 2024

		State/UT	Tamil Nadu
CI	. N N	Rank	4
SI. No.	Maximum Ma Obtained Ma		177 143 (81%)
1		5%, Y: 80-94%, R:<80%)	92
2	•	3%, 1. 80-94%, R.<80%) :≥95%, Y: 80-94%, R:<80%)	88
3		95%, Y: 80-94%, R:<80%)	>=95
4		uency of Social Media updates (G: ≥ 45, Y:40- 44, R:<40 indigenous posts) of	55
	Q1, Q2, Q3 8		
5	Status of AEP	integration in state school curriculum (G:Yes, R:No)	Yes
6	Status of SCA	(G: At least one meeting held since 2020, R: other than G)	Meeting held in 2021
7	Status of State	e Rules (G: Notified, R: Not notified)	Notified
8	Status of Oml	oudsman (G: Appointed, R: Not appointed)	Appointed
9		arding (G: ≥95%, Y: 90-<95%, R:<90%)	100
10	+	ing (G: ≥95%, Y: 90-<95%, R:<90%)	100
11		HRG against estimates (G: ≥90%, Y: 80-<90%, R:<80%)	105
12		nong HRG (G: ≥95%, Y: 90-<95%, R:<90%)	75
13	HIV testing ar	nong prisoners (G: ≥50%, Y: 40% to <50%, R:<40%)	45
14		HRGs at TI-Clinics (G: ≥90%, Y: 75-89%, R:<75%)	58
15	Percentage o	f HRGs screened for Syphilis (G: ≥90%, Y: 75-89%, R:<75%)	77
16		G: ≥50%, Y: 30% to <50%, R:<30%)	27
17		f fund released to TI (G: ≥50%, Y: 45-<50%, R:<45%)	94
18	_	f TIs trained by Kshmata Kendra (KK) against the AAP targets (G: ≥75%, Y: 70-	54
	<75%, R:<709		
19		gainst Target-at risk % (G: ≥95%, Y: 80-94%, R:<80%)	350
20		gainst target-PW (G: ≥95%, Y: 80-94%, R:<80%)	79
21	Percentage o	f pregnant women screened for Syphilis (G: ≥95%, Y: 80-94%, R:<80%)	99
22	Treatment pro	ovided to Syphilis reactive pregnant women (G: ≥95%, Y: 80-94%, R:<80%)	100
23	Index testing	among newly detected HIV positive clients (G: ≥95%, Y: 80-94%, R:<80%)	33
24	Percentage of R:<80%)	99	
25	-	ged at DSRC against the target (G: ≥90%, Y: 75-89%, R:<75%)	213
26		screened for HIV (G: >75%, Y: 50-75%, R:<50%)	69
27		screened for Syphilis (G: >75%, Y: 50-75%, R:<50%)	91
28		t women who initiated ART (G: ≥95%, Y: 80-94%, R:<80%)	99
29	Proportion of	LFU-PLHIV, out of those initiated on ART in FY 2023-24 (G:<2%, Y: 2 to 5%,	1
30		PLHIV initiated on ART, out of those registered in FY 2023-24 (G:>98%, Y: 95	96
31	to 98%, R:<95	reported died, out of those initiated on ART in FY 202324 (G:<2%, Y: 2 to 5 %,	6
	R:>5 %)	4	
32	% of SRL accr	edited (G:100%, Y: 80-99%, R:<80%)	100
33		on of ICTCs in re-testing (G: ≥95%, Y: 85-94, R:<85%)	100
34	Number of ab	ostracts selected from studies conducted in FY21-22	4
		25 to <100%, R: ≤25%)	
35	Number of or R: ≤25%)	ngoing studies from FY22-23 (G:100%, Y: >25 to <100%,	4
36	Submission o	f research proposals from FY23-24 to NACO (G:100%,	2
37	Y: >25 to <10	ıta Analysis by SACS (G:2, Y: 1, R: No Secondary Data Analysis Plan Submitted)	2
88		vith respect to funds released during FY 2022-23 (G: o <90%, R: <85%)	104
39	Submission o	f Provisional Utilization Certificate (UC) in GFR 12A for the FY 2022-23 (G : by Y : by 31-May-2023, R : after	15-05-2023
10		f audited UC in GFR 12A for the FY 2022-23 (G : by 30Jun-2023, Y : by 30-Sep- r 30-Sep-2023)	16-11-2023
11	Submission o	; 30-39-2023) f EC/ GB ratification for approval of Expenditure incurred during FY 2021-22 (G: 22, Y: by 30-Sept-2022, R: after 30-Sept-2022)	27-09-2022
12		ssion of CST-SCM Report (G:>95%, Y: 80-95%, R:<80%)	93
		·	
13 14		rence to CST-SCM Report (G:>95%, Y: 80-95%, R:<80%) ssion of BSD & STI-SCM Report (G: ≥90%, Y: 75-	94 - 92
	<90%, R:<	75%)	Calaura Niat A . II. III.
۸/- ۰	Green=3 Mark		Colour=Not Applicable
vveig	ght points	Indicator SI. No.	
	3	1, 23, 29	
	2	2, 3, 9, 10, 22, 30, 34, 42, 44	
		4, 5, 6, 7, 8, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 24, 25, 26, 27, 28, 31, 3:	2 33 35 36 37 38 39 40







1. Status of HIV/AIDS Epidemic			
A. Epidemic Estimates (2023)			
Indicator	Male	Female	Total
1. IPR	-	-	1.87
2. IMR	-	-	0.68
3. Adult (15-49 yrs) HIV Prevalence (%)	0.45	0.42	0.44
4. Estimated people living with HIV	82,614	75,550	158,164
5. ART coverage (%)	61.93	77.45	69.73
6. Estimated children living with HIV	1,719	1,574	3,293
7. Annual new HIV infections	1,681	1,281	2,962
8. Annual AIDS-related deaths (ARD)	2,203	613	2,816
9. Change in annual new HIV infections since 2010 (%)	-57.63	-58.44	-57.98
10. Change in annual ARD since 2010(%)	-76.79	-89.59	-81.69
11. EMTCT need	-	1,118	1,118

B. High risk population size (2020-22), safe practices (2021) and prevalence (2021/2023) **HIV Prevalence** Condom Use New Needle/ Estimates Size Population Group (%) Syringe use (%) (%) 99.90 1. Female Sex Workers 75,381 1.81 89.70 2. Men who have sex with men 16,427 2.67 3. Injecting Drug Users 816 100.00 0.40 4. Hijra/Transgender People 995 4.00 87.60 0.80 5. Migrants 75,601 6. Truckers 47,000 51.60 0.80 49,381 66.70 2.75 7. Prison inmates

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)						
Indicator	Male	Female	Total			
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)	30.50	30.70	-			
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	30.30	32.90				
3. Adults willing to care for a relative with HIV/AIDS in own home (%)	65.40	61.90	-			
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	70.40	58.90	-			
5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)	4.40	0.40	-			
5.1 Condom use during last higher-risk intercourse (%)	47.60	36.80	-			
6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)	5.96	0.18				
6.1 Condom use during last higher-risk intercourse (%)	32.26	50.00	-			

2. Progress on 95-95-95 (2023-24)			
73 68 65 68 71 76	295 295 295 295 295 91	78 80 77 66 80 77	
PLHIV who know their HIV status (%)	PLHIV who know their HIV status and are on ART (%) ■ 2020-21 ■ 2021-22	PLHIV who are on ART and virally suppressed (%) 2022-23 2023-24	

Indicators	Male	Female	Total*
1. Estimated PLHIV size (2023)	82,614	75,550	1,58,164
2. PLHIV who know their HIV Status	56,980	62,939	120,633
3. PLHIV who know their HIV status and are on ART	61,489	70,354	1,32,526
4. PLHIV who are on ART and tested for their viral load	35,549	41,870	77,705
4.1 PLHIV who are virally suppressed	34,104	40,552	74,945

^{*} Including of H/TG PLHIV

A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2023-24
Schools with operational Adolescent Education Program (AEP)	1,000
2. Colleges with operational Red Ribbon Clubs (RRC)	770
3. Persons trained under mainstreaming	671
4. No. of calls received at helpline	_

B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management

Indicator	2023-24			
NACO Supported Designated STI/	50			
RTI Clinics (DSRC)	Male	Female	TG	Total
2. Total STI/RTI Clients managed				510,811
3. RPR Tests conducted	40,967	73,058	1,504	1,15,529
4. Syphilis seropositivity (%)	1.36	0.38	3.19	0.77

4. Prevention of new HIV infections among high-risk group and bridge population

A. Targeted Intervention (TI) Projects and Opioid Substitution Therapy (OST)

Indicator	2023-24
1. Targeted Intervention (TI) Projects	53
2. OST centres (Excluding Satellite OST centres)	1

B. Female Sex Workers

Indicator	2023-24
1. Estimated size	75,380
2. Coverage (%)	>=95
3. Condoms distributed	22,306,580
4. Tested for HIV (April 2022-September 2022)	104,543
4.1. HIV sero-positive (%)	0.32
4.1.1. Linked to ART	320
5. Tested for HIV (October 2022 -March 2023)	111,004
5.1. HIV sero-positive (%)	0.30
5.1.1. Linked to ART	330
6. Clinic Visits	407,821
7. STI/RTI treated	3,358
8. Presumptive treatment	15,558

2023-24
16,427
>=95
49,11,198
23,251
0.64
119
24,863
0.61
141
80,982
213
3,003

D. Injecting Drug Users	
Indicator	2023-24
1. Estimated size	815
2. Coverage (%)	>=95
3. Needles distributed	4,27,654
4. Syringes distributed	4,27,654
5. On OST	26
6. Tested for HIV (April 2022 -September 2022)	1,079
6.1. HIV sero-positive (%)	0.09
6.1.1 Linked to ART	1
7. Tested for HIV (October 2022 -March 2023)	1,262
7.1. HIV sero-positive (%)	0.08
7.1.1. Linked to ART	1

E. Hijra/Transgender person	
Indicator	2023-24
1. Estimated size	995
2. Coverage (%)	>=95
3. Condoms distributed	15,90,936
4. Tested for HIV (April 2022-September 2022)	3,106
4.1. HIV sero-positive (%)	0.00
4.1.1. Linked to ART	20
5. Tested for HIV (October 2022 -March 2023)	3,721
5.1. HIV sero-positive (%)	0.00
5.1.1. Linked to ART	21
6. Clinic Visits	11,506
7. STI/RTI treated	18
8. Presumptive treatment	412

F. Migrants	
Indicator	2023-24
1. Estimated size	75,601
2. Coverage (%)	>=95
3. Tested for HIV	37,327
3.1. HIV sero-positive (%)	0.14
3.2. Linked to ART	51

G. Truckers	
Indicator	2023-24
1. Estimated size	47,000
2. Coverage (%)	>=95
3. Tested for HIV	16,867
3.1. HIV sero-positive (%)	0.06
3.2. On ART	10

H. Prison Inmates	
Indicator	2023-24
1. Total prisons	37
2. Prisons covered under programme	36
3. Total inmates admitted	49,381
4. Inmates Covered (%)	89
5. Tested for HIV	43,960
5.1. HIV sero-positive (%)	0.27
5.2. On ART (%)	>=95

I. Link Worker Scheme	
Indicator	2023-24
Districts covered under scheme	11
Vulnerable population covered	110,831
3. Tested for HIV	64,285
3.1. HIV sero-positive (%)	0.23
3.2. Linked to ART (%)	100.00

J. Opioid Substitution Therapy	
Indicator	2023-24
1. OST Centres	1
1.1. OSTC in Public Health Settings	1
1.2. OSTC in NGO Settings	-
1.3. No. of Satellite OST Centres	-
2. IDU on OST	26

A. HIV counselling and testing services (HCTS)

A. The counselling and testing services (The	C1 <i>S</i> ,
Indicator	2023-24
1. HCTC confirmatory facilities	165
2. Sampoorna Suraksha Kendras	9

B. HIV testing among vulnerable population (excluding pregnant women)

Indicator	2023-24			
	Male	Female	TG	Total
1. Tested for HIV	623,682	568,228	3,256	1,195,166
1.1 HIV Positives	6,042	4,595	117	10,754
1.2 HIV sero -positivity (%)	0.97	0.81	3.59	0.90
Spouse/sexual partner of HIV positive people tested	3,735	3,719	35	7,489
2.1 HIV Positives	1,324	1,184	5	2,513
2.2 HIV sero -positivity (%)	35	32	14	33.56
No. of contacts with 'at- risk' population through 'Sampoorna Suraksha'	-	-	-	10,232

6. Initiation and retention on ART of HIV infected people

A. Treatment facilities

Indicator	2023-24
1. ART Centres	27
2.Centre of Excellence	
2.1. Centre of Excellence (Adult)	1
2.2 Centre of Excellent (Paediatric)	1
3. Link ART Centres	68
4. Care Support Centres	13

B. Treatment uptake

Indicator	2023-24			
	Male	Female	TG	Total
HIV positive cases diagnosed (At ICTC)	6,042	5,047	117	11,206
New PLHIV Registered at ART center	6,091	5,121	129	11,341
2.1 Initiated on ART	5,980	4,980	129	11,089
3. PLHIV alive and on ART	61,489	70,354	683	1,32,526
4. 12 months retention on ART (%)				93.6
5. Lost to follow-up cases	6,591	5,716	66	12,373

7. Viral Suppression and laboratories	
A. Laboratory facilities and service uptake	
Indicator	2023-24
Viral load laboratories (programme and non- programme labs)	4
 1.1 Accredited Viral load laboratories (out of 64 VL labs) 	3
2. Viral load tests conducted	86,595
2.1. Virally suppressed (%)	93.2
3. National reference laboratories (NRL)	1
3.1 Accredited NRL	1
4. State reference laboratories (SRL)	3
4.1 Accredited SRL	3
5. CD4 machines	21
5.1 CD4 tests conducted	44,036
6. External Quality Assurance of ICTC	
6.1 Average Participation (%)	>=95
6.2. Average Discordance (%)	0.00
7. "Certificate of Excellence" by NACO	
7.1 No. of ICTCs received "Certificate of Excellence"	70

8. Elimination of mother to child transmission of HIV & Syphilis

HIV & Syphilis	
A. HIV	
Indicator	2023-24
1. Estimated pregnant women (PW)	687,530
2. HIV testing among PW	823,246
3. HIV sero-positivity (%) among tested	0.05
4. HIV Positive PW (old + new detections)	1,055
4.1 On life-long ART	1,048
5. Live births among HIV positive PW	639
5.1 Babies given ARV Prophylaxis (%)	>=95
(Dahisa tastad LIIV/// wask (manth)	668

3.1 Babies given Ait v 1 Tophylaxis (70)	, , ,
6. Babies tested HIV (6 week- 6 month)	668
6.1 Babies confirmed HIV Positive (6 week- 6 month)	2
7. HIV testing among exposed babies at 18 months	
7.1 HIV exposed babies tested at 18 months	665
7.2 Babies confirmed HIV positive at 18 months	12
8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months)	18

	B. Syphilis	
ſ	Indicator	2023-24
	1. Syphilis testing among PW	920,424
	2.Sero-positivity (%) among tested	0.01
ſ	3. Put on treatment	61

9. Elimination of HIV/AIDS related Stigma and Discrimination

9. HIV positive babies initiated on ART

Indicator	2023-24
1. State rules notified for HIV/AIDS Prevention and Control Act (2017)	No
2. State designated/appointed ombudsman	No

10. HIV-TB Co-morbidities A. HRG and Bridge Population								
Indicator	ndicator 2023-24							
	Quarter	FSW	MSM	IDU	TG	Migrants	Truckers	Total
	Quarter 1	192,096	35287	841	4128	44694	39463	316,509
C II TD	Quarter 2	179,774	31742	794	4114	52412	44001	312,837
Screened for TB	Quarter 3	171,790	31704	1179	4293	52959	67810	329,735
	Quarter 4	175,824	36012	1211	4518	60224	77148	354,937
	Quarter 1	2,479	413	0	37	43	0	2,972
T . I(TD	Quarter 2	2,520	483	0	22	41	2	3,068
Tested for TB	Quarter 3	2,653	639	0	11	40	7	3,350
	Quarter 4	2,427	296	0	15	40	4	2,782
	Quarter 1	18	14	0	0	2	0	34
Diamana daniah TD	Quarter 2	12	8	0	0	2	0	22
Diagnosed with TB	Quarter 3	12	9	0	1	2	0	24
	Quarter 4	13	7	0	0	0	0	20
	Quarter 1	16	14	0	0	2	0	32
Initiated on TB	Quarter 2	15	5	0	0	2	0	22
treatment	Quarter 3	10	6	0	0	2	0	18
	Quarter 4	10	8	0	0	0	0	18

B. HIV-TB Coinfected at ART Centre Indicator 2023-24 PLHIV with presumptive TB PLHIV PLHIV PLHIV PLHIV Co-infected enrolled at Co-infected initiated on ART PLHIV tested for TB diagnosed with TB initiated on IPT Moths attending underwent ART Centre 4S screening ARTC 72,871 66,825 403 Apr - 23 1,656 1,626 153 74,060 69,008 1,416 1,269 186 652 May - 23 Jun - 23 72,398 67,134 1,378 1,301 180 795 Jul - 23 74,974 68,859 1,202 1,122 180 1,248 76,870 70,362 1,228 117 729 Aug - 23 1,167 Sep - 23 78,418 72,901 1,634 1,551 114 531 77,683 72,281 1,779 139 379 Oct - 23 1,702 1,551 156 433 Nov - 23 75,678 69,122 1,448 Dec - 23 84,190 76,491 1,630 1,583 114 427 Jan - 24 85,175 1,909 77,481 1,794 133 360 Feb - 24 79,192 72,134 2,076 1,998 131 684 Mar - 24 82,903 73,044 1,828 1,794 118 777 April 2023-1,751 1,633 March 2024

	State/UT	Telangana
	Rank	17
SI.	Maximum Marks	177
10.	Obtained Marks	127 (72%)
1	First 95 (G:≥95%, Y: 80-94%, R:<80%)	76
2	Second 95 (G:≥95%, Y: 80-94%, R:<80%)	>=95
3	Third 95 (G:≥95%, Y: 80-94%, R:<80%)	>=95
4	Average Frequency of Social Media updates (G: ≥ 45, Y:40- 44, R:<40 indigenous posts) of Q1, Q2, Q3 & Q4	23
5	Status of AEP integration in state school curriculum (G:Yes, R:No)	Yes
6	Status of SCA (G: At least one meeting held since 2020, R: other than G)	Not constituted
7	Status of State Rules (G: Notified, R: Not notified)	Not Notified
8	Status of Ombudsman (G: Appointed, R: Not appointed)	Not Appointed
9	TI/LWS onboarding (G: ≥95%, Y: 90-<95%, R:<90%)	100
10	OST onboarding (G: ≥95%, Y: 90-<95%, R:<90%)	100
11	Coverage of HRG against estimates (G: ≥90%, Y: 80-<90%, R:<80%)	228
12	HIV testing among HRG (G: ≥95%, Y: 90-<95%, R:<90%)	93
13		55
	HIV testing among prisoners (G: ≥50%, Y: 40% to <50%, R:<40%)	
14	Clinic visit of HRGs at TI-Clinics (G: ≥90%, Y: 75-89%, R:<75%)	85
15	Percentage of HRGs screened for Syphilis (G: ≥90%, Y: 75-89%, R:<75%)	82
16	IDU on OST (G: ≥50%, Y: 30% to <50%, R:<30%)	4
17	Percentage of fund released to TI (G: ≥50%, Y: 45-<50%, R:<45%)	98
18	Percentage of TIs trained by Kshmata Kendra (KK) against the AAP targets (G: ≥75%, Y: 70-<75%, R:<70%)	100
19	HIV testing against Target-at risk % (G: ≥95%, Y: 80-94%, R:<80%)	211
20	HIV testing against target at hisk is (G. ≥95%, Y. 80-94%, R.<80%)	120
21	Percentage of pregnant women screened for Syphilis (G: ≥95%, Y: 80-94%, R:<80%)	134
22	Treatment provided to Syphilis reactive pregnant women (G: ≥95%, Y: 80-94%, R:<80%)	95
	· · · · · · · · · · · · · · · · · · ·	
23	Index testing among newly detected HIV positive clients (G: ≥95%, Y: 80-94%, R:<80%)	40
24	Percentage of 6 weeks - <2 months EID testing against live birth (G: ≥95%, Y: 80-94%, R:<80%)	98
25	Clients managed at DSRC against the target (G: ≥90%, Y: 75-89%, R:<75%)	131
26	STI attendees screened for HIV (G: >75%, Y: 50-75%, R:<50%)	53
27	STI attendees screened for Syphilis (G: >75%, Y: 50-75%, R:<50%)	49
28	% of pregnant women who initiated ART (G: ≥95%, Y: 80-94%, R:<80%)	99
29	Proportion of LFU-PLHIV, out of those initiated on ART in FY 2023-24 (G:<2%, Y: 2 to 5%, R:>5%)	4
30	Proportion of PLHIV initiated on ART, out of those registered in FY 2023-24 (G:>98%, Y: 95 to 98%, R:<95%)	98
31	Proportion of reported died, out of those initiated on ART in FY 202324 (G:<2%, Y: 2 to 5 %, R:>5 %)	7
32	% of SRL accredited (G:100%, Y: 80-99%, R:<80%)	100
33	% participation of ICTCs in re-testing (G: ≥95%, Y: 85-94, R:<85%)	99
34	Number of abstracts selected from studies conducted in FY21-22	0
	(G:100%, Y: >25 to <100%, R: ≤25%)	
35	Number of ongoing studies from FY22-23 (G:100%, Y: >25 to <100%,	3
36	R: ≤25%) Submission of research proposals from FY23-24 to NACO (G:100%,	1
50	Y: >25 to <100%, R: ≤25%)	'
37		2
	Secondary Data Analysis by SACS (G:2, Y: 1, R: No Secondary Data Analysis Plan Submitted)	
38	Expenditure with respect to funds released during FY 2022-23 (G: ≥90%, Y: 85 to <90%, R: <85%)	100
39	Submission of Provisional Utilization Certificate (UC) in GFR 12A for the FY 2022-23 (G : by 30-Apr-2023, Y : by 31-May-2023, R : after	12-06-2023
40	31-May-2023) Submission of audited UC in GFR 12A for the FY 2022-23 (G : by 30Jun-2023, Y : by 30-Sep-	04-12-2023
	2023, R : after 30-Sep-2023)	
41	Submission of EC/ GB ratification for approval of Expenditure incurred during FY 2021-22 (G: by 30-Jun-2022, Y: by 30-Sept-2022, R: after 30-Sept-2022)	20-10-2023
42	Timely Submission of CST-SCM Report (G:>95%, Y: 80-95%, R:<80%)	93
43	Format Adherence to CST-SCM Report (G:>95%, Y: 80-95%, R:<80%)	94
	·	
44	Timely Submission of BSD & STI-SCM Report (G: ≥90%, Y: 75- <90%, R:<75%)	75
	Green=3 Marks Yellow=2Marks Red=1 Mark No Co	olour=Not Applicable
Wei	ght points Indicator SI. No.	
	3 1, 23, 29	
	2 2, 3, 9, 10, 22, 30, 34, 42, 44	
		22 25 27 27 22 22
	4, 5, 6, 7, 8, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 24, 25, 26, 27, 28, 31, 32,	





TRIPURA

1. Status of HIV/AIDS Epidemic				
A. Epidemic Estimates (2023)				
Indicator	Male	Female	Total	
1. IPR	-	-	13.13	
2. IMR	-	-	17.50	
3. Adult (15-49 yrs) HIV Prevalence (%)	0.52	0.23	0.37	
4. Estimated people living with HIV	7,097	3,029	10,126	
5. ART coverage (%)	62.23	37.19	54.76	
6. Estimated children living with HIV	78	75	153	
7. Annual new HIV infections	939	391	1,330	
8. Annual AIDS-related deaths (ARD)	23	21	44	
9. Change in annual new HIV infections since 2010 (%)	521.85	520.63	524.41	
10. Change in annual ARD since 2010(%)	228.57	320.00	300.00	
11. EMTCT need	-	65	65	


B. High risk population size (2020-22), safe practices (2021) and prevalence (2021/2023)

Population Group	Estimates Size	Condom Use (%)	New Needle/ Syringe use (%)	HIV Prevalence (%)
1. Female Sex Workers	6,242	99.30	-	2.90
2. Men who have sex with men	876	-	ı	-
3. Injecting Drug Users	6,500	-	92.80	18.00
4. Hijra/Transgender People	159	-	ı	-
5. Migrants	35,800	-	-	-
6. Truckers	1,000	-	-	-
7. Prison inmates	5,457	-	88.20	6.00

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)

Indicator	Male	Female	Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)	29.90	15.40	-
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	31.90	11.60	-
3. Adults willing to care for a relative with HIV/AIDS in own home (%)	49.70	47.80	-
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	59.40	53.10	-
5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)	0.40	0.10	-
5.1 Condom use during last higher-risk intercourse (%)	7.60	0.00	-
6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)	0.48	0.32	-
6.1 Condom use during last higher-risk intercourse (%)	0.00	0.00	-

2. Progress on 95-95-95 (2023-24)



Indicators	Male	Female	Total*
1. Estimated PLHIV size (2023)	7,097	3,029	10,126
2. PLHIV who know their HIV Status	5,268	1,171	6,441
3. PLHIV who know their HIV status and are on ART	4,354	1,094	5,450
4. PLHIV who are on ART and tested for their viral load	1,024	511	1,536
4.1 PLHIV who are virally suppressed	975	487	1,464

A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2023-24
Schools with operational Adolescent Education Program (AEP)	400
2. Colleges with operational Red Ribbon Clubs (RRC)	31
3. Persons trained under mainstreaming	1,103
4. No. of calls received at helpline	_

B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management

Indicator	2023-24			
NACO Supported Designated STI/	18			
RTI Clinics (DSRC)	Male	Female	TG	Total
2. Total STI/RTI Clients managed				61,908
3. RPR Tests conducted	17,493	18,506	35	36,034
4. Syphilis seropositivity (%)	0.34	0.12	2.86	0.23

4. Prevention of new HIV infections among high-risk group and bridge population

A. Targeted Intervention (TI) Projects and Opioid Substitution Therapy (OST)

Indicator	2023-24
1. Targeted Intervention (TI) Projects	15
2. OST centres (Excluding Satellite OST centres)	6

B. Female Sex Workers

Di i dillale dell'i i di ilei	
Indicator	2023-24
1. Estimated size	6,242
2. Coverage (%)	>=95
3. Condoms distributed	4,82,750
4. Tested for HIV (April 2022-September 2022)	3,419
4.1. HIV sero-positive (%)	0.23
4.1.1. Linked to ART	5
5. Tested for HIV (October 2022 -March 2023)	3,763
5.1. HIV sero-positive (%)	0.16
5.1.1. Linked to ART	7
6. Clinic Visits	14,303
7. STI/RTI treated	231
8. Presumptive treatment	1,234

C. Men who have Sex with Men

Indicatort	2023-24
1. Estimated size	875
2. Coverage (%)	>=95
3. Condoms distributed	56,693
4. Tested for HIV (April 2022-September 2022)	582
4.1. HIV sero-positive (%)	1.37
4.1.1. Linked to ART	8
5. Tested for HIV (October 2022 -March 2023)	633
5.1. HIV sero-positive (%)	1.58
5.1.1. Linked to ART	10
6. Clinic Visits	2,320
7. STI/RTI treated	20
8. Presumptive treatment	196

D. Injecting Drug Users	
Indicator	2023-24
1. Estimated size	6,499
2. Coverage (%)	>=95
3. Needles distributed	14,71,501
4. Syringes distributed	15,73,732
5. On OST	2,640
6. Tested for HIV (April 2022 -September 2022)	4,292
6.1. HIV sero-positive (%)	10.09
6.1.1 Linked to ART	351
7. Tested for HIV (October 2022 -March 2023)	4,494
7.1. HIV sero-positive (%)	4.61
7.1.1. Linked to ART	152

E. Hijra/Transgender person	
Indicator	2023-24
1. Estimated size	158
2. Coverage (%)	89
3. Condoms distributed	5,330
4. Tested for HIV (April 2022-September 2022)	63
4.1. HIV sero-positive (%)	0.00
4.1.1. Linked to ART	-
5. Tested for HIV (October 2022 -March 2023)	59
5.1. HIV sero-positive (%)	0.00
5.1.1. Linked to ART	-
6. Clinic Visits	247
7. STI/RTI treated	-
8. Presumptive treatment	102

F. Migrants	
Indicator	2023-24
1. Estimated size	35,800
2. Coverage (%)	58
3. Tested for HIV	4,923
3.1. HIV sero-positive (%)	0.10
3.2. Linked to ART	5

G. Truckers	
Indicator	2023-24
1. Estimated size	1,000
2. Coverage (%)	>=95
3. Tested for HIV	1,677
3.1. HIV sero-positive (%)	0.60
3.2. On ART	8

H. Prison Inmates					
Indicator	2023-24				
1. Total prisons	13				
2. Prisons covered under programme	12				
3. Total inmates admitted	5,457				
4. Inmates Covered (%)	61				
5. Tested for HIV	3,340				
5.1. HIV sero-positive (%)	2.04				
5.2. On ART (%)	73.53				

I. Link Worker Scheme	
Indicator	2023-24
1. Districts covered under scheme	2
Vulnerable population covered	20,888
3. Tested for HIV	16,839
3.1. HIV sero-positive (%)	0.43
3.2. Linked to ART (%)	98.63

J. Opioid Substitution Therapy	
Indicator	2023-24
1. OST Centres	6
1.1. OSTC in Public Health Settings	6
1.2. OSTC in NGO Settings	-
1.3. No. of Satellite OST Centres	5
2. IDU on OST	2,640

A. HIV counselling and testing services (HCTS)

The first country and cooming continues (,
Indicator	2023-24
1. HCTC confirmatory facilities	26
2. Sampoorna Suraksha Kendras	-

B. HIV testing among vulnerable population (excluding pregnant women)

Indicator	2023-24			
	Male	Female	TG	Total
1. Tested for HIV	87,652	47,582	35	1,35,269
1.1 HIV Positives	1,594	159	1	1,754
1.2 HIV sero -positivity (%)	1.82	0.33	2.86	1.30
Spouse/sexual partner of HIV positive people tested	497	281	-	778
2.1 HIV Positives	88	73	1	162
2.2 HIV sero -positivity (%)	18	26	-	20.82
No. of contacts with 'at- risk' population through 'Sampoorna Suraksha'	-	-	-	-

6. Initiation and retention on ART of HIV infected people

A. Treatment facilities

Indicator	2023-24
1. ART Centres	3
2.Centre of Excellence	
2.1. Centre of Excellence (Adult)	-
2.2 Centre of Excellent (Paediatric)	-
3. Link ART Centres	5
4. Care Support Centres	1

B. Treatment uptake

Indicator	2023-24			
	Male	Female	TG	Total
HIV positive cases diagnosed (At ICTC)	1,594	195	1	1,790
New PLHIV Registered at ART center	1,527	183	1	1,711
2.1 Initiated on ART	1,524	183	1	1,708
3. PLHIV alive and on ART	4,354	1,094	2	5,450
4. 12 months retention on ART (%)				54.3
5. Lost to follow-up cases	940	91	-	1,031

A. Laboratory facilities and service uptake	
Indicator 1. Viral load laboratories (programme and non-	2023-2
programme labs) 1.1 Accredited Viral load laboratories (out of	
64 VL labs)	
2. Viral load tests conducted	1,64
2.1. Virally suppressed (%)	93.
3. National reference laboratories (NRL)	
3.1 Accredited NRL	
4. State reference laboratories (SRL)	
4.1 Accredited SRL	
5. CD4 machines	
5.1 CD4 tests conducted	1,38
6. External Quality Assurance of ICTC	
6.1 Average Participation (%)	10
6.2. Average Discordance (%)	0.0
7. "Certificate of Excellence" by NACO	
7.1 No. of ICTCs received "Certificate of Excellence"	
8. Elimination of mother to child trans HIV & Syphilis	mission of
A. HIV	
Indicator	2023-2
1. Estimated pregnant women (PW)	59,09
2. HIV testing among PW	46,76
3. HIV sero-positivity (%) among tested	0.0
	0.0
4. HIV Positive PW (old + new detections)	
4. HIV Positive PW (old + new detections) 4.1 On life-long ART	6
	6
4.1 On life-long ART	6 4
4.1 On life-long ART 5. Live births among HIV positive PW	6 4 1 94.1
4.1 On life-long ART 5. Live births among HIV positive PW 5.1 Babies given ARV Prophylaxis (%)	6 4 1 94.1
4.1 On life-long ART 5. Live births among HIV positive PW 5.1 Babies given ARV Prophylaxis (%) 6. Babies tested HIV (6 week- 6 month) 6.1 Babies confirmed HIV Positive	6 4 1 94.1
4.1 On life-long ART 5. Live births among HIV positive PW 5.1 Babies given ARV Prophylaxis (%) 6. Babies tested HIV (6 week- 6 month) 6.1 Babies confirmed HIV Positive (6 week- 6 month)	6 4 1 94.1
4.1 On life-long ART 5. Live births among HIV positive PW 5.1 Babies given ARV Prophylaxis (%) 6. Babies tested HIV (6 week- 6 month) 6.1 Babies confirmed HIV Positive (6 week- 6 month) 7. HIV testing among exposed babies at 18 months	6 4 1 94.1
4.1 On life-long ART 5. Live births among HIV positive PW 5.1 Babies given ARV Prophylaxis (%) 6. Babies tested HIV (6 week- 6 month) 6.1 Babies confirmed HIV Positive (6 week- 6 month) 7. HIV testing among exposed babies at 18 months 7.1 HIV exposed babies tested at 18 months	6 4 1 94.1
4.1 On life-long ART 5. Live births among HIV positive PW 5.1 Babies given ARV Prophylaxis (%) 6. Babies tested HIV (6 week- 6 month) 6.1 Babies confirmed HIV Positive (6 week- 6 month) 7. HIV testing among exposed babies at 18 months 7.1 HIV exposed babies tested at 18 months 7.2 Babies confirmed HIV positive at 18 months 8. Total Babies Identified HIV Positive (6 weeks to	6 4 1 94.1
4.1 On life-long ART 5. Live births among HIV positive PW 5.1 Babies given ARV Prophylaxis (%) 6. Babies tested HIV (6 week- 6 month) 6.1 Babies confirmed HIV Positive (6 week- 6 month) 7. HIV testing among exposed babies at 18 months 7.1 HIV exposed babies tested at 18 months 7.2 Babies confirmed HIV positive at 18 months 8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months) 9. HIV positive babies initiated on ART	6 4 1 94.1
4.1 On life-long ART 5. Live births among HIV positive PW 5.1 Babies given ARV Prophylaxis (%) 6. Babies tested HIV (6 week- 6 month) 6.1 Babies confirmed HIV Positive (6 week- 6 month) 7. HIV testing among exposed babies at 18 months 7.1 HIV exposed babies tested at 18 months 7.2 Babies confirmed HIV positive at 18 months 8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months)	6 4 1 94.1 1
4.1 On life-long ART 5. Live births among HIV positive PW 5.1 Babies given ARV Prophylaxis (%) 6. Babies tested HIV (6 week- 6 month) 6.1 Babies confirmed HIV Positive (6 week- 6 month) 7. HIV testing among exposed babies at 18 months 7.1 HIV exposed babies tested at 18 months 7.2 Babies confirmed HIV positive at 18 months 8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months) 9. HIV positive babies initiated on ART	6 4 1 94.1 1
4.1 On life-long ART 5. Live births among HIV positive PW 5.1 Babies given ARV Prophylaxis (%) 6. Babies tested HIV (6 week- 6 month) 6.1 Babies confirmed HIV Positive	2023-2 53,79
4.1 On life-long ART 5. Live births among HIV positive PW 5.1 Babies given ARV Prophylaxis (%) 6. Babies tested HIV (6 week- 6 month) 6.1 Babies confirmed HIV Positive (6 week- 6 month) 7. HIV testing among exposed babies at 18 months 7.1 HIV exposed babies tested at 18 months 7.2 Babies confirmed HIV positive at 18 months 8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months) 9. HIV positive babies initiated on ART B. Syphilis Indicator 1. Syphilis testing among PW	2023-2 53,79
4.1 On life-long ART 5. Live births among HIV positive PW 5.1 Babies given ARV Prophylaxis (%) 6. Babies tested HIV (6 week- 6 month) 6.1 Babies confirmed HIV Positive	2023-2 53,79
4.1 On life-long ART 5. Live births among HIV positive PW 5.1 Babies given ARV Prophylaxis (%) 6. Babies tested HIV (6 week- 6 month) 6.1 Babies confirmed HIV Positive	2023-2 53,79 0.0
4.1 On life-long ART 5. Live births among HIV positive PW 5.1 Babies given ARV Prophylaxis (%) 6. Babies tested HIV (6 week- 6 month) 6.1 Babies confirmed HIV Positive	2023-2 53,79

2. State designated/appointed ombudsman

Yes

10. HIV-TB Co-morbidities								
A. HRG and Bridge Population								
Indicator	Indicator 2023-24							
	Quarter	FSW	MSM	IDU	TG	Migrants	Truckers	Total
	Quarter 1	3,355	356	6,097	26	1,230	399	11,463
Screened for TB	Quarter 2	4,273	422	6,894	71	862	489	13,011
Screened for TB	Quarter 3	4,676	473	7,507	86	1,241	535	14,518
	Quarter 4	5,022	478	7,691	89	981	558	14,819
	Quarter 1	35	6	125	-	1	2	169
Tested for TB	Quarter 2	17	-	107	-	-	-	124
lested for TB	Quarter 3	11	5	32	-	-	-	48
	Quarter 4	12	-	47	-	-	-	59
	Quarter 1	-	-	-	-	-	1	1
Diagrapas d with TD	Quarter 2	-	-	2	-	-	-	2
Diagnosed with TB	Quarter 3	1	-	2	-	-	-	3
	Quarter 4	-	-	2	-	-	-	2
	Quarter 1	-	-	-	-	-	-	-
Initiated on TB	Quarter 2	-	-	2	-	-	-	2
treatment	Quarter 3	-	-	1	-	-	-	1
	Quarter 4	-	-	-	-	-	-	-

B. HIV-TB Coinfected at ART Centre 2023-24 Indicator PLHIV with presumptive TB Co-infected enrolled at ARTC PLHIV PLHIV PLHIV PLHIV Co-infected initiated on ART PLHIV tested for TB attending diagnosed with TB initiated on IPT Moths underwent ART Centre 4S screening Apr - 23 23 17 18 1,636 1,631 2 7 2,098 28 24 May - 23 2,087 3 1,947 1,939 26 24 Jul - 23 2,186 2,168 32 32 2 5 2,159 2,146 15 13 Aug - 23 4 Sep - 23 2,181 2,175 18 18 Oct - 23 2,087 2,079 21 18 3 3 2,081 35 2,075 30 Nov - 23 Dec - 23 2,400 2,397 21 19 11 Jan - 24 2,466 2,464 19 2 16 2 2,466 19 Feb - 24 2,464 16 Mar - 24 2,659 2,659 34 28 1 18 April 2023-27 March 2024

		State/UT	Tripura
		Rank	23
SI. No.	Maximum Mar		177
1	Obtained Mark		123 (69%)
2	_	%, Y: 80-94%, R:<80%)	64 85
3		≥95%, Y: 80-94%, R:<80%) 5%, Y: 80-94%, R:<80%)	>=95
4		so, 1: 60-74%, K:<60%) sency of Social Media updates (G: ≥ 45, Y:40- 44, R:<40 indigenous posts) of	
4	Q1, Q2, Q3 &	· · · · · · · · · · · · · · · · · · ·	30
5	Status of AEP i	ntegration in state school curriculum (G:Yes, R:No)	Yes
6	Status of SCA	(G: At least one meeting held since 2020, R: other than G)	Meeting held in 2015
7	Status of State	Rules (G: Notified, R: Not notified)	Notified
8	Status of Omb	udsman (G: Appointed, R: Not appointed)	Appointed
9	TI/LWS onboa	rding (G: ≥95%, Y: 90-<95%, R:<90%)	100
10		ng (G: ≥95%, Y: 90-<95%, R:<90%)	55
11		RG against estimates (G: ≥90%, Y: 80-<90%, R:<80%)	107
12	HIV testing am	ong HRG (G: ≥95%, Y: 90-<95%, R:<90%)	69
13		ong prisoners (G: ≥50%, Y: 40% to <50%, R:<40%)	59
4		IRGs at TI-Clinics (G: ≥90%, Y: 75-89%, R:<75%)	83
5		HRGs screened for Syphilis (G: ≥90%, Y: 75-89%, R:<75%)	79
6		i: ≥50%, Y: 30% to <50%, R:<30%)	69
7	J	fund released to TI (G: ≥50%, Y: 45-<50%, R:<45%)	100
8	_	TIs trained by Kshmata Kendra (KK) against the AAP targets (G: ≥75%, Y: 70-	100
9	<75%, R:<70%	o) ainst Target-at risk % (G: ≥95%, Y: 80-94%, R:<80%)	104
20			196 78
20		ainst target-PW (G: ≥95%, Y: 80-94%, R:<80%)	90
		pregnant women screened for Syphilis (G: ≥95%, Y: 80-94%, R:<80%)	
22		vided to Syphilis reactive pregnant women (G: ≥95%, Y: 80-94%, R:<80%)	95
23	Index testing a	mong newly detected HIV positive clients (G: ≥95%, Y: 80-94%, R:<80%)	18
24	Percentage of R:<80%)	6 weeks - <2 months EID testing against live birth (G: ≥95%, Y: 80-94%,	100
:5	Clients manag	ed at DSRC against the target (G: ≥90%, Y: 75-89%, R:<75%)	96
:6	STI attendees	screened for HIV (G: >75%, Y: 50-75%, R:<50%)	97
7	STI attendees	screened for Syphilis (G: >75%, Y: 50-75%, R:<50%)	99
28	% of pregnant	women who initiated ART (G: ≥95%, Y: 80-94%, R:<80%)	79
29	Proportion of L R:>5%)	FU-PLHIV, out of those initiated on ART in FY 2023-24 (G:<2%, Y: 2 to 5%,	16
30	Proportion of F to 98%, R:<95	PLHIV initiated on ART, out of those registered in FY 2023-24 (G:>98%, Y: 95 %)	100
31	Proportion of r R:>5 %)	eported died, out of those initiated on ART in FY 202324 (G:<2%, Y: 2 to 5 %	5, 2
32	% of SRL accre	dited (G:100%, Y: 80-99%, R:<80%)	100
33	% participation	n of ICTCs in re-testing (G: ≥95%, Y: 85-94, R:<85%)	100
4	Number of abs	stracts selected from studies conducted in FY21-22	3
	(G:100%, Y: >2	25 to <100%, R: ≤25%)	
5	Number of ong R: ≤25%)	going studies from FY22-23 (G:100%, Y: >25 to <100%,	1
6		research proposals from FY23-24 to NACO (G:100%,	1
	Y: >25 to <100	0%, R: ≤25%)	
7	Secondary Dat	a Analysis by SACS (G:2, Y: 1, R: No Secondary Data Analysis Plan Submitted) 2
8		ith respect to funds released during FY 2022-23 (G: > <90%, R: <85%)	108
39	Submission of	Provisional Utilization Certificate (UC) in GFR 12A for the FY 2022-23 (G : by	08-05-2023
	30-Apr-2023, \ 31-May-2023)	∕ : by 31-May-2023, R : after	
ŀO	Submission of 2023, R : after	audited UC in GFR 12A for the FY 2022-23 (G : by 30Jun-2023, Y : by 30-Sep 30-Sep-2023)	07-07-2023
ŀ1		EC/ GB ratification for approval of Expenditure incurred during FY 2021-22	20-07-2023
	(G: by 30-Jun- R: after 30-Sep	2022, Y: by 30-Sept-2022, pt-2022)	
2	Timely Submis	sion of CST-SCM Report (G:>95%, Y: 80-95%, R:<80%)	89
13	Format Adhere	ence to CST-SCM Report (G:>95%, Y: 80-95%, R:<80%)	91
14	Timely Submis	sion of BSD & STI-SCM Report (G: ≥90%, Y: 75- 75%)	50
	Green=3 Marks		Colour=Not Applicable
۸/۵:			o Colour=Not Applicable
veic	ght points	Indicator SI. No.	
	3	1, 23, 29	
	2	2, 3, 9, 10, 22, 30, 34, 42, 44	
	-	4, 5, 6, 7, 8, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 24, 25, 26, 27, 28, 31,	







1. Status of HIV/AIDS Epidemic			
A. Epidemic Estimates (2023)			
Indicator	Male	Female	Total
1. IPR	-	-	3.97
2. IMR	-	-	2.06
3. Adult (15-49 yrs) HIV Prevalence (%)	0.13	0.08	0.10
4. Estimated people living with HIV	1,22,446	75,006	1,97,452
5. ART coverage (%)	55.09	73.90	62.43
6. Estimated children living with HIV	3,120	2,766	5,886
7. Annual new HIV infections	5,201	2,640	7,841
8. Annual AIDS-related deaths (ARD)	1,447	369	1,816
9. Change in annual new HIV infections since 2010 (%)	-31.45	-32.89	-31.94
10. Change in annual ARD since 2010(%)	-71.74	-83.10	-75.14
11. EMTCT need	-	2,097	2,097

B. High risk population size (2020-22), safe practices (2021) and prevalence (2021/2023) Condom Use **HIV Prevalence** New Needle/ Estimates Size Population Group (%) Syringe use (%) (%) 97.60 1. Female Sex Workers 40,480 1.04 84.20 2. Men who have sex with men 19,668 1.10 3. Injecting Drug Users 35,412 89.10 5.45 4. Hijra/Transgender People 9,846 3.60 5. Migrants 3,27,000 4.10 0.67 6. Truckers 72,000 73.60 58.00 0.70 2,31,543 76.90 43.20 2.50 7. Prison inmates

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)			
Indicator	Male	Female	Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)	22.10	13.10	-
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	19.80	11.60	-
3. Adults willing to care for a relative with HIV/AIDS in own home (%)	70.00	64.10	-
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	67.40	57.60	-
5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)	5.30	0.70	-
5.1 Condom use during last higher-risk intercourse (%)	58.50	70.50	-
6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)	8.67	1.32	-
6.1 Condom use during last higher-risk intercourse (%)	60.43	79.17	-

2. Progress on	95-95-95 (20)	23-24)
55 58 59 61 65 69	82 84 84 84 86 87	88 87 85 93
PLHIV who know their HIV status (%)	PLHIV who know their HIV status and are on ART (%)	PLHIV who are on ART and virally suppressed (%)
■ 2018-19 ■ 2019-20	■ 2020-21 ■ 2021-22	■ 2022-23 ■ 2023-24

Indicators	Male	Female	Total*
1. Estimated PLHIV size (2023)	1,22,446	75,006	1,97,452
2. PLHIV who know their HIV Status	75,513	59,280	1,35,232
3. PLHIV who know their HIV status and are on ART	64,301	52,735	1,17,413
4. PLHIV who are on ART and tested for their viral load	44,496	39,137	83,906
4.1 PLHIV who are virally suppressed	43,265	38,295	81,829

^{*} Including of H/TG PLHIV

A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2023-24
Schools with operational Adolescent Education Program (AEP)	-
2. Colleges with operational Red Ribbon Clubs (RRC)	373
3. Persons trained under mainstreaming	22,556
4. No. of calls received at helpline	-

B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management

Indicator	2023-24			
NACO Supported Designated STI/	115			
RTI Clinics (DSRC)	Male	Female	TG	Total
2. Total STI/RTI Clients managed				14,91,120
3. RPR Tests conducted	1,51,766	2,38,112	2,618	3,92,496
4. Syphilis seropositivity (%)	0.82	0.21	1.26	0.45

4. Prevention of new HIV infections among high-risk group and bridge population

A. Targeted Intervention (TI) Projects and Opioid Substitution Therapy (OST)

Indicator	2023-24
1. Targeted Intervention (TI) Projects	87
2. OST centres (Excluding Satellite OST centres)	18

B. Female Sex Workers

Indicator	2023-24
1. Estimated size	40,479
2. Coverage (%)	79.96
3. Condoms distributed	61,58,933
4. Tested for HIV (April 2022-September 2022)	22,843
4.1. HIV sero-positive (%)	0.25
4.1.1. Linked to ART	44
5. Tested for HIV (October 2022 -March 2023)	25,597
5.1. HIV sero-positive (%)	0.19
5.1.1. Linked to ART	44
6. Clinic Visits	90,195
7. STI/RTI treated	3,068
8. Presumptive treatment	8,092

C. Men who have Sex with Men

or men uno have been unan men	
Indicatort	2023-24
1. Estimated size	19,668
2. Coverage (%)	82
3. Condoms distributed	26,87,910
4. Tested for HIV (April 2022-September 2022)	11,905
4.1. HIV sero-positive (%)	0.66
4.1.1. Linked to ART	71
5. Tested for HIV (October 2022 -March 2023)	11,900
5.1. HIV sero-positive (%)	0.76
5.1.1. Linked to ART	75
6. Clinic Visits	46,791
7. STI/RTI treated	682
8. Presumptive treatment	3,158

D. Injecting Drug Users	
Indicator	2023-24
1. Estimated size	35,412
2. Coverage (%)	76
3. Needles distributed	1,12,43,395
4. Syringes distributed	58,38,496
5. On OST	657
6. Tested for HIV (April 2022 -September 2022)	19,067
6.1. HIV sero-positive (%)	1.04
6.1.1 Linked to ART	160
7. Tested for HIV (October 2022 -March 2023)	20,179
7.1. HIV sero-positive (%)	0.78
7.1.1. Linked to ART	141

E. Hijra/Transgender person	
Indicator	2023-24
1. Estimated size	9,846
2. Coverage (%)	65
3. Condoms distributed	10,95,519
4. Tested for HIV (April 2022-September 2022)	4,421
4.1. HIV sero-positive (%)	0.57
4.1.1. Linked to ART	25
5. Tested for HIV (October 2022 -March 2023)	5,235
5.1. HIV sero-positive (%)	0.50
5.1.1. Linked to ART	24
6. Clinic Visits	19,279
7. STI/RTI treated	244
8. Presumptive treatment	1,450

F. Migrants	
Indicator	2023-24
1. Estimated size	3,27,000
2. Coverage (%)	38
3. Tested for HIV	18,279
3.1. HIV sero-positive (%)	0.26
3.2. Linked to ART	43

G. Truckers	
Indicator	2023-24
1. Estimated size	72,000
2. Coverage (%)	76
3. Tested for HIV	14,149
3.1. HIV sero-positive (%)	0.20
3.2. On ART	24

H. Prison Inmates	
Indicator	2023-24
1. Total prisons	75
2. Prisons covered under programme	74
3. Total inmates admitted	2,31,543
4. Inmates Covered (%)	91
5. Tested for HIV	2,11,262
5.1. HIV sero-positive (%)	0.37
5.2. On ART (%)	>=95

I. Link Worker Scheme	
Indicator	2023-24
Districts covered under scheme	9
Vulnerable population covered	1,70,791
3. Tested for HIV	58,207
3.1. HIV sero-positive (%)	0.19
3.2. Linked to ART (%)	>=95

J. Opioid Substitution Therapy	
Indicator	2023-24
1. OST Centres	18
1.1. OSTC in Public Health Settings	18
1.2. OSTC in NGO Settings	-
1.3. No. of Satellite OST Centres	3
2. IDU on OST	2,380

A. HIV counselling and testing services (HCTS)

A. HIV counselling and testing services (HC15)				
Indicator	2023-24			
1. HCTC confirmatory facilities	399			
2. Sampoorna Suraksha Kendras	26			

B. HIV testing among vulnerable population (excluding pregnant women)

Indicator	2023-24				
	Male	Female	TG	Total	
1. Tested for HIV	19,40,374	16,89,222	6,116	36,35,712	
1.1 HIV Positives	10,864	4,720	109	15,693	
1.2 HIV sero -positivity (%)	0.56	0.28	1.78	0.43	
Spouse/sexual partner of HIV positive people tested	4,707	5,142	23	9,872	
2.1 HIV Positives	2,475	2,178	12	4,665	
2.2 HIV sero -positivity (%)	53	42	52	47.25	
No. of contacts with 'at- risk' population through 'Sampoorna Suraksha'	-	-	-	24,726	

6. Initiation and retention on ART of HIV infected people

A. Treatment facilities

Indicator	2023-24
1. ART Centres	57
2.Centre of Excellence	
2.1. Centre of Excellence (Adult)	1
2.2 Centre of Excellent (Paediatric)	-
3. Link ART Centres	33
4. Care Support Centres	27

B. Treatment uptake

Indicator	2023-24			
	Male	Female	TG	Total
HIV positive cases diagnosed (At ICTC)	10,864	5,702	109	16,675
New PLHIV Registered at ART center	10,329	5,434	74	15,837
2.1 Initiated on ART	9,961	5,342	71	15,374
3. PLHIV alive and on ART	64,301	52,735	377	1,17,413
4. 12 months retention on ART (%)				93.7
5. Lost to follow-up cases	3,740	1,413	24	5,177

7. Viral Suppression and laboratories	
A. Laboratory facilities and service uptake	
Indicator	2023-2
Viral load laboratories (programme and non- programme labs)	
1.1 Accredited Viral load laboratories (out of 64 VL labs)	
2. Viral load tests conducted	91,50
2.1. Virally suppressed (%)	>=9
3. National reference laboratories (NRL)	
3.1 Accredited NRL	
4. State reference laboratories (SRL)	
4.1 Accredited SRL	
5. CD4 machines	3
5.1 CD4 tests conducted	48,98
6. External Quality Assurance of ICTC	
6.1 Average Participation (%)	>=9
6.2. Average Discordance (%)	0.0
7. "Certificate of Excellence" by NACO	
7.1 No. of ICTCs received "Certificate of Excellence"	4
8. Elimination of mother to child trans HIV & Syphilis A. HIV	mission of
Indicator	2023-2
1. Estimated pregnant women (PW)	66,41,05
2. HIV testing among PW	66,36,13
3. HIV sero-positivity (%) among tested	0.0
4. HIV Positive PW (old + new detections)	2,00
4.1 On life-long ART	1,91
5. Live births among HIV positive PW	1,33
5.1 Babies given ARV Prophylaxis (%)	>=9
6. Babies tested HIV (6 week- 6 month)	1,39
6.1 Babies confirmed HIV Positive (6 week- 6 month)	
7. HIV testing among exposed babies at 18 months	
7.1 HIV exposed babies tested at 18 months	1,01
7.2 Babies confirmed HIV positive at 18 months	3
8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months)	4
9. HIV positive babies initiated on ART	3
B. Syphilis	
Indicator	2023-2
1. Syphilis testing among PW	55,89,89
2.Sero-positivity (%) among tested	0.0
3. Put on treatment	68
9. Elimination of HIV/AIDS related Stigma and Discrimination	
Indicator	2023-2
State rules notified for HIV/AIDS Prevention and	2023-2
Control Act (2017)	Ye
	I .

2. State designated/appointed ombudsman

Yes

10. HIV-TB Co-morbidities								
A. HRG and Bridge Population								
Indicator	2023-24							
	Quarter	FSW	MSM	IDU	TG	Migrants	Truckers	Total
	Quarter 1	19,466	10,660	18,065	4,029	4,962	10,990	68,172
C IC TD	Quarter 2	23,545	12,292	22,185	5,047	7,692	11,050	81,811
Screened for TB	Quarter 3	24,502	12,009	21,841	4,988	10,199	10,857	84,396
	Quarter 4	25,794	12,831	22,348	5,169	11,959	10,719	88,820
	Quarter 1	361	176	310	45	25	28	945
To the older TD	Quarter 2	747	259	481	82	32	31	1,632
Tested for TB	Quarter 3	716	309	486	94	53	40	1,698
	Quarter 4	769	382	550	83	51	41	1,876
Diagnosed with TB	Quarter 1	1	8	8	4	3	1	25
	Quarter 2	8	3	15	2	-	1	29
	Quarter 3	6	7	7	1	2	3	26
	Quarter 4	6	3	9	-	4	-	22
	Quarter 1	2	8	6	4	3	1	24
Initiated on TB	Quarter 2	7	3	13	2	-	1	26
treatment	Quarter 3	6	7	5	1	1	3	23
	Quarter 4	5	2	10	-	4	-	21

B. HIV-TB Coinfected at ART Centre Indicator 2023-24 PLHIV PLHIV PLHIV with PLHIV PLHIV Co-infected enrolled at Co-infected initiated on ART PLHIV tested for TB presumptive TB diagnosed with TB initiated on IPT Moths attending underwent ART Centre 4S screening ARTC 80,689 80,595 Apr - 23 1,813 1,804 182 1,384 86,350 1,826 1,822 230 1,413 May - 23 86,315 Jun - 23 84,317 84,182 1,864 1,859 182 1,975 Jul - 23 87,180 87,157 2,051 2,045 183 2,084 86,170 2,102 2,097 154 1,057 Aug - 23 86,170 Sep - 23 88,636 88,636 2,148 2,126 118 1,385 85,895 85,895 2,048 1,953 Oct - 23 2,042 135 137 87,080 85,885 1,920 1,448 Nov - 23 1,915 Dec - 23 97,260 97,260 2,398 2,394 141 1,514 Jan - 24 95,392 95,392 2,201 2,198 134 1,369 1,200 Feb - 24 88,493 88,493 2,201 2,195 169 Mar - 24 90,858 90,854 2,202 2,196 186 1,369 April 2023-3,120 2,973 March 2024

NATIONAL AIDS & STD CONTROL PROGRAMME STATE/UT SCORECARD, FY 2023-24

		State/UT	Uttar Pradesh
C1		Rank	28
SI. No.	Maximum Ma		177
	Obtained Ma		119 (67%)
2		95%, Y: 80-94%, R:<80%)	69 87
3		5:≥95%, Y: 80-94%, R:<80%) ±95%, Y: 80-94%, R:<80%)	>=95
4	-	guency of Social Media updates (G: ≥ 45, Y:40- 44, R:<40 indigenous posts) of	
4	Q1, Q2, Q3		3
5	Status of AEF	P integration in state school curriculum (G:Yes, R:No)	No
6		A (G: At least one meeting held since 2020, R: other than G)	Meeting held in 2020
7		te Rules (G: Notified, R: Not notified)	Notified
8		budsman (G: Appointed, R: Not appointed)	Appointed
9		earding (G: ≥95%, Y: 90-<95%, R:<90%)	98
0		ding (G: ≥95%, Y: 90-<95%, R:<90%)	81 71
2	_	HRG against estimates (G: ≥90%, Y: 80-<90%, R:<80%) mong HRG (G: ≥95%, Y: 90-<95%, R:<90%)	86
3		mong prisoners (G: ≥50%, Y: 40% to <50%, R:<40%)	51
4		HRGs at TI-Clinics (G: ≥90%, Y: 75-89%, R:<75%)	83
5		of HRGs screened for Syphilis (G: ≥90%, Y: 75-89%, R:<75%)	85
6		(G: ≥50%, Y: 30% to <50%, R:<30%)	21
7		of fund released to TI (G: ≥50%, Y: 45-<50%, R:<45%)	95
8		of fund released to 11 (G: ≥50%, 1: 45-<50%, R:<45%) of TIs trained by Kshmata Kendra (KK) against the AAP targets (G: ≥75%, Y: 70	
_	<75%, R:<70		
9	-	gainst Target-at risk % (G: ≥95%, Y: 80-94%, R:<80%)	227
0		gainst target-PW (G: ≥95%, Y: 80-94%, R:<80%)	79
1		of pregnant women screened for Syphilis (G: ≥95%, Y: 80-94%, R:<80%)	84
2	_	rovided to Syphilis reactive pregnant women (G: ≥95%, Y: 80-94%, R:<80%)	72
:3		among newly detected HIV positive clients (G: ≥95%, Y: 80-94%, R:<80%)	37
4	_	of 6 weeks - $<$ 2 months EID testing against live birth (G: \ge 95%, Y: 80-94%,	100
.4	R:<80%)	of 6 weeks - <2 months EID testing against live birth (G. 273%, 1. 60-74%,	100
:5	Clients mana	ged at DSRC against the target (G: ≥90%, Y: 75-89%, R:<75%)	108
6	STI attendee	s screened for HIV (G: >75%, Y: 50-75%, R:<50%)	54
:7	STI attendee	s screened for Syphilis (G: >75%, Y: 50-75%, R:<50%)	31
8	% of pregnar	nt women who initiated ART (G: ≥95%, Y: 80-94%, R:<80%)	95
9		FLFU-PLHIV, out of those initiated on ART in FY 2023-24 (G:<2%, Y: 2 to 5%,	2
80	R:>5%)	f BLUIN :-::::	97
.0	to 98%, R:<9	f PLHIV initiated on ART, out of those registered in FY 2023-24 (G:>98%, Y: 95 '5%)	97
1	Proportion of R:>5 %)	f reported died, out of those initiated on ART in FY 202324 (G:<2%, Y: 2 to 5 %	7
2		redited (G:100%, Y: 80-99%, R:<80%)	100
3		on of ICTCs in re-testing (G: ≥95%, Y: 85-94, R:<85%)	95
4		bstracts selected from studies conducted in FY21-22	2
		>25 to <100%, R: ≤25%)	_
5		ngoing studies from FY22-23 (G:100%, Y: >25 to <100%,	0
	R: ≤25%)		
6	Submission o	of research proposals from FY23-24 to NACO (G:100%,	2
		00%, R: ≤25%)	
7	Secondary D	ata Analysis by SACS (G:2, Y: 1, R: No Secondary Data Analysis Plan Submitted	d) 2
8		with respect to funds released during FY 2022-23 (G:	101
	-	to <90%, R: <85%)	45.05.0000
19		of Provisional Utilization Certificate (UC) in GFR 12A for the FY 2022-23 (G : by , Y : by 31-May-2023, R : after 3)	15-05-2023
0		of audited UC in GFR 12A for the FY 2022-23 (G : by 30Jun-2023, Y : by 30-Se	o- 26-10-2023
		er 30-Sep-2023)	
1		of EC/ GB ratification for approval of Expenditure incurred during FY 2021-22 n-2022, Y: by 30-Sept-2022, ept-2022)	21-07-2023
2		ission of CST-SCM Report (G:>95%, Y: 80-95%, R:<80%)	94
3	-	erence to CST-SCM Report (G:>95%, Y: 80-95%, R:<80%)	96
4		ission of BSD & STI-SCM Report (G: ≥90%, Y: 75-	83
	Green=3 Mark		o Colour=Not Applicable
Veid	ght points	Indicator SI. No.	2 2010ai – Not Applicable
· veic	-		
	2	1, 23, 29	
		4, 5, 6, 7, 8, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 24, 25, 26, 27, 28, 31	22 22 25 27 27 20 20 40
		- i - 4. J. G. 7. G. I I. IZ. IJ. I4. IJ. IG. IZ. I B. IZ. IB. IZ. ZU. Z I. Z4. Z5. Z6. Z7. Z8. 31.	34 33 33 30 37 38 39 40

HIV testing against target-at risk (SI. No. 19): over-achievements above 120% are marked in red



UTTARAKHAND

1. Status of HIV/AIDS Epidemic					
A. Epidemic Estimates (2023)					
Indicator	Male	Female	Total		
1. IPR	-	-	3.89		
2. IMR	-	-	1.68		
3. Adult (15-49 yrs) HIV Prevalence (%)	0.15	0.10	0.13		
4. Estimated people living with HIV	7,255	5,046	12,301		
5. ART coverage (%)	58.20	54.45	56.85		
6. Estimated children living with HIV	177	151	328		
7. Annual new HIV infections	289	190	479		
8. Annual AIDS-related deaths (ARD)	99	85	184		
9. Change in annual new HIV infections since 2010 (%)	-56.61	-53.32	-55.36		
10. Change in annual ARD since 2010(%)	-52.86	-7.61	-39.07		
11. EMTCT need	-	80	80		

B. High risk population size (2020-22), safe practices (2021) and prevalence (2021/2023) Condom Use **HIV Prevalence** New Needle/ Estimates Size Population Group (%) Syringe use (%) (%) 94.90 1. Female Sex Workers 7,213 0.42 100.00 2.68 2. Men who have sex with men 2,883 3. Injecting Drug Users 3,835 90.00 9.77 4. Hijra/Transgender People 321 5. Migrants 90,000 6. Truckers 40,000 62.40 2.10 24,325 66.70 1.38 7. Prison inmates

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)				
Indicator	Male	Female	Total	
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)	35.90	24.50	-	
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	27.10	21.50	-	
3. Adults willing to care for a relative with HIV/AIDS in own home (%)	80.70	70.30	-	
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	72.40	65.80	-	
5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)	6.30	0.00	-	
5.1 Condom use during last higher-risk intercourse (%)	61.00	-	-	
6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)	13.17	0.00	-	
6.1 Condom use during last higher-risk intercourse (%)	59.72	-	-	

2. Progress on 95-95-95 (2023-24)				
44 49 52 56 61 68	78 76 71 77 80	86 86 86 81 62 62		
PLHIV who know their HIV status (%)	PLHIV who know their HIV status and are on ART (%)	and virally suppressed (%)		
■ 2018-19 ■ 2019-20	■ 2020-21 ■ 2021-22	2 2022-23 2023-24		

Indicators	Male	Female	Total*
1. Estimated PLHIV size (2023)	7,255	5,046	12,301
2. PLHIV who know their HIV Status	5,225	3,137	8,398
3. PLHIV who know their HIV status and are on ART	4,068	2,619	6,709
4. PLHIV who are on ART and tested for their viral load	2,643	2,003	4,665
4.1 PLHIV who are virally suppressed	2,580	1,951	4,549

^{*} Including of H/TG PLHIV

3. Prevention of new HIV infections among general population

A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2023-24
Schools with operational Adolescent Education Program (AEP)	2,349
2. Colleges with operational Red Ribbon Clubs (RRC)	100
3. Persons trained under mainstreaming	-
4. No. of calls received at helpline	-

B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management

Indicator	2023-24				
NACO Supported Designated STI/	27				
RTI Clinics (DSRC)	Male	Female	TG	Total	
2. Total STI/RTI Clients managed				98,321	
3. RPR Tests conducted	8,327	24,447	31	32,805	
4. Syphilis seropositivity (%)	2.75	0.27	9.68	0.91	

4. Prevention of new HIV infections among high-risk group and bridge population

A. Targeted Intervention (TI) Projects and Opioid Substitution Therapy (OST)

Indicator	2023-24
1. Targeted Intervention (TI) Projects	35
2. OST centres (Excluding Satellite OST centres)	8

B. Female Sex Workers

C. Men who have Sex with Men

Indicator	2023-24
1. Estimated size	7,213
2. Coverage (%)	>=95
3. Condoms distributed	10,73,719
4. Tested for HIV (April 2022-September 2022)	5,275
4.1. HIV sero-positive (%)	0.15
4.1.1. Linked to ART	8
5. Tested for HIV (October 2022 -March 2023)	6,086
5.1. HIV sero-positive (%)	0.16
5.1.1. Linked to ART	10
6. Clinic Visits	22,822
7. STI/RTI treated	1,098
8. Presumptive treatment	1,582

Indicatort 2023-24 1. Estimated size 2,882 2. Coverage (%) >=95 4,32,344 3. Condoms distributed 4. Tested for HIV (April 2022-September 2022) 2,572 4.1. HIV sero-positive (%) 0.27 4.1.1. Linked to ART 5. Tested for HIV (October 2022 -March 2023) 2,683 5.1. HIV sero-positive (%) 0.41 5.1.1. Linked to ART 11 6. Clinic Visits 10,227

309

581

D. Injecting Drug Users				
Indicator	2023-24			
1. Estimated size	3,835			
2. Coverage (%)	91			
3. Needles distributed	16,04,069			
4. Syringes distributed	8,08,423			
5. On OST	2,380			
6. Tested for HIV (April 2022 -September 2022)	2,302			
6.1. HIV sero-positive (%)	1.69			
6.1.1 Linked to ART	31			
7. Tested for HIV (October 2022 -March 2023)	2,539			
7.1. HIV sero-positive (%)	1.42			
7.1.1. Linked to ART	37			

E. Hijra/Transgender person				
Indicator	2023-24			
1. Estimated size	321			
2. Coverage (%)	87			
3. Condoms distributed	42,055			
4. Tested for HIV (April 2022-September 2022)	223			
4.1. HIV sero-positive (%)	0.45			
4.1.1. Linked to ART	1			
5. Tested for HIV (October 2022 -March 2023)	255			
5.1. HIV sero-positive (%)	0.39			
5.1.1. Linked to ART	1			
6. Clinic Visits	957			
7. STI/RTI treated	53			
8. Presumptive treatment	84			

F. Migrants				
Indicator	2023-24			
1. Estimated size	90,000			
2. Coverage (%)	>=95			
3. Tested for HIV	21,702			
3.1. HIV sero-positive (%)	0.10			
3.2. Linked to ART	22			

G. Truckers	
Indicator	2023-24
1. Estimated size	40,000
2. Coverage (%)	>=95
3. Tested for HIV	6,038
3.1. HIV sero-positive (%)	0.12
3.2. On ART	5

H. Prison Inmates	
Indicator	2023-24
1. Total prisons	11
2. Prisons covered under programme	10
3. Total inmates admitted	24,325
4. Inmates Covered (%)	57
5. Tested for HIV	13,909
5.1. HIV sero-positive (%)	1.51
5.2. On ART (%)	92.38

I. Link Worker Scheme	
Indicator	2023-24
Districts covered under scheme	0
Vulnerable population covered	-
3. Tested for HIV	-
3.1. HIV sero-positive (%)	-
3.2. Linked to ART (%)	-

7. STI/RTI treated

8. Presumptive treatment

J. Opioid Substitution Therapy	
Indicator	2023-24
1. OST Centres	8
1.1. OSTC in Public Health Settings	7
1.2. OSTC in NGO Settings	1
1.3. No. of Satellite OST Centres	-
2. IDU on OST	657

5. Early detection of HIV infected people

A. HIV counselling and testing services (HCTS)

	The counseling and testing services (The	J. J,
Inc	icator	2023-24
1. l	HCTC confirmatory facilities	44
	2. Sampoorna Suraksha Kendras	1

B. HIV testing among vulnerable population (excluding pregnant women)

Indicator	2023-24			
	Male	Female	TG	Total
1. Tested for HIV	2,26,243	1,80,621	533	4,07,397
1.1 HIV Positives	1,108	332	2	1,442
1.2 HIV sero -positivity (%)	0.49	0.18	0.38	0.35
Spouse/sexual partner of HIV positive people tested	270	382	1	653
2.1 HIV Positives	88	100	-	188
2.2 HIV sero -positivity (%)	33	26	-	28.79
No. of contacts with 'at- risk' population through 'Sampoorna Suraksha'	-	-	-	861

6. Initiation and retention on ART of HIV infected people

A. Treatment facilities

Indicator	2023-24
1. ART Centres	11
2.Centre of Excellence	
2.1. Centre of Excellence (Adult)	-
2.2 Centre of Excellent (Paediatric)	-
3. Link ART Centres	13
4. Care Support Centres	2

B. Treatment uptake

Indicator	2023-24			
	Male	Female	TG	Total
HIV positive cases diagnosed (At ICTC)	1,108	394	2	1,504
New PLHIV Registered at ART center	1,121	393	3	1,517
2.1 Initiated on ART	1,076	384	3	1,463
3. PLHIV alive and on ART	4,068	2,619	22	6,709
4. 12 months retention on ART (%)				>=95
5. Lost to follow-up cases	964	402	7	1,373

7. Viral Suppression and laboratories	
A. Laboratory facilities and service uptake	
Indicator	2023-24
Viral load laboratories (programme and non- programme labs)	0
 1.1 Accredited Viral load laboratories (out of 64 VL labs) 	0
2. Viral load tests conducted	5,048
2.1. Virally suppressed (%)	94.7
3. National reference laboratories (NRL)	-
3.1 Accredited NRL	-
4. State reference laboratories (SRL)	1
4.1 Accredited SRL	1
5. CD4 machines	3
5.1 CD4 tests conducted	3,824
6. External Quality Assurance of ICTC	
6.1 Average Participation (%)	86
6.2. Average Discordance (%)	0.00
7. "Certificate of Excellence" by NACO	
7.1 No. of ICTCs received "Certificate of Excellence"	5

8. Elimination of mother to child transmission of HIV & Syphilis

HIV & Syphilis	
A. HIV	
Indicator	2023-24
1. Estimated pregnant women (PW)	2,17,250
2. HIV testing among PW	1,90,004
3. HIV sero-positivity (%) among tested	0.03
4. HIV Positive PW (old + new detections)	>=95
4.1 On life-long ART	63
5. Live births among HIV positive PW	48
5.1 Babies given ARV Prophylaxis (%)	>=95

6. Babies tested HIV (6 week- 6 month)	58
6.1 Babies confirmed HIV Positive (6 week- 6 month)	-
7. HIV testing among exposed babies at 18 months	
7.1 HIV exposed babies tested at 18 months	40
7.2 Babies confirmed HIV positive at 18 months	1
8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months)	1

B. Syphilis	
Indicator	2023-24
1. Syphilis testing among PW	2,38,907
2.Sero-positivity (%) among tested	0.01

9. Elimination of HIV/AIDS related Stigma and Discrimination

9. HIV positive babies initiated on ART

3. Put on treatment

Indicator	2023-24
1. State rules notified for HIV/AIDS Prevention and Control Act (2017)	No
2. State designated/appointed ombudsman	Yes

26

10. HIV-TB Co-mo	orbidities							
A. HRG and Bridge Population								
Indicator				202	23-24			
	Quarter	FSW	MSM	IDU	TG	Migrants	Truckers	Total
	Quarter 1	5,595	2,347	2,146	208	14,546	10,250	35,092
Screened for TB	Quarter 2	5,641	2,512	2,299	243	21,565	9,677	41,937
Screened for 1B	Quarter 3	5,598	2,454	2,250	247	24,982	10,430	45,961
	Quarter 4	5,839	2,385	2,161	236	25,877	9,621	46,119
	Quarter 1	113	16	54	7	32	3	225
Tested for TB	Quarter 2	114	43	72	10	112	11	362
rested for 16	Quarter 3	134	64	75	18	116	10	417
	Quarter 4	150	73	50	26	97	3	399
	Quarter 1	6	-	-	-	17	-	23
Diagnosed with TB	Quarter 2	4	-	2	-	13	3	22
Diagnosed with 16	Quarter 3	3	-	6	-	23	1	33
	Quarter 4	5	-	6	-	13	-	24
	Quarter 1	6	-	-	-	11	-	17
Initiated on TB	Quarter 2	4	-	2	-	13	3	22
treatment	Quarter 3	3	-	6	-	23	1	33
	Quarter 4	5	-	5	-	13	-	23

B. HIV-TB Coinfected at ART Centre Indicator 2023-24 Co-infected enrolled at PLHIV with presumptive TB PLHIV PLHIV PLHIV PLHIV Co-infected initiated on ART PLHIV tested for TB diagnosed with TB initiated on IPT Moths attending underwent ART Centre 4S screening ARTC 2,412 2,621 97 Apr - 23 61 19 96 2,703 80 44 11 88 2,553 May - 23 Jun - 23 3,013 2,721 88 85 21 59 Jul - 23 2,935 2,706 86 71 24 46 3,037 2,302 82 69 22 40 Aug - 23 Sep - 23 3,011 2,805 82 75 16 45 3,684 Oct - 23 4,150 74 14 29 115 13 37 3,264 3,020 78 Nov - 23 136 Dec - 23 3,900 3,434 178 31 16 14 Jan - 24 5,042 4,782 106 41 14 48 23 Feb - 24 3,458 3,283 123 43 38 Mar - 24 3,823 3,654 133 36 20 36 April 2023-199 136 March 2024

NATIONAL AIDS & STD CONTROL PROGRAMME STATE/UT SCORECARD, FY 2023-24

		State/UT	Uttarakhand	
SI.	Maximum Ma	Rank	22 177	
51. No.	Maximum Mar Obtained Mar		124 (70%)	
1		ss 5%, Y: 80-94%, R:<80%)	68	
2		≥95%, Y: 80-94%, R:<80%)	80	
3		95%, Y: 80-94%, R:<80%)	>=95	
4	•	uency of Social Media updates (G: ≥ 45, Y:40- 44, R:<40 indigenous posts) o		
	Q1, Q2, Q3 &			
5	Status of AEP	integration in state school curriculum (G:Yes, R:No)	Yes	
6	Status of SCA	(G: At least one meeting held since 2020, R: other than G)	Meeting held in 2019	
7	Status of State	e Rules (G: Notified, R: Not notified)	Not Notified	
8		oudsman (G: Appointed, R: Not appointed)	Appointed	
9		arding (G: ≥95%, Y: 90-<95%, R:<90%)	95	
10		ng (G: ≥95%, Y: 90-<95%, R:<90%)	100	
11		HRG against estimates (G: ≥90%, Y: 80-<90%, R:<80%)	101	
12		nong HRG (G: ≥95%, Y: 90-<95%, R:<90%)	81	
13		nong prisoners (G: ≥50%, Y: 40% to <50%, R:<40%)	52	
14		HRGs at TI-Clinics (G: ≥90%, Y: 75-89%, R:<75%)	82 82	
16		HRGs screened for Syphilis (G: ≥90%, Y: 75-89%, R:<75%) G: ≥50%, Y: 30% to <50%, R:<30%)	38	
7		fund released to TI (G: ≥50%, N: <50%)	101	
8		TIs trained by Kshmata Kendra (KK) against the AAP targets (G: ≥75%, Y: 70		
J	<75%, R:<70%		130	
9		ainst Target-at risk % (G: ≥95%, Y: 80-94%, R:<80%)	233	
20		ainst target-PW (G: ≥95%, Y: 80-94%, R:<80%)	86	
1		pregnant women screened for Syphilis (G: ≥95%, Y: 80-94%, R:<80%)	107	
22	Treatment pro	ovided to Syphilis reactive pregnant women (G: ≥95%, Y: 80-94%, R:<80%)	100	
23	•	among newly detected HIV positive clients (G: ≥95%, Y: 80-94%, R:<80%)	22	
24		6 weeks - <2 months EID testing against live birth (G: ≥95%, Y: 80-94%,	88	
	R:<80%)	o weeks - <2 months Elb testing against live birth (d. 27376, 1. 00-7476,		
25	·	ed at DSRC against the target (G: ≥90%, Y: 75-89%, R:<75%)	107	
26		screened for HIV (G: >75%, Y: 50-75%, R:<50%)	42	
27		screened for Syphilis (G: >75%, Y: 50-75%, R:<50%)	52	
28	% of pregnant	: women who initiated ART (G: ≥95%, Y: 80-94%, R:<80%)	67	
29	Proportion of	LFU-PLHIV, out of those initiated on ART in FY 2023-24 (G:<2%, Y: 2 to 5%,	4	
	R:>5%)			
30	Proportion of to 98%, R:<95	PLHIV initiated on ART, out of those registered in FY 2023-24 (G:>98%, Y: 95%)	96	
31		reported died, out of those initiated on ART in FY 202324 (G:<2%, Y: 2 to 5 to	6	
32	% of SRL accre	edited (G:100%, Y: 80-99%, R:<80%)	100	
33	% participatio	n of ICTCs in re-testing (G: ≥95%, Y: 85-94, R:<85%)	86	
4		stracts selected from studies conducted in FY21-22	1	
5		25 to <100%, R: ≤25%) going studies from FY22-23 (G:100%, Y: >25 to <100%,	4	
	R: ≤25%)			
6	Submission of Y: >25 to <10	research proposals from FY23-24 to NACO (G:100%, 0%, R: ≤25%)	2	
7		ta Analysis by SACS (G:2, Y: 1, R: No Secondary Data Analysis Plan Submitte	d) 2	
88	-	vith respect to funds released during FY 2022-23 (G:	129	
		o <90%, R: <85%)	129	
39	Submission of	Provisional Utilization Certificate (UC) in GFR 12A for the FY 2022-23 (G : by Y : by 31-May-2023, R : after	25-05-2023	
0	Submission of	audited UC in GFR 12A for the FY 2022-23 (G : by 30Jun-2023, Y : by 30-Se	p- 02-01-2024	
		30-Sep-2023)		
1	Submission of EC/ GB ratification for approval of Expenditure incurred during FY 2021-22 (G: by 30-Jun-2022, Y: by 30-Sept-2022, R: after 30-Sept-2022)			
2		ssion of CST-SCM Report (G:>95%, Y: 80-95%, R:<80%)	93	
13	Format Adher	ence to CST-SCM Report (G:>95%, Y: 80-95%, R:<80%)	91	
14	Timely Submis	ssion of BSD & STI-SCM Report (G: ≥90%, Y: 75- 75%)	92	
	Green=3 Marks		Io Colour=Not Applicable	
Veic	ght points	Indicator SI. No.	11 22 2	
	3	1, 23, 29		
	2	2, 3, 9, 10, 22, 30, 34, 42, 44		
		_ · · · · · · · · · · · · · · · · · · ·		

HIV testing against target-at risk (SI. No. 19): over-achievements above 120% are marked in red



WEST BENGAL



1. Status of HIV/AIDS Epidemic			
A. Epidemic Estimates (2023)			
Indicator	Male	Female	Total
1. IPR	-	-	2.53
2. IMR	-	-	1.44
3. Adult (15-49 yrs) HIV Prevalence (%)	0.09	0.08	0.08
4. Estimated people living with HIV	42,816	34,404	77,220
5. ART coverage (%)	81.15	70.85	77.07
6. Estimated children living with HIV	1,269	1,207	2,476
7. Annual new HIV infections	1,032	924	1,956
8. Annual AIDS-related deaths (ARD)	289	420	709
9. Change in annual new HIV infections since 2010 (%)	-55.01	-54.42	-54.73
10. Change in annual ARD since 2010(%)	-89.44	-79.82	-85.28
11. EMTCT need	-	592	592

B. High risk population size (2020-22), safe practices (2021) and prevalence (2021/2023) Condom Use New Needle/ **HIV Prevalence** Estimates Size Population Group (%) Syringe use (%) (%) 99.20 1. Female Sex Workers 20,452 1.27 85.10 4.36 2. Men who have sex with men 3,532 3. Injecting Drug Users 2,334 95.40 7.40 4. Hijra/Transgender People 5,134 9.15 5. Migrants 30,000 61.90 3.20 6. Truckers 60,000 66.80 45.80 2.01 1,56,437 44.70 65.60 0.42 7. Prison inmates

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)				
Indicator	Male	Female	Total	
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%)	15.50	18.50	-	
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%)	14.30	17.40	-	
3. Adults willing to care for a relative with HIV/AIDS in own home (%)	59.30	66.50	-	
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%)	56.70	64.20	-	
5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%)	1.70	1.00	-	
5.1 Condom use during last higher-risk intercourse (%)	63.60	52.40	-	
6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%)	3.55	1.52	-	
6.1 Condom use during last higher-risk intercourse (%)	67.86	62.50	-	

2. Progress on 95-95-95 (2023-24)					
65 71 73 77 82 87	89 87 85 84 86 88	89 90 87 8			
PLHIV who know their HIV status (%)	PLHIV who know their HIV status and are on ART (%)	PLHIV who are on ART and virally suppressed (%) 2022-23 2023-24			

Indicators	Male	Female	Total*
1. Estimated PLHIV size (2023)	42,816	34,404	77,220
2. PLHIV who know their HIV Status	39,756	27,117	67,339
3. PLHIV who know their HIV status and are on ART	34,489	24,187	59,066
4. PLHIV who are on ART and tested for their viral load	22,065	16,000	38,313
4.1 PLHIV who are virally suppressed	21,923	15,835	38,002

^{*} Including of H/TG PLHIV

3. Prevention of new HIV infections among general population

A. Information, Education, Communication, Youth and Mainstreaming

Indicator	2023-24
Schools with operational Adolescent Education Program (AEP)	2,950
2. Colleges with operational Red Ribbon Clubs (RRC)	666
3. Persons trained under mainstreaming	5,253
4. No. of calls received at helpline	-

B. Sexually Transmitted Infections (STI)/Reproductive Tract Infections (RTI) Management

Indicator	2023-24			
NACO Supported Designated STI/	48			
RTI Clinics (DSRC)	Male	Female	TG	Total
2. Total STI/RTI Clients managed				3,21,584
3. RPR Tests conducted	60,272	1,00,623	657	1,61,552
4. Syphilis seropositivity (%)	3.21	0.63	9.13	1.63

4. Prevention of new HIV infections among high-risk group and bridge population

A. Targeted Intervention (TI) Projects and Opioid Substitution Therapy (OST)

Indicator	2023-24
1. Targeted Intervention (TI) Projects	46
2. OST centres (Excluding Satellite OST centres)	8

B. Female Sex Workers

Indicator	2023-24
1. Estimated size	20,452
2. Coverage (%)	>=95
3. Condoms distributed	67,04,176
4. Tested for HIV (April 2022-September 2022)	16,775
4.1. HIV sero-positive (%)	0.15
4.1.1. Linked to ART	21
5. Tested for HIV (October 2022 -March 2023)	16,852
5.1. HIV sero-positive (%)	0.09
5.1.1. Linked to ART	15
6. Clinic Visits	62,488
7. STI/RTI treated	672
8. Presumptive treatment	2,618

C. Men who have Sex with Men Indicatort 2023-24 1. Estimated size 3,532 2. Coverage (%) 3. Condoms distributed 2,02,299 4. Tested for HIV (April 2022-September 2022) 1,459 4.1. HIV sero-positive (%) 1.51 4.1.1. Linked to ART 5. Tested for HIV (October 2022 -March 2023) 1,612 5.1. HIV sero-positive (%) 0.68 5.1.1. Linked to ART 10 6. Clinic Visits 5,837 7. STI/RTI treated 35 8. Presumptive treatment 247

D. Injecting Drug Users	
Indicator	2023-24
1. Estimated size	2,333
2. Coverage (%)	>=95
3. Needles distributed	10,65,682
4. Syringes distributed	5,37,566
5. On OST	948
6. Tested for HIV (April 2022 -September 2022)	1,716
6.1. HIV sero-positive (%)	0.87
6.1.1 Linked to ART	13
7. Tested for HIV (October 2022 -March 2023)	1,615
7.1. HIV sero-positive (%)	0.62
7.1.1. Linked to ART	7

E. Hijra/Transgender person	
Indicator	2023-24
1. Estimated size	5,134
2. Coverage (%)	53
3. Condoms distributed	2,53,008
4. Tested for HIV (April 2022-September 2022)	2,096
4.1. HIV sero-positive (%)	0.81
4.1.1. Linked to ART	14
5. Tested for HIV (October 2022 -March 2023)	2,313
5.1. HIV sero-positive (%)	0.35
5.1.1. Linked to ART	8
6. Clinic Visits	8,362
7. STI/RTI treated	78
8. Presumptive treatment	242

F. Migrants	
Indicator	2023-24
1. Estimated size	30,000
2. Coverage (%)	>=95
3. Tested for HIV	11,791
3.1. HIV sero-positive (%)	0.06
3.2. Linked to ART	6

G. Truckers	
Indicator	2023-24
1. Estimated size	60,000
2. Coverage (%)	>=95
3. Tested for HIV	15,350
3.1. HIV sero-positive (%)	0.14
3.2. On ART	15

H. Prison Inmates	
Indicator	2023-24
1. Total prisons	60
2. Prisons covered under programme	58
3. Total inmates admitted	1,56,437
4. Inmates Covered (%)	27
5. Tested for HIV	41,586
5.1. HIV sero-positive (%)	0.19
5.2. On ART (%)	73.08

I. Link Worker Scheme	
Indicator	2023-24
Districts covered under scheme	11
Vulnerable population covered	1,82,687
3. Tested for HIV	81,813
3.1. HIV sero-positive (%)	0.40
3.2. Linked to ART (%)	94.55

J. Opioid Substitution Therapy	
Indicator	2023-24
1. OST Centres	8
1.1. OSTC in Public Health Settings	7
1.2. OSTC in NGO Settings	1
1.3. No. of Satellite OST Centres	3
2. IDU on OST	948

5. Early detection of HIV infected people

A. HIV counselling and testing services (HCTS)

•	*
Indicator	2023-24
1. HCTC confirmatory facilities	311
2. Sampoorna Suraksha Kendras	13

B. HIV testing among vulnerable population (excluding pregnant women)

Indicator	2023-24			
	Male	Female	TG	Total
1. Tested for HIV	14,85,392	11,55,327	8,302	26,49,021
1.1 HIV Positives	4,858	1,732	88	6,678
1.2 HIV sero -positivity (%)	0.33	0.15	1.06	0.25
Spouse/sexual partner of HIV positive people tested	2,628	3,459	45	6,132
2.1 HIV Positives	1,156	841	9	2,006
2.2 HIV sero -positivity (%)	44	24	20	32.71
3. No. of contacts with 'at- risk' population through 'Sampoorna Suraksha'	-	-	-	1,910

6. Initiation and retention on ART of HIV infected people

A. Treatment facilities

Indicator	2023-24
1. ART Centres	26
2.Centre of Excellence	
2.1. Centre of Excellence (Adult)	1
2.2 Centre of Excellent (Paediatric)	1
3. Link ART Centres	55
4. Care Support Centres	13

B. Treatment uptake

Indicator	2023-24			
	Male	Female	TG	Total
HIV positive cases diagnosed (At ICTC)	4,858	2,036	88	6,982
New PLHIV Registered at ART center	4,687	1,965	78	6,730
2.1 Initiated on ART	4,438	1,890	76	6,404
3. PLHIV alive and on ART	34,489	24,187	390	59,066
4. 12 months retention on ART (%)				93.2
5. Lost to follow-up cases	5,845	3,309	62	9,216

7. Viral Suppression and laboratories		
A. Laboratory facilities and service uptake		
Indicator	2023-24	
 Viral load laboratories (programme and non- programme labs) 	2	
1.1 Accredited Viral load laboratories (out of 64 VL labs)	2	
2. Viral load tests conducted	41,577	
2.1. Virally suppressed (%)	>=95	
3. National reference laboratories (NRL)	2	
3.1 Accredited NRL	2	
4. State reference laboratories (SRL)	5	
4.1 Accredited SRL	5	
5. CD4 machines	20	
5.1 CD4 tests conducted	23,036	
6. External Quality Assurance of ICTC		
6.1 Average Participation (%)	>=95	
6.2. Average Discordance (%)	0.00	
7. "Certificate of Excellence" by NACO		
7.1 No. of ICTCs received "Certificate of Excellence"	35	

8. Elimination of mother to child transmission of HIV & Syphilis

HIV & Syphilis	
A. HIV	
Indicator	2023-24
1. Estimated pregnant women (PW)	16,24,780
2. HIV testing among PW	14,01,302
3. HIV sero-positivity (%) among tested	0.02
4. HIV Positive PW (old + new detections)	599
4.1 On life-long ART	586
5. Live births among HIV positive PW	458
5.1 Babies given ARV Prophylaxis (%)	>=95
6. Babies tested HIV (6 week- 6 month)	436
6.1 Babies confirmed HIV Positive (6 week- 6 month)	1
7. HIV testing among exposed babies at 18 months	
7.1 HIV exposed babies tested at 18 months	364
7.2 Babies confirmed HIV positive at 18 months	14
8. Total Babies Identified HIV Positive (6 weeks to upto 18 Months)	19
	i e

B. Syphilis	
Indicator	2023-24
1. Syphilis testing among PW	15,91,709
2.Sero-positivity (%) among tested	0.03
3. Put on treatment	421

9. Elimination of HIV/AIDS related Stigma and Discrimination

9. HIV positive babies initiated on ART

Indicator	2023-24
1. State rules notified for HIV/AIDS Prevention and Control Act (2017)	Yes
2. State designated/appointed ombudsman	Yes

19

Quarter 4

10. HIV-TB Co-morbidities A. HRG and Bridge Population Indicator 2023-24 Quarter FSW MSM IDU TG Migrants Truckers Total 3,052 8,750 Quarter 1 14,584 1,585 999 1,782 30,752 Quarter 2 14,686 1,278 841 2,134 2,648 8,795 30,382 Screened for TB Quarter 3 14,601 1,247 474 2,208 3,319 10,049 31,898 2,410 9,067 Quarter 4 14,046 1,562 947 2,463 30,495 Quarter 1 27 14 40 49 216 86 19 21 5 Quarter 2 66 111 Tested for TB Quarter 3 46 10 1 25 112 2 196 Quarter 4 40 19 3 17 573 2 654 3 3 Quarter 1 Quarter 2 Diagnosed with TB Quarter 3 Quarter 4 1 3 1 1 Quarter 1 3 3 Quarter 2 Initiated on TB treatment Quarter 3

B. HIV-TB Coinfected at ART Centre Indicator 2023-24 Co-infected initiated on PLHIV PLHIV PLHIV with PLHIV **PLHIV** Co-infected PLHIV tested diagnosed with TB presumptive TB initiated on enrolled at Moths attending underwent for TB ART Centre 4S screening IPT ARTC ART Apr - 23 19,573 19,351 316 310 33 532 46 353 565 May - 23 23,740 23,510 347 Jun - 23 24,799 24,628 322 316 62 614 Jul - 23 24,745 24,419 394 386 45 585 415 44 583 25,515 25,350 401 Aug - 23 Sep - 23 26,201 26,119 368 363 31 524 Oct - 23 20,384 20,300 295 290 29 405 37 Nov - 23 26,987 26,855 333 330 468 Dec - 23 29,490 29,405 429 423 17 403 Jan - 24 30.064 29,958 329 323 26 420 Feb - 24 25,190 23,504 385 374 46 446 Mar - 24 24,184 24,071 400 369 43 355 April 2023-1,185 1,097 March 2024

1

3

NATIONAL AIDS & STD CONTROL PROGRAMME STATE/UT SCORECARD, FY 2023-24

		West Bengal	
~1	NA NA	Rank	7
SI. 10.	Maximum Ma	177	
	Obtained Ma		135 (76%) 87
2		95%, Y: 80-94%, R:<80%) 5:≥95%, Y: 80-94%, R:<80%)	88
3		>=95	
4		:95%, Y: 80-94%, R:<80%) quency of Social Media updates (G: ≥ 45, Y:40- 44, R:<40 indigenous posts) of	57
	Q1, Q2, Q3 8		
5	Status of AEF	P integration in state school curriculum (G:Yes, R:No)	Yes
6		A (G: At least one meeting held since 2020, R: other than G)	Not constituted
7	Status of Stat	te Rules (G: Notified, R: Not notified)	Notified
8	Status of Om	budsman (G: Appointed, R: Not appointed)	Appointed
9	TI/LWS onbo	100	
0	OST onboard	ding (G: ≥95%, Y: 90-<95%, R:<90%)	100
1	Coverage of	HRG against estimates (G: ≥90%, Y: 80-<90%, R:<80%)	98
2	HIV testing a	mong HRG (G: ≥95%, Y: 90-<95%, R:<90%)	89
3		mong prisoners (G: ≥50%, Y: 40% to <50%, R:<40%)	24
4	Clinic visit of	HRGs at TI-Clinics (G: ≥90%, Y: 75-89%, R:<75%)	83
5	Percentage o	of HRGs screened for Syphilis (G: ≥90%, Y: 75-89%, R:<75%)	84
6	IDU on OST	(G: ≥50%, Y: 30% to <50%, R:<30%)	72
7		of fund released to TI (G: ≥50%, Y: 45-<50%, R:<45%)	73
8	_	of TIs trained by Kshmata Kendra (KK) against the AAP targets (G: ≥75%, Y: 70-	100
	<75%, R:<70	· ·	
9		gainst Target-at risk % (G: ≥95%, Y: 80-94%, R:<80%)	477
0		gainst target-PW (G: ≥95%, Y: 80-94%, R:<80%)	86
1	Percentage o	of pregnant women screened for Syphilis (G: ≥95%, Y: 80-94%, R:<80%)	98
2	Treatment pr	ovided to Syphilis reactive pregnant women (G: ≥95%, Y: 80-94%, R:<80%)	93
3	Index testing	among newly detected HIV positive clients (G: ≥95%, Y: 80-94%, R:<80%)	47
4	Percentage of R:<80%)	of 6 weeks - <2 months EID testing against live birth (G: ≥95%, Y: 80-94%,	98
5	Clients mana	ged at DSRC against the target (G: ≥90%, Y: 75-89%, R:<75%)	52
6		s screened for HIV (G: >75%, Y: 50-75%, R:<50%)	57
7		s screened for Syphilis (G: >75%, Y: 50-75%, R:<50%)	64
8	% of pregnar	98	
9	Proportion of R:>5%)	f LFU-PLHIV, out of those initiated on ART in FY 2023-24 (G:<2%, Y: 2 to 5%,	2
0	Proportion of to 98%, R:<9	95	
1	Proportion of R:>5 %)	4	
2	% of SRL acc	redited (G:100%, Y: 80-99%, R:<80%)	100
3	% participation	on of ICTCs in re-testing (G: ≥95%, Y: 85-94, R:<85%)	98
4	Number of a R: ≤25%)	bstracts selected from studies conducted in FY21-22 (G:100%, Y: >25 to <100%,	3
5	Number of o	ngoing studies from FY22-23 (G:100%, Y: >25 to <100%,	4
	R: ≤25%)		
6	Y: >25 to <10	of research proposals from FY23-24 to NACO (G:100%, 00%, R: ≤25%)	2
7	Secondary D	ata Analysis by SACS (G:2, Y: 1, R: No Secondary Data Analysis Plan Submitted)	2
8	· ·	with respect to funds released during FY 2022-23 (G: to <90%, R: <85%)	152
9		of Provisional Utilization Certificate (UC) in GFR 12A for the FY 2022-23 (G : by , Y : by 31-May-2023, R : after	06-06-2023
0	Submission of	of audited UC in GFR 12A for the FY 2022-23 (G : by 30Jun-2023, Y : by 30-Sep- er 30-Sep-2023)	04-12-2023
1	Submission of (G: by 30-Jur R: after 30-Se	21-02-2023	
2	Timely Subm	ission of CST-SCM Report (G:>95%, Y: 80-95%, R:<80%)	98
3	Format Adhe	erence to CST-SCM Report (G:>95%, Y: 80-95%, R:<80%)	94
4		ission of BSD & STI-SCM Report (G: ≥90%, Y: 75-	92
	Green=3 Mark	S Yellow=2Marks Red=1 Mark No Co	lour=Not Applicable
Veiç	ght points	Indicator SI. No.	
	3	1, 23, 29	
2		2, 3, 9, 10, 22, 30, 34, 42, 44	
	2	2, 3, 7, 10, 22, 30, 34, 42, 44	

HIV testing against target-at risk (SI. No. 19): over-achievements above 120% are marked in red



"Sankalak - Status of National AIDS & STD Response" is the evidence-based flagship report of the National AIDS & STD Control Programme (NACP), outlining the efforts toward achieving the 2030 goal of ending AIDS as a public health threat. It provides comprehensive programmatic and epidemiological data at both the national and state/union territory levels under NACP. This sixth edition of 'Sankalak' presents the progress made across the prevention-detection-treatment spectrum for the financial year 2023-24.

